<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31599329</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>142</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor.</ArticleTitle><Pagination><StartPage>3636</StartPage><EndPage>3654</EndPage><MedlinePgn>3636-3654</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awz288</ELocationID><Abstract><AbstractText>Accumulating data support the role of tau pathology in cognitive decline in ageing and Alzheimer's disease, but underlying mechanisms remain ill-defined. Interestingly, ageing and Alzheimer's disease have been associated with an abnormal upregulation of adenosine A2A receptor (A2AR), a fine tuner of synaptic plasticity. However, the link between A2AR signalling and tau pathology has remained largely unexplored. In the present study, we report for the first time a significant upregulation of A2AR in patients suffering from frontotemporal lobar degeneration with the MAPT P301L mutation. To model these alterations, we induced neuronal A2AR upregulation in a tauopathy mouse model (THY-Tau22) using a new conditional strain allowing forebrain overexpression of the receptor. We found that neuronal A2AR upregulation increases tau hyperphosphorylation, potentiating the onset of tau-induced memory deficits. This detrimental effect was linked to a singular microglial signature as revealed by RNA sequencing analysis. In particular, we found that A2AR overexpression in THY-Tau22 mice led to the hippocampal upregulation of C1q complement protein-also observed in patients with frontotemporal lobar degeneration-and correlated with the loss of glutamatergic synapses, likely underlying the observed memory deficits. These data reveal a key impact of overactive neuronal A2AR in the onset of synaptic loss in tauopathies, paving the way for new therapeutic approaches.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faivre</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietrowski</LastName><ForeName>Marie J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institut du Fer &#xe0; Moulin, Inserm UMR-S 1270, Sorbonne Universit&#xe9;, F, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Murcia</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deleau</LastName><ForeName>Aude</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huin</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Jan N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozlov</LastName><ForeName>Stanislav</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danis</LastName><ForeName>Cl&#xe9;ment</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Lille, CNRS UMR8576, Unit&#xe9; de Glycobiologie Structurale et Fonctionnelle, LabEx DISTALZ, Lille, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Temido-Ferreira</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coelho</LastName><ForeName>Joana E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe9;riaux</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eddarkaoui</LastName><ForeName>Sabiha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gras</LastName><ForeName>St&#xe9;phanie Le</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>CNRS, Inserm, UMR 7104, GenomEast Platform, Institut de G&#xe9;n&#xe9;tique et de Biologie Mol&#xe9;culaire et Cellulaire (IGBMC), Universit&#xe9; de Strasbourg, F Illkirch, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumoulin</LastName><ForeName>M&#xe9;lanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Lille, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cellai</LastName><ForeName>Lucrezia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NeuroCEB Brain Bank</CollectiveName></Author><Author ValidYN="Y"><LastName>Landrieu</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University of Lille, CNRS UMR8576, Unit&#xe9; de Glycobiologie Structurale et Fonctionnelle, LabEx DISTALZ, Lille, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chern</LastName><ForeName>Yijuang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamdane</LastName><ForeName>Malika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu&#xe9;e</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutillier</LastName><ForeName>Anne-Laurence</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Laboratoire de Neuroscience Cognitives et Adaptatives (LNCA), CNRS UMR 7364, Universit&#xe9; de Strasbourg, F Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levi</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut du Fer &#xe0; Moulin, Inserm UMR-S 1270, Sorbonne Universit&#xe9;, F, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halle</LastName><ForeName>Annett</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuropathology, University of Bonn Medical Center, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Luisa V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000627179">ADORA2A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000629553">Adora2a protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043705">Receptor, Adenosine A2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2019 Nov 1;142(11):3323-3324. doi: 10.1093/brain/awz335.</RefSource><PMID Version="1">31665752</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043705" MajorTopicYN="N">Receptor, Adenosine A2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065853" MajorTopicYN="N">Spatial Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">A2A receptor</Keyword><Keyword MajorTopicYN="N">C1q</Keyword><Keyword MajorTopicYN="N">adenosine</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31599329</ArticleId><ArticleId IdType="pmc">PMC6821333</ArticleId><ArticleId IdType="doi">10.1093/brain/awz288</ArticleId><ArticleId IdType="pii">5584878</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albasanz JL, Perez S, Barrachina M, Ferrer I, Mart&#xed;n M. Up-regulation of adenosine receptors in the frontal cortex in Alzheimer&#x2019;s disease. Brain Pathol 2008; 18: 211&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095610</ArticleId><ArticleId IdType="pubmed">18241242</ArticleId></ArticleIdList></Reference><Reference><Citation>Albasanz JL, Rodr&#xed;guez A, Ferrer I, Mart&#xed;n M. Adenosine A2A receptors are up-regulated in Pick&#x2019;s disease frontal cortex. Brain Pathol 2006; 16: 249&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095809</ArticleId><ArticleId IdType="pubmed">17107593</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol 2010; 11: R106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218662</ArticleId><ArticleId IdType="pubmed">20979621</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Pyl PT, Huber W. HTSeq&#x2014;a Python framework to work with high-throughput sequencing data. Bioinformatics 2015; 31: 166&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287950</ArticleId><ArticleId IdType="pubmed">25260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Audrain M, Haure-Mirande J-V, Wang M, Kim SH, Fanutza T, Chakrabarty P, et al.Integrative approach to sporadic Alzheimer&#x2019;s disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447470</ArticleId><ArticleId IdType="pubmed">30283031</ArticleId></ArticleIdList></Reference><Reference><Citation>Augusto E, Matos M, S&#xe9;vigny J, El-Tayeb A, Bynoe MS, M&#xfc;ller CE, et al.Ecto-5&#x2032;-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions. J Neurosci 2013; 33: 11390&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3724543</ArticleId><ArticleId IdType="pubmed">23843511</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C, Santamaria G, La Vitola P, Brandi E, Grandi F, Viscomi AR, et al.Doxycycline counteracts neuroinflammation restoring memory in Alzheimer&#x2019;s disease mouse models. Neurobiol Aging 2018; 70: 128&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">30007162</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron R, Babcock AA, Nemirovsky A, Finsen B, Monsonego A. Accelerated microglial pathology is associated with A&#x3b2; plaques in mouse models of Alzheimer&#x2019;s disease. Aging Cell 2014; 13: 584&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326940</ArticleId><ArticleId IdType="pubmed">24641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Batalha VL, Ferreira DG, Coelho JE, Valadas JS, Gomes R, Temido-Ferreira M, et al.The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function. Sci Rep 2016; 6: 31493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4980603</ArticleId><ArticleId IdType="pubmed">27510168</ArticleId></ArticleIdList></Reference><Reference><Citation>Batalha VL, Pego JM, Fontinha BM, Costenla AR, Valadas JS, Baqi Y, et al.Adenosine A(2A) receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation. Mol Psychiatry 2013; 18: 320&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">22371048</ArticleId></ArticleIdList></Reference><Reference><Citation>Belarbi K, Burnouf S, Fernandez-Gomez F-J, Desmerci&#xe8;res J, Troquier L, Brouillette J, et al.Loss of medial septum cholinergic neurons in THY-Tau22 mouse model: what links with tau pathology? Curr Alzheimer Res 2011; 8: 633&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21605043</ArticleId></ArticleIdList></Reference><Reference><Citation>Belarbi K, Schindowski K, Burnouf S, Caillierez R, Grosjean M-E, Demeyer D, et al.Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer&#x2019;s disease. Curr Alzheimer Res 2009; 6: 152&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859345</ArticleId><ArticleId IdType="pubmed">19355850</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc: Series B (Methodological) 1995; 57: 289&#x2013;300.</Citation></Reference><Reference><Citation>Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis 2004; 17: 359&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">15571972</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum D, Hourez R, Galas M-C, Popoli P, Schiffmann SN. Adenosine receptors and Huntington&#x2019;s disease: implications for pathogenesis and therapeutics. Lancet Neurol 2003; 2: 366&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849153</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgin KE, Waxham MN, Rickling S, Westgate SA, Mobley WC, Kelly PT. In situ hybridization histochemistry of Ca2+/calmodulin-dependent protein kinase in developing rat brain. J Neurosci 1990; 10: 1788&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570308</ArticleId><ArticleId IdType="pubmed">2162385</ArticleId></ArticleIdList></Reference><Reference><Citation>Burlot M-A, Braudeau J, Michaelsen-Preusse K, Potier B, Ayciriex S, Varin J, et al.Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. Hum Mol Genet 2015; 24: 5965&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">26358780</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, et al.NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell 2013; 12: 11&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23082852</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. Nat Rev Neurosci 2018; 19: 622&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255106</ArticleId><ArticleId IdType="pubmed">30206328</ArticleId></ArticleIdList></Reference><Reference><Citation>Canas PM, Duarte JMN, Rodrigues RJ, K&#xf6;falvi A, Cunha RA. Modification upon aging of the density of presynaptic modulation systems in the hippocampus. Neurobiol Aging 2009a; 30: 1877&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">18304697</ArticleId></ArticleIdList></Reference><Reference><Citation>Canas PM, Porci&#xfa;ncula LO, Cunha GMA, Silva CG, Machado NJ, Oliveira JMA, et al.Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 2009b; 29: 14741&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665997</ArticleId><ArticleId IdType="pubmed">19940169</ArticleId></ArticleIdList></Reference><Reference><Citation>Canas PM, Porci&#xfa;ncula LO, Sim&#xf5;es AP, Augusto E, Silva HB, Machado NJ, et al.Neuronal adenosine A2A receptors are critical mediators of neurodegeneration triggered by convulsions. eNeuro 2018; 5: ENEURO.0385-18.2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6325550</ArticleId><ArticleId IdType="pubmed">30627646</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#xe7;alves FQ, Lopes JP, Silva HB, Lemos C, Silva AC, Gon&#xe7;alves N, et al.Synaptic and memory dysfunction in a &#xdf;-amyloid model of early Alzheimer's disease depends on increased formation of ATP-derived extracellular adenosine. Neurobiol Dis 2019; 132: 104570. doi: 10.1016/j.nbd.2019.104570.</Citation><ArticleIdList><ArticleId IdType="pubmed">31394204</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Cassel R, Schneider-Anthony A, Merienne K, Cosquer B, Tzeplaeff L, et al.Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator. EMBO Mol Med 2018; 10. pii: e8587. doi: 10.15252/emmm.201708587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6220301</ArticleId><ArticleId IdType="pubmed">30275019</ArticleId></ArticleIdList></Reference><Reference><Citation>Costenla AR, Di&#xf3;genes MJ, Canas PM, Rodrigues RJ, Nogueira C, Maroco J, et al.Enhanced role of adenosine A(2A) receptors in the modulation of LTP in the rat hippocampus upon ageing. Eur J Neurosci 2011; 34: 12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21615561</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha RA. How does adenosine control neuronal dysfunction and neurodegeneration? J Neurochem 2016; 139: 1019&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">27365148</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejanovic B, Huntley MA, De Mazi&#xe8;re A, Meilandt WJ, Wu T, Srinivasan K, et al.Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron 2018; 100: 1322&#x2013;36.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30392797</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Bennecib M, Grignon Y, Uchihara T, He Y, Piette F, et al.Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol Aging 1997; 18: 267&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9263190</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Braak H, Brion J-P, Bu&#xe9;e L, Del Tredici K, Goedert M, et al.PART is part of Alzheimer disease. Acta Neuropathol 2015; 129: 749&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405349</ArticleId><ArticleId IdType="pubmed">25628035</ArticleId></ArticleIdList></Reference><Reference><Citation>Faivre E, Coelho JE, Zornbach K, Malik E, Baqi Y, Schneider M, et al.Beneficial effect of a selective adenosine A2A receptor antagonist in the APPswe/PS1dE9 mouse model of Alzheimer&#x2019;s Disease. Front Mol Neurosci 2018; 11: 235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052540</ArticleId><ArticleId IdType="pubmed">30050407</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Chu S-H, Hernandez MX, Fang MJ, Modarresi L, Selvan P, et al.Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. J Neuroinflammation 2017; 14: 48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340039</ArticleId><ArticleId IdType="pubmed">28264694</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Kawas CH, Troncoso JC, Tenner AJ. Neuronal localization of C1q in preclinical Alzheimer&#x2019;s disease. Neurobiol Dis 2004; 15: 40&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">14751769</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest SL, Kril JJ, Stevens CH, Kwok JB, Hallupp M, Kim WS, et al.Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain 2018; 141: 521&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5888940</ArticleId><ArticleId IdType="pubmed">29253099</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#xe7;alves FQ, Lopes JP, Silva HB, Lemos C, Silva AC, Gon&#xe7;alves N, et al.Synaptic and memory dysfunction in a &#xdf;-amyloid model of early Alzheimer's disease depends on increased formation of ATP-derived extracellular adenosine. Neurobiol Dis 2019; 132: 104570. doi: 10.1016/j.nbd.2019.104570.</Citation><ArticleIdList><ArticleId IdType="pubmed">31394204</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Dickson D, Sliwinski MJ, Buschke H, Katz M, Crystal H, et al.Memory and mental status correlates of modified Braak staging. Neurobiol Aging 1999; 20: 573&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10674422</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Z, Kuhn JA, Wang X, Colquitt B, Solorzano C, Vaman S, et al.Injured sensory neuron&#x2013;derived CSF1 induces microglial proliferation and DAP12-dependent pain. Nat Neurosci 2016; 19: 94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4703328</ArticleId><ArticleId IdType="pubmed">26642091</ArticleId></ArticleIdList></Reference><Reference><Citation>Han HJ, Allen CC, Buchovecky CM, Yetman MJ, Born HA, Marin MA, et al.Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J Neurosci 2012; 32: 10574&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431916</ArticleId><ArticleId IdType="pubmed">22855807</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdane M, Bu&#xe9;e L. The complex p25/Cdk5 kinase in neurofibrillary degeneration and neuronal death: the missing link to cell cycle. Biotechnol J 2007; 2: 967&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">17571276</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtman IR, Raj DD, Miller JA, Schaafsma W, Yin Z, Brouwer N, et al.Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis. Acta Neuropathol Commun 2015; 3: 31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489356</ArticleId><ArticleId IdType="pubmed">26001565</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al.Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016; 352: 712&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Huin V, Deramecourt V, Caparros-Lefebvre D, Maurage C-A, Duyckaerts C, Kovari E, et al.The MAPT gene is differentially methylated in the progressive supranuclear palsy brain. Mov Disord 2016; 31: 1883&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">27709663</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al.Association of missense and 5&#x2019;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Tosakulwong N, Whitwell JL, Knopman DS, Machulda MM, et al.Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathol 2017; 133: 705&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091858</ArticleId><ArticleId IdType="pubmed">28160067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013; 501: 45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaster MP, Machado NJ, Silva HB, Nunes A, Ardais AP, Santana M, et al.Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress. Proc Natl Acad Sci USA 2015; 112: 7833&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4485143</ArticleId><ArticleId IdType="pubmed">26056314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly PT, Shields S, Conway K, Yip R, Burgin K. Developmental changes in calmodulin-kinase II activity at brain synaptic junctions: alterations in holoenzyme composition. J Neurochem 1987; 49: 1927&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">2824699</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al.A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 2017; 169: 1276&#x2013;90.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987; 15: 8125&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC306349</ArticleId><ArticleId IdType="pubmed">3313277</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Schatz MC, Lin J, Pop M, Salzberg SL. Searching for SNPs with cloud computing. Genome Biol 2009; 10: R134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091327</ArticleId><ArticleId IdType="pubmed">19930550</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent C, Burnouf S, Ferry B, Batalha VL, Coelho JE, Baqi Y, et al.A2A adenosine receptor deletion is protective in a mouse model of tauopathy. Mol Psychiatry 2016; 21: 97&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">25450226</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent C, Doroth&#xe9;e G, Hunot S, Martin E, Monnet Y, Duchamp M, et al.Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain 2017; 140: 184&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382942</ArticleId><ArticleId IdType="pubmed">27818384</ArticleId></ArticleIdList></Reference><Reference><Citation>Leboucher A, Laurent C, Fernandez-Gomez F-J, Burnouf S, Troquier L, Eddarkaoui S, et al.Detrimental effects of diet-induced obesity on pathology are independent of insulin resistance in transgenic mice. Diabetes 2013; 62: 1681&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636620</ArticleId><ArticleId IdType="pubmed">23250356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebouvier T, Pasquier F, Bu&#xe9;e L. Update on tauopathies. Curr Opin Neurol. 2017; 30: 589&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">28914736</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C-C, Chang C-P, Lin C-J, Lai H-L, Kao Y-H, Cheng S-J, et al.Adenosine augmentation evoked by an ENT1 inhibitor improves memory impairment and neuronal plasticity in the APP/PS1 mouse model of Alzheimer&#x2019;s disease. Mol Neurobiol 2018; 55: 8936&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">29616397</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Rial D, Canas PM, Yoo J-H, Li W, Zhou X, et al.Optogenetic activation of intracellular adenosine A2A receptor signaling in the hippocampus is sufficient to trigger CREB phosphorylation and impair memory. Mol Psychiatry 2015; 20: 1339&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539301</ArticleId><ArticleId IdType="pubmed">25687775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes LV, Cunha RA, Ribeiro JA. Increase in the number, G protein coupling, and efficiency of facilitatory adenosine A2A receptors in the limbic cortex, but not striatum, of aged rats. J Neurochem 1999; 73: 1733&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10501222</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes S, Vaz-Silva J, Pinto V, Dalla C, Kokras N, Bedenk B, et al.Tau protein is essential for stress-induced brain pathology. Proc Natl Acad Sci 2016; 113: E3755&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4932951</ArticleId><ArticleId IdType="pubmed">27274066</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Elwood F, Britschgi M, Villeda S, Zhang H, Ding Z, et al.Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J Exp Med 2013; 210: 157&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549715</ArticleId><ArticleId IdType="pubmed">23296467</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado RA, Benjumea-Cuartas V, Zapata Berruecos JF, Agudelo-Fl&#xf3;res PM, Salazar-Pel&#xe1;ez LM. Reelin, tau phosphorylation and psychiatric complications in patients with hippocampal sclerosis and structural abnormalities in temporal lobe epilepsy. Epilepsy Behav EB 2019; 96: 192&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31150999</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado NJ, Sim&#xf5;es AP, Silva HB, Ardais AP, Kaster MP, Gar&#xe7;&#xe3;o P, et al.Caffeine reverts memory but not mood impairment in a depression-prone mouse strain with up-regulated adenosine A2A receptor in hippocampal glutamate synapses. Mol Neurobiol 2017; 54: 1552&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">26860412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem 2016; 138: 54&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">27306735</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Adaikkan C, Gao F, Young JZ, Manet E, Hemberg M, et al.Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Rep 2017; 21: 366&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Matos M, Augusto E, Machado NJ, dos Santos-Rodrigues A, Cunha RA, Agostinho P. Astrocytic adenosine A2A receptors control the amyloid-&#x3b2; peptide-induced decrease of glutamate uptake. J Alzheimers Dis 2012; 31: 555&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">22647260</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr AG, Hsiao EC, Wang MM, Ho K, Kim DH, Wang X, et al.Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. Nat Neurosci 2015; 18: 423&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4340760</ArticleId><ArticleId IdType="pubmed">25622143</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr AG, Lo I, Schumacher H, Ho K, Gill M, Guo W, et al.Istradefylline reduces memory deficits in aging mice with amyloid pathology. Neurobiol Dis 2018; 110: 29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747997</ArticleId><ArticleId IdType="pubmed">29100987</ArticleId></ArticleIdList></Reference><Reference><Citation>Paiva I, Carvalho K, Santos P, Cellai L, Angeliki Maria. et al. A2AR-induced transcriptional deregulation in astrocytes: an in vitro study. Glia 2019. doi: 10.1002/glia.23688.</Citation><ArticleIdList><ArticleId IdType="pubmed">31328322</ArticleId></ArticleIdList></Reference><Reference><Citation>Plescher M, Seifert G, Hansen JN, Bedner P, Steinh&#xe4;user C, Halle A. Plaque-dependent morphological and electrophysiological heterogeneity of microglia in an Alzheimer&#x2019;s disease mouse model. Glia 2018; 66: 1464&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">29493017</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebola N, Sebasti&#xe3;o AM, de Mendonca A, Oliveira CR, Ribeiro JA, Cunha RA. Enhanced adenosine A2A receptor facilitation of synaptic transmission in the hippocampus of aged rats. J Neurophysiol 2003; 90: 1295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">12904509</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues RJ, Marques JM, Cunha RA. Purinergic signalling and brain development. Semin Cell Dev Biol 2018, pii: S1084-9521. doi: 10.1016/j.semcdb.2018.12.001.</Citation><ArticleIdList><ArticleId IdType="pubmed">30529149</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, et al.Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012; 74: 691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Bretteville A, Leroy K, B&#xe9;gard S, Brion J-P, Hamdane M, et al.Alzheimer&#x2019;s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 2006; 169: 599&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz WK, Baitinger C, Schulman H, Kelly PT. Developmental changes in Ca2+/calmodulin-dependent protein kinase II in cultures of hippocampal pyramidal neurons and astrocytes. J Neurosci 1988; 8: 1039&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569222</ArticleId><ArticleId IdType="pubmed">3346714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin M-L, Grognet P, Bombois S, et al.Biochemistry of Tau in Alzheimer&#x2019;s disease and related neurological disorders. Expert Rev Proteomics 2008; 5: 207&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">18466052</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva AC, Lemos C, Gon&#xe7;alves FQ, Pli&#xe1;ssova AV, Machado NJ, Silva HB, et al.Blockade of adenosine A2A receptors recovers early deficits of memory and plasticity in the triple transgenic mouse model of Alzheimer&#x2019;s disease. Neurobiol Dis 2018; 117: 72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">29859867</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer&#x2019;s disease. Neuron 2014; 82: 756&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K, Friedman BA, Larson JL, Lauffer BE, Goldstein LD, Appling LL, et al.Untangling the brain&#x2019;s neuroinflammatory and neurodegenerative transcriptional responses. Nat Commun 2016; 7: 11295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4844685</ArticleId><ArticleId IdType="pubmed">27097852</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, Madison DV, Mateos JM, Fraser DA, Lovelett EA, Coutellier L, et al.A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci 2013; 33: 13460&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al.The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 2017; 45: D362&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210637</ArticleId><ArticleId IdType="pubmed">27924014</ArticleId></ArticleIdList></Reference><Reference><Citation>Temido-Ferreira M, Ferreira DG, Batalha VL, Marques-Morgado I, Coelho JE, Pereira P, et al.Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors. Mol Psychiatry 2018, doi: 10.1038/s41380-018-0110-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387321</ArticleId><ArticleId IdType="pubmed">29950682</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25: 1105&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672628</ArticleId><ArticleId IdType="pubmed">19289445</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Jeugd A, Ahmed T, Burnouf S, Belarbi K, Hamdame M, Grosjean M-E, et al.Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol Learn Mem 2011; 95: 296&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">21167950</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Jeugd A, Vermaercke B, Derisbourg M, Lo AC, Hamdane M, Blum D, et al.Progressive age-related cognitive decline in tau mice. J Alzheimers Dis 2013; 37: 777&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">23948912</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasek MJ, Garber C, Dorsey D, Durrant DM, Bollman B, Soung A. et al. A complement-microglial axis drives synapse loss during virus-induced memory impairment. Nature 2016; 534: 538&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5452615</ArticleId><ArticleId IdType="pubmed">27337340</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana da Silva S, Haberl MG, Zhang P, Bethge P, Lemos C, Gon&#xe7;alves N, et al.Early synaptic deficits in the APP/PS1 mouse model of Alzheimer&#x2019;s disease involve neuronal adenosine A2A receptors. Nat Commun 2016; 7: 11915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4915032</ArticleId><ArticleId IdType="pubmed">27312972</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohleb ES. Neuron-microglia interactions in mental health disorders: &#x201c;For Better, and For Worse.&#x201d; Front Immunol 2016; 7: 544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5126117</ArticleId><ArticleId IdType="pubmed">27965671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohleb ES, Terwilliger R, Duman CH, Duman RS. Stress-induced neuronal CSF1 provokes microglia-mediated neuronal remodeling and depressive-like behavior. Biol Psychiatry 2018; 83: 38&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6506225</ArticleId><ArticleId IdType="pubmed">28697890</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, et al.An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 2014; 34: 11929&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31637161</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2198-3844</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>20</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</Title><ISOAbbreviation>Adv Sci (Weinh)</ISOAbbreviation></Journal><ArticleTitle>Blood-Brain Barrier Dysfunction in a 3D In Vitro Model of Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>1900962</StartPage><MedlinePgn>1900962</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1900962</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/advs.201900962</ELocationID><Abstract><AbstractText>Harmful materials in the blood are prevented from entering the healthy brain by a highly selective blood-brain barrier (BBB), and impairment of barrier function has been associated with a variety of neurological diseases. In Alzheimer's disease (AD), BBB breakdown has been shown to occur even before cognitive decline and brain pathology. To investigate the role of the cerebral vasculature in AD, a physiologically relevant 3D human neural cell culture microfluidic model is developed having a brain endothelial cell monolayer with a BBB-like phenotype. This model is shown to recapitulate several key aspects of BBB dysfunction observed in AD patients: increased BBB permeability, decreased expression of claudin-1, claudin-5, and VE-cadherin, increased expression of matrix-metalloproteinase-2 and reactive oxygen species, and deposition of &#x3b2;-amyloid (A&#x3b2;) peptides at the vascular endothelium. Thus, it provides a well-controlled platform for investigating BBB function as well as for screening of new drugs that need to pass the BBB to gain access to neural tissues.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Published by WILEY&#x2010;VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Yoojin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Mechanical Engineering Massachusetts Institute of Technology 500 Technology Square, MIT Building, Room NE47-321 Cambridge MA 02139 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Se Hoon</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit McCance Center for Brain Health Mass General Institute for Neurodegenerative Disease Department of Neurology Massachusetts General Hospital Harvard Medical School Charlestown MA 02129 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eunhee</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit McCance Center for Brain Health Mass General Institute for Neurodegenerative Disease Department of Neurology Massachusetts General Hospital Harvard Medical School Charlestown MA 02129 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bylykbashi</LastName><ForeName>Enjana</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit McCance Center for Brain Health Mass General Institute for Neurodegenerative Disease Department of Neurology Massachusetts General Hospital Harvard Medical School Charlestown MA 02129 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jeong Ah</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Biomedical Omics Group Korea Basic Science Institute Cheongju 28119 Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bio-Analytical Science University of Science and Technology Daejeon 34113 Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Seok</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>KU-KIST Graduate School of Converging Science and Technology Korea University Seoul 02841 Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Mechanical Engineering Korea University Seoul 02841 Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Doo Yeon</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit McCance Center for Brain Health Mass General Institute for Neurodegenerative Disease Department of Neurology Massachusetts General Hospital Harvard Medical School Charlestown MA 02129 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamm</LastName><ForeName>Roger D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0002-7232-304X</Identifier><AffiliationInfo><Affiliation>Department of Mechanical Engineering Massachusetts Institute of Technology 500 Technology Square, MIT Building, Room NE47-321 Cambridge MA 02139 USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Engineering Massachusetts Institute of Technology 500 Technology Square, MIT Building, Room NE47-321 Cambridge MA 02139 USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Singapore-MIT Alliance for Research &amp; Technology (SMART) BioSystems and Micromechanics (BioSyM) Singapore 138602 Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit McCance Center for Brain Health Mass General Institute for Neurodegenerative Disease Department of Neurology Massachusetts General Hospital Harvard Medical School Charlestown MA 02129 USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG061891</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS105027</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Adv Sci (Weinh)</MedlineTA><NlmUniqueID>101664569</NlmUniqueID><ISSNLinking>2198-3844</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3D Alzheimer's disease model</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">blood&#x2013;brain barrier</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>8</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31637161</ArticleId><ArticleId IdType="pmc">PMC6794630</ArticleId><ArticleId IdType="doi">10.1002/advs.201900962</ArticleId><ArticleId IdType="pii">ADVS1253</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tanzi R. E., Bertram L., Cell 2005, 120, 545.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballabh P., Braun A., Nedergaard M., Neurobiol. Dis. 2004, 16, 1.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207256</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R., Zlokovic B. V, Curr. Alzheimer Res. 2007, 4, 191.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430246</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipser B. D., Johanson C. E., Gonzalez L., Berzin T. M., Tavares R., Hulette C. M., Vitek M. P., Hovanesian V., Stopa E. G., Neurobiol. Aging 2007, 28, 977.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic B., Alzheimer's Dementia 2015, 11, P114.</Citation></Reference><Reference><Citation>Nation D. A., Sweeney M. D., Montagne A., Sagare A. P., D'Orazio L. M., Pachicano M., Sepehrband F., Nelson A. R., Buennagel D. P., Harrington M. G., Benzinger T. L. S., Fagan A. M., Ringman J. M., Schneider L. S., Morris J. C., Chui H. C., Law M., Toga A. W., Zlokovic B. V., Nat. Med. 2019, 25, 270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367058</ArticleId><ArticleId IdType="pubmed">30643288</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M. D., Zhao Z., Montagne A., Nelson A. R., Zlokovic B. V, Physiol. Rev. 2019, 99, 21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6335099</ArticleId><ArticleId IdType="pubmed">30280653</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M. D., Kisler K., Montagne A., Toga A. W., Zlokovic B. V, Nat. Neurosci. 2018, 21, 1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6198802</ArticleId><ArticleId IdType="pubmed">30250261</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A., Zhao Z., Zlokovic B. V, J. Exp. Med. 2017, 214, 3151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5679168</ArticleId><ArticleId IdType="pubmed">29061693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y. H., Choi S. H., D'avanzo C., Hebisch M., Sliwinski C., Bylykbashi E., Washicosky K. J., Klee J. B., Br&#xfc;stle O., Tanzi R. E., Kim D. Y., Nat. Protoc. 2015, 10, 985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4499058</ArticleId><ArticleId IdType="pubmed">26068894</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S. H., Kim Y. H., Hebisch M., Sliwinski C., Lee S., D'Avanzo C., Chen H., Hooli B., Asselin C., Muffat J., Klee J. B., Zhang C., Wainger B. J., Peitz M., Kovacs D. M., Woolf C. J., Wagner S. L., Tanzi R. E., Kim D. Y., Nature 2014, 515, 274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>Weksler B. B., Subileau E. A., Perri&#xe8;re N., Charneau P., Holloway K., Leveque M., Tricoire&#x2010;Leignel H., Nicotra A., Bourdoulous S., Turowski P., Male D. K., Roux F., Greenwood J., Romero I. A., Couraud P. O., FASEB J. 2005, 19, 1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141364</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman N. A., Rasil A. N. H. M., Meyding&#x2010;Lamade U., Craemer E. M., Diah S., Tuah A. A., Muharram S. H., Brain Res. 2016, 1642, 532.</Citation><ArticleIdList><ArticleId IdType="pubmed">27086967</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J., J. Alzheimer's Dis. 2001, 3, 75.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214075</ArticleId></ArticleIdList></Reference><Reference><Citation>Massaad C. A, Curr. Neuropharmacol. 2011, 9, 662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3263460</ArticleId><ArticleId IdType="pubmed">22654724</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrano A., Hoozemans J. J. M., van der Vies S. M., Rozemuller A. J. M., van Horssen J., de Vries H. E., Antioxid. Redox Signaling 2011, 15, 1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">21294650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Smith M. A., Honda K., Aliev G., Moreira P. I., Nunomura A., Casadesus G., Harris P. L. R., Siedlak S. L., Perry G., J. Neurol. Sci. 2007, 257, 240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1952687</ArticleId><ArticleId IdType="pubmed">17337008</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T., Thomas G., McLendon C., Sutton T., Mullan M., Nature 1996, 380, 168.</Citation><ArticleIdList><ArticleId IdType="pubmed">8600393</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C., Zhang F., Niwa K., Eckman C., Turner S. K., Fischer E., Younkin S., Borchelt D. R., Hsiao K. K., Carlson G. A., Nat. Neurosci. 1999, 2, 157.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195200</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum H., Roebuck K. A., Am. J. Physiol.: Cell Physiol. 2001, 280, C719.</Citation><ArticleIdList><ArticleId IdType="pubmed">11245588</ArticleId></ArticleIdList></Reference><Reference><Citation>Bredt D. S., Snyder S. H., Annu. Rev. Biochem. 1994, 63, 175.</Citation><ArticleIdList><ArticleId IdType="pubmed">7526779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sowers J. R., N. Engl. J. Med. 2002, 346, 1999.</Citation><ArticleIdList><ArticleId IdType="pubmed">12075063</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Cen J., Huang Y., Shen H., Yao L., Wang Y., Chen Z., PLoS One 2011, 6, e20599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157343</ArticleId><ArticleId IdType="pubmed">21857898</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg G. A., Estrada E. Y., Dencoff J. E., Stroke 1998, 29, 2189.</Citation><ArticleIdList><ArticleId IdType="pubmed">9756602</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasaki A., Shimizu F., Sano Y., Fujisawa M., Takahashi T., Haruki H., Abe M., Koga M., Kanda T., J. Neurol., Neurosurg. Psychiatry 2014, 85, 419.</Citation><ArticleIdList><ArticleId IdType="pubmed">24259591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez&#x2010;Guillamon M., Mawhirt S., Fossati S., Blais S., Pares M., Penalba A., Boada M., Couraud P.&#x2010;O., Neubert T. A., Montaner J., Ghiso J., Rostagno A., J. Biol. Chem. 2010, 285, 27144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930713</ArticleId><ArticleId IdType="pubmed">20576603</ArticleId></ArticleIdList></Reference><Reference><Citation>Duits F. H., Hernandez&#x2010;Guillamon M., Montaner J., Goos J. D. C., Monta&#xf1;ola A., Wattjes M. P., Barkhof F., Scheltens P., Teunissen C. E., van der Flier W. M., J. Alzheimer's Dis. 2015, 48, 711.</Citation><ArticleIdList><ArticleId IdType="pubmed">26402072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim N. K.&#x2010;H., Villemagne V. L., Soon C. P. W., Laughton K. M., Rowe C. C., McLean C. A., Masters C. L., Evin G., Li Q.&#x2010;X., J. Alzheimer's Dis. 2011, 26, 779.</Citation><ArticleIdList><ArticleId IdType="pubmed">21694463</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochfort K. D., Cummins P. M., Biochem. Soc. Trans. 2015, 43, 702.</Citation><ArticleIdList><ArticleId IdType="pubmed">26551716</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng J., Wang L., Zhang L.&#x2010;Y., Qin C., Song Y., Ma Y., Chen Y., Chen S., Wang Y., Zhang Z., Yang G.&#x2010;Y., Front. Aging Neurosci. 2018, 10, 129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5949351</ArticleId><ArticleId IdType="pubmed">29867440</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J. A., Codreanu S. G., Shi M., Sherrod S. D., Markov D. A., Neely M. D., Britt C. M., Hoilett O. S., Reiserer R. S., Samson P. C., McCawley L. J., Webb D. J., Bowman A. B., McLean J. A., Wikswo J. P., J. Neuroinflammation 2016, 13, 306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5153753</ArticleId><ArticleId IdType="pubmed">27955696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y.&#x2010;P., Kita M., Shinmura K., Yan X.&#x2010;Q., Fukuyama R., Fushiki S., Imanishi J., J. Interferon Cytokine Res. 2000, 20, 403.</Citation><ArticleIdList><ArticleId IdType="pubmed">10805375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakshit S., Chandrasekar B. S., Saha B., Victor E. S., Majumdar S., Nandi D., Biochim. Biophys. Acta 2014, 1843, 2645.</Citation><ArticleIdList><ArticleId IdType="pubmed">24983769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng C. T., Fong L. Y., Low Y. Y., Ban J., Hakim M. N., Ahmad Z., Physiol. Res. 2016, 65, 1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">27539106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng C. T., Fong L. Y., Sulaiman M. R., Moklas M. A. M., Yong Y. K., Hakim M. N., Ahmad Z., J. Interferon Cytokine Res. 2015, 35, 513.</Citation><ArticleIdList><ArticleId IdType="pubmed">25830506</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrobak I., Lenna S., Stawski L., Trojanowska M., J. Cell. Physiol. 2013, 228, 1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4072032</ArticleId><ArticleId IdType="pubmed">23359533</ArticleId></ArticleIdList></Reference><Reference><Citation>Grammas P., Martinez J. M., J. Alzheimer's Dis. 2014, 42, S537.</Citation><ArticleIdList><ArticleId IdType="pubmed">25079808</ArticleId></ArticleIdList></Reference><Reference><Citation>Qosa H., Mohamed L. A., Al Rihani S. B., Batarseh Y. S., Duong Q.&#x2010;V., Keller J. N., Kaddoumi A., J. Alzheimer's Dis. 2016, 53, 1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4992409</ArticleId><ArticleId IdType="pubmed">27392852</ArticleId></ArticleIdList></Reference><Reference><Citation>Qosa H., LeVine H., Keller J. N., Kaddoumi A., Biochim. Biophys. Acta 2014, 1842, 1806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4133170</ArticleId><ArticleId IdType="pubmed">24997450</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Shang D.&#x2010;S., Zhao W.&#x2010;D., Tian L., Li B., Fang W.&#x2010;G., Zhu L., Man S.&#x2010;M., Chen Y.&#x2010;H., J. Immunol. 2009, 182, 5778.</Citation><ArticleIdList><ArticleId IdType="pubmed">19380826</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai L. M., Holloway K. A., Male D. K., Loughlin A. J., Romero I. A., J. Cell. Mol. Med. 2010, 14, 1101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3822747</ArticleId><ArticleId IdType="pubmed">19438816</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M. D., Sagare A. P., Zlokovic B. V, Nat. Rev. Neurol. 2018, 14, 133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A., Barnes S. R., Sweeney M. D., Halliday M. R., Sagare A. P., Zhao Z., Toga A. W., Jacobs R. E., Liu C. Y., Amezcua L., Harrington M. G., Chui H. C., Law M., Zlokovic B. V., Neuron 2015, 85, 296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4350773</ArticleId><ArticleId IdType="pubmed">25611508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell R. D., Winkler E. A., Sagare A. P., Singh I., LaRue B., Deane R., Zlokovic B. V, Neuron 2010, 68, 409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056408</ArticleId><ArticleId IdType="pubmed">21040844</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A., Nikolakopoulou A. M., Zhao Z., Sagare A. P., Si G., Lazic D., Barnes S. R., Daianu M., Ramanathan A., Go A., Lawson E. J., Wang Y., Mack W. J., Thompson P. M., Schneider J. A., Varkey J., Langen R., Mullins E., Jacobs R. E., Zlokovic B. V., Nat. Med. 2018, 24, 326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5840035</ArticleId><ArticleId IdType="pubmed">29400711</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez&#x2010;Arellano J. J., Parpura V., Zorec R., Verkhratsky A., Neuroscience 2016, 323, 170.</Citation><ArticleIdList><ArticleId IdType="pubmed">25595973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. I., Abaci H. E., Shuler M. L., Biotechnol. Bioeng. 2017, 114, 184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6650146</ArticleId><ArticleId IdType="pubmed">27399645</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantle J. L., Lee K. H., Alzheimer's Dementia 2015, 11, P850.</Citation></Reference><Reference><Citation>Canfield S. G., Stebbins M. J., Morales B. S., Asai S. W., Vatine G. D., Svendsen C. N., Palecek S. P., Shusta E. V, J. Neurochem. 2017, 140, 874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5339046</ArticleId><ArticleId IdType="pubmed">27935037</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelt&#x2010;Menzel A., Cubukova A., G&#xfc;nther K., Edenhofer F., Piontek J., Krause G., St&#xfc;ber T., Walles H., Neuhaus W., Metzger M., Stem Cell Rep. 2017, 8, 894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390136</ArticleId><ArticleId IdType="pubmed">28344002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciocan E., Ciocan R., in Conf. Proc. IEEE Eng. Med. Biol. Soc., IEEE, 2009, pp. 4925&#x2013;4928.</Citation><ArticleIdList><ArticleId IdType="pubmed">19963869</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters J., PLoS One 2010, 5, e15709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012091</ArticleId><ArticleId IdType="pubmed">21209950</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanujan S., Pluen A., McKee T. D., Brown E. B., Boucher Y., Jain R. K., Biophys. J. 2002, 83, 1650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1302261</ArticleId><ArticleId IdType="pubmed">12202388</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31597708</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>20</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI.</ArticleTitle><Pagination><StartPage>e1881</StartPage><EndPage>e1889</EndPage><MedlinePgn>e1881-e1889</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000008467</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To examine whether the use of sex-specific norms and cut scores to identify memory impairment improves diagnostic accuracy of amnestic mild cognitive impairment (aMCI) compared to non-sex-specific (typical) norms/cut scores given the female advantage in verbal memory.</AbstractText><AbstractText Label="METHODS">We calculated sex-specific and typical norms/cut scores (age and education specific) for impairment on the Rey Auditory Verbal Learning Test in the Mayo Clinic Study of Aging. Norms/cut scores were applied to 453 women and 532 men from the Alzheimer's Disease Neuroimaging Initiative. We compared sex differences in rates of aMCI (Jak/Bondi criteria) for sex-specific vs typical norms/cut scores. Using sex-specific cut scores as the true condition and typical cut scores as the predicted condition, we categorized participants as true positives (TPs), false positives (FPs), true negative (TNs), or false negative (FNs). In cross-sectional analyses within sex, we compared positivity rates of CSF hyperphosphorylated tau/&#x3b2;-amyloid (A&#x3b2;) and cortical A&#x3b2; deposition ([<sup>18</sup>F]AV45 PET) and <i>APOE</i> &#x3b5;4 frequency among diagnostic comparison groups.</AbstractText><AbstractText Label="RESULTS">The frequency of aMCI was higher in men when using typical norms/cut scores. Using sex-adjusted norms/cut scores led to the identification of 10% FNs (missed aMCI cases) among women and 10% FPs among men. Biomarker analyses supported the hypothesis that sex-specific diagnostic criteria improves diagnostic accuracy. Biomarkers rates were higher in FNs vs TNs and similar in FNs and TPs. Biomarker rates were lower in FPs vs TPs and similar between FPs and TNs.</AbstractText><AbstractText Label="CONCLUSION">Results suggest that non-sex-specific aMCI diagnostic criteria led to a 20% diagnostic error rate. Accounting for sex differences in verbal memory performance may improve aMCI classification.</AbstractText><CopyrightInformation>&#xa9; 2019 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sundermann</LastName><ForeName>Erin E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry (E.E.S., M.W.B.), University of California, San Diego; Departments of Psychiatry, Psychology, and Obstetrics &amp; Gynecology (P.M.), University of Illinois at Chicago; Department of Radiology and Neurology (A.B.), State University of New York, Stony Brook; Einstein Aging Study and Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Departments of Health Sciences Research and Neurology (M.M.M.) and Departments of Psychiatry and Psychology (M.M.), Mayo Clinic, Rochester, MN; and Veterans Affairs San Diego Healthcare System (M.W.B.), CA. esundermann@einstein.yu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maki</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry (E.E.S., M.W.B.), University of California, San Diego; Departments of Psychiatry, Psychology, and Obstetrics &amp; Gynecology (P.M.), University of Illinois at Chicago; Department of Radiology and Neurology (A.B.), State University of New York, Stony Brook; Einstein Aging Study and Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Departments of Health Sciences Research and Neurology (M.M.M.) and Departments of Psychiatry and Psychology (M.M.), Mayo Clinic, Rochester, MN; and Veterans Affairs San Diego Healthcare System (M.W.B.), CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biegon</LastName><ForeName>Anat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry (E.E.S., M.W.B.), University of California, San Diego; Departments of Psychiatry, Psychology, and Obstetrics &amp; Gynecology (P.M.), University of Illinois at Chicago; Department of Radiology and Neurology (A.B.), State University of New York, Stony Brook; Einstein Aging Study and Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Departments of Health Sciences Research and Neurology (M.M.M.) and Departments of Psychiatry and Psychology (M.M.), Mayo Clinic, Rochester, MN; and Veterans Affairs San Diego Healthcare System (M.W.B.), CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry (E.E.S., M.W.B.), University of California, San Diego; Departments of Psychiatry, Psychology, and Obstetrics &amp; Gynecology (P.M.), University of Illinois at Chicago; Department of Radiology and Neurology (A.B.), State University of New York, Stony Brook; Einstein Aging Study and Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Departments of Health Sciences Research and Neurology (M.M.M.) and Departments of Psychiatry and Psychology (M.M.), Mayo Clinic, Rochester, MN; and Veterans Affairs San Diego Healthcare System (M.W.B.), CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry (E.E.S., M.W.B.), University of California, San Diego; Departments of Psychiatry, Psychology, and Obstetrics &amp; Gynecology (P.M.), University of Illinois at Chicago; Department of Radiology and Neurology (A.B.), State University of New York, Stony Brook; Einstein Aging Study and Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Departments of Health Sciences Research and Neurology (M.M.M.) and Departments of Psychiatry and Psychology (M.M.), Mayo Clinic, Rochester, MN; and Veterans Affairs San Diego Healthcare System (M.W.B.), CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machulda</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry (E.E.S., M.W.B.), University of California, San Diego; Departments of Psychiatry, Psychology, and Obstetrics &amp; Gynecology (P.M.), University of Illinois at Chicago; Department of Radiology and Neurology (A.B.), State University of New York, Stony Brook; Einstein Aging Study and Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Departments of Health Sciences Research and Neurology (M.M.M.) and Departments of Psychiatry and Psychology (M.M.), Mayo Clinic, Rochester, MN; and Veterans Affairs San Diego Healthcare System (M.W.B.), CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bondi</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry (E.E.S., M.W.B.), University of California, San Diego; Departments of Psychiatry, Psychology, and Obstetrics &amp; Gynecology (P.M.), University of Illinois at Chicago; Department of Radiology and Neurology (A.B.), State University of New York, Stony Brook; Einstein Aging Study and Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Departments of Health Sciences Research and Neurology (M.M.M.) and Departments of Psychiatry and Psychology (M.M.), Mayo Clinic, Rochester, MN; and Veterans Affairs San Diego Healthcare System (M.W.B.), CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG026431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG049810</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 AG044170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007288</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG055151</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026728</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073219" MajorTopicYN="Y">Memory and Learning Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31597708</ArticleId><ArticleId IdType="pmc">PMC6946472</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000008467</ArticleId><ArticleId IdType="pii">WNL.0000000000008467</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bleecker ML, Bolla-Wilson K, Agnew J, Meyers DA. Age-related sex differences in verbal memory. J Clin Psychol 1988;44:403&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">3384968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer JH, Delis DC, Daniel MH. Sex differences in verbal learning. J Clin Psychol 1988;44:907&#x2013;915.</Citation></Reference><Reference><Citation>Barrett-Connor E, Kritz-Silverstein D. Gender differences in cognitive function with age: the Rancho Bernardo study. J Am Geriatr Soc 1999;47:159&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">9988286</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundermann EE, Biegon A, Rubin LH, Lipton RB, Landau S, Maki PM. Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy. Neurology 2016a;86:1368&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4831033</ArticleId><ArticleId IdType="pubmed">26984945</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundermann EE, Maki PM, Rubin LH, Lipton RB, Landau S, Biegon A. The female advantage in verbal memory: evidence for a sex-specific cognitive reserve. Neurology 2016b;87:1916&#x2013;1924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5100712</ArticleId><ArticleId IdType="pubmed">27708128</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundermann EE, Biegon A, Rubin LH, Lipton RB, Landau S, Maki PM. Does the female advantage in verbal memory contribute to underestimating Alzheimer's disease pathology? J Alzheimers Dis 2017;56:947&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7644197</ArticleId><ArticleId IdType="pubmed">28106548</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994;271:1004&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">8139057</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">11939702</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Zarahn E, Hilton HJ, Flynn J, DeLaPaz R, Rakitin B. Exploring the neural basis of cognitive reserve. J Clin Exp Neuropsychol 2003;25:691&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815506</ArticleId></ArticleIdList></Reference><Reference><Citation>Beinhoff U, Tumani H, Brettschneider J, Bittner D, Riepe MW. Gender-specificities in Alzheimer's disease and mild cognitive impairment. J Neurol 2008;255:117&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">18202815</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine K, Laws KR, Gale TM, Kondel TK. Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis. J Clin Exp Neuropsychol 2012;34:989&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">22913619</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. . Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010;74:201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Edmonds EC, Jak AJ, et al. . Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J Alzheimers Dis 2014;42:275&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4133291</ArticleId><ArticleId IdType="pubmed">24844687</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M. Rey Auditory Verbal Learning Test: A Handbook. Los Angeles: Western Psychological Services; 1996.</Citation></Reference><Reference><Citation>Gale SD, Baxter L, Connor DJ, Herring A, Comer J. Sex differences on the Rey Auditory Verbal Learning Test and the Brief Visuospatial Memory Test-Revised in the elderly: normative data in 172 participants. J Clin Exp Neuropsychol 2007;29:561&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">17564921</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, et al. . Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983;17:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. . Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AD, Pontecorvo MJ, Clark CM, et al. . Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012;53:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">22331215</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Jak AJ, Preis SR, Beiser AS, et al. . Neuropsychological criteria for mild cognitive impairment and dementia risk in the Framingham Heart Study. J Int Neuropsychol Soc 2016;22:937&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5045758</ArticleId><ArticleId IdType="pubmed">27029348</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirk SD, Mitchell MB, Shaughnessy LW, et al. . A webbased normative calculator for the Uniform Data Set (UDS) neuropsychological test battery. Alzheimers Res Ther 2011;3:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308021</ArticleId><ArticleId IdType="pubmed">22078663</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Salmon D, Mercaldo N, et al. . The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord 2009;23:91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743984</ArticleId><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell JZK, Berg JL, Cummings JL, Banks SJ; Alzheimer's Disease Neuroimaging Initiative. Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume. Alzheimers Res Ther 2017;9:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5596932</ArticleId><ArticleId IdType="pubmed">28899422</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KA, Choudhury KR, Rathakrishnan BG, et al. . Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimer's Dement 2015;1:103&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593067</ArticleId><ArticleId IdType="pubmed">26451386</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu SC, Pa J, Kukull W, et al. . Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol 2017;74:1178&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759346</ArticleId><ArticleId IdType="pubmed">28846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Combarros O, Leno C, Oterino A, et al. . Gender effect on apolipoprotein E epsilon4 allele-associated risk for sporadic Alzheimer's disease. Acta Neurol Scand 1998;97:68&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9482681</ArticleId></ArticleIdList></Reference><Reference><Citation>Beydoun MA, Boueiz A, Abougergi MS, et al. . Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline. Neurobiol Aging 2012;33:720&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2974952</ArticleId><ArticleId IdType="pubmed">20619505</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. . The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology 2012;78:342&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280046</ArticleId><ArticleId IdType="pubmed">22282647</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodaty H, Heffernan M, Kochan NA, et al. . Mild cognitive impairment in a community sample: the Sydney Memory and Ageing Study. Alzheimers Dement 2013;9:310&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">23110866</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C, Kuo L, Derby CA, Lipton RB, Hall CB. Multi-stage transitional models with random effects and their application to the Einstein Aging Study. Biom J 2011;53:938&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809140</ArticleId><ArticleId IdType="pubmed">22020750</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreano JM, Cahill L. Sex influences on the neurobiology of learning and memory. Learn Mem 2009;16:248&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">19318467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherwin BB, Tulandi T. &#x201c;Add-back&#x201d; estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 1996;81:2545&#x2013;2549.</Citation><ArticleIdList><ArticleId IdType="pubmed">8675575</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosgrove KP, Mazure CM, Staley JK. Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol Psychiatry 2007;62:847&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2711771</ArticleId><ArticleId IdType="pubmed">17544382</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters M. Sex differences in human brain size and the general meaning of differences in brain size. Can J Psychol 1991;45:507&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">1777850</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur RC, Turetsky BI, Matsui M, et al. . Sex differences in brain gray and white matter in healthy young adults: correlations with cognitive performance. J Neurosci 1999;19:4065&#x2013;4072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782697</ArticleId><ArticleId IdType="pubmed">10234034</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipek PA, Richelme C, Kennedy DN, Caviness VS Jr. The young adult human brain: an MRI-based morphometric analysis. Cereb Cortex 1994;4:344&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">7950308</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo CA, Lancaster JL, Xiong J, Cook C, Fox P. MR imaging volumetry of subcortical structures and cerebellar hemispheres in normal persons. Am J Neuroradiol 2003;24:644&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8148703</ArticleId><ArticleId IdType="pubmed">12695196</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura D. Sex differences in cerebral organization for speech and praxic functions. Can J Psychol 1983;37:19&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">6196100</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallentin M. Putative sex differences in verbal abilities and language cortex: a critical review. Brain Lang 2009;108:175&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">18722007</ArticleId></ArticleIdList></Reference><Reference><Citation>Berenbaum SA, Baxter L, Seidenberg M, Hermann B. Role of the hippocampus in sex differences in verbal memory: memory outcome following left anterior temporal lobectomy. Neuropsychology 1997;11:585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">9345702</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss EM, Ragland JD, Brensinger CM, Bilker WB, Deisenhammer EA, Delazer M. Sex differences in clustering and switching in verbal fluency tasks. J Int Neuropsychol Soc 2006;12:502&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">16981602</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005;62:1160&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009779</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, et al. . Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31601677</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>216</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model.</ArticleTitle><Pagination><StartPage>2546</StartPage><EndPage>2561</EndPage><MedlinePgn>2546-2561</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20190980</ELocationID><Abstract><AbstractText>Chronic activation of brain innate immunity is a prominent feature of Alzheimer's disease (AD) and primary tauopathies. However, to what degree innate immunity contributes to neurodegeneration as compared with pathological protein-induced neurotoxicity, and the requirement of a particular glial cell type in neurodegeneration, are still unclear. Here we demonstrate that microglia-mediated damage, rather than pathological tau-induced direct neurotoxicity, is the leading force driving neurodegeneration in a tauopathy mouse model. Importantly, the progression of ptau pathology is also driven by microglia. In addition, we found that <i>APOE</i>, the strongest genetic risk factor for AD, regulates neurodegeneration predominantly by modulating microglial activation, although a minor role of apoE in regulating ptau and insoluble tau formation independent of its immunomodulatory function was also identified. Our results suggest that therapeutic strategies targeting microglia may represent an effective approach to prevent disease progression in the setting of tauopathy.</AbstractText><CopyrightInformation>&#xa9; 2019 Shi et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manis</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7912-2016</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Justin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0769-604X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kairuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0001-8402-2634</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Duke University School of Medicine, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remolina Serrano</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5937-0212</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoyle</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-3400-0856</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO holtzman@neuro.wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>SWISSPROT</DataBankName><AccessionNumberList><AccessionNumber>P36931</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000631">Aminopyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>6783M2LV5X</RegistryNumber><NameOfSubstance UI="C000600259">pexidartinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Exp Med. 2019 Nov 4;216(11):2451-2452. doi: 10.1084/jem.20191536.</RefSource><PMID Version="1">31645368</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000631" MajorTopicYN="N">Aminopyridines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="N">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31601677</ArticleId><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="doi">10.1084/jem.20190980</ArticleId><ArticleId IdType="pii">jem.20190980</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arriagada, P.V., Growdon J.H., Hedley-Whyte E.T., and Hyman B.T.. 1992. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology. 42:631&#x2013;639. 10.1212/WNL.42.3.631</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.42.3.631</ArticleId><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, R.E., Bryant A., Hu M., Robbins A.B., Hopp S.C., and Hyman B.T.. 2018. Partial reduction of microglia does not affect tau pathology in aged mice. J. Neuroinflammation. 15:311. 10.1186/s12974-018-1348-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1348-5</ArticleId><ArticleId IdType="pmc">PMC6230271</ArticleId><ArticleId IdType="pubmed">30413160</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu, V., Nacu V., Charles J.F., Henne W.M., McMahon H.T., Nandi S., Ketchum H., Harris R., Nakamura M.C., and Stanley E.R.. 2012. PSTPIP2 deficiency in mice causes osteopenia and increased differentiation of multipotent myeloid precursors into osteoclasts. Blood. 120:3126&#x2013;3135. 10.1182/blood-2012-04-425595</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-04-425595</ArticleId><ArticleId IdType="pmc">PMC3471520</ArticleId><ArticleId IdType="pubmed">22923495</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu, V., Gokhan &#x15e;., Nandi S., Mehler M.F., and Stanley E.R.. 2016. Emerging roles for CSF-1 receptor and its ligands in the nervous system. Trends Neurosci. 39:378&#x2013;393. 10.1016/j.tins.2016.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2016.03.005</ArticleId><ArticleId IdType="pmc">PMC4884457</ArticleId><ArticleId IdType="pubmed">27083478</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon, A., Spires-Jones T.L., Pitstick R., Carlson G.A., and Hyman B.T.. 2009. Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol. 68:757&#x2013;761. 10.1097/NEN.0b013e3181a9fc66</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181a9fc66</ArticleId><ArticleId IdType="pmc">PMC2756569</ArticleId><ArticleId IdType="pubmed">19535996</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon, A., Fox L.M., Pitstick R., Carlson G.A., Bacskai B.J., Spires-Jones T.L., and Hyman B.T.. 2010. Caspase activation precedes and leads to tangles. Nature. 464:1201&#x2013;1204. 10.1038/nature08890</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08890</ArticleId><ArticleId IdType="pmc">PMC3091360</ArticleId><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore, M.R., Najafi A.R., Koike M.A., Dagher N.N., Spangenberg E.E., Rice R.A., Kitazawa M., Matusow B., Nguyen H., West B.L., and Green K.N.. 2014. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 82:380&#x2013;397. 10.1016/j.neuron.2014.02.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.02.040</ArticleId><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Erny, D., Hrab&#x11b; de Angelis A.L., Jaitin D., Wieghofer P., Staszewski O., David E., Keren-Shaul H., Mahlakoiv T., Jakobshagen K., Buch T., et al. . 2015. Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18:965&#x2013;977. 10.1038/nn.4030</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4030</ArticleId><ArticleId IdType="pmc">PMC5528863</ArticleId><ArticleId IdType="pubmed">26030851</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale, S.C., Gao L., Mikacenic C., Coyle S.M., Rafaels N., Murray Dudenkov T., Madenspacher J.H., Draper D.W., Ge W., Aloor J.J., et al. . 2014. APO&#x3b5;4 is associated with enhanced in vivo innate immune responses in human subjects. J. Allergy Clin. Immunol. 134:127&#x2013;134. 10.1016/j.jaci.2014.01.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2014.01.032</ArticleId><ArticleId IdType="pmc">PMC4125509</ArticleId><ArticleId IdType="pubmed">24655576</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesdorffer, C.S., and Longo D.L.. 2015. Drug-induced megaloblastic anemia. N. Engl. J. Med. 373:1649&#x2013;1658. 10.1056/NEJMra1508861</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1508861</ArticleId><ArticleId IdType="pubmed">26488695</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K.A., Whitwell J.L., Ahmed Z., Shiung M.M., Weigand S.D., Knopman D.S., Boeve B.F., Parisi J.E., Petersen R.C., Dickson D.W., and Jack C.R. Jr. 2008. &#x3b2;-amyloid burden is not associated with rates of brain atrophy. Ann. Neurol. 63:204&#x2013;212. 10.1002/ana.21223</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21223</ArticleId><ArticleId IdType="pmc">PMC2735194</ArticleId><ArticleId IdType="pubmed">17894374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazawa, M., Oddo S., Yamasaki T.R., Green K.N., and LaFerla F.M.. 2005. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer&#x2019;s disease. J. Neurosci. 25:8843&#x2013;8853. 10.1523/JNEUROSCI.2868-05.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2868-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725603</ArticleId><ArticleId IdType="pubmed">16192374</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann, S., Madore C., Cialic R., Baufeld C., Calcagno N., El Fatimy R., Beckers L., O&#x2019;Loughlin E., Xu Y., Fanek Z., et al. . 2017. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 47:566&#x2013;581.e9. 10.1016/j.immuni.2017.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla, K.V., Wegmann S., Kopeikina K.J., Hawkes J., Rudinskiy N., Andermann M.L., Spires-Jones T.L., Bacskai B.J., and Hyman B.T.. 2014. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc. Natl. Acad. Sci. USA. 111:510&#x2013;514. 10.1073/pnas.1318807111</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318807111</ArticleId><ArticleId IdType="pmc">PMC3890777</ArticleId><ArticleId IdType="pubmed">24368848</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns, C.E.G., Ulrich J.D., Finn M.B., Stewart F.R., Koscal L.J., Remolina Serrano J., Robinson G.O., Anderson E., Colonna M., and Holtzman D.M.. 2017. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl. Acad. Sci. USA. 114:11524&#x2013;11529. 10.1073/pnas.1710311114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1710311114</ArticleId><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y., Liu L., Barger S.W., and Griffin W.S.. 2003. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23:1605&#x2013;1611. 10.1523/JNEUROSCI.23-05-01605.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-05-01605.2003</ArticleId><ArticleId IdType="pmc">PMC3833596</ArticleId><ArticleId IdType="pubmed">12629164</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, J., Elwood F., Britschgi M., Villeda S., Zhang H., Ding Z., Zhu L., Alabsi H., Getachew R., Narasimhan R., et al. . 2013. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J. Exp. Med. 210:157&#x2013;172. 10.1084/jem.20120412</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20120412</ArticleId><ArticleId IdType="pmc">PMC3549715</ArticleId><ArticleId IdType="pubmed">23296467</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandi, S., Gokhan S., Dai X.M., Wei S., Enikolopov G., Lin H., Mehler M.F., and Stanley E.R.. 2012. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev. Biol. 367:100&#x2013;113. 10.1016/j.ydbio.2012.03.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2012.03.026</ArticleId><ArticleId IdType="pmc">PMC3388946</ArticleId><ArticleId IdType="pubmed">22542597</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimenova, A.A., Raj T., and Goate A.M.. 2018. Untangling genetic risk for Alzheimer&#x2019;s disease. Biol. Psychiatry. 83:300&#x2013;310. 10.1016/j.biopsych.2017.05.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2017.05.014</ArticleId><ArticleId IdType="pmc">PMC5699970</ArticleId><ArticleId IdType="pubmed">28666525</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, Y., and Holtzman D.M.. 2018. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 18:759&#x2013;772. 10.1038/s41577-018-0051-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0051-1</ArticleId><ArticleId IdType="pmc">PMC6425488</ArticleId><ArticleId IdType="pubmed">30140051</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, Y., Yamada K., Liddelow S.A., Smith S.T., Zhao L., Luo W., Tsai R.M., Spina S., Grinberg L.T., Rojas J.C., et al. . Alzheimer&#x2019;s Disease Neuroimaging Initiative . 2017. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 549:523&#x2013;527. 10.1038/nature24016</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluijter, M., van der Sluis T.C., van der Velden P.A., Versluis M., West B.L., van der Burg S.H., and van Hall T.. 2014. Inhibition of CSF-1R supports T-cell mediated melanoma therapy. PLoS One. 9:e104230. 10.1371/journal.pone.0104230</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0104230</ArticleId><ArticleId IdType="pmc">PMC4128661</ArticleId><ArticleId IdType="pubmed">25110953</ArticleId></ArticleIdList></Reference><Reference><Citation>Thion, M.S., Low D., Silvin A., Chen J., Grisel P., Schulte-Schrepping J., Blecher R., Ulas T., Squarzoni P., Hoeffel G., et al. . 2018. Microbiome influences prenatal and adult microglia in a sex-specific manner. Cell. 172:500&#x2013;516.e16. 10.1016/j.cell.2017.11.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.11.042</ArticleId><ArticleId IdType="pmc">PMC5786503</ArticleId><ArticleId IdType="pubmed">29275859</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitek, M.P., Brown C.M., and Colton C.A.. 2009. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging. 30:1350&#x2013;1360. 10.1016/j.neurobiolaging.2007.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.11.014</ArticleId><ArticleId IdType="pmc">PMC2782461</ArticleId><ArticleId IdType="pubmed">18155324</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y., Berezovska O., and Fedoroff S.. 1999. Expression of colony stimulating factor-1 receptor (CSF-1R) by CNS neurons in mice. J. Neurosci. Res. 57:616&#x2013;632. 10.1002/(SICI)1097-4547(19990901)57:5&lt;616::AID-JNR4&gt;3.0.CO;2-E</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19990901)57:5&lt;616::AID-JNR4&gt;3.0.CO;2-E</ArticleId><ArticleId IdType="pubmed">10462686</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, Y., Nwabuisi-Heath E., Dumanis S.B., Tai L.M., Yu C., Rebeck G.W., and LaDu M.J.. 2012. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia. 60:559&#x2013;569. 10.1002/glia.22289</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22289</ArticleId><ArticleId IdType="pmc">PMC3276698</ArticleId><ArticleId IdType="pubmed">22228589</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31628033</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4186</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>Structure (London, England : 1993)</Title><ISOAbbreviation>Structure</ISOAbbreviation></Journal><ArticleTitle>Insight into the Structure of the "Unstructured" Tau Protein.</ArticleTitle><Pagination><StartPage>1710</StartPage><EndPage>1715.e4</EndPage><MedlinePgn>1710-1715.e4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.str.2019.09.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-2126(19)30309-0</ELocationID><Abstract><AbstractText>Combining structural proteomics experimental data with computational methods is a powerful tool for protein structure prediction. Here, we apply a recently developed approach for de novo protein structure determination based on the incorporation of short-distance crosslinking data as constraints in discrete molecular dynamics simulations (CL-DMD), for the determination of the conformational ensemble of tau protein in solution. The predicted structures were in&#xa0;agreement with surface modification and long-distance crosslinking data. Tau in solution was found as an ensemble of rather compact globular conformations with distinct topology, inter-residue contacts, and a number of transient secondary-structure elements. Regions important for pathological aggregation consistently were found to contain &#x3b2; strands. The determined structures are compatible with the tau protein in solution being a molten globule at near-ground state with persistent residual structural features which we were able to capture by CL-DMD. The predicted structure may facilitate an understanding of the misfolding and oligomerization pathways of the tau protein.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Popov</LastName><ForeName>Konstantin I</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makepeace</LastName><ForeName>Karl A T</ForeName><Initials>KAT</Initials><AffiliationInfo><Affiliation>University of Victoria-Genome British Columbia Proteomics Centre, 3101-4464 Markham Street, Vancouver Island Technology Park, Victoria, BC V8Z7X8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrotchenko</LastName><ForeName>Evgeniy V</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, H3T 1E2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dokholyan</LastName><ForeName>Nikolay V</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Department of Biochemistry &amp; Molecular Biology, Penn State College of Medicine, Hershey, PA 17033, USA. Electronic address: dokh@psu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borchers</LastName><ForeName>Christoph H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>University of Victoria-Genome British Columbia Proteomics Centre, 3101-4464 Markham Street, Vancouver Island Technology Park, Victoria, BC V8Z7X8, Canada; Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, H3T 1E2, Canada; Department of Biochemistry and Microbiology, University of Victoria, Petch Building, Room 270d, 3800 Finnerty Road, Victoria, BC V8P 5C2, Canada; Gerald Bronfman Department of Oncology, Jewish General Hospital, McGill University, Montreal, QC, H3T 1E2, Canada. Electronic address: christoph.borchers@mcgill.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM080742</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM114015</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM123247</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Structure</MedlineTA><NlmUniqueID>101087697</NlmUniqueID><ISSNLinking>0969-2126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">crosslinking</Keyword><Keyword MajorTopicYN="N">discrete molecular dynamics</Keyword><Keyword MajorTopicYN="N">intrinsically disordered proteins</Keyword><Keyword MajorTopicYN="N">protein structure determination</Keyword><Keyword MajorTopicYN="N">structural proteomics</Keyword><Keyword MajorTopicYN="N">tau protein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31628033</ArticleId><ArticleId IdType="doi">10.1016/j.str.2019.09.003</ArticleId><ArticleId IdType="pii">S0969-2126(19)30309-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31617877</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association Between High School Personality Phenotype and Dementia 54 Years Later in Results From a National US Sample.</ArticleTitle><Pagination><StartPage>148</StartPage><EndPage>154</EndPage><MedlinePgn>148-154</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2019.3120</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Personality phenotype has been associated with subsequent dementia in studies of older adults. However, neuropathologic changes often precede cognitive symptoms by many years and may affect personality itself. Therefore, it is unclear whether supposed dementia-prone personality profiles (high neuroticism and low conscientiousness) are true risk factors or merely reflections of preexisting disease.</AbstractText><AbstractText Label="OBJECTIVES">To examine whether personality during adolescence-a time when preclinical dementia pathology is unlikely to be present-confers risk of dementia in later life and to test whether associations could be accounted for by health factors in adolescence or differed across socioeconomic status (SES).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Cohort study in the United States. Participants were members of Project Talent, a national sample of high school students in 1960. Individuals were identified who received a dementia-associated International Classification of Diseases, Ninth Revision (ICD-9) diagnosis code during any year between 2011 and 2013. The dates of our analysis were March 2018 to May 2019.</AbstractText><AbstractText Label="EXPOSURES">Ten personality traits were measured by the 150-item Project Talent Personality Inventory. Socioeconomic status was measured by a composite based on parental educational level, income, occupation, and property ownership. Participants were also surveyed on demographic factors and height and weight.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Medicare records were collected, with dementia diagnoses in the period of 2011 to 2013 classified according to the US Centers for Medicare &amp; Medicaid Services ICD-9-based algorithm. Cox proportional hazards regression models estimated the relative risk of dementia based on the 10 personality traits, testing interactions with SES and adjusting for demographic confounders.</AbstractText><AbstractText Label="RESULTS">The sample of 82&#x202f;232 participants was 50.1% female, with a mean (SD) age of 15.8 (1.7) years at baseline and 69.5 (1.2) years at follow-up. Lower risk of dementia was associated with higher levels of vigor (hazard ratio for 1 SD, 0.93; 95% CI, 0.90-0.97; P&#x2009;&lt;&#x2009;.001). Calm and maturity showed protective associations with later dementia that increased with SES. At 1 SD of SES, calm showed a hazard ratio of 0.89 (95% CI, 0.84-0.95; P&#x2009;&lt;&#x2009;.001 for the interaction) and maturity showed a hazard ratio of 0.90 (95% CI, 0.85-0.96; P&#x2009;=&#x2009;.001 for the interaction).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study's findings suggest that the adolescent personality traits associated with later-life dementia are similar to those observed in studies of older persons. Moreover, the reduction in dementia risk associated with a calm and mature adolescent phenotype may be greater at higher levels of SES. Personality phenotype may be a true independent risk factor for dementia by age 70 years, preceding it by almost 5 decades and interacting with adolescent socioeconomic conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Benjamin P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Rochester Medical Center, Rochester, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>American Institutes for Research, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>American Institutes for Research, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horner</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>American Institutes for Research, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manly</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapham</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>American Institutes for Research, Washington, DC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="Y">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013334" MajorTopicYN="N">Students</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Chapman and Ms Lapham reported receiving grants from the National Institute on Aging (NIA). No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31617877</ArticleId><ArticleId IdType="pmc">PMC6802373</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2019.3120</ArticleId><ArticleId IdType="pii">2752387</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Low LF, Harrison F, Lackersteen SM. Does personality affect risk for dementia? a systematic review and meta-analysis. Am J Geriatr Psychiatry. 2013;21(8):713-728. doi:10.1016/j.jagp.2012.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2012.08.004</ArticleId><ArticleId IdType="pubmed">23567438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogg T, Roberts BW. Conscientiousness and health-related behaviors: a meta-analysis of the leading behavioral contributors to mortality. Psychol Bull. 2004;130(6):887-919. doi:10.1037/0033-2909.130.6.887</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0033-2909.130.6.887</ArticleId><ArticleId IdType="pubmed">15535742</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchow EI, Suchy Y, Thorgusen SR, Williams P. More than education: openness to experience contributes to cognitive reserve in older adulthood. J Aging Sci. 2013;1:2. doi:10.4172/2329-8847.1000109</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2329-8847.1000109</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Bennett DA, et al. . Proneness to psychological distress and risk of Alzheimer disease in a biracial community. Neurology. 2005;64(2):380-382. doi:10.1212/01.WNL.0000149525.53525.E7</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000149525.53525.E7</ArticleId><ArticleId IdType="pubmed">15668449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Bennett DA, Mendes de Leon CF, Bienias JL, Morris MC, Evans DA. Distress proneness and cognitive decline in a population of older persons. Psychoneuroendocrinology. 2005;30(1):11-17. doi:10.1016/j.psyneuen.2004.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2004.04.005</ArticleId><ArticleId IdType="pubmed">15358438</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen BS. Allostasis and the epigenetics of brain and body health over the life course: the brain on stress. JAMA Psychiatry. 2017;74(6):551-552. doi:10.1001/jamapsychiatry.2017.0270</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2017.0270</ArticleId><ArticleId IdType="pubmed">28445556</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, Borenstein AR, Gosche KM, Snowdon DA. Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol. 2005;18(4):218-223. doi:10.1177/0891988705281869</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988705281869</ArticleId><ArticleId IdType="pmc">PMC1405917</ArticleId><ArticleId IdType="pubmed">16306243</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoneda T, Rush J, Berg AI, Johansson B, Piccinin AM. Trajectories of personality traits preceding dementia diagnosis. J Gerontol B Psychol Sci Soc Sci. 2017;72(6):922-931. doi:10.1093/geronb/gbw006</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronb/gbw006</ArticleId><ArticleId IdType="pmc">PMC5927080</ArticleId><ArticleId IdType="pubmed">26945005</ArticleId></ArticleIdList></Reference><Reference><Citation>Tautvydait&#x117; D, Antonietti JP, Henry H, von Gunten A, Popp J. Relations between personality changes and cerebrospinal fluid biomarkers of Alzheimer&#x2019;s disease pathology. J Psychiatr Res. 2017;90:12-20. doi:10.1016/j.jpsychires.2016.12.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2016.12.024</ArticleId><ArticleId IdType="pubmed">28213293</ArticleId></ArticleIdList></Reference><Reference><Citation>Robins Wahlin TB, Byrne GJ. Personality changes in Alzheimer&#x2019;s disease: a systematic review. Int J Geriatr Psychiatry. 2011;26(10):1019-1029. doi:10.1002/gps.2655</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.2655</ArticleId><ArticleId IdType="pubmed">21905097</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsis S, Carpenter BD, Storandt M. Personality change precedes clinical diagnosis of dementia of the Alzheimer type. J Gerontol B Psychol Sci Soc Sci. 2005;60(2):P98-P101. doi:10.1093/geronb/60.2.P98</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronb/60.2.P98</ArticleId><ArticleId IdType="pubmed">15746024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocnet C, Rossier J, Antonietti JP, von Gunten A. Personality features and cognitive level in patients at an early stage of Alzheimer&#x2019;s disease. Pers Individ Dif. 2013;54(2):174-179. doi:10.1016/j.paid.2012.08.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.paid.2012.08.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson J, Balota DA, Head D. Exploring the relationship between personality and regional brain volume in healthy aging. Neurobiol Aging. 2011;32(12):2162-2171. doi:10.1016/j.neurobiolaging.2009.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.12.009</ArticleId><ArticleId IdType="pmc">PMC2891197</ArticleId><ArticleId IdType="pubmed">20036035</ArticleId></ArticleIdList></Reference><Reference><Citation>Terracciano A, An Y, Sutin AR, Thambisetty M, Resnick SM. Personality change in the preclinical phase of Alzheimer disease. JAMA Psychiatry. 2017;74(12):1259-1265. doi:10.1001/jamapsychiatry.2017.2816</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2017.2816</ArticleId><ArticleId IdType="pmc">PMC5710607</ArticleId><ArticleId IdType="pubmed">28975188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Rosa-Neto P, Hsiung GYR, et al. . Early-onset familial Alzheimer&#x2019;s disease (EOFAD). Can J Neurol Sci. 2012;39(4):436-445. doi:10.1017/S0317167100013949</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0317167100013949</ArticleId><ArticleId IdType="pubmed">22728850</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, et al. . Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer&#x2019;s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11(12):1048-1056. doi:10.1016/S1474-4422(12)70228-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70228-4</ArticleId><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The pathological process underlying Alzheimer&#x2019;s disease in individuals under thirty. Acta Neuropathol. 2011;121(2):171-181. doi:10.1007/s00401-010-0789-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0789-4</ArticleId><ArticleId IdType="pubmed">21170538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampson SE. Personality processes: mechanisms by which personality traits &#x201c;get outside the skin.&#x201d; Annu Rev Psychol. 2012;63:315-339. doi:10.1146/annurev-psych-120710-100419</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-psych-120710-100419</ArticleId><ArticleId IdType="pmc">PMC3193854</ArticleId><ArticleId IdType="pubmed">21740225</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts BW, Kuncel N, Shiner RN, Caspi A, Goldberg L. The power of personality: a comparative analysis of the predictive validity of personality traits, SES, and IQ. Perspect Psychol Sci. 2007;4(2):313-346. doi:10.1111/j.1745-6916.2007.00047.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-6916.2007.00047.x</ArticleId><ArticleId IdType="pmc">PMC4499872</ArticleId><ArticleId IdType="pubmed">26151971</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Sommerlad A, Orgeta V, et al. . Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31363-6</ArticleId><ArticleId IdType="pubmed">28735855</ArticleId></ArticleIdList></Reference><Reference><Citation>Downey A, Stroud C, Landis S, Leshner AI, eds; National Academies of Sciences, Engineering, and Medicine; Health and Medicine Divisio n; Board on Health Sciences Policy; Committee on Preventing Dementia and Cognitive Impairment . Preventing Cognitive Decline and Dementia: A Way Forward. Washington, DC: National Academies Press; 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">28650595</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Evans DA, Bienias JL, Mendes de Leon CF, Schneider JA, Bennett DA. Proneness to psychological distress is associated with risk of Alzheimer&#x2019;s disease. Neurology. 2003;61(11):1479-1485. doi:10.1212/01.WNL.0000096167.56734.59</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000096167.56734.59</ArticleId><ArticleId IdType="pubmed">14663028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Arnold SE, Schneider JA, Li Y, Bennett DA. Chronic distress, age-related neuropathology, and late-life dementia. Psychosom Med. 2007;69(1):47-53. doi:10.1097/01.psy.0000250264.25017.21</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.psy.0000250264.25017.21</ArticleId><ArticleId IdType="pubmed">17244848</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Schneider JA, Arnold SE, Bienias JL, Bennett DA. Conscientiousness and the incidence of Alzheimer disease and mild cognitive impairment. Arch Gen Psychiatry. 2007;64(10):1204-1212. doi:10.1001/archpsyc.64.10.1204</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.64.10.1204</ArticleId><ArticleId IdType="pubmed">17909133</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadar D, Lassale C, Davies H, Llewellyn DJ, Batty GD, Steptoe A. Individual and area-based socioeconomic factors associated with dementia incidence in England: evidence from a 12-year follow-up in the English Longitudinal Study of Ageing. JAMA Psychiatry. 2018;75(7):723-732. doi:10.1001/jamapsychiatry.2018.1012</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2018.1012</ArticleId><ArticleId IdType="pmc">PMC6145673</ArticleId><ArticleId IdType="pubmed">29799983</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaycroft MF. The High School Years: Growth in Cognitive Skills. Palo Alto, CA: American Institute for Research; 1967.</Citation></Reference><Reference><Citation>Huang AR, Strombotne K, Achorn DL, Mokyr Horner E, Lapham S Methodology, generalizability, and research applications of the Project Talent&#x2013;Medicare data linkage. Paper presented at: Population Association of America 2018 Annual Meeting; April 26, 2018; Denver, CO.</Citation></Reference><Reference><Citation>Cohen J. Statistical Power Analysis for the Behavioral Sciences. Mahwah, NJ: Lawrence Erlbaum Associates; 1988.</Citation></Reference><Reference><Citation>Pozzebon J, Damian RI, Hill PL, Lin Y, Lapham S, Roberts BW. Establishing the validity and reliability of the Project Talent Personality Inventory. Front Psychol. 2013;4:968. doi:10.3389/fpsyg.2013.00968</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2013.00968</ArticleId><ArticleId IdType="pmc">PMC3871717</ArticleId><ArticleId IdType="pubmed">24399984</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronic Conditions Data Warehouse (CCW)  CCW Medicare administrative data user guide. https://www2.ccwdata.org/web/guest/home/. Published 2017. Accessed March 14, 2019.</Citation></Reference><Reference><Citation>Taylor DH Jr, Fillenbaum GG, Ezell ME. The accuracy of Medicare claims data in identifying Alzheimer&#x2019;s disease. J Clin Epidemiol. 2002;55(9):929-937. doi:10.1016/S0895-4356(02)00452-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(02)00452-3</ArticleId><ArticleId IdType="pubmed">12393082</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise LL, McLaughlin DH, Steel L. 
The Project TALENT Data Bank Handbook. Palo Alto, CA: American Institutes for Research; March 1979. 
https://www.projecttalent.org/wp-content/uploads/2017/02/Data_Bank_Handbook_(1979).pdf. Accessed September 11, 2019.</Citation></Reference><Reference><Citation>Huang AR, Strombotne KL, Horner EM, Lapham SJ. Adolescent cognitive aptitudes and later-in-life Alzheimer disease and related disorders. JAMA Netw Open. 2018;1(5):e181726. doi:10.1001/jamanetworkopen.2018.1726</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2018.1726</ArticleId><ArticleId IdType="pmc">PMC6324501</ArticleId><ArticleId IdType="pubmed">30646141</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57(1):289-300.</Citation></Reference><Reference><Citation>Lash TL, Fox MP, Fink K. Applying Quantitative Bias Analysis to Epidemiologic Data. New York, NY: Springer; 2009. doi:10.1007/978-0-387-87959-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-0-387-87959-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Gradus JL, Horv&#xe1;th-Puh&#xf3; E, Lash TL, et al. . Stress disorders and dementia in the Danish population. Am J Epidemiol. 2019;188(3):493-499. doi:10.1093/aje/kwy269</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwy269</ArticleId><ArticleId IdType="pmc">PMC6395166</ArticleId><ArticleId IdType="pubmed">30576420</ArticleId></ArticleIdList></Reference><Reference><Citation>Telama R. Tracking of physical activity from childhood to adulthood: a review. Obes Facts. 2009;2(3):187-195. doi:10.1159/000222244</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000222244</ArticleId><ArticleId IdType="pmc">PMC6516203</ArticleId><ArticleId IdType="pubmed">20054224</ArticleId></ArticleIdList></Reference><Reference><Citation>Terracciano A, Sutin AR, An Y, et al. . Personality and risk of Alzheimer&#x2019;s disease: new data and meta-analysis. Alzheimers Dement. 2014;10(2):179-186. doi:10.1016/j.jalz.2013.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.03.002</ArticleId><ArticleId IdType="pmc">PMC3783589</ArticleId><ArticleId IdType="pubmed">23706517</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes RE, Courneya KS, Jones LW. The theory of planned behavior and lower-order personality traits: interaction effects in the exercise domain. Pers Individ Dif. 2005;38(2):251-265. doi:10.1016/j.paid.2004.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.paid.2004.04.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovio S, K&#xe5;reholt I, Helkala EL, et al. . Leisure-time physical activity at midlife and the risk of dementia and Alzheimer&#x2019;s disease. Lancet Neurol. 2005;4(11):705-711. doi:10.1016/S1474-4422(05)70198-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70198-8</ArticleId><ArticleId IdType="pubmed">16239176</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Buchman AS, Barnes LL, Bennett DA. Effect of a purpose in life on risk of incident Alzheimer disease and mild cognitive impairment in community-dwelling older persons. Arch Gen Psychiatry. 2010;67(3):304-310. doi:10.1001/archgenpsychiatry.2009.208</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archgenpsychiatry.2009.208</ArticleId><ArticleId IdType="pmc">PMC2897172</ArticleId><ArticleId IdType="pubmed">20194831</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3(6):343-353. doi:10.1016/S1474-4422(04)00767-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(04)00767-7</ArticleId><ArticleId IdType="pubmed">15157849</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Krueger KR, Arnold SE, et al. . Loneliness and risk of Alzheimer disease. Arch Gen Psychiatry. 2007;64(2):234-240. doi:10.1001/archpsyc.64.2.234</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.64.2.234</ArticleId><ArticleId IdType="pubmed">17283291</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Arnold SE, Schneider JA, Kelly JF, Tang Y, Bennett DA. Chronic psychological distress and risk of Alzheimer&#x2019;s disease in old age. Neuroepidemiology. 2006;27(3):143-153. doi:10.1159/000095761</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000095761</ArticleId><ArticleId IdType="pubmed">16974109</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A, Garofalo JP, Yali AM. Socioeconomic status and chronic stress: does stress account for SES effects on health? Ann N Y Acad Sci. 1999;896(1):131-144. doi:10.1111/j.1749-6632.1999.tb08111.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1999.tb08111.x</ArticleId><ArticleId IdType="pubmed">10681894</ArticleId></ArticleIdList></Reference><Reference><Citation>Financial security and mobility. The PEW Charitable Trusts website. http://www.pewstates.org/projects/economic-mobility-project-328061. Published 2012. Accessed December 30, 2012.</Citation></Reference><Reference><Citation>Lynch J, Smith GD. A life course approach to chronic disease epidemiology. Annu Rev Public Health. 2005;26:1-35. doi:10.1146/annurev.publhealth.26.021304.144505</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.publhealth.26.021304.144505</ArticleId><ArticleId IdType="pubmed">15760279</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ TC, Hannah J, Batty GD, Booth CC, Deary IJ, Starr JM. Childhood cognitive ability and incident dementia: the 1932 Scottish Mental Survey cohort into their tenth decade. Epidemiology. 2017;28(3):361-364. doi:10.1097/EDE.0000000000000626</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000626</ArticleId><ArticleId IdType="pmc">PMC5381709</ArticleId><ArticleId IdType="pubmed">28151744</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer&#x2019;s disease in late life: findings from the Nun Study. JAMA. 1996;275(7):528-532. doi:10.1001/jama.1996.03530310034029</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1996.03530310034029</ArticleId><ArticleId IdType="pubmed">8606473</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstr&#xf6;m P, Nordstr&#xf6;m A, Eriksson M, Wahlund LO, Gustafson Y. Risk factors in late adolescence for young-onset dementia in men: a nationwide cohort study. JAMA Intern Med. 2013;173(17):1612-1618. doi:10.1001/jamainternmed.2013.9079</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.9079</ArticleId><ArticleId IdType="pubmed">23939347</ArticleId></ArticleIdList></Reference><Reference><Citation>Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA. Early- versus late-onset Alzheimer&#x2019;s disease: more than age alone. J Alzheimers Dis. 2010;19(4):1401-1408. doi:10.3233/JAD-2010-1337</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-1337</ArticleId><ArticleId IdType="pubmed">20061618</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes J, Dickerson BC, Frost C, Jiskoot LC, Wolk D, van der Flier WM. Alzheimer&#x2019;s disease first symptoms are age dependent: evidence from the NACC dataset. Alzheimers Dement. 2015;11(11):1349-1357. doi:10.1016/j.jalz.2014.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.12.007</ArticleId><ArticleId IdType="pmc">PMC4619185</ArticleId><ArticleId IdType="pubmed">25916562</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman BP, Huang A, Horner E, et al. . High school personality traits and 48-year all-cause mortality risk: results from a national sample of 26&#x2009;845 baby boomers. J Epidemiol Community Health. 2019;73(2):106-110. doi:10.1136/jech-2018-211076</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech-2018-211076</ArticleId><ArticleId IdType="pmc">PMC6352396</ArticleId><ArticleId IdType="pubmed">30459261</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31619788</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>574</Volume><Issue>7778</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Regulation of lifespan by neural excitation and REST.</ArticleTitle><Pagination><StartPage>359</StartPage><EndPage>364</EndPage><MedlinePgn>359-364</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-1647-8</ELocationID><Abstract><AbstractText>The mechanisms that extend lifespan in humans are poorly understood. Here we show that extended longevity in humans is associated with a distinct transcriptome signature in the cerebral cortex that is characterized by downregulation of genes related to neural excitation and synaptic function. In Caenorhabditis elegans, neural excitation increases with age and inhibition of excitation globally, or in glutamatergic or cholinergic neurons, increases longevity. Furthermore, longevity is dynamically regulated by the excitatory-inhibitory balance of neural circuits. The transcription factor REST is upregulated in humans with extended longevity and represses excitation-related genes. Notably, REST-deficient mice exhibit increased cortical activity and neuronal excitability during ageing. Similarly, loss-of-function mutations in the C. elegans REST orthologue genes spr-3 and spr-4 elevate neural excitation and reduce the lifespan of long-lived daf-2 mutants. In wild-type worms, overexpression of spr-4 suppresses excitation and extends lifespan. REST, SPR-3, SPR-4 and reduced excitation activate the longevity-associated transcription factors FOXO1 and DAF-16 in mammals and worms, respectively. These findings reveal a conserved mechanism of ageing that is mediated by neural circuit activity and regulated by REST.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zullo</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Drake</LastName><ForeName>Derek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aron</LastName><ForeName>Liviu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Hern</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhamne</LastName><ForeName>Sameer C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>F. M. Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davidsohn</LastName><ForeName>Noah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Chai-An</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science, The University of Texas McGovern Medical School, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>William H</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotenberg</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>F. M. Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Church</LastName><ForeName>George M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colai&#xe1;covo</LastName><ForeName>Monica P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yankner</LastName><ForeName>Bruce A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA. bruce_yankner@hms.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH113279</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA016672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 MH057881</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY024376</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY011930</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG050830</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM072551</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH084053</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 OD006849</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH066392</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH075916</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY024376</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000222</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY011930</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH097276</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH093725</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 AG044161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG36836</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG46152</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH080405</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026651</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH085542</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029742">Caenorhabditis elegans Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C117552">FOX-1 protein, C elegans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092779">RE1-silencing transcription factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C474656">SPR-3 protein, C elegans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C474657">SPR-4 protein, C elegans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C108831">daf-16 protein, C elegans</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2019 Oct;574(7778):338-340. doi: 10.1038/d41586-019-02958-x.</RefSource><PMID Version="1">31619782</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lab Anim (NY). 2020 Jan;49(1):22. doi: 10.1038/s41684-019-0448-x.</RefSource><PMID Version="1">31819279</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029742" MajorTopicYN="N">Caenorhabditis elegans Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051858" MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="Y">Longevity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057507" MajorTopicYN="N">Mice, 129 Strain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31619788</ArticleId><ArticleId IdType="mid">NIHMS1540363</ArticleId><ArticleId IdType="pmc">PMC6893853</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1647-8</ArticleId><ArticleId IdType="pii">10.1038/s41586-019-1647-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Satoh A, Imai S-i, Guarente L. The brain, sirtuins, and ageing. Nat Rev Neurosci. 2017;18(6):362&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">28515492</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop NA, Lu T, Yankner BA. Neural mechanisms of ageing and cognitive decline. Nature. 2010;464(7288):529&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927852</ArticleId><ArticleId IdType="pubmed">20336135</ArticleId></ArticleIdList></Reference><Reference><Citation>Ailion M, Inoue T, Weaver CI, Holdcraft RW, Thomas JH. Neurosecretory control of aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1999;96(13):7394&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22096</ArticleId><ArticleId IdType="pubmed">10377425</ArticleId></ArticleIdList></Reference><Reference><Citation>Apfeld J, Kenyon C. Regulation of lifespan by sensory perception in Caenorhabditis elegans. Nature. 1999;402(6763):804&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617200</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcedo J, Kenyon C. Regulation of C. elegans longevity by specific gustatory and olfactory neurons. Neuron. 2004;41(1):45&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715134</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop NA, Guarente L. Two neurons mediate diet-restriction-induced longevity in C. elegans. Nature. 2007;447(7144):545&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17538612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolkow CA, Kimura KD, Lee M-S, Ruvkun G. Regulation of C. elegans Life-Span by Insulinlike Signaling in the Nervous System. Science. 2000;290(5489):147&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">11021802</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429(6994):883&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, Gaiteri C, Sullivan SE, White CC, Tasaki S, Xu J, Taga M, Klein HU, Patrick E, Komashko V, McCabe C, Smith R, Bradshaw EM, Root DE, Regev A, Yu L, Chibnik LB, Schneider JA, Young-Pearse TL, Bennett DA, De Jager PL. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat Neurosci. 2018;21(6):811&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, Ruderfer DM, Oh EC, Topol A, Shah HR, Klei LL, Kramer R, Pinto D, Gumus ZH, Cicek AE, Dang KK, Browne A, Lu C, Xie L, Readhead B, Stahl EA, Xiao J, Parvizi M, Hamamsy T, Fullard JF, Wang YC, Mahajan MC, Derry JM, Dudley JT, Hemby SE, Logsdon BA, Talbot K, Raj T, Bennett DA, De Jager PL, Zhu J, Zhang B, Sullivan PF, Chess A, Purcell SM, Shinobu LA, Mangravite LM, Toyoshiba H, Gur RE, Hahn CG, Lewis DA, Haroutunian V, Peters MA, Lipska BK, Buxbaum JD, Schadt EE, Hirai K, Roeder K, Brennand KJ, Katsanis N, Domenici E, Devlin B, Sklar P. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci. 2016;19(11):1442&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5083142</ArticleId><ArticleId IdType="pubmed">27668389</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs JR, van der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, Lai SL, Arepalli S, Dillman A, Rafferty IP, Troncoso J, Johnson R, Zielke HR, Ferrucci L, Longo DL, Cookson MR, Singleton AB. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 2010;6(5):e1000952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869317</ArticleId><ArticleId IdType="pubmed">20485568</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilliard MA, Apicella AJ, Kerr R, Suzuki H, Bazzicalupo P, Schafer WR. In vivo imaging of C. elegans ASH neurons: cellular response and adaptation to chemical repellents. The EMBO Journal. 2005;24(1):63&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544906</ArticleId><ArticleId IdType="pubmed">15577941</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokala N, Liu Q, Gordus A, Bargmann CI. Inducible and titratable silencing of Caenorhabditis elegans neurons in vivo with histamine-gated chloride channels. Proc Natl Acad Sci U S A. 2014;111(7):2770&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932931</ArticleId><ArticleId IdType="pubmed">24550306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton B, Dong Y, Shindo M, Liu W, Odell I, Ruvkun G, Lee SS. A systematic RNAi screen for longevity genes in C. elegans. Genes &amp; Development. 2005;19(13):1544&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1172061</ArticleId><ArticleId IdType="pubmed">15998808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Aron L, Zullo J, Pan Y, Kim H, Chen Y, Yang T-H, Kim H-M, Drake D, Liu XS, Bennett DA, Colaiacovo MP, Yankner BA. REST and stress resistance in ageing and Alzheimer/&#x2019;s disease. Nature. 2014;507(7493):448&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4110979</ArticleId><ArticleId IdType="pubmed">24670762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu XL, Cheng X, Cai L, Tan GH, Xu L, Feng XY, Lu TJ, Xiong H, Fei J, Xiong ZQ. Conditional deletion of NRSF in forebrain neurons accelerates epileptogenesis in the kindling model. Cereb Cortex. 2011;21(9):2158&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">21339379</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan GP, Dey D, Chen Y, Patterson KP, Magnetta EJ, Hall AM, Dube CM, Mei YT, Baram TZ. Dual and Opposing Roles of MicroRNA-124 in Epilepsy Are Mediated through Inflammatory and NRSF-Dependent Gene Networks. Cell Rep. 2016;14(10):2402&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4794429</ArticleId><ArticleId IdType="pubmed">26947066</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert Luke A, Larson Matthew H, Morsut L, Liu Z, Brar Gloria A, Torres Sandra E, Stern-Ginossar N, Brandman O, Whitehead Evan H, Doudna Jennifer A, Lim Wendell A, Weissman Jonathan S, Qi Lei S. CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes. Cell. 2013;154(2):442&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3770145</ArticleId><ArticleId IdType="pubmed">23849981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lithgow GJ, White TM, Melov S, Johnson TE. Thermotolerance and extended life-span conferred by single-gene mutations and induced by thermal stress. Proc Natl Acad Sci U S A. 1995;92(16):7540&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41375</ArticleId><ArticleId IdType="pubmed">7638227</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P, Sun R, Yao M, Chen W, Wang Z, Fei J. A C-terminal truncated mutation of spr-3 gene extends lifespan in Caenorhabditis elegans. Acta Biochim Biophys Sin (Shanghai). 2013;45(7):540&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23692984</ArticleId></ArticleIdList></Reference><Reference><Citation>Calixto A, Chelur D, Topalidou I, Chen X, Chalfie M. Enhanced neuronal RNAi in C. elegans using SID-1. Nat Methods. 2010;7(7):554&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2894993</ArticleId><ArticleId IdType="pubmed">20512143</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K, Dorman JB, Rodan A, Kenyon C. daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science. 1997;278(5341):1319&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9360933</ArticleId></ArticleIdList></Reference><Reference><Citation>Evason K, Huang C, Yamben I, Covey DF, Kornfeld K. Anticonvulsant medications extend worm life-span. Science. 2005;307(5707):258&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653505</ArticleId></ArticleIdList></Reference><Reference><Citation>Evason K, Collins JJ, Huang C, Hughes S, Kornfeld K. Valproic acid extends Caenorhabditis elegans lifespan. Aging Cell. 2008;7(3):305&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6838649</ArticleId><ArticleId IdType="pubmed">18248662</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, McCue HV, Wong SQ, Kashyap SS, Kraemer BC, Barclay JW, Burgoyne RD, Morgan A. Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression. Mol Neurodegener. 2015;10:51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4587861</ArticleId><ArticleId IdType="pubmed">26419537</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi D, Lignani G, Ferrea E, Contestabile A, Paonessa F, D&#x2019;Alessandro R, Lippiello P, Boido D, Fassio A, Meldolesi J, Valtorta F, Benfenati F, Baldelli P. REST/NRSF-mediated intrinsic homeostasis protects neuronal networks from hyperexcitability. EMBO J. 2013;32(22):2994&#x2013;3007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831314</ArticleId><ArticleId IdType="pubmed">24149584</ArticleId></ArticleIdList></Reference><Reference><Citation>Pecoraro-Bisogni F, Lignani G, Contestabile A, Castroflorio E, Pozzi D, Rocchi A, Prestigio C, Orlando M, Valente P, Massacesi M, Benfenati F, Baldelli P. REST-Dependent Presynaptic Homeostasis Induced by Chronic Neuronal Hyperactivity. Mol Neurobiol. 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">28786015</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wang WJ, Cao H, Lu J, Wu C, Hu FY, Guo J, Zhao L, Yang F, Zhang YX, Li W, Zheng GY, Cui H, Chen X, Zhu Z, He H, Dong B, Mo X, Zeng Y, Tian XL. Genetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations. Hum Mol Genet. 2009;18(24):4897&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790334</ArticleId><ArticleId IdType="pubmed">19793722</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Curr Alzheimer Res. 2012;9(6):628&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res. 2012;9(6):646&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu X, Fu X, Sun H, Beremand PD, Thomas TL, Klein WH. A gene network downstream of transcription factor Math5 regulates retinal progenitor cell competence and ganglion cell fate. Dev Biol. 2005;280(2):467&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">15882586</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao CA, Tsai WW, Cho JH, Pan P, Barton MC, Klein WH. Neuronal transcriptional repressor REST suppresses an Atoh7-independent program for initiating retinal ganglion cell development. Dev Biol. 2011;349(1):90&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993882</ArticleId><ArticleId IdType="pubmed">20969844</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhamne SC, Silverman JL, Super CE, Lammers SHT, Hameed MQ, Modi ME, Copping NA, Pride MC, Smith DG, Rotenberg A, Crawley JN, Sahin M. Replicable in vivo physiological and behavioral phenotypes of the Shank3B null mutant mouse model of autism. Mol Autism. 2017;8:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5472997</ArticleId><ArticleId IdType="pubmed">28638591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly E, Schaeffer SM, Dhamne SC, Lipton JO, Lindemann L, Honer M, Jaeschke G, Super CE, Lammers SH, Modi ME, Silverman JL, Dreier JR, Kwiatkowski DJ, Rotenberg A, Sahin M. mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex. Neuropsychopharmacology. 2018;43(6):1457&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5916364</ArticleId><ArticleId IdType="pubmed">29206810</ArticleId></ArticleIdList></Reference><Reference><Citation>Purtell H, Dhamne SC, Gurnani S, Bainbridge E, Modi ME, Lammers SHT, Super CE, Hameed MQ, Johnson EL 3rd, Sahin M, Rotenberg A. Electrographic spikes are common in wildtype mice. Epilepsy Behav. 2018;89:94&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7325561</ArticleId><ArticleId IdType="pubmed">30399547</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuskaitis CJ, Jones BM, Wolfson RL, Super CE, Dhamne SC, Rotenberg A, Sabatini DM, Sahin M, Poduri A. A mouse model of DEPDC5-related epilepsy: Neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility. Neurobiol Dis. 2018;111:91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803417</ArticleId><ArticleId IdType="pubmed">29274432</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S The genetics of Caenorhabditis elegans. Genetics. 1974;77(1):71&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakowski B, Eimer S, G&#xf6;bel C, B&#xf6;ttcher A, Wagler B, Baumeister R. Two suppressors of sel-12 encode C2H2 zinc-finger proteins that regulate presenilin transcription in Caenorhabditis elegans. Development. 2003;130(10):2117&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">12668626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A C. elegans mutant that lives twice as long as wild type. Nature. 1993;366(6454):461&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8247153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohnishi N, Kuhara A, Nakamura F, Okochi Y, Mori I. Bidirectional regulation of thermotaxis by glutamate transmissions in Caenorhabditis elegans. The EMBO Journal. 2011;30(7):1376&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094115</ArticleId><ArticleId IdType="pubmed">21304490</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarriault S, Greenwald I. Suppressors of the egg-laying defective phenotype of sel-12 presenilin mutants implicate the CoREST corepressor complex in LIN-12/Notch signaling in C. elegans. Genes &amp; Development. 2002;16(20):2713&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187465</ArticleId><ArticleId IdType="pubmed">12381669</ArticleId></ArticleIdList></Reference><Reference><Citation>Winston WM, Molodowitch C, Hunter CP. Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1. Science. 2002;295(5564):2456&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11834782</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium CeDM. large-scale screening for targeted knockouts in the Caenorhabditis elegans genome. G3 (Bethesda). 2012;2(11):1415&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484672</ArticleId><ArticleId IdType="pubmed">23173093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nottke AC, Beese-Sims SE, Pantalena LF, Reinke V, Shi Y, Colaiacovo MP. SPR-5 is a histone H3K4 demethylase with a role in meiotic double-strand break repair. Proc Natl Acad Sci U S A. 2011;108(31):12805&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150895</ArticleId><ArticleId IdType="pubmed">21768382</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer EL, Becker B, Latza C, Antebi A, Shi Y. Mutation of C. elegans demethylase spr-5 extends transgenerational longevity. Cell Res. 2016;26(2):229&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4746603</ArticleId><ArticleId IdType="pubmed">26691751</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert VJ, Katic I, Bessereau JL. Mos1 transposition as a tool to engineer the Caenorhabditis elegans genome by homologous recombination. Methods. 2009;49(3):263&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19250968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamath RS, Ahringer J. Genome-wide RNAi screening in Caenorhabditis elegans. Methods. 2003;30(4):313&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">12828945</ArticleId></ArticleIdList></Reference><Reference><Citation>Frokjaer-Jensen C, Davis MW, Ailion M, Jorgensen EM. Improved Mos1-mediated transgenesis in C. elegans. Nat Methods. 2012;9(2):117&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725292</ArticleId><ArticleId IdType="pubmed">22290181</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarov M, Murray JI, Schanze K, Pozniakovski A, Niu W, Angermann K, Hasse S, Rupprecht M, Vinis E, Tinney M, Preston E, Zinke A, Enst S, Teichgraber T, Janette J, Reis K, Janosch S, Schloissnig S, Ejsmont RK, Slightam C, Xu X, Kim SK, Reinke V, Stewart AF, Snyder M, Waterston RH, Hyman AA. A genome-scale resource for in vivo tag-based protein function exploration in C. elegans. Cell. 2012;150(4):855&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979301</ArticleId><ArticleId IdType="pubmed">22901814</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995;57(1):289&#x2013;300.</Citation></Reference><Reference><Citation>Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004;32(Database issue):D91&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308747</ArticleId><ArticleId IdType="pubmed">14681366</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. Bioinformatics. 2011;27(7):1017&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065696</ArticleId><ArticleId IdType="pubmed">21330290</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma&#x2019;ayan A. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637064</ArticleId><ArticleId IdType="pubmed">23586463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepper RG, Ashraf J, Kaletsky R, Kleemann G, Murphy CT, Bussemaker HJ. PQM-1 complements DAF-16 as a key transcriptional regulator of DAF-2-mediated development and longevity. Cell. 2013;154(3):676&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3763726</ArticleId><ArticleId IdType="pubmed">23911329</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexa A RJ. topGO: Enrichment Analysis for Gene Ontology R package version 2340 (2018).</Citation></Reference><Reference><Citation>Wang M, Zhao Y, Zhang B. Efficient Test and Visualization of Multi-Set Intersections. Sci Rep. 2015;5:16923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658477</ArticleId><ArticleId IdType="pubmed">26603754</ArticleId></ArticleIdList></Reference><Reference><Citation>LIptak T On the Combination of independent tests. Magyar Tud Akad Mat Kutato Int Kozl. 1958(3):171&#x2013;97.</Citation></Reference><Reference><Citation>Dewey M Metap: Meta Analysis of Significance Values R package Version 10. 2018.</Citation></Reference><Reference><Citation>Zaykin DV. Optimally weighted Z-test is a powerful method for combining probabilities in meta-analysis. J Evol Biol. 2011;24(8):1836&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135688</ArticleId><ArticleId IdType="pubmed">21605215</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31623919</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Patient-Tailored, Connectivity-Based Forecasts of Spreading Brain Atrophy.</ArticleTitle><Pagination><StartPage>856</StartPage><EndPage>868.e5</EndPage><MedlinePgn>856-868.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2019.08.037</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(19)30743-3</ELocationID><Abstract><AbstractText>Neurodegenerative diseases appear to progress by spreading via brain connections. Here we evaluated this transneuronal degeneration hypothesis by attempting to predict future atrophy in a longitudinal cohort of patients with behavioral variant frontotemporal dementia (bvFTD) and semantic variant primary progressive aphasia (svPPA). We determined patient-specific "epicenters" at baseline, located each patient's epicenters in the healthy functional connectome, and derived two region-wise graph theoretical metrics to predict future atrophy: (1) shortest path length to the epicenter and (2) nodal hazard, the cumulative atrophy of a region's first-degree neighbors. Using these predictors and baseline atrophy, we could accurately predict longitudinal atrophy in most patients. The regions most vulnerable to subsequent atrophy were functionally connected to the epicenter and had intermediate levels of baseline atrophy. These findings provide novel, longitudinal evidence that neurodegeneration progresses along connectional pathways and, further developed, could lead to network-based clinical tools for prognostication and disease monitoring.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jesse A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Jersey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neuhaus</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Department of Epidemiology and Biostatistics, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sible</LastName><ForeName>Isabel J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sias</LastName><ForeName>Ana C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suzee E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Department of Epidemiology and Biostatistics, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marx</LastName><ForeName>Gabe A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of California, Los Angeles, Department of Neurology and Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Dan H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>University of California, Los Angeles, Department of Neurology and Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorno-Tempini</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Memory and Aging Center, Department of Neurology, San Francisco, CA, USA. Electronic address: bill.seeley@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058233</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052943</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS100440</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG055698</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG052648</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 DC015544</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055121</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS050915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="Y">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">brain networks</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">functional connectivity</Keyword><Keyword MajorTopicYN="N">graph theory</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">voxel-based morphometry</Keyword></KeywordList><CoiStatement>DECLARATION OF INTERESTS. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31623919</ArticleId><ArticleId IdType="mid">NIHMS1062764</ArticleId><ArticleId IdType="pmc">PMC7012373</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.08.037</ArticleId><ArticleId IdType="pii">S0896-6273(19)30743-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ashburner J, and Friston KJ (2005). Unified segmentation. Neuroimage 26, 839&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, and Ridgway GR (2013). Symmetric diffeomorphic modeling of longitudinal structural MRI. Front. Neurosci 6, 197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564017</ArticleId><ArticleId IdType="pubmed">23386806</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr DJ, Levy R, Scheepers C, and Tily HJ (2013). Random effects structure for confirmatory hypothesis testing: Keep it maximal. J. Mem. Lang 68, 255&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3881361</ArticleId><ArticleId IdType="pubmed">24403724</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al.; Dominantly Inherited Alzheimer Network (2012). Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med 367, 795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Beirowski B, Adalbert R, Wagner D, Grumme DS, Addicks K, Ribchester RR, and Coleman MP (2005). The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves. BMC Neurosci. 6, 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549193</ArticleId><ArticleId IdType="pubmed">15686598</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer TD, Arnold R, Allinson KSJ, Coles JP, Aigbirhio FI, et al. (2018). [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J. Neurol. Neurosurg. Psychiatry 89, 1032&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166613</ArticleId><ArticleId IdType="pubmed">28912300</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, La Joie R, Landeau B, Belliard S, de La Sayette V, Eustache F, Desgranges B, and Ch&#xe9;telat G (2019). Distinct interplay between atrophy and hypometabolism in Alzheimer&#x2019;s versus semantic dementia. Cereb. Cortex 29, 1889&#x2013;1899.</Citation><ArticleIdList><ArticleId IdType="pubmed">29668866</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondel VD, Guillaume J-L, Lambiotte R, and Lefebvre E (2008). Fast unfolding of communities in large networks. J. Stat. Mech 2008, P10008.</Citation></Reference><Reference><Citation>Braak H, and Braak E (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambati SM, Rankin KP, Narvid J, Seeley WW, Dean D, Rosen HJ, Miller BL, Ashburner J, and Gorno-Tempini ML (2009). Atrophy progression in semantic dementia with asymmetric temporal involvement: a tensor-based morphometry study. Neurobiol. Aging 30, 103&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643844</ArticleId><ArticleId IdType="pubmed">17604879</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Lee VM-Y, and Trojanowski JQ (2015). Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat. Rev. Neurosci 16, 109&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4312418</ArticleId><ArticleId IdType="pubmed">25588378</ArticleId></ArticleIdList></Reference><Reference><Citation>Broe M, Hodges JR, Schofield E, Shepherd CE, Kril JJ, and Halliday GM (2003). Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology 60, 1005&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">12654969</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaert DV, Ribbens A, Maes F, Swinnen SP, and Wenderoth N (2014). Assessing age-related gray matter decline with voxel-based morphometry depends significantly on segmentation and normalization procedures. Front. Aging Neurosci 6, 124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066859</ArticleId><ArticleId IdType="pubmed">25002845</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan D, Fox NC, Scahill RI, Crum WR, Whitwell JL, Leschziner G, Rossor AM, Stevens JM, Cipolotti L, and Rossor MN (2001). Patterns of temporal lobe atrophy in semantic dementia and Alzheimer&#x2019;s disease. Ann. Neurol 49, 433&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">11310620</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciric R, Wolf DH, Power JD, Roalf DR, Baum GL, Ruparel K, Shinohara RT, Elliott MA, Eickhoff SB, Davatzikos C, et al. (2017). Benchmarking of participant-level confound regression strategies for the control of motion artifact in studies of functional connectivity. Neuroimage 154, 174&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5483393</ArticleId><ArticleId IdType="pubmed">28302591</ArticleId></ArticleIdList></Reference><Reference><Citation>Crossley NA, Mechelli A, Scott J, Carletti F, Fox PT, McGuire P, and Bullmore ET (2014). The hubs of the human connectome are generally implicated in the anatomy of brain disorders. Brain 137, 2382&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107735</ArticleId><ArticleId IdType="pubmed">25057133</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Rombouts SA, Barkhof F, Scheltens P, Stam CJ, Smith SM, and Beckmann CF (2006). Consistent resting-state networks across healthy subjects. Proc. Natl. Acad. Sci. USA 103, 13848&#x2013;13853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564249</ArticleId><ArticleId IdType="pubmed">16945915</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, et al. (2012). Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Corjuc BT, Oakley DH, Nobuhara CK, Bannon RN, Chase A, Commins C, Gonzalez JA, Dooley PM, Frosch MP, and Hyman BT (2018). Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer&#x2019;s Disease Brain. Front. Neurosci 12, 267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928393</ArticleId><ArticleId IdType="pubmed">29740275</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards-Lee T, Miller BL, Benson DF, Cummings JL, Russell GL, Boone K, and Mena I (1997). The temporal variant of frontotemporal dementia. Brain 120, 1027&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">9217686</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, Yang Z, Chu C, Xie S, Laird AR, et al. (2016). The Human Brainnetome Atlas: A New Brain Atlas Based on Connectional Architecture. Cereb. Cortex 26, 3508&#x2013;3526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961028</ArticleId><ArticleId IdType="pubmed">27230218</ArticleId></ArticleIdList></Reference><Reference><Citation>Feiler MS, Strobel B, Freischmidt A, Helferich AM, Kappel J, Brewer BM, Li D, Thal DR, Walther P, Ludolph AC, et al. (2015). TDP-43 is intercellularly transmitted across axon terminals. J. Cell Biol 211, 897&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4657165</ArticleId><ArticleId IdType="pubmed">26598621</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornito A, Zalesky A, and Breakspear M (2015). The connectomics of brain disorders. Nat. Rev. Neurosci 16, 159&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">25697159</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, and Diamond MI (2010). Prion-like mechanisms in neurodegenerative diseases. Nat. Rev. Neurosci 11, 155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrard P, and Hodges JR (2000). Semantic dementia: clinical, radiological and pathological perspectives. J. Neurol 247, 409&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">10929269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennatas ED, Avants BB, Wolf DH, Satterthwaite TD, Ruparel K, Ciric R, Hakonarson H, Gur RE, and Gur RC (2017). Age-related effects and sex differences in gray matter density, volume, mass, and cortical thickness from childhood to young adulthood. J. Neurosci 37, 5065&#x2013;5073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444192</ArticleId><ArticleId IdType="pubmed">28432144</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasser MF, Coalson TS, Robinson EC, Hacker CD, Harwell J, Yacoub E, Ugurbil K, Andersson J, Beckmann CF, Jenkinson M, et al. (2016). A multi-modal parcellation of human cerebral cortex. Nature 536, 171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4990127</ArticleId><ArticleId IdType="pubmed">27437579</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Clavaguera F, and Tolnay M (2010). The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 33, 317&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">20493564</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon EM, Laumann TO, Adeyemo B, and Petersen SE (2017). Individual Variability of the System-Level Organization of the Human Brain. Cereb. Cortex 27, 386&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939195</ArticleId><ArticleId IdType="pubmed">26464473</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, et al. (2011). Classification of primary progressive aphasia and its variants. Neurology 76, 1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratton C, Laumann TO, Nielsen AN, Greene DJ, Gordon EM, Gilmore AW, Nelson SM, Coalson RS, Snyder AZ, Schlaggar BL, et al. (2018). Functional Brain Networks Are Dominated by Stable Group and Individual Factors, Not Cognitive or Daily Variation. Neuron 98, 439&#x2013;452.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5912345</ArticleId><ArticleId IdType="pubmed">29673485</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, and Lee VMY (2014). Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med 20, 130&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011661</ArticleId><ArticleId IdType="pubmed">24504409</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo CC, Gorno-Tempini ML, Gesierich B, Henry M, Trujillo A, Shany-Ur T, Jovicich J, Robinson SD, Kramer JH, Rankin KP, et al. (2013). Anterior temporal lobe degeneration produces widespread network-driven dysfunction. Brain 136, 2979&#x2013;2991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857932</ArticleId><ArticleId IdType="pubmed">24072486</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Cammoun L, Gigandet X, Meuli R, Honey CJ, Wedeen VJ, and Sporns O (2008). Mapping the structural core of human cerebral cortex. PLoS Biol. 6, e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443193</ArticleId><ArticleId IdType="pubmed">18597554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrylycz M, Miller JA, Menon V, Feng D, Dolbeare T, Guillozet-Bongaarts AL, Jegga AG, Aronow BJ, Lee C-K, Bernard A, et al. (2015). Canonical genetic signatures of the adult human brain. Nat. Neurosci 18, 1832&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4700510</ArticleId><ArticleId IdType="pubmed">26571460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock E-M, and Polymenidou M (2016). Prion-like propagation as a pathogenic principle in frontotemporal dementia. J. Neurochem 138 (Suppl 1), 163&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6680357</ArticleId><ArticleId IdType="pubmed">27502124</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y, Sotero RC, Toussaint PJ, and Evans AC; Alzheimer&#x2019;s Disease Neuroimaging Initiative (2014). Epidemic spreading model to characterize misfolded proteins propagation in aging and associated neurodegenerative disorders. PLoS Comput. Biol 10, e1003956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4238950</ArticleId><ArticleId IdType="pubmed">25412207</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, and Trojanowski JQ (2010). Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 9, 119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr., Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, Kantarci K, Bernstein MA, Senjem ML, Gunter JL, et al.; Alzheimer&#x2019;s Disease Neuroimaging Initiative (2012). Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch. Neurol 69, 856&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595157</ArticleId><ArticleId IdType="pubmed">22409939</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Perrotin A, Barr&#xe9; L, Hommet C, M&#xe9;zenge F, Ibazizene M, Camus V, Abbas A, Landeau B, Guilloteau D, et al. (2012). Region-specific hierarchy between atrophy, hypometabolism, and &#x3b2;-amyloid (A&#x3b2;) load in Alzheimer&#x2019;s disease dementia. J. Neurosci 32, 16265&#x2013;16273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794030</ArticleId><ArticleId IdType="pubmed">23152610</ArticleId></ArticleIdList></Reference><Reference><Citation>Landin-Romero R, Kumfor F, Leyton CE, Irish M, Hodges JR, and Piguet O (2017). Disease-specific patterns of cortical and subcortical degeneration in a longitudinal study of Alzheimer&#x2019;s disease and behavioural-variant frontotemporal dementia. Neuroimage 151, 72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">27012504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Sias AC, Mandelli ML, Brown JA, Brown AB, Khazenzon AM, Vidovszky AA, Zanto TP, Karydas AM, Pribadi M, et al. (2016). Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. Neuroimage Clin. 14, 286&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349617</ArticleId><ArticleId IdType="pubmed">28337409</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, and Duff K (2012). Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7, e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier-Hein KH, Neher PF, Houde J-C, C&#xf4;t&#xe9; M-A, Garyfallidis E, Zhong J, Chamberland M, Yeh F-C, Lin Y-C, Ji Q, et al. (2017). The challenge of mapping the human connectome based on diffusion tractography. Nat. Commun 8, 1349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5677006</ArticleId><ArticleId IdType="pubmed">29116093</ArticleId></ArticleIdList></Reference><Reference><Citation>Makaretz SJ, Quimby M, Collins J, Makris N, McGinnis S, Schultz A, Vasdev N, Johnson KA, and Dickerson BC (2018). Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J. Neurol. Neurosurg. Psychiatry 89, 1024&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964045</ArticleId><ArticleId IdType="pubmed">28986472</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi&#x161;i&#x107; B, Betzel RF, Nematzadeh A, Go&#xf1;i J, Griffa A, Hagmann P, Flammini A, Ahn Y-Y, and Sporns O (2015). Cooperative and Competitive Spreading Dynamics on the Human Connectome. Neuron 86, 1518&#x2013;1529.</Citation><ArticleIdList><ArticleId IdType="pubmed">26087168</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutlu J, Landeau B, Gaubert M, de La Sayette V, Desgranges B, and Ch&#xe9;telat G (2017). Distinct influence of specific versus global connectivity on the different Alzheimer&#x2019;s disease biomarkers. Brain 140, 3317&#x2013;3328.</Citation><ArticleIdList><ArticleId IdType="pubmed">29194503</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman M (2018). Networks (Oxford University Press; ).</Citation></Reference><Reference><Citation>Pereira JMS, Acosta-Cabronero J, Pengas G, Xiong L, Nestor PJ, and Williams GB (2013). VBM with viscous fluid registration of gray matter segments in SPM. Front. Aging Neurosci 5, 30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711012</ArticleId><ArticleId IdType="pubmed">23874298</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlson E, Maday S, Fu MM, Moughamian AJ, and Holzbaur ELF (2010). Retrograde axonal transport: pathways to cell death? Trends Neurosci. 33, 335&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902719</ArticleId><ArticleId IdType="pubmed">20434225</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry DC, Brown JA, Possin KL, Datta S, Trujillo A, Radke A, Karydas A, Kornak J, Sias AC, Rabinovici GD, et al. (2017). Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain 140, 3329&#x2013;3345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841140</ArticleId><ArticleId IdType="pubmed">29053860</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, Brown HJ, Lee EB, Trojanowski JQ, and Lee VM-Y (2018). Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat. Commun 9, 4220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JD, Cohen AL, Nelson SM, Wig GS, Barnes KA, Church JA, Vogel AC, Laumann TO, Miezin FM, Schlaggar BL, and Petersen SE (2011). Functional network organization of the human brain. Neuron 72, 665&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3222858</ArticleId><ArticleId IdType="pubmed">22099467</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JD, Barnes KA, Snyder AZ, Schlaggar BL, and Petersen SE (2012). Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 59, 2142&#x2013;2154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254728</ArticleId><ArticleId IdType="pubmed">22019881</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, LoCastro E, Kuceyeski A, Tosun D, Relkin N, and Weiner M; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) (2015). Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimer&#x2019;s Disease. Cell Rep. 10, 359&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747552</ArticleId><ArticleId IdType="pubmed">25600871</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranasinghe KG, Rankin KP, Pressman PS, Perry DC, Lobach IV, Seeley WW, Coppola G, Karydas AM, Grinberg LT, Shany-Ur T, et al. (2016). Distinct subtypes of behavioral variant frontotemporal dementia based on patterns of network degeneration. JAMA Neurol. 73, 1078&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024785</ArticleId><ArticleId IdType="pubmed">27429218</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, et al. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Reveley C, Seth AK, Pierpaoli C, Silva AC, Yu D, Saunders RC, Leopold DA, and Ye FQ (2015). Superficial white matter fiber systems impede detection of long-range cortical connections in diffusion MR tractography. Proc. Natl. Acad. Sci. USA 112, E2820&#x2013;E2828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4450402</ArticleId><ArticleId IdType="pubmed">25964365</ArticleId></ArticleIdList></Reference><Reference><Citation>Richiardi J, Altmann A, Milazzo A-C, Chang C, Chakravarty MM, Banaschewski T, Barker GJ, Bokde ALW, Bromberg U, B&#xfc;chel C,et al.; IMAGEN consortium (2015). BRAIN NETWORKS. Correlated gene expression supports synchronous activity in brain networks. Science 348, 1241&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829082</ArticleId><ArticleId IdType="pubmed">26068849</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Clarkson MJ, Kittus R, Rossor MN, Ourselin S, Warren JD, and Fox NC (2012). Rates of hemispheric and lobar atrophy in the language variants of frontotemporal lobar degeneration. J. Alzheimers Dis 30, 407&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4606976</ArticleId><ArticleId IdType="pubmed">22406442</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, Swieten J van Dopper E, Jiskoot L, van Minkelen R, Rombouts SA Cardoso MJ, Clegg S, et al. (2015). Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. The Lancet Neurology 14, 253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen HJ, Gorno-Tempini ML, Goldman WP, Perry RJ, Schuff N, Weiner M, Feiwell R, Kramer JH, and Miller BL (2002). Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 58, 198&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11805245</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinov M, and Sporns O (2010). Complex network measures of brain connectivity: uses and interpretations. Neuroimage 52, 1059&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pubmed">19819337</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinov M, and Sporns O (2011). Weight-conserving characterization of complex functional brain networks. Neuroimage 56, 2068&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pubmed">21459148</ArticleId></ArticleIdList></Reference><Reference><Citation>Satterthwaite TD, Elliott MA, Gerraty RT, Ruparel K, Loughead J, Calkins ME, Eickhoff SB, Hakonarson H, Gur RC, Gur RE, and Wolf DH (2013). An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data. Neuroimage 64, 240&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811142</ArticleId><ArticleId IdType="pubmed">22926292</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW (2017). Mapping Neurodegenerative Disease Onset and Progression. Cold Spring Harb. Perspect. Biol 9, a023622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538416</ArticleId><ArticleId IdType="pubmed">28289062</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Bauer AM, Miller BL, Gorno-Tempini ML, Kramer JH, Weiner M, and Rosen HJ (2005). The natural history of temporal variant frontotemporal dementia. Neurology 64, 1384&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376750</ArticleId><ArticleId IdType="pubmed">15851728</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, Reiss AL, and Greicius MD (2007). Dissociable intrinsic connectivity networks for salience processing and executive control. J. Neurosci 27, 2349&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680293</ArticleId><ArticleId IdType="pubmed">17329432</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford R, Rascovsky K, Kramer JH, Weiner M, Miller BL, and Gorno-Tempini ML (2008). Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch. Neurol 65, 249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544627</ArticleId><ArticleId IdType="pubmed">18268196</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, and Greicius MD (2009). Neurodegenerative diseases target large-scale human brain networks. Neuron 62, 42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Shehzad Z, Kelly AMC, Reiss PT, Gee DG, Gotimer K, Uddin LQ, Lee SH, Margulies DS, Roy AK, Biswal BB, et al. (2009). The resting brain: unconstrained yet reliable. Cereb. Cortex 19, 2209&#x2013;2229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896030</ArticleId><ArticleId IdType="pubmed">19221144</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, et al. (2004). Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23 (Suppl 1), S208&#x2013;S219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas C, Ye FQ, Irfanoglu MO, Modi P, Saleem KS, Leopold DA, and Pierpaoli C (2014). Anatomical accuracy of brain connections derived from diffusion MRI tractography is inherently limited. Proc. Natl. Acad. Sci. USA 111, 16574&#x2013;16579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4246325</ArticleId><ArticleId IdType="pubmed">25368179</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson SA, Patterson K, and Hodges JR (2003). Left/right asymmetry of atrophy in semantic dementia: behavioral-cognitive implications. Neurology 61, 1196&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pubmed">14610120</ArticleId></ArticleIdList></Reference><Reference><Citation>Torok J, Maia PD, Powell F, Pandya S, and Raj A; Alzheimer&#x2019;s Disease Neuroimaging Initiative (2018). A method for inferring regional origins of neurodegeneration (Brain J. Neurol).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837438</ArticleId><ArticleId IdType="pubmed">29409009</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V, O&#x2019;Neil JP, Janabi M, Baker S, Lee SE, et al. (2019). 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther 11, 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6357510</ArticleId><ArticleId IdType="pubmed">30704514</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Heuvel MP, and Sporns O (2013). Network hubs in the human brain. Trends Cogn. Sci 17, 683&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">24231140</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Maaten L, and Hinton G (2008). Visualizing Data using t-SNE. J. Mach. Learn. Res 9, 2579&#x2013;2605.</Citation></Reference><Reference><Citation>Whitwell JL, Przybelski SA, Weigand SD, Ivnik RJ, Vemuri P, Gunter JL, Senjem ML, Shiung MM, Boeve BF, Knopman DS, et al. (2009). Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain 132, 2932&#x2013;2946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768663</ArticleId><ArticleId IdType="pubmed">19762452</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood SN (2017). Generalized Additive Models: An Introduction with R, Second Edition (CRC Press; ).</Citation></Reference><Reference><Citation>Yeh F-C, Panesar S, Fernandes D, Meola A, Yoshino M, Fernandez-Miranda JC, Vettel JM, and Verstynen T (2018). Population-averaged atlas of the macroscale human structural connectome and its network topology. Neuroimage 178, 57&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6921501</ArticleId><ArticleId IdType="pubmed">29758339</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo BTT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, Roffman JL, Smoller JW, Z&#xf6;llei L, Polimeni JR, et al. (2011). The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J. Neurophysiol 106, 1125&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174820</ArticleId><ArticleId IdType="pubmed">21653723</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, Firth NC, Cash DM, Thomas DL, Dick KM, Cardoso J, et al.; Genetic FTD Initiative (GENFI); Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) (2018). Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nat. Commun 9, 4273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6189176</ArticleId><ArticleId IdType="pubmed">30323170</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeighami Y, Ulla M, Iturria-Medina Y, Dadar M, Zhang Y, Larcher KM-H, Fonov V, Evans AC, Collins DL, and Dagher A (2015). Network structure of brain atrophy in de novo Parkinson&#x2019;s disease. eLife 4, 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4596689</ArticleId><ArticleId IdType="pubmed">26344547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Mormino EC, Sun N, Sperling RA, Sabuncu MR, and Yeo BTT; Alzheimer&#x2019;s Disease Neuroimaging Initiative (2016). Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. USA 113, E6535&#x2013;E6544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5081632</ArticleId><ArticleId IdType="pubmed">27702899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Gennatas ED, Kramer JH, Miller BL, and Seeley WW (2012). Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 73, 1216&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31631020</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-6711</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Stem cell reports</Title><ISOAbbreviation>Stem Cell Reports</ISOAbbreviation></Journal><ArticleTitle>A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies.</ArticleTitle><Pagination><StartPage>939</StartPage><EndPage>955</EndPage><MedlinePgn>939-955</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stemcr.2019.09.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-6711(19)30335-2</ELocationID><Abstract><AbstractText>Primary tauopathies are characterized neuropathologically by inclusions containing abnormal forms of the microtubule-associated protein tau (MAPT) and clinically by diverse neuropsychiatric, cognitive, and motor impairments. Autosomal dominant mutations in the MAPT gene cause heterogeneous forms of frontotemporal lobar degeneration with tauopathy (FTLD-Tau). Common and rare variants in the MAPT gene increase the risk for sporadic FTLD-Tau, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). We generated a collection of fibroblasts from 140 MAPT mutation/risk variant carriers, PSP, CBD, and cognitively normal controls; 31 induced pluripotent stem cell (iPSC) lines from MAPT mutation carriers, non-carrier family members, and autopsy-confirmed PSP patients; 33 genome engineered iPSCs that were corrected or mutagenized; and forebrain neural progenitor cells (NPCs). Here, we present a resource of fibroblasts, iPSCs, and NPCs with comprehensive clinical histories that can be accessed by the scientific community for disease modeling and development of novel therapeutics for tauopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, 425 South Euclid Avenue, Campus Box 8134, St. Louis, MO 63110, USA. Electronic address: karchc@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kao</LastName><ForeName>Aimee W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Division of Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onanuga</LastName><ForeName>Khadijah</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, 1 Discovery Drive, Rensselaer, NY 12144, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, 425 South Euclid Avenue, Campus Box 8134, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argouarch</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gladstone Institutes of Neurological Disease, Department of Neurology, Neuroscience Graduate Program, University of California, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gladstone Institutes of Neurological Disease, Department of Neurology, Neuroscience Graduate Program, University of California, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohn</LastName><ForeName>Peter Dongmin</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Gladstone Institutes of Neurological Disease, Department of Neurology, Neuroscience Graduate Program, University of California, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowles</LastName><ForeName>Kathryn R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Departments of Neuroscience, Neurology and Genetics &amp; Genomic Sciences, Icahn School of Medicine, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>M Catarina</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Chemical Neurobiology Laboratory, Center for Genomic Medicine, Departments of Neurology &amp; Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Jacob A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, 425 South Euclid Avenue, Campus Box 8134, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, 425 South Euclid Avenue, Campus Box 8134, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugh</LastName><ForeName>Derian A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Departments of Neuroscience, Neurology and Genetics &amp; Genomic Sciences, Icahn School of Medicine, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghoshal</LastName><ForeName>Nupur</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, 425 South Euclid Avenue, Campus Box 8134, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yadong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institutes of Neurological Disease, Department of Neurology, Neuroscience Graduate Program, University of California, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suzee E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Division of Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theofilas</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Fermin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIlroy</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, 1 Discovery Drive, Rensselaer, NY 12144, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crary</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Departments of Neuroscience, Neurology and Genetics &amp; Genomic Sciences, Icahn School of Medicine, New York, NY 10029, USA; Department of Pathology, Fishberg Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haggarty</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Chemical Neurobiology Laboratory, Center for Genomic Medicine, Departments of Neurology &amp; Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichida</LastName><ForeName>Justin K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Molecular Cellular and Developmental Biology, Neuroscience Research Institute, Biomolecular Science and Engineering Program, University of California, Santa Barbara, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Division of Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institutes of Neurological Disease, Department of Neurology, Neuroscience Graduate Program, University of California, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Departments of Neuroscience, Neurology and Genetics &amp; Genomic Sciences, Icahn School of Medicine, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Temple</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, 1 Discovery Drive, Rensselaer, NY 12144, USA. Electronic address: sallytemple@neuralsci.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Tau Consortium Stem Cell Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG023481</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058233</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HD001459</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054008</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG052648</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095252</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG045390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097277</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cell Reports</MedlineTA><NlmUniqueID>101611300</NlmUniqueID><ISSNLinking>2213-6711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="N">Gene Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRISPR/Cas9</Keyword><Keyword MajorTopicYN="N">MAPT</Keyword><Keyword MajorTopicYN="N">corticobasal degeneration</Keyword><Keyword MajorTopicYN="N">fibroblasts</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cells</Keyword><Keyword MajorTopicYN="N">neural progenitor cells</Keyword><Keyword MajorTopicYN="N">progressive supranuclear palsy</Keyword><Keyword MajorTopicYN="N">tau</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Alquezar</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bowles</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's disease, Depts. of Neuroscience, Neurology and Genetics &amp; Genomic Sciences, Icahn School of Medicine, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Butler</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, 1 Discovery Drive, Rensselaer, NY 12144, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Crary</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Pathology, Fishberg Department of Neuroscience, Friedman Brain Institute, Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institutes of Neurological Disease, Department of Neurology, Neuroscience Graduate Program, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's disease, Depts. of Neuroscience, Neurology and Genetics &amp; Genomic Sciences, Icahn School of Medicine, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Haggarty</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Chemical Neurobiology Laboratory, Center for Genomic Medicine, Departments of Neurology &amp; Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Israel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Molecular Cellular and Developmental Biology, Neuroscience Research Institute, Biomolecular Science and Engineering Program, University of California, Santa Barbara, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hennes</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gladstone Institutes of Neurological Disease, Department of Neurology, Neuroscience Graduate Program, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ichida</LastName><ForeName>Justin K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Kampmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Institute for Neurodegenerative Diseases and California Institute for Quantitative Biomedical Research, University of California, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Kao</LastName><ForeName>Aimee W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Division of Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St Louis, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Molecular Cellular and Developmental Biology, Neuroscience Research Institute, Biomolecular Science and Engineering Program, University of California, Santa Barbara, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St Louis, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Onanuga</LastName><ForeName>Khadijah</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, 1 Discovery Drive, Rensselaer, NY 12144, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Silva</LastName><ForeName>M Catarina</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Chemical Neurobiology Laboratory, Center for Genomic Medicine, Departments of Neurology &amp; Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Temple</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, 1 Discovery Drive, Rensselaer, NY 12144, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gladstone Institutes of Neurological Disease, Department of Neurology, Neuroscience Graduate Program, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31631020</ArticleId><ArticleId IdType="pmc">PMC6895712</ArticleId><ArticleId IdType="doi">10.1016/j.stemcr.2019.09.006</ArticleId><ArticleId IdType="pii">S2213-6711(19)30335-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arai T., Ikeda K., Akiyama H., Nonaka T., Hasegawa M., Ishiguro K., Iritani S., Tsuchiya K., Iseki E., Yagishita S. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann. Neurol. 2004;55:72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">14705114</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Ikeda K., Akiyama H., Tsuchiya K., Yagishita S., Takamatsu J. Intracellular processing of aggregated tau differs between corticobasal degeneration and progressive supranuclear palsy. Neuroreport. 2001;12:935&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">11303763</ArticleId></ArticleIdList></Reference><Reference><Citation>Behnam M., Ghorbani F., Shin J.H., Kim D.S., Jang H., Nouri N., Sedghi M., Salehi M., Ansari B., Basiri K. Homozygous MAPT R406W mutation causing FTDP phenotype: a unique instance of a unique mutation. Gene. 2015;570:150&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">26086902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhutani K., Nazor K.L., Williams R., Tran H., Dai H., Dzakula Z., Cho E.H., Pang A.W., Rao M., Cao H. Whole-genome mutational burden analysis of three pluripotency induction methods. Nat. Commun. 2016;7:10536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4762882</ArticleId><ArticleId IdType="pubmed">26892726</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas M.H.U., Almeida S., Lopez-Gonzalez R., Mao W., Zhang Z., Karydas A., Geschwind M.D., Biernat J., Mandelkow E.M., Futai K. MMP-9 and MMP-2 contribute to neuronal cell death in iPSC models of frontotemporal dementia with MAPT mutations. Stem Cell Reports. 2016;7:316&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5032669</ArticleId><ArticleId IdType="pubmed">27594586</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve B.F., Tremont-Lukats I.W., Waclawik A.J., Murrell J.R., Hermann B., Jack C.R., Jr., Shiung M.M., Smith G.E., Nair A.R., Lindor N. Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. Brain. 2005;128:752&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615814</ArticleId></ArticleIdList></Reference><Reference><Citation>Boselli M., Lee B.H., Robert J., Prado M.A., Min S.W., Cheng C., Silva M.C., Seong C., Elsasser S., Hatle K.M. An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons. J.&#xa0;Biol. Chem. 2017;292:19209&#x2013;19225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5702663</ArticleId><ArticleId IdType="pubmed">28972160</ArticleId></ArticleIdList></Reference><Reference><Citation>Budde J., Martinez R., Hsu S., Wen N., Chen J., Coppola G., Goate A.M., Cruchaga C., Karch C.M. Precision genome-editing with CRISPR/Cas9 in human induced pluripotent stem cells. bioRxiv. 2017</Citation></Reference><Reference><Citation>Butler V.J., Salazar D.A., Soriano-Castell D., Alves-Ferreira M., Dennissen F.J.A., Vohra M., Oses-Prieto J.A., Li K.H., Wang A.L., Jing B. Tau/MAPT disease-associated variant A152T alters tau function and toxicity via impaired retrograde axonal transport. Hum. Mol. Genet. 2019;28:1498&#x2013;1514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6489414</ArticleId><ArticleId IdType="pubmed">30590647</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns N.J., Bigio E.H., Mackenzie I.R.A., Neumann M., Lee V.M.-Y., Hatanpaa K.J., White C.L., Schneider J.A., Grinberg L.T., Halliday G. Neuropathologic diagnostic and&#xa0;nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C., Fass D.M., Folz-Donahue K., MacDonald M.E., Haggarty S.J. Highly expandable human iPS cell-derived neural progenitor cells (NPC) and neurons for central nervous system disease modeling and high-throughput screening. Curr. Protoc. Hum. Genet. 2017;92:21 28 21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5293008</ArticleId><ArticleId IdType="pubmed">28075486</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G., Chinnathambi S., Lee J.J., Dombroski B.A., Baker M.C., Soto-Ortolaza A.I., Lee S.E., Klein E., Huang A.Y., Sears R. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum. Mol. Genet. 2012;21:3500&#x2013;3512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392107</ArticleId><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M., Theuns J., Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 2012;33:1340&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465795</ArticleId><ArticleId IdType="pubmed">22581678</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayanandan R., Van Slegtenhorst M., Mack T.G., Ko L., Yen S.H., Leroy K., Brion J.P., Anderton B.H., Hutton M., Lovestone S. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett. 1999;446:228&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">10100846</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker J.M., Kruger L., Sydow A., Dennissen F.J., Siskova Z., Mandelkow E., Mandelkow E.M. The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity. EMBO Rep. 2016;17:552&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818782</ArticleId><ArticleId IdType="pubmed">26931569</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson D.W., Rademakers R., Hutton M.L. Progressive supranuclear palsy: pathology and genetics. Brain Pathol. 2007;17:74&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095545</ArticleId><ArticleId IdType="pubmed">17493041</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi D., Samata B., Katsukawa M., Kikuchi T., Morizane A., Ono Y., Sekiguchi K., Nakagawa M., Parmar M., Takahashi J. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports. 2014;2:337&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964289</ArticleId><ArticleId IdType="pubmed">24672756</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrlich M., Hallmann A.L., Reinhardt P., Arauzo-Bravo M.J., Korr S., Ropke A., Psathaki O.E., Ehling P., Meuth S.G., Oblak A.L. Distinct neurodegenerative changes in an&#xa0;induced pluripotent stem cell model of frontotemporal dementia linked to mutant TAU protein. Stem Cell Reports. 2015;5:83&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4618448</ArticleId><ArticleId IdType="pubmed">26143746</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkabetz Y., Panagiotakos G., Al Shamy G., Socci N.D., Tabar V., Studer L. Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev. 2008;22:152&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192751</ArticleId><ArticleId IdType="pubmed">18198334</ArticleId></ArticleIdList></Reference><Reference><Citation>Espuny-Camacho I., Arranz A.M., Fiers M., Snellinx A., Ando K., Munck S., Bonnefont J., Lambot L., Corthout N., Omodho L. Hallmarks of Alzheimer's disease in stem-cell-derived human neurons transplanted into mouse brain. Neuron. 2017;93:1066&#x2013;1081.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28238547</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteras N., Rohrer J.D., Hardy J., Wray S., Abramov A.Y. Mitochondrial hyperpolarization in iPSC-derived neurons from patients of FTDP-17 with 10+16 MAPT mutation leads&#xa0;to oxidative stress and neurodegeneration. Redox. Biol. 2017;12:410&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5357682</ArticleId><ArticleId IdType="pubmed">28319892</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer D., Mukrasch M.D., Von Bergen M., Klos-Witkowska A., Biernat J., Griesinger C., Mandelkow E., Zweckstetter M. Structural and microtubule binding properties of tau mutants of frontotemporal dementias. Biochemistry. 2007;46:2574&#x2013;2582.</Citation><ArticleIdList><ArticleId IdType="pubmed">17297915</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong H., Wang C., Knoferle J., Walker D., Balestra M.E., Tong L.M., Leung L., Ring K.L., Seeley W.W., Karydas A. Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Reports. 2013;1:226&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849235</ArticleId><ArticleId IdType="pubmed">24319659</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman M.S., Zhukareva V., Bergeron C., Chin S.S., Grossman M., Clark C., Lee V.M., Trojanowski J.Q. Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am. J. Pathol. 2002;160:2045&#x2013;2053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850831</ArticleId><ArticleId IdType="pubmed">12057909</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier-Kemper A., Weissmann C., Golovyashkina N., Sebo-Lemke Z., Drewes G., Gerke V., Heinisch J.J., Brandt R. The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner. J.&#xa0;Cell Biol. 2011;192:647&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044115</ArticleId><ArticleId IdType="pubmed">21339331</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990;9:4225&#x2013;4230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552204</ArticleId><ArticleId IdType="pubmed">2124967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallmann A.L., Arauzo-Bravo M.J., Mavrommatis L., Ehrlich M., Ropke A., Brockhaus J., Missler M., Sterneckert J., Scholer H.R., Kuhlmann T. Astrocyte pathology in a human neural stem cell model of frontotemporal dementia caused by mutant TAU protein. Sci. Rep. 2017;7:42991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5335603</ArticleId><ArticleId IdType="pubmed">28256506</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefti M.M., Farrell K., Kim S., Bowles K.R., Fowkes M.E., Raj T., Crary J.F. High-resolution temporal and regional mapping of MAPT expression and splicing in human brain development. PLoS One. 2018;13:e0195771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5892924</ArticleId><ArticleId IdType="pubmed">29634760</ArticleId></ArticleIdList></Reference><Reference><Citation>Heuer E., Rosen R.F., Cintron A., Walker L.C. Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr. Pharm. Des. 2012;18:1159&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381739</ArticleId><ArticleId IdType="pubmed">22288403</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger G.U., Melhem N.M., Dickson D.W., Sleiman P.M.A., Wang L.-S., Klei L., Rademakers R., de Silva R., Litvan I., Riley D.E. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 2011;43:699&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer M., Craxton M., Jakes R., Arendt T., Goedert M. Tau gene (MAPT) sequence variation among primates. Gene. 2004;341:313&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474313</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh C.J., Zhang B., Victor M.B., Dahiya S., Batista L.F., Horvath S., Yoo A.S. Maintenance of age in human neurons generated by microRNA-based neuronal conversion of fibroblasts. eLife. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5067114</ArticleId><ArticleId IdType="pubmed">27644593</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima M., Tabira T., Poorkaj P., Schellenberg G.D., Trojanowski J.Q., Lee V.M., Schmidt M.L., Takahashi K., Nabika T., Matsumoto T. A distinct familial presenile dementia with&#xa0;a novel missense mutation in the tau gene. Neuroreport. 1999;10:497&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">10208578</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Sahara N., Kanaan N.M., Tsukita K., Kondo T., Kutoku Y., Ohsawa Y., Sunada Y., Kawakami K., Hotta A. Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. Sci. Rep. 2016;6:34904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056519</ArticleId><ArticleId IdType="pubmed">27721502</ArticleId></ArticleIdList></Reference><Reference><Citation>Iovino M., Agathou S., Gonzalez-Rueda A., Del Castillo Velasco-Herrera M., Borroni B., Alberici A., Lynch T., O'Dowd S., Geti I., Gaffney D. Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations. Brain. 2015;138:3345&#x2013;3359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4620511</ArticleId><ArticleId IdType="pubmed">26220942</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen J.C., Warrington E.K., Morris H.R., Lantos P., Brown J., Revesz T., Wood N., Khan M.N., Cipolotti L., Fox N.C. Clinical features of frontotemporal dementia due to the intronic tau 10(+16) mutation. Neurology. 2002;58:1161&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971081</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., Wen N., Li Z., Dube U., Del Aguila J., Budde J., Martinez R., Hsu S., Fernandez M.V., Cairns N.J. Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP. Transl. Psychiatry. 2018;8:265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6293323</ArticleId><ArticleId IdType="pubmed">30546007</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch C.M., Jeng A.T., Goate A.M. Extracellular tau levels are influenced by variability in tau that is associated with tauopathies. J.&#xa0;Biol. Chem. 2012;287:42751&#x2013;42762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522274</ArticleId><ArticleId IdType="pubmed">23105105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpinen H., Goncalves A., Leha A., Afzal V., Alasoo K., Ashford S., Bala S., Bensaddek D., Casale F.P., Culley O.J. Common genetic variation drives molecular heterogeneity in human iPSCs. Nature. 2017;546:370&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524171</ArticleId><ArticleId IdType="pubmed">28489815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan P., Turner-Bridger B., Peter M., Momoh A., Arambepola D., Robinson H.P., Livesey F.J. Development and function of human cerebral cortex neural networks from pluripotent stem cells in&#xa0;vitro. Development. 2015;142:3178&#x2013;3187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4582178</ArticleId><ArticleId IdType="pubmed">26395144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik K.S., Orecchio L.D., Bakalis S., Neve R.L. Developmentally regulated expression of specific tau sequences. Neuron. 1989;2:1389&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">2560640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs G.G. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol. Appl. Neurobiol. 2015;41:3&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">25495175</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs G.G., Pittman A., Revesz T., Luk C., Lees A., Kiss E., Tariska P., Laszlo L., Molnar K., Molnar M.J. MAPT S305I mutation: implications for argyrophilic grain disease. Acta Neuropathol. 2008;116:103&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">18066559</ArticleId></ArticleIdList></Reference><Reference><Citation>Lantos P.L., Cairns N.J., Khan M.N., King A., Revesz T., Janssen J.C., Morris H., Rossor M.N. Neuropathologic variation in frontotemporal dementia due to the intronic tau 10(+16) mutation. Neurology. 2002;58:1169&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971082</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Gong C.-X. Tau exon 10 alternative splicing and tauopathies. Mol. Neurodegener. 2008;3:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2483273</ArticleId><ArticleId IdType="pubmed">18616804</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S., Djukic B., Taneja P., Yu G.Q., Lo I., Davis A., Craft R., Guo W., Wang X., Kim D. Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep. 2016;17:530&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818780</ArticleId><ArticleId IdType="pubmed">26931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Maherali N., Sridharan R., Xie W., Utikal J., Eminli S., Arnold K., Stadtfeld M., Yachechko R., Tchieu J., Jaenisch R. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell. 2007;1:55&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18371336</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkle F.T., Ghosh S., Kamitaki N., Mitchell J., Avior Y., Mello C., Kashin S., Mekhoubad S., Ilic D., Charlton M. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature. 2017;545:229&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427175</ArticleId><ArticleId IdType="pubmed">28445466</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J., Paquola A.C.M., Ku M., Hatch E., Bohnke L., Ladjevardi S., McGrath S., Campbell B., Lee H., Herdy J.R. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell. 2015;17:705&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5929130</ArticleId><ArticleId IdType="pubmed">26456686</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J.D., Ganat Y.M., Kishinevsky S., Bowman R.L., Liu B., Tu E.Y., Mandal P.K., Vera E., Shim J.W., Kriks S. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell. 2013;13:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4153390</ArticleId><ArticleId IdType="pubmed">24315443</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra S.S., Murrell J.R., Gearing M., Spillantini M.G., Goedert M., Crowther R.A., Levey A.I., Jones R., Green J., Shoffner J.M. Tau pathology in a family with dementia and a P301L mutation in tau. J.&#xa0;Neuropathol. Exp. Neurol. 1999;58:335&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218629</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyasaka T., Morishima-Kawashima M., Ravid R., Heutink P., van Swieten J.C., Nagashima K., Ihara Y. Molecular analysis of mutant and wild-type tau deposited in the brain affected by the FTDP-17 R406W mutation. Am. J. Pathol. 2001;158:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850291</ArticleId><ArticleId IdType="pubmed">11159174</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratore C.R., Srikanth P., Callahan D.G., Young-Pearse T.L. Comparison and optimization of hiPSC forebrain cortical differentiation protocols. PLoS One. 2014;9:e105807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4148335</ArticleId><ArticleId IdType="pubmed">25165848</ArticleId></ArticleIdList></Reference><Reference><Citation>Murrell J.R., Spillantini M.G., Zolo P., Guazzelli M., Smith M.J., Hasegawa M., Redi F., Crowther R.A., Pietrini P., Ghetti B. Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits. J.&#xa0;Neuropathol. Exp. Neurol. 1999;58:1207&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng A.S., Sias A.C., Pressman P.S., Fong J.C., Karydas A.M., Zanto T.P., De May M., Coppola G., Geschwind D.H., Miller B.L. Young-onset frontotemporal dementia in a homozygous tau R406W mutation carrier. Ann. Clin. Transl Neurol. 2015;2:1124&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4693591</ArticleId><ArticleId IdType="pubmed">26734663</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda D., Samuel J.C., Massie M., Feinstein S.C., Wilson L. Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. Proc. Natl. Acad. Sci. U S A. 2003;100:9548&#x2013;9553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170955</ArticleId><ArticleId IdType="pubmed">12886013</ArticleId></ArticleIdList></Reference><Reference><Citation>Paonessa F., Evans L.D., Solanki R., Larrieu D., Wray S., Hardy J., Jackson S.P., Livesey F.J. microtubules deform the nuclear membrane and disrupt nucleocytoplasmic transport in tau-mediated frontotemporal dementia. Cell Rep. 2019;26:582&#x2013;593.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6335264</ArticleId><ArticleId IdType="pubmed">30650353</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry D.C., Brown J.A., Possin K.L., Datta S., Trujillo A., Radke A., Karydas A., Kornak J., Sias A.C., Rabinovici G.D. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2017;140:3329&#x2013;3345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841140</ArticleId><ArticleId IdType="pubmed">29053860</ArticleId></ArticleIdList></Reference><Reference><Citation>Pir G.J., Choudhary B., Mandelkow E., Mandelkow E.M. Tau mutant A152T, a risk factor for FTD/PSP, induces neuronal dysfunction and reduced lifespan independently of aggregation in a C. elegans Tauopathy model. Mol. Neurodegener. 2016;11:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4847334</ArticleId><ArticleId IdType="pubmed">27118310</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L.A., Grabowski T.J., Schmidt M.L., Morris J.C., Goate A., Solodkin A., Van Hoesen G.W., Schelper R.L., Talbot C.J., Wragg M.A. Autosomal dominant dementia with widespread neurofibrillary tangles. Ann. Neurol. 1997;42:564&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">9382467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C., Barthelemy N.R., Mawuenyega K.G., Patterson B.W., Gordon B.A., Jockel-Balsarotti J., Sullivan M., Crisp M.J., Kasten T., Kirmess K.M. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97:1284&#x2013;1298.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Saurat N.G., Livesey F.J., Moore S. Cortical differentiation of human pluripotent cells for in&#xa0;vitro modeling of Alzheimer's disease. Methods Mol. Biol. 2016;1303:267&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">26235073</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo J., Kritskiy O., Watson L.A., Barker S.J., Dey D., Raja W.K., Lin Y.T., Ko T., Cho S., Penney J. Inhibition of p25/Cdk5 attenuates tauopathy in mouse and iPSC models of frontotemporal dementia. J.&#xa0;Neurosci. 2017;37:9917&#x2013;9924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5637118</ArticleId><ArticleId IdType="pubmed">28912154</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva M.C., Cheng C., Mair W., Almeida S., Fong H., Biswas M.H.U., Zhang Z., Huang Y., Temple S., Coppola G. Human iPSC-derived neuronal model of tau-A152T frontotemporal dementia reveals tau-mediated mechanisms of neuronal vulnerability. Stem Cell Reports. 2016;7:325&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5032560</ArticleId><ArticleId IdType="pubmed">27594585</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva M.C., Ferguson F.M., Cai Q., Donovan K.A., Nandi G., Patnaik D., Zhang T., Huang H.T., Lucente D.E., Dickerson B.C. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. eLife. 2019;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450673</ArticleId><ArticleId IdType="pubmed">30907729</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoglund L., Viitanen M., Kalimo H., Lannfelt L., Jonhagen M.E., Ingelsson M., Glaser A., Herva R. The tau S305S mutation causes frontotemporal dementia with parkinsonism. Eur. J. Neurol. 2008;15:156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">18093153</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn P., Tracy T., Huang C., Yan R., Camargo C., Mok S., Freilich R., Roberson E., Karch C., Gestwicki J. Pathogenic Tau impairs axon initial segment plasticity and excitability homeostasis. Neuron. 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880876</ArticleId><ArticleId IdType="pubmed">31542321</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Crowther R.A., Goedert M. Comparison of the neurofibrillary pathology in Alzheimer's disease and familial presenile dementia with tangles. Acta Neuropathol. 1996;92:42&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">8811124</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S., Farlow M.R., Unverzagt F.W., Kareken D.A., Murrell J.R., Fraser G., Epperson F., Crowther R.A., Spillantini M.G., Goedert M. The tauopathy associated with mutation&#xa0;+3 in intron 10 of Tau: characterization of the MSTD family. Brain. 2008;131:72&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702832</ArticleId><ArticleId IdType="pubmed">18065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S., Schonhaut D.R., Boeve B.F., Seeley W.W., Ossenkoppele R., O'Neil J.P., Lazaris A., Rosen H.J., Boxer A.L., Perry D.C. Frontotemporal dementia with the V337M MAPT mutation: tau-PET and pathology correlations. Neurology. 2017;88:758&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344079</ArticleId><ArticleId IdType="pubmed">28130473</ArticleId></ArticleIdList></Reference><Reference><Citation>Sposito T., Preza E., Mahoney C.J., Seto-Salvia N., Ryan N.S., Morris H.R., Arber C., Devine M.J., Houlden H., Warner T.T. Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10&#xa0;+ 16 splice-site mutation in MAPT. Hum. Mol. Genet. 2015;24:5260&#x2013;5269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550814</ArticleId><ArticleId IdType="pubmed">26136155</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford P.M., Halliday G.M., Brooks W.S., Kwok J.B., Storey C.E., Creasey H., Morris J.G., Fulham M.J., Schofield P.R. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain. 2000;123(Pt 5):880&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">10775534</ArticleId></ArticleIdList></Reference><Reference><Citation>Tcw J., Wang M., Pimenova A.A., Bowles K.R., Hartley B.J., Lacin E., Machlovi S.I., Abdelaal R., Karch C.M., Phatnani H. An efficient platform for astrocyte differentiation from human induced pluripotent stem cells. Stem Cell Reports. 2017;9:600&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5550034</ArticleId><ArticleId IdType="pubmed">28757165</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian R., Gachechiladze M.A., Ludwig C.H., Laurie M.T., Hong J.Y., Nathaniel D., Prabhu A.V., Fernandopulle M.S., Patel R., Abshari M. CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons. Neuron. 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813890</ArticleId><ArticleId IdType="pubmed">31422865</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabzuni D., Wray S., Vandrovcova J., Ramasamy A., Walker R., Smith C., Luk C., Gibbs J.R., Dillman A., Hernandez D.G. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum. Mol. Genet. 2012;21:4094&#x2013;4103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428157</ArticleId><ArticleId IdType="pubmed">22723018</ArticleId></ArticleIdList></Reference><Reference><Citation>van Swieten J., Spillantini M.G. Hereditary frontotemporal dementia caused by Tau gene mutations. Brain Pathol. 2007;17:63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095608</ArticleId><ArticleId IdType="pubmed">17493040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Ward M.E., Chen R., Liu K., Tracy T.E., Chen X., Xie M., Sohn P.D., Ludwig C., Meyer-Franke A. Scalable production of iPSC-derived human neurons to identify Tau-lowering compounds by high-content screening. Stem Cell Reports. 2017;9:1221&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639430</ArticleId><ArticleId IdType="pubmed">28966121</ArticleId></ArticleIdList></Reference><Reference><Citation>Wren M.C., Zhao J., Liu C.C., Murray M.E., Atagi Y., Davis M.D., Fu Y., Okano H.J., Ogaki K., Strongosky A.J. Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. Mol. Neurodegener. 2015;10:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4572645</ArticleId><ArticleId IdType="pubmed">26373282</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y., Higuchi M., Zhang B., Huang S.-M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M.-Y. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31642932</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Association of Apolipoprotein E &#x25b;4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults.</ArticleTitle><Pagination><StartPage>e1913909</StartPage><MedlinePgn>e1913909</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1913909</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2019.13909</ELocationID><Abstract><AbstractText Label="IMPORTANCE">While amyloidosis is an early event in the Alzheimer disease (AD) biomarker cascade, a complex interplay among the apolipoprotein E (APOE) &#x25b;4 allele, educational levels, and sex may be associated with an individual's resilience to dementia.</AbstractText><AbstractText Label="OBJECTIVE">To assess whether APOE &#x25b;4, educational levels, and sex are associated with regional tau deposition and tau-mediated metabolic dysfunction in older adults.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Population-based cohort study of individuals aged 65 years and older enrolled between January 1, 2004, and May 1, 2018, in the Mayo Clinic Study of Aging, a prospective longitudinal study of cognitive aging in Olmsted County, Minnesota.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcomes were cross-sectional tau burden and the fluorodeoxyglucose (FDG) to tau ratio (as a measure of tau-mediated metabolic dysfunction) assessed by positron emission tomography for 43 atlas-defined regions, with specific focus on the entorhinal, inferior temporal, and posterior cingulate cortices.</AbstractText><AbstractText Label="EXPOSURES">Using linear regression, APOE &#x25b;4 status and years of education were the primary exposure variables, with sex additionally investigated through interaction models.</AbstractText><AbstractText Label="RESULTS">The sample included 325 individuals (173 [53%] male; mean [SD] age, 76.1 [7.2] years; 291 [90%] cognitively unimpaired). Although APOE &#x25b;4 was nominally associated with higher tau deposition (&#x3b2;&#x2009;=&#x2009;0.05 [95% CI, 0.02-0.09]; P&#x2009;=&#x2009;.001; Cohen d&#x2009;=&#x2009;0.40) and lower FDG to tau ratio (&#x3b2;&#x2009;=&#x2009;-0.05 [95% CI, -0.08 to -0.01]; P&#x2009;=&#x2009;.008; Cohen d&#x2009;=&#x2009;0.33) in the entorhinal cortex, these associations were completely attenuated after controlling for global amyloid burden. Education was not associated with regional tau burden or FDG to tau ratio. In the 3 regions of interest, global amyloid burden accounted for the largest proportion of variance in tau deposition among the candidate variables assessed. In the entorhinal cortex, significant interactions were identified between APOE &#x25b;4 and global amyloid burden on tau (&#x3b2;&#x2009;=&#x2009;0.25; SE&#x2009;=&#x2009;0.06; P&#x2009;&lt;&#x2009;.001) and between sex and tau burden on FDG metabolism (&#x3b2;&#x2009;=&#x2009;0.10; SE&#x2009;=&#x2009;0.05; P&#x2009;=&#x2009;.049).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">These results suggest that (1) tau deposition is most significantly associated with amyloidosis; (2) in the presence of abundant amyloidosis, APOE &#x25b;4 may be associated with accelerated entorhinal cortex tau deposition; and (3) women may have lower resilience to tau, manifested by a higher degree of metabolic dysfunction in the entorhinal cortex in response to tau pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramanan</LastName><ForeName>Vijay K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic-Rochester, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic-Rochester, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic-Rochester, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic-Rochester, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Val J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic-Rochester, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic-Rochester, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic-Rochester, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic-Rochester, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic-Rochester, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic-Rochester, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic-Rochester, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG056366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018898</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 AG058738</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097495</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="Y">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008910" MajorTopicYN="N" Type="Geographic">Minnesota</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Knopman reported serving on a data safety monitoring board for the DIAN study, serving as an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California, and receiving research support from the National Institutes of Health (NIH) outside the submitted work. Dr Graff-Radford reported receiving research support from the National Institute on Aging outside the submitted work. Dr Lowe reported receiving consulting fees from Bayer Schering Pharma, Piramal Life Sciences, and Merck Research and grants from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH outside the submitted work. Dr Petersen reported receiving consulting fees from Hoffman-La Roche Inc, Merck Inc, Genentech Inc, Biogen Inc, GE Healthcare, and Eisai Inc outside the submitted work. Dr Jack reported consulting for Eli Lilly, serving on an independent data monitoring board for Roche, and serving as a speaker for Eisai but receives no personal compensation from any commercial entity; he also reported receiving research support from the NIH and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr Mielke reported serving as a consultant to Eli Lilly and receiving research support from the NIH, Department of Defense, and unrestricted research grants from Biogen outside the submitted work. Dr Vemuri reported receiving grants from the NIH during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31642932</ArticleId><ArticleId IdType="pmc">PMC6820045</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.13909</ArticleId><ArticleId IdType="pii">2753401</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):-. doi:10.1016/S1474-4422(12)70291-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-547. doi:10.1212/WNL.0000000000002923</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002923</ArticleId><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age-specific and sex-specific prevalence of cerebral &#x3b2;-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017;16(6):435-444. doi:10.1016/S1474-4422(17)30077-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30077-7</ArticleId><ArticleId IdType="pmc">PMC5516534</ArticleId><ArticleId IdType="pubmed">28456479</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan VK, Risacher SL, Nho K, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer&#x2019;s disease implicates microglial activation gene IL1RAP. Brain. 2015;138(Pt 10):3076-3088. doi:10.1093/brain/awv231</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv231</ArticleId><ArticleId IdType="pmc">PMC4671479</ArticleId><ArticleId IdType="pubmed">26268530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan VK, Risacher SL, Nho K, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry. 2014;19(3):351-357. doi:10.1038/mp.2013.19</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2013.19</ArticleId><ArticleId IdType="pmc">PMC3661739</ArticleId><ArticleId IdType="pubmed">23419831</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. . Effect of intellectual enrichment on AD biomarker trajectories: longitudinal imaging study. Neurology. 2016;86(12):1128-1135. doi:10.1212/WNL.0000000000002490</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002490</ArticleId><ArticleId IdType="pmc">PMC4820132</ArticleId><ArticleId IdType="pubmed">26911640</ArticleId></ArticleIdList></Reference><Reference><Citation>Protas HD, Chen K, Langbaum JB, et al. . Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol. 2013;70(3):320-325. doi:10.1001/2013.jamaneurol.286</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2013.jamaneurol.286</ArticleId><ArticleId IdType="pmc">PMC3745014</ArticleId><ArticleId IdType="pubmed">23599929</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, et al. . Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2009;106(16):6820-6825. doi:10.1073/pnas.0900345106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900345106</ArticleId><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010;67(3):308-316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886799</ArticleId><ArticleId IdType="pubmed">20373342</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Goedert M, et al. . Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91(23):11183-11186. doi:10.1073/pnas.91.23.11183</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.23.11183</ArticleId><ArticleId IdType="pmc">PMC45191</ArticleId><ArticleId IdType="pubmed">7972031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadhwani AR, Affaneh A, Van Gulden S, Kessler JA. Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in Alzheimer disease. Ann Neurol. 2019;85(5):726-739. doi:10.1002/ana.25455</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25455</ArticleId><ArticleId IdType="pmc">PMC8123085</ArticleId><ArticleId IdType="pubmed">30840313</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523-527. doi:10.1038/nature24016</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaza-Urquijo EM, Gonneaud J, Fouquet M, et al. . Interaction between years of education and APOE &#x3b5;4 status on frontal and temporal metabolism. Neurology. 2015;85(16):1392-1399. doi:10.1212/WNL.0000000000002034</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002034</ArticleId><ArticleId IdType="pmc">PMC4626241</ArticleId><ArticleId IdType="pubmed">26408498</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA. Aging and Alzheimer&#x2019;s disease: lessons from the Nun Study. Gerontologist. 1997;37(2):150-156. doi:10.1093/geront/37.2.150</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geront/37.2.150</ArticleId><ArticleId IdType="pubmed">9127971</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolstad S, Nordlund A, Eckerstr&#xf6;m C, et al. . High education may offer protection against tauopathy in patients with mild cognitive impairment. J Alzheimers Dis. 2010;21(1):221-228. doi:10.3233/JAD-2010-091012</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-091012</ArticleId><ArticleId IdType="pubmed">20413900</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida RP, Schultz SA, Austin BP, et al. . Effect of cognitive reserve on age-related changes in cerebrospinal fluid biomarkers of Alzheimer disease. JAMA Neurol. 2015;72(6):699-706. doi:10.1001/jamaneurol.2015.0098</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.0098</ArticleId><ArticleId IdType="pmc">PMC4639566</ArticleId><ArticleId IdType="pubmed">25893879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Insel PS, Stern Y, Weiner MW; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology. 2013;80(13):1194-1201. doi:10.1212/WNL.0b013e31828970c2</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828970c2</ArticleId><ArticleId IdType="pmc">PMC3691784</ArticleId><ArticleId IdType="pubmed">23486873</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. Neurology. 2018;90(15):695-703. doi:10.1212/WNL.0000000000005303</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005303</ArticleId><ArticleId IdType="pmc">PMC5894932</ArticleId><ArticleId IdType="pubmed">29592885</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher DW, Bennett DA, Dong H. Sexual dimorphism in predisposition to Alzheimer&#x2019;s disease. Neurobiol Aging. 2018;70:308-324. doi:10.1016/j.neurobiolaging.2018.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.04.004</ArticleId><ArticleId IdType="pmc">PMC6368179</ArticleId><ArticleId IdType="pubmed">29754747</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu SC, Pa J, Kukull W, et al. . Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol. 2017;74(10):1178-1189. doi:10.1001/jamaneurol.2017.2188</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2188</ArticleId><ArticleId IdType="pmc">PMC5759346</ArticleId><ArticleId IdType="pubmed">28846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer&#x2019;s disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37-48. doi:10.2147/CLEP.S37929</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37929</ArticleId><ArticleId IdType="pmc">PMC3891487</ArticleId><ArticleId IdType="pubmed">24470773</ArticleId></ArticleIdList></Reference><Reference><Citation>Nebel RA, Aggarwal NT, Barnes LL, et al. . Understanding the impact of sex and gender in Alzheimer&#x2019;s disease: a call to action. Alzheimers Dement. 2018;14(9):1171-1183. doi:10.1016/j.jalz.2018.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.04.008</ArticleId><ArticleId IdType="pmc">PMC6400070</ArticleId><ArticleId IdType="pubmed">29907423</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Dumitrescu L, Barnes LL, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium and the Alzheimer&#x2019;s Disease Neuroimaging Initiative . Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol. 2018;75(8):989-998. doi:10.1001/jamaneurol.2018.0821</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0821</ArticleId><ArticleId IdType="pmc">PMC6142927</ArticleId><ArticleId IdType="pubmed">29801024</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Mormino EC, Chhatwal J, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiol Aging. 2019;78:178-185. doi:10.1016/j.neurobiolaging.2019.02.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.02.019</ArticleId><ArticleId IdType="pmc">PMC6545139</ArticleId><ArticleId IdType="pubmed">30947113</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A, Tian L, Henderson VW, Greicius MD; Alzheimer&#x2019;s Disease Neuroimaging Initiative Investigators . Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75(4):563-573. doi:10.1002/ana.24135</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24135</ArticleId><ArticleId IdType="pmc">PMC4117990</ArticleId><ArticleId IdType="pubmed">24623176</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Mormino EC, Rabin JS, et al. . Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol. 2019;76(5):542-551. doi:10.1001/jamaneurol.2018.4693</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.4693</ArticleId><ArticleId IdType="pmc">PMC6515599</ArticleId><ArticleId IdType="pubmed">30715078</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. . The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58-69. doi:10.1159/000115751</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000115751</ArticleId><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, et al. . Prevalence of mild cognitive impairment is higher in men: the Mayo Clinic Study of Aging. Neurology. 2010;75(10):889-897. doi:10.1212/WNL.0b013e3181f11d85</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f11d85</ArticleId><ArticleId IdType="pmc">PMC2938972</ArticleId><ArticleId IdType="pubmed">20820000</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ III. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012;87(12):1202-1213. doi:10.1016/j.mayocp.2012.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2012.08.012</ArticleId><ArticleId IdType="pmc">PMC3541925</ArticleId><ArticleId IdType="pubmed">23199802</ArticleId></ArticleIdList></Reference><Reference><Citation>St Sauver JL, Grossardt BR, Yawn BP, et al. . Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol. 2012;41(6):1614-1624. doi:10.1093/ije/dys195</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dys195</ArticleId><ArticleId IdType="pmc">PMC3535751</ArticleId><ArticleId IdType="pubmed">23159830</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545-548.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. . Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann Neurol. 2017;82(5):706-718. doi:10.1002/ana.25071</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25071</ArticleId><ArticleId IdType="pmc">PMC5696029</ArticleId><ArticleId IdType="pubmed">29023983</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Defining imaging biomarker cut points for brain aging and Alzheimer&#x2019;s disease. Alzheimers Dement. 2017;13(3):205-216. doi:10.1016/j.jalz.2016.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.08.005</ArticleId><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh compound-B. Ann Neurol. 2004;55(3):306-319. doi:10.1002/ana.20009</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20009</ArticleId><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Bruinsma TJ, Wiste HJ, et al. . Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology. 2019;93(1):e29-e39. doi:10.1212/WNL.0000000000007728</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007728</ArticleId><ArticleId IdType="pmc">PMC6659005</ArticleId><ArticleId IdType="pubmed">31147421</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lowe VJ, Knopman DS, et al. . Tau-PET uptake: regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement (Amst). 2016;6:21-30. doi:10.1016/j.dadm.2016.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2016.12.010</ArticleId><ArticleId IdType="pmc">PMC5257031</ArticleId><ArticleId IdType="pubmed">28138510</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119. doi:10.1002/ana.24546</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Geroldi C, Pihlajam&#xe4;ki M, Laakso MP, et al. . APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology. 1999;53(8):1825-1832. doi:10.1212/WNL.53.8.1825</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.8.1825</ArticleId><ArticleId IdType="pubmed">10563634</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Liu CC, Van Ingelgom AJ, et al. . APOE &#x3b5;2 is associated with increased tau pathology in primary tauopathy. Nat Commun. 2018;9(1):4388. doi:10.1038/s41467-018-06783-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06783-0</ArticleId><ArticleId IdType="pmc">PMC6197187</ArticleId><ArticleId IdType="pubmed">30348994</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y, Li Z, Kapoor M, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Alzheimer Disease Genetic Consortium . Genome-wide association study identifies four novel loci associated with Alzheimer&#x2019;s endophenotypes and disease modifiers. Acta Neuropathol. 2017;133(5):839-856. doi:10.1007/s00401-017-1685-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1685-y</ArticleId><ArticleId IdType="pmc">PMC5613285</ArticleId><ArticleId IdType="pubmed">28247064</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain. 2016;139(pt 5):1551-1567. doi:10.1093/brain/aww027</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww027</ArticleId><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Lesnick TG, et al. . Brain &#x3b2;-amyloid load approaches a plateau. Neurology. 2013;80(10):890-896. doi:10.1212/WNL.0b013e3182840bbe</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182840bbe</ArticleId><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Dumitrescu L, Oksol A, Wagener M, Gifford KA, Jefferson AL; Alzheimer&#x2019;s Disease Neuroimaging Initiative . APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer&#x2019;s disease. PLoS One. 2017;12(11):e0188501. doi:10.1371/journal.pone.0188501</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0188501</ArticleId><ArticleId IdType="pmc">PMC5708777</ArticleId><ArticleId IdType="pubmed">29190651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell WR, An Y, Kageyama Y, et al. . Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer&#x2019;s disease. Alzheimers Dement. 2019;15(1):8-16. doi:10.1016/j.jalz.2018.07.215</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.07.215</ArticleId><ArticleId IdType="pmc">PMC6542566</ArticleId><ArticleId IdType="pubmed">30465754</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel JM, Yu L, De Jager PL, Schneider JA, Bennett DA. Association of APOE with tau-tangle pathology with and without &#x3b2;-amyloid. Neurobiol Aging. 2016;37:19-25. doi:10.1016/j.neurobiolaging.2015.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.09.011</ArticleId><ArticleId IdType="pmc">PMC4716785</ArticleId><ArticleId IdType="pubmed">26481403</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Bourakova V, Visani A, et al. Does APOE E4 have an a(beta)-independent effecton tau pathology? neuroimaging investigations in cognitively normal elders and patients with Alzheimer&#x2019;s disease. In: Proceedings from the 142nd Annual Meeting of the American Neurological Association; October 15-17, 2017; San Diego, CA. Abstract M183.</Citation></Reference><Reference><Citation>Ulrich JD, Ulland TK, Mahan TE, et al. . ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med. 2018;215(4):1047-1058. doi:10.1084/jem.20171265</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171265</ArticleId><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Carson MJ, El Khoury J, et al. . Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14(4):388-405. doi:10.1016/S1474-4422(15)70016-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)70016-5</ArticleId><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Wiste HJ, Weigand SD, et al. . Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology. 2012;79(15):1570-1577. doi:10.1212/WNL.0b013e31826e2696</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826e2696</ArticleId><ArticleId IdType="pmc">PMC3475629</ArticleId><ArticleId IdType="pubmed">22972644</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, Desikan RS, Dale AM, McEvoy LK; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Higher rates of decline for women and apolipoprotein E epsilon4 carriers. AJNR Am J Neuroradiol. 2013;34(12):2287-2293. doi:10.3174/ajnr.A3601</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A3601</ArticleId><ArticleId IdType="pmc">PMC3894062</ArticleId><ArticleId IdType="pubmed">23828104</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazure CM, Swendsen J. Sex differences in Alzheimer&#x2019;s disease and other dementias. Lancet Neurol. 2016;15(5):451-452. doi:10.1016/S1474-4422(16)00067-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00067-3</ArticleId><ArticleId IdType="pmc">PMC4864429</ArticleId><ArticleId IdType="pubmed">26987699</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti MT, Iulita MF, Cavedo E, et al. ; Women&#x2019;s Brain Project and the Alzheimer Precision Medicine Initiative . Sex differences in Alzheimer disease&#x2014;the gateway to precision medicine. Nat Rev Neurol. 2018;14(8):457-469. doi:10.1038/s41582-018-0032-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0032-9</ArticleId><ArticleId IdType="pubmed">29985474</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoenig MC, Bischof GN, Hammes J, et al. . Tau pathology and cognitive reserve in Alzheimer&#x2019;s disease. Neurobiol Aging. 2017;57:1-7. doi:10.1016/j.neurobiolaging.2017.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.05.004</ArticleId><ArticleId IdType="pubmed">28577411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoenig MC, Bischof GN, Onur OA, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Level of education mitigates the impact of tau pathology on neuronal function. Eur J Nucl Med Mol Imaging. 2019;46(9):1787-1795. doi:10.1007/s00259-019-04342-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-019-04342-3</ArticleId><ArticleId IdType="pubmed">31183635</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaza-Urquijo EM, Przybelski SA, Lesnick TL, et al. . The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain. 2019;142(4):1134-1147. doi:10.1093/brain/awz037</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz037</ArticleId><ArticleId IdType="pmc">PMC6439329</ArticleId><ArticleId IdType="pubmed">30851100</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczynski B, Jagust W, Chui HC, Reed B. An inverse association of cardiovascular risk and frontal lobe glucose metabolism. Neurology. 2009;72(8):738-743. doi:10.1212/01.wnl.0000343005.35498.e5</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000343005.35498.e5</ArticleId><ArticleId IdType="pmc">PMC2677543</ArticleId><ArticleId IdType="pubmed">19237703</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS, Yang HS, Schultz AP, et al. . Vascular risk and &#x3b2;-amyloid are synergistically associated with cortical tau. Ann Neurol. 2019;85(2):272-279. doi:10.1002/ana.25399</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25399</ArticleId><ArticleId IdType="pmc">PMC6351182</ArticleId><ArticleId IdType="pubmed">30565287</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Chiotis K, Lemoine L, et al. . Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24(8):1112-1134. doi:10.1038/s41380-018-0342-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0342-8</ArticleId><ArticleId IdType="pmc">PMC6756230</ArticleId><ArticleId IdType="pubmed">30635637</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, et al. . Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503-1527. doi:10.1093/brain/awz099</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Yu L, Lamar M, Schneider JA, Boyle PA, Bennett DA. Education and cognitive reserve in old age. Neurology. 2019;92(10):e1041-e1050. doi:10.1212/WNL.0000000000007036</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007036</ArticleId><ArticleId IdType="pmc">PMC6442015</ArticleId><ArticleId IdType="pubmed">30728309</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS. Lowering of amyloid-beta by &#x3b2;-secretase inhibitors&#x2014;some informative failures. N Engl J Med. 2019;380(15):1476-1478. doi:10.1056/NEJMe1903193</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe1903193</ArticleId><ArticleId IdType="pubmed">30970194</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31645758</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>574</Volume><Issue>7780</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Dietary salt promotes cognitive impairment through tau phosphorylation.</ArticleTitle><Pagination><StartPage>686</StartPage><EndPage>690</EndPage><MedlinePgn>686-690</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-1688-z</ELocationID><Abstract><AbstractText>Dietary habits and vascular risk factors promote both Alzheimer's disease and cognitive impairment caused by vascular factors<sup>1-3</sup>. Furthermore, accumulation of hyperphosphorylated tau, a microtubule-associated protein and a hallmark of Alzheimer's pathology<sup>4</sup>, is also linked to vascular cognitive impairment<sup>5,6</sup>. In mice, a salt-rich diet leads to cognitive dysfunction associated with a nitric oxide deficit in cerebral endothelial cells and cerebral hypoperfusion<sup>7</sup>. Here we report that dietary salt induces hyperphosphorylation of tau followed by cognitive dysfunction in mice, and that these effects are prevented by restoring endothelial nitric oxide production. The nitric oxide deficiency reduces neuronal calpain nitrosylation and results in enzyme activation, which, in turn, leads to tau phosphorylation by activating cyclin-dependent kinase&#xa0;5. Salt-induced cognitive impairment is not observed in tau-null mice or in mice treated with anti-tau antibodies, despite persistent cerebral hypoperfusion and neurovascular dysfunction. These findings identify a causal link between dietary salt, endothelial dysfunction and tau pathology, independent of haemodynamic insufficiency. Avoidance of excessive salt intake and maintenance of vascular health may help to stave off the vascular and neurodegenerative pathologies that underlie dementia in the elderly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faraco</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. gif2004@med.cornell.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochrainer</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segarra</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaeffer</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santisteban</LastName><ForeName>Monica M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anrather</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iadecola</LastName><ForeName>Costantino</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. coi2001@med.cornell.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS095441</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS109588</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS089323</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01-NS095441</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017673">Sodium Chloride, Dietary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Jan;16(1):2-3. doi: 10.1038/s41582-019-0289-7.</RefSource><PMID Version="1">31712717</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2020 Feb;578(7793):E9. doi: 10.1038/s41586-019-1925-5.</RefSource><PMID Version="1">31932732</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017673" MajorTopicYN="N">Sodium Chloride, Dietary</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests. D.M.H. is listed as an inventor on a patent licensed by Washington University to C2N Diagnostics and subsequently AbbVie on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali, Genentech, and Proclara. C.I. is on the scientific advisory board of Broadview Ventures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31645758</ArticleId><ArticleId IdType="mid">NIHMS1605533</ArticleId><ArticleId IdType="pmc">PMC7380655</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1688-z</ArticleId><ArticleId IdType="pii">10.1038/s41586-019-1688-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scarmeas N, Anastasiou CA &amp; Yannakoulia M Nutrition and prevention of cognitive impairment. Lancet Neurol, 10.1016/S1474-4422(18)30338-7 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30338-7</ArticleId><ArticleId IdType="pubmed">30244829</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Rest O, Berendsen AA, Haveman-Nies A &amp; de Groot LC Dietary patterns, cognitive decline, and dementia: a systematic review. Adv Nutr 6, 154&#x2013;168, 10.3945/an.114.007617 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/an.114.007617</ArticleId><ArticleId IdType="pmc">PMC4352174</ArticleId><ArticleId IdType="pubmed">25770254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendig MD &amp; Morris MJ Reviewing the effects of dietary salt on cognition: mechanisms and future directions. Asia Pac J Clin Nutr 28, 6&#x2013;14, 10.6133/apjcn.201903_28(1).0002 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.6133/apjcn.201903_28(1).0002</ArticleId><ArticleId IdType="pubmed">30896408</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B &amp; Karran E The Cellular Phase of Alzheimer&#x2019;s Disease. Cell 164, 603&#x2013;615, 10.1016/j.cell.2015.12.056 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.056</ArticleId><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Nation DA et al. Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. JAMA Neurol 72, 546&#x2013;553, 10.1001/jamaneurol.2014.4477 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4477</ArticleId><ArticleId IdType="pmc">PMC4428938</ArticleId><ArticleId IdType="pubmed">25822631</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ et al. Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging. JAMA Neurol 75, 999&#x2013;1007, 10.1001/jamaneurol.2018.0975 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0975</ArticleId><ArticleId IdType="pmc">PMC6142932</ArticleId><ArticleId IdType="pubmed">29799981</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G et al. Dietary salt promotes neurovascular and cognitive dysfunction through a gut-initiated TH17 response. Nat Neurosci 21, 240&#x2013;249, 10.1038/s41593-017-0059-z (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-017-0059-z</ArticleId><ArticleId IdType="pmc">PMC6207376</ArticleId><ArticleId IdType="pubmed">29335605</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiocco AJ et al. Sodium intake and physical activity impact cognitive maintenance in older adults: the NuAge Study. Neurobiol Aging 33, 829 e821&#x2013;828, 10.1016/j.neurobiolaging.2011.07.004 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.07.004</ArticleId><ArticleId IdType="pubmed">21855174</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardener H, Rundek T, Wright CB, Elkind MS &amp; Sacco RL Dietary sodium and risk of stroke in the Northern Manhattan study. Stroke 43, 1200&#x2013;1205, 10.1161/STROKEAHA.111.641043 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.111.641043</ArticleId><ArticleId IdType="pmc">PMC3347890</ArticleId><ArticleId IdType="pubmed">22499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal JA et al. Lifestyle and neurocognition in older adults with cognitive impairments: A randomized trial. Neurology 92, e212&#x2013;e223, 10.1212/WNL.0000000000006784 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006784</ArticleId><ArticleId IdType="pmc">PMC6340382</ArticleId><ArticleId IdType="pubmed">30568005</ArticleId></ArticleIdList></Reference><Reference><Citation>Heye AK et al. Blood pressure and sodium: Association with MRI markers in cerebral small vessel disease. J Cereb Blood Flow Metab 36, 264&#x2013;274, 10.1038/jcbfm.2015.64 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2015.64</ArticleId><ArticleId IdType="pmc">PMC4758556</ArticleId><ArticleId IdType="pubmed">25899292</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C The pathobiology of vascular dementia. Neuron 80, 844&#x2013;866, 10.1016/j.neuron.2013.10.008 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.008</ArticleId><ArticleId IdType="pmc">PMC3842016</ArticleId><ArticleId IdType="pubmed">24267647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD et al. Vascular dysfunction-The disregarded partner of Alzheimer&#x2019;s disease. Alzheimers Dement 15, 158&#x2013;167, 10.1016/j.jalz.2018.07.222 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.07.222</ArticleId><ArticleId IdType="pmc">PMC6338083</ArticleId><ArticleId IdType="pubmed">30642436</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al. Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. J Cereb Blood Flow Metab 36, 1653&#x2013;1667, 10.1177/0271678X16662891 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X16662891</ArticleId><ArticleId IdType="pmc">PMC5076792</ArticleId><ArticleId IdType="pubmed">27496552</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall RS et al. Recovery of brain function during induced cerebral hypoperfusion. Brain 124, 1208&#x2013;1217 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11353736</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y &amp; Mandelkow E Tau in physiology and pathology. Nat Rev Neurosci 17, 5&#x2013;21, 10.1038/nrn.2015.1 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2015.1</ArticleId><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y et al. Sodium Intake Regulates Glucose Homeostasis through the PPARdelta/Adiponectin-Mediated SGLT2 Pathway. Cell Metab 23, 699&#x2013;711, 10.1016/j.cmet.2016.02.019 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2016.02.019</ArticleId><ArticleId IdType="pubmed">27053360</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21, 1154&#x2013;1162, 10.1038/nm.3951 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3951</ArticleId><ArticleId IdType="pmc">PMC4598295</ArticleId><ArticleId IdType="pubmed">26390242</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2, 157&#x2013;161, 10.1038/5715 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/5715</ArticleId><ArticleId IdType="pubmed">10195200</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G et al. Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension. J Clin Invest 126, 4674&#x2013;4689, 10.1172/JCI86950 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI86950</ArticleId><ArticleId IdType="pmc">PMC5127678</ArticleId><ArticleId IdType="pubmed">27841763</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Stieler JT &amp; Holzer M Tau and tauopathies. Brain Res Bull 126, 238&#x2013;292, 10.1016/j.brainresbull.2016.08.018 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2016.08.018</ArticleId><ArticleId IdType="pubmed">27615390</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360&#x2013;364, 10.1038/35012636 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35012636</ArticleId><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615&#x2013;622, 10.1038/45159 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/45159</ArticleId><ArticleId IdType="pubmed">10604467</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin SA &amp; Katusic ZS Loss of Endothelial Nitric Oxide Synthase Promotes p25 Generation and Tau Phosphorylation in a Murine Model of Alzheimer&#x2019;s Disease. Circ Res 119, 1128&#x2013;1134, 10.1161/CIRCRESAHA.116.309686 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.309686</ArticleId><ArticleId IdType="pmc">PMC5085902</ArticleId><ArticleId IdType="pubmed">27601478</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibb JA et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402, 669&#x2013;671, 10.1038/45251 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/45251</ArticleId><ArticleId IdType="pubmed">10604473</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla V et al. A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer&#x2019;s disease phenotypes in model mice. FASEB J 27, 174&#x2013;186, 10.1096/fj.12-217497 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.12-217497</ArticleId><ArticleId IdType="pmc">PMC3528323</ArticleId><ArticleId IdType="pubmed">23038754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T et al. Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites. J Biol Chem 288, 7968&#x2013;7977, 10.1074/jbc.M112.433326 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.433326</ArticleId><ArticleId IdType="pmc">PMC3597833</ArticleId><ArticleId IdType="pubmed">23362255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono Y, Saido TC &amp; Sorimachi H Calpain research for drug discovery: challenges and potential. Nat Rev Drug Discov 15, 854&#x2013;876, 10.1038/nrd.2016.212 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2016.212</ArticleId><ArticleId IdType="pubmed">27833121</ArticleId></ArticleIdList></Reference><Reference><Citation>Etwebi Z, Landesberg G, Preston K, Eguchi S &amp; Scalia R Mechanistic Role of the Calcium-Dependent Protease Calpain in the Endothelial Dysfunction Induced by MPO (Myeloperoxidase). Hypertension 71, 761&#x2013;770, 10.1161/HYPERTENSIONAHA.117.10305 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.117.10305</ArticleId><ArticleId IdType="pmc">PMC6467284</ArticleId><ArticleId IdType="pubmed">29507101</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu J et al. S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by beta-amyloid peptide. Proc Natl Acad Sci U S A 108, 14330&#x2013;14335, 10.1073/pnas.1105172108 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1105172108</ArticleId><ArticleId IdType="pmc">PMC3161554</ArticleId><ArticleId IdType="pubmed">21844361</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron 96, 17&#x2013;42, 10.1016/j.neuron.2017.07.030 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.030</ArticleId><ArticleId IdType="pmc">PMC5657612</ArticleId><ArticleId IdType="pubmed">28957666</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402&#x2013;414, 10.1016/j.neuron.2013.07.046 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.046</ArticleId><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Powles J et al. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open 3, e003733, 10.1136/bmjopen-2013-003733 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2013-003733</ArticleId><ArticleId IdType="pmc">PMC3884590</ArticleId><ArticleId IdType="pubmed">24366578</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>REFERENCES (METHODS ONLY)</Title><Reference><Citation>Hochrainer K et al. The ubiquitin ligase HERC3 attenuates NF-kappaB-dependent transcription independently of its enzymatic activity by delivering the RelA subunit for degradation. Nucleic Acids Res 43, 9889&#x2013;9904, 10.1093/nar/gkv1064 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1064</ArticleId><ArticleId IdType="pmc">PMC4787756</ArticleId><ArticleId IdType="pubmed">26476452</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla V et al. TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice. J Alzheimers Dis 56, 335&#x2013;349, 10.3233/JAD-160916 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160916</ArticleId><ArticleId IdType="pmc">PMC10020940</ArticleId><ArticleId IdType="pubmed">28085018</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G et al. Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation. Hypertension 62, 759&#x2013;766, 10.1161/HYPERTENSIONAHA.113.01761 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.113.01761</ArticleId><ArticleId IdType="pmc">PMC3874144</ArticleId><ArticleId IdType="pubmed">23959559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober F et al. High-resolution myocardial perfusion mapping in small animals in vivo by spin-labeling gradient-echo imaging. Magn Reson Med 51, 62&#x2013;67, 10.1002/mrm.10676 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.10676</ArticleId><ArticleId IdType="pubmed">14705046</ArticleId></ArticleIdList></Reference><Reference><Citation>Petry FR et al. Specificity of anti-tau antibodies when analyzing mice models of Alzheimer&#x2019;s disease: problems and solutions. PLoS One 9, e94251, 10.1371/journal.pone.0094251 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0094251</ArticleId><ArticleId IdType="pmc">PMC4008431</ArticleId><ArticleId IdType="pubmed">24788298</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G et al. Hypertension enhances Abeta-induced neurovascular dysfunction, promotes beta-secretase activity, and leads to amyloidogenic processing of APP. J Cereb Blood Flow Metab 36, 241&#x2013;252, 10.1038/jcbfm.2015.79 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2015.79</ArticleId><ArticleId IdType="pmc">PMC4758560</ArticleId><ArticleId IdType="pubmed">25920959</ArticleId></ArticleIdList></Reference><Reference><Citation>Voit A et al. Reducing sarcolipin expression mitigates Duchenne muscular dystrophy and associated cardiomyopathy in mice. Nat Commun 8, 1068, 10.1038/s41467-017-01146-7 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01146-7</ArticleId><ArticleId IdType="pmc">PMC5648780</ArticleId><ArticleId IdType="pubmed">29051551</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W et al. Metabolic stress-induced cardiomyopathy is caused by mitochondrial dysfunction due to attenuated Erk5 signaling. Nat Commun 8, 494, 10.1038/s41467-017-00664-8 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00664-8</ArticleId><ArticleId IdType="pmc">PMC5591279</ArticleId><ArticleId IdType="pubmed">28887535</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrester MT, Foster MW, Benhar M &amp; Stamler JS Detection of protein S-nitrosylation with the biotin-switch technique. Free Radic Biol Med 46, 119&#x2013;126, 10.1016/j.freeradbiomed.2008.09.034 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2008.09.034</ArticleId><ArticleId IdType="pmc">PMC3120222</ArticleId><ArticleId IdType="pubmed">18977293</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SJ &amp; Stackman RW Jr. Assessing rodent hippocampal involvement in the novel object recognition task. A review. Behav Brain Res 285, 105&#x2013;117, 10.1016/j.bbr.2014.08.002 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2014.08.002</ArticleId><ArticleId IdType="pmc">PMC7008635</ArticleId><ArticleId IdType="pubmed">25169255</ArticleId></ArticleIdList></Reference><Reference><Citation>Grayson B et al. Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. Behav Brain Res 285, 176&#x2013;193, 10.1016/j.bbr.2014.10.025 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2014.10.025</ArticleId><ArticleId IdType="pubmed">25447293</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Leary TP &amp; Brown RE Optimization of apparatus design and behavioral measures for the assessment of visuo-spatial learning and memory of mice on the Barnes maze. Learn Mem 20, 85&#x2013;96, 10.1101/lm.028076.112 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.028076.112</ArticleId><ArticleId IdType="pubmed">23322557</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31664019</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Cryo-EM structure and polymorphism of A&#x3b2; amyloid fibrils purified from Alzheimer's brain tissue.</ArticleTitle><Pagination><StartPage>4760</StartPage><MedlinePgn>4760</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4760</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-12683-8</ELocationID><Abstract><AbstractText>The formation of A&#x3b2; amyloid fibrils is a neuropathological hallmark of Alzheimer's disease and cerebral amyloid angiopathy. However, the structure of A&#x3b2; amyloid fibrils from brain tissue is poorly understood. Here we report the purification of A&#x3b2; amyloid fibrils from meningeal&#xa0;Alzheimer's brain tissue and their structural analysis with cryo-electron microscopy. We show that these fibrils are polymorphic but consist of similarly structured protofilaments. Brain derived A&#x3b2; amyloid fibrils are right-hand twisted and their peptide fold differs sharply from previously analyzed A&#x3b2; fibrils that were formed in vitro. These data underscore the importance to use patient-derived amyloid fibrils when investigating the structural basis of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kollmer</LastName><ForeName>Marius</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9551-6357</Identifier><AffiliationInfo><Affiliation>Institute of Protein Biochemistry, Ulm University, Helmholtzstrasse 8/1, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Close</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Protein Biochemistry, Ulm University, Helmholtzstrasse 8/1, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funk</LastName><ForeName>Leonie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Protein Biochemistry, Ulm University, Helmholtzstrasse 8/1, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Jay</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6905-745X</Identifier><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queensland Brain Institute, The University of Queensland, St Lucia Campus, Brisbane, QLD, 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bsoul</LastName><ForeName>Aref</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Protein Biochemistry, Ulm University, Helmholtzstrasse 8/1, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schierhorn</LastName><ForeName>Angelika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry and Biotechnology, Martin-Luther-University, 06120, Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Protein Biochemistry, Ulm University, Helmholtzstrasse 8/1, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigurdson</LastName><ForeName>Christina J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9045-1072</Identifier><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xe4;ndrich</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Protein Biochemistry, Ulm University, Helmholtzstrasse 8/1, 89081, Ulm, Germany. marcus.faendrich@uni-ulm.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS069566</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076896</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069338" MajorTopicYN="N">Neuropathology</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31664019</ArticleId><ArticleId IdType="pmc">PMC6820800</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-12683-8</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-12683-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu. Rev. Biochem. 2017;86:27&#x2013;68. doi: 10.1146/annurev-biochem-061516-045115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-061516-045115</ArticleId><ArticleId IdType="pubmed">28498720</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 2016;8:595&#x2013;608. doi: 10.15252/emmm.201606210.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Walter J, Saido TC, F&#xe4;ndrich M. Neuropathology and biochemistry of A&#x3b2; and its aggregates in Alzheimer&#x2019;s disease. Acta Neuropathol. 2015;129:167&#x2013;182. doi: 10.1007/s00401-014-1375-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1375-y</ArticleId><ArticleId IdType="pubmed">25534025</ArticleId></ArticleIdList></Reference><Reference><Citation>Charidimou A, et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain. 2017;140:1829&#x2013;1850. doi: 10.1093/brain/awx047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx047</ArticleId><ArticleId IdType="pmc">PMC6059159</ArticleId><ArticleId IdType="pubmed">28334869</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer&#x2019;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984;120:885&#x2013;890. doi: 10.1016/S0006-291X(84)80190-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(84)80190-4</ArticleId><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA. 1985;82:4245&#x2013;4249. doi: 10.1073/pnas.82.12.4245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.82.12.4245</ArticleId><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer&#x2019;s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007;8:101&#x2013;112. doi: 10.1038/nrm2101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2101</ArticleId><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, et al. Comparison of Alzheimer Abeta(1-40) and Abeta(1-42) amyloid fibrils reveals similar protofilament structures. Proc. Natl. Acad. Sci. USA. 2009;106:19813&#x2013;19818. doi: 10.1073/pnas.0905007106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0905007106</ArticleId><ArticleId IdType="pmc">PMC2764733</ArticleId><ArticleId IdType="pubmed">19843697</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsbury CS, et al. Studies on the in vitro assembly of a beta 1-40: implications for the search for a beta fibril formation inhibitors. J. Struct. Biol. 2000;130:217&#x2013;231. doi: 10.1006/jsbi.2000.4259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jsbi.2000.4259</ArticleId><ArticleId IdType="pubmed">10940227</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse C, et al. Quaternary structure of a mature amyloid fibril from Alzheimer&#x2019;s Abeta(1-40) peptide. J. Mol. Biol. 2006;362:347&#x2013;354. doi: 10.1016/j.jmb.2006.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2006.07.011</ArticleId><ArticleId IdType="pubmed">16920151</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular structural basis for polymorphism in Alzheimer&#x2019;s beta-amyloid fibrils. Proc. Natl. Acad. Sci. USA. 2008;105:18349&#x2013;18354. doi: 10.1073/pnas.0806270105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0806270105</ArticleId><ArticleId IdType="pmc">PMC2587602</ArticleId><ArticleId IdType="pubmed">19015532</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse C, F&#xe4;ndrich M, Grigorieff N. Paired beta-sheet structure of an Abeta(1-40) amyloid fibril revealed by electron microscopy. Proc. Natl. Acad. Sci. USA. 2008;105:7462&#x2013;7466. doi: 10.1073/pnas.0712290105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0712290105</ArticleId><ArticleId IdType="pmc">PMC2396686</ArticleId><ArticleId IdType="pubmed">18483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, et al. Molecular structure of &#x3b2;-amyloid fibrils in Alzheimer&#x2019;s disease brain tissue. Cell. 2013;154:1257&#x2013;1268. doi: 10.1016/j.cell.2013.08.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.08.035</ArticleId><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, et al. Peptide dimer structure in an A&#x3b2;(1-42) fibril visualized with cryo-EM. Proc. Natl. Acad. Sci. USA. 2015;112:11858&#x2013;11863. doi: 10.1073/pnas.1503455112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1503455112</ArticleId><ArticleId IdType="pmc">PMC4586870</ArticleId><ArticleId IdType="pubmed">26351699</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;tz AK, et al. Atomic-resolution three-dimensional structure of amyloid &#x3b2; fibrils bearing the Osaka mutation. Angew. Chem. Int. Ed. Engl. 2015;54:331&#x2013;335. doi: 10.1002/anie.201408598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201408598</ArticleId><ArticleId IdType="pmc">PMC4502972</ArticleId><ArticleId IdType="pubmed">25395337</ArticleId></ArticleIdList></Reference><Reference><Citation>Sgourakis NG, Yau WM, Qiang W. Modeling an in-register, parallel &#x201c;iowa&#x201d; a&#x3b2; fibril structure using solid-state NMR data from labeled samples with rosetta. Structure. 2015;23:216&#x2013;227. doi: 10.1016/j.str.2014.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2014.10.022</ArticleId><ArticleId IdType="pubmed">25543257</ArticleId></ArticleIdList></Reference><Reference><Citation>Colvin MT, et al. Atomic resolution structure of monomorphic A&#x3b2;42 amyloid fibrils. J. Am. Chem. Soc. 2016;138:9663&#x2013;9674. doi: 10.1021/jacs.6b05129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.6b05129</ArticleId><ArticleId IdType="pmc">PMC5389415</ArticleId><ArticleId IdType="pubmed">27355699</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xe4;lti MA, et al. Atomic-resolution structure of a disease-relevant A&#x3b2;(1-42) amyloid fibril. Proc. Natl. Acad. Sci. USA. 2016;113:4976&#x2013;4984. doi: 10.1073/pnas.1600749113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1600749113</ArticleId><ArticleId IdType="pmc">PMC5003276</ArticleId><ArticleId IdType="pubmed">27469165</ArticleId></ArticleIdList></Reference><Reference><Citation>Gremer L, et al. Fibril structure of amyloid-&#x3b2;(1-42) by cryo-electron microscopy. Science. 2017;358:116&#x2013;119. doi: 10.1126/science.aao2825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao2825</ArticleId><ArticleId IdType="pmc">PMC6080689</ArticleId><ArticleId IdType="pubmed">28882996</ArticleId></ArticleIdList></Reference><Reference><Citation>Annamalai K, et al. Polymorphism of amyloid fibrils in vivo. Angew. Chem. Int. Ed. Engl. 2016;55:4822&#x2013;4825. doi: 10.1002/anie.201511524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201511524</ArticleId><ArticleId IdType="pmc">PMC4864496</ArticleId><ArticleId IdType="pubmed">26954430</ArticleId></ArticleIdList></Reference><Reference><Citation>Annamalai K, et al. Common fibril structures imply systemically conserved protein misfolding pathways in vivo. Angew. Chem. Int. Ed. Engl. 2017;56:7510&#x2013;7514. doi: 10.1002/anie.201701761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201701761</ArticleId><ArticleId IdType="pubmed">28544119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. Interprotofilament interactions between Alzheimer&#x2019;s Abeta1-42 peptides in amyloid fibrils revealed by cryo EM. Proc. Natl. Acad. Sci. USA. 2009;106:4653&#x2013;4658. doi: 10.1073/pnas.0901085106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0901085106</ArticleId><ArticleId IdType="pmc">PMC2660777</ArticleId><ArticleId IdType="pubmed">19264960</ArticleId></ArticleIdList></Reference><Reference><Citation>Chothia C. Conformation of twisted beta-pleated sheets in proteins. J. Mol. Biol. 1973;75:295&#x2013;302. doi: 10.1016/0022-2836(73)90022-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2836(73)90022-3</ArticleId><ArticleId IdType="pubmed">4728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberta F, et al. Cryo-EM fibril structures from systemic AA amyloidosis reveal the species complementarity of pathological amyloids. Nat. Commun. 2019;10:1104. doi: 10.1038/s41467-019-09033-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09033-z</ArticleId><ArticleId IdType="pmc">PMC6405766</ArticleId><ArticleId IdType="pubmed">30846696</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. ELife. 2019;8:e43584. doi: 10.7554/eLife.43584.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.43584</ArticleId><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat. Neurosci. 2018;21:1341&#x2013;1349. doi: 10.1038/s41593-018-0238-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0238-6</ArticleId><ArticleId IdType="pmc">PMC6375686</ArticleId><ArticleId IdType="pubmed">30258241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihse E, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid. 2013;20:142&#x2013;150. doi: 10.3109/13506129.2013.797890.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13506129.2013.797890</ArticleId><ArticleId IdType="pubmed">23713495</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberta F, et al. Morphological and primary structural consistency of fibrils from different AA patients (common variant) Amyloid. 2019;26:164&#x2013;170. doi: 10.1080/13506129.2019.1628015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13506129.2019.1628015</ArticleId><ArticleId IdType="pubmed">31240945</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568:420&#x2013;423. doi: 10.1038/s41586-019-1026-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1026-5</ArticleId><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergstr&#xf6;m J, et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J. Pathol. 2005;206:224&#x2013;232. doi: 10.1002/path.1759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1759</ArticleId><ArticleId IdType="pubmed">15810051</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermark GT, F&#xe4;ndrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu. Rev. Pathol. 2015;10:321&#x2013;344. doi: 10.1146/annurev-pathol-020712-163913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathol-020712-163913</ArticleId><ArticleId IdType="pubmed">25387054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer JR, Mastronarde DN, McIntosh JR. Computer visualization of three-dimensional image data using IMOD. J. Struct. Biol. 1996;116:71&#x2013;76. doi: 10.1006/jsbi.1996.0013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jsbi.1996.0013</ArticleId><ArticleId IdType="pubmed">8742726</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ, et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods. 2017;14:331&#x2013;332. doi: 10.1038/nmeth.4193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4193</ArticleId><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K. Gctf: Real-time CTF determination and correction. J. Struct. Biol. 2016;193:1&#x2013;12. doi: 10.1016/j.jsb.2015.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2015.11.003</ArticleId><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Scheres SHW. Helical reconstruction in RELION. J. Struct. Biol. 2017;198:163&#x2013;176. doi: 10.1016/j.jsb.2017.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2017.02.003</ArticleId><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010;66:486&#x2013;501. doi: 10.1107/S0907444910007493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444910007493</ArticleId><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010;66:213&#x2013;221. doi: 10.1107/S0907444909052925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909052925</ArticleId><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV, Headd JJ, Terwilliger TC, Adams PD. New tool: phenix. real_space_refine. Comput. Crystallogr. Newsl. 2013;4:43&#x2013;44.</Citation></Reference><Reference><Citation>Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 2010;66:12&#x2013;21. doi: 10.1107/S0907444909042073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909042073</ArticleId><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF, et al. Changes in amyloid-&#x3b2; and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med. 2013;5:194re2. doi: 10.1126/scitranslmed.3006446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3006446</ArticleId><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rennegarbe M, Lenter I, Schierhorn A, Sawilla R, Haupt C. Influence of C-terminal truncation of murine Serum amyloid A on fibril structure. Sci. Rep. 2017;7:6170. doi: 10.1038/s41598-017-06419-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-06419-1</ArticleId><ArticleId IdType="pmc">PMC5522423</ArticleId><ArticleId IdType="pubmed">28733641</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32015339</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study.</ArticleTitle><Pagination><StartPage>667</StartPage><MedlinePgn>667</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">667</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-14279-8</ELocationID><Abstract><AbstractText>Each additional copy of the apolipoprotein E4 (APOE4) allele is associated with a higher risk of Alzheimer's dementia, while the APOE2 allele is associated with a lower risk of Alzheimer's dementia, it is not yet known whether APOE2 homozygotes have a particularly low risk. We generated Alzheimer's dementia odds ratios and other findings in more than 5,000 clinically characterized and neuropathologically characterized Alzheimer's dementia cases and controls. APOE2/2 was associated with a low Alzheimer's dementia odds ratios compared to APOE2/3 and 3/3, and an exceptionally low odds ratio compared to APOE4/4, and the impact of APOE2 and APOE4 gene dose was significantly greater in the neuropathologically confirmed group than in more than 24,000 neuropathologically unconfirmed cases and controls. Finding and targeting the factors by which APOE and its variants influence Alzheimer's disease could have a major impact on the understanding, treatment and prevention of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-0705-3696</Identifier><AffiliationInfo><Affiliation>Banner Alzheimer's Institute and Arizona Alzheimer's Consortium, 901 E Willetta Street, Phoenix, AZ, 85006, USA. eric.reiman@bannerhealth.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Arizona, 714 E Van Buren Street, Phoenix, AZ, 85006, USA. eric.reiman@bannerhealth.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Arizona State University, 522 N Central Avenue, Phoenix, AZ, 85004, USA. eric.reiman@bannerhealth.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurogenomics Division, Translational Genomics Research Institute and Arizona Alzheimer's Consortium, 445 N Fifth Street, Phoenix, AZ, 85004, USA. eric.reiman@bannerhealth.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arboleda-Velasquez</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-3192-9117</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, 20 Staniford Street, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, Translational Genomics Research Institute and Arizona Alzheimer's Consortium, 445 N Fifth Street, Phoenix, AZ, 85004, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute and Arizona Alzheimer's Consortium, 901 E Willetta Street, Phoenix, AZ, 85006, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ, 85259, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yinghua</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute and Arizona Alzheimer's Consortium, 901 E Willetta Street, Phoenix, AZ, 85006, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute and Arizona Alzheimer's Consortium, 901 E Willetta Street, Phoenix, AZ, 85006, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Science, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL, Institute of Neurology, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul Vonsattel</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>New York Brain Bank and Department of Pathology, New York-Presbyterian Hospital at Columbia University Medical Center, 630 West 168th Street, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Departments of Neuroscience and Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Departments of Neurological Sciences and Pathology (Neuropathology), and Rush Alzheimer's Disease Center, Rush University Medical Center, 1725 W Harrison Street, Chicago, IL, 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, 710 West 168th Street, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, Seattle, WA, 98101, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98198, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98198, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M Ilyas</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Alzheimer's Disease Research Center, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA, 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kofler</LastName><ForeName>Julia K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA, 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duque</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, 1120 NW 14th Street, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Department of Human Genetics, and Dr. John T. Macdonald Foundation, University of Miami, 1501 NW 10th Avenue, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gwirtsman</LastName><ForeName>Harry E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Vanderbilt University, 1601 23rd Avenue South, Nashville, TN, 37212, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry, Neuroscience and Genetics and Genomic Sciences, Mount Sinai School of Medicine, 1468 Madison Avenue, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, 114 16th Street, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino F</ForeName><Initials>BF</Initials><Identifier Source="ORCID">0000-0002-1842-8019</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, 340 West 10th Street, Indianapolis, IN, 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0002-9268-810X</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, 3400 Spruce Street, Philadelphia, PA, 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><Identifier Source="ORCID">0000-0002-7959-9401</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, 410W 10th Street, Indianapolis, IN, 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-4351-4728</Identifier><AffiliationInfo><Affiliation>Institute for Computational Biology and Department of Population and Quantitative Health Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Gertrude H. Sergievsky Center Department of Neurology, Columbia University, 710 West 168th Street, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-7283-8804</Identifier><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Department of Human Genetics, and Dr. John T. Macdonald Foundation, University of Miami, 1501 NW 10th Avenue, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Departments of Neurological Sciences and Pathology (Neuropathology), and Rush Alzheimer's Disease Center, Rush University Medical Center, 1725 W Harrison Street, Chicago, IL, 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><Identifier Source="ORCID">0000-0002-9239-8794</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, 3400 Spruce Street, Philadelphia, PA, 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Genetics Section, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Boston University School of Public Health, 715 Albany Street, Boston, MA, 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, 3400 Spruce Street, Philadelphia, PA, 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Department of Human Genetics, and Dr. John T. Macdonald Foundation, University of Miami, 1501 NW 10th Avenue, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah R</ForeName><Initials>GR</Initials><Identifier Source="ORCID">0000-0002-3230-8697</Identifier><AffiliationInfo><Affiliation>Biomedical Genetics Section, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Genetics Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG051504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061796</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG064877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066518</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501542/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG058922</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062715</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/N026004/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG057902</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053329">Apolipoprotein E2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053329" MajorTopicYN="N">Apolipoprotein E2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="Y">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069338" MajorTopicYN="N">Neuropathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>E.B.L. receives royalties from UpToDate, and the other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Abner</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Perrie M</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albin</LastName><ForeName>Roger L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atwood</LastName><ForeName>Craig S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barber</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barral</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beekly</LastName><ForeName>Duane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowen</LastName><ForeName>James D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>James R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cantwell</LastName><ForeName>Laura B</ForeName><Initials>LB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cao</LastName><ForeName>Chuanhai</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlson</LastName><ForeName>Chris S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carney</LastName><ForeName>Regina M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cribbs</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crocco</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dick</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nilufer</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>Denis A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fairchild</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fallon</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fardo</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghisays</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton-Nelson</LastName><ForeName>Kara L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huebinger</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hulette</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jarvik</LastName><ForeName>Gail P</ForeName><Initials>GP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jin</LastName><ForeName>Lee-Way</ForeName><Initials>LW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>Mindy J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JSK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kunkle</LastName><ForeName>Brian W</ForeName><Initials>BW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuzma</LastName><ForeName>Amanda P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leung</LastName><ForeName>Yuk Ye</ForeName><Initials>YY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Ge</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipton</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malamon</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martiniuk</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mash</LastName><ForeName>Deborah C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCormick</LastName><ForeName>Wayne C</ForeName><Initials>WC</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCurry</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDavid</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonough</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Joshua W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Shubhabrata</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Bryant</LastName><ForeName>Sid</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paulson</LastName><ForeName>Henry L</ForeName><Initials>HL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Aimee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qu</LastName><ForeName>Liming</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Ashok</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reisch</LastName><ForeName>Joan S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger N</ForeName><Initials>RN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Royall</LastName><ForeName>Donald R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sager</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sonnen</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>George-Hyslop</LastName><ForeName>Peter St</ForeName><Initials>PS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Debby W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valladares</LastName><ForeName>Otto</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Eldik</LastName><ForeName>Linda J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilhelmsen</LastName><ForeName>Kirk C</ForeName><Initials>KC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wingo</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wright</LastName><ForeName>Clinton B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Chang-En</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32015339</ArticleId><ArticleId IdType="pmc">PMC6997393</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-14279-8</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-14279-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coon KD, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer&#x2019;s disease. J. Clin. Psychiatry. 2007;68:613&#x2013;618. doi: 10.4088/JCP.v68n0419.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v68n0419</ArticleId><ArticleId IdType="pubmed">17474819</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994;7:180&#x2013;184. doi: 10.1038/ng0694-180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0694-180</ArticleId><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama. 1997;278:1349&#x2013;1356. doi: 10.1001/jama.1997.03550160069041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03550160069041</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Arboleda-Velasquez, J.F. et al. Resistance to autosomal dominant Alzheimer&#x2019;s in an APOE3-Christchurch homozygote. Nat Med.25, 1680&#x2013;1683 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="pubmed">31686034</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Huang Y, Rall SC., Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J. Lipid Res. 1999;40:1933&#x2013;1949.</Citation><ArticleIdList><ArticleId IdType="pubmed">10552997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J. Neurosci. 2012;32:15181&#x2013;15192. doi: 10.1523/JNEUROSCI.1542-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1542-12.2012</ArticleId><ArticleId IdType="pmc">PMC3493562</ArticleId><ArticleId IdType="pubmed">23100439</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsell SE, et al. Characterizing apolipoprotein E epsilon4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal beta-amyloid peptide plaques. JAMA Neurol. 2015;72:1124&#x2013;1131. doi: 10.1001/jamaneurol.2015.1721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1721</ArticleId><ArticleId IdType="pmc">PMC4833059</ArticleId><ArticleId IdType="pubmed">26302353</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2009;106:6820&#x2013;6825. doi: 10.1073/pnas.0900345106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900345106</ArticleId><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924&#x2013;1938. doi: 10.1001/jama.2015.4668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet. 2014;10:e1004606. doi: 10.1371/journal.pgen.1004606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004606</ArticleId><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price, V., Baker, E. &amp; Shoai, M. Genetic analysis suggests high misassignment rates in clinical Alzheimer&#x2019;s cases and controls. Neurobiol. Aging77, 178&#x2013;182 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30851568</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT. APOEepsilon2 is associated with milder clinical and pathological Alzheimer disease. Ann. Neurol. 2015;77:917&#x2013;929. doi: 10.1002/ana.24369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24369</ArticleId><ArticleId IdType="pmc">PMC4447539</ArticleId><ArticleId IdType="pubmed">25623662</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, et al. APOE epsilon2 is associated with increased tau pathology in primary tauopathy. Nat. Commun. 2018;9:4388. doi: 10.1038/s41467-018-06783-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06783-0</ArticleId><ArticleId IdType="pmc">PMC6197187</ArticleId><ArticleId IdType="pubmed">30348994</ArticleId></ArticleIdList></Reference><Reference><Citation>Feussner G, Albanese M, Valencia A. Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg136&#x2013;&gt;Cys) variant. Atherosclerosis. 1996;126:177&#x2013;184. doi: 10.1016/0021-9150(96)05870-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9150(96)05870-4</ArticleId><ArticleId IdType="pubmed">8902143</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, et al. Tau internalization is regulated by 6-O sulfation on heparan sulfate proteoglycans (HSPGs) Sci. Rep. 2018;8:6382. doi: 10.1038/s41598-018-24904-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-24904-z</ArticleId><ArticleId IdType="pmc">PMC5913225</ArticleId><ArticleId IdType="pubmed">29686391</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, et al. A transcriptomic atlas of aged human microglia. Nat. Commun. 2018;9:539. doi: 10.1038/s41467-018-02926-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-02926-5</ArticleId><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV, et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of beta-amyloidosis. Neuron. 2017;96:1013&#x2013;1023 e1014. doi: 10.1016/j.neuron.2017.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.11.014</ArticleId><ArticleId IdType="pmc">PMC5728673</ArticleId><ArticleId IdType="pubmed">29216448</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J. Mol. Med. (Berl.) 2016;94:739&#x2013;746. doi: 10.1007/s00109-016-1427-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-016-1427-y</ArticleId><ArticleId IdType="pmc">PMC4921111</ArticleId><ArticleId IdType="pubmed">27277824</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 2018;18:759&#x2013;772. doi: 10.1038/s41577-018-0051-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0051-1</ArticleId><ArticleId IdType="pmc">PMC6425488</ArticleId><ArticleId IdType="pubmed">30140051</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527. doi: 10.1038/nature24016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat. Med. 2018;24:647&#x2013;657. doi: 10.1038/s41591-018-0004-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0004-z</ArticleId><ArticleId IdType="pmc">PMC5948154</ArticleId><ArticleId IdType="pubmed">29632371</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, Painter MM, Bu G, Kanekiyo T. Apolipoprotein E as a therapeutic target in Alzheimer&#x2019;s disease: a review of basic research and clinical evidence. CNS Drugs. 2016;30:773&#x2013;789. doi: 10.1007/s40263-016-0361-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-016-0361-4</ArticleId><ArticleId IdType="pmc">PMC5526196</ArticleId><ArticleId IdType="pubmed">27328687</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak AC, et al. Effects of the absence of apolipoprotein E on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol. 2014;71:1228&#x2013;1236. doi: 10.1001/jamaneurol.2014.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2011</ArticleId><ArticleId IdType="pmc">PMC4714860</ArticleId><ArticleId IdType="pubmed">25111166</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R. Understanding conflicting neuropathological findings in patients clinically diagnosed as having Alzheimer dementia. JAMA Neurol. 2015;72:1106&#x2013;1108. doi: 10.1001/jamaneurol.2015.1804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1804</ArticleId><ArticleId IdType="pubmed">26302229</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat. Genet. 2011;43:436&#x2013;441. doi: 10.1038/ng.801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke WJ, et al. Reliability of the Washington University Clinical Dementia Rating. Arch. Neurol. 1988;45:31&#x2013;32. doi: 10.1001/archneur.1988.00520250037015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1988.00520250037015</ArticleId><ArticleId IdType="pubmed">3337672</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Hart MN, Terry RD. Making the diagnosis of Alzheimer&#x2019;s disease. A primer for practicing pathologists. Arch. Pathol. Lab. Med. 1993;117:132&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">8427562</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997;56:1095&#x2013;1097. doi: 10.1097/00005072-199710000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199710000-00002</ArticleId><ArticleId IdType="pubmed">9329452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat. Genet. 2019;51:414&#x2013;430. doi: 10.1038/s41588-019-0358-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch. Neurol. 2010;67:1473&#x2013;1484. doi: 10.1001/archneurol.2010.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.201</ArticleId><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31686034</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report.</ArticleTitle><Pagination><StartPage>1680</StartPage><EndPage>1683</EndPage><MedlinePgn>1680-1683</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-019-0611-3</ELocationID><Abstract><AbstractText>We identified a PSEN1 (presenilin 1) mutation carrier from the world's largest autosomal dominant Alzheimer's disease kindred, who did not develop mild cognitive impairment until her seventies, three decades after the expected age of clinical onset. The individual had two copies of the APOE3 Christchurch (R136S) mutation, unusually high brain amyloid levels and limited tau and neurodegenerative measurements. Our findings have implications for the role of APOE in the pathogenesis, treatment and prevention of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Arboleda-Velasquez</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-3192-9117</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. joseph_arboleda@meei.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia de la Universidad de Antioquia, Medellin, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>O'Hare</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delgado-Tirado</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marino</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chmielewska</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston College, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saez-Torres</LastName><ForeName>Kahira L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amarnani</LastName><ForeName>Dhanesh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital and Department of Neurology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital and Department of Neurology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital and the Department of Neurology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyton-Cifuentes</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7450-4207</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Escuela de Ingenieria de Antioquia-EIA, Medellin, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baena</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia de la Universidad de Antioquia, Medellin, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguillon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia de la Universidad de Antioquia, Medellin, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rios-Romenets</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia de la Universidad de Antioquia, Medellin, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giraldo</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia de la Universidad de Antioquia, Medellin, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzm&#xe1;n-V&#xe9;lez</LastName><ForeName>Edmarie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital and the Department of Psychiatry, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital and the Department of Psychiatry, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, Gordon College, Wenham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardilla-Delgado</LastName><ForeName>Enmanuelle</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1149-3157</Identifier><AffiliationInfo><Affiliation>Massachusetts General Hospital and the Department of Psychiatry, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artola</LastName><ForeName>Arabiye</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital and the Department of Psychiatry, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Justin S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital and Department of Neurology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acosta-Uribe</LastName><ForeName>Juliana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia de la Universidad de Antioquia, Medellin, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular Cellular Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalli</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0419-1206</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular Cellular Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular Cellular Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Ji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yinghua</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiyyagura</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Department of Medicine, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naymik</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gai</LastName><ForeName>Xiaowu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bootwalla</LastName><ForeName>Moiz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Jianling</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4941-3538</Identifier><AffiliationInfo><Affiliation>Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Lishuang</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0436-0199</Identifier><AffiliationInfo><Affiliation>Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Leo A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0001-9106-6416</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><Identifier Source="ORCID">0000-0002-6058-8032</Identifier><AffiliationInfo><Affiliation>The Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital and Department of Neurology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital and the Department of Neurology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital and Department of Radiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-0705-3696</Identifier><AffiliationInfo><Affiliation>The Banner Alzheimer's Institute, Phoenix, AZ, USA. eric.reiman@bannerhealth.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Arizona, Tucson, AZ, USA. eric.reiman@bannerhealth.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Arizona State University, Tempe, AZ, USA. eric.reiman@bannerhealth.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, USA. eric.reiman@bannerhealth.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials><Identifier Source="ORCID">0000-0001-9714-8244</Identifier><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia de la Universidad de Antioquia, Medellin, Colombia. yquiroz@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital and Department of Neurology, Harvard Medical School, Boston, MA, USA. yquiroz@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital and the Department of Psychiatry, Harvard Medical School, Boston, MA, USA. yquiroz@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG055444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS110048</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP5 OD019833</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH3 NS100121</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RM1 NS132996</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053329">Apolipoprotein E2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053329" MajorTopicYN="N">Apolipoprotein E2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. P.N.T. has received personal compensation for consulting, serving on scientific advisory boards, or other activities with AbbVie, AC Immune, Acadia, Auspex, Boehringer Ingelheim, Chase Pharmaceuticals, Corium, Eisai, GliaCure, INSYS Therapeutics, Pfizer, T3D, AstraZeneca, Avanir, Biogen, Eli Lilly, H. Lundbeck A/S, Merck and Company, and Roche; holds a provisional patent on &#x201c;Biomarkers of Alzheimer&#x2019;s Disease&#x201d; at the University of Rochester; holds stock options in Adamas; received research support from AstraZeneca, Avanir, Biogen, Eli Lilly, H. Lundbeck A/S, Merck and Company, Roche, Amgen, Avid, Functional Neuromodulation, GE Healthcare, Genentech, Novartis, Takeda, Targacept, the National Institute on Aging, and the Arizona Department of Health Services. H.Z. has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Biogen and Alzecure, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (outside submitted work). R.A.S. has received personal compensation from AC Immune, Eisai, Roche, and Takeda, and research grant support from Eli Lilly and Janssen. All other authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31686034</ArticleId><ArticleId IdType="mid">NIHMS1539807</ArticleId><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="doi">10.1038/s41591-019-0611-3</ArticleId><ArticleId IdType="pii">10.1038/s41591-019-0611-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Quiroz YT, et al. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurol 75, 548&#x2013;556 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885174</ArticleId><ArticleId IdType="pubmed">29435558</ArticleId></ArticleIdList></Reference><Reference><Citation>Llado A, et al. A novel PSEN1 mutation (K239N) associated with Alzheimer&#x2019;s disease with wide range age of onset and slow progression. Eur J Neurol 17, 994&#x2013;996 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20158511</ArticleId></ArticleIdList></Reference><Reference><Citation>Thordardottir S, et al. Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. Alzheimers Res Ther 10, 45 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5944151</ArticleId><ArticleId IdType="pubmed">29747683</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight WD, et al. Pure progressive amnesia and the APPV717G mutation. Alzheimer Dis Assoc Disord 23, 410&#x2013;414 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19950418</ArticleId></ArticleIdList></Reference><Reference><Citation>Velez JI, et al. APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer&#x2019;s disease. Mol Psychiatry 21, 916&#x2013;924 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5414071</ArticleId><ArticleId IdType="pubmed">26619808</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Baena N, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer&#x2019;s disease: a retrospective cohort study. Lancet Neurol 10, 213&#x2013;220 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21296022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardell MR, Brennan SO, Janus ED, Fraser R &amp; Carrell RW Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J Clin Invest 80, 483&#x2013;490 (1987).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC442261</ArticleId><ArticleId IdType="pubmed">3038959</ArticleId></ArticleIdList></Reference><Reference><Citation>Smedley D, et al. A Whole-Genome Analysis Framework for Effective Identification of Pathogenic Regulatory Variants in Mendelian Disease. Am J Hum Genet 99, 595&#x2013;606 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5011059</ArticleId><ArticleId IdType="pubmed">27569544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalli MA, et al. Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer&#x2019;s disease. Mol Psychiatry 20, 1294&#x2013;1300 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759097</ArticleId><ArticleId IdType="pubmed">26324103</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7, 180&#x2013;184 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Huang Y &amp; Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 40, 1933&#x2013;1949 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10552997</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nat Med 25, 277&#x2013;283 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci 32, 15181&#x2013;15192 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493562</ArticleId><ArticleId IdType="pubmed">23100439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalazar A, et al. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J Biol Chem 263, 3542&#x2013;3545 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2831187</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, et al. Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs). Sci Rep 8, 6382 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5913225</ArticleId><ArticleId IdType="pubmed">29686391</ArticleId></ArticleIdList></Reference><Reference><Citation>Smedley D, et al. A Whole-Genome Analysis Framework for Effective Identification of Pathogenic Regulatory Variants in Mendelian Disease. American Journal of Human Genetics 99, 595&#x2013;606 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5011059</ArticleId><ArticleId IdType="pubmed">27569544</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamauchi Y, et al. Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study. Biochemistry 47, 6702&#x2013;6710 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844924</ArticleId><ArticleId IdType="pubmed">18507396</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre-Acevedo DC, et al. Validity and reliability of the CERAD-Col neuropsychological battery. Validez y fiabilidad de la bater&#xed;a neuropsicol&#xf3;gica CERAD-Col 45, 655&#x2013;660 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18050096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Huang Y &amp; Rall SC Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. Journal of lipid research 40, 1933&#x2013;1949 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10552997</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher S, et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biology 12, R1 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091298</ArticleId><ArticleId IdType="pubmed">21205303</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, et al. A rapid and cost-effective method for genotyping apolipoprotein e gene polymorphism. Molecular Neurodegeneration 11, 2 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4710020</ArticleId><ArticleId IdType="pubmed">26754117</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: A cross-sectional study. JAMA Neurology 72, 316&#x2013;324 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="pubmed">25580592</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, et al. Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Annals of Neurology 69, 1032&#x2013;1042 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Diagnostic criteria for the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurobiology of Aging, S85&#x2013;88 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9330992</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, R&#xfc;b U, Schultz C &amp; Tredici KD Vulnerability of cortical neurons to Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Journal of Alzheimer&#x2019;s Disease 9, 35&#x2013;44 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16914843</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Annals of Neurology 79, 110&#x2013;119 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoup TM, et al. A concise radiosynthesis of the tau radiopharmaceutical, [18F]T807. Journal of Labelled Compounds and Radiopharmaceuticals 56, 736&#x2013;740 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114396</ArticleId><ArticleId IdType="pubmed">24339014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. Journal of Alzheimer&#x2019;s Disease 34, 457&#x2013;468 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23948934</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, et al. Evaluation of Tau imaging in staging Alzheimer disease and revealing interactions between &#x3b2;-Amyloid and tauopathy. JAMA Neurology 73, 1070&#x2013;1077 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237382</ArticleId><ArticleId IdType="pubmed">27454922</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J Graphical analysis of PET data applied to reversible and irreversible tracers. Nuclear Medicine and Biology (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11091109</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, et al. Subjective cognitive concerns, amyloid-b, and neurodegeneration in clinically normal elderly. Neurology 85, 56&#x2013;62 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4501939</ArticleId><ArticleId IdType="pubmed">26048028</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, et al. Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden. Journal of Neuroscience 29, 12686&#x2013;12694 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Gissl&#xe9;n M, et al. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine 3, 135&#x2013;140 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, et al. Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid Peptide. Journal of Neuroscience 32, 15181&#x2013;15192 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493562</ArticleId><ArticleId IdType="pubmed">23100439</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535&#x2013;539 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry E, et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 5, 212ra161 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334150</ArticleId><ArticleId IdType="pubmed">24259049</ArticleId></ArticleIdList></Reference><Reference><Citation>Futamura M, et al. Two-step mechanism of binding of apolipoprotein E to heparin: Implications for the kinetics of apolipoprotein E-heparan sulfate proteoglycan complex formation on cell surfaces. Journal of Biological Chemistry 280, 5414&#x2013;5422 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15583000</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E &amp; Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nature biotechnology 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31682678</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Associations Between Vascular Risk Across Adulthood and Brain Pathology in Late Life: Evidence From a British Birth Cohort.</ArticleTitle><Pagination><StartPage>175</StartPage><EndPage>183</EndPage><MedlinePgn>175-183</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.3774</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Midlife vascular risk burden is associated with late-life dementia. Less is known about if and how risk exposure in early adulthood influences late-life brain health.</AbstractText><AbstractText Label="OBJECTIVE">To determine the associations between vascular risk in early adulthood, midlife, and late life with late-life brain structure and pathology using measures of white matter-hyperintensity volume, &#x3b2;-amyloid load, and whole-brain and hippocampal volumes.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This prospective longitudinal cohort study, Insight 46, is part of the Medical Research Council National Survey of Health and Development, which commenced in 1946. Participants had vascular risk factors evaluated at ages 36 years (early adulthood), 53 years (midlife), and 69 years (early late life). Participants were assessed with multimodal magnetic resonance imaging and florbetapir-amyloid positron emission tomography scans between May 2015 and January 2018 at University College London. Participants with at least 1 available imaging measure, vascular risk measurements at 1 or more points, and no dementia were included in analyses.</AbstractText><AbstractText Label="EXPOSURES">Office-based Framingham Heart study-cardiovascular risk scores (FHS-CVS) were derived at ages 36, 53, and 69 years using systolic blood pressure, antihypertensive medication usage, smoking, diabetic status, and body mass index. Analysis models adjusted for age at imaging, sex, APOE genotype, socioeconomic position, and, where appropriate, total intracranial volume.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">White matter-hyperintensity volume was generated from T1/fluid-attenuated inversion recovery scans using an automated technique and whole-brain volume and hippocampal volume were generated from automated in-house pipelines; &#x3b2;-amyloid status was determined using a gray matter/eroded subcortical white matter standardized uptake value ratio threshold of 0.61.</AbstractText><AbstractText Label="RESULTS">A total of 502 participants were assessed as part of Insight 46, and 463 participants (236 male [51.0%]) with at least 1 available imaging measure (mean [SD] age at imaging, 70.7 [0.7] years; 83 &#x3b2;-amyloid positive [18.2%]) who fulfilled eligibility criteria were included. Among them, FHS-CVS increased with age (36 years: median [interquartile range], 2.7% [1.5%-3.6%]; 53 years: 10.9% [6.7%-15.6%]; 69 years: 24.3% [14.9%-34.9%]). At all points, these scores were associated with smaller whole-brain volumes (36 years: &#x3b2; coefficient per 1% increase, -3.6 [95% CI, -7.0 to -0.3]; 53 years: -0.8 [95% CI, -1.5 to -0.08]; 69 years: -0.6 [95% CI, -1.1 to -0.2]) and higher white matter-hyperintensity volume (exponentiated coefficient: 36 years, 1.09 [95% CI, 1.01-1.18]; 53 years, 1.02 [95% CI, 1.00-1.04]; 69 years, 1.01 [95% CI, 1.00-1.02]), with largest effect sizes at age 36 years. At no point were FHS-CVS results associated with &#x3b2;-amyloid status.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Higher vascular risk is associated with smaller whole-brain volume and greater white matter-hyperintensity volume at age 69 to 71 years, with the strongest association seen with early adulthood vascular risk. There was no evidence that higher vascular risk influences amyloid deposition, at least up to age 71 years. Reducing vascular risk with appropriate interventions should be considered from early adulthood to maximize late-life brain health.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, Department of Medical Statistics, University of London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudre</LastName><ForeName>Carole H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cash</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Ian B</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keshavan</LastName><ForeName>Ashvini</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchanan</LastName><ForeName>Sarah M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keuss</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Sarah-Naomi</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Kirsty</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray-Smith</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coath</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modat</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Leonard Wolfson Experimental Neurology Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_UU_12019/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12019/3</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>200109/Z/15/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00019/3</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2020 Feb 1;77(2):160-161. doi: 10.1001/jamaneurol.2019.3785.</RefSource><PMID Version="1">31682673</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Fox&#x2019;s research group has received payment for consultancy or for conducting studies from Avid Radiopharmaceuticals, Biogen, Eli Lilly Research Laboratories, General Electric Healthcare, and Roche; Dr Fox receives no personal compensation for these activities. Dr Schott reports grants from Weston Brain Foundation during the conduct of the study and personal fees from Axon Neuroscience, Roche, Eli Lilly, General Electric Healthcare, Merck Sharp &amp; Dohme, Oxford University Press, Biogen, and EU Horizon 2020 outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31682678</ArticleId><ArticleId IdType="pmc">PMC6830432</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.3774</ArticleId><ArticleId IdType="pii">2753445</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince M, Albanese E, Guerchet M, Prina M World Alzheimer report 2014: dementia and risk reduction, an analysis of protective and modifiable factors. https://www.alz.co.uk/research/WorldAlzheimerReport2014.pdf. Published 2014. Accessed September 24, 2019.</Citation></Reference><Reference><Citation>Launer LJ, Ross GW, Petrovitch H, et al. . Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49-55. doi:10.1016/S0197-4580(00)00096-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00096-8</ArticleId><ArticleId IdType="pubmed">10794848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivim&#xe4;ki M, Luukkonen R, Batty GD, et al. . Body mass index and risk of dementia: Analysis of individual-level data from 1.3 million individuals. Alzheimers Dement. 2018;14(5):601-609. doi:10.1016/j.jalz.2017.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.09.016</ArticleId><ArticleId IdType="pmc">PMC5948099</ArticleId><ArticleId IdType="pubmed">29169013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Chen C, Hua S, et al. . An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer&#x2019;s disease. Diabetes Res Clin Pract. 2017;124:41-47. doi:10.1016/j.diabres.2016.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2016.10.024</ArticleId><ArticleId IdType="pubmed">28088029</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong G, Wang Y, Zhang Y, Guo JJ, Zhao Y. Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers. PLoS One. 2015;10(3):e0118333. doi:10.1371/journal.pone.0118333</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0118333</ArticleId><ArticleId IdType="pmc">PMC4357455</ArticleId><ArticleId IdType="pubmed">25763939</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Albert MS, Alonso A, et al. . Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74(10):1246-1254. doi:10.1001/jamaneurol.2017.1658</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1658</ArticleId><ArticleId IdType="pmc">PMC5710244</ArticleId><ArticleId IdType="pubmed">28783817</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Tan L, Wang H-F, et al. . Meta-analysis of modifiable risk factors for Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2015;86(12):1299-1306. doi:10.1136/jnnp-2015-310548</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310548</ArticleId><ArticleId IdType="pubmed">26294005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Zhou Y, et al. . Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443-1450. doi:10.1001/jama.2017.3090</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.3090</ArticleId><ArticleId IdType="pmc">PMC5921896</ArticleId><ArticleId IdType="pubmed">28399252</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Knopman DS, Lesnick TG, et al. . Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals. JAMA Neurol. 2017;74(6):718-726. doi:10.1001/jamaneurol.2017.0244</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0244</ArticleId><ArticleId IdType="pmc">PMC5649401</ArticleId><ArticleId IdType="pubmed">28418521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JAR, Carare RO. Disruption of arterial perivascular drainage of amyloid-&#x3b2; from the brains of mice expressing the human APOE &#x3b5;4 allele. PLoS One. 2012;7(7):e41636. doi:10.1371/journal.pone.0041636</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0041636</ArticleId><ArticleId IdType="pmc">PMC3404985</ArticleId><ArticleId IdType="pubmed">22848551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Fratiglioni L, Laukka EJ, et al. . Effects of vascular risk factors and APOE &#x3b5;4 on white matter integrity and cognitive decline. Neurology. 2015;84(11):1128-1135. doi:10.1212/WNL.0000000000001379</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001379</ArticleId><ArticleId IdType="pmc">PMC4371409</ArticleId><ArticleId IdType="pubmed">25672924</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuh D, Pierce M, Adams J, et al. ; NSHD scientific and data collection team . Cohort profile: updating the cohort profile for the MRC National Survey of Health and Development: a new clinic-based data collection for ageing research. Int J Epidemiol. 2011;40(1):e1-e9. doi:10.1093/ije/dyq231</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyq231</ArticleId><ArticleId IdType="pmc">PMC3043283</ArticleId><ArticleId IdType="pubmed">21345808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane CA, Parker TD, Cash DM, et al. . Study protocol: Insight 46&#x2014;a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurol. 2017;17(1):75. doi:10.1186/s12883-017-0846-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-017-0846-x</ArticleId><ArticleId IdType="pmc">PMC5395844</ArticleId><ArticleId IdType="pubmed">28420323</ArticleId></ArticleIdList></Reference><Reference><Citation>James SN, Lane CA, Parker TD, et al. . Using a birth cohort to study brain health and preclinical dementia: recruitment and participation rates in Insight 46. BMC Res Notes. 2018;11(1):885. doi:10.1186/s13104-018-3995-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-018-3995-0</ArticleId><ArticleId IdType="pmc">PMC6293512</ArticleId><ArticleId IdType="pubmed">30545411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy R, Ghosh AK, Deanfield J, Kuh D, Hughes AD. Birthweight, childhood growth and left ventricular structure at age 60-64 years in a British birth cohort study. Int J Epidemiol. 2016;45(4):1091-1102. doi:10.1093/ije/dyw150</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw150</ArticleId><ArticleId IdType="pmc">PMC5841632</ArticleId><ArticleId IdType="pubmed">27413103</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KK, Barnes J, Modat M, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Brain MAPS: an automated, accurate and robust brain extraction technique using a template library. Neuroimage. 2011;55(3):1091-1108. doi:10.1016/j.neuroimage.2010.12.067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.12.067</ArticleId><ArticleId IdType="pmc">PMC3554789</ArticleId><ArticleId IdType="pubmed">21195780</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorge Cardoso M, Leung K, Modat M, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal. 2013;17(6):671-684. doi:10.1016/j.media.2013.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.media.2013.02.006</ArticleId><ArticleId IdType="pubmed">23510558</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone IB, Leung KK, Clegg S, et al. . Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance. Neuroimage. 2015;104:366-372. doi:10.1016/j.neuroimage.2014.09.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2014.09.034</ArticleId><ArticleId IdType="pmc">PMC4265726</ArticleId><ArticleId IdType="pubmed">25255942</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Cardoso MJ, Bouvy WH, Biessels GJ, Barnes J, Ourselin S. Bayesian model selection for pathological neuroimaging data applied to white matter lesion segmentation. IEEE Trans Med Imaging. 2015;34(10):2079-2102. doi:10.1109/TMI.2015.2419072</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TMI.2015.2419072</ArticleId><ArticleId IdType="pubmed">25850086</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agostino RB Sr, Vasan RS, Pencina MJ, et al. . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753. doi:10.1161/CIRCULATIONAHA.107.699579</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.699579</ArticleId><ArticleId IdType="pubmed">18212285</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A, Moebus S, M&#xf6;hlenkamp S, et al. ; Heinz Nixdorf Recall Study Investigative Group . Algorithms for converting random-zero to automated oscillometric blood pressure values, and vice versa. Am J Epidemiol. 2006;164(1):85-94. doi:10.1093/aje/kwj160</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwj160</ArticleId><ArticleId IdType="pubmed">16675536</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce MB, Silverwood RJ, Nitsch D, et al. ; NSHD Scientific and Data Collection Teams . Clinical disorders in a post war British cohort reaching retirement: evidence from the First National Birth Cohort study. PLoS One. 2012;7(9):e44857. doi:10.1371/journal.pone.0044857</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044857</ArticleId><ArticleId IdType="pmc">PMC3447001</ArticleId><ArticleId IdType="pubmed">23028647</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawle MJ, Davis D, Bendayan R, Wong A, Kuh D, Richards M. Apolipoprotein-E (Apoe) &#x3b5;4 and cognitive decline over the adult life course. Transl Psychiatry. 2018;8(1):18. doi:10.1038/s41398-017-0064-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-017-0064-8</ArticleId><ArticleId IdType="pmc">PMC5802532</ArticleId><ArticleId IdType="pubmed">29317609</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Roberts R. Vascular risk factors: imaging and neuropathologic correlates. J Alzheimers Dis. 2010;20(3):699-709. doi:10.3233/JAD-2010-091555</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-091555</ArticleId><ArticleId IdType="pmc">PMC2883660</ArticleId><ArticleId IdType="pubmed">20182020</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, Davis-Plourde K, Himali JJ, et al. . Vascular risk at younger ages most strongly associates with current and future brain volume. Neurology. 2018;91(16):e1479-e1486. doi:10.1212/WNL.0000000000006360</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006360</ArticleId><ArticleId IdType="pmc">PMC6202941</ArticleId><ArticleId IdType="pubmed">30232248</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson W, Lewandowski AJ, Forkert ND, et al. . Association of cardiovascular risk factors with MRI indices of cerebrovascular structure and function and white matter hyperintensities in young adults. JAMA. 2018;320(7):665-673. doi:10.1001/jama.2018.11498</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.11498</ArticleId><ArticleId IdType="pmc">PMC6142949</ArticleId><ArticleId IdType="pubmed">30140877</ArticleId></ArticleIdList></Reference><Reference><Citation>Merz AA, Cheng S. Sex differences in cardiovascular ageing. Heart. 2016;102(11):825-831. doi:10.1136/heartjnl-2015-308769</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2015-308769</ArticleId><ArticleId IdType="pmc">PMC5993677</ArticleId><ArticleId IdType="pubmed">26917537</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Hughes TM, White LR. Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study. Ann Neurol. 2011;70(5):774-780. doi:10.1002/ana.22520</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22520</ArticleId><ArticleId IdType="pmc">PMC3241005</ArticleId><ArticleId IdType="pubmed">22162060</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenger N. Tailoring cardiovascular risk assessment and prevention for women: one size does not fit all. Glob Cardiol Sci Pract. 2017;2017(1):e201701. doi:10.21542/gcsp.2017.1</Citation><ArticleIdList><ArticleId IdType="doi">10.21542/gcsp.2017.1</ArticleId><ArticleId IdType="pmc">PMC5621718</ArticleId><ArticleId IdType="pubmed">28971101</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed BR, Marchant NL, Jagust WJ, DeCarli CC, Mack W, Chui HC. Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging. 2012;33(9):1979-1987. doi:10.1016/j.neurobiolaging.2011.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.002</ArticleId><ArticleId IdType="pmc">PMC3371309</ArticleId><ArticleId IdType="pubmed">22078485</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu DC, Mormino EC, Schultz AP, et al. ; Harvard Aging Brain Study . Lower late-life body-mass index is associated with higher cortical amyloid burden in clinically normal elderly. J Alzheimers Dis. 2016;53(3):1097-1105. doi:10.3233/JAD-150987</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150987</ArticleId><ArticleId IdType="pmc">PMC4976009</ArticleId><ArticleId IdType="pubmed">27340843</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath ER, Beiser AS, DeCarli C, et al. . Blood pressure from mid- to late life and risk of incident dementia. Neurology. 2017;89(24):2447-2454. doi:10.1212/WNL.0000000000004741</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004741</ArticleId><ArticleId IdType="pmc">PMC5729797</ArticleId><ArticleId IdType="pubmed">29117954</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer&#x2019;s disease and other neurological disorders. Lancet Neurol. 2011;10(3):241-252. doi:10.1016/S1474-4422(10)70325-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70325-2</ArticleId><ArticleId IdType="pmc">PMC3132088</ArticleId><ArticleId IdType="pubmed">21349439</ArticleId></ArticleIdList></Reference><Reference><Citation>Paternoster L, Mart&#xed;nez Gonz&#xe1;lez NA, Lewis S, Sudlow C. Association between apolipoprotein E genotype and carotid intima-media thickness may suggest a specific effect on large artery atherothrombotic stroke. Stroke. 2008;39(1):48-54. doi:10.1161/STROKEAHA.107.488866</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.107.488866</ArticleId><ArticleId IdType="pmc">PMC2577179</ArticleId><ArticleId IdType="pubmed">18063831</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigue KM, Rieck JR, Kennedy KM, Devous MD Sr, Diaz-Arrastia R, Park DC. Risk factors for &#x3b2;-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol. 2013;70(5):600-606. doi:10.1001/jamaneurol.2013.1342</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.1342</ArticleId><ArticleId IdType="pmc">PMC3968915</ArticleId><ArticleId IdType="pubmed">23553344</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Reed T, Miller BL, Wolf PA, Swan GE, Carmelli D. Impact of apolipoprotein E epsilon4 and vascular disease on brain morphology in men from the NHLBI twin study. Stroke. 1999;30(8):1548-1553. doi:10.1161/01.STR.30.8.1548</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.30.8.1548</ArticleId><ArticleId IdType="pubmed">10436099</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw F-E, Richard F, de Groot JC, et al. . Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke. 2004;35(5):1057-1060. doi:10.1161/01.STR.0000125859.71051.83</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000125859.71051.83</ArticleId><ArticleId IdType="pubmed">15060316</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih Y-H, Tsai S-F, Huang S-H, et al. . Hypertension impairs hippocampus-related adult neurogenesis, CA1 neuron dendritic arborization and long-term memory. Neuroscience. 2016;322:346-357. doi:10.1016/j.neuroscience.2016.02.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2016.02.045</ArticleId><ArticleId IdType="pubmed">26921651</ArticleId></ArticleIdList></Reference><Reference><Citation>Nation DA, Edmonds EC, Bangen KJ, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative Investigators . Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. JAMA Neurol. 2015;72(5):546-553. doi:10.1001/jamaneurol.2014.4477</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4477</ArticleId><ArticleId IdType="pmc">PMC4428938</ArticleId><ArticleId IdType="pubmed">25822631</ArticleId></ArticleIdList></Reference><Reference><Citation>Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017;183:57-70. doi:10.1016/j.trsl.2017.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2017.01.001</ArticleId><ArticleId IdType="pmc">PMC5393930</ArticleId><ArticleId IdType="pubmed">28130064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane CA, Barnes J, Nicholas JM, et al. . Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurol. 2019;18(10):942-952. doi:10.1016/S1474-4422(19)30228-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30228-5</ArticleId><ArticleId IdType="pmc">PMC6744368</ArticleId><ArticleId IdType="pubmed">31444142</ArticleId></ArticleIdList></Reference><Reference><Citation>Adak S, Illouz K, Gorman W, et al. . Predicting the rate of cognitive decline in aging and early Alzheimer disease. Neurology. 2004;63(1):108-114. doi:10.1212/01.WNL.0000132520.69612.AB</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000132520.69612.AB</ArticleId><ArticleId IdType="pubmed">15249619</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. . Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain. 2015;138(pt 3):761-771. doi:10.1093/brain/awu393</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu393</ArticleId><ArticleId IdType="pmc">PMC4339775</ArticleId><ArticleId IdType="pubmed">25595145</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31721283</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>87</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia.</ArticleTitle><Pagination><StartPage>52</StartPage><EndPage>62</EndPage><MedlinePgn>52-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.25645</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To investigate whether midlife atherosclerosis is associated with different dementia subtypes and related underlying pathologies.</AbstractText><AbstractText Label="METHODS">Participants comprised the cardiovascular cohort of the Swedish prospective population-based Malm&#xf6; Diet and Cancer Study (N = 6,103). Carotid plaques and intima media thickness (IMT) were measured at baseline (1991-1994). Dementia incidence until 2014 was obtained from national registers. Diagnoses were reviewed and validated in medical records. In a cognitively unimpaired subcohort (n = 330), &#x3b2;-amyloid<sub>42</sub> and tau were quantified in cerebrospinal fluid (CSF), and white matter hyperintensity volume, lacunar infarcts, and cerebral microbleeds were estimated on magnetic resonance imaging (2009-2015).</AbstractText><AbstractText Label="RESULTS">During 20&#x2009;years of follow-up, 462 individuals developed dementia (mean age at baseline = 57.5&#x2009;&#xb1;&#x2009;5.9&#x2009;years, 58% women). Higher IMT in midlife was associated with an increased hazard ratio (HR) of all-cause dementia (adjusted HR = 1.14 [95% confidence interval (CI) = 1.03-1.26]) and vascular dementia (adjusted HR = 1.32 [95% CI = 1.10-1.57]) but not Alzheimer disease (AD) dementia (adjusted HR = 0.95 [95% CI = 0.77-1.17]). Carotid plaques were associated with vascular dementia when assessed as a 3-graded score (adjusted HR = 1.90 [95% CI = 1.07-3.38]). In the cognitively unimpaired subcohort (53.8&#x2009;&#xb1;&#x2009;4.6&#x2009;years at baseline, 60% women), higher IMT in midlife was associated with development of small vessel disease (adjusted odds ratio [OR] = 1.47 [95% CI = 1.05-2.06]) but not significantly with abnormal CSF AD biomarkers (adjusted OR = 1.28 [95% CI = 0.87-1.90] for A&#x3b2;<sub>42</sub> and 1.35 [95% CI = 0.86-2.13] for A&#x3b2;<sub>42</sub> /p-tau). Carotid plaques revealed no significant association with any of the underlying brain pathologies.</AbstractText><AbstractText Label="INTERPRETATION">Our findings support an association between midlife atherosclerosis and development of vascular dementia and cerebral small vessel disease but not between atherosclerosis and subsequent AD dementia or AD pathology. ANN NEUROL 2020;87:52-62.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gustavsson</LastName><ForeName>Anna-M&#xe4;rta</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-9655-7388</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Malm&#xf6;.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Westen</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8649-9874</Identifier><AffiliationInfo><Affiliation>Diagnostic Radiology, Department of Clinical Sciences Lund, Lund University, Lund.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Malm&#xf6;.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engstr&#xf6;m</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiovascular Epidemiology, Department of Clinical Sciences Malm&#xf6;, Lund University, Malm&#xf6;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xe4;gga</LastName><ForeName>Katarina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Malm&#xf6;.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Acute Internal Medicine and Geriatrics, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Malm&#xf6;.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Governmental funding of clinical research within the Swedish NHS (National Health Services)</Agency><Country>International</Country></Grant><Grant><Agency>H2020 European Research Council</Agency><Country>International</Country></Grant><Grant><Agency>Knut och Alice Wallenbergs Stiftelse</Agency><Country>International</Country></Grant><Grant><Agency>Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University</Agency><Country>International</Country></Grant><Grant><Agency>The Parkinson foundation of Sweden</Agency><Country>International</Country></Grant><Grant><Agency>Vetenskapsr&#xe5;det</Agency><Country>International</Country></Grant><Grant><Agency>Swedish federal government</Agency><Country>International</Country></Grant><Grant><Agency>Parkinson Research Foundation</Agency><Country>International</Country></Grant><Grant><Agency>Parkinson Foundation of Sweden</Agency><Country>International</Country></Grant><Grant><Agency>Swedish Brain Foundation</Agency><Country>International</Country></Grant><Grant><Agency>Swedish Alzheimer Foundation</Agency><Country>International</Country></Grant><Grant><Agency>Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's Disease) at Lund University</Agency><Country>International</Country></Grant><Grant><Agency>Marianne and Marcus Wallenberg Foundation</Agency><Country>International</Country></Grant><Grant><Agency>Knut and Alice Wallenberg Foundation</Agency><Country>International</Country></Grant><Grant><Agency>Swedish Research Council</Agency><Country>International</Country></Grant><Grant><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Neurol. 2020 May;87(5):788. doi: 10.1002/ana.25715.</RefSource><PMID Version="1">32154602</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020520" MajorTopicYN="N">Brain Infarction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020300" MajorTopicYN="N">Intracranial Hemorrhages</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Nothing to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31721283</ArticleId><ArticleId IdType="pmc">PMC6973178</ArticleId><ArticleId IdType="doi">10.1002/ana.25645</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late&#x2010;life Alzheimer disease. Ann Intern Med 2002;137:149&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">12160362</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Xu W, Fratiglioni L. Vascular and psychosocial factors in Alzheimer's disease: epidemiological evidence toward intervention. J Alzheimers Dis 2010;20:689&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">20182015</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider AL, Zhou Y, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA 2017;317:1443&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5921896</ArticleId><ArticleId IdType="pubmed">28399252</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagga K, Gustavsson AM, Stomrud E, et al. Increased midlife triglycerides predict brain beta&#x2010;amyloid and tau pathology 20&#x2009;years later. Neurology 2018;90:e73&#x2013;e81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754649</ArticleId><ArticleId IdType="pubmed">29196581</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Knopman DS, Lesnick TG, et al. Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals. JAMA Neurol 2017;74:718&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5649401</ArticleId><ArticleId IdType="pubmed">28418521</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Hardy J. Genetics of Alzheimer's disease. Neurotherapeutics 2014;11:732&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362699</ArticleId><ArticleId IdType="pubmed">25113539</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim WLF, Martins IJ, Martins RN. The involvement of lipids in Alzheimer's disease. J Genet Genom 2014;41:261&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">24894353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lusis AJ. Atherosclerosis. Nature 2000;407:233&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826222</ArticleId><ArticleId IdType="pubmed">11001066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima&#x2010;media thickness: a systematic review and meta&#x2010;analysis. Circulation 2007;115:459&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">17242284</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcaillon L, Plichart M, Zureik M, et al. Carotid plaque as a predictor of dementia in older adults: the Three&#x2010;City Study. Alzheimers Dement 2015;11:239&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">25510384</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oijen M, de Jong FJ, Witteman JC, et al. Atherosclerosis and risk for dementia. Ann Neurol 2007;61:403&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">17328068</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AB, Fitzpatrick AL, Lopez O, et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 2005;53:1101&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">16108925</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendell CR, Waldstein SR, Ferrucci L, et al. Carotid atherosclerosis and prospective risk of dementia. Stroke 2012;43:3319&#x2013;3324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3508298</ArticleId><ArticleId IdType="pubmed">23103489</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed BR, Marchant NL, Jagust WJ, et al. Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging 2012;33:1979&#x2013;1987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371309</ArticleId><ArticleId IdType="pubmed">22078485</ArticleId></ArticleIdList></Reference><Reference><Citation>Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993;233:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">8429286</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosvall M, Ostergren PO, Hedblad B, et al. Occupational status, educational level, and the prevalence of carotid atherosclerosis in a general population sample of middle&#x2010;aged Swedish men and women: results from the Malmo Diet and Cancer Study. Am J Epidemiol 2000;152:334&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">10968378</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjer J, Carlsson S, Elmstahl S, et al. The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non&#x2010;participants. Eur J Cancer Prev 2001;10:489&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">11916347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142234</ArticleId><ArticleId IdType="pubmed">21658213</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association, 2013.</Citation></Reference><Reference><Citation>Rosvall M, Persson M, Ostling G, et al. Risk factors for the progression of carotid intima&#x2010;media thickness over a 16&#x2010;year follow&#x2010;up period: the Malmo Diet and Cancer Study. Atherosclerosis 2015;239:615&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">25746169</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta&#x2010;amyloid 42: a cross&#x2010;validation study against amyloid positron emission tomography. JAMA Neurol 2014;71:1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Benaglia T, Chauveau D, Hunter DR, Young DS. mixtools: an R package for analyzing finite mixture models. J Stat Softw 2009;32:1&#x2013;29.</Citation></Reference><Reference><Citation>Schmidt P, Gaser C, Arsic M, et al. An automated tool for detection of FLAIR&#x2010;hyperintense white&#x2010;matter lesions in multiple sclerosis. Neuroimage 2012;59:3774&#x2013;3783.</Citation><ArticleIdList><ArticleId IdType="pubmed">22119648</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714437</ArticleId><ArticleId IdType="pubmed">23867200</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation 2016;133:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4741409</ArticleId><ArticleId IdType="pubmed">26858290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009;170:244&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732996</ArticleId><ArticleId IdType="pubmed">19494242</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. Clinicopathological analysis of dementia disorders in the elderly&#x2014;an update. J Alzheimers Dis 2006;9(suppl):61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914845</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009;66:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Palmqvist S, Ljung H, et al. Cerebral hypoperfusion is not associated with an increase in amyloid beta pathology in middle&#x2010;aged or elderly people. Alzheimers Dement 2018;14:54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5766833</ArticleId><ArticleId IdType="pubmed">28719802</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005;64:494&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699381</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Cao D, Garber DW, et al. Association of aortic atherosclerosis with cerebral beta&#x2010;amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am J Pathol 2003;163:2155&#x2013;2164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892402</ArticleId><ArticleId IdType="pubmed">14633589</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Iadecola C. Impaired A&#x3b2; clearance: a potential link between atherosclerosis and Alzheimer's disease. Front Aging Neurosci 2015;7:115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468824</ArticleId><ArticleId IdType="pubmed">26136682</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolan H, Crain B, Troncoso J, et al. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Ann Neurol 2010;68:231&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030772</ArticleId><ArticleId IdType="pubmed">20695015</ArticleId></ArticleIdList></Reference><Reference><Citation>Della&#x2010;Morte D, Dong C, Markert MS, et al. Carotid intima&#x2010;media thickness is associated with white matter hyperintensities: the Northern Manhattan Study. Stroke 2018;49:304&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5780238</ArticleId><ArticleId IdType="pubmed">29284725</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero JR, Beiser A, Seshadri S, et al. Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. Stroke 2009;40:1590&#x2013;1596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705324</ArticleId><ArticleId IdType="pubmed">19265054</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui HC, Zheng L, Reed BR, et al. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence&#x2010;based review. Alzheimers Res Ther 2012;4:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3471388</ArticleId><ArticleId IdType="pubmed">22182734</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31611708</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core blood-brain barrier dysfunction module.</ArticleTitle><Pagination><StartPage>1892</StartPage><EndPage>1902</EndPage><MedlinePgn>1892-1902</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0497-x</ELocationID><Abstract><AbstractText>Blood vessels in the CNS form a specialized and critical structure, the blood-brain barrier (BBB). We present a resource to understand the molecular mechanisms that regulate BBB function in health and dysfunction during disease. Using endothelial cell enrichment and RNA sequencing, we analyzed the gene expression of endothelial cells in mice, comparing brain endothelial cells with peripheral endothelial cells. We also assessed the regulation of CNS endothelial gene expression in models of stroke, multiple sclerosis, traumatic brain injury and seizure, each having profound BBB disruption. We found that although each is caused by a distinct trigger, they exhibit strikingly similar endothelial gene expression changes during BBB disruption, comprising a core BBB dysfunction module that shifts the CNS endothelial cells into a peripheral endothelial cell-like state. The identification of a common pathway for BBB dysfunction suggests that targeting therapeutic agents to limit it may be effective across multiple neurological disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Munji</LastName><ForeName>Roeben Nocon</ForeName><Initials>RN</Initials><Identifier Source="ORCID">0000-0003-1313-8968</Identifier><AffiliationInfo><Affiliation>Departments of Pharmacology and Neurosciences, University of California, San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Soung</LastName><ForeName>Allison Luen</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-1590-6038</Identifier><AffiliationInfo><Affiliation>Departments of Pharmacology and Neurosciences, University of California, San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Geoffrey Aaron</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0002-3651-5976</Identifier><AffiliationInfo><Affiliation>Departments of Pharmacology and Neurosciences, University of California, San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohet</LastName><ForeName>Fabien</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Departments of Pharmacology and Neurosciences, University of California, San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semple</LastName><ForeName>Bridgette Deanne</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trivedi</LastName><ForeName>Alpa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gimlin</LastName><ForeName>Kayleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotoda</LastName><ForeName>Masakazu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery and Neurobiology, Barrow Aneurysm and AVM Research Center, Barrow Neurological Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korai</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery and Neurobiology, Barrow Aneurysm and AVM Research Center, Barrow Neurological Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aydin</LastName><ForeName>Sidar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Pharmacology and Neurosciences, University of California, San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batugal</LastName><ForeName>Austin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Pharmacology and Neurosciences, University of California, San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabangcala</LastName><ForeName>Anne Christelle</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Departments of Pharmacology and Neurosciences, University of California, San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schupp</LastName><ForeName>Patrick Georg</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oldham</LastName><ForeName>Michael Clark</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-7633-6932</Identifier><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Tomoki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery and Neurobiology, Barrow Aneurysm and AVM Research Center, Barrow Neurological Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noble-Haeusslein</LastName><ForeName>Linda J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daneman</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7749-6353</Identifier><AffiliationInfo><Affiliation>Departments of Pharmacology and Neurosciences, University of California, San Diego, San Diego, CA, USA. Rdaneman@ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS091281</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA151022</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS055876</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH113896</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050159</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007546</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS077767</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS082280</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008440</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007198</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063308">Myelin-Oligodendrocyte Glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C526792">myelin oligodendrocyte glycoprotein (35-50), Ala(37)-</NameOfSubstance></Chemical><Chemical><RegistryNumber>6SO6U10H04</RegistryNumber><NameOfSubstance UI="D001710">Biotin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.2.31</RegistryNumber><NameOfSubstance UI="D037342">Pertussis Toxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>SIV03811UC</RegistryNumber><NameOfSubstance UI="D007608">Kainic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001710" MajorTopicYN="N">Biotin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="N">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020244" MajorTopicYN="N">Infarction, Middle Cerebral Artery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007608" MajorTopicYN="N">Kainic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063308" MajorTopicYN="N">Myelin-Oligodendrocyte Glycoprotein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037342" MajorTopicYN="N">Pertussis Toxin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31611708</ArticleId><ArticleId IdType="mid">NIHMS1537438</ArticleId><ArticleId IdType="pmc">PMC6858546</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0497-x</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0497-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Daneman R. The blood-brain barrier in health and disease. Ann Neurol 72, 648&#x2013;672 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23280789</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178&#x2013;201 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18215617</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin LL &amp; Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci 22, 11&#x2013;28 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10202530</ArticleId></ArticleIdList></Reference><Reference><Citation>Janzer RC &amp; Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325, 253&#x2013;257 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3543687</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart PA &amp; Wiley MJ. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail--chick transplantation chimeras. Dev Biol 84, 183&#x2013;192 (1981).</Citation><ArticleIdList><ArticleId IdType="pubmed">7250491</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A. et al. Pericytes regulate the blood-brain barrier. Nature 468, 557&#x2013;561 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Zhou L, Kebede AA &amp; Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 468, 562&#x2013;566 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241506</ArticleId><ArticleId IdType="pubmed">20944625</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin LL. et al. A cell culture model of the blood-brain barrier. J Cell Biol 115, 1725&#x2013;1735 (1991).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289219</ArticleId><ArticleId IdType="pubmed">1661734</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidenfeller C, Svendsen CN &amp; Shusta EV. Differentiating embryonic neural progenitor cells induce blood-brain barrier properties. J Neurochem 101, 555&#x2013;565 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657050</ArticleId><ArticleId IdType="pubmed">17254017</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R. et al. Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc Natl Acad Sci U S A 106, 641&#x2013;646 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626756</ArticleId><ArticleId IdType="pubmed">19129494</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebner S. et al. Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Biol 183, 409&#x2013;417 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575783</ArticleId><ArticleId IdType="pubmed">18955553</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenman JM. et al. Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science 322, 1247&#x2013;1250 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19023080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. et al. Norrin/Frizzled4 signaling in retinal vascular development and blood brain barrier plasticity. Cell 151, 1332&#x2013;1344 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535266</ArticleId><ArticleId IdType="pubmed">23217714</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y &amp; Nathans J. Gpr124 controls CNS angiogenesis and blood-brain barrier integrity by promoting ligand-specific canonical wnt signaling. Dev Cell 31, 248&#x2013;256 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223636</ArticleId><ArticleId IdType="pubmed">25373781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y. et al. Canonical WNT signaling components in vascular development and barrier formation. J Clin Invest 124, 3825&#x2013;3846 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4151216</ArticleId><ArticleId IdType="pubmed">25083995</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinzon-Daza ML. et al. The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. J Cereb Blood Flow Metab 34, 1258&#x2013;1269, doi:10.1038/jcbfm.2014.100 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2014.100</ArticleId><ArticleId IdType="pmc">PMC4126086</ArticleId><ArticleId IdType="pubmed">24896565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidou S. et al. An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis. Proc Natl Acad Sci U S A 103, 16770&#x2013;16775 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1636530</ArticleId><ArticleId IdType="pubmed">17075074</ArticleId></ArticleIdList></Reference><Reference><Citation>Keuschnigg J. et al. The prototype endothelial marker PAL-E is a leukocyte trafficking molecule. Blood 114, 478&#x2013;484 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19420356</ArticleId></ArticleIdList></Reference><Reference><Citation>Shue EH. et al. Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. BMC Neurosci 9, 29 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2270280</ArticleId><ArticleId IdType="pubmed">18302779</ArticleId></ArticleIdList></Reference><Reference><Citation>Doring A, Wild M, Vestweber D, Deutsch U &amp; Engelhardt B. E- and P-selectin are not required for the development of experimental autoimmune encephalomyelitis in C57BL/6 and SJL mice. J Immunol 179, 8470&#x2013;8479 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18056394</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S &amp; Barber R. Expression of P-selectin and intercellular adhesion molecule-1 in human brain after focal infarction or cardiac arrest. Neuropathol Appl Neurobiol 27, 465&#x2013;473 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11903929</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada Y. et al. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 25, 202&#x2013;211 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7505494</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayadas TN, Johnson RC, Rayburn H, Hynes RO &amp; Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 74, 541&#x2013;554 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">7688665</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J. et al. Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke 31, 3047&#x2013;3053 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11108771</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin AY. et al. Reduced blood brain barrier breakdown in P-selectin deficient mice following transient ischemic stroke: a future therapeutic target for treatment of stroke. BMC Neurosci 11, 12 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829030</ArticleId><ArticleId IdType="pubmed">20122276</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowes MP, Zivin JA &amp; Rothlein R. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol 119, 215&#x2013;219 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8094342</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly ES Jr. et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 97, 209&#x2013;216 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC507081</ArticleId><ArticleId IdType="pubmed">8550836</ArticleId></ArticleIdList></Reference><Reference><Citation>Henninger DD. et al. Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. J Immunol 158, 1825&#x2013;1832 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9029122</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyck R. et al. T-cell interaction with ICAM-1/ICAM-2 double-deficient brain endothelium in vitro: the cytoplasmic tail of endothelial ICAM-1 is necessary for transendothelial migration of T cells. Blood 102, 3675&#x2013;3683 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12893765</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharief MK, Noori MA, Ciardi M, Cirelli A &amp; Thompson EJ. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage. J Neuroimmunol 43, 15&#x2013;21 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8096220</ArticleId></ArticleIdList></Reference><Reference><Citation>Derada Troletti C, de Goede P, Kamermans A &amp; de Vries HE. Molecular alterations of the blood-brain barrier under inflammatory conditions: The role of endothelial to mesenchymal transition. Biochim Biophys Acta 1862, 452&#x2013;460, doi:10.1016/j.bbadis.2015.10.010 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2015.10.010</ArticleId><ArticleId IdType="pubmed">26493443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T. et al. Microvascular endothelial cells engulf myelin debris and promote macrophage recruitment and fibrosis after neural injury. Nat Neurosci 22, 421&#x2013;435, doi:10.1038/s41593-018-0324-9 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0324-9</ArticleId><ArticleId IdType="pmc">PMC6913093</ArticleId><ArticleId IdType="pubmed">30664769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ley K. The role of selectins in inflammation and disease. Trends Mol Med 9, 263&#x2013;268 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12829015</ArticleId></ArticleIdList></Reference><Reference><Citation>Conductier G, Blondeau N, Guyon A, Nahon JL &amp; Rovere C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 224, 93&#x2013;100, doi:10.1016/j.jneuroim.2010.05.010 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2010.05.010</ArticleId><ArticleId IdType="pubmed">20681057</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal BB, Shishodia S, Ashikawa K &amp; Bharti AC. The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Curr Drug Targets Inflamm Allergy 1, 327&#x2013;341 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">14561180</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing C. et al. Neuronal production of lipocalin-2 as a help-me signal for glial activation. Stroke 45, 2085&#x2013;2092, doi:10.1161/STROKEAHA.114.005733 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.114.005733</ArticleId><ArticleId IdType="pmc">PMC4122238</ArticleId><ArticleId IdType="pubmed">24916903</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira AC. et al. From the periphery to the brain: Lipocalin-2, a friend or foe? Prog Neurobiol 131, 120&#x2013;136, doi:10.1016/j.pneurobio.2015.06.005 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2015.06.005</ArticleId><ArticleId IdType="pubmed">26159707</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng B, Chen J, Bai B &amp; Xin Q. Neuroprotection of apelin and its signaling pathway. Peptides 37, 171&#x2013;173, doi:10.1016/j.peptides.2012.07.012 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2012.07.012</ArticleId><ArticleId IdType="pubmed">22820556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S, Kwon HJ, Johng H, Zang K &amp; Huang Z. Radial glial neural progenitors regulate nascent brain vascular network stabilization via inhibition of Wnt signaling. PLoS Biol 11, e1001469, doi:10.1371/journal.pbio.1001469 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1001469</ArticleId><ArticleId IdType="pmc">PMC3551952</ArticleId><ArticleId IdType="pubmed">23349620</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C. et al. Conditional ablation of neuroprogenitor cells in adult mice impedes recovery of poststroke cognitive function and reduces synaptic connectivity in the perforant pathway. J Neurosci 33, 17314&#x2013;17325, doi:10.1523/JNEUROSCI.2129-13.2013 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2129-13.2013</ArticleId><ArticleId IdType="pmc">PMC3812503</ArticleId><ArticleId IdType="pubmed">24174664</ArticleId></ArticleIdList></Reference><Reference><Citation>Akamatsu Y. et al. Impaired leptomeningeal collateral flow contributes to the poor outcome following experimental stroke in the Type 2 diabetic mice. J Neurosci 35, 3851&#x2013;3864, doi:10.1523/JNEUROSCI.3838-14.2015 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3838-14.2015</ArticleId><ArticleId IdType="pmc">PMC4348184</ArticleId><ArticleId IdType="pubmed">25740515</ArticleId></ArticleIdList></Reference><Reference><Citation>Semple BD. et al. Early Gelatinase Activity Is Not a Determinant of Long-Term Recovery after Traumatic Brain Injury in the Immature Mouse. PLoS One 10, e0143386, doi:10.1371/journal.pone.0143386 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0143386</ArticleId><ArticleId IdType="pmc">PMC4654502</ArticleId><ArticleId IdType="pubmed">26588471</ArticleId></ArticleIdList></Reference><Reference><Citation>Semple BD, Blomgren K, Gimlin K, Ferriero DM &amp; Noble-Haeusslein LJ. Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species. Prog Neurobiol 106&#x2013;107, 1&#x2013;16, doi:10.1016/j.pneurobio.2013.04.001 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2013.04.001</ArticleId><ArticleId IdType="pmc">PMC3737272</ArticleId><ArticleId IdType="pubmed">23583307</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R. et al. The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS One 5, e13741 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966423</ArticleId><ArticleId IdType="pubmed">21060791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui JH. et al. Radial glia require PDGFD-PDGFRbeta signalling in human but not mouse neocortex. Nature 515, 264&#x2013;268, doi:10.1038/nature13973 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13973</ArticleId><ArticleId IdType="pmc">PMC4231536</ArticleId><ArticleId IdType="pubmed">25391964</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P &amp; Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559, doi:10.1186/1471-2105-9-559 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-9-559</ArticleId><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldham MC. et al. Functional organization of the transcriptome in human brain. Nat Neurosci 11, 1271&#x2013;1282, doi:10.1038/nn.2207 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2207</ArticleId><ArticleId IdType="pmc">PMC2756411</ArticleId><ArticleId IdType="pubmed">18849986</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31727856</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>366</Volume><Issue>6469</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>29</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Brain cell type-specific enhancer-promoter interactome maps and disease<b>-</b>risk association.</ArticleTitle><Pagination><StartPage>1134</StartPage><EndPage>1139</EndPage><MedlinePgn>1134-1139</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aay0793</ELocationID><Abstract><AbstractText>Noncoding genetic variation is a major driver of phenotypic diversity, but functional interpretation is challenging. To better understand common genetic variation associated with brain diseases, we defined noncoding regulatory regions for major cell types of the human brain. Whereas psychiatric disorders were primarily associated with variants in transcriptional enhancers and promoters in neurons, sporadic Alzheimer's disease (AD) variants were largely confined to microglia enhancers. Interactome maps connecting disease-risk variants in cell-type-specific enhancers to promoters revealed an extended microglia gene network in AD. Deletion of a microglia-specific enhancer harboring AD-risk variants ablated <i>BIN1</i> expression in microglia, but not in neurons or astrocytes. These findings revise and expand the list of genes likely to be influenced by noncoding variants in AD and suggest the probable cell types in which they function.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Nott</LastName><ForeName>Alexi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2029-7193</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Holtman</LastName><ForeName>Inge R</ForeName><Initials>IR</Initials><Identifier Source="ORCID">0000-0001-9752-4756</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section Molecular Neurobiology, Department of Biomedical Sciences of Cells &amp; Systems, University Medical Center Groningen, University of Groningen, 9713 AV Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Coufal</LastName><ForeName>Nicole G</ForeName><Initials>NG</Initials><Identifier Source="ORCID">0000-0001-6547-1733</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlachetzki</LastName><ForeName>Johannes C M</ForeName><Initials>JCM</Initials><Identifier Source="ORCID">0000-0002-7801-9743</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Rong</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0660-0387</Identifier><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Claudia Z</ForeName><Initials>CZ</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pena</LastName><ForeName>Monique</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Jiayang</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8007-4995</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keulen</LastName><ForeName>Zahara</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasillas</LastName><ForeName>Martina P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-9337-0136</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3301-7912</Identifier><AffiliationInfo><Affiliation>Flow Cytometry Core Facility, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nickl</LastName><ForeName>Christian K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schafer</LastName><ForeName>Simon T</ForeName><Initials>ST</Initials><Identifier Source="ORCID">0000-0002-2370-3652</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Zeyang</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-3870-1390</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rissman</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brewer</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gosselin</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5327-2868</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de Recherche du Centre Hospitalier Universitaire de Qu&#xe9;bec-Universit&#xe9; Laval, D&#xe9;partement de M&#xe9;decine Mol&#xe9;culaire, Facult&#xe9; de M&#xe9;decine, Universit&#xe9; Laval, Qu&#xe9;bec G1V 4G2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonda</LastName><ForeName>David D</ForeName><Initials>DD</Initials><Identifier Source="ORCID">0000-0002-4681-7337</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, University of California, San Diego-Rady Children's Hospital, San Diego, CA 92123, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of California, San Diego-Rady Children's Hospital, San Diego, CA 92123, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenfeld</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Department and School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McVicker</LastName><ForeName>Graham</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0991-0951</Identifier><AffiliationInfo><Affiliation>The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials><Identifier Source="ORCID">0000-0002-0938-4106</Identifier><AffiliationInfo><Affiliation>Section Molecular Neurobiology, Department of Biomedical Sciences of Cells &amp; Systems, University Medical Center Groningen, University of Groningen, 9713 AV Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Christopher K</ForeName><Initials>CK</Initials><Identifier Source="ORCID">0000-0003-4344-3592</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA. ckg@ucsd.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, Center for Epigenomics, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG056306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057706</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA023100</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR001444</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS109200</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD023689</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS096170</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK063491</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061521</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA014195</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101410">BIN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002843">Chromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Genet. 2020 Feb;21(2):69. doi: 10.1038/s41576-019-0206-3.</RefSource><PMID Version="1">31822792</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002843" MajorTopicYN="N">Chromatin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004742" MajorTopicYN="N">Enhancer Elements, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31727856</ArticleId><ArticleId IdType="mid">NIHMS1066836</ArticleId><ArticleId IdType="pmc">PMC7028213</ArticleId><ArticleId IdType="doi">10.1126/science.aay0793</ArticleId><ArticleId IdType="pii">science.aay0793</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lake BB et al., Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science (New York, NY) 352, 1586&#x2013;1590 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5038589</ArticleId><ArticleId IdType="pubmed">27339989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB et al., Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nature Biotechnology 36, 70&#x2013;80 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al., Single-cell transcriptomic analysis of Alzheimer's disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Chen-Plotkin AS, The Post-GWAS Era: From Association to Function. Am J Hum Genet 102, 717&#x2013;730 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986732</ArticleId><ArticleId IdType="pubmed">29727686</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurano MT et al., Systematic localization of common disease-associated variation in regulatory DNA. Science 337, 1190&#x2013;1195 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771521</ArticleId><ArticleId IdType="pubmed">22955828</ArticleId></ArticleIdList></Reference><Reference><Citation>Hnisz D et al., Super-enhancers in the control of cell identity and disease. Cell 155, 934&#x2013;947 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3841062</ArticleId><ArticleId IdType="pubmed">24119843</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S, Romanoski CE, Benner C, Glass CK, The selection and function of cell type-specific enhancers. Nature reviews Molecular cell biology 16, 144 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517609</ArticleId><ArticleId IdType="pubmed">25650801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumbach MR et al., HiChIP: efficient and sensitive analysis of protein-directed genome architecture. Nature methods 13, 919 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501173</ArticleId><ArticleId IdType="pubmed">27643841</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X et al., ATAC-see reveals the accessible genome by transposase-mediated imaging and sequencing. Nat Methods 13, 1013&#x2013;1020 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5509561</ArticleId><ArticleId IdType="pubmed">27749837</ArticleId></ArticleIdList></Reference><Reference><Citation>Creyghton MP et al., Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proceedings of the National Academy of Sciences of the United States of America 107, 21931&#x2013;21936 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003124</ArticleId><ArticleId IdType="pubmed">21106759</ArticleId></ArticleIdList></Reference><Reference><Citation>Heintzman ND et al., Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 39, 311&#x2013;318 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17277777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y et al., Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37&#x2013;53 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D et al., Comprehensive functional genomic resource and integrative model for the human brain. Science (New York, NY) 362, eaat8464 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6413328</ArticleId><ArticleId IdType="pubmed">30545857</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D et al., An environment-dependent transcriptional network specifies human microglia identity. Science (New York, NY) 356, eaal3222 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordao MJC et al., Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science 363, (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30679343</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B et al., An atlas of genetic correlations across human diseases and traits. Nature Genetics 47, 1236&#x2013;1241 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4797329</ArticleId><ArticleId IdType="pubmed">26414676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW et al., Genetic meta-analysis of diagnosed Alzheimer&amp;apos;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nature Genetics 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE et al., Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nature Genetics 51, 404&#x2013;413 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KL et al., A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. Nat Neurosci 20, 1052&#x2013;1061 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759334</ArticleId><ArticleId IdType="pubmed">28628103</ArticleId></ArticleIdList></Reference><Reference><Citation>Novikova G et al., Integration of Alzheimer&#x2019;s disease genetics and myeloid cell genomics identifies novel causal variants, regulatory elements, genes and pathways. bioRxiv, 694281 (2019).</Citation></Reference><Reference><Citation>Tansey KE, Hill MJ, Enrichment of schizophrenia heritability in both neuronal and glia cell regulatory elements. Transl Psychiatry 8, 7 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802526</ArticleId><ArticleId IdType="pubmed">29317610</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansey KE, Cameron D, Hill MJ, Genetic risk for Alzheimer's disease is concentrated in specific macrophage and microglial transcriptional networks. Genome Med 10, 14 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828245</ArticleId><ArticleId IdType="pubmed">29482603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert SA et al., The Human Transcription Factors. Cell 175, 598&#x2013;599 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30290144</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang R et al., Mapping of long-range chromatin interactions by proximity ligation-assisted ChIP-seq. Cell research 26, 1345&#x2013;1348 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5143423</ArticleId><ArticleId IdType="pubmed">27886167</ArticleId></ArticleIdList></Reference><Reference><Citation>Juric I et al., MAPS: Model-based analysis of long-range chromatin interactions from PLAC-seq and HiChIP experiments. PLoS Comput Biol 15, e1006982 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6483256</ArticleId><ArticleId IdType="pubmed">30986246</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotti A et al., BIN1 favors the spreading of Tau via extracellular vesicles. Sci Rep 9, 9477 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6603165</ArticleId><ArticleId IdType="pubmed">31263146</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al., A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell 169, 1276&#x2013;1290 e1217 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31738372</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>164</StartPage><EndPage>174</EndPage><MedlinePgn>164-174</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.3762</ELocationID><Abstract><AbstractText Label="IMPORTANCE">There are no disease-modifying treatments for Alzheimer disease (AD), the most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic effects of &#x3b2;-amyloid in vitro and in animal models of AD, and is a credible repurposed treatment candidate.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether 24 months of minocycline treatment can modify cognitive and functional decline in patients with mild AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Participants were recruited into a double-blind randomized clinical trial from May 23, 2014, to April 14, 2016, with 24 months of treatment and follow-up. This multicenter study in England and Scotland involved 32 National Health Service memory clinics within secondary specialist services for people with dementia. From 886 screened patients, 554 patients with a diagnosis of mild AD (Standardised Mini-Mental State Examination [sMMSE] score &#x2265;24) were randomized.</AbstractText><AbstractText Label="INTERVENTIONS">Participants were randomly allocated 1:1:1 in a semifactorial design to receive minocycline (400 mg/d or 200 mg/d) or placebo for 24 months.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Primary outcome measures were decrease in sMMSE score and Bristol Activities of Daily Living Scale (BADLS), analyzed by intention-to-treat repeated-measures regression.</AbstractText><AbstractText Label="RESULTS">Of 544 eligible participants (241 women and 303 men), the mean (SD) age was 74.3 (8.2) years, and the mean (SD) sMMSE score was 26.4 (1.9). Fewer participants completed 400-mg minocycline hydrochloride treatment (28.8% [53 of 184]) than 200-mg minocycline treatment (61.9% [112 of 181]) or placebo (63.7% [114 of 179]; P&#x2009;&lt;&#x2009;.001), mainly because of gastrointestinal symptoms (42 in the 400-mg group, 15 in the 200-mg group, and 10 in the placebo group; P&#x2009;&lt;&#x2009;.001), dermatologic adverse effects (10 in the 400-mg group, 5 in the 200-mg group, and 1 in the placebo group; P&#x2009;=&#x2009;.02), and dizziness (14 in the 400-mg group, 3 in the 200-mg group, and 1 in the placebo group; P&#x2009;=&#x2009;.01). Assessment rates were lower in the 400-mg group: 68.4% (119 of 174 expected) for sMMSE at 24 months compared with 81.8% (144 of 176) for the 200-mg group and 83.8% (140 of 167) for the placebo group. Decrease in sMMSE scores over 24 months in the combined minocycline group was similar to that in the placebo group (4.1 vs 4.3 points). The combined minocycline group had mean sMMSE scores 0.1 points higher than the placebo group (95% CI, -1.1 to 1.2; P&#x2009;=&#x2009;.90). The decrease in mean sMMSE scores was less in the 400-mg group than in the 200-mg group (3.3 vs 4.7 points; treatment effect&#x2009;=&#x2009;1.2; 95% CI, -0.1 to 2.5; P&#x2009;=&#x2009;.08). Worsening of BADLS scores over 24 months was similar in all groups: 5.7 in the 400-mg group, 6.6 in the 200-mg group, and 6.2 in the placebo groups (treatment effect for minocycline vs placebo&#x2009;=&#x2009;-0.53; 95% CI, -2.4 to 1.3; P&#x2009;=&#x2009;.57; treatment effect for 400 mg vs 200 mg of minocycline&#x2009;=&#x2009;-0.31; 95% CI, -0.2 to 1.8; P&#x2009;=&#x2009;.77). Results were similar in different patient subgroups and in sensitivity analyses adjusting for missing data.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Minocycline did not delay the progress of cognitive or functional impairment in people with mild AD during a 2-year period. This study also found that 400 mg of minocycline is poorly tolerated in this population.</AbstractText><AbstractText Label="TRIAL REGISTRATION">isrctn.org Identifier: ISRCTN16105064.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zubko</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Old Age Psychiatry, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Rosie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harper</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pank</LastName><ForeName>Lynn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Norwich Medical School, University of East Anglia, Norwich, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabet</LastName><ForeName>Naji</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry, University of Sussex, Brighton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bentham</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Birmingham and Solihull Mental Health National Health Service Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McShane</LastName><ForeName>Rupert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical School, University of Exeter, Exeter, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noble</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilforooshan</LastName><ForeName>Ramin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Surrey and Borders Partnership National Health Service Foundation Trust, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilcock</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Minocycline in Alzheimer Disease Efficacy (MADE) Trialist Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN16105064</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_13091</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NIHR/CS/010/019</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>FYY3R43WGO</RegistryNumber><NameOfSubstance UI="D008911">Minocycline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2020 Feb 1;77(2):162-163. doi: 10.1001/jamaneurol.2019.3784.</RefSource><PMID Version="1">31738375</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Neurol. 2020 Mar;27(3):e14. doi: 10.1111/ene.14141.</RefSource><PMID Version="1">31823426</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Mar;16(3):131-132. doi: 10.1038/s41582-019-0307-9.</RefSource><PMID Version="1">31919414</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2020 Aug 1;77(8):1037-1038. doi: 10.1001/jamaneurol.2020.1154.</RefSource><PMID Version="1">32421157</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2020 Aug 1;77(8):1038. doi: 10.1001/jamaneurol.2020.1157.</RefSource><PMID Version="1">32421177</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008911" MajorTopicYN="N">Minocycline</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Howard reported receiving grants from the National Institute for Health Research and Medical Research Council during the conduct of the study; and serving as a Scientific Trustee for Alzheimer&#x2019;s Research UK. Dr O&#x2019;Brien reported receiving grants and personal fees from Avid/Lilly, grants from Alliance Medical, and personal fees from TauRx, Eisai, GE Healthcare, and Axon outside the submitted work. Dr Tabet reported receiving grants from Brighton and Sussex Medical School during the conduct of the study. Dr Livingston reported receiving grants from the National Institute for Health Research during the conduct of the study. Mr Bentham reported receiving grants from EME during the conduct of the study and personal fees from TauRx Therapeutics outside the submitted work. Dr McShane reported receiving grants from the Oxford Health NHS Foundation Trust during the conduct of the study. Dr Ritchie reported receiving other from Merck Sharpe &amp; Dome, Nutricia, and Eli Lilly; and grants and other from Actinogen, Jannsen, and Biogen outside the submitted work. Dr Lovestone reported receiving grants from Alzheimer's Society during the conduct of the study; receiving personal fees from Eisai and Merck; other from Lilly and SomaLogic; and grants from AstraZeneca and EU-IMI with EFPIA companies outside the submitted work; having a patent to Biomarkers pertaining to Alzheimer disease pending and issued; and is currently an employee of Janssen-Cilag Ltd. Dr Ballard reported receiving grants and personal fees from Acadia Pharmaceuticals and Lundbeck Pharmaceuticals; personal fees from Axovant, Otsuka, Biogen Pharmaceuticals, and Eli Lilly Pharmaceutical; and grants from the National Institutes of Health during the conduct of the study. Professor Gray reported receiving grants from the UK MRC EME programme during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>11</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31738372</ArticleId><ArticleId IdType="pmc">PMC6865324</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.3762</ArticleId><ArticleId IdType="pii">2755279</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Disease International World Alzheimer Report 2015: The Global Impact of Dementia. London, UK: Alzheimer&#x2019;s Disease International; 2015.</Citation></Reference><Reference><Citation>Vradenburg G. A pivotal moment in Alzheimer&#x2019;s disease and dementia: how global unity of purpose and action can beat the disease by 2025. Expert Rev Neurother. 2015;15(1):73-82. doi:10.1586/14737175.2015.995638</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737175.2015.995638</ArticleId><ArticleId IdType="pubmed">25576089</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Goate AM. Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77(1):43-51. doi:10.1016/j.biopsych.2014.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2014.05.006</ArticleId><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Donat CK, Sastre M. In vivo imaging of glial activation in Alzheimer&#x2019;s disease. Front Neurol. 2018;9:625. doi:10.3389/fneur.2018.00625</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00625</ArticleId><ArticleId IdType="pmc">PMC6090997</ArticleId><ArticleId IdType="pubmed">30131755</ArticleId></ArticleIdList></Reference><Reference><Citation>VanItallie TB. Alzheimer&#x2019;s disease: innate immunity gone awry? Metabolism. 2017;69S:S41-S49. doi:10.1016/j.metabol.2017.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2017.01.014</ArticleId><ArticleId IdType="pubmed">28129888</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Ye RD. Microglial A&#x3b2; receptors in Alzheimer&#x2019;s disease. Cell Mol Neurobiol. 2015;35(1):71-83. doi:10.1007/s10571-014-0101-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-014-0101-6</ArticleId><ArticleId IdType="pmc">PMC11486233</ArticleId><ArticleId IdType="pubmed">25149075</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Carson MJ, El Khoury J, et al. . Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14(4):388-405. doi:10.1016/S1474-4422(15)70016-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)70016-5</ArticleId><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett A, Pickett J, Burns A, et al. . Drug repositioning for Alzheimer&#x2019;s disease. Nat Rev Drug Discov. 2012;11(11):833-846. doi:10.1038/nrd3869</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3869</ArticleId><ArticleId IdType="pubmed">23123941</ArticleId></ArticleIdList></Reference><Reference><Citation>Appleby BS, Cummings JL. Discovering new treatments for Alzheimer&#x2019;s disease by repurposing approved medications. Curr Top Med Chem. 2013;13(18):2306-2327. doi:10.2174/15680266113136660162</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/15680266113136660162</ArticleId><ArticleId IdType="pubmed">24059463</ArticleId></ArticleIdList></Reference><Reference><Citation>Familian A, Boshuizen RS, Eikelenboom P, Veerhuis R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia. 2006;53(3):233-240. doi:10.1002/glia.20268</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20268</ArticleId><ArticleId IdType="pubmed">16220550</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabrook TJ, Jiang L, Maier M, Lemere CA. Minocycline affects microglia activation, A&#x3b2; deposition, and behavior in APP-tg mice. Glia. 2006;53(7):776-782. doi:10.1002/glia.20338</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20338</ArticleId><ArticleId IdType="pubmed">16534778</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH. Minocycline reduces the development of abnormal tau species in models of Alzheimer&#x2019;s disease. FASEB J. 2009;23(3):739-750. doi:10.1096/fj.08-113795</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-113795</ArticleId><ArticleId IdType="pubmed">19001528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti MT, Allard S, Partridge V, Ducatenzeiler A, Cuello AC. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer&#x2019;s disease&#x2013;like amyloid pathology. J Neuroinflammation. 2012;9:62. doi:10.1186/1742-2094-9-62</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-62</ArticleId><ArticleId IdType="pmc">PMC3352127</ArticleId><ArticleId IdType="pubmed">22472085</ArticleId></ArticleIdList></Reference><Reference><Citation>Biscaro B, Lindvall O, Tesco G, Ekdahl CT, Nitsch RM. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer&#x2019;s disease. Neurodegener Dis. 2012;9(4):187-198. doi:10.1159/000330363</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000330363</ArticleId><ArticleId IdType="pmc">PMC7068786</ArticleId><ArticleId IdType="pubmed">22584394</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcez ML, Mina F, Bellettini-Santos T, et al. . Minocycline reduces inflammatory parameters in the brain structures and serum and reverses memory impairment caused by the administration of amyloid &#x3b2; (1-42) in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2017;77:23-31. doi:10.1016/j.pnpbp.2017.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2017.03.010</ArticleId><ArticleId IdType="pubmed">28336494</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y, Kim HS, Shin KY, et al. . Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer&#x2019;s disease models. Neuropsychopharmacology. 2007;32(11):2393-2404. doi:10.1038/sj.npp.1301377</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1301377</ArticleId><ArticleId IdType="pubmed">17406652</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Molloy DW, Standish TI. A guide to the standardized Mini-Mental State Examination. Int Psychogeriatr. 1997;9(suppl 1):87-94. doi:10.1017/S1041610297004754</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610297004754</ArticleId><ArticleId IdType="pubmed">9447431</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing. 1996;25(2):113-120. doi:10.1093/ageing/25.2.113</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/25.2.113</ArticleId><ArticleId IdType="pubmed">8670538</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data? Neuropsychopharmacology. 1992;6(1):39-48.</Citation><ArticleIdList><ArticleId IdType="pubmed">1571068</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguel-&#xc1;lvarez M, Santos-Lozano A, Sanchis-Gomar F, et al. . Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer&#x2019;s disease: a systematic review and meta-analysis of treatment effect. Drugs Aging. 2015;32(2):139-147. doi:10.1007/s40266-015-0239-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40266-015-0239-z</ArticleId><ArticleId IdType="pubmed">25644018</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Gau BA, Welsh KA, et al. . Inverse association of anti-inflammatory treatments and Alzheimer&#x2019;s disease: initial results of a co-twin control study. Neurology. 1994;44(2):227-232. doi:10.1212/WNL.44.2.227</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.44.2.227</ArticleId><ArticleId IdType="pubmed">8309563</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28(5):639-647. doi:10.1016/j.neurobiolaging.2006.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.03.013</ArticleId><ArticleId IdType="pubmed">16697488</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Moore DH, Miller RG, et al. ; Western ALS Study Group . Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6(12):1045-1053. doi:10.1016/S1474-4422(07)70270-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70270-3</ArticleId><ArticleId IdType="pubmed">17980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington Study Group DOMINO Investigators A futility study of minocycline in Huntington&#x2019;s disease. Mov Disord. 2010;25(13):2219-2224. doi:10.1002/mds.23236</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23236</ArticleId><ArticleId IdType="pmc">PMC8801051</ArticleId><ArticleId IdType="pubmed">20721920</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodel R, Spottke A, Gerhard A, et al. . Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010;25(1):97-107. doi:10.1002/mds.22732</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22732</ArticleId><ArticleId IdType="pubmed">20014118</ArticleId></ArticleIdList></Reference><Reference><Citation>Deakin B, Suckling J, Barnes TRE, et al. ; BeneMin Study team . The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. Lancet Psychiatry. 2018;5(11):885-894. doi:10.1016/S2215-0366(18)30345-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(18)30345-6</ArticleId><ArticleId IdType="pmc">PMC6206257</ArticleId><ArticleId IdType="pubmed">30322824</ArticleId></ArticleIdList></Reference><Reference><Citation>Metz LM, Li DKB, Traboulsee AL, et al. ; Minocycline in MS Study Team . Trial of minocycline in a clinically isolated syndrome of multiple sclerosis. N Engl J Med. 2017;376(22):2122-2133. doi:10.1056/NEJMoa1608889</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1608889</ArticleId><ArticleId IdType="pubmed">28564557</ArticleId></ArticleIdList></Reference><Reference><Citation>Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol. 2010;67(12):1442-1448. doi:10.1001/archneurol.2010.191</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.191</ArticleId><ArticleId IdType="pmc">PMC3127230</ArticleId><ArticleId IdType="pubmed">20697034</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott G, Zetterberg H, Jolly A, et al. . Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. Brain. 2018;141(2):459-471. doi:10.1093/brain/awx339</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx339</ArticleId><ArticleId IdType="pmc">PMC5837493</ArticleId><ArticleId IdType="pubmed">29272357</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31748742</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>575</Volume><Issue>7784</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>NLRP3 inflammasome activation drives tau pathology.</ArticleTitle><Pagination><StartPage>669</StartPage><EndPage>673</EndPage><MedlinePgn>669-673</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-1769-z</ELocationID><Abstract><AbstractText>Alzheimer's disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline<sup>1</sup>. The NLRP3 inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1&#x3b2; release<sup>2</sup>. Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathology in mice<sup>3</sup>, the precise effect on tau pathology remains unknown. Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases. Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-containing brain homogenates induced tau pathology in an NLRP3-dependent manner. These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer's disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ising</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venegas</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shuangshuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheiblich</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Susanne V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira-Saecker</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albasset</LastName><ForeName>Shadi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McManus</LastName><ForeName>R&#xf3;is&#xed;n M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tejera</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griep</LastName><ForeName>Angelika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santarelli</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brosseron</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opitz</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stunden</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>IFM Therapeutics GmbH, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merten</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayed</LastName><ForeName>Rakez</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases and Departments of Neurology, Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golenbock</LastName><ForeName>Douglas T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Divison of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU-Lille, UMR-S 1172, "Alzheimer &amp; Tauopathies", Labex DISTALZ, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latz</LastName><ForeName>Eicke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Divison of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu&#xe9;e</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU-Lille, UMR-S 1172, "Alzheimer &amp; Tauopathies", Labex DISTALZ, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany. michael.heneka@ukbonn.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. michael.heneka@ukbonn.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Divison of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA. michael.heneka@ukbonn.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG054025</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG059752</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG059752-02</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Jan;16(1):4. doi: 10.1038/s41582-019-0299-5.</RefSource><PMID Version="1">31811274</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Signal Transduct Target Ther. 2020 Apr 1;5(1):37. doi: 10.1038/s41392-020-0145-7.</RefSource><PMID Version="1">32296063</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. M.T.H. serves as advisory board member at IFM Therapeutics and Alector. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31748742</ArticleId><ArticleId IdType="mid">NIHMS1574861</ArticleId><ArticleId IdType="pmc">PMC7324015</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1769-z</ArticleId><ArticleId IdType="pii">10.1038/s41586-019-1769-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ising C &amp; Heneka MT Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. Cell Death Dis. 9, 120 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833757</ArticleId><ArticleId IdType="pubmed">29371603</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, McManus RM &amp; Latz E Inflammasome signalling in brain function and neurodegenerative disease. Nat. Rev. Neurosci 19, 610&#x2013;621 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30206330</ArticleId></ArticleIdList></Reference><Reference><Citation>Venegas C et al. Microglia-derived ASC specks cross-seed amyloid-&#x3b2; in Alzheimer&#x2019;s disease. Nature 552, 355&#x2013;361 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29293211</ArticleId></ArticleIdList></Reference><Reference><Citation>Halle A et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol 9, 857&#x2013;865 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101478</ArticleId><ArticleId IdType="pubmed">18604209</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT et al. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature 493, 674&#x2013;678 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J &amp; Dickson DW Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. (Berl.) 131, 27&#x2013;48 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26576562</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K et al. Alzheimer&#x2019;s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol 169, 599&#x2013;616 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Youm Y-H et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 18, 519&#x2013;532 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4017327</ArticleId><ArticleId IdType="pubmed">24093676</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JM et al. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer&#x2019;s disease. Neurobiol. Aging 35, 1012&#x2013;1023 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24262201</ArticleId></ArticleIdList></Reference><Reference><Citation>Minter MR et al. Soluble amyloid triggers a myeloid differentiation factor 88 and interferon regulatory factor 7 dependent neuronal type-1 interferon response in vitro. J. Neuroinflammation 12, 71 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407532</ArticleId><ArticleId IdType="pubmed">25879763</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta 1739, 198&#x2013;210 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15615638</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Guti&#xe9;rrez S, Leung D, Ficarro S, Peters EC &amp; Cravatt BF Targeted disruption of the PME-1 gene causes loss of demethylated PP2A and perinatal lethality in mice. PloS One 3, e2486 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438471</ArticleId><ArticleId IdType="pubmed">18596935</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent C et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain J. Neurol 140, 184&#x2013;200 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382942</ArticleId><ArticleId IdType="pubmed">27818384</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluffo H et al. Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury. Brain Pathol. Zurich Switz 22, 318&#x2013;328 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092960</ArticleId><ArticleId IdType="pubmed">21951326</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein I &amp; Finkbeiner S The Arc of cognition: Signaling cascades regulating Arc and implications for cognitive function and disease. Semin. Cell Dev. Biol 77, 63&#x2013;72 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5865643</ArticleId><ArticleId IdType="pubmed">29559111</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskar K et al. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68, 19&#x2013;31 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2950825</ArticleId><ArticleId IdType="pubmed">20920788</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancu I-C et al. Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol. (Berl.) (2019). doi:10.1007/s00401-018-01957-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-01957-y</ArticleId><ArticleId IdType="pmc">PMC6426830</ArticleId><ArticleId IdType="pubmed">30721409</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci 18, 1584&#x2013;1593 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, van Dorpe J &amp; Nitsch RM Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491&#x2013;1495 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T et al. Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am. J. Pathol 171, 2012&#x2013;2020 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2111123</ArticleId><ArticleId IdType="pubmed">18055549</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiei SS, Guerrero-Mu&#xf1;oz MJ &amp; Castillo-Carranza DL Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. Front. Aging Neurosci 9, 83 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378766</ArticleId><ArticleId IdType="pubmed">28420982</ArticleId></ArticleIdList></Reference><Reference><Citation>Usenovic M et al. Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells. J. Neurosci. Off. J. Soc. Neurosci 35, 14234&#x2013;14250 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605424</ArticleId><ArticleId IdType="pubmed">26490863</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Jeng AT &amp; Goate AM Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J. Biol. Chem 287, 42751&#x2013;42762 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522274</ArticleId><ArticleId IdType="pubmed">23105105</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med 211, 387&#x2013;393 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanneganti T-D et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440, 233&#x2013;236 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16407888</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR &amp; Kayed R Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039&#x2013;10041 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21047142</ArticleId></ArticleIdList></Reference><Reference><Citation>Ising C et al. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J. Exp. Med 214, 1227&#x2013;1238 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5413341</ArticleId><ArticleId IdType="pubmed">28416651</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 45, D362&#x2013;D368 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210637</ArticleId><ArticleId IdType="pubmed">27924014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31768052</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A single-cell atlas of entorhinal cortex from individuals with Alzheimer's disease reveals cell-type-specific gene expression regulation.</ArticleTitle><Pagination><StartPage>2087</StartPage><EndPage>2097</EndPage><MedlinePgn>2087-2097</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0539-4</ELocationID><Abstract><AbstractText>There is currently little information available about how individual cell types contribute to Alzheimer's disease. Here we applied single-nucleus RNA sequencing to entorhinal cortex samples from control and Alzheimer's disease brains (n&#x2009;=&#x2009;6 per group), yielding a total of 13,214 high-quality nuclei. We detail cell-type-specific gene expression patterns, unveiling how transcriptional changes in specific cell subpopulations are associated with Alzheimer's disease. We report that the Alzheimer's disease risk gene APOE is specifically repressed in Alzheimer's disease oligodendrocyte progenitor cells and astrocyte subpopulations and upregulated in an Alzheimer's disease-specific microglial subopulation. Integrating transcription factor regulatory modules with Alzheimer's disease risk loci revealed drivers of cell-type-specific state transitions towards Alzheimer's disease. For example, transcription factor EB, a master regulator of lysosomal function, regulates multiple disease genes in a specific Alzheimer's disease astrocyte subpopulation. These results provide insights into the coordinated control of Alzheimer's disease risk genes and their cell-type-specific contribution to disease susceptibility. These results are available at http://adsn.ddnetbio.com.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Grubman</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4408-4499</Identifier><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chew</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ouyang</LastName><ForeName>John F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-1239-1577</Identifier><AffiliationInfo><Affiliation>Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Guizhi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choo</LastName><ForeName>Xin Yi</ForeName><Initials>XY</Initials><Identifier Source="ORCID">0000-0002-1783-0102</Identifier><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Catriona</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0302-5727</Identifier><AffiliationInfo><Affiliation>Victorian Brain Bank, Florey Institute of Neurosciences, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Rebecca K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>ARC Center of Excellence in Plant Energy Biology, The University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckberry</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ARC Center of Excellence in Plant Energy Biology, The University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas-Landin</LastName><ForeName>Dulce B</ForeName><Initials>DB</Initials><Identifier Source="ORCID">0000-0002-4773-9406</Identifier><AffiliationInfo><Affiliation>ARC Center of Excellence in Plant Energy Biology, The University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poppe</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ARC Center of Excellence in Plant Energy Biology, The University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pflueger</LastName><ForeName>Jahnvi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ARC Center of Excellence in Plant Energy Biology, The University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lister</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6637-7239</Identifier><AffiliationInfo><Affiliation>ARC Center of Excellence in Plant Energy Biology, The University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rackham</LastName><ForeName>Owen J L</ForeName><Initials>OJL</Initials><Identifier Source="ORCID">0000-0002-4390-0872</Identifier><AffiliationInfo><Affiliation>Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore. owen.rackham@duke-nus.edu.sg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petretto</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2163-5921</Identifier><AffiliationInfo><Affiliation>Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore. enrico.petretto@duke-nus.edu.sg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polo</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2531-778X</Identifier><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia. jose.polo@monash.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, Victoria, Australia. jose.polo@monash.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia. jose.polo@monash.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U120097112</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Jan;16(1):1. doi: 10.1038/s41582-019-0300-3.</RefSource><PMID Version="1">31827266</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001271" MajorTopicYN="N">Atlases as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073637" MajorTopicYN="N">Oligodendrocyte Precursor Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0539-4</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0539-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang, K.-L. et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer&#x2019;s disease. Nat. Neurosci. 20, 1052&#x2013;1061 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28628103</ArticleId><ArticleId IdType="pmc">5759334</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24162737</ArticleId><ArticleId IdType="pmc">3896259</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, B. et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell 153, 707&#x2013;720 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23622250</ArticleId><ArticleId IdType="pmc">3677161</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xfc;ger, P. et al. Microglia turnover with aging and in an Alzheimer&#x2019;s model via long-term in vivo single-cell imaging. Nat. Neurosci. 20, 1371&#x2013;1376 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28846081</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse, P. J. et al. Alzheimer&#x2019;s disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237&#x2013;1239 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7058341</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong, S. et al. A single-cell RNA-seq survey of the developmental landscape of the human prefrontal cortex. Nature 555, 524&#x2013;528 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29539641</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys, H. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease.Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31042697</ArticleId><ArticleId IdType="pmc">6865822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelmsson, U. et al. Injury leads to the appearance of cells with characteristics of both microglia and astrocytes in mouse and human brain. Cereb. Cortex 27, 3360&#x2013;3377 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28398520</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel, A. et al. Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science 347, 1138&#x2013;1142 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25700174</ArticleId></ArticleIdList></Reference><Reference><Citation>Darmanis, S. et al. A survey of human brain transcriptome diversity at the single cell level. Proc. Natl Acad. Sci. USA 112, 7285&#x2013;7290 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26060301</ArticleId><ArticleId IdType="pmc">4466750</ArticleId></ArticleIdList></Reference><Reference><Citation>Miceli, F., et al. KCNQ3-Related Disorders. in Gene Reviews (ed. Adam, M. P.) https://www.ncbi.nlm.nih.gov/books/NBK201978/ (Univ. Washington, 2014).</Citation></Reference><Reference><Citation>Ebermann, I. et al. GPR98 mutations cause Usher syndrome type 2 in males. J. Med. Genet. 46, 277&#x2013;280 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19357117</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman, A., Choo, X. Y., Chew, G., Ouyang, J. F. &amp; Sun, G. Mouse and human microglial phenotypes in Alzheimer&#x2019;s disease are controlled by amyloid plaque phagocytosis through Hif1&#x3b1;. Preprint at biorXiv https://www.biorxiv.org/content/10.1101/639054v1 (2019).</Citation></Reference><Reference><Citation>Veereshwarayya, V., Kumar, P., Rosen, K. M., Mestril, R. &amp; Querfurth, H. W. Differential effects of mitochondrial heat shock protein 60 and related molecular chaperones to prevent intracellular &#x3b2;-amyloid-induced inhibition of complex IV and limit apoptosis. J. Biol. Chem. 281, 29468&#x2013;29478 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16887805</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper, B. &amp; Karran, E. The cellular phase of Alzheimer&#x2019;s disease. Cell 164, 603&#x2013;615 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, H. et al. Rapid cell death is preceded by amyloid plaque-mediated oxidative stress. Proc. Natl Acad. Sci. USA 110, 7904&#x2013;7909 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23610434</ArticleId><ArticleId IdType="pmc">3651444</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28099414</ArticleId><ArticleId IdType="pmc">5404890</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566&#x2013;581.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28930663</ArticleId><ArticleId IdType="pmc">5719893</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rossi, P. et al. Predominant expression of Alzheimer&#x2019;s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts. Mol. Neurodegener. 11, 59 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27488240</ArticleId><ArticleId IdType="pmc">4973113</ArticleId></ArticleIdList></Reference><Reference><Citation>Savvaki, M. et al. The expression of TAG-1 in glial cells is sufficient for the formation of the juxtaparanodal complex and the phenotypic rescue of tag-1 homozygous mutants in the CNS. J. Neurosci. 30, 13943&#x2013;13954 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20962216</ArticleId><ArticleId IdType="pmc">6634759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis, G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer&#x2019;s disease. Neurobiol. Aging 25, 5&#x2013;18 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14675724</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrendt, G. et al. Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia 61, 273&#x2013;286 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23090919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake, B. B. et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science 352, 1586&#x2013;1590 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27339989</ArticleId><ArticleId IdType="pmc">5038589</ArticleId></ArticleIdList></Reference><Reference><Citation>John Lin, C.-C. et al. Identification of diverse astrocyte populations and their malignant analogs. Nat. Neurosci. 20, 396&#x2013;405 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28166219</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi, S. et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci. 8, 745&#x2013;751 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15895088</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro, M. et al. Expression profile of long non-coding RNAs in serum of patients with multiple sclerosis. J. Mol. Neurosci. 59, 18&#x2013;23 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27034068</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallin, M. D. et al. Bipolar I disorder and schizophrenia: a 440&#x2013;single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am. J. Hum. Genet. 77, 918&#x2013;936 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16380905</ArticleId><ArticleId IdType="pmc">1285177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall, C. N., Klein-Fl&#xfc;gge, M. C., Howarth, C. &amp; Attwell, D. Oxidative phosphorylation, not glycolysis, powers presynaptic and postsynaptic mechanisms underlying brain information processing. J. Neurosci. 32, 8940&#x2013;8951 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22745494</ArticleId><ArticleId IdType="pmc">3390246</ArticleId></ArticleIdList></Reference><Reference><Citation>Romito-DiGiacomo, R. R., Menegay, H., Cicero, S. A. &amp; Herrup, K. Effects of Alzheimer&#x2019;s disease on different cortical layers: the role of intrinsic differences in Abeta susceptibility. J. Neurosci. 27, 8496&#x2013;8504 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17687027</ArticleId><ArticleId IdType="pmc">6672937</ArticleId></ArticleIdList></Reference><Reference><Citation>Bis, J. C. et al. Whole exome sequencing study identifies novel rare and common Alzheimer&#x2019;s-Associated variants involved in immune response and transcriptional regulation. Mol. Psychiatry https://doi.org/10.1038/s41380-018-0112-7 (2018).</Citation></Reference><Reference><Citation>Sims, R. et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat. Genet. 49, 1373&#x2013;1384 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28714976</ArticleId><ArticleId IdType="pmc">5669039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajiho, H. et al. Characterization of RIN3 as a guanine nucleotide exchange factor for the Rab5 subfamily GTPase Rab31. J. Biol. Chem. 286, 24364&#x2013;24373 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21586568</ArticleId><ArticleId IdType="pmc">3129215</ArticleId></ArticleIdList></Reference><Reference><Citation>He, Z.-Y., Li, L., Wang, Y.-Z., Liu, X. &amp; Yuan, L.-Y. Associations between thromboxane A synthase 1 gene polymorphisms and the risk of ischemic stroke in a Chinese Han population.Neural Regen. Res. 13, 463 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29623931</ArticleId><ArticleId IdType="pmc">5900509</ArticleId></ArticleIdList></Reference><Reference><Citation>Diener, H. C. et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1&#x2013;13 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8981292</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris, D. et al. Inhibition of Alzheimer&#x2019;s beta-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP-dependent mechanism. Exp. Neurol. 157, 211&#x2013;221 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10222124</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association. 2018 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 14, 367&#x2013;429 (2018).</Citation></Reference><Reference><Citation>Raj, T. et al. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer&#x2019;s disease susceptibility. Nat. Genet. 50, 1584&#x2013;1592 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30297968</ArticleId><ArticleId IdType="pmc">6354244</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, M. G. et al. Genome wide profiling of altered gene expression in the neocortex of Alzheimer&#x2019;s disease. J. Neurosci. Res. 88, 1157&#x2013;1169 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19937809</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock, E. M., Buechel, H. M., Popovic, J., Geddes, J. W. &amp; Landfield, P. W. Microarray analyses of laser-captured hippocampus reveal distinct gray and white matter signatures associated with incipient Alzheimer&#x2019;s disease. J. Chem. Neuroanat. 42, 118&#x2013;126 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21756998</ArticleId><ArticleId IdType="pmc">3163806</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, Y.-T. et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer&#x2019;s disease phenotypes in human iPSC-derived brain cell types. Neuron 98, 1294 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29953873</ArticleId><ArticleId IdType="pmc">6048952</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis, G. et al. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. Arch. Gen. Psychiatry 63, 63&#x2013;72 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16389198</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis, J. et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol. Psychiatry 18, 1225&#x2013;1234 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23399914</ArticleId><ArticleId IdType="pmc">3807661</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, L. et al. Association of brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. JAMA Neurol. 72, 15&#x2013;24 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25365775</ArticleId><ArticleId IdType="pmc">4344367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert, J.-C. et al. Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer&#x2019;s disease. Mol. Psychiatry 18, 461&#x2013;470 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22430674</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokama, M. et al. Altered expression of diabetes-related genes in Alzheimer&#x2019;s disease brains: the Hisayama study. Cereb. Cortex 24, 2476&#x2013;2488 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23595620</ArticleId></ArticleIdList></Reference><Reference><Citation>Shijo, M. et al. Association of adipocyte enhancer-binding protein 1 with Alzheimer&#x2019;s disease pathology in human hippocampi. Brain Pathol. 28, 58&#x2013;71 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">27997051</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynard, M. A. et al. Human HIF-3&#x3b1;4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB J. 19, 1396&#x2013;1406 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16126907</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini-Stoica, H. et al. TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. J. Exp. Med. 215, 2355&#x2013;2377 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30108137</ArticleId><ArticleId IdType="pmc">6122971</ArticleId></ArticleIdList></Reference><Reference><Citation>de Toledo-Morrell, L., Goncharova, I., Dickerson, B., Wilson, R. S. &amp; Bennett, D. A. From healthy aging to early Alzheimer&#x2019;s disease: in vivo detection of entorhinal cortex atrophy. Ann. N. Y. Acad. Sci. 911, 240&#x2013;253 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10911878</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie, A. T. et al. Brain cell type specific gene expression and co-expression network architectures. Sci. Rep. 8, 8868 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29892006</ArticleId><ArticleId IdType="pmc">5995803</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib, N. et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods 14, 955&#x2013;958 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28846088</ArticleId><ArticleId IdType="pmc">5623139</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirosh, I. et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature 539, 309&#x2013;313 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27806376</ArticleId><ArticleId IdType="pmc">5465819</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, Y., Wang, L., Yin, Y. &amp; Yang, E. Systematic analysis of gene expression patterns associated with postmortem interval in human tissues. Sci. Rep. 7, 5435 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28710439</ArticleId><ArticleId IdType="pmc">5511187</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler, A., Hoffman, P., Smibert, P., Papalexi, E. &amp; Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29608179</ArticleId><ArticleId IdType="pmc">6700744</ArticleId></ArticleIdList></Reference><Reference><Citation>Lummertz da Rocha, E. et al. Reconstruction of complex single-cell trajectories using CellRouter. Nat. Commun. 9, 892 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29497036</ArticleId><ArticleId IdType="pmc">5832860</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Maaten, L. &amp; Hinton, G. Visualizing data using t-SNE. J. Mach. Learn. Res. 9, 2579&#x2013;2605 (2008).</Citation></Reference><Reference><Citation>Lambert, S. A. et al. The human transcription factors. Cell 175, 598&#x2013;599 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30290144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolde, R. Pheatmap: pretty heatmaps. R package version 61, 926 (2012).</Citation></Reference><Reference><Citation>Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer: 2016)..</Citation></Reference><Reference><Citation>Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498&#x2013;2504 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14597658</ArticleId><ArticleId IdType="pmc">403769</ArticleId></ArticleIdList></Reference><Reference><Citation>Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005&#x2013;D1012 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30445434</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene, N. G. &amp; Grant, S. G. N. Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment. Front. Neurosci. 10, 16 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26858593</ArticleId><ArticleId IdType="pmc">4730103</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie, A. T., Katsyv, I., Song, W.-M., Wang, M. &amp; Zhang, B. DGCA: a comprehensive R package for differential gene correlation analysis. BMC Syst. Biol. 10, 106 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27846853</ArticleId><ArticleId IdType="pmc">5111277</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon, S. &amp; Gentleman, R. Using GOstats to test gene lists for GO term association. Bioinformatics 23, 257&#x2013;258 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17098774</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini, Y. &amp; Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289&#x2013;300 (1995).</Citation></Reference><Reference><Citation>Li, H. et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat. Genet. 49, 708&#x2013;718 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28319088</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, G., Wang, L.-G., Han, Y. &amp; He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284&#x2013;287 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22455463</ArticleId><ArticleId IdType="pmc">3339379</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway, J. R., Lex, A. &amp; Gehlenborg, N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics 33, 2938&#x2013;2940 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28645171</ArticleId><ArticleId IdType="pmc">5870712</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31801888</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>521</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Paroxysmal slow cortical activity in Alzheimer's disease and epilepsy is associated with blood-brain barrier dysfunction.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaaw8954</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaw8954</ELocationID><Abstract><AbstractText>A growing body of evidence shows that epileptic activity is frequent but often undiagnosed in patients with Alzheimer's disease (AD) and has major therapeutic implications. Here, we analyzed electroencephalogram (EEG) data from patients with AD and found an EEG signature of transient slowing of the cortical network that we termed paroxysmal slow wave events (PSWEs). The occurrence per minute of the PSWEs was correlated with level of cognitive impairment. Interictal (between seizures) PSWEs were also found in patients with epilepsy, localized to cortical regions displaying blood-brain barrier (BBB) dysfunction, and in three rodent models with BBB pathology: aged mice, young 5x familial AD model, and status epilepticus-induced epilepsy in young rats. To investigate the potential causative role of BBB dysfunction in network modifications underlying PSWEs, we infused the serum protein albumin directly into the cerebral ventricles of na&#xef;ve young rats. Infusion of albumin, but not artificial cerebrospinal fluid control, resulted in high incidence of PSWEs. Our results identify PSWEs as an EEG manifestation of nonconvulsive seizures in patients with AD and suggest BBB pathology as an underlying mechanism and as a promising therapeutic target.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Milikovsky</LastName><ForeName>Dan Z</ForeName><Initials>DZ</Initials><Identifier Source="ORCID">0000-0002-4826-5273</Identifier><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ofer</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4866-0828</Identifier><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senatorov</LastName><ForeName>Vladimir V</ForeName><Initials>VV</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berkeley Stem Cell Center, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Aaron R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0003-1897-2230</Identifier><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prager</LastName><ForeName>Ofer</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheintuch</LastName><ForeName>Liron</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4245-5786</Identifier><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elazari</LastName><ForeName>Netta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veksler</LastName><ForeName>Ronel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zelig</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weissberg</LastName><ForeName>Itai</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bar-Klein</LastName><ForeName>Guy</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8717-1878</Identifier><AffiliationInfo><Affiliation>Howard Hughes Medical Institute and the Institute of Genetic Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swissa</LastName><ForeName>Evyatar</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanael</LastName><ForeName>Erez</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Koret School of Veterinary Medicine, Hebrew University of Jerusalem, P.O. Box 12, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben-Arie</LastName><ForeName>Gal</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3862-2086</Identifier><AffiliationInfo><Affiliation>Department of Medical Imaging, Soroka University Medical Center, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schefenbauer</LastName><ForeName>Osnat</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamintsky</LastName><ForeName>Lyna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Neuroscience, Dalhousie University, Halifax, NS B3H4R2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saar-Ashkenazy</LastName><ForeName>Rotem</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8098-1771</Identifier><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Social Work, Ashkelon Academic College, Ashkelon 78211, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelef</LastName><ForeName>Ilan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging, Soroka University Medical Center, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shamir</LastName><ForeName>Merav H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Koret School of Veterinary Medicine, Hebrew University of Jerusalem, P.O. Box 12, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Ilan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-7420-4055</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Wolfson Medical Center, Holon 58100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glik</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cognitive Neurology Clinic, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benninger</LastName><ForeName>Felix</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3097-4693</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3830-5999</Identifier><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Alon</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4780-8456</Identifier><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel. alon.friedman@dal.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Neuroscience, Dalhousie University, Halifax, NS B3H4R2, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>366355</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Feb;16(2):66. doi: 10.1038/s41582-019-0304-z.</RefSource><PMID Version="1">31853097</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="Y">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010477" MajorTopicYN="N">Perfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31801888</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaw8954</ArticleId><ArticleId IdType="pii">11/521/eaaw8954</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31801886</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>521</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Blood-brain barrier dysfunction in aging induces hyperactivation of TGF&#x3b2; signaling and chronic yet reversible neural dysfunction.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaaw8283</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaw8283</ELocationID><Abstract><AbstractText>Aging involves a decline in neural function that contributes to cognitive impairment and disease. However, the mechanisms underlying the transition from a young-and-healthy to aged-and-dysfunctional brain are not well understood. Here, we report breakdown of the vascular blood-brain barrier (BBB) in aging humans and rodents, which begins as early as middle age and progresses to the end of the life span. Gain-of-function and loss-of-function manipulations show that this BBB dysfunction triggers hyperactivation of transforming growth factor-&#x3b2; (TGF&#x3b2;) signaling in astrocytes, which is necessary and sufficient to cause neural dysfunction and age-related pathology in rodents. Specifically, infusion of the serum protein albumin into the young rodent brain (mimicking BBB leakiness) induced astrocytic TGF&#x3b2; signaling and an aged brain phenotype including aberrant electrocorticographic activity, vulnerability to seizures, and cognitive impairment. Furthermore, conditional genetic knockdown of astrocytic TGF&#x3b2; receptors or pharmacological inhibition of TGF&#x3b2; signaling reversed these symptomatic outcomes in aged mice. Last, we found that this same signaling pathway is activated in aging human subjects with BBB dysfunction. Our study identifies dysfunction in the neurovascular unit as one of the earliest triggers of neurological aging and demonstrates that the aging brain may retain considerable latent capacity, which can be revitalized by therapeutic inhibition of TGF&#x3b2; signaling.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Senatorov</LastName><ForeName>Vladimir V</ForeName><Initials>VV</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute and Berkeley Stem Cell Center, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Aaron R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0003-1897-2230</Identifier><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute and Berkeley Stem Cell Center, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milikovsky</LastName><ForeName>Dan Z</ForeName><Initials>DZ</Initials><Identifier Source="ORCID">0000-0002-4826-5273</Identifier><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ofer</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4866-0828</Identifier><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saar-Ashkenazy</LastName><ForeName>Rotem</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8098-1771</Identifier><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charbash</LastName><ForeName>Adiel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahan</LastName><ForeName>Naznin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chin</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7805-7240</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihaly</LastName><ForeName>Eszter</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jessica M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-3366-1916</Identifier><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramsay</LastName><ForeName>Harrison J</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-4536-9341</Identifier><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moghbel</LastName><ForeName>Ariana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1136-5174</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preininger</LastName><ForeName>Marcela K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eddings</LastName><ForeName>Chelsy R</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0000-0003-3003-8379</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Helen V</ForeName><Initials>HV</Initials><AffiliationInfo><Affiliation>School of Public Health, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Rishi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1039-1490</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yizhuo</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4453-0719</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghanim</LastName><ForeName>Hana</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4102-2367</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Huanjie</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6047-0053</Identifier><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veksler</LastName><ForeName>Ronel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudmant</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><Identifier Source="ORCID">0000-0002-9573-8248</Identifier><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section for Translational Epilepsy Research, Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Barry</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Innovation Pathways, Palo Alto, CA 94301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogawski</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-3296-8193</Identifier><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dillin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7427-2629</Identifier><AffiliationInfo><Affiliation>Glenn Center for Aging Research, Howard Hughes Medical Institute, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Alon</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4780-8456</Identifier><AffiliationInfo><Affiliation>Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Neuroscience and Brain Repair Center, Dalhousie University, Halifax, NS B3H4R2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3830-5999</Identifier><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute and Berkeley Stem Cell Center, University of California, Berkeley, Berkeley, CA 94720, USA. danielak@berkeley.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Canadian Institute for Advanced Research, Toronto, ON M5G1M1, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS066005</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS066005</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042679</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG054147</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.30</RegistryNumber><NameOfSubstance UI="D000077293">Receptor, Transforming Growth Factor-beta Type I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Epilepsy Curr. 2020 Apr 29;20(3):165-167. doi: 10.1177/1535759720917920.</RefSource><PMID Version="1">32550839</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077293" MajorTopicYN="N">Receptor, Transforming Growth Factor-beta Type I</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31801886</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaw8283</ArticleId><ArticleId IdType="pii">11/521/eaaw8283</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31802237</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>463</StartPage><EndPage>484</EndPage><MedlinePgn>463-484</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-019-02103-y</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by a specific pattern of neuropathological changes, including extracellular amyloid &#x3b2; (A&#x3b2;) deposits, intracellular neurofibrillary tangles (NFTs), granulovacuolar degeneration (GVD) representing cytoplasmic vacuolar lesions, synapse dysfunction and neuronal loss. Necroptosis, a programmed form of necrosis characterized by the assembly of the necrosome complex composed of phosphorylated proteins, i.e. receptor-interacting serine/threonine-protein kinase 1 and 3 (pRIPK1 and pRIPK3) and mixed lineage kinase domain-like protein (pMLKL), has recently been shown to be involved in AD. However, it is not yet clear whether necrosome assembly takes place in brain regions showing AD-related neuronal loss and whether it is associated with AD-related neuropathological changes. Here, we analyzed brains of AD, pathologically defined preclinical AD (p-preAD) and non-AD control cases to determine the neuropathological characteristics and distribution pattern of the necrosome components. We demonstrated that all three activated necrosome components can be detected in GVD lesions (GVDn+, i.e. GVD with activated necrosome) in neurons, that they colocalize with classical GVD markers, such as pTDP-43 and CK1&#x3b4;, and similarly to these markers detect GVD lesions. GVDn&#x2009;+&#x2009;neurons inversely correlated with neuronal density in the early affected CA1 region of the hippocampus and in the late affected frontal cortex layer III. Additionally, AD-related GVD lesions were associated with AD-defining parameters, showing the strongest correlation and partial colocalization with NFT pathology. Therefore, we conclude that the presence of the necrosome in GVD plays a role in AD, possibly by representing an AD-specific form of necroptosis-related neuron death. Hence, necroptosis-related neuron loss could be an interesting therapeutic target for treating AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koper</LastName><ForeName>Marta J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology, Leuven Brain Institute (LBI), KU Leuven (University of Leuven), O&amp;N IV, Herestraat 49, box 1032, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for the Research of Neurodegenerative Diseases, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven (University of Leuven), O&amp;N IV Herestraat 49, box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain and Disease Research, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Schoor</LastName><ForeName>Evelien</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology, Leuven Brain Institute (LBI), KU Leuven (University of Leuven), O&amp;N IV, Herestraat 49, box 1032, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain and Disease Research, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Neurobiology, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ospitalieri</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology, Leuven Brain Institute (LBI), KU Leuven (University of Leuven), O&amp;N IV, Herestraat 49, box 1032, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology Group, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, UZ Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenbulcke</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Arnim</LastName><ForeName>Christine A F</ForeName><Initials>CAF</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tousseyn</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balusu</LastName><ForeName>Sriram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for the Research of Neurodegenerative Diseases, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven (University of Leuven), O&amp;N IV Herestraat 49, box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain and Disease Research, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5455-5819</Identifier><AffiliationInfo><Affiliation>Laboratory for the Research of Neurodegenerative Diseases, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven (University of Leuven), O&amp;N IV Herestraat 49, box 602, 3000, Leuven, Belgium. bart.destrooper@kuleuven.vib.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain and Disease Research, VIB, Leuven, Belgium. bart.destrooper@kuleuven.vib.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University Hospital Leuven, Leuven, Belgium. bart.destrooper@kuleuven.vib.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar Rudolf</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-1036-1075</Identifier><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology, Leuven Brain Institute (LBI), KU Leuven (University of Leuven), O&amp;N IV, Herestraat 49, box 1032, 3000, Leuven, Belgium. dietmar.thal@kuleuven.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University Hospital Leuven, Leuven, Belgium. dietmar.thal@kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079302" MajorTopicYN="N">Necroptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Granulovacuolar degeneration</Keyword><Keyword MajorTopicYN="N">Necroptosis</Keyword><Keyword MajorTopicYN="N">Necrosome</Keyword><Keyword MajorTopicYN="N">Neuronal loss</Keyword><Keyword MajorTopicYN="N">pMLKL</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31802237</ArticleId><ArticleId IdType="doi">10.1007/s00401-019-02103-y</ArticleId><ArticleId IdType="pii">10.1007/s00401-019-02103-y</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31831638</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>367</Volume><Issue>6477</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>31</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Microglia monitor and protect neuronal function through specialized somatic purinergic junctions.</ArticleTitle><Pagination><StartPage>528</StartPage><EndPage>537</EndPage><MedlinePgn>528-537</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aax6752</ELocationID><Abstract><AbstractText>Microglia are the main immune cells in the brain and have roles in brain homeostasis and neurological diseases. Mechanisms underlying microglia-neuron communication remain elusive. Here, we identified an interaction site between neuronal cell bodies and microglial processes in mouse and human brain. Somatic microglia-neuron junctions have a specialized nanoarchitecture optimized for purinergic signaling. Activity of neuronal mitochondria was linked with microglial junction formation, which was induced rapidly in response to neuronal activation and blocked by inhibition of P2Y12 receptors. Brain injury-induced changes at somatic junctions triggered P2Y12 receptor-dependent microglial neuroprotection, regulating neuronal calcium load and functional connectivity. Thus, microglial processes at these junctions could potentially monitor and protect neuronal functions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cser&#xe9;p</LastName><ForeName>Csaba</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5513-2471</Identifier><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>P&#xf3;sfai</LastName><ForeName>Bal&#xe1;zs</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-1035-565X</Identifier><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Szent&#xe1;gothai J&#xe1;nos Doctoral School of Neuroscience, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe9;n&#xe1;rt</LastName><ForeName>Nikolett</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-7456-949X</Identifier><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fekete</LastName><ForeName>Rebeka</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4311-6623</Identifier><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Szent&#xe1;gothai J&#xe1;nos Doctoral School of Neuroscience, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe1;szl&#xf3;</LastName><ForeName>Zs&#xf3;fia I</ForeName><Initials>ZI</Initials><Identifier Source="ORCID">0000-0001-5317-1207</Identifier><AffiliationInfo><Affiliation>Szent&#xe1;gothai J&#xe1;nos Doctoral School of Neuroscience, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Momentum Laboratory of Molecular Neurobiology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lele</LastName><ForeName>Zsolt</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-2672-144X</Identifier><AffiliationInfo><Affiliation>Momentum Laboratory of Molecular Neurobiology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orsolits</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2557-0926</Identifier><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moln&#xe1;r</LastName><ForeName>G&#xe1;bor</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7959-139X</Identifier><AffiliationInfo><Affiliation>MTA-SZTE Research Group for Cortical Microcircuits of the Hungarian Academy of Sciences, Department of Physiology, Anatomy and Neuroscience, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heindl</LastName><ForeName>Steffanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3576-2702</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarcz</LastName><ForeName>Anett D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ujv&#xe1;ri</LastName><ForeName>Katinka</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;rnyei</LastName><ForeName>Zsuzsanna</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-8281-7994</Identifier><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xf3;th</LastName><ForeName>Krisztina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7926-2983</Identifier><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Szent&#xe1;gothai J&#xe1;nos Doctoral School of Neuroscience, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szabadits</LastName><ForeName>Eszter</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperl&#xe1;gh</LastName><ForeName>Be&#xe1;ta</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0099-591X</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Pharmacology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baranyi</LastName><ForeName>M&#xe1;ria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Pharmacology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Csiba</LastName><ForeName>L&#xe1;szl&#xf3;</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MTA-DE Cerebrovascular and Neurodegenerative Research Group, Department of Neurology, University of Debrecen, Debrecen, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hortob&#xe1;gyi</LastName><ForeName>Tibor</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5732-7942</Identifier><AffiliationInfo><Affiliation>Institute of Pathology, Faculty of Medicine, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Age-Related Medicine, SESAM, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magl&#xf3;czky</LastName><ForeName>Zs&#xf3;fia</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Human Brain Research Laboratory, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinecz</LastName><ForeName>Bernadett</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-3784-252X</Identifier><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szab&#xf3;</LastName><ForeName>G&#xe1;bor</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5438-5151</Identifier><AffiliationInfo><Affiliation>Medical Gene Technology Unit, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erd&#xe9;lyi</LastName><ForeName>Ferenc</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7164-209X</Identifier><AffiliationInfo><Affiliation>Medical Gene Technology Unit, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szip&#x151;cs</LastName><ForeName>R&#xf3;bert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0259-3981</Identifier><AffiliationInfo><Affiliation>Institute for Solid State Physics and Optics of Wigner RCP, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamkun</LastName><ForeName>Michael M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-0455-6167</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gesierich</LastName><ForeName>Benno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duering</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2302-3136</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katona</LastName><ForeName>Istv&#xe1;n</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2808-3330</Identifier><AffiliationInfo><Affiliation>Momentum Laboratory of Molecular Neurobiology, Institute of Experimental Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liesz</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9069-2594</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam&#xe1;s</LastName><ForeName>G&#xe1;bor</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-7905-6001</Identifier><AffiliationInfo><Affiliation>MTA-SZTE Research Group for Cortical Microcircuits of the Hungarian Academy of Sciences, Department of Physiology, Anatomy and Neuroscience, University of Szeged, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xe9;nes</LastName><ForeName>&#xc1;d&#xe1;m</ForeName><Initials>&#xc1;</Initials><Identifier Source="ORCID">0000-0001-6919-4905</Identifier><AffiliationInfo><Affiliation>Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, Hungary. denes.adam@koki.mta.hu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM084136</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM109888</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058925">Receptors, Purinergic P2Y12</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051669">Shab Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2020 Jan 31;367(6477):510-511. doi: 10.1126/science.aba4472.</RefSource><PMID Version="1">32001643</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007365" MajorTopicYN="N">Intercellular Junctions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058925" MajorTopicYN="N">Receptors, Purinergic P2Y12</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051669" MajorTopicYN="N">Shab Potassium Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31831638</ArticleId><ArticleId IdType="doi">10.1126/science.aax6752</ArticleId><ArticleId IdType="pii">science.aax6752</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31853635</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins.</ArticleTitle><Pagination><StartPage>503</StartPage><EndPage>526</EndPage><MedlinePgn>503-526</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-019-02114-9</ELocationID><Abstract><AbstractText>Neurodegenerative diseases are an enormous public health problem, affecting tens of millions of people worldwide. Nearly all of these diseases are characterized by oligomerization and fibrillization of neuronal proteins, and there is great interest in therapeutic targeting of these aggregates. Here, we show that soluble aggregates of &#x3b1;-synuclein and tau bind to plate-immobilized PrP in vitro and on mouse cortical neurons, and that this binding requires at least one of the same N-terminal sites at which soluble A&#x3b2; aggregates bind. Moreover, soluble aggregates of tau, &#x3b1;-synuclein and A&#x3b2; cause both functional (impairment of LTP) and structural (neuritic dystrophy) compromise and these deficits are absent when PrP is ablated, knocked-down, or when neurons are pre-treated with anti-PrP blocking antibodies. Using an all-human experimental paradigm involving: (1) isogenic iPSC-derived neurons expressing or lacking PRNP, and (2) aqueous extracts from brains of individuals who died with Alzheimer's disease, dementia with Lewy bodies, and Pick's disease, we demonstrate that A&#x3b2;, &#x3b1;-synuclein and tau are toxic to neurons in a manner that requires PrP<sup>C</sup>. These results indicate that PrP is likely to play an important role in a variety of late-life neurodegenerative diseases and that therapeutic targeting of PrP, rather than individual disease proteins, may have more benefit for conditions which involve the aggregation of more than one protein.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corbett</LastName><ForeName>Grant T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zemin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colom-Cadena</LastName><ForeName>Marti</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences and UK Dementia Research Institute, University of Edinburgh, Edinburgh, EH89JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences and UK Dementia Research Institute, University of Edinburgh, Edinburgh, EH89JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Meichen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asfaw</LastName><ForeName>Adhana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Tia C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Lai</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Program for Interdisciplinary Neuroscience, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeSousa</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Massachusetts General Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRC Prion Unit at UCL, UCL Institute of Prion Diseases, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Boston University School of Medicine, Boston, MA, 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkinton</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Neuroscience, IMED Biotechnology Unit, AstraZeneca, Cambridge, CB21 6GH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences and UK Dementia Research Institute, University of Edinburgh, Edinburgh, EH89JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young-Pearse</LastName><ForeName>Tracy L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Billinton</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience, IMED Biotechnology Unit, AstraZeneca, Cambridge, CB21 6GH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Road, Boston, MA, 02115, USA. dwalsh3@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U123160657</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>T32 AG000222</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UP_1604/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00024/9</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0400713</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R21 AG053827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055909</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Apr;16(4):187-188. doi: 10.1038/s41582-020-0332-8.</RefSource><PMID Version="1">32123368</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">Dementia with Lewy bodies</Keyword><Keyword MajorTopicYN="N">Prion protein</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">&#x3b1;-Synuclein</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>12</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31853635</ArticleId><ArticleId IdType="pmc">PMC7035229</ArticleId><ArticleId IdType="doi">10.1007/s00401-019-02114-9</ArticleId><ArticleId IdType="pii">10.1007/s00401-019-02114-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Falsig J. Prion propagation, toxicity and degradation. Nat Neurosci. 2012;15:936&#x2013;939. doi: 10.1038/nn.3120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3120</ArticleId><ArticleId IdType="pubmed">22735515</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P, Knowles TP, Linse S. On the lag phase in amyloid fibril formation. Phys Chem Chem Phys. 2015;17:7606&#x2013;7618. doi: 10.1039/c4cp05563b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c4cp05563b</ArticleId><ArticleId IdType="pmc">PMC4498454</ArticleId><ArticleId IdType="pubmed">25719972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayachit U (2015) The ParaView guide: a parallel visualization application. Kitware, Clifton Park</Citation></Reference><Reference><Citation>Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA. 2010;107:2295&#x2013;2300. doi: 10.1073/pnas.0911829107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0911829107</ArticleId><ArticleId IdType="pmc">PMC2836680</ArticleId><ArticleId IdType="pubmed">20133875</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672. doi: 10.1038/nrn2194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2194</ArticleId><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron GS, Wehrly K, Dorward DW, Chesebro B, Caughey B. Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrP(Sc)) into contiguous membranes. EMBO J. 2002;21:1031&#x2013;1040. doi: 10.1093/emboj/21.5.1031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/21.5.1031</ArticleId><ArticleId IdType="pmc">PMC125906</ArticleId><ArticleId IdType="pubmed">11867531</ArticleId></ArticleIdList></Reference><Reference><Citation>Beland M, Roucou X. The prion protein unstructured N-terminal region is a broad-spectrum molecular sensor with diverse and contrasting potential functions. J Neurochem. 2012;120:853&#x2013;868. doi: 10.1111/j.1471-4159.2011.07613.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07613.x</ArticleId><ArticleId IdType="pubmed">22145935</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B. The toxic A&#x3b2; oligomer and Alzheimer&#x2019;s disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349&#x2013;357. doi: 10.1038/nn.3028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3028</ArticleId><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Beraldo FH, Arantes CP, Santos TG, Machado CF, Roffe M, Hajj GN, et al. Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin gamma1 chain. FASEB J. 2011;25:265&#x2013;279. doi: 10.1096/fj.10-161653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.10-161653</ArticleId><ArticleId IdType="pubmed">20876210</ArticleId></ArticleIdList></Reference><Reference><Citation>Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, Walsh DM. Aggregation and catabolism of disease-associated intra-A&#x3b2; mutations: reduced proteolysis of A&#x3b2;A21G by neprilysin. Neurobiol Dis. 2008;31:442&#x2013;450. doi: 10.1016/j.nbd.2008.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.06.001</ArticleId><ArticleId IdType="pmc">PMC3160758</ArticleId><ArticleId IdType="pubmed">18602473</ArticleId></ArticleIdList></Reference><Reference><Citation>Biasini E, Turnbaugh JA, Unterberger U, Harris DA. Prion protein at the crossroads of physiology and disease. Trends Neurosci. 2012;35:92&#x2013;103. doi: 10.1016/j.tins.2011.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2011.10.002</ArticleId><ArticleId IdType="pmc">PMC3273588</ArticleId><ArticleId IdType="pubmed">22137337</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993;73:1339&#x2013;1347. doi: 10.1016/0092-8674(93)90360-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90360-3</ArticleId><ArticleId IdType="pubmed">8100741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature. 1992;356:577&#x2013;582. doi: 10.1038/356577a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/356577a0</ArticleId><ArticleId IdType="pubmed">1373228</ArticleId></ArticleIdList></Reference><Reference><Citation>Buell AK, Galvagnion C, Gaspar R, Sparr E, Vendruscolo M, Knowles TP, et al. Solution conditions determine the relative importance of nucleation and growth processes in alpha-synuclein aggregation. Proc Natl Acad Sci USA. 2014;111:7671&#x2013;7676. doi: 10.1073/pnas.1315346111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1315346111</ArticleId><ArticleId IdType="pmc">PMC4040554</ArticleId><ArticleId IdType="pubmed">24817693</ArticleId></ArticleIdList></Reference><Reference><Citation>Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, et al. Prion protein and A&#x3b2;-related synaptic toxicity impairment. EMBO Mol Med. 2010;2:306&#x2013;314. doi: 10.1002/emmm.201000082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201000082</ArticleId><ArticleId IdType="pmc">PMC2962809</ArticleId><ArticleId IdType="pubmed">20665634</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Baron GS, Chesebro B, Jeffrey M. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem. 2009;78:177&#x2013;204. doi: 10.1146/annurev.biochem.78.082907.145410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.78.082907.145410</ArticleId><ArticleId IdType="pmc">PMC2794486</ArticleId><ArticleId IdType="pubmed">19231987</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Brown K, Raymond GJ, Katzenstein GE, Thresher W. Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected] J Virol. 1994;68:2135&#x2013;2141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236688</ArticleId><ArticleId IdType="pubmed">7511169</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267&#x2013;298. doi: 10.1146/annurev.neuro.26.010302.081142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.26.010302.081142</ArticleId><ArticleId IdType="pubmed">12704221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-beta (A&#x3b2;) oligomers: role OF N-terminal residues. J Biol Chem. 2010;285:26377&#x2013;26383. doi: 10.1074/jbc.M110.145516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.145516</ArticleId><ArticleId IdType="pmc">PMC2924066</ArticleId><ArticleId IdType="pubmed">20576610</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L. Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci. 2011;31:10427&#x2013;10431. doi: 10.1523/JNEUROSCI.1459-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1459-11.2011</ArticleId><ArticleId IdType="pmc">PMC3314063</ArticleId><ArticleId IdType="pubmed">21775587</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, et al. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci USA. 2013;110:9758&#x2013;9763. doi: 10.1073/pnas.1218402110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1218402110</ArticleId><ArticleId IdType="pmc">PMC3683769</ArticleId><ArticleId IdType="pubmed">23703910</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998;4:1318&#x2013;1320. doi: 10.1038/3311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/3311</ArticleId><ArticleId IdType="pubmed">9809558</ArticleId></ArticleIdList></Reference><Reference><Citation>Dohler F, Sepulveda-Falla D, Krasemann S, Altmeppen H, Schluter H, Hildebrand D, et al. High molecular mass assemblies of amyloid-beta oligomers bind prion protein in patients with Alzheimer&#x2019;s disease. Brain. 2014;137:873&#x2013;886. doi: 10.1093/brain/awt375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt375</ArticleId><ArticleId IdType="pubmed">24519981</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 1998;440:71&#x2013;75. doi: 10.1016/s0014-5793(98)01418-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0014-5793(98)01418-5</ArticleId><ArticleId IdType="pubmed">9862428</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, Wildburger NC, Jiang H, Gangolli M, Cairns NJ, Bateman RJ, et al. Soluble amyloid-beta aggregates from human Alzheimer&#x2019;s disease brains. Sci Rep. 2016;6:38187. doi: 10.1038/srep38187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep38187</ArticleId><ArticleId IdType="pmc">PMC5137165</ArticleId><ArticleId IdType="pubmed">27917876</ArticleId></ArticleIdList></Reference><Reference><Citation>Fa M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, et al. Extracellular tau oligomers produce an immediate impairment of LTP and memory. Sci Rep. 2016;6:19393. doi: 10.1038/srep19393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep19393</ArticleId><ArticleId IdType="pmc">PMC4726138</ArticleId><ArticleId IdType="pubmed">26786552</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R, et al. Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature. 2018;561:137&#x2013;140. doi: 10.1038/s41586-018-0454-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0454-y</ArticleId><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zivanov J, Zhang W, Murzin AG, Garringer HJ, Vidal R, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568:420&#x2013;423. doi: 10.1038/s41586-019-1026-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1026-5</ArticleId><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira DG, Temido-Ferreira M, Vicente Miranda H, Batalha VL, Coelho JE, Szego EM, et al. alpha-synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B. Nat Neurosci. 2017;20:1569&#x2013;1579. doi: 10.1038/nn.4648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4648</ArticleId><ArticleId IdType="pubmed">28945221</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature. 2017;547:185&#x2013;190. doi: 10.1038/nature23002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23002</ArticleId><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluharty BR, Biasini E, Stravalaci M, Sclip A, Diomede L, Balducci C, et al. An N-terminal fragment of the prion protein binds to amyloid-beta oligomers and inhibits their neurotoxicity in vivo. J Biol Chem. 2013;288:7857&#x2013;7866. doi: 10.1074/jbc.M112.423954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.423954</ArticleId><ArticleId IdType="pmc">PMC3597823</ArticleId><ArticleId IdType="pubmed">23362282</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, et al. Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun. 2011;2:336. doi: 10.1038/ncomms1341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms1341</ArticleId><ArticleId IdType="pmc">PMC3156817</ArticleId><ArticleId IdType="pubmed">21654636</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn MW, McAllister AK. Immunocytochemistry and quantification of protein colocalization in cultured neurons. Nat Protoc. 2006;1:1287&#x2013;1296. doi: 10.1038/nprot.2006.220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.220</ArticleId><ArticleId IdType="pubmed">17406413</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes LA, Hipp SA, Rijal Upadhaya A, Balakrishnan K, Ospitalieri S, Koper MJ, Largo-Barrientos P, et al. A&#x3b2;-induced acceleration of Alzheimer-related tau-pathology spreading and its association with prion protein. Acta Neuropathol. 2019;138:913&#x2013;941. doi: 10.1007/s00401-019-02053-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02053-5</ArticleId><ArticleId IdType="pubmed">31414210</ArticleId></ArticleIdList></Reference><Reference><Citation>Grey M, Dunning CJ, Gaspar R, Grey C, Brundin P, Sparr E, et al. Acceleration of alpha-synuclein aggregation by exosomes. J Biol Chem. 2015;290:2969&#x2013;2982. doi: 10.1074/jbc.M114.585703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.585703</ArticleId><ArticleId IdType="pmc">PMC4317028</ArticleId><ArticleId IdType="pubmed">25425650</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084&#x2013;6089.</Citation><ArticleIdList><ArticleId IdType="pubmed">3084478</ArticleId></ArticleIdList></Reference><Reference><Citation>Guix FX, Corbett GT, Cha DJ, Mustapic M, Liu W, Mengel D, Chen Z, Aikawa E, Young-Pearse T, Kapogiannis D, et al. Detection of aggregation-competent tau in neuron-derived extracellular vesicles. Int J Mol Sci. 2018 doi: 10.3390/ijms19030663.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19030663</ArticleId><ArticleId IdType="pmc">PMC5877524</ArticleId><ArticleId IdType="pubmed">29495441</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrand E, Boland B, Walsh DM, Linse S. Amyloid beta-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. ACS Chem Neurosci. 2010;1:13&#x2013;18. doi: 10.1021/cn900015v.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn900015v</ArticleId><ArticleId IdType="pmc">PMC3368626</ArticleId><ArticleId IdType="pubmed">22778803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, et al. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry. 2006;45:15157&#x2013;15167. doi: 10.1021/bi061850f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi061850f</ArticleId><ArticleId IdType="pubmed">17176037</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Tings T, Gall S, Madlung A, Giese A, Siebert H, et al. Evidence of presynaptic location and function of the prion protein. J Neurosci. 1999;19:8866&#x2013;8875. doi: 10.1523/JNEUROSCI.19-20-08866.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.19-20-08866.1999</ArticleId><ArticleId IdType="pmc">PMC6782778</ArticleId><ArticleId IdType="pubmed">10516306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong W, Wang Z, Liu W, O&#x2019;Malley TT, Jin M, Willem M, et al. Diffusible, highly bioactive oligomers represent a critical minority of soluble A&#x3b2; in Alzheimer&#x2019;s disease brain. Acta Neuropathol. 2018;136:19&#x2013;40. doi: 10.1007/s00401-018-1846-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1846-7</ArticleId><ArticleId IdType="pmc">PMC6647843</ArticleId><ArticleId IdType="pubmed">29687257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu NW, Corbett GT, Moore S, Klyubin I, O&#x2019;Malley TT, Walsh DM, et al. Extracellular forms of abeta and tau from iPSC models of Alzheimer&#x2019;s disease disrupt synaptic plasticity. Cell Rep. 2018;23:1932&#x2013;1938. doi: 10.1016/j.celrep.2018.04.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.04.040</ArticleId><ArticleId IdType="pmc">PMC5972225</ArticleId><ArticleId IdType="pubmed">29768194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu NW, Nicoll AJ, Zhang D, Mably AJ, O&#x2019;Malley T, Purro SA, et al. mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo. Nat Commun. 2014;5:3374. doi: 10.1038/ncomms4374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4374</ArticleId><ArticleId IdType="pmc">PMC4354159</ArticleId><ArticleId IdType="pubmed">24594908</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson GS, Hill AF, Joseph C, Hosszu L, Power A, Waltho JP, et al. Multiple folding pathways for heterologously expressed human prion protein. Biochim Biophys Acta. 1999;1431:1&#x2013;13. doi: 10.1016/S0167-4838(99)00038-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-4838(99)00038-2</ArticleId><ArticleId IdType="pubmed">10209273</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, O&#x2019;Nuallain B, Hong W, Boyd J, Lagomarsino VN, O&#x2019;Malley TT, et al. An in vitro paradigm to assess potential anti-Abeta antibodies for Alzheimer&#x2019;s disease. Nat Commun. 2018;9:2676. doi: 10.1038/s41467-018-05068-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05068-w</ArticleId><ArticleId IdType="pmc">PMC6041266</ArticleId><ArticleId IdType="pubmed">29992960</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech S, Banker G. Culturing hippocampal neurons. Nat Protoc. 2006;1:2406&#x2013;2415. doi: 10.1038/nprot.2006.356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.356</ArticleId><ArticleId IdType="pubmed">17406484</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanmert D, Cantlon A, Muratore CR, Jin M, O&#x2019;Malley TT, Lee G, et al. C-terminally truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death. J Neurosci. 2015;35:10851&#x2013;10865. doi: 10.1523/JNEUROSCI.0387-15.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0387-15.2015</ArticleId><ArticleId IdType="pmc">PMC6605107</ArticleId><ArticleId IdType="pubmed">26224867</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpuj MV, Giles K, Gelibter-Niv S, Scott MR, Lingappa VR, Szoka FC, et al. Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells. Mol Med. 2007;13:190&#x2013;198. doi: 10.2119/2006-00073.Karpuj.</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/2006-00073.Karpuj</ArticleId><ArticleId IdType="pmc">PMC1892763</ArticleId><ArticleId IdType="pubmed">17592554</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay KR, Smith C, Wright AK, Serrano-Pozo A, Pooler AM, Koffie R, et al. Studying synapses in human brain with array tomography and electron microscopy. Nat Protoc. 2013;8:1366&#x2013;1380. doi: 10.1038/nprot.2013.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.078</ArticleId><ArticleId IdType="pmc">PMC3712649</ArticleId><ArticleId IdType="pubmed">23787894</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A, Munoz D. Relationship between frontotemporal dementia and corticobasal degeneration/progressive supranuclear palsy. Dement Geriatr Cogn Disord. 2004;17:282&#x2013;286. doi: 10.1159/000077155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000077155</ArticleId><ArticleId IdType="pubmed">15178937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels Helmut W., Nguyen Louis N., Nabavi Sadegh, Malinow Roberto. The prion protein as a receptor for amyloid-&#x3b2;. Nature. 2010;466(7308):E3&#x2013;E4. doi: 10.1038/nature09217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09217</ArticleId><ArticleId IdType="pmc">PMC3057871</ArticleId><ArticleId IdType="pubmed">20703260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453. doi: 10.1073/pnas.95.11.6448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6448</ArticleId><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128&#x2013;1132. doi: 10.1038/nature07761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07761</ArticleId><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Le NTT, Wu B, Harris DA. Prion neurotoxicity. Brain Pathol. 2019;29:263&#x2013;277. doi: 10.1111/bpa.12694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12694</ArticleId><ArticleId IdType="pmc">PMC6894960</ArticleId><ArticleId IdType="pubmed">30588688</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin AA. Treating disease at the RNA level with oligonucleotides. N Engl J Med. 2019;380:57&#x2013;70. doi: 10.1056/NEJMra1705346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1705346</ArticleId><ArticleId IdType="pubmed">30601736</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402&#x2013;408. doi: 10.1006/meth.2001.1262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R. Molecular structure of beta-amyloid fibrils in Alzheimer&#x2019;s disease brain tissue. Cell. 2013;154:1257&#x2013;1268. doi: 10.1016/j.cell.2013.08.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.08.035</ArticleId><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallucci GR, White MD, Farmer M, Dickinson A, Khatun H, Powell AD, et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron. 2007;53:325&#x2013;335. doi: 10.1016/j.neuron.2007.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.005</ArticleId><ArticleId IdType="pubmed">17270731</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985;82:4245&#x2013;4249. doi: 10.1073/pnas.82.12.4245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.82.12.4245</ArticleId><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM, O'Malley TT, Liu W, Mably AJ, Brinkmalm G, Portelius E, Wittbold WM 3rd, Frosch MP, Walsh DM. The aqueous phase of Alzheimer's disease brain contains assemblies built from approximately 4 and approximately 7 kDa Abeta species. Alzheimers Dement. 2015;11:1286&#x2013;1305. doi: 10.1016/j.jalz.2015.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.01.005</ArticleId><ArticleId IdType="pmc">PMC4592782</ArticleId><ArticleId IdType="pubmed">25846299</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina M, Avila J. The role of extracellular Tau in the spreading of neurofibrillary pathology. Front Cell Neurosci. 2014;8:113. doi: 10.3389/fncel.2014.00113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00113</ArticleId><ArticleId IdType="pmc">PMC4005959</ArticleId><ArticleId IdType="pubmed">24795568</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengel D, Hong W, Corbett GT, Liu W, DeSousa A, Solforosi L, et al. PrP-grafted antibodies bind certain amyloid beta-protein aggregates, but do not prevent toxicity. Brain Res. 2019;1710:125&#x2013;135. doi: 10.1016/j.brainres.2018.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.12.038</ArticleId><ArticleId IdType="pmc">PMC6431553</ArticleId><ArticleId IdType="pubmed">30593771</ArticleId></ArticleIdList></Reference><Reference><Citation>Minikel EV, Vallabh SM, Lek M, Estrada K, Samocha KE, Sathirapongsasuti JF, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8:322&#x2013;329. doi: 10.1126/scitranslmed.aad5169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad5169</ArticleId><ArticleId IdType="pmc">PMC4774245</ArticleId><ArticleId IdType="pubmed">26791950</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers JK, Pace CN, Scholtz JM. Helix propensities are identical in proteins and peptides. Biochemistry. 1997;36:10923&#x2013;10929. doi: 10.1021/bi9707180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi9707180</ArticleId><ArticleId IdType="pubmed">9283083</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazor Friberg K, Hung G, Wancewicz E, Giles K, Black C, Freier S, et al. Intracerebral infusion of antisense oligonucleotides into prion-infected mice. Mol Ther Nucl Acids. 2012;1:e9. doi: 10.1038/mtna.2011.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2011.6</ArticleId><ArticleId IdType="pmc">PMC3381600</ArticleId><ArticleId IdType="pubmed">23344724</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll AJ, Panico S, Freir DB, Wright D, Terry C, Risse E, et al. Amyloid-beta nanotubes are associated with prion protein-dependent synaptotoxicity. Nat Commun. 2013;4:2416. doi: 10.1038/ncomms3416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3416</ArticleId><ArticleId IdType="pmc">PMC3908552</ArticleId><ArticleId IdType="pubmed">24022506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ondrejcak Tomas, Klyubin Igor, Corbett Grant T., Fraser Graham, Hong Wei, Mably Alexandra J., Gardener Matthew, Hammersley Jayne, Perkinton Michael S., Billinton Andrew, Walsh Dominic M., Rowan Michael J. Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo. The Journal of Neuroscience. 2018;38(50):10595&#x2013;10606. doi: 10.1523/JNEUROSCI.1700-18.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1700-18.2018</ArticleId><ArticleId IdType="pmc">PMC6290298</ArticleId><ArticleId IdType="pubmed">30355631</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Dowd ST, Ardah MT, Johansson P, Lomakin A, Benedek GB, Roberts KA, et al. The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer&#x2019;s disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. J Alzheimers Dis. 2013;33:923&#x2013;928. doi: 10.3233/JAD-2012-121393.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-121393</ArticleId><ArticleId IdType="pubmed">23034520</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA. 1993;90:10962&#x2013;10966. doi: 10.1073/pnas.90.23.10962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.23.10962</ArticleId><ArticleId IdType="pmc">PMC47901</ArticleId><ArticleId IdType="pubmed">7902575</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst A, Anderton BH, Ulrich J, Kohler R, Kahn J, Heitz PU. Pick&#x2019;s disease: an immunocytochemical study of neuronal changes. Monoclonal antibodies show that Pick bodies share antigenic determinants with neurofibrillary tangles and neurofilaments. Acta Neuropathol. 1983;60:175&#x2013;182. doi: 10.1007/BF00691864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00691864</ArticleId><ArticleId IdType="pubmed">6193675</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95:13363&#x2013;13383. doi: 10.1073/pnas.95.23.13363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.23.13363</ArticleId><ArticleId IdType="pmc">PMC33918</ArticleId><ArticleId IdType="pubmed">9811807</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang W, Yau WM, Lu JX, Collinge J, Tycko R. Structural variation in amyloid-beta fibrils from Alzheimer&#x2019;s disease clinical subtypes. Nature. 2017;541:217&#x2013;221. doi: 10.1038/nature20814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20814</ArticleId><ArticleId IdType="pmc">PMC5233555</ArticleId><ArticleId IdType="pubmed">28052060</ArticleId></ArticleIdList></Reference><Reference><Citation>Resenberger UK, Harmeier A, Woerner AC, Goodman JL, Muller V, Krishnan R, et al. The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. EMBO J. 2011;30:2057&#x2013;2070. doi: 10.1038/emboj.2011.86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.86</ArticleId><ArticleId IdType="pmc">PMC3098494</ArticleId><ArticleId IdType="pubmed">21441896</ArticleId></ArticleIdList></Reference><Reference><Citation>Resenberger UK, Winklhofer KF, Tatzelt J. Neuroprotective and neurotoxic signaling by the prion protein. Top Curr Chem. 2011;305:101&#x2013;119. doi: 10.1007/128_2011_160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/128_2011_160</ArticleId><ArticleId IdType="pubmed">21598098</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandberg MK, Al-Doujaily H, Sharps B, De Oliveira MW, Schmidt C, Richard-Londt A, et al. Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nat Commun. 2014;5:4347. doi: 10.1038/ncomms5347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5347</ArticleId><ArticleId IdType="pmc">PMC4104459</ArticleId><ArticleId IdType="pubmed">25005024</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783&#x2013;784. doi: 10.1038/nmeth.3047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3047</ArticleId><ArticleId IdType="pmc">PMC4486245</ArticleId><ArticleId IdType="pubmed">25075903</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676&#x2013;682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Folding proteins in fatal ways. Nature. 2003;426:900&#x2013;904. doi: 10.1038/nature02264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02264</ArticleId><ArticleId IdType="pubmed">14685251</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. State of aggregation. Nat Neurosci. 2011;14:399. doi: 10.1038/nn0411-399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn0411-399</ArticleId><ArticleId IdType="pubmed">21445061</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith LM, Kostylev MA, Lee S, Strittmatter SM. Systematic and standardized comparison of reported amyloid-beta receptors for sufficiency, affinity, and Alzheimer&#x2019;s disease relevance. J Biol Chem. 2019;294:6042&#x2013;6053. doi: 10.1074/jbc.RA118.006252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.006252</ArticleId><ArticleId IdType="pmc">PMC6463724</ArticleId><ArticleId IdType="pubmed">30787106</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4:49&#x2013;60. doi: 10.1038/nrn1007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1007</ArticleId><ArticleId IdType="pubmed">12511861</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson&#x2019;s disease and dementia with lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469&#x2013;6473. doi: 10.1073/pnas.95.11.6469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6469</ArticleId><ArticleId IdType="pmc">PMC27806</ArticleId><ArticleId IdType="pubmed">9600990</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci. 2012;15:1227&#x2013;1235. doi: 10.1038/nn.3178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3178</ArticleId><ArticleId IdType="pmc">PMC3431439</ArticleId><ArticleId IdType="pubmed">22820466</ArticleId></ArticleIdList></Reference><Reference><Citation>Usenovic M, Niroomand S, Drolet RE, Yao L, Gaspar RC, Hatcher NG, et al. Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells. J Neurosci. 2015;35:14234&#x2013;14250. doi: 10.1523/JNEUROSCI.1523-15.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1523-15.2015</ArticleId><ArticleId IdType="pmc">PMC6605424</ArticleId><ArticleId IdType="pubmed">26490863</ArticleId></ArticleIdList></Reference><Reference><Citation>La Vitola P, Beeg M, Balducci C, Santamaria G, Restelli E, Colombo L, et al. Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects. Brain. 2019;142:249&#x2013;254. doi: 10.1093/brain/awy318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy318</ArticleId><ArticleId IdType="pubmed">30601948</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Hartley DM, Selkoe DJ. The many faces of A&#x3b2;: structures and activity. Curr Med Chem Immunol Endocr Metab Agents. 2003;3:277&#x2013;291. doi: 10.2174/1568013033483311.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568013033483311</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci. 2016;17:251&#x2013;260. doi: 10.1038/nrn.2016.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.13</ArticleId><ArticleId IdType="pmc">PMC6701169</ArticleId><ArticleId IdType="pubmed">26988744</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Teplow DB. Alzheimer&#x2019;s disease and the amyloid beta-protein. Prog Mol Biol Transl Sci. 2012;107:101&#x2013;124. doi: 10.1016/B978-0-12-385883-2.00012-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-385883-2.00012-6</ArticleId><ArticleId IdType="pubmed">22482449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Jackson RJ, Hong W, Taylor WM, Corbett GT, Moreno A, et al. Human brain-derived abeta oligomers bind to synapses and disrupt synaptic activity in a manner that requires APP. J Neurosci. 2017;37:11947&#x2013;11966. doi: 10.1523/JNEUROSCI.2009-17.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2009-17.2017</ArticleId><ArticleId IdType="pmc">PMC5719975</ArticleId><ArticleId IdType="pubmed">29101243</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams TL, Choi JK, Surewicz K, Surewicz WK. Soluble prion protein binds isolated low molecular weight amyloid-beta oligomers causing cytotoxicity inhibition. ACS Chem Neurosci. 2015;6:1972&#x2013;1980. doi: 10.1021/acschemneuro.5b00229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.5b00229</ArticleId><ArticleId IdType="pubmed">26466138</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Li S, Xu H, Walsh DM, Selkoe DJ. Large soluble oligomers of amyloid beta-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J Neurosci. 2017;37:152&#x2013;163. doi: 10.1523/JNEUROSCI.1698-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1698-16.2016</ArticleId><ArticleId IdType="pmc">PMC5214627</ArticleId><ArticleId IdType="pubmed">28053038</ArticleId></ArticleIdList></Reference><Reference><Citation>Younan ND, Sarell CJ, Davies P, Brown DR, Viles JH. The cellular prion protein traps Alzheimer&#x2019;s Abeta in an oligomeric form and disassembles amyloid fibers. FASEB J. 2013;27:1847&#x2013;1858. doi: 10.1096/fj.12-222588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.12-222588</ArticleId><ArticleId IdType="pmc">PMC3767752</ArticleId><ArticleId IdType="pubmed">23335053</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahn R, von Schroetter C, Wuthrich K. Human prion proteins expressed in Escherichia coli and purified by high-affinity column refolding. FEBS Lett. 1997;417:400&#x2013;404. doi: 10.1016/S0014-5793(97)01330-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(97)01330-6</ArticleId><ArticleId IdType="pubmed">9409760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng H, Guo M, Martins-Taylor K, Wang X, Zhang Z, Park JW, et al. Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells. PLoS ONE. 2010;5:e11853. doi: 10.1371/journal.pone.0011853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011853</ArticleId><ArticleId IdType="pmc">PMC2912324</ArticleId><ArticleId IdType="pubmed">20686615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78:785&#x2013;798. doi: 10.1016/j.neuron.2013.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.05.029</ArticleId><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31860001</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Intracranial Atherosclerotic Disease With Brain &#x3b2;-Amyloid Deposition: Secondary Analysis of the ARIC Study.</ArticleTitle><Pagination><StartPage>350</StartPage><EndPage>357</EndPage><MedlinePgn>350-357</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.4339</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Intracranial atherosclerotic disease (ICAD) is an important cause of stroke and has also been recently identified as an important risk factor for all-cause dementia, but the mechanism of its association with cognitive performance is not fully understood.</AbstractText><AbstractText Label="OBJECTIVE">To test the hypothesis that ICAD is associated with cerebral &#x3b2;-amyloid deposition as a marker of Alzheimer disease.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional analysis of data collected from August 2011 through November 2014 was a community-based cohort study conducted in 3 US communities. Of 346 adults without dementia aged 70 to 90 years who were sequentially recruited from 3 of 4 sites of the larger Atherosclerosis Risk in Communities study into a study of brain florbetapir positron emission tomography (ARIC-PET), 300 met inclusion criteria. A total of 589 were approached about recruitment, of whom 346 (58.7%) consented (the remainder either met exclusion criteria for ARIC-PET or refused to participate). Data were analyzed from July 2017 through October 2019.</AbstractText><AbstractText Label="EXPOSURES">Intracranial atherosclerotic disease presence, frequency, and extent of stenosis, by high-resolution vessel wall magnetic resonance imaging.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Global cortical standardized uptake value ratio (SUVR) of greater than 1.2 as measured by florbetapir PET. Models were conducted using logistic regression methods. In secondary analyses, we tested effect modifications by apolipoprotein E &#x3b5;4 genotype with interaction terms and in stratified models and evaluated regional patterns of associations.</AbstractText><AbstractText Label="RESULTS">In 300 participants (mean [SD] age, 76 [5] years; 132 African American individuals [44%], 167 women [56%], and 94 carriers of at least 1 apolipoprotein E &#x3b5;4 allele [31%]), ICAD was found in 105 participants (35%) and mean (SD) SUVR was higher in individuals with vs without intracranial plaques (1.34 [0.29] vs 1.27 [0.23]; P&#x2009;=&#x2009;.03). In adjusted models, ICAD presence (plaque presence [adjusted odds ratio (aOR), 1.20; 95% CI, 0.69-2.07] and frequency [aOR, 1.10; 95% CI, 0.96-1.26]) was not associated significantly with elevated SUVR in the total sample. Furthermore, modest stenosis of the intracranial vessels (defined as &gt;50% stenosis) was not associated with elevated SUVR (aOR, 2.33; 95% CI, 0.82-6.60).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this community-based cohort of adults without dementia, intracranial atherosclerotic plaque or stenosis was not associated with brain &#x3b2;-amyloid deposition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mount Sinai Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Dean</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagenknecht</LastName><ForeName>Lynne E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dearborn</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconness Medical Center, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wasserman</LastName><ForeName>Bruce A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL105626</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG052573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700004I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040282</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700002I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700005I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700003I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 HL106232</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL105930</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700001I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2020 Mar 1;77(3):394. doi: 10.1001/jamaneurol.2020.0139.</RefSource><PMID Version="1">32150221</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002533" MajorTopicYN="N">Cerebral Angiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002537" MajorTopicYN="N">Intracranial Arteriosclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058226" MajorTopicYN="N">Plaque, Atherosclerotic</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Gottesman reported grants from the National Institutes of Health (NIH)/National Institute on Aging (NIA) and serves as an associate editor for <i>Neurology</i>, which is published by the American Academy of Neurology. Drs Mosley and Wagenknecht reported grants from NIH during the conduct of the study. Dr Knopman reported personal fees from DIAN TU and grants from Biogen and Lilly. Dr Wong reported grants and nonfinancial support from AVID, Lilly, and Roche Neuroscience and grants from Five Eleven Pharma and Lundbeck. Dr Dearborn-Tomazos reported personal fees from Bristol-Myers. Dr Wasserman reported grants from the NIH (National Heart, Lung, and Blood Institute [NHLBI]) during the conduct of the study and had a patent to 13/922,111 issued. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31860001</ArticleId><ArticleId IdType="pmc">PMC6990749</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.4339</ArticleId><ArticleId IdType="pii">2757603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beach TG, Wilson JR, Sue LI, et al. . Circle of Willis atherosclerosis: association with Alzheimer&#x2019;s disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol. 2007;113(1):13-21. doi:10.1007/s00401-006-0136-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0136-y</ArticleId><ArticleId IdType="pubmed">17021755</ArticleId></ArticleIdList></Reference><Reference><Citation>Dearborn JL, Zhang Y, Qiao Y, et al. . Intracranial atherosclerosis and dementia: the Atherosclerosis Risk in Communities (ARIC) study. Neurology. 2017;88(16):1556-1563. doi:10.1212/WNL.0000000000003837</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003837</ArticleId><ArticleId IdType="pmc">PMC5395073</ArticleId><ArticleId IdType="pubmed">28330958</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Zhou Y, et al. . Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443-1450. doi:10.1001/jama.2017.3090</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.3090</ArticleId><ArticleId IdType="pmc">PMC5921896</ArticleId><ArticleId IdType="pubmed">28399252</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Griswold ME, Lirette ST, et al. . Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: Atherosclerosis Risk in Communities-Neurocognitive Study. Stroke. 2015;46(2):433-440. doi:10.1161/STROKEAHA.114.007847</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.114.007847</ArticleId><ArticleId IdType="pmc">PMC4308430</ArticleId><ArticleId IdType="pubmed">25563642</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao Y, Guallar E, Suri FK, et al. . MR imaging measures of intracranial atherosclerosis in a population-based study. Radiology. 2016;280(3):860-868. doi:10.1148/radiol.2016151124</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2016151124</ArticleId><ArticleId IdType="pmc">PMC5006718</ArticleId><ArticleId IdType="pubmed">27022858</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Zhou Y, et al. . The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE. Neurology. 2016;87(5):473-480. doi:10.1212/WNL.0000000000002914</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002914</ArticleId><ArticleId IdType="pmc">PMC4970663</ArticleId><ArticleId IdType="pubmed">27371485</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI. A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol. 2000;21(4):643-646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7976653</ArticleId><ArticleId IdType="pubmed">10782772</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. ; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators . Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305-1316. doi:10.1056/NEJMoa043033</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043033</ArticleId><ArticleId IdType="pubmed">15800226</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Perrotin A, Barr&#xe9; L, et al. . Region-specific hierarchy between atrophy, hypometabolism, and &#x3b2;-amyloid (A&#x3b2;) load in Alzheimer&#x2019;s disease dementia. J Neurosci. 2012;32(46):16265-16273. doi:10.1523/JNEUROSCI.2170-12.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2170-12.2012</ArticleId><ArticleId IdType="pmc">PMC6794030</ArticleId><ArticleId IdType="pubmed">23152610</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Aubert L, Nemmi F, P&#xe9;ran P, et al. . Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging. 2014;41(5):836-843. doi:10.1007/s00259-013-2656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-013-2656-8</ArticleId><ArticleId IdType="pmc">PMC3978219</ArticleId><ArticleId IdType="pubmed">24435769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong DF, Rosenberg PB, Zhou Y, et al. . In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913-920. doi:10.2967/jnumed.109.069088</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.109.069088</ArticleId><ArticleId IdType="pmc">PMC3101877</ArticleId><ArticleId IdType="pubmed">20501908</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1994;14(7):1098-1104. doi:10.1161/01.ATV.14.7.1098</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.14.7.1098</ArticleId><ArticleId IdType="pubmed">8018665</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedel J, H&#xe4;gele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29(6):1075-1080.</Citation><ArticleIdList><ArticleId IdType="pubmed">6851096</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao Y, Suri FK, Zhang Y, et al. . Racial differences in prevalence and risk for intracranial atherosclerosis in a US community-based population. JAMA Cardiol. 2017;2(12):1341-1348. doi:10.1001/jamacardio.2017.4041</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2017.4041</ArticleId><ArticleId IdType="pmc">PMC5814999</ArticleId><ArticleId IdType="pubmed">29094154</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Albert MS, Alonso A, et al. . Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74(10):1246-1254. doi:10.1001/jamaneurol.2017.1658</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1658</ArticleId><ArticleId IdType="pmc">PMC5710244</ArticleId><ArticleId IdType="pubmed">28783817</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Tyas SL, Maarouf CL, et al. . Intracranial atherosclerosis as a contributing factor to Alzheimer&#x2019;s disease dementia. Alzheimers Dement. 2011;7(4):436-444. doi:10.1016/j.jalz.2010.08.228</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.08.228</ArticleId><ArticleId IdType="pmc">PMC3117084</ArticleId><ArticleId IdType="pubmed">21388893</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: the Northern Manhattan Stroke Study. Stroke. 1995;26(1):14-20. doi:10.1161/01.STR.26.1.14</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.26.1.14</ArticleId><ArticleId IdType="pubmed">7839388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannai T, Mano T, Chen X, et al. . Chronic cerebral hypoperfusion shifts the equilibrium of amyloid &#x3b2; oligomers to aggregation-prone species with higher molecular weight. Sci Rep. 2019;9(1):2827. doi:10.1038/s41598-019-39494-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39494-7</ArticleId><ArticleId IdType="pmc">PMC6391466</ArticleId><ArticleId IdType="pubmed">30808940</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y, Yamashita T, Nakano Y, et al. . Chronic cerebral hypoperfusion accelerates Alzheimer&#x2019;s Disease pathology with cerebrovascular remodeling in a novel mouse model. J Alzheimers Dis. 2016;53(3):893-905. doi:10.3233/JAD-160345</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160345</ArticleId><ArticleId IdType="pubmed">27314529</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Iadecola C. Impaired A&#x3b2; clearance: a potential link between atherosclerosis and Alzheimer&#x2019;s disease. Front Aging Neurosci. 2015;7:115. doi:10.3389/fnagi.2015.00115</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2015.00115</ArticleId><ArticleId IdType="pmc">PMC4468824</ArticleId><ArticleId IdType="pubmed">26136682</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Gottesman RF. Neurovascular and cognitive dysfunction in hypertension. Circ Res. 2019;124(7):1025-1044. doi:10.1161/CIRCRESAHA.118.313260</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.118.313260</ArticleId><ArticleId IdType="pmc">PMC6527115</ArticleId><ArticleId IdType="pubmed">30920929</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996;380(6570):168-171. doi:10.1038/380168a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/380168a0</ArticleId><ArticleId IdType="pubmed">8600393</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Nostrand WE. The influence of the amyloid &#xdf;-protein and its precursor in modulating cerebral hemostasis. Biochim Biophys Acta. 2016;1862(5):1018-1026. doi:10.1016/j.bbadis.2015.10.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2015.10.020</ArticleId><ArticleId IdType="pmc">PMC4821744</ArticleId><ArticleId IdType="pubmed">26519139</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Albert M, et al. . Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurol. 2014;71(10):1218-1227. doi:10.1001/jamaneurol.2014.1646</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1646</ArticleId><ArticleId IdType="pmc">PMC4226067</ArticleId><ArticleId IdType="pubmed">25090106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31888969</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.</ArticleTitle><Pagination><StartPage>e950</StartPage><EndPage>e960</EndPage><MedlinePgn>e950-e960</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000008864</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Recent studies suggest that white matter hyperintensities (WMH) on MRI, which primarily reflect small vessel cerebrovascular disease, may play a role in the evolution of Alzheimer disease (AD). In a longitudinal study, we investigated whether WMH promote the progression of AD pathology, or alter the association between AD pathology and risk of progression from normal cognition to mild cognitive impairment (MCI).</AbstractText><AbstractText Label="METHODS">Two sets of analyses were conducted. The relationship between whole brain WMH load, based on fluid-attenuated inversion recovery MRI, obtained in initially cognitively normal participants (n = 274) and time to onset of symptoms of MCI (n = 60) was examined using Cox regression models. In a subset of the participants with both MRI and CSF data (n = 204), the interaction of WMH load and CSF AD biomarkers was also evaluated.</AbstractText><AbstractText Label="RESULTS">Baseline WMH load interacted with CSF total tau (t-tau) with respect to symptom onset, but not with CSF &#x3b2;-amyloid 1-42 or phosphorylated tau (p-tau) 181. WMH volume was associated with time to symptom onset of MCI among individuals with low t-tau (hazard ratio [HR] 1.35, confidence interval [CI] 1.06-1.73, <i>p</i> = 0.013), but not those with high t-tau (HR 0.86, CI 0.56-1.32, <i>p</i> = 0.47). The rate of change in the CSF biomarkers over time was not associated with the rate of change in WMH volumes.</AbstractText><AbstractText Label="CONCLUSION">These results suggest that WMH primarily affect the risk of progression when CSF measures of neurodegeneration or neuronal injury (as reflected by t-tau) are low. However, CSF biomarkers of amyloid and p-tau and WMH appear to have largely independent and nonsynergistic effects on the risk of progression to MCI.</AbstractText><CopyrightInformation>&#xa9; 2019 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soldan</LastName><ForeName>Anja</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6193-0418</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis. asoldan1@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettigrew</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4264-275X</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Mei-Cheng</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moghekar</LastName><ForeName>Abhay</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9464-1551</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Baljeet</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>BIOCARD Research Team</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG033655</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31888969</ArticleId><ArticleId IdType="pmc">PMC7238945</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000008864</ArticleId><ArticleId IdType="pii">WNL.0000000000008864</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease: lessons from pathology. BMC Med 2014;12:206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226890</ArticleId><ArticleId IdType="pubmed">25385447</ArticleId></ArticleIdList></Reference><Reference><Citation>Koncz R, Sachdev PS. Are the brain's vascular and Alzheimer pathologies additive or interactive? Curr Opin Psychiatry 2018;31:147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">29232251</ArticleId></ArticleIdList></Reference><Reference><Citation>Roseborough A, Ramirez J, Black SE, Edwards JD. Associations between amyloid beta and white matter hyperintensities: a systematic review. Alzheimers Dement 2017;13:1154&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">28322203</ArticleId></ArticleIdList></Reference><Reference><Citation>Marnane M, Al-Jawadi OO, Mortazavi S, et al. . Periventricular hyperintensities are associated with elevated cerebral amyloid. Neurology 2016;86:535&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4753726</ArticleId><ArticleId IdType="pubmed">26747881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, Goos JD, Teunissen CE, et al. . Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. JAMA Neurol 2014;71:855&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">24818585</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott JA, Braskie MN, Tosun D, et al. . Cerebral amyloid is associated with greater white-matter hyperintensity accrual in cognitively normal older adults. Neurobiol Aging 2016;48:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5798609</ArticleId><ArticleId IdType="pubmed">27639120</ArticleId></ArticleIdList></Reference><Reference><Citation>Shams S, Granberg T, Martola J, et al. . Cerebrospinal fluid profiles with increasing number of cerebral microbleeds in a continuum of cognitive impairment. J Cereb Blood Flow Metab 2016;36:621&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4794093</ArticleId><ArticleId IdType="pubmed">26661151</ArticleId></ArticleIdList></Reference><Reference><Citation>van Westen D, Lindqvist D, Blennow K, et al. . Cerebral white matter lesions: associations with Abeta isoforms and amyloid PET. Sci Rep 2016;6:20709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4746584</ArticleId><ArticleId IdType="pubmed">26856756</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietroboni AM, Scarioni M, Carandini T, et al. . CSF beta-amyloid and white matter damage: a new perspective on Alzheimer's disease. J Neurol Neurosurg Psychiatry 2018;89:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">29054920</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Soldan A, Gottesman R, et al. . Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype. Curr Alzheimer Res 2014;11:773&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4163954</ArticleId><ArticleId IdType="pubmed">25212916</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Miller BL, Swan GE, et al. . Predictors of brain morphology for the men of the NHLBI twin study. Stroke 1999;30:529&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">10066847</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljabar P, Heckemann RA, Hammers A, Hajnal JV, Rueckert D. Multi-atlas based segmentation of brain images: atlas selection and its effect on accuracy. Neuroimage 2009;46:726&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">19245840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochunov P, Lancaster JL, Thompson P, et al. . Regional spatial normalization: toward an optimal target. J Comput Assist Tomogr 2001;25:805&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584245</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher E, Carmichael O, Decarli C. MRI non-uniformity correction through interleaved bias estimation and B-spline deformation with a template. Conf Proc IEEE Eng Med Biol Soc 2012;2012:106&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775836</ArticleId><ArticleId IdType="pubmed">23365843</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher E, Singh B, Harvey D, Carmichael O, DeCarli C. Adaptive image segmentation for robust measurement of longitudinal brain tissue change. Conf Proc IEEE Eng Med Biol Soc 2012;2012:5319&#x2013;5322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776590</ArticleId><ArticleId IdType="pubmed">23367130</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghekar A, Goh J, Li M, Albert M, O'Brien RJ. Cerebrospinal fluid Abeta and tau level fluctuation in an older clinical cohort. Arch Neurol 2012;69:246&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310240</ArticleId><ArticleId IdType="pubmed">22332192</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghekar A, Li S, Lu Y, et al. . CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology 2013;81:1753&#x2013;1758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821715</ArticleId><ArticleId IdType="pubmed">24132375</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. . Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, et al. . CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, et al. . Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettigrew C, Soldan A, Zhu Y, et al. . Cognitive reserve and cortical thickness in preclinical Alzheimer's disease. Brain Imaging Behav 2017;11:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743433</ArticleId><ArticleId IdType="pubmed">27544202</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016;87:539&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, et al. . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006;129:3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H. Review: tau in biofluids: relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol 2017;43:194&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">28054371</ArticleId></ArticleIdList></Reference><Reference><Citation>Esiri MM, Joachim C, Sloan C, et al. . Cerebral subcortical small vessel disease in subjects with pathologically confirmed Alzheimer disease: a clinicopathologic study in the Oxford Project to Investigate Memory and Ageing (OPTIMA). Alzheimer Dis Assoc Disord 2014;28:30&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">23842286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Olichney JM, Hansen LA, Hofstetter CR, Thal LJ. Small concomitant vascular lesions do not influence rates of cognitive decline in patients with Alzheimer disease. Arch Neurol 2000;57:1474&#x2013;1479.</Citation><ArticleIdList><ArticleId IdType="pubmed">11030800</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes J, Carmichael OT, Leung KK, et al. . Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. Neurobiol Aging 2013;34:1996&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810644</ArticleId><ArticleId IdType="pubmed">23522844</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiford CM, Manning EN, Bartlett JW, et al. . White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy. Hippocampus 2017;27:249&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5324634</ArticleId><ArticleId IdType="pubmed">27933676</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo RY, Jagust WJ. Vascular burden and Alzheimer disease pathologic progression. Neurology 2012;79:1349&#x2013;1355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448744</ArticleId><ArticleId IdType="pubmed">22972646</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattringer T, Enzinger C, Ropele S, et al. . Vascular risk factors, white matter hyperintensities and hippocampal volume in normal elderly individuals. Dement Geriatr Cogn Disord 2012;33:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">22377559</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosheny RL, Insel PS, Truran D, et al. . Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol Aging 2015;36:273&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5832349</ArticleId><ArticleId IdType="pubmed">25175807</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Viqar F, Zimmerman ME, et al. . White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol 2016;79:929&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4884146</ArticleId><ArticleId IdType="pubmed">27016429</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Zimmerman ME, Narkhede A, et al. . White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. PLoS One 2018;13:e0195838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942789</ArticleId><ArticleId IdType="pubmed">29742105</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickman AM, Schupf N, Manly JJ, et al. . APOE epsilon4 and risk for Alzheimer's disease: do regionally distributed white matter hyperintensities play a role? Alzheimers Dement 2014;10:619&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252241</ArticleId><ArticleId IdType="pubmed">25304991</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedictus MR, Goos JD, Binnewijzend MA, et al. . Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. Neurobiol Aging 2013;34:2488&#x2013;2494.</Citation><ArticleIdList><ArticleId IdType="pubmed">23731952</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Pious NM, Jicha GA, et al. . APOE-epsilon2 and APOE-epsilon4 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol 2013;72:708&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715146</ArticleId><ArticleId IdType="pubmed">23771217</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Fleischman DA, et al. . White matter hyperintensities, incident mild cognitive impairment, and cognitive decline in old age. Ann Clin Transl Neurol 2016;3:791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5048389</ArticleId><ArticleId IdType="pubmed">27752514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Weigand SD, Przybelski SA, et al. . MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology 2013;81:126&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3770173</ArticleId><ArticleId IdType="pubmed">23761624</ArticleId></ArticleIdList></Reference><Reference><Citation>Silbert LC, Howieson DB, Dodge H, Kaye JA. Cognitive impairment risk: white matter hyperintensity progression matters. Neurology 2009;73:120&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2713187</ArticleId><ArticleId IdType="pubmed">19597134</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EE, Egorova S, Blacker D, et al. . Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol 2008;65:94&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">18195145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorius N, Locascio JJ, Rentz DM, et al. . Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum. Alzheimer Dis Assoc Disord 2015;29:18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366000</ArticleId><ArticleId IdType="pubmed">24787033</ArticleId></ArticleIdList></Reference><Reference><Citation>Silbert LC, Dodge HH, Perkins LG, et al. . Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology 2012;79:741&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421153</ArticleId><ArticleId IdType="pubmed">22843262</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke SL, Hu T, Fava NM, et al. . Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging 2018;31:140&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039284</ArticleId><ArticleId IdType="pubmed">29319430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangen KJ, Preis SR, Delano-Wood L, et al. . Baseline white matter hyperintensities and hippocampal volume are associated with conversion from normal cognition to mild cognitive impairment in the framingham offspring study. Alzheimer Dis Assoc Disord 2018;32:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5821543</ArticleId><ArticleId IdType="pubmed">28984639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortamais M, Artero S, Ritchie K. White matter hyperintensities as early and independent predictors of Alzheimer's disease risk. J Alzheimers Dis 2014;42(suppl 4):S393&#x2013;S400.</Citation><ArticleIdList><ArticleId IdType="pubmed">25261452</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, et al. . Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013;80:1784&#x2013;1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31894103</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>524</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaau5732</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aau5732</ELocationID><Abstract><AbstractText>&#x3b2;-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological hallmarks of Alzheimer's disease (AD) and are thought to play crucial roles in a neurodegenerative cascade leading to dementia. Both lesions can now be visualized in vivo using positron emission tomography (PET) radiotracers, opening new opportunities to study disease mechanisms and improve patients' diagnostic and prognostic evaluation. In a group of 32 patients at early symptomatic AD stages, we tested whether &#x3b2;-amyloid and tau-PET could predict subsequent brain atrophy measured using longitudinal magnetic resonance imaging acquired at the time of PET and 15 months later. Quantitative analyses showed that the global intensity of tau-PET, but not &#x3b2;-amyloid-PET, signal predicted the rate of subsequent atrophy, independent of baseline cortical thickness. Additional investigations demonstrated that the specific distribution of tau-PET signal was a strong indicator of the topography of future atrophy at the single patient level and that the relationship between baseline tau-PET and subsequent atrophy was particularly strong in younger patients. These data support disease models in which tau pathology is a major driver of local neurodegeneration and highlight the relevance of tau-PET as a precision medicine tool to help predict individual patient's progression and design future clinical trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>La Joie</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2581-8100</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. renaud.lajoie@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visani</LastName><ForeName>Adrienne V</ForeName><Initials>AV</Initials><Identifier Source="ORCID">0000-0002-5379-3687</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Suzanne L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jesse A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-3139-9451</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourakova</LastName><ForeName>Viktoriya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Jungho</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1189-2051</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaudhary</LastName><ForeName>Kiran</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0252-4129</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8434-9669</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iaccarino</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0053-9519</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janabi</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0134-0317</Identifier><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesman-Segev</LastName><ForeName>Orit H</ForeName><Initials>OH</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Zachary A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neil</LastName><ForeName>James P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-4980-4240</Identifier><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Julio C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-1308-646X</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0003-2784-7992</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0002-2152-4220</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0002-4458-113X</Identifier><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG045333</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG057195</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG045289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG023481</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG055698</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG059888</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. Renaud La Joie, Adrienne A. Visani, Jesse A. Brown, Viktoriya Bourakova, Jungho Cha, Kiran Chaudhary, Lauren Edwards, Leonardo Iaccarino, Mustafa Janabi, Orit Lesman-Segev, Zachary Miller, James P O&#x2019;Neil and Julie Pham report no disclosure.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31894103</ArticleId><ArticleId IdType="mid">NIHMS1557357</ArticleId><ArticleId IdType="pmc">PMC7035952</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aau5732</ArticleId><ArticleId IdType="pii">12/524/eaau5732</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ, National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease, Alzheimers Dement 8, 1&#x2013;13 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Delatour B, Potier M-C, Classification and basic pathology of Alzheimer disease, Acta Neuropathol. (Berl.) 118, 5&#x2013;36 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19381658</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang G, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L&#xe5;ngstr&#xf6;m B, Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B, Ann. Neurol 55, 306&#x2013;319 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su M-Y, Shankle WR, Elizarov A, Kolb HC, Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807, J. Alzheimers Dis. JAD 34, 457&#x2013;468 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, Lyoo CH, Ryu YH, Lee MS, Tau PET in Alzheimer disease and mild cognitive impairment, Neurology 87, 375&#x2013;383 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27358341</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino L, Tammewar G, Ayakta N, Baker SL, Bejanin A, Boxer AL, Gorno-Tempini ML, Janabi M, Kramer JH, Lazaris A, Lockhart SN, Miller BL, Miller ZA, O&#x2019;Neil JP, Ossenkoppele R, Rosen HJ, Schonhaut DR, Jagust WJ, Rabinovici GD, Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer&#x2019;s Disease, NeuroImage Clin 17, 452&#x2013;464 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684433</ArticleId><ArticleId IdType="pubmed">29159058</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrallah IM, Chen YJ, Hsieh M-K, Phillips JS, Ternes K, Stockbower GE, Sheline Y, McMillan CT, Grossman M, Wolk DA, 18F-Flortaucipir PET/MRI Correlations in Nonamnestic and Amnestic Variants of Alzheimer Disease, J. Nucl. Med. Off. Publ. Soc. Nucl. Med 59, 299&#x2013;306 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348438</ArticleId><ArticleId IdType="pubmed">28747523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, Lockhart SN, Ayakta N, Baker SL, O&#x2019;Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD, Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease, Brain J. Neurol 139, 1551&#x2013;1567 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Dronse J, Fliessbach K, Bischof GN, von Reutern B, Faber J, Hammes J, Kuhnert G, Neumaier B, Onur OA, Kukolja J, van Eimeren T, Jessen F, Fink GR, Klockgether T, Drzezga A, In vivo Patterns of Tau Pathology, Amyloid-&#x3b2; Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer&#x2019;s Disease, J. Alzheimers Dis. JAD 55, 465&#x2013;471 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27802224</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O&#x2019;Neil JP, Gorno-Tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD, Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x2019;s disease, Brain J. Neurol 140, 3286&#x2013;3300 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Devous MD, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA, 18F-AV-1451-A05 investigators, Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition, Brain J. Neurol 140, 748&#x2013;763 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382945</ArticleId><ArticleId IdType="pubmed">28077397</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiford CM, Ridgway GR, Cash DM, Modat M, Nicholas J, Manning EN, Malone IB, Biessels GJ, Ourselin S, Carmichael OT, Cardoso MJ, Barnes J, Alzheimer&#x2019;s Disease Neuroimaging Initiative, Patterns of progressive atrophy vary with age in Alzheimer&#x2019;s disease patients, Neurobiol. Aging 63, 22&#x2013;32 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5805840</ArticleId><ArticleId IdType="pubmed">29220823</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Jeon S, Kang SJ, Lee J-M, Lee J-H, Kim GH, Shin JS, Kim CH, Noh Y, Im K, Kim ST, Chin J, Seo SW, Na DL, Longitudinal changes of cortical thickness in early- versus late-onset Alzheimer&#x2019;s disease, Neurobiol. Aging 34, 1921.e9&#x2013;1921.e15 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23391426</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, Desikan RS, Dale AM, McEvoy LK, Alzheimer&#x2019;s Disease Neuroimaging Initiative, Rates of decline in Alzheimer disease decrease with age, PloS One 7, e42325 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3410919</ArticleId><ArticleId IdType="pubmed">22876315</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisse LEM, Das SR, Davatzikos C, Dickerson BC, Xie SX, Yushkevich PA, Wolk DA, Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration, NeuroImage Clin 18, 407&#x2013;412 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816023</ArticleId><ArticleId IdType="pubmed">29487798</ArticleId></ArticleIdList></Reference><Reference><Citation>LaPoint MR, Chhatwal JP, Sepulcre J, Johnson KA, Sperling RA, Schultz AP, The association between tau PET and retrospective cortical thinning in clinically normal elderly, NeuroImage 157, 612&#x2013;622 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5772972</ArticleId><ArticleId IdType="pubmed">28545932</ArticleId></ArticleIdList></Reference><Reference><Citation>Das SR, Xie L, Wisse LEM, Ittyerah R, Tustison NJ, Dickerson BC, Yushkevich PA, Wolk DA, Alzheimer&#x2019;s Disease Neuroimaging Initiative, Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake, Neurobiol. Aging 66, 49&#x2013;58 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5924615</ArticleId><ArticleId IdType="pubmed">29518752</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC, Cerebral atrophy in mild cognitive impairment and Alzheimer disease, Neurology 80, 648&#x2013;654 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590059</ArticleId><ArticleId IdType="pubmed">23303849</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabuncu MR, Desikan RS, Sepulcre J, Yeo BTT, Liu H, Schmansky NJ, Reuter M, Weiner MW, Buckner RL, Sperling RA, Fischl B, for the A. D. N. Initiative, The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease, Arch. Neurol 68, 1040&#x2013;1048 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248949</ArticleId><ArticleId IdType="pubmed">21825241</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, Vellas B, Alzheimer&#x2019;s Disease Neuroimaging Initiative, Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer&#x2019;s disease clinical trials, Alzheimers Dement. J. Alzheimers Assoc 9, S45&#x2013;55 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22658286</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M, Classification of primary progressive aphasia and its variants, Neurology 76, 1006&#x2013;1014 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, Dickerson BC, Vandenberghe R, Ahmed S, Bak TH, Boeve BF, Butler C, Cappa SF, Ceccaldi M, de Souza LC, Dubois B, Felician O, Galasko D, Graff-Radford J, Graff-Radford NR, Hof PR, Krolak-Salmon P, Lehmann M, Magnin E, Mendez MF, Nestor PJ, Onyike CU, Pelak VS, Pijnenburg Y, Primativo S, Rossor MN, Ryan NS, Scheltens P, Shakespeare TJ, Su&#xe1;rez Gonz&#xe1;lez A, Tang-Wai DF, Yong KXX, Carrillo M, Fox NC, Alzheimer&#x2019;s Association ISTAART Atypical Alzheimer&#x2019;s Disease and Associated Syndromes Professional Interest Area, Consensus classification of posterior cortical atrophy, Alzheimers Dement. J. Alzheimers Assoc 13, 870&#x2013;884 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5788455</ArticleId><ArticleId IdType="pubmed">28259709</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Bejanin A, Fagan AM, Ayakta N, Baker SL, Bourakova V, Boxer AL, Cha J, Karydas A, Jerome G, Maass A, Mensing A, Miller ZA, O&#x2019;Neil JP, Pham J, Rosen HJ, Tsai R, Visani AV, Miller BL, Jagust WJ, Rabinovici GD, Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample, Neurology 90, e282&#x2013;e290 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5798657</ArticleId><ArticleId IdType="pubmed">29282337</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Ridgway GR, Symmetric Diffeomorphic Modeling of Longitudinal Structural MRI, Front. Neurosci 6 (2013), doi:10.3389/fnins.2012.00197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2012.00197</ArticleId><ArticleId IdType="pmc">PMC3564017</ArticleId><ArticleId IdType="pubmed">23386806</ArticleId></ArticleIdList></Reference><Reference><Citation>Potvin O, Dieumegarde L, Duchesne S, Alzheimer&#x2019;s Disease Neuroimaging Initiative, Normative morphometric data for cerebral cortical areas over the lifetime of the adult human brain, NeuroImage 156, 315&#x2013;339 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28512057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, La Joie R, Landeau B, Belliard S, de La Sayette V, Eustache F, Desgranges B, Ch&#xe9;telat G, Distinct Interplay Between Atrophy and Hypometabolism in Alzheimer&#x2019;s Versus Semantic Dementia, Cereb. Cortex N. Y. N 1991 (2018), doi:10.1093/cercor/bhy069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhy069</ArticleId><ArticleId IdType="pubmed">29668866</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, La Joie R, Maass A, Baker SL, Swinnerton K, Fenton L, Mellinger TJ, Edwards L, Pham J, Miller BL, Rabinovici GD, Jagust WJ, Longitudinal tau accumulation and atrophy in aging and alzheimer disease, Ann. Neurol 85, 229&#x2013;240 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579738</ArticleId><ArticleId IdType="pubmed">30597624</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlund L-O, Blennow K, Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients, Neurosci. Lett 339, 99&#x2013;102 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12614904</ArticleId></ArticleIdList></Reference><Reference><Citation>Henneman WJP, Vrenken H, Barnes J, Sluimer IC, Verwey NA, Blankenstein MA, Klein M, Fox NC, Scheltens P, Barkhof F, van der Flier WM, Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease, Neurology 73, 935&#x2013;940 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839552</ArticleId><ArticleId IdType="pubmed">19770469</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM, Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease, JAMA Neurol 72, 656&#x2013;665 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4551490</ArticleId><ArticleId IdType="pubmed">25867677</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM, CSF Biomarkers in Prediction of Cerebral and Clinical Change in Mild Cognitive Impairment and Alzheimer&#x2019;s Disease, J. Neurosci 30, 2088&#x2013;2101 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828879</ArticleId><ArticleId IdType="pubmed">20147537</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR, Weiner MW, Alzheimer&#x2019;s Disease Neuroimaging Initiative, MRI of hippocampal volume loss in early Alzheimer&#x2019;s disease in relation to ApoE genotype and biomarkers, Brain J. Neurol 132, 1067&#x2013;1077 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668943</ArticleId><ArticleId IdType="pubmed">19251758</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P, Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study, Neurobiol. Aging 31, 758&#x2013;764 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">18692273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Sch&#xf6;ll M, Strandberg O, Smith R, Palmqvist S, Insel PS, H&#xe4;gerstr&#xf6;m D, Ohlsson T, Zetterberg H, J&#xf6;gi J, Blennow K, Hansson O, 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer&#x2019;s disease, EMBO Mol. Med 9, 1212&#x2013;1223 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5582410</ArticleId><ArticleId IdType="pubmed">28743782</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal JP, Schultz AP, Marshall GA, Boot B, Gomez-Isla T, Dumurgier J, LaPoint M, Scherzer C, Roe AD, Hyman BT, Sperling RA, Johnson KA, Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly, Neurology 87, 920&#x2013;926 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035159</ArticleId><ArticleId IdType="pubmed">27473132</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC, Reduced sample sizes for atrophy outcomes in Alzheimer&#x2019;s disease trials: baseline adjustment, Neurobiol. Aging 31, 1452&#x2013;1462.e2 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947486</ArticleId><ArticleId IdType="pubmed">20620665</ArticleId></ArticleIdList></Reference><Reference><Citation>Cash DM, Rohrer JD, Ryan NS, Ourselin S, Fox NC, Imaging endpoints for clinical trials in Alzheimer&#x2019;s disease, Alzheimers Res. Ther 6, 87 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304258</ArticleId><ArticleId IdType="pubmed">25621018</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Dickson DW, Murray ME, Weigand SD, Tosakulwong N, Senjem ML, Knopman DS, Boeve BF, Parisi JE, Petersen RC, Jack CR, Josephs KA, Neuroimaging correlates of pathologically defined subtypes of Alzheimer&#x2019;s disease: a case-control study, Lancet Neurol 11, 868&#x2013;877 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490201</ArticleId><ArticleId IdType="pubmed">22951070</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Mormino EC, Sun N, Sperling RA, Sabuncu MR, Yeo BTT, Alzheimer&#x2019;s Disease Neuroimaging Initiative, Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer&#x2019;s disease, Proc. Natl. Acad. Sci. U. S. A 113, E6535&#x2013;E6544 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5081632</ArticleId><ArticleId IdType="pubmed">27702899</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW, Neuropathologically defined subtypes of Alzheimer&#x2019;s disease with distinct clinical characteristics: a retrospective study, Lancet Neurol 10, 785&#x2013;796 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutman BA, Wang Y, Yanovsky I, Hua X, Toga AW, Jack CR, Weiner MW, Thompson PM, Empowering Imaging Biomarkers of Alzheimer&#x2019;s Disease, Neurobiol. Aging 36 Suppl 1, S69&#x2013;S80 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4268333</ArticleId><ArticleId IdType="pubmed">25260848</ArticleId></ArticleIdList></Reference><Reference><Citation>Edland SD, Ard MC, Sridhar J, Cobia D, Martersteck A, Mesulam MM, Rogalski EJ, Proof of concept demonstration of optimal composite MRI endpoints for clinical trials, Alzheimers Dement. N. Y. N 2, 177&#x2013;181 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363955</ArticleId><ArticleId IdType="pubmed">28345017</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Perrotin A, Barr&#xe9; L, Hommet C, M&#xe9;zenge F, Ibazizene M, Camus V, Abbas A, Landeau B, Guilloteau D, de La Sayette V, Eustache F, Desgranges B, Ch&#xe9;telat G, Region-specific hierarchy between atrophy, hypometabolism, and &#x3b2;-amyloid (A&#x3b2;) load in Alzheimer&#x2019;s disease dementia, J. Neurosci. Off. J. Soc. Neurosci 32, 16265&#x2013;16273 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794030</ArticleId><ArticleId IdType="pubmed">23152610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeke C, Martins RN, O&#x2019;Keefe GJ, Salvado O, Masters CL, Rowe CC, Relationship between atrophy and beta-amyloid deposition in Alzheimer disease, Ann. Neurol 67, 317&#x2013;324 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20373343</ArticleId></ArticleIdList></Reference><Reference><Citation>Falke E, Nissanov J, Mitchell TW, Bennett DA, Trojanowski JQ, Arnold SE, Subicular dendritic arborization in Alzheimer&#x2019;s disease correlates with neurofibrillary tangle density, Am. J. Pathol 163, 1615&#x2013;1621 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868320</ArticleId><ArticleId IdType="pubmed">14507668</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT, Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease, Ann. Neurol 41, 17&#x2013;24 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupont A-C, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N, Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases, Int. J. Mol. Sci 18 (2017), doi:10.3390/ijms18040785.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18040785</ArticleId><ArticleId IdType="pmc">PMC5412369</ArticleId><ArticleId IdType="pubmed">28387722</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgeat P, Ch&#xe9;telat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O, Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia, Neurology 74, 121&#x2013;127 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20065247</ArticleId></ArticleIdList></Reference><Reference><Citation>Klupp E, Grimmer T, Tahmasian M, Sorg C, Yakushev I, Yousefi BH, Drzezga A, F&#xf6;rster S, Prefrontal hypometabolism in Alzheimer disease is related to longitudinal amyloid accumulation in remote brain regions, J. Nucl. Med. Off. Publ. Soc. Nucl. Med 56, 399&#x2013;404 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25678488</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Dickson DW, Tosakulwong N, Weigand SD, Murray ME, Petrucelli L, Liesinger AM, Senjem ML, Spychalla AJ, Knopman DS, Parisi JE, Petersen RC, Jack CR, Whitwell JL, Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer&#x2019;s disease: a longitudinal retrospective study, Lancet Neurol 16, 917&#x2013;924 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5646369</ArticleId><ArticleId IdType="pubmed">28919059</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Graff-Radford J, Tosakulwong N, Weigand SD, Machulda MM, Senjem ML, Spychalla AJ, Vemuri P, Jones DT, Drubach DA, Knopman DS, Boeve BF, Ertekin-Taner N, Petersen RC, Lowe VJ, Jack CR, Josephs KA, Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer&#x2019;s disease, Alzheimers Dement. J. Alzheimers Assoc 14, 1005&#x2013;1014 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097955</ArticleId><ArticleId IdType="pubmed">29605222</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerritsen AAJ, Bakker C, Verhey FRJ, de Vugt ME, Melis RJF, Koopmans RTCM, 4C study team, Prevalence of Comorbidity in Patients With Young-Onset Alzheimer Disease Compared With Late-Onset: A Comparative Cohort Study, J. Am. Med. Dir. Assoc 17, 318&#x2013;323 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26778489</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Carrillo MC, Forman M, DeSanti S, Miller DS, Kozauer N, Petersen RC, Randolph C, Knopman DS, Smith EE, Isaac M, Mattsson N, Bain LJ, Hendrix JA, Sims JR, Multiple comorbid neuropathologies in the setting of Alzheimer&#x2019;s disease neuropathology and implications for drug development, Alzheimers Dement. Transl. Res. Clin. Interv 3, 83&#x2013;91 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651346</ArticleId><ArticleId IdType="pubmed">29067320</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Bennett DA, Boyle PA, Leurgans S, Schneider JA, Dementia from Alzheimer disease and mixed pathologies in the oldest old, JAMA 307, 1798&#x2013;1800 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3368581</ArticleId><ArticleId IdType="pubmed">22550192</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Verwer EE, Meltzer AC, Kim SJW, Ag&#xfc;ero C, Gonzalez J, Makaretz SJ, Siao Tick Chong M, Ramanan P, Amaral AC, Normandin MD, Vanderburg CR, Gomperts SN, Johnson KA, Frosch MP, G&#xf3;mez-Isla T, Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson&#x2019;s case, Acta Neuropathol. Commun 5, 75 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5648451</ArticleId><ArticleId IdType="pubmed">29047416</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander K, Lashley T, Gami P, Gendron T, Lythgoe MF, Rohrer JD, Schott JM, Revesz T, Fox NC, &#xc5;rstad E, Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer&#x2019;s disease, primary tauopathies, and other dementias, Alzheimers Dement. J. Alzheimers Assoc 12, 1116&#x2013;1124 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26892233</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JY, Cho H, Ahn SJ, Lee JH, Ryu YH, Lee MS, Lyoo CH, Off-Target 18F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation, J. Nucl. Med. Off. Publ. Soc. Nucl. Med 59, 117&#x2013;120 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28775201</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SL, Maass A, Jagust WJ, Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data, Data Brief 15, 648&#x2013;657 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5671473</ArticleId><ArticleId IdType="pubmed">29124088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart SN, Ayakta N, Winer JR, La Joie R, Rabinovici GD, Jagust WJ, Elevated (18)F-AV-1451 PET tracer uptake detected in incidental imaging findings, Neurology 88, 1095&#x2013;1097 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5384840</ArticleId><ArticleId IdType="pubmed">28188303</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V, O&#x2019;Neil JP, Janabi M, Baker S, Lee SE, Perry DC, Bajorek L, Karydas A, Spina S, Grinberg LT, Seeley WW, Ramos EM, Coppola G, Gorno-Tempini ML, Miller BL, Rosen HJ, Jagust W, Boxer AL, Rabinovici GD, 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes, Alzheimers Res. Ther 11, 13 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6357510</ArticleId><ArticleId IdType="pubmed">30704514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakota L, Brandt R, Tau Biology and Tau-Directed Therapies for Alzheimer&#x2019;s Disease, Drugs 76, 301&#x2013;313 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4757605</ArticleId><ArticleId IdType="pubmed">26729186</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH, The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease, Alzheimers Dement. J. Alzheimers Assoc 7, 263&#x2013;269 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH, The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease, Alzheimers Dement. J. Alzheimers Assoc 7, 270&#x2013;279 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, Mormino EC, O&#x2019;Neil JP, Janabi M, Karydas A, Growdon ME, Jang JY, Huang EJ, Dearmond SJ, Trojanowski JQ, Grinberg LT, Gorno-Tempini ML, Seeley WW, Miller BL, Jagust WJ, Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD, Neurology 77, 2034&#x2013;2042 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236517</ArticleId><ArticleId IdType="pubmed">22131541</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedrichsen J, Balsters JH, Flavell J, Cussans E, Ramnani N, A probabilistic MR atlas of the human cerebellum, NeuroImage 46, 39&#x2013;46 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19457380</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, Rabinovici GD, Jagust WJ, Alzheimer&#x2019;s Disease Neuroimaging Initiative, Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer&#x2019;s disease, NeuroImage 157, 448&#x2013;463 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, Mitchell TN, Brooks DJ, Duncan JS, Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe, Hum. Brain Mapp 19, 224&#x2013;247 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871794</ArticleId><ArticleId IdType="pubmed">12874777</ArticleId></ArticleIdList></Reference><Reference><Citation>Girard H, Potvin O, Nugent S, Dallaire-Th&#xe9;roux C, Cunnane S, Duchesne S, Alzheimer&#x2019;s Disease Neuroimaging Initiative, Faster progression from MCI to probable AD for carriers of a single-nucleotide polymorphism associated with type 2 diabetes, Neurobiol. Aging 64, 157.e11&#x2013;157.e17 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29338921</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernet CR, Wilcox R, Rousselet GA, Robust correlation analyses: false positive and power validation using a new open source matlab toolbox, Front. Psychol 3, 606 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541537</ArticleId><ArticleId IdType="pubmed">23335907</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia M, Wang J, He Y, BrainNet Viewer: A Network Visualization Tool for Human Brain Connectomics, PLOS ONE 8, e68910 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701683</ArticleId><ArticleId IdType="pubmed">23861951</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31915375</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>577</Volume><Issue>7790</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>399</StartPage><EndPage>404</EndPage><MedlinePgn>399-404</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-1895-7</ELocationID><Abstract><AbstractText>Alzheimer's disease is an incurable neurodegenerative disorder in which neuroinflammation has a critical function<sup>1</sup>. However, little is known about the contribution of the adaptive immune response in Alzheimer's disease<sup>2</sup>. Here, using integrated analyses of multiple cohorts, we identify peripheral and central adaptive immune changes in Alzheimer's disease. First, we performed mass cytometry of peripheral blood mononuclear cells and discovered an immune signature of Alzheimer's disease that consists of increased numbers of CD8<sup>+</sup> T effector memory CD45RA<sup>+</sup> (T<sub>EMRA</sub>) cells. In a second cohort, we found that CD8<sup>+</sup> T<sub>EMRA</sub> cells were negatively associated with cognition. Furthermore, single-cell RNA sequencing revealed that T cell receptor (TCR) signalling was enhanced in these cells. Notably, by using several strategies of single-cell TCR sequencing in a third cohort, we discovered clonally expanded CD8<sup>+</sup> T<sub>EMRA</sub> cells in the cerebrospinal fluid of patients with Alzheimer's disease. Finally, we used machine learning, cloning and peptide screens to demonstrate the specificity of clonally expanded TCRs in the cerebrospinal fluid of patients with Alzheimer's disease to two separate Epstein-Barr virus antigens. These results reveal an adaptive immune response in the blood and cerebrospinal fluid in Alzheimer's disease and provide evidence of clonal, antigen-experienced T cells patrolling the intrathecal space of brains affected by age-related neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gate</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. dgate@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Administration Palo Alto Healthcare System, Palo Alto, CA, USA. dgate@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saligrama</LastName><ForeName>Naresha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leventhal</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry, Engineering and Medicine for Human Health, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unger</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Middeldorp</LastName><ForeName>Jinte</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Administration Palo Alto Healthcare System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Neuroscience, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehallier</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Administration Palo Alto Healthcare System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Channappa</LastName><ForeName>Divya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Los Santos</LastName><ForeName>Mark B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McBride</LastName><ForeName>Alisha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Administration Palo Alto Healthcare System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pluvinage</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stem Cell Biology and Regenerative Medicine Graduate Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elahi</LastName><ForeName>Fanny</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California at San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Grace Kyin-Ye</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Functional Imaging in Neuropsychiatric Disorders Laboratory, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yongha</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Functional Imaging in Neuropsychiatric Disorders Laboratory, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greicius</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Functional Imaging in Neuropsychiatric Disorders Laboratory, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Anthony D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Psychology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aigner</LastName><ForeName>Ludwig</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Mark M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Administration Palo Alto Healthcare System, Palo Alto, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry, Engineering and Medicine for Human Health, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG048076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG055255-01A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045034 05</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS112458</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG055255</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG045333</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 NS112458</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI057229</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG023481</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2020 Jan;577(7790):322-323. doi: 10.1038/d41586-019-03892-8.</RefSource><PMID Version="1">31937952</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Mar;16(3):128-129. doi: 10.1038/s41582-020-0317-7.</RefSource><PMID Version="1">31988485</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2020 Apr;19(4):285-287. doi: 10.1016/S1474-4422(20)30076-4.</RefSource><PMID Version="1">32199089</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Signal Transduct Target Ther. 2020 Apr 13;5(1):48. doi: 10.1038/s41392-020-0125-y.</RefSource><PMID Version="1">32296032</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011948" MajorTopicYN="N">Receptors, Antigen, T-Cell</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020539" MajorTopicYN="N">Sequence Analysis, Protein</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. D.G., N.S., M.M.D. and T.W.-C. are co-inventors on a patent application related to this work. Patent STDU2&#x2013;36496/US-1/PRO is for compositions and methods for measuring T cell markers associated with Alzheimer&#x2019;s disease.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31915375</ArticleId><ArticleId IdType="mid">NIHMS1583541</ArticleId><ArticleId IdType="pmc">PMC7445078</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1895-7</ArticleId><ArticleId IdType="pii">10.1038/s41586-019-1895-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ransohoff RM How neuroinflammation contributes to neurodegeneration. Science 353, 777&#x2013;783 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindestam Arlehamn CS, Garretti F, Sulzer D &amp; Sette A Roles for the adaptive immune system in Parkinson&#x2019;s and Alzheimer&#x2019;s diseases. Curr. Opin. Immunol 59, 115&#x2013;120 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6774843</ArticleId><ArticleId IdType="pubmed">31430650</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337&#x2013;341 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F, Lenig D, F&#xf6;rster R, Lipp M &amp; Lanzavecchia A Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708&#x2013;712 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10537110</ArticleId></ArticleIdList></Reference><Reference><Citation>Han A, Glanville J, Hansmann L &amp; Davis MM Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat. Biotechnol 32, 684&#x2013;692 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4337815</ArticleId><ArticleId IdType="pubmed">24952902</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K et al. Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer&#x2019;s disease-patients and T-cell hyporeactivity in an Alzheimer&#x2019;s disease-mouse model: implications for immunotherapy. Neuromolecular Med. 9, 340&#x2013;354 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17963048</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J et al. CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer&#x2019;s disease. J. Neuroimmunol 132, 164&#x2013;172 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12417447</ArticleId></ArticleIdList></Reference><Reference><Citation>Togo T et al. Occurrence of T cells in the brain of Alzheimer&#x2019;s disease and other neurological diseases. J. Neuroimmunol 124, 83&#x2013;92 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11958825</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi VR, Garcia M, Rey L &amp; Cacabelos R Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer&#x2019;s Disease (AD) individuals. J. Neuroimmunol 97, 163&#x2013;171 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10408971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bongioanni P, Boccardi B, Borgna M, Castagna M &amp; Mondino C T-cell interferon gamma binding in patients with dementia of the Alzheimer type. Arch. Neurol 54, 457&#x2013;462 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9109748</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsonego A et al. Increased T cell reactivity to amyloid &#x3b2; protein in older humans and patients with Alzheimer disease. J. Clin. Invest 112, 415&#x2013;422 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166296</ArticleId><ArticleId IdType="pubmed">12897209</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsonego A, Imitola J, Zota V, Oida T &amp; Weiner HL Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid &#x3b2;-peptide presentation to Th1 cells. J. Immunol 171, 2216&#x2013;2224 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12928365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F, Geginat J &amp; Lanzavecchia A Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol 22, 745&#x2013;763 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15032595</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruggner RV, Bodenmiller B, Dill DL, Tibshirani RJ &amp; Nolan GP Automated identification of stratifying signatures in cellular subpopulations. Proc. Natl Acad. Sci. USA 111, E2770&#x2013;E2777 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084463</ArticleId><ArticleId IdType="pubmed">24979804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivisakk P et al. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc. Natl Acad. Sci. USA 100, 8389&#x2013;8394 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166239</ArticleId><ArticleId IdType="pubmed">12829791</ArticleId></ArticleIdList></Reference><Reference><Citation>Giunti D et al. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J. Leukoc. Biol 73, 584&#x2013;590 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12714572</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D et al. T cells from patients with Parkinson&#x2019;s disease recognize a-synuclein peptides. Nature 546, 656&#x2013;661 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626019</ArticleId><ArticleId IdType="pubmed">28636593</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith LK et al. P2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nat. Med 21, 932&#x2013;937 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4529371</ArticleId><ArticleId IdType="pubmed">26147761</ArticleId></ArticleIdList></Reference><Reference><Citation>Argaet VP et al. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J. Exp. Med 180, 2335&#x2013;2340 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2191762</ArticleId><ArticleId IdType="pubmed">7964506</ArticleId></ArticleIdList></Reference><Reference><Citation>Glanville J et al. Identifying specificity groups in the T cell receptor repertoire. Nature 547, 94&#x2013;98 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5794212</ArticleId><ArticleId IdType="pubmed">28636589</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc 53, 695&#x2013;699 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Leipold MD, Newell EW &amp; Maecker HT Multiparameter phenotyping of human PBMCs using mass cytometry. Methods Mol. Biol 1343, 81&#x2013;95 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4748856</ArticleId><ArticleId IdType="pubmed">26420710</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL et at. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng 17, 157&#x2013;165 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL et al. Mutant presenilins specifically elevate the levels of the 42 residue &#x3b2;-amyloid peptide in vivo: evidence for augmentation of a 42-specific y secretase. Hum. Mol. Genet 13, 159&#x2013;170 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschallinger J et al. The L-type calcium channel Cav1.3 is required for proper hippocampal neurogenesis and cognitive functions. Cell Calcium 58, 606&#x2013;616 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26459417</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger MS et al. Doublecortin expression in CD8+ T-cells and microglia at sites of amyloid-&#x3b2; plaques: a potential role in shaping plaque pathology? Alzheimers Dement. 14, 1022&#x2013;1037 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29630865</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-Perotin S, Alvarez-Buylla A &amp; Garcia-Verdugo JM Identification and Characterization of Neural Progenitor Cells in the Adult Mammalian Brain. Advances in Anatomy, Embryology and Cell Biology Vol. 203 (Springer, 2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19552108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirerol-Piquer MS et al. GFP immunogold staining, from light to electron microscopy, in mammalian cells. Micron 43, 589&#x2013;599 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22227011</ArticleId></ArticleIdList></Reference><Reference><Citation>Han A et al. Dietary gluten triggers concomitant activation of CD4+ and CD8+ &#x3b1;&#x3b2; T cells and y&#x3b4; T cells in celiac disease. Proc. Natl Acad. Sci. USA 110, 13073&#x2013;13078 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740842</ArticleId><ArticleId IdType="pubmed">23878218</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E &amp; Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T et al. Comprehensive integration of single-cell data. Cell 177, 1888&#x2013;1902 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31915256</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Longitudinal Basal Forebrain Degeneration Interacts with TREM2/C3 Biomarkers of Inflammation in Presymptomatic Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>1931</StartPage><EndPage>1942</EndPage><MedlinePgn>1931-1942</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1184-19.2019</ELocationID><Abstract><AbstractText>Cholinergic inputs originating from the peripheral nervous system regulate the inflammatory immune responses of macrophages during clearance of blood-based pathogens. Because microglia are involved in clearing amyloid and tau pathology from the central nervous system, we hypothesized that cholinergic input originating from the basal forebrain might similarly regulate inflammatory immune responses to these pathologies in the aging brain. To explore this hypothesis, we leveraged the Alzheimer's Disease Neuroimaging Initiative dataset. Cognitively normal older male and female human adults were differentiated according to the relative concentration of phosphorylated tau and amyloid in their cerebrospinal fluid, yielding neurotypical and preclinical, cognitively healthy, subgroups. We then tracked these two groups longitudinally with structural MRI and biomarkers of inflammation, including soluble sTREM2 levels in the CSF and complement <i>C3</i> expression in the blood transcriptome. Longitudinal loss of basal forebrain volume was larger in the preclinical compared with the neurotypical subgroup. Across preclinical adults, loss of basal forebrain volume was associated with greater longitudinal accumulation of sTREM2 and higher peripheral blood <i>C3</i> expression. None of these relationships were attributable to degeneration in the whole-brain gray matter volume. Preclinical APOE e4 carriers exhibited the largest loss of basal forebrain volume and highest C3 expression. Consistent with the known anti-inflammatory influence of the peripheral cholinergic pathways on macrophages, our findings indicate that a loss of central cholinergic input originating from the basal forebrain might remove a key check on microglial inflammation induced by amyloid and tau accumulation.<b>SIGNIFICANCE STATEMENT</b> In the peripheral nervous system, cholinergic modulation holds the reactivity of macrophages to blood-based pathogens in check, promoting clearance while preventing runaway inflammation and immune-triggered cell death. Microglia are the brain's resident macrophages and play an important role in clearing accumulated amyloid and tau from neurons. Here, we demonstrate that a loss of cholinergic integrity in the CNS, indexed by longitudinal decreases of basal forebrain volume, interacts with multiple biomarkers of inflammation in cognitively normal older adults with abnormal amyloid and tau pathology. These interactions were not detected in cognitively normal older adults with "neurotypical" levels of amyloid and tau. An age-related loss of cholinergic neuromodulation may remove key checks on microglial reactivity to amyloid and tau.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 the authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schmitz</LastName><ForeName>Taylor W</ForeName><Initials>TW</Initials><Identifier Source="ORCID">0000-0003-0585-7524</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario N6A5C1, Canada, taylor.schmitz@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Mind Institute, University of Western Ontario, London, Ontario N6A 3K7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soreq</LastName><ForeName>Hermona</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Edmond &amp; Lily Safra Center for Brain Sciences and the Department of Biological Chemistry, Hebrew University of Jerusalem, Jerusalem, 9190401 Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poirier</LastName><ForeName>Judes</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8018-4545</Identifier><AffiliationInfo><Affiliation>Centre for Studies in the Prevention of Alzheimer's Disease, Douglas Mental Health University Institute, Verdun, Quebec, HRH 1R3 Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute, Department of Neurology and Neurosurgery, H3A 2B4 McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Psychiatry and Psychology, H3A 1A1 McGill University, Montreal, Quebec, Canada, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spreng</LastName><ForeName>R Nathan</ForeName><Initials>RN</Initials><Identifier Source="ORCID">0000-0003-1530-8916</Identifier><AffiliationInfo><Affiliation>Centre for Studies in the Prevention of Alzheimer's Disease, Douglas Mental Health University Institute, Verdun, Quebec, HRH 1R3 Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute, Department of Neurology and Neurosurgery, H3A 2B4 McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Psychiatry and Psychology, H3A 1A1 McGill University, Montreal, Quebec, Canada, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McConnell Brain Imaging Centre, McGill University, Montreal, QC, H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R03 AG060263</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C038245">C3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066187" MajorTopicYN="N">Basal Forebrain</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">basal forebrain cholinergic system</Keyword><Keyword MajorTopicYN="N">complement C3</Keyword><Keyword MajorTopicYN="N">phosphorylated tau</Keyword><Keyword MajorTopicYN="N">preclinical Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">soluble TREM2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31915256</ArticleId><ArticleId IdType="pmc">PMC7046458</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1184-19.2019</ArticleId><ArticleId IdType="pii">JNEUROSCI.1184-19.2019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed Z, Cooper J, Murray TK, Garn K, McNaughton E, Clarke H, Parhizkar S, Ward MA, Cavallini A, Jackson S, Bose S, Clavaguera F, Tolnay M, Lavenir I, Goedert M, Hutton ML, O'Neill MJ (2014) A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol 127:667&#x2013;683. 10.1007/s00401-014-1254-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1254-6</ArticleId><ArticleId IdType="pmc">PMC4252866</ArticleId><ArticleId IdType="pubmed">24531916</ArticleId></ArticleIdList></Reference><Reference><Citation>Akasofu S, Kimura M, Kosasa T, Sawada K, Ogura H (2008) Study of neuroprotection of donepezil, a therapy for Alzheimer's disease. Chem Biol Interact 175:222&#x2013;226. 10.1016/j.cbi.2008.04.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2008.04.045</ArticleId><ArticleId IdType="pubmed">18571635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J. (2007) A fast diffeomorphic image registration algorithm. Neuroimage 38:95&#x2013;113. 10.1016/j.neuroimage.2007.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2007.07.007</ArticleId><ArticleId IdType="pubmed">17761438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Ridgway GR (2012) Symmetric diffeomorphic modeling of longitudinal structural MRI. Front Neurosci 6:197. 10.3389/fnins.2012.00197</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2012.00197</ArticleId><ArticleId IdType="pmc">PMC3564017</ArticleId><ArticleId IdType="pubmed">23386806</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbash S, Garfinkel BP, Maoz R, Simchovitz A, Nadorp B, Guffanti A, Bennett ER, Nadeau C, T&#xfc;rk A, Paul L, Reda T, Li Y, Buchman AS, Greenberg DS, Seitz A, Bennett DA, Giavalisco P, Soreq H (2017) Alzheimer's brains show inter-related changes in RNA and lipid metabolism. Neurobiol Dis 106:1&#x2013;13. 10.1016/j.nbd.2017.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2017.06.008</ArticleId><ArticleId IdType="pmc">PMC5560656</ArticleId><ArticleId IdType="pubmed">28630030</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekris LM, Khrestian M, Dyne E, Shao Y, Pillai JA, Rao SM, Bemiller SM, Lamb B, Fernandez HH, Leverenz JB (2018) Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease. J Neuroimmunol 319:19&#x2013;27. 10.1016/j.jneuroim.2018.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2018.03.003</ArticleId><ArticleId IdType="pmc">PMC6036902</ArticleId><ArticleId IdType="pubmed">29685286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood&#x2013;brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118:103&#x2013;113. 10.1007/s00401-009-0522-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0522-3</ArticleId><ArticleId IdType="pmc">PMC2853006</ArticleId><ArticleId IdType="pubmed">19319544</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner T, Zetterberg H, Teunissen CE, Ostlund RE Jr, Militello M, Andreasson U, Hubeek I, Gibson D, Chu DC, Eichenlaub U, Heiss P, Kobold U, Leinenbach A, Madin K, Manuilova E, Rabe C, Blennow K (2016) Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1&#x2013;42) in human cerebrospinal fluid. Alzheimers Dement 12:517&#x2013;526. 10.1016/j.jalz.2015.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.09.009</ArticleId><ArticleId IdType="pubmed">26555316</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonham LW, Desikan RS, Yokoyama JS (2016) The relationship between complement factor C3, APOE epsilon4, amyloid and tau in Alzheimer's disease. Acta Neuropathol Commun 4:65. 10.1186/s40478-016-0339-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0339-y</ArticleId><ArticleId IdType="pmc">PMC4928261</ArticleId><ArticleId IdType="pubmed">27357286</ArticleId></ArticleIdList></Reference><Reference><Citation>Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405:458&#x2013;462. 10.1038/35013070</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35013070</ArticleId><ArticleId IdType="pubmed">10839541</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnevale D, De Simone R, Minghetti L (2007) Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol Disord Drug Targets 6:388&#x2013;397. 10.2174/187152707783399193</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152707783399193</ArticleId><ArticleId IdType="pubmed">18220778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavedo E, Grothe MJ, Colliot O, Lista S, Chupin M, Dormont D, Houot M, Leh&#xe9;ricy S, Teipel S, Dubois B, Hampel H (2017) Reduced basal forebrain atrophy progression in a randomized donepezil trial in prodromal Alzheimer's disease. Sci Rep 7:11706. 10.1038/s41598-017-09780-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09780-3</ArticleId><ArticleId IdType="pmc">PMC5601919</ArticleId><ArticleId IdType="pubmed">28916821</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke LE, Liddelow SA, Chakraborty C, M&#xfc;nch AE, Heiman M, Barres BA (2018) Normal aging induces A1-like astrocyte reactivity. Proc Natl Acad Sci U S A 115:E1896&#x2013;E1905. 10.1073/pnas.1800165115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1800165115</ArticleId><ArticleId IdType="pmc">PMC5828643</ArticleId><ArticleId IdType="pubmed">29437957</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921&#x2013;923. 10.1126/science.8346443</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>da Fonseca AC, Matias D, Garcia C, Amaral R, Geraldo LH, Freitas C, Lima FR (2014) The impact of microglial activation on blood&#x2013;brain barrier in brain diseases. Front Cell Neurosci 8:362. 10.3389/fncel.2014.00362</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00362</ArticleId><ArticleId IdType="pmc">PMC4217497</ArticleId><ArticleId IdType="pubmed">25404894</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73:685&#x2013;697. 10.1016/j.neuron.2011.11.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L (2005) Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 2:4. 10.1186/1742-2094-2-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-2-4</ArticleId><ArticleId IdType="pmc">PMC548670</ArticleId><ArticleId IdType="pubmed">15670336</ArticleId></ArticleIdList></Reference><Reference><Citation>Egea J, Buendia I, Parada E, Navarro E, Le&#xf3;n R, Lopez MG (2015) Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. Biochem Pharmacol 97:463&#x2013;472. 10.1016/j.bcp.2015.07.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2015.07.032</ArticleId><ArticleId IdType="pubmed">26232730</ArticleId></ArticleIdList></Reference><Reference><Citation>Eickhoff SB, Stephan KE, Mohlberg H, Grefkes C, Fink GR, Amunts K, Zilles K (2005) A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. Neuroimage 25:1325&#x2013;1335. 10.1016/j.neuroimage.2004.12.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2004.12.034</ArticleId><ArticleId IdType="pubmed">15850749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Franzmeier N, Su&#xe1;rez-Calvet M, Morenas-Rodriguez E, Caballero MAA, Kleinberger G, Piccio L, Cruchaga C, Deming Y, Dichgans M, Trojanowski JQ, Shaw LM, Weiner MW, Haass C (2019) Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med 11:eaav6221. 10.1126/scitranslmed.aav6221</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aav6221</ArticleId><ArticleId IdType="pmc">PMC7050285</ArticleId><ArticleId IdType="pubmed">31462511</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM (2011) Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1&#x2013;42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 68:1137&#x2013;1144. 10.1001/archneurol.2011.105</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.105</ArticleId><ArticleId IdType="pmc">PMC3154969</ArticleId><ArticleId IdType="pubmed">21555603</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Cabello S, Kronbichler M, Van Dijk KR, Goodman JA, Spreng RN, Schmitz TW (2020) Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration. Brain, in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092749</ArticleId><ArticleId IdType="pubmed">32203580</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe M, Heinsen H, Teipel SJ (2012) Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer's disease. Biol Psychiatry 71:805&#x2013;813. 10.1016/j.biopsych.2011.06.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2011.06.019</ArticleId><ArticleId IdType="pmc">PMC3701122</ArticleId><ArticleId IdType="pubmed">21816388</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe M, Heinsen H, Teipel S (2013) Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiol Aging 34:1210&#x2013;1220. 10.1016/j.neurobiolaging.2012.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.10.018</ArticleId><ArticleId IdType="pmc">PMC4058576</ArticleId><ArticleId IdType="pubmed">23158764</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;nblatt E, Bartl J, Zehetmayer S, Ringel TM, Bauer P, Riederer P, Jacob CP (2009) Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J Alzheimers Dis 16:627&#x2013;634. 10.3233/JAD-2009-0996</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-0996</ArticleId><ArticleId IdType="pubmed">19276557</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanin G, Shenhar-Tsarfaty S, Yayon N, Yau YH, Hoe YY, Bennett ER, Sklan EH, Rao DC, Rankinen T, Bouchard C, Geifman-Shochat S, Shifman S, Greenberg DS, Soreq H (2014) Competing targets of microRNA-608 affect anxiety and hypertension. Hum Mol Genet 23:4569&#x2013;4580. 10.1093/hmg/ddu170</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu170</ArticleId><ArticleId IdType="pmc">PMC4119407</ArticleId><ArticleId IdType="pubmed">24722204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM (2018) CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 14:1470&#x2013;1481 10.1016/j.jalz.2018.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.01.010</ArticleId><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hayes AF. (2012) PROCESS: a versatile computational tool for observed variable mediation, moderation, and conditional process modeling [White paper]. http://www.afhayes.com/public/process2012.pdf.</Citation></Reference><Reference><Citation>Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16:358&#x2013;372. 10.1038/nrn3880</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3880</ArticleId><ArticleId IdType="pubmed">25991443</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, &#xd6;hrfelt A, Blennow K, Hardy J, Schott J, Mills K, Zetterberg H (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener 11:3. 10.1186/s13024-016-0071-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0071-x</ArticleId><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352:712&#x2013;716. 10.1126/science.aad8373</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Liu CC, Chen XF, Zhang YW, Xu H, Bu G (2015) Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and abeta metabolism in apoE4-targeted replacement mice. Mol Neurodegener 10:6. 10.1186/s13024-015-0001-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0001-3</ArticleId><ArticleId IdType="pmc">PMC4356137</ArticleId><ArticleId IdType="pubmed">25871773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Watts KD, Tailor P, Nguyen TP, Howell JC, Lee RC, Seyfried NT, Gearing M, Hales CM, Levey AI, Lah JJ, Lee EK (2016) CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease. Acta Neuropathol Commun 4:14. 10.1186/s40478-016-0277-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0277-8</ArticleId><ArticleId IdType="pmc">PMC4758165</ArticleId><ArticleId IdType="pubmed">26887322</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang J, Hwang H, Lee HW, Suk K (2010) Microglia signaling as a target of donepezil. Neuropharmacology 58:1122&#x2013;1129. 10.1016/j.neuropharm.2010.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2010.02.003</ArticleId><ArticleId IdType="pubmed">20153342</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, Schuff N, Krueger G, Killiany RJ, Decarli CS, Dale AM, Carmichael OW, Tosun D, Weiner MW (2010) Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement 6:212&#x2013;220. 10.1016/j.jalz.2010.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.03.004</ArticleId><ArticleId IdType="pmc">PMC2886577</ArticleId><ArticleId IdType="pubmed">20451869</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207&#x2013;216. 10.1016/S1474-4422(12)70291-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs HI, Hedden T, Schultz AP, Sepulcre J, Perea RD, Amariglio RE, Papp KV, Rentz DM, Sperling RA, Johnson KA (2018) Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci 21:424&#x2013;431. 10.1038/s41593-018-0070-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0070-z</ArticleId><ArticleId IdType="pmc">PMC5857215</ArticleId><ArticleId IdType="pubmed">29403032</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Xu H, Bu G (2014) ApoE and abeta in Alzheimer's disease: accidental encounters or partners? Neuron 81:740&#x2013;754. 10.1016/j.neuron.2014.01.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.045</ArticleId><ArticleId IdType="pmc">PMC3983361</ArticleId><ArticleId IdType="pubmed">24559670</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, Itzkovitz S, Colonna M, Schwartz M, Amit I (2017) A unique microglia type associated with restricting development of Alzheimer's disease. Cell 169:1276&#x2013;1290.e17. 10.1016/j.cell.2017.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, Mayeux R, Duff KE, Small SA (2014) Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci 17:304&#x2013;311. 10.1038/nn.3606</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3606</ArticleId><ArticleId IdType="pmc">PMC4044925</ArticleId><ArticleId IdType="pubmed">24362760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilimann I, Grothe M, Heinsen H, Alho EJ, Grinberg L, Amaro E Jr, Dos Santos GA, da Silva RE, Mitchell AJ, Frisoni GB, Bokde AL, Fellgiebel A, Filippi M, Hampel H, Kl&#xf6;ppel S, Teipel SJ (2014) Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study. J Alzheimers Dis 40:687&#x2013;700. 10.3233/JAD-132345</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-132345</ArticleId><ArticleId IdType="pmc">PMC4120953</ArticleId><ArticleId IdType="pubmed">24503619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Su&#xe1;rez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lle&#xf3; A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, S&#xe1;nchez-Valle R, Antonell A, Ramirez A, et al. (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6:243ra286. 10.1126/scitranslmed.3009093</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3009093</ArticleId><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, Karhunen PJ (2009) Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 65:650&#x2013;657. 10.1002/ana.21696</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21696</ArticleId><ArticleId IdType="pubmed">19557866</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehner KR, Silverman HA, Addorisio ME, Roy A, Al-Onaizi MA, Levine Y, Olofsson PS, Chavan SS, Gros R, Nathanson NM, Al-Abed Y, Metz CN, Prado VF, Prado MA, Tracey KJ, Pavlov VA (2019) Forebrain cholinergic signaling regulates innate immune responses and inflammation. Front Immunol 10:585. 10.3389/fimmu.2019.00585</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00585</ArticleId><ArticleId IdType="pmc">PMC6455130</ArticleId><ArticleId IdType="pubmed">31024522</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM (2017) TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A 114:11524&#x2013;11529. 10.1073/pnas.1710311114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1710311114</ArticleId><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Barres BA (2017) Reactive astrocytes: production, function, and therapeutic potential. Immunity 46:957&#x2013;967. 10.1016/j.immuni.2017.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.06.006</ArticleId><ArticleId IdType="pubmed">28636962</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, M&#xfc;nch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, et al. (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481&#x2013;487. 10.1038/nature21029</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA (2006) The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 147:126&#x2013;132. 10.1016/j.lab.2005.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lab.2005.10.005</ArticleId><ArticleId IdType="pubmed">16503242</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106&#x2013;118. 10.1038/nrneurol.2012.263</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.263</ArticleId><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes OC, Xu S, Yu B, Chertkow HM, Wang E, Schipper HM (2007) Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 28:1795&#x2013;1809. 10.1016/j.neurobiolaging.2006.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.08.004</ArticleId><ArticleId IdType="pubmed">16979800</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone IB, Leung KK, Clegg S, Barnes J, Whitwell JL, Ashburner J, Fox NC, Ridgway GR (2015) Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance. Neuroimage 104:366&#x2013;372. 10.1016/j.neuroimage.2014.09.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2014.09.034</ArticleId><ArticleId IdType="pmc">PMC4265726</ArticleId><ArticleId IdType="pubmed">25255942</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 6:13. 10.12703/P6-13</Citation><ArticleIdList><ArticleId IdType="doi">10.12703/P6-13</ArticleId><ArticleId IdType="pmc">PMC3944738</ArticleId><ArticleId IdType="pubmed">24669294</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M. (2004) The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn Mem 11:43&#x2013;49. 10.1101/lm.69204</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.69204</ArticleId><ArticleId IdType="pubmed">14747516</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. (1999) Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24:521&#x2013;529. 10.1016/S0896-6273(00)81109-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)81109-5</ArticleId><ArticleId IdType="pubmed">10595506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. (2013) Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. J Comp Neurol 521:4124&#x2013;4144. 10.1002/cne.23415</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.23415</ArticleId><ArticleId IdType="pmc">PMC4175400</ArticleId><ArticleId IdType="pubmed">23852922</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Geula C (1988) Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 275:216&#x2013;240. 10.1002/cne.902750205</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.902750205</ArticleId><ArticleId IdType="pubmed">3220975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Mufson EJ, Wainer BH, Levey AI (1983a) Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 10:1185&#x2013;1201. 10.1016/0306-4522(83)90108-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(83)90108-2</ArticleId><ArticleId IdType="pubmed">6320048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Mufson EJ, Levey AI, Wainer BH (1983b) Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214:170&#x2013;197. 10.1002/cne.902140206</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.902140206</ArticleId><ArticleId IdType="pubmed">6841683</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer PF, Savard M, Poirier J, Labont&#xe9; A, Rosa-Neto P, Weitz TM, Town T, Breitner J (2018) Bi-directional association of cerebrospinal fluid immune markers with stage of Alzheimer's disease pathogenesis. J Alzheimers Dis 63:577&#x2013;590. 10.3233/JAD-170887</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170887</ArticleId><ArticleId IdType="pmc">PMC5929310</ArticleId><ArticleId IdType="pubmed">29660934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L (2005) Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative (ADNI). Alzheimers Dement 1:55&#x2013;66. 10.1016/j.jalz.2005.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2005.06.003</ArticleId><ArticleId IdType="pmc">PMC1864941</ArticleId><ArticleId IdType="pubmed">17476317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, K&#xf6;vari E, et al. (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362&#x2013;381. 10.1097/NEN.0b013e31825018f7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordengen K, Kirsebom BE, Henjum K, Selnes P, G&#xed;slad&#xf3;ttir B, Wettergreen M, Torsetnes SB, Grontvedt GR, Waterloo KK, Aarsland D, Nilsson LNG, Fladby T (2019) Glial activation and inflammation along the Alzheimer's disease continuum. J Neuroinflammation 16:46. 10.1186/s12974-019-1399-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1399-2</ArticleId><ArticleId IdType="pmc">PMC6383268</ArticleId><ArticleId IdType="pubmed">30791945</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, M&#xfc;ller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, et al. (2019) Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci 22:191&#x2013;204. 10.1038/s41593-018-0296-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0296-9</ArticleId><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, Chavan S, Al-Abed Y, Tracey KJ (2009) Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun 23:41&#x2013;45. 10.1016/j.bbi.2008.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2008.06.011</ArticleId><ArticleId IdType="pmc">PMC4533839</ArticleId><ArticleId IdType="pubmed">18639629</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Deming Y, Del-&#xc1;guila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C (2016) Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131:925&#x2013;933. 10.1007/s00401-016-1533-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1533-5</ArticleId><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohanka M. (2014) Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. Int J Mol Sci 15:9809&#x2013;9825. 10.3390/ijms15069809</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms15069809</ArticleId><ArticleId IdType="pmc">PMC4100123</ArticleId><ArticleId IdType="pubmed">24893223</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J. (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 17:525&#x2013;530. 10.1016/0166-2236(94)90156-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-2236(94)90156-2</ArticleId><ArticleId IdType="pubmed">7532337</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J. (2008) Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease. Alzheimers Dement 4:S91&#x2013;S97. 10.1016/j.jalz.2007.11.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2007.11.012</ArticleId><ArticleId IdType="pubmed">18632009</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 92:12260&#x2013;12264. 10.1073/pnas.92.26.12260</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.26.12260</ArticleId><ArticleId IdType="pmc">PMC40336</ArticleId><ArticleId IdType="pubmed">8618881</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Polydoro M, Maury EA, Nicholls SB, Reddy SM, Wegmann S, William C, Saqran L, Cagsal-Getkin O, Pitstick R, Beier DR, Carlson GA, Spires-Jones TL, Hyman BT (2015) Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. Acta Neuropathol Commun 3:14. 10.1186/s40478-015-0199-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0199-x</ArticleId><ArticleId IdType="pmc">PMC4371800</ArticleId><ArticleId IdType="pubmed">25853174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK, McLarnon JG (2009) A leaky blood&#x2013;brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J Cell Mol Med 13:2911&#x2013;2925. 10.1111/j.1582-4934.2008.00434.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00434.x</ArticleId><ArticleId IdType="pmc">PMC4498946</ArticleId><ArticleId IdType="pubmed">18657226</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467&#x2013;1472. 10.1212/WNL.43.8.1467</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.8.1467</ArticleId><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Schadt EE, Woo S, Hao K (2012) Bayesian method to predict individual SNP genotypes from gene expression data. Nat Genet 44:603&#x2013;608. 10.1038/ng.2248</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2248</ArticleId><ArticleId IdType="pubmed">22484626</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, Wahl S, Benzinger TLS, Holtzman DM, Morris JC, Fagan AM (2018) Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement 14:1460&#x2013;1469. 10.1016/j.jalz.2018.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.01.013</ArticleId><ArticleId IdType="pmc">PMC6119652</ArticleId><ArticleId IdType="pubmed">29501462</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz TW, Spreng RN (2016) Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat Commun 7:13249. 10.1038/ncomms13249</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13249</ArticleId><ArticleId IdType="pmc">PMC5097157</ArticleId><ArticleId IdType="pubmed">27811848</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz TW, Mur M, Aghourian M, Bedard MA, Spreng RN (2018) Longitudinal Alzheimer's degeneration reflects the spatial topography of cholinergic basal forebrain projections. Cell Rep 24:38&#x2013;46. 10.1016/j.celrep.2018.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.06.001</ArticleId><ArticleId IdType="pmc">PMC8840819</ArticleId><ArticleId IdType="pubmed">29972789</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65:403&#x2013;413. 10.1002/ana.21610</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21610</ArticleId><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, Stevens B, Lemere CA (2017a) Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med 9:eaaf6295. 10.1126/scitranslmed.aaf6295</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6295</ArticleId><ArticleId IdType="pmc">PMC6936623</ArticleId><ArticleId IdType="pubmed">28566429</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, et al. (2017b) ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549:523&#x2013;527. 10.1038/nature24016</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, Tan J (2004) Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 89:337&#x2013;343. 10.1046/j.1471-4159.2004.02347.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2004.02347.x</ArticleId><ArticleId IdType="pubmed">15056277</ArticleId></ArticleIdList></Reference><Reference><Citation>Simchovitz A, Hanan M, Niederhoffer N, Madrer N, Yayon N, Bennett ER, Greenberg DS, Kadener S, Soreq H (2019) NEAT1 is overexpressed in Parkinson's disease substantia nigra and confers drug-inducible neuroprotection from oxidative stress. FASEB J 33:11223&#x2013;11234. 10.1096/fj.201900830R</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201900830R</ArticleId><ArticleId IdType="pmc">PMC6766647</ArticleId><ArticleId IdType="pubmed">31311324</ArticleId></ArticleIdList></Reference><Reference><Citation>Soreq H. (2015) Checks and balances on cholinergic signaling in brain and body function. Trends Neurosci 38:448&#x2013;458. 10.1016/j.tins.2015.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2015.05.007</ArticleId><ArticleId IdType="pubmed">26100140</ArticleId></ArticleIdList></Reference><Reference><Citation>Soreq H, Seidman S (2001) Acetylcholinesterase: new roles for an old actor. Nat Rev Neurosci 2:294&#x2013;302. 10.1038/35067589</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35067589</ArticleId><ArticleId IdType="pubmed">11283752</ArticleId></ArticleIdList></Reference><Reference><Citation>Soreq L, Guffanti A, Salomonis N, Simchovitz A, Israel Z, Bergman H, Soreq H (2014) Long non-coding RNA and alternative splicing modulations in Parkinson's leukocytes identified by RNA sequencing. PLoS Comput Biol 10:e1003517. 10.1371/journal.pcbi.1003517</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003517</ArticleId><ArticleId IdType="pmc">PMC3961179</ArticleId><ArticleId IdType="pubmed">24651478</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90:1977&#x2013;1981. 10.1073/pnas.90.5.1977</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.5.1977</ArticleId><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Araque Caballero M&#xc1;, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C (2016a) Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8:369ra178. 10.1126/scitranslmed.aag1767</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aag1767</ArticleId><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Kleinberger G, Araque Caballero M&#xc1;, Brendel M, Rominger A, Alcolea D, Fortea J, Lle&#xf3; A, Blesa R, Gispert JD, S&#xe1;nchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Trasch&#xfc;tz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, et al. (2016b) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8:466&#x2013;476. 10.15252/emmm.201506123</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201506123</ArticleId><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Morenas-Rodr&#xed;guez E, Kleinberger G, Schlepckow K, Araque Caballero M&#xc1;, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, Levin J, Deming Y, Piccio L, Karch CM, Cruchaga C, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C (2019) Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-beta pathology. Mol Neurodegener 14:1. 10.1186/s13024-018-0301-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0301-5</ArticleId><ArticleId IdType="pmc">PMC6327425</ArticleId><ArticleId IdType="pubmed">30630532</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PF, Fan C, Perou CM (2006) Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141B:261&#x2013;268. 10.1002/ajmg.b.30272</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.30272</ArticleId><ArticleId IdType="pubmed">16526044</ArticleId></ArticleIdList></Reference><Reference><Citation>Takada-Takatori Y, Kume T, Ohgi Y, Fujii T, Niidome T, Sugimoto H, Akaike A (2008) Mechanisms of alpha7-nicotinic receptor up-regulation and sensitization to donepezil induced by chronic donepezil treatment. Eur J Pharmacol 590:150&#x2013;156. 10.1016/j.ejphar.2008.06.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2008.06.027</ArticleId><ArticleId IdType="pubmed">18585378</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Flatz WH, Heinsen H, Bokde AL, Schoenberg SO, St&#xf6;ckel S, Dietrich O, Reiser MF, M&#xf6;ller HJ, Hampel H (2005) Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain 128:2626&#x2013;2644. 10.1093/brain/awh589</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh589</ArticleId><ArticleId IdType="pubmed">16014654</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Flatz W, Ackl N, Grothe M, Kilimann I, Bokde AL, Grinberg L, Amaro E Jr, Kljajevic V, Alho E, Knels C, Ebert A, Heinsen H, Danek A (2014) Brain atrophy in primary progressive aphasia involves the cholinergic basal forebrain and Ayala's nucleus. Psychiatry Res 221:187&#x2013;194. 10.1016/j.pscychresns.2013.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pscychresns.2013.10.003</ArticleId><ArticleId IdType="pmc">PMC4086659</ArticleId><ArticleId IdType="pubmed">24434193</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracey KJ. (2002) The inflammatory reflex. Nature 420:853&#x2013;859. 10.1038/nature01321</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01321</ArticleId><ArticleId IdType="pubmed">12490958</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM (2010) Update on the biomarker core of the Alzheimer's disease neuroimaging initiative subjects. Alzheimers Dement 6:230&#x2013;238. 10.1016/j.jalz.2010.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.03.008</ArticleId><ArticleId IdType="pmc">PMC2867838</ArticleId><ArticleId IdType="pubmed">20451871</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Evans S, Choudary P, Tomita H, Meador-Woodruff J, Molnar M, Li J, Lopez JF, Myers R, Cox D, Watson SJ, Akil H, Jones EG, Bunney WE (2004) Gender-specific gene expression in post-mortem human brain: localization to sex chromosomes. Neuropsychopharmacology 29:373&#x2013;384. 10.1038/sj.npp.1300337</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1300337</ArticleId><ArticleId IdType="pmc">PMC3130534</ArticleId><ArticleId IdType="pubmed">14583743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421:384&#x2013;388. 10.1038/nature01339</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01339</ArticleId><ArticleId IdType="pubmed">12508119</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Gerstein M, Snyder M (2009) RNA-seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10:57&#x2013;63. 10.1038/nrg2484</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg2484</ArticleId><ArticleId IdType="pmc">PMC2949280</ArticleId><ArticleId IdType="pubmed">19015660</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Williams J, Nathans J (2014) Complete morphologies of basal forebrain cholinergic neurons in the mouse. Elife 3:e02444. 10.7554/eLife.02444</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.02444</ArticleId><ArticleId IdType="pmc">PMC4038840</ArticleId><ArticleId IdType="pubmed">24894464</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Dejanovic B, Gandham VD, Gogineni A, Edmonds R, Schauer S, Srinivasan K, Huntley MA, Wang Y, Wang TM, Hedehus M, Barck KH, Stark M, Ngu H, Foreman O, Meilandt WJ, Elstrott J, Chang MC, Hansen DV, Carano RA, et al. (2019) Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep 28:2111&#x2013;2123.e6. 10.1016/j.celrep.2019.07.060</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.07.060</ArticleId><ArticleId IdType="pubmed">31433986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaborszky L, Hoemke L, Mohlberg H, Schleicher A, Amunts K, Zilles K (2008) Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage 42:1127&#x2013;1141. 10.1016/j.neuroimage.2008.05.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2008.05.055</ArticleId><ArticleId IdType="pmc">PMC2577158</ArticleId><ArticleId IdType="pubmed">18585468</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA (2012) Genomic analysis of reactive astrogliosis. J Neurosci 32:6391&#x2013;6410. 10.1523/JNEUROSCI.6221-11.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6221-11.2012</ArticleId><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Davis MD, Martens YA, Shinohara M, Graff-Radford NR, Younkin SG, Wszolek ZK, Kanekiyo T, Bu G (2017) APOE epsilon4/epsilon4 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum Mol Genet 26:2690&#x2013;2700. 10.1093/hmg/ddx155</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx155</ArticleId><ArticleId IdType="pmc">PMC5886091</ArticleId><ArticleId IdType="pubmed">28444230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Xu J (2015) Identification of Alzheimer's disease-associated long noncoding RNAs. Neurobiol Aging 36:2925&#x2013;2931. 10.1016/j.neurobiolaging.2015.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.07.015</ArticleId><ArticleId IdType="pubmed">26318290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31932797</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>142</EndPage><MedlinePgn>131-142</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-019-0695-9</ELocationID><Abstract><AbstractText>Glia have been implicated in Alzheimer's disease (AD) pathogenesis. Variants of the microglia receptor triggering receptor expressed on myeloid cells 2 (TREM2) increase AD risk, and activation of disease-associated microglia (DAM) is dependent on TREM2 in mouse models of AD. We surveyed gene-expression changes associated with AD pathology and TREM2 in 5XFAD mice and in human AD by single-nucleus RNA sequencing. We confirmed the presence of Trem2-dependent DAM and identified a previously undiscovered Serpina3n<sup>+</sup>C4b<sup>+</sup> reactive oligodendrocyte population in mice. Interestingly, remarkably different glial phenotypes were evident in human AD. Microglia signature was reminiscent of IRF8-driven reactive microglia in peripheral-nerve injury. Oligodendrocyte signatures suggested impaired axonal myelination and metabolic adaptation to neuronal degeneration. Astrocyte profiles indicated weakened metabolic coordination with neurons. Notably, the reactive phenotype of microglia was less evident in TREM2-R47H and TREM2-R62H carriers than in non-carriers, demonstrating a TREM2 requirement in both mouse and human AD, despite the marked species-specific differences.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yingyue</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0923-1046</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Wilbur M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andhey</LastName><ForeName>Prabhakar S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swain</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0683-368X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Bluefin Biomedicine, Beverly, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>NanoString, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poliani</LastName><ForeName>Pietro L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Pathology Unit, Molecular and Translational Medicine Department, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cominelli</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pathology Unit, Molecular and Translational Medicine Department, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grover</LastName><ForeName>Shikha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Chemistry &amp; Biochemistry, University of Missouri-St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilfillan</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cella</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulland</LastName><ForeName>Tyler K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaitsev</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Computer Technologies Department, ITMO University, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyashita</LastName><ForeName>Akinori</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2508-9649</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8828-8085</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sainouchi</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakita</LastName><ForeName>Akiyoshi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center and Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center and Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Chemistry &amp; Biochemistry, University of Missouri-St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beausoleil</LastName><ForeName>Sean A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-3356-4641</Identifier><AffiliationInfo><Affiliation>Bluefin Biomedicine, Beverly, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight ADRC, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight ADRC, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artyomov</LastName><ForeName>Maxim N</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0002-1133-4212</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. martyomov@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5222-4987</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. mcolonna@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R15 GM119070</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG059176</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007200</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059082</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051485</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Med. 2020 Jun;26(6):981. doi: 10.1038/s41591-020-0922-4.</RefSource><PMID Version="1">32409732</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests Statement. M. Colonna receives research support from Pfizer, Amgen, Alector and Ono.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31932797</ArticleId><ArticleId IdType="mid">NIHMS1542659</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pii">10.1038/s41591-019-0695-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Long JM &amp; Holtzman DM Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell 179, 312&#x2013;339 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B &amp; Karran E The Cellular Phase of Alzheimer&#x2019;s Disease. Cell 164, 603&#x2013;615 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock DT &amp; Latz E Innate immunity in Alzheimer&#x2019;s disease. Nat. Immunol. 16, 229&#x2013;236 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25689443</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A et al. Alzheimer&#x2019;s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631&#x2013;643 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer&#x2019;s disease. Nature 518, 365&#x2013;369 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfried NT et al. A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer&#x2019;s Disease. Cell Syst. 4, 60&#x2013;72.e4 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269514</ArticleId><ArticleId IdType="pubmed">27989508</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D et al. An environment-dependent transcriptional network specifies human microglia identity. Science 356, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M et al. A transcriptomic atlas of aged human microglia. Nat. Commun 9, 539 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566, 388&#x2013;392 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30760929</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep. 21, 366&#x2013;380 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ, Friedman BA, Dejanovic B &amp; Sheng M Microglia in Brain Development, Homeostasis, and Neurodegeneration. Annu. Rev. Genet (2019) doi:10.1146/annurev-genet-112618-043515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-genet-112618-043515</ArticleId><ArticleId IdType="pubmed">31518519</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK &amp; Colonna M TREM2 - a key player in microglial biology and Alzheimer disease. Nat. Rev. Neurol 14, 667&#x2013;675 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer&#x2019;s Disease Model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J. Exp. Med 212, 287&#x2013;295 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM et al. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. Med jem.20171529 (2018) doi:10.1084/jem.20171529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171529</ArticleId><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P et al. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron 90, 724&#x2013;739 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med 213, 667&#x2013;675 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;kel S et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature 566, 543&#x2013;547 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544546</ArticleId><ArticleId IdType="pubmed">30747918</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L et al. Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. Am. J. Pathol 157, 2003&#x2013;2010 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885780</ArticleId><ArticleId IdType="pubmed">11106573</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson LN et al. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer&#x2019;s disease. J. Neurosci 21, 1444&#x2013;1451 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762932</ArticleId><ArticleId IdType="pubmed">11222634</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler C &amp; Yao S The midkine family of growth factors: diverse roles in nervous system formation and maintenance. Br. J. Pharmacol 171, 905&#x2013;912 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3925029</ArticleId><ArticleId IdType="pubmed">24125182</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinuevo JL et al. Current state of Alzheimer&#x2019;s fluid biomarkers. Acta Neuropathol. (Berl.) 136, 821&#x2013;853 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280827</ArticleId><ArticleId IdType="pubmed">30488277</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T et al. IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype. Cell Rep. 1, 334&#x2013;340 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4158926</ArticleId><ArticleId IdType="pubmed">22832225</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN et al. Coding mutations in SORL1 and Alzheimer&#x2019;s disease. Ann. Neurol 77, 215&#x2013;227 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367199</ArticleId><ArticleId IdType="pubmed">25382023</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelova DM &amp; Brown DR Microglia and the aging brain: are senescent microglia the key to neurodegeneration? J. Neurochem (2019) doi:10.1111/jnc.14860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14860</ArticleId><ArticleId IdType="pubmed">31478208</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou MS et al. Neuron-Astrocyte Metabolic Coupling Protects against Activity-Induced Fatty Acid Toxicity. Cell 177, 1522&#x2013;1535.e14 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31130380</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeon RJ, Jurynec MJ &amp; Buck CR The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar. J. Neurosci 19, 10778&#x2013;10788 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6784959</ArticleId><ArticleId IdType="pubmed">10594061</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz CC et al. Common variation in NCAN, a risk factor for bipolar disorder and schizophrenia, influences local cortical folding in schizophrenia. Psychol. Med 44, 811&#x2013;820 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23795679</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter-Landsberg C The cytoskeleton in oligodendrocytes. Microtubule dynamics in health and disease. J. Mol. Neurosci. MN 35, 55&#x2013;63 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18058074</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecollari V, Nieuwenhuis B &amp; Verhaagen J A perspective on the role of class III semaphorin signaling in central nervous system trauma. Front. Cell. Neurosci 8, (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4209881</ArticleId><ArticleId IdType="pubmed">25386118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H et al. miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS. Dev. Cell 40, 566&#x2013;582.e5 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5569304</ArticleId><ArticleId IdType="pubmed">28350989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L et al. Epidermal growth factor receptor is a preferred target for treating amyloid-&#x3b2;-induced memory loss. Proc. Natl. Acad. Sci. U. S. A 109, 16743&#x2013;16748 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3478595</ArticleId><ArticleId IdType="pubmed">23019586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothhammer V et al. Microglial control of astrocytes in response to microbial metabolites. Nature 557, 724&#x2013;728 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6422159</ArticleId><ArticleId IdType="pubmed">29769726</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA et al. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J. Neurosci 23, 5219&#x2013;5226 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741153</ArticleId><ArticleId IdType="pubmed">12832546</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P et al. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease. JAMA Neurol. 72, 333&#x2013;339 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5924703</ArticleId><ArticleId IdType="pubmed">25599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Harboe M, Torvund-Jensen J, Kjaer-Sorensen K &amp; Laursen LS Ephrin-A1-EphA4 signaling negatively regulates myelination in the central nervous system. Glia 66, 934&#x2013;950 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29350423</ArticleId></ArticleIdList></Reference><Reference><Citation>Tozaki-Saitoh H et al. Transcription factor MafB contributes to the activation of spinal microglia underlying neuropathic pain development. Glia 67, 729&#x2013;740 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30485546</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P et al. Senolytic therapy alleviates A&#x3b2;-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer&#x2019;s disease model. Nat. Neurosci (2019) doi:10.1038/s41593-019-0372-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0372-9</ArticleId><ArticleId IdType="pmc">PMC6605052</ArticleId><ArticleId IdType="pubmed">30936558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yee A, Brewer HB, Das S &amp; Potter H Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372, 92&#x2013;94 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Sanghera DK, Ferrell RE &amp; DeKosky ST APOE*4-associated Alzheimer&#x2019;s disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nat. Genet 10, 486&#x2013;488 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7670501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Additional references for online methods and supplementary material</Title><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E &amp; Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiss GK et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol 26, 317&#x2013;325 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18278033</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlister GC et al. MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. Anal. Chem 86, 7150&#x2013;7158 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4215866</ArticleId><ArticleId IdType="pubmed">24927332</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttlin EL et al. A Tissue-Specific Atlas of Mouse Protein Phosphorylation and Expression. Cell 143, 1174&#x2013;1189 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035969</ArticleId><ArticleId IdType="pubmed">21183079</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias JE &amp; Gygi SP Target-decoy search strategy for mass spectrometry-based proteomics. Methods Mol. Biol. Clifton NJ 604, 55&#x2013;71 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922680</ArticleId><ArticleId IdType="pubmed">20013364</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlister GC et al. Increasing the multiplexing capacity of TMTs using reporter ion isotopologues with isobaric masses. Anal. Chem 84, 7469&#x2013;7478 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715028</ArticleId><ArticleId IdType="pubmed">22880955</ArticleId></ArticleIdList></Reference><Reference><Citation>Beausoleil SA, Vill&#xe9;n J, Gerber SA, Rush J &amp; Gygi SP A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat. Biotechnol 24, 1285&#x2013;1292 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16964243</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jungbauer L, Yu C &amp; LaDu MJ Preparing synthetic A&#x3b2; in different aggregation states. Methods Mol. Biol. Clifton NJ 670, 13&#x2013;32 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752843</ArticleId><ArticleId IdType="pubmed">20967580</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouwens LK et al. A&#x3b2;42 Protofibrils Interact with and Are Trafficked through Microglial-Derived Microvesicles. ACS Chem. Neurosci 9, 1416&#x2013;1425 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29543435</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun 10, 1523 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Skillb&#xe4;ck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, Weiner MW, and Blennow K (2016). Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 73, 60&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5624219</ArticleId><ArticleId IdType="pubmed">26524180</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K, and Alzheimer&#x2019;s Disease Neuroimaging Initiative (2017). Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 74, 557&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, et al. (2010). YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer&#x2019;s disease. Biol. Psychiatry 68, 903&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3011944</ArticleId><ArticleId IdType="pubmed">21035623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayton S, Faux NG, and Bush AI (2015). Ferritin levels in the cerebrospinal fluid predict Alzheimer&#x2019;s disease outcomes and are regulated by APOE. Nat. Commun 6, 1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479012</ArticleId><ArticleId IdType="pubmed">25988319</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C-T, Liao Y-C, Lee W-J, Wang S-J, and Fuh J-L (2016). SORL1 gene, plasma biomarkers, and the risk of Alzheimer&#x2019;s disease for the Han Chinese population in Taiwan. Alzheimers Res. Ther 8, 53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5200969</ArticleId><ArticleId IdType="pubmed">28034305</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L-H, Westerteicher C, Wang X-H, Kratzer M, Tsolakidou A, Jiang M, Grimmer T, Laws SM, Alexopoulos P, Bujo H, et al. (2012). SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer&#x2019;s disease. Eur. Arch. Psychiatry Clin. Neurosci 262, 529&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286501</ArticleId></ArticleIdList></Reference><Reference><Citation>Forlenza OV, Diniz BS, Teixeira AL, Radanovic M, Talib LL, Rocha NP, and Gattaz WF (2015). Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer&#x2019;s Disease. Neuromolecular Med 17, 326&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">26138246</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P, Caselli RJ, Baxter L, Serrano G, Yin J, Beach TG, Reiman EM, and Shi J (2015). Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease. JAMA Neurol. 72, 333&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5924703</ArticleId><ArticleId IdType="pubmed">25599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma VR, Varma S, An Y, Hohman TJ, Seddighi S, Casanova R, Beri A, Dammer EB, Seyfried NT, Pletnikova O, et al. (2017). Alpha-2 macroglobulin in Alzheimer&#x2019;s disease: a marker of neuronal injury through the RCAN1 pathway. Mol. Psychiatry 22, 13&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726508</ArticleId><ArticleId IdType="pubmed">27872486</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31940483</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>14</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>GluN2A NMDA Receptor Enhancement Improves Brain Oscillations, Synchrony, and Cognitive Functions in Dravet Syndrome and Alzheimer's Disease Models.</ArticleTitle><Pagination><StartPage>381</StartPage><EndPage>396.e4</EndPage><MedlinePgn>381-396.e4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2019.12.030</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(19)31680-8</ELocationID><Abstract><AbstractText>NMDA receptors (NMDARs) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and neurodegenerative disorders. However, the in&#xa0;vivo consequences and therapeutic potential of pharmacologically enhancing NMDAR function via allosteric modulation are largely unknown. We examine the in&#xa0;vivo effects of GNE-0723, a positive allosteric modulator of GluN2A-subunit-containing NMDARs, on brain network and cognitive functions in mouse models of Dravet syndrome (DS) and Alzheimer's disease (AD). GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency (12-20&#xa0;Hz) oscillations. Interestingly, DS and AD mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony. GNE-0723 treatment reduces aberrant low-frequency oscillations and epileptiform discharges and improves cognitive functions in DS and AD mouse models. GluN2A-subunit-containing NMDAR enhancers may have therapeutic benefits in brain disorders with network hypersynchrony and cognitive impairments.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Jesse E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA. Electronic address: hanson.jesse@gene.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Keran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elstrott</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Imaging, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saillet</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Abdullah S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simms</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yelin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tzu-Ming</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zhiyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liederer</LastName><ForeName>Bianca M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deshmukh</LastName><ForeName>Gauri</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solanoy</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Connie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmaceuticals, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sellers</LastName><ForeName>Benjamin D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Department of Discovery Chemistry, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volgraf</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Discovery Chemistry, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Jacob B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Discovery Chemistry, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hackos</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weimer</LastName><ForeName>Robby M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA; Department of Biomedical Imaging, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>T Michael</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palop</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: jorge.palop@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K99 AG062776</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047313</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062629</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062234</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003521">Cyclopropanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C510307">cyclopropanecarbonitrile</NameOfSubstance></Chemical><Chemical><RegistryNumber>VH92ICR8HX</RegistryNumber><NameOfSubstance UI="C440500">N-methyl D-aspartate receptor subtype 2A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003521" MajorTopicYN="N">Cyclopropanes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004831" MajorTopicYN="N">Epilepsies, Myoclonic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP</Keyword><Keyword MajorTopicYN="N">EEG</Keyword><Keyword MajorTopicYN="N">J20</Keyword><Keyword MajorTopicYN="N">MK-801</Keyword><Keyword MajorTopicYN="N">Nav1.1</Keyword><Keyword MajorTopicYN="N">SCN1A</Keyword><Keyword MajorTopicYN="N">epilepsy</Keyword><Keyword MajorTopicYN="N">interneuron</Keyword><Keyword MajorTopicYN="N">learning</Keyword><Keyword MajorTopicYN="N">memory</Keyword></KeywordList><CoiStatement>DECLARATION OF INTERESTS. All Genentech authors are current or former employees of Genentech Inc. J.J.P. received research funding from Genentech Inc. Y.C. is currently employed by the Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. H.S. and K.S.-L. are currently employed by Denali Therapeutics, T.-M.W. by Merck, and J.B.S. by E-Scape Bio. M.S. is currently employed by the Broad Institute of MIT and Harvard.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31940483</ArticleId><ArticleId IdType="mid">NIHMS1550149</ArticleId><ArticleId IdType="pmc">PMC7017907</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2019.12.030</ArticleId><ArticleId IdType="pii">S2211-1247(19)31680-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Addis L, Virdee JK, Vidler LR, Collier DA, Pal DK, and Ursu D (2017). Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency - molecular profiling and functional rescue. Sci. Rep 7, 66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427847</ArticleId><ArticleId IdType="pubmed">28242877</ArticleId></ArticleIdList></Reference><Reference><Citation>Adell A, Jim&#xe9;nez-S&#xe1;nchez L, L&#xf3;pez-Gil X, and Rom&#xf3;n T (2012). Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Schizophr. Bull 38, 9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245580</ArticleId><ArticleId IdType="pubmed">21965469</ArticleId></ArticleIdList></Reference><Reference><Citation>Boly M, Jones B, Findlay G, Plumley E, Mensen A, Hermann B, Tononi G, and Maganti R (2017). Altered sleep homeostasis correlates with cognitive impairment in patients with focal epilepsy. Brain 140, 1026&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837505</ArticleId><ArticleId IdType="pubmed">28334879</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce-Rustay JM, and Holmes A (2006). Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 31, 2405&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">16482087</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvill GL, Regan BM, Yendle SC, O&#x2019;Roak BJ, Lozovaya N, Bruneau N, Burnashev N, Khan A, Cook J, Geraghty E, et al. (2013). GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat. Genet 45, 1073&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868952</ArticleId><ArticleId IdType="pubmed">23933818</ArticleId></ArticleIdList></Reference><Reference><Citation>Catterall WA, Kalume F, and Oakley JC (2010). NaV1.1 channels and epilepsy. J. Physiol 588, 1849&#x2013;1859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901973</ArticleId><ArticleId IdType="pubmed">20194124</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SM, Tsien RW, Goff DC, and Halassa MM (2015). The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr. Res 167, 98&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724170</ArticleId><ArticleId IdType="pubmed">25583246</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett BF, Leiser SC, Ling HP, Nagy R, Breysse N, Zhang X, Hazra A, Brown JT, Randall AD, Wood A, et al. (2013). Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer&#x2019;s disease. J. Neurosci 33, 7020&#x2013;7026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618875</ArticleId><ArticleId IdType="pubmed">23595759</ArticleId></ArticleIdList></Reference><Reference><Citation>Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, Al-monte A, Murray E, Mosely C, Barber J, et al. (2007). Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J. Physiol 581, 107&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2075223</ArticleId><ArticleId IdType="pubmed">17303642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao XM, Hashimoto T, and Tamminga CA (1998). Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain. Synapse 29, 14&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">9552172</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao K, Tankovic A, Zhang Y, Kusumoto H, Zhang J, Chen W, Xiang-Wei W, Shaulsky GH, Hu C, Traynelis SF, et al. (2017). A de novo loss-of-function GRIN2A mutation associated with childhood focal epilepsy and acquired epileptic aphasia. PLoS ONE 12, e0170818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5300259</ArticleId><ArticleId IdType="pubmed">28182669</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheyara AL, Ponnusamy R, Djukic B, Craft RJ, Ho K, Guo W, Finucane MM, Sanchez PE, and Mucke L (2014). Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann. Neurol 76, 443&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338764</ArticleId><ArticleId IdType="pubmed">25042160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Burgos G, and Lewis DA (2012). NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr. Bull 38, 950&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446219</ArticleId><ArticleId IdType="pubmed">22355184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackos DH, and Hanson JE (2017). Diverse modes of NMDA receptor positive allosteric modulation: mechanisms and consequences. Neuropharmacology 112, 34&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">27484578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackos DH, Lupardus PJ, Grand T, Chen Y, Wang TM, Reynen P, Gustafson A, Wallweber HJ, Volgraf M, Sellers BD, et al. (2016). Positive allosteric modulators of GluN2A-containing NMDARs with distinct modes of action and impacts on circuit function. Neuron 89, 983&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">26875626</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamm V, H&#xe9;raud C, Bott J-B, Herbeaux K, Strittmatter C, Mathis C, and Goutagny R (2017). Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimer&#x2019;s disease. Sci. Adv 3, e1601068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325539</ArticleId><ArticleId IdType="pubmed">28275722</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Tai C, Westenbroek RE, Yu FH, Cheah CS, Potter GB, Rubenstein JL, Scheuer T, de la Iglesia HO, and Catterall WA (2012). Autistic-like behaviour in Scn1a+/&#x2212; mice and rescue by enhanced GABA-mediated neurotransmission. Nature 489, 385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448848</ArticleId><ArticleId IdType="pubmed">22914087</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson JE, Meilandt WJ, Gogineni A, Reynen P, Herrington J, Weimer RM, Scearce-Levie K, and Zhou Q (2014). Chronic GluN2B antagonism disrupts behavior in wild-type mice without protecting against synapse loss or memory impairment in Alzheimer&#x2019;s disease mouse models. J. Neurosci 34, 8277&#x2013;8288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608240</ArticleId><ArticleId IdType="pubmed">24920631</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham GE, Fukunaga Y, and Bading H (2002). Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci 5, 405&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">11953750</ArticleId></ArticleIdList></Reference><Reference><Citation>Homayoun H, and Moghaddam B (2007). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci 27, 11496&#x2013;11500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2954603</ArticleId><ArticleId IdType="pubmed">17959792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu NW, Klyubin I, Anwyl R, and Rowan MJ (2009). GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo. Proc. Natl. Acad. Sci. USA 106, 20504&#x2013;20509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787128</ArticleId><ArticleId IdType="pubmed">19918059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu T, Xiao Z, Mao R, Chen B, Lu MN, Tong J, Mei R, Li SS, Xiao ZC, Zhang LF, and Xiyang YB (2017). Navb2 knockdown improves cognition in APP/PS1 mice by partially inhibiting seizures and APP amyloid processing. Oncotarget 8, 99284&#x2013;99295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5725092</ArticleId><ArticleId IdType="pubmed">29245901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes P, Dragunow M, Beilharz E, Lawlor P, and Gluckman P (1993). MK801 induces immediate-early gene proteins and BDNF mRNA in rat cerebrocortical neurones. Neuroreport 4, 183&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">8453057</ArticleId></ArticleIdList></Reference><Reference><Citation>Javitt DC, and Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">1654746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadotani H, Hirano T, Masugi M, Nakamura K, Nakao K, Katsuki M, and Nakanishi S (1996). Motor discoordination results from combined gene disruption of the NMDA receptor NR2A and NR2C subunits, but not from single disruption of the NR2A or NR2C subunit. J. Neurosci 16, 7859&#x2013;7867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579203</ArticleId><ArticleId IdType="pubmed">8987814</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe LA, Bernardinelli Y, and Muller D (2013). GluN3A: an NMDA receptor subunit with exquisite properties and functions. Neural Plast. 2013, 145387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3872238</ArticleId><ArticleId IdType="pubmed">24386575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, Pettingell WH, He P, Lee VM, Woolf CJ, and Kovacs DM (2007). BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat. Cell Biol. 9, 755&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747787</ArticleId><ArticleId IdType="pubmed">17576410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotermanski SE, and Johnson JW (2009). Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer&#x2019;s drug memantine. J. Neurosci 29, 2774&#x2013;2779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679254</ArticleId><ArticleId IdType="pubmed">19261873</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr., and Charney DS (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">8122957</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarewicz MT, Ehrlichman RS, Maxwell CR, Gandal MJ, Finkel LH, and Siegel SJ (2010). Ketamine modulates theta and gamma oscillations. J. Cogn. Neurosci 22, 1452&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pubmed">19583475</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemke JR, Lal D, Reinthaler EM, Steiner I, Nothnagel M, Alber M, Geider K, Laube B, Schwake M, Finsterwalder K, et al. (2013). Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat. Genet 45, 1067&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">23933819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesca G, Rudolf G, Bruneau N, Lozovaya N, Labalme A, Boutry-Kryza N, Salmi M, Tsintsadze T, Addis L, Motte J, et al. (2013). GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat. Genet 45, 1061&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">23933820</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, and Selkoe DJ (2011). Soluble Ab oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci 31, 6627&#x2013;6638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA (2005). The molecular basis of memantine action in Alzheimer&#x2019;s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res. 2, 155&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">15974913</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis RP, Lee J, and Stephenson R (2004). Design and validation of a computer-based sleep-scoring algorithm. J. Neurosci. Methods 133, 71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">14757347</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Losa M, Tracy TE, Ma K, Verret L, Clemente-Perez A, Khan AS, Cobos I, Ho K, Gan L, Mucke L, et al. (2018). Nav1.1-overexpressing interneuron transplants restore brain rhythms and cognition in a mouse model of Alzheimer&#x2019;s disease. Neuron 98, 75&#x2013;89.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886814</ArticleId><ArticleId IdType="pubmed">29551491</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto JY, Stead M, Kucewicz MT, Matsumoto AJ, Peters PA, Brinkmann BH, Danstrom JC, Goerss SJ, Marsh WR, Meyer FB, and Worrell GA (2013). Network oscillations modulate interictal epileptiform spike rate during human memory. Brain 136, 2444&#x2013;2456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722348</ArticleId><ArticleId IdType="pubmed">23803305</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller OH, Moran JT, and Hall BJ (2016). Two cellular hypotheses explaining the initiation of ketamine&#x2019;s antidepressant actions: direct inhibition and disinhibition. Neuropharmacology 100, 17&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">26211972</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra P, and Bokil H (2008). Observed Brain Dynamics (Oxford University Press; ).</Citation></Reference><Reference><Citation>Mony L, Kew JN, Gunthorpe MJ, and Paoletti P (2009). Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br. J. Pharmacol 157, 1301&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765303</ArticleId><ArticleId IdType="pubmed">19594762</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, and McConlogue L (2000). High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci 20, 4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogiwara I, Miyamoto H, Morita N, Atapour N, Mazaki E, Inoue I, Takeuchi T, Itohara S, Yanagawa Y, Obata K, et al. (2007). Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J. Neurosci 27, 5903&#x2013;5914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672241</ArticleId><ArticleId IdType="pubmed">17537961</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, and Mucke L (2016). Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat. Rev. Neurosci 17, 777&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8162106</ArticleId><ArticleId IdType="pubmed">27829687</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, et al. (2007). Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron 55, 697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P, Bellone C, and Zhou Q (2013). NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci 14, 383&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">23686171</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadia S, and Hardingham GE (2007). The dichotomy of NMDA receptor signaling. Neuroscientist 13, 572&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830536</ArticleId><ArticleId IdType="pubmed">18000068</ArticleId></ArticleIdList></Reference><Reference><Citation>Perszyk RE, DiRaddo JO, Strong KL, Low CM, Ogden KK, Khatri A, Vargish GA, Pelkey KA, Tricoire L, Liotta DC, et al. (2016). GluN2D-containing N-methyl-d-aspartate receptors mediate synaptic transmission in hippocampal interneurons and regulate interneuron activity. Mol. Pharmacol 90, 689&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5118640</ArticleId><ArticleId IdType="pubmed">27625038</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard N, Takesian AE, Fagiolini M, and Hensch TK (2019). NMDA 2A receptors in parvalbumin cells mediate sex-specific rapid ketamine response on cortical activity. Mol. Psychiatry 24, 828&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6756203</ArticleId><ArticleId IdType="pubmed">30696941</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivolta D, Heidegger T, Scheller B, Sauer A, Schaum M, Birkner K, Singer W, Wibral M, and Uhlhaas PJ (2015). Ketamine dysregulates the amplitude and connectivity of high-frequency oscillations in cortical-subcortical networks in humans: evidence from resting-state magnetoencephalography-recordings. Schizophr. Bull 41, 1105&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4535642</ArticleId><ArticleId IdType="pubmed">25987642</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinstein M, Han S, Tai C, Westenbroek RE, Hunker A, Scheuer T, and Catterall WA (2015). Dissecting the phenotypes of Dravet syndrome by gene deletion. Brain 138, 2219&#x2013;2233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5022661</ArticleId><ArticleId IdType="pubmed">26017580</ArticleId></ArticleIdList></Reference><Reference><Citation>Saletu B, Anderer P, and Saletu-Zyhlarz GM (2006). EEG topography and tomography (LORETA) in the classification and evaluation of the pharmacodynamics of psychotropic drugs. Clin. EEG Neurosci. 37, 66&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">16733939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, and Mucke L (2012). Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer&#x2019;s disease model. Proc. Natl. Acad. Sci. USA 109, E2895&#x2013;E2903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479491</ArticleId><ArticleId IdType="pubmed">22869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapkota K, Mao Z, Synowicki P, Lieber D, Liu M, Ikezu T, Gautam V, and Monaghan DT (2016). GluN2D N-methyl-d-aspartate receptor subunit contribution to the stimulation of brain activity and gamma oscillations by ketamine: implications for schizophrenia. J. Pharmacol. Exp. Ther 356, 702&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4767398</ArticleId><ArticleId IdType="pubmed">26675679</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A, Macosko EZ, Wysoker A, Goldman M, Krienen FM, de Rivera H, Bien E, Baum M, Bortolin L, Wang S, et al. (2018). Molecular diversity and specializations among the cells of the adult mouse brain. Cell 174, 1015&#x2013;1030.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Serraz B, Grand T, and Paoletti P (2016). Altered zinc sensitivity of NMDA receptors harboring clinically-relevant mutations. Neuropharmacology 109, 196&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">27288002</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaffer CL, Hurst RS, Scialis RJ, Osgood SM, Bryce DK, Hoffmann WE, Lazzaro JT, Hanks AN, Lotarski S, Weber ML, et al. (2013). Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574. J. Pharmacol. Exp. Ther 347, 212&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">23899905</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, and Greengard P (2005). Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nat. Neurosci 8, 1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai C, Abe Y, Westenbroek RE, Scheuer T, and Catterall WA (2014). Impaired excitability of somatostatin- and parvalbumin-expressing cortical interneurons in a mouse model of Dravet syndrome. Proc. Natl. Acad. Sci. USA 111, E3139&#x2013;E3148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4121787</ArticleId><ArticleId IdType="pubmed">25024183</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanahira C, Higo S, Watanabe K, Tomioka R, Ebihara S, Kaneko T, and Tamamaki N (2009). Parvalbumin neurons in the forebrain as revealed by parvalbumin-Cre transgenic mice. Neurosci. Res 63, 213&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">19167436</ArticleId></ArticleIdList></Reference><Reference><Citation>Texid&#xf3; L, Mart&#xed;n-Satu&#xe9; M, Alberdi E, Solsona C, and Matute C (2011). Amyloid b peptide oligomers directly activate NMDA receptors. Cell Calcium 49, 184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">21349580</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, and Dingledine R (2010). Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev 62, 405&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964903</ArticleId><ArticleId IdType="pubmed">20716669</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, and Strittmatter SM (2012). Alzheimer amyloid-b oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci 15, 1227&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431439</ArticleId><ArticleId IdType="pubmed">22820466</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lier H, Drinkenburg WH, van Eeten YJ, and Coenen AM (2004). Effects of diazepam and zolpidem on EEG beta frequencies are behavior-specific in rats. Neuropharmacology 47, 163&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">15223295</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaudano AE, Ruggieri A, Avanzini P, Gessaroli G, Cantalupo G, Coppola A, Sisodiya SM, and Meletti S (2017). Photosensitive epilepsy is associated with reduced inhibition of alpha rhythm generating networks. Brain 140, 981&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837657</ArticleId><ArticleId IdType="pubmed">28334965</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, et al. (2012). Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemure E, Volgraf M, Jiang Y, Wu G, Ly CQ, Yuen PW, Lu A, Luo X, Liu M, Zhang S, et al. (2016). GluN2A-selective pyridopyrimidinone series of NMDAR positive allosteric modulators with an improved in vivo profile. ACS Med. Chem. Lett 8, 84&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5238474</ArticleId><ArticleId IdType="pubmed">28105280</ArticleId></ArticleIdList></Reference><Reference><Citation>Volgraf M, Sellers BD, Jiang Y, Wu G, Ly CQ, Villemure E, Pastor RM, Yuen PW, Lu A, Luo X, et al. (2016). Discovery of GluN2A-selective NMDA receptor positive allosteric modulators (PAMs): tuning deactivation kinetics via structure-based design. J. Med. Chem 59, 2760&#x2013;2779.</Citation><ArticleIdList><ArticleId IdType="pubmed">26919761</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia P, Chen HS, Zhang D, and Lipton SA (2010). Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J. Neurosci 30, 11246&#x2013;11250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932667</ArticleId><ArticleId IdType="pubmed">20720132</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakawa K (2009). Molecular basis of severe myoclonic epilepsy in infancy. Brain Dev. 31, 401&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">19203854</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Snyder LB, Balakrishnan A, Brown JM, Sivarao DV, Easton A, Fernandes A, Gulianello M, Hanumegowda UM, Huang H, et al. (2016). Discovery and preclinical evaluation of BMS-955829, a potent positive allosteric modulator of mGluR5. ACS Med. Chem. Lett 7, 289&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4789665</ArticleId><ArticleId IdType="pubmed">26985317</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, Spain WJ, McKnight GS, Scheuer T, and Catterall WA (2006). Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat. Neurosci 9, 1142&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921370</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan H, Hansen KB, Zhang J, Pierson TM, Markello TC, Fajardo KV, Holloman CM, Golas G, Adams DR, Boerkoel CF, et al. (2014). Functional analysis of a de novo GRIN2A missense mutation associated with early-onset epileptic encephalopathy. Nat. Commun 5, 3251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934797</ArticleId><ArticleId IdType="pubmed">24504326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zajaczkowski W, Czyrak A, and Wedzony K (2003). A competitive antagonist of NMDA receptors CGP 40116 attenuates experimental symptoms of schizophrenia evoked by MK-801. Pol. J. Pharmacol 55, 703&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">14704466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, and Sheng M (2013). NMDA receptors in nervous system diseases. Neuropharmacology 74, 69&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">23583930</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31941827</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>526</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>&#x3b2;-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3&#x3b2;/tau cascade.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaay6931</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aay6931</ELocationID><Abstract><AbstractText>The brain noradrenergic system is critical for normal cognition and is affected at early stages in Alzheimer's disease (AD). Here, we reveal a previously unappreciated direct role of norepinephrine signaling in connecting &#x3b2;-amyloid (A&#x3b2;) and tau, two key pathological components of AD pathogenesis. Our results show that A&#x3b2; oligomers bind to an allosteric site on &#x3b1;<sub>2A</sub> adrenergic receptor (&#x3b1;<sub>2A</sub>AR) to redirect norepinephrine-elicited signaling to glycogen synthase kinase 3&#x3b2; (GSK3&#x3b2;) activation and tau hyperphosphorylation. This norepinephrine-dependent mechanism sensitizes pathological GSK3&#x3b2;/tau activation in response to nanomolar accumulations of extracellular A&#x3b2;, which is 50- to 100-fold lower than the amount required to activate GSK3&#x3b2; by A&#x3b2; alone. The significance of our findings is supported by in vivo evidence in two mouse models, human tissue sample analysis, and longitudinal clinical data. Our study provides translational insights into mechanisms underlying A&#x3b2; proteotoxicity, which might have strong implications for the interpretation of A&#x3b2; clearance trial results and future drug design and for understanding the selective vulnerability of noradrenergic neurons in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6403-9009</Identifier><AffiliationInfo><Affiliation>Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gannon</LastName><ForeName>Mary</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9591-9711</Identifier><AffiliationInfo><Affiliation>Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yunjia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Shun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8994-5542</Identifier><AffiliationInfo><Affiliation>Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Sixue</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2981-9154</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Southern Research Institute, Birmingham, AL 35205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-9734-8809</Identifier><AffiliationInfo><Affiliation>Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Jiahui</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3016-1249</Identifier><AffiliationInfo><Affiliation>Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sha</LastName><ForeName>Bingdong</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5196-2125</Identifier><AffiliationInfo><Affiliation>Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhenghui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9659-9251</Identifier><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1970-6903</Identifier><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0002-5291-1469</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA 98104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Kai</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5415-9020</Identifier><AffiliationInfo><Affiliation>Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials><Identifier Source="ORCID">0000-0002-1810-9763</Identifier><AffiliationInfo><Affiliation>Alzheimer's Disease Center, Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-1079-5914</Identifier><AffiliationInfo><Affiliation>Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. qinwang@uab.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH081917</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056815</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG053760</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG072122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG035982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064664</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG058839</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b><i>Competing interests:</i></b> E.D.R. has served on scientific advisory boards for Biogen, AVROBIO, AGTC, and Novartis. Q.W., M.G., F.Z., Y.C., K.J., S.Y., W.F., B.S., J.T., Z.L., S.Z., H.X., T.Saito, T.Saido have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31941827</ArticleId><ArticleId IdType="mid">NIHMS1669492</ArticleId><ArticleId IdType="pmc">PMC7891768</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aay6931</ArticleId><ArticleId IdType="pii">12/526/eaay6931</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ, Hardy J, The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Duff K, Linking Abeta and tau in late-onset Alzheimer&#x2019;s disease: a dual pathway hypothesis. Neuron 60, 534&#x2013;542 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA, Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science 256, 184&#x2013;185 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco JC, Li C, Bodea LG, Martinez-Marmol R, Meunier FA, Gotz J, Amyloid-beta and tau complexity - towards improved biomarkers and targeted therapies. Nature reviews. Neurology 14, 22&#x2013;39 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29242522</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, Hou J, Ping J, Cai D, Advances in developing novel therapeutic strategies for Alzheimer&#x2019;s disease. Molecular neurodegeneration 13, 64 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6291983</ArticleId><ArticleId IdType="pubmed">30541602</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L, Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science 316, 750&#x2013;754 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancu IC, Vasconcelos B, Terwel D, Dewachter I, Models of beta-amyloid induced Tau-pathology: the long and &#x201c;folded&#x201d; road to understand the mechanism. Molecular neurodegeneration 9, 51 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255655</ArticleId><ArticleId IdType="pubmed">25407337</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Maeda S, Vossel K, Mucke L, The many faces of tau. Neuron 70, 410&#x2013;426 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319390</ArticleId><ArticleId IdType="pubmed">21555069</ArticleId></ArticleIdList></Reference><Reference><Citation>Simic G, Babic Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milosevic N, Bazadona D, Buee L, de Silva R, Di Giovanni G, Wischik C, Hof PR, Tau Protein Hyperphosphorylation and Aggregation in Alzheimer&#x2019;s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules 6, 6 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4808800</ArticleId><ArticleId IdType="pubmed">26751493</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Holzer M, Rub U, Waldmann G, Gunzel S, Zedlick D, Schober R, Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Experimental neurology 163, 98&#x2013;110 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10785448</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross JA, Reyes BAS, Van Bockstaele EJ, Amyloid beta peptides, locus coeruleus-norepinephrine system and dense core vesicles. Brain research 1702, 46&#x2013;53 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375485</ArticleId><ArticleId IdType="pubmed">29577889</ArticleId></ArticleIdList></Reference><Reference><Citation>Gannon M, Che P, Chen Y, Jiao K, Roberson ED, Wang Q, Noradrenergic dysfunction in Alzheimer&#x2019;s disease. Front Neurosci 9, 220 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469831</ArticleId><ArticleId IdType="pubmed">26136654</ArticleId></ArticleIdList></Reference><Reference><Citation>Gannon M, Wang Q, Complex noradrenergic dysfunction in Alzheimer&#x2019;s disease: Low norepinephrine input is not always to blame. Brain research, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6855395</ArticleId><ArticleId IdType="pubmed">29307592</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskind MA, Peskind ER, Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer disease and associated disorders 8 Suppl 3, 54&#x2013;60 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7999346</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann N, Lanctot KL, Khan LR, The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 16, 261&#x2013;276 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15377733</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, Raskind MA, Peskind ER, Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 17, 744&#x2013;751 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842091</ArticleId><ArticleId IdType="pubmed">19700947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S, et al., Alzheimer&#x2019;s disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 4, 1077&#x2013;1086 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7704571</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, Chen DC, Klein PS, Lee VM, Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272, 25326&#x2013;25332 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9312151</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J, Lithium inhibits Alzheimer&#x2019;s disease-like tau protein phosphorylation in neurons. FEBS Lett 411, 183&#x2013;188 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9271202</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolan PJ, Johnson GV, The role of tau kinases in Alzheimer&#x2019;s disease. Curr Opin Drug Discov Devel 13, 595&#x2013;603 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941661</ArticleId><ArticleId IdType="pubmed">20812151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, Killick R, Lovestone S, The GSK3 hypothesis of Alzheimer&#x2019;s disease. Journal of neurochemistry 104, 1433&#x2013;1439 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073119</ArticleId><ArticleId IdType="pubmed">18088381</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A, GSK-3 is essential in the pathogenesis of Alzheimer&#x2019;s disease. Journal of Alzheimer&#x2019;s disease : JAD 9, 309&#x2013;317 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16914869</ArticleId></ArticleIdList></Reference><Reference><Citation>Maqbool M, Mobashir M, Hoda N, Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer&#x2019;s disease. Eur J Med Chem 107, 63&#x2013;81 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26562543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hein L, Adrenoceptors and signal transduction in neurons. Cell Tissue Res. 326, 541&#x2013;551 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16896948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottingham C, Chen H, Chen Y, Peng Y, Wang Q, Genetic variations of alpha(2)-adrenergic receptors illuminate the diversity of receptor functions. Current topics in membranes 67, 161&#x2013;190 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21771490</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark RB, Knoll BJ, G protein pathways. Iyengar R, Hildebrandt JD, Eds., (Academic Press, 2002), vol. 343, pp. 506&#x2013;529.</Citation></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR, Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol.Eng 17, 157&#x2013;165 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC, Single App knock-in mouse models of Alzheimer&#x2019;s disease. Nat Neurosci 17, 661&#x2013;663 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ, Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nature medicine 14, 837&#x2013;842 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CD, Buck MA, Fraser CM, Site-directed mutagenesis of alpha 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol Pharmacol 40, 168&#x2013;179 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1678850</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Li Y, Zhang Y, Chen Y, Shields AD, Winder DG, Angelotti T, Jiao K, Limbird LE, Zhou Y, Wang Q, Epitope-tagged Receptor Knock-in Mice Reveal That Differential Desensitization of {alpha}2-Adrenergic Responses Is because of Ligand-selective Internalization. J.Biol.Chem 284, 13233&#x2013;13243 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676055</ArticleId><ArticleId IdType="pubmed">19276088</ArticleId></ArticleIdList></Reference><Reference><Citation>May LT, Leach K, Sexton PM, Christopoulos A, Allosteric modulation of G protein-coupled receptors. Annual review of pharmacology and toxicology 47, 1&#x2013;51 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17009927</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster DJ, Conn PJ, Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders. Neuron 94, 431&#x2013;446 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482176</ArticleId><ArticleId IdType="pubmed">28472649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirouac L, Rajic AJ, Cribbs DH, Padmanabhan J, Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer&#x2019;s Disease. eNeuro 4, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5367084</ArticleId><ArticleId IdType="pubmed">28374012</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, Bru-Mercier G, Dickinson B, Scullion S, Sheng M, Collingridge G, Cho K, Abeta(1&#x2013;42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Nat Neurosci 14, 545&#x2013;547 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21441921</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ, Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535&#x2013;539 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, Zhang M, Yang Y, Cai F, Woodgett J, Song W, Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. The Journal of clinical investigation 123, 224&#x2013;235 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3533290</ArticleId><ArticleId IdType="pubmed">23202730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Peng Y, Che P, Gannon M, Liu Y, Li L, Bu G, van Groen T, Jiao K, Wang Q, alpha(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. Proc Natl Acad Sci U S A 111, 17296&#x2013;17301 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4260556</ArticleId><ArticleId IdType="pubmed">25404298</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, Goate AM, Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Molecular neurodegeneration 12, 43 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L, Zhang B, Gathagan RJ, Yue C, Dengler C, Stieber A, Nitla M, Coulter DA, Abel T, Brunden KR, Trojanowski JQ, Lee VM, Amyloid-beta plaques enhance Alzheimer&#x2019;s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nature medicine 24, 29&#x2013;38 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="pubmed">29200205</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O&#x2019;Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM, In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23, 8844&#x2013;8853 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Nyborg AC, Murphy MP, Chang L, Stanczyk FZ, Golde TE, Pike CJ, Androgens modulate beta-amyloid levels in male rat brain. Journal of neurochemistry 87, 1052&#x2013;1055 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14622134</ArticleId></ArticleIdList></Reference><Reference><Citation>Novo M, Freire S, Al-Soufi W, Critical aggregation concentration for the formation of early Amyloid-beta (1&#x2013;42) oligomers. Sci Rep 8, 1783 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5789034</ArticleId><ArticleId IdType="pubmed">29379133</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN, Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association 5, 18&#x2013;29 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663406</ArticleId><ArticleId IdType="pubmed">19118806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW, Drugs for allosteric sites on receptors. Annual review of pharmacology and toxicology 54, 165&#x2013;184 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063350</ArticleId><ArticleId IdType="pubmed">24111540</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottingham C, Chen Y, Jiao K, Wang Q, The Antidepressant Desipramine Is an Arrestin-biased Ligand at the {alpha}2A-Adrenergic Receptor Driving Receptor Down-regulation in Vitro and in Vivo. J.Biol.Chem 286, 36063&#x2013;36075 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3195605</ArticleId><ArticleId IdType="pubmed">21859713</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Liu Y, Cottingham C, McMahon L, Jiao K, Greengard P, Wang Q, Neurabin scaffolding of adenosine receptor and RGS4 regulates anti-seizure effect of endogenous adenosine. J Neurosci 32, 2683&#x2013;2695 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310383</ArticleId><ArticleId IdType="pubmed">22357852</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ, Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nature medicine 14, 837&#x2013;842 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ, Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108, 5819&#x2013;5824 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirk SD, Mitchell MB, Shaughnessy LW, Sherman JC, Locascio JJ, Weintraub S, Atri A, A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery. Alzheimers Res Ther 3, 32 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308021</ArticleId><ArticleId IdType="pubmed">22078663</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, Sunahara RK, Chae PS, Gellman SH, Dror RO, Shaw DE, Weis WI, Caffrey M, Gmeiner P, Kobilka BK, Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 469, 236&#x2013;240 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074335</ArticleId><ArticleId IdType="pubmed">21228876</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran L, Basdevant N, Prevost C, Ha-Duong T, Structure of ring-shaped Abeta(4)(2) oligomers determined by conformational selection. Sci Rep 6, 21429 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751476</ArticleId><ArticleId IdType="pubmed">26868929</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaselli S, Esposito V, Vangone P, van Nuland NA, Bonvin AM, Guerrini R, Tancredi T, Temussi PA, Picone D, The alpha-to-beta conformational transition of Alzheimer&#x2019;s Abeta-(1&#x2013;42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chembiochem 7, 257&#x2013;267 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16444756</ArticleId></ArticleIdList></Reference><Reference><Citation>Small-Molecule Drug Discovery Suite 2015&#x2013;1. Schr&#xf6;dinger, LLC, New York, NY: (2015).</Citation></Reference><Reference><Citation>Kozakov D, Brenke R, Comeau SR, Vajda S, PIPER: an FFT-based protein docking program with pairwise potentials. Proteins 65, 392&#x2013;406 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16933295</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang GY, Kozakov D, Brenke R, Comeau SR, Vajda S, DARS (Decoys As the Reference State) potentials for protein-protein docking. Biophys J 95, 4217&#x2013;4227 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2567923</ArticleId><ArticleId IdType="pubmed">18676649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Li Y, Zhang Y, Chen Y, Shields AD, Winder DG, Angelotti T, Jiao K, Limbird LE, Zhou Y, Wang Q, Epitope-tagged receptor knock-in mice reveal that differential desensitization of alpha2-adrenergic responses is because of ligand-selective internalization. J Biol Chem 284, 13233&#x2013;13243 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676055</ArticleId><ArticleId IdType="pubmed">19276088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Chen Y, Cottingham C, Peng N, Jiao K, Limbird LE, Wyss JM, Wang Q, Enhanced hypotensive, bradycardic, and hypnotic responses to alpha2-adrenergic agonists in spinophilin-null mice are accompanied by increased G protein coupling to the alpha2A-adrenergic receptor. Mol Pharmacol 78, 279&#x2013;286 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917858</ArticleId><ArticleId IdType="pubmed">20430865</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Maeso J, Rodriguez-Puertas R, Gabilondo AM, Meana JJ, Characterization of receptor-mediated [35S]GTPgammaS binding to cortical membranes from postmortem human brain. Eur J Pharmacol 390, 25&#x2013;36 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10708703</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Peng Y, Che P, Gannon M, Liu Y, Li L, Bu G, van Groen T, Jiao K, Wang Q, alpha(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. Proc Natl Acad Sci U S A 111, 17296&#x2013;17301 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4260556</ArticleId><ArticleId IdType="pubmed">25404298</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Gannon M, Chen Y, Zhou L, Jiao K, Wang Q, The amyloid precursor protein modulates alpha2A-adrenergic receptor endocytosis and signaling through disrupting arrestin 3 recruitment. FASEB J 31, 4434&#x2013;4446 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5602903</ArticleId><ArticleId IdType="pubmed">28646018</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR, Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Human molecular genetics 13, 159&#x2013;170 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR, Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomolecular engineering 17, 157&#x2013;165 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC, Single App knock-in mouse models of Alzheimer&#x2019;s disease. Nat Neurosci 17, 661&#x2013;663 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Harmelink C, Peng Y, Chen Y, Wang Q, Jiao K, CHD7 interacts with BMP R-SMADs to epigenetically regulate cardiogenesis in mice. Human molecular genetics 23, 2145&#x2013;2156 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959819</ArticleId><ArticleId IdType="pubmed">24293546</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottingham C, Li X, Wang Q, Noradrenergic antidepressant responses to desipramine in vivo are reciprocally regulated by arrestin3 and spinophilin. Neuropharmacology 62, 2354&#x2013;2362 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314098</ArticleId><ArticleId IdType="pubmed">22369787</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis TL, Cao D, Lu H, Mans RA, Su YR, Jungbauer L, Linton MF, Fazio S, LaDu MJ, Li L, Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem 285, 36958&#x2013;36968 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978624</ArticleId><ArticleId IdType="pubmed">20847045</ArticleId></ArticleIdList></Reference><Reference><Citation>van Groen T, Kadish I, Funke SA, Bartnik D, Willbold D, Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged AbetaPP/PS1 double transgenic mice. Journal of Alzheimer&#x2019;s disease : JAD 34, 609&#x2013;620 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558238</ArticleId><ArticleId IdType="pubmed">23271316</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS, Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol 79, 632&#x2013;646 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810609</ArticleId><ArticleId IdType="pubmed">19799873</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ, Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535&#x2013;539 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31953405</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>17</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>347</StartPage><MedlinePgn>347</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">347</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-14159-1</ELocationID><Abstract><AbstractText>In Alzheimer's diseases (AD), tau pathology is strongly associated with cognitive decline. Preclinical evidence suggests that tau spreads across connected neurons in an activity-dependent manner. Supporting this, cross-sectional AD studies show that tau deposition patterns resemble functional brain networks. However, whether higher functional connectivity is associated with higher rates of tau accumulation is unclear. Here, we combine resting-state fMRI with longitudinal tau-PET in two independent samples including 53 (ADNI) and 41 (BioFINDER) amyloid-biomarker defined AD subjects and 28 (ADNI) vs. 16 (BioFINDER) amyloid-negative healthy controls. In both samples, AD subjects show faster tau accumulation than controls. Second, in AD, higher fMRI-assessed connectivity between 400 regions of interest (ROIs) is associated with correlated tau-PET accumulation in corresponding ROIs. Third, we show that a model including baseline connectivity and tau-PET is associated with future tau-PET accumulation. Together, connectivity is associated with tau spread in AD, supporting the view of transneuronal tau propagation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Franzmeier</LastName><ForeName>Nicolai</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9736-2283</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universitat M&#xfc;nchen, Ludwig-Maximilians-Universitat LMU, Munich, Germany. nicolai.franzmeier@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neitzel</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universitat M&#xfc;nchen, Ludwig-Maximilians-Universitat LMU, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubinski</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universitat M&#xfc;nchen, Ludwig-Maximilians-Universitat LMU, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7147-0112</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Skane University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Skane University Hospital, Malmo, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universitat M&#xfc;nchen, Ludwig-Maximilians-Universitat LMU, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062715</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiminez</LastName><ForeName>Gus</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCArli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borowski</LastName><ForeName>Bret</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Householder</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reinwald</LastName><ForeName>Lisa Taylor</ForeName><Initials>LT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figurski</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelley</LastName><ForeName>Faber</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungeun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>Raina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beccera</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teodoro</LastName><ForeName>Liberty</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albers</LastName><ForeName>Colleen S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyer</LastName><ForeName>Javier Villanueva</ForeName><Initials>JV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rountree</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dang</LastName><ForeName>Mimi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Householder</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>OliverNG</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockington</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greig</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvin</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pogorelec</LastName><ForeName>Dana M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerbone</LastName><ForeName>Brittany</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>Christina A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Terence Z</ForeName><Initials>TZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinha</LastName><ForeName>Partha</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oates</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Catherine Mc Adams</ForeName><Initials>CMA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arrastia</LastName><ForeName>Ramon Diaz</ForeName><Initials>RD</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>Kristen Martin</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tingus</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woo</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DHS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Radford</LastName><ForeName>Neill R Graff</ForeName><Initials>NRG</Initials></Investigator><Investigator ValidYN="Y"><LastName>ParfittH</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kendall</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging Yuek Robin</ForeName><Initials>GYR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Past</LastName><ForeName>Michele Assaly</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sirrel</LastName><ForeName>Sherye A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolday</LastName><ForeName>Saba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allard</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adeli</LastName><ForeName>Anahita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kitzmiller</LastName><ForeName>Tamar J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>SinkS</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabether</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasternak</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>Nunzio</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>Raymundo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarrael</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponto</LastName><ForeName>Laura L Boles</ForeName><Initials>LLB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Hyungsub</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Karen Elizabeth</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raudin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Balebail Ashok</ForeName><Initials>BA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31953405</ArticleId><ArticleId IdType="pmc">PMC6969065</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-14159-1</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-14159-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR, Jr, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535&#x2013;562. doi: 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 2016;8:595&#x2013;608. doi: 10.15252/emmm.201606210.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011;70:960&#x2013;969. doi: 10.1097/NEN.0b013e318232a379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Saper CB, Wainer BH, German DC. Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer's disease. Neuroscience. 1987;23:389&#x2013;398. doi: 10.1016/0306-4522(87)90063-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(87)90063-7</ArticleId><ArticleId IdType="pubmed">2449630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, et al. Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron. 2016;92:796&#x2013;812. doi: 10.1016/j.neuron.2016.09.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.055</ArticleId><ArticleId IdType="pmc">PMC5392364</ArticleId><ArticleId IdType="pubmed">27974162</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudher A, et al. What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol. Commun. 2017;5:99. doi: 10.1186/s40478-017-0488-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0488-7</ArticleId><ArticleId IdType="pmc">PMC5735872</ArticleId><ArticleId IdType="pubmed">29258615</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 2011;286:15317&#x2013;15331. doi: 10.1074/jbc.M110.209296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.209296</ArticleId><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Del Tredici K, Thomas TL, Braak H, Diamond MI. Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer&#x2019;s disease and PART. Acta Neuropathol. 2018;136:57&#x2013;67. doi: 10.1007/s00401-018-1855-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1855-6</ArticleId><ArticleId IdType="pmc">PMC6015098</ArticleId><ArticleId IdType="pubmed">29752551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Thomas TL, Del Tredici K, Braak H, Diamond MI. Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue. Acta Neuropathol. Commun. 2017;5:41. doi: 10.1186/s40478-017-0442-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0442-8</ArticleId><ArticleId IdType="pmc">PMC5461712</ArticleId><ArticleId IdType="pubmed">28587664</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697. doi: 10.1016/j.neuron.2011.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Boluda S, et al. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. Acta Neuropathol. 2015;129:221&#x2013;237. doi: 10.1007/s00401-014-1373-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1373-0</ArticleId><ArticleId IdType="pmc">PMC4305460</ArticleId><ArticleId IdType="pubmed">25534024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 2014;127:667&#x2013;683. doi: 10.1007/s00401-014-1254-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1254-6</ArticleId><ArticleId IdType="pmc">PMC4252866</ArticleId><ArticleId IdType="pubmed">24531916</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S, et al. Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep. 2015;11:1176&#x2013;1183. doi: 10.1016/j.celrep.2015.04.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.04.043</ArticleId><ArticleId IdType="pubmed">25981034</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389&#x2013;394. doi: 10.1038/embor.2013.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2013.15</ArticleId><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 2016;19:1085&#x2013;1092. doi: 10.1038/nn.4328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4328</ArticleId><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl M, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971&#x2013;982. doi: 10.1016/j.neuron.2016.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoenig MC, et al. Networks of tau distribution in Alzheimer's disease. Brain. 2018;141:568&#x2013;581. doi: 10.1093/brain/awx353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx353</ArticleId><ArticleId IdType="pubmed">29315361</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N, et al. Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease. Brain. 2019;142:1093&#x2013;1107. doi: 10.1093/brain/awz026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz026</ArticleId><ArticleId IdType="pmc">PMC6439332</ArticleId><ArticleId IdType="pubmed">30770704</ArticleId></ArticleIdList></Reference><Reference><Citation>Cope TE, et al. Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy. Brain. 2018;141:550&#x2013;567. doi: 10.1093/brain/awx347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx347</ArticleId><ArticleId IdType="pmc">PMC5837359</ArticleId><ArticleId IdType="pubmed">29293892</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberman RP, Branch A, Gallagher M. Targeting neural hyperactivity as a treatment to stem progression of late-onset Alzheimer's disease. Neurotherapeutics. 2017;14:662&#x2013;676. doi: 10.1007/s13311-017-0541-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-017-0541-z</ArticleId><ArticleId IdType="pmc">PMC5509635</ArticleId><ArticleId IdType="pubmed">28560709</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, et al. Resting-state fMRI in the Human Connectome Project. Neuroimage. 2013;80:144&#x2013;168. doi: 10.1016/j.neuroimage.2013.05.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2013.05.039</ArticleId><ArticleId IdType="pmc">PMC3720828</ArticleId><ArticleId IdType="pubmed">23702415</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer Alexander, Kong Ru, Gordon Evan M, Laumann Timothy O, Zuo Xi-Nian, Holmes Avram J, Eickhoff Simon B, Yeo B T Thomas. Local-Global Parcellation of the Human Cerebral Cortex from Intrinsic Functional Connectivity MRI. Cerebral Cortex. 2017;28(9):3095&#x2013;3114. doi: 10.1093/cercor/bhx179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhx179</ArticleId><ArticleId IdType="pmc">PMC6095216</ArticleId><ArticleId IdType="pubmed">28981612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, et al. Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. Neuroimage Clin. 2019;23:101848. doi: 10.1016/j.nicl.2019.101848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.101848</ArticleId><ArticleId IdType="pmc">PMC6510968</ArticleId><ArticleId IdType="pubmed">31077982</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data. Data Brief. 2017;15:648&#x2013;657. doi: 10.1016/j.dib.2017.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dib.2017.10.024</ArticleId><ArticleId IdType="pmc">PMC5671473</ArticleId><ArticleId IdType="pubmed">29124088</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. NeuroImage. 2017;157:448&#x2013;463. doi: 10.1016/j.neuroimage.2017.05.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.05.058</ArticleId><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Longitudinal tau PET in ageing and Alzheimer&#x2019;s disease. Brain. 2018;141:1517&#x2013;1528. doi: 10.1093/brain/awy059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy059</ArticleId><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DT, et al. Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex. 2017;97:143&#x2013;159. doi: 10.1016/j.cortex.2017.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cortex.2017.09.018</ArticleId><ArticleId IdType="pmc">PMC5773067</ArticleId><ArticleId IdType="pubmed">29102243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutlu J, et al. Distinct influence of specific versus global connectivity on the different Alzheimer's disease biomarkers. Brain. 2017;140:3317&#x2013;3328. doi: 10.1093/brain/awx279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx279</ArticleId><ArticleId IdType="pubmed">29194503</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, et al. Network diffusion model of progression predicts longitudinal patterns of atrophy and metabolism in Alzheimer's disease. Cell Rep. 2015;10:359&#x2013;369. doi: 10.1016/j.celrep.2014.12.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.12.034</ArticleId><ArticleId IdType="pmc">PMC5747552</ArticleId><ArticleId IdType="pubmed">25600871</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson KM, et al. Gene expression links functional networks across cortex and striatum. Nat. Commun. 2018;9:1428. doi: 10.1038/s41467-018-03811-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03811-x</ArticleId><ArticleId IdType="pmc">PMC5897339</ArticleId><ArticleId IdType="pubmed">29651138</ArticleId></ArticleIdList></Reference><Reference><Citation>Richiardi J, et al. BRAIN NETWORKS. Correlated gene expression supports synchronous activity in brain networks. Science. 2015;348:1241&#x2013;1244. doi: 10.1126/science.1255905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1255905</ArticleId><ArticleId IdType="pmc">PMC4829082</ArticleId><ArticleId IdType="pubmed">26068849</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe M. J., et al. Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.&#xa0;Brain. 141, 2755&#x2013;2771 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6113636</ArticleId><ArticleId IdType="pubmed">30016411</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, et al. Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat. Med. 2018;24:1910&#x2013;1918. doi: 10.1038/s41591-018-0206-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0206-4</ArticleId><ArticleId IdType="pmc">PMC6518398</ArticleId><ArticleId IdType="pubmed">30374196</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N, Rubinski A, Neitzel J, Ewers M. The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. Nat. Commun. 2019;10:1766. doi: 10.1038/s41467-019-09564-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09564-5</ArticleId><ArticleId IdType="pmc">PMC6467911</ArticleId><ArticleId IdType="pubmed">30992433</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele Rik, Smith Ruben, Ohlsson Tomas, Strandberg Olof, Mattsson Niklas, Insel Philip S., Palmqvist Sebastian, Hansson Oskar. Associations between tau, A&#x3b2;, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601&#x2013;e612. doi: 10.1212/WNL.0000000000006875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006875</ArticleId><ArticleId IdType="pmc">PMC6382060</ArticleId><ArticleId IdType="pubmed">30626656</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018;91:e859&#x2013;e866. doi: 10.1212/WNL.0000000000006075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006075</ArticleId><ArticleId IdType="pmc">PMC6133625</ArticleId><ArticleId IdType="pubmed">30068637</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo JJ, Li JY, Yang Z, Liu Z, Feng JS. Efficacy and safety of anti-amyloid-beta immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis. Ann. Clin. Transl. Neurol. 2017;4:931&#x2013;942. doi: 10.1002/acn3.469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.469</ArticleId><ArticleId IdType="pmc">PMC5740249</ArticleId><ArticleId IdType="pubmed">29296624</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dyck CH. Anti-amyloid-beta monoclonal antibodies for Alzheimer's disease: pitfalls and promise. Biol. Psychiatry. 2018;83:311&#x2013;319. doi: 10.1016/j.biopsych.2017.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2017.08.010</ArticleId><ArticleId IdType="pmc">PMC5767539</ArticleId><ArticleId IdType="pubmed">28967385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E, Nordberg A. Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. Alzheimers Dement (Amst.) 2018;10:232&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5956931</ArticleId><ArticleId IdType="pubmed">29780868</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol. Psychiatry. 2019;24:1112&#x2013;1134. doi: 10.1038/s41380-018-0342-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0342-8</ArticleId><ArticleId IdType="pmc">PMC6756230</ArticleId><ArticleId IdType="pubmed">30635637</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguero, C. et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol. Commun. 7, 37 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410510</ArticleId><ArticleId IdType="pubmed">30857558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lace G, et al. Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. Brain. 2009;132:1324&#x2013;1334. doi: 10.1093/brain/awp059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp059</ArticleId><ArticleId IdType="pubmed">19321462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs HIL, et al. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat. Neurosci. 2018;21:424&#x2013;431. doi: 10.1038/s41593-018-0070-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0070-z</ArticleId><ArticleId IdType="pmc">PMC5857215</ArticleId><ArticleId IdType="pubmed">29403032</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Fischl B. Avoiding asymmetry-induced bias in longitudinal image processing. Neuroimage. 2011;57:19&#x2013;21. doi: 10.1016/j.neuroimage.2011.02.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.02.076</ArticleId><ArticleId IdType="pmc">PMC3260043</ArticleId><ArticleId IdType="pubmed">21376812</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison Theresa M., La Joie Renaud, Maass Anne, Baker Suzanne L., Swinnerton Kaitlin, Fenton Laura, Mellinger Taylor J., Edwards Lauren, Pham Julie, Miller Bruce L., Rabinovici Gil D., Jagust William J. Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Annals of Neurology. 2019;85(2):229&#x2013;240. doi: 10.1002/ana.25406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25406</ArticleId><ArticleId IdType="pmc">PMC6579738</ArticleId><ArticleId IdType="pubmed">30597624</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. Brain : a J. Neurol. 2019;142:1723&#x2013;1735. doi: 10.1093/brain/awz090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz090</ArticleId><ArticleId IdType="pmc">PMC6536847</ArticleId><ArticleId IdType="pubmed">31009046</ArticleId></ArticleIdList></Reference><Reference><Citation>Honey CJ, et al. Predicting human resting-state functional connectivity from structural connectivity. Proc. Natl Acad. Sci. USA. 2009;106:2035&#x2013;2040. doi: 10.1073/pnas.0811168106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0811168106</ArticleId><ArticleId IdType="pmc">PMC2634800</ArticleId><ArticleId IdType="pubmed">19188601</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhinav K, et al. Advanced diffusion MRI fiber tracking in neurosurgical and neurodegenerative disorders and neuroanatomical studies: A review. Biochim. Biophys. Acta. 2014;1842:2286&#x2013;2297. doi: 10.1016/j.bbadis.2014.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2014.08.002</ArticleId><ArticleId IdType="pubmed">25127851</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandjean J, Zerbi V, Balsters JH, Wenderoth N, Rudin M. Structural basis of large-scale functional connectivity in the mouse. J. Neurosci. 2017;37:8092&#x2013;8101. doi: 10.1523/JNEUROSCI.0438-17.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0438-17.2017</ArticleId><ArticleId IdType="pmc">PMC6596781</ArticleId><ArticleId IdType="pubmed">28716961</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755&#x2013;766. doi: 10.1007/s00401-014-1349-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1349-0</ArticleId><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF. Primary age-related tauopathy and the amyloid cascade hypothesis: the exception that proves the rule? J. Neurol. Neuromed. 2016;1:53&#x2013;57. doi: 10.29245/2572.942X/2016/6.1059.</Citation><ArticleIdList><ArticleId IdType="doi">10.29245/2572.942X/2016/6.1059</ArticleId><ArticleId IdType="pmc">PMC5094182</ArticleId><ArticleId IdType="pubmed">27819070</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons, G. S., Lee, V. M. Y. &amp; Trojanowski, J. Q. Mechanisms of cell-to-cell transmission of pathological tau: a review. JAMA Neurol.76, 101&#x2013;108 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382549</ArticleId><ArticleId IdType="pubmed">30193298</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686&#x2013;1689. doi: 10.1126/science.1162844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1162844</ArticleId><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, et al. Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA. 2012;109:8740&#x2013;8745. doi: 10.1073/pnas.1206171109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206171109</ArticleId><ArticleId IdType="pmc">PMC3365221</ArticleId><ArticleId IdType="pubmed">22592800</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012;72:578&#x2013;586. doi: 10.1002/ana.23650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23650</ArticleId><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201&#x2013;209. doi: 10.1212/WNL.0b013e3181cb3e25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181cb3e25</ArticleId><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71:1282&#x2013;1289. doi: 10.1001/jamaneurol.2014.1358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1358</ArticleId><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurfjell L, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J. Nucl. Med. 2014;55:1623&#x2013;1628. doi: 10.2967/jnumed.114.142109.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.114.142109</ArticleId><ArticleId IdType="pubmed">25146124</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, et al. Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology. 2018;90:e388&#x2013;e395. doi: 10.1212/WNL.0000000000004887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004887</ArticleId><ArticleId IdType="pmc">PMC5791788</ArticleId><ArticleId IdType="pubmed">29321235</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy K, Birn RM, Handwerker DA, Jones TB, Bandettini PA. The impact of global signal regression on resting state correlations: are anti-correlated networks introduced? NeuroImage. 2009;44:893&#x2013;905. doi: 10.1016/j.neuroimage.2008.09.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2008.09.036</ArticleId><ArticleId IdType="pmc">PMC2750906</ArticleId><ArticleId IdType="pubmed">18976716</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy K, Fox MD. Towards a consensus regarding global signal regression for resting state functional connectivity MRI. NeuroImage. 2016;154:169&#x2013;173. doi: 10.1016/j.neuroimage.2016.11.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2016.11.052</ArticleId><ArticleId IdType="pmc">PMC5489207</ArticleId><ArticleId IdType="pubmed">27888059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn A, et al. Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology. J. Nucl. Med. 2017;58:623&#x2013;631. doi: 10.2967/jnumed.116.174508.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.116.174508</ArticleId><ArticleId IdType="pubmed">27765859</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016;139:2372&#x2013;2379. doi: 10.1093/brain/aww163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww163</ArticleId><ArticleId IdType="pmc">PMC4995360</ArticleId><ArticleId IdType="pubmed">27357347</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 1998;39:904&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo BT, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J. Neurophysiol. 2011;106:1125&#x2013;1165. doi: 10.1152/jn.00338.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00338.2011</ArticleId><ArticleId IdType="pmc">PMC3174820</ArticleId><ArticleId IdType="pubmed">21653723</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie, M. et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol.78, 787&#x2013;800 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement. 2017;13:205&#x2013;216. doi: 10.1016/j.jalz.2016.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.08.005</ArticleId><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Di X, et al. Do all roads lead to Rome? A comparison of brain networks derived from inter-subject volumetric and metabolic covariance and moment-to-moment hemodynamic correlations in old individuals. Brain Struct. Funct. 2017;222:3833&#x2013;3845. doi: 10.1007/s00429-017-1438-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-017-1438-7</ArticleId><ArticleId IdType="pmc">PMC10650976</ArticleId><ArticleId IdType="pubmed">28474183</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067&#x2013;1074. doi: 10.1212/WNL.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31983538</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Human Herpesvirus 6 Detection in Alzheimer's Disease Cases and Controls across Multiple Cohorts.</ArticleTitle><Pagination><StartPage>1027</StartPage><EndPage>1035.e2</EndPage><MedlinePgn>1027-1035.e2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2019.12.031</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(19)31097-9</ELocationID><Abstract><AbstractText>The interplay between viral infection and Alzheimer's disease (AD) has long been an area of interest, but proving causality has been elusive. Several recent studies have renewed the debate concerning the role of herpesviruses, and human herpesvirus 6 (HHV-6) in particular, in AD. We screened for HHV-6 detection across three independent AD brain repositories using (1) RNA sequencing (RNA-seq) datasets and (2) DNA samples extracted from AD and non-AD control brains. The RNA-seq data were screened for pathogens against taxon references from over 25,000 microbes, including 118 human viruses, whereas DNA samples were probed for PCR reactivity to HHV-6A and HHV-6B. HHV-6 demonstrated little specificity to AD brains over controls by either method, whereas other viruses, such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV), were detected at comparable levels. These direct methods of viral detection do not suggest an association between HHV-6 and AD.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allnutt</LastName><ForeName>Mary Alice</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Viral Immunology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kory</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Bioinformatics Section, Information Technology &amp; Bioinformatics Program, Division of Intramural Research (DIR), National Institute of Neurological Disorders and Stroke/National Institute of Health, Bethesda, MD 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Alzheimer Disease Center, RUSH University, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connor</LastName><ForeName>Sarah M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Johns Hopkins University Medical Center, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletnikova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Johns Hopkins University Medical Center, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resnick</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Sonja W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Viral Immunology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20814, USA. Electronic address: jacobsons@ninds.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z99 NS999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA NS003154</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015654" MajorTopicYN="N">Herpesvirus 6, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">herpesvirus</Keyword><Keyword MajorTopicYN="N">human herpesvirus 6</Keyword></KeywordList><CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31983538</ArticleId><ArticleId IdType="mid">NIHMS1569250</ArticleId><ArticleId IdType="pmc">PMC7182308</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.12.031</ArticleId><ArticleId IdType="pii">S0896-6273(19)31097-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agostini S, Mancuso R, Baglio F, Cabinio M, Hernis A, Guerini FR, Calabrese E, Nemni R, and Clerici M (2016). Lack of evidence for a role of HHV-6 in the pathogenesis of Alzheimer&#x2019;s disease. J Alzheimers Dis 49, 229&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">26444787</ArticleId></ArticleIdList></Reference><Reference><Citation>Balin BJ, and Hudson AP (2014). Etiology and pathogenesis of late-onset Alzheimer&#x2019;s disease. Curr Allergy Asthma Rep 14, 417.</Citation><ArticleIdList><ArticleId IdType="pubmed">24429902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball MJ (1982). &#x201c;Limbic predilection in Alzheimer dementia: is reactivated herpesvirus involved?&#x201d;. Can J Neurol Sci 9, 303&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">7116237</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolini L, Piras E, Sullivan K, Gillen S, Bumbut A, Lin CM, Leibovitch EC, Graves JS, Waubant EL, Chamberlain JM, et al. (2018). Detection of HHV-6 and EBV and Cytokine Levels in Saliva From Children With Seizures: Results of a Multi-Center Cross-Sectional Study. Front Neurol 9, 834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6182262</ArticleId><ArticleId IdType="pubmed">30344507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartsch T, Rempe T, Leypoldt F, Riedel C, Jansen O, Berg D, and Deuschl G (2019). The spectrum of progressive multifocal leukoencephalopathy: a practical approach. Eur J Neurol 26, 566&#x2013;e541.</Citation><ArticleIdList><ArticleId IdType="pubmed">30629326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, and Wilson RS (2012a). Overview and findings from the religious orders study. Curr Alzheimer Res 9, 628&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, and Wilson RS (2012b). Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res 9, 646&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauwendraat C, Pletnikova O, Geiger JT, Murphy NA, Abramzon Y, Rudow G, Mamais A, Sabir MS, Crain B, Ahmed S, et al. (2019). Genetic analysis of neurodegenerative diseases in a pathology cohort. Neurobiol Aging 76, 214 e211&#x2013;214 e219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391207</ArticleId><ArticleId IdType="pubmed">30528841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookstaver PB, Mohorn PL, Shah A, Tesh LD, Quidley AM, Kothari R, Bland CM, and Weissman S (2017). Management of Viral Central Nervous System Infections: A Primer for Clinicians. J Cent Nerv Syst Dis 9, 1179573517703342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5415352</ArticleId><ArticleId IdType="pubmed">28579869</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgade K, Garneau H, Giroux G, Le Page AY, Bocti C, Dupuis G, Frost EH, and Fulop T Jr. (2015). beta-Amyloid peptides display protective activity against the human Alzheimer&#x2019;s disease-associated herpes simplex virus-1. Biogerontology 16, 85&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">25376108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgade K, Le Page A, Bocti C, Witkowski JM, Dupuis G, Frost EH, and Fulop T Jr. (2016). Protective Effect of Amyloid-beta Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model. J Alzheimers Dis 50, 1227&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">26836158</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Jiang H, Wildburger N, and Esparza TJ (2017). Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer&#x2019;s disease. Alzheimers Res Ther 9, 62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5561579</ArticleId><ArticleId IdType="pubmed">28818091</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone I, Lazzarotto T, Ianni M, Porcellini E, Forti P, Masliah E, Gabrielli L, and Licastro F (2014). Herpes virus in Alzheimer&#x2019;s disease: relation to progression of the disease. Neurobiol Aging 35, 122&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">23916950</ArticleId></ArticleIdList></Reference><Reference><Citation>Cermelli C, Berti R, Soldan SS, Mayne M, D&#x2019;Ambrosia J M, Ludwin SK, and Jacobson S (2003). High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis 187, 1377&#x2013;1387.</Citation><ArticleIdList><ArticleId IdType="pubmed">12717618</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan PK, Ng HK, Hui M, and Cheng AF (2001). Prevalence and distribution of human herpesvirus 6 variants A and B in adult human brain. J Med Virol 64, 42&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">11285567</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapenko S, Roga S, Skuja S, Rasa S, Cistjakovs M, Svirskis S, Zaserska Z, Groma V, and Murovska M (2016). Detection frequency of human herpesviruses-6A, -6B, and -7 genomic sequences in central nervous system DNA samples from post-mortem individuals with unspecified encephalopathy. J Neurovirol 22, 488&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">26727906</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, and Collin F (2018). Oxidative stress and the amyloid beta peptide in Alzheimer&#x2019;s disease. Redox Biol 14, 450&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5680523</ArticleId><ArticleId IdType="pubmed">29080524</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, Rodriguez AS, Mitchell T, Washicosky KJ, Gyorgy B, Breakefield XO, Tanzi RE, and Moir RD (2018). Alzheimer&#x2019;s Disease-Associated beta-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. Neuron 99, 56&#x2013;63.e53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075814</ArticleId><ArticleId IdType="pubmed">30001512</ArticleId></ArticleIdList></Reference><Reference><Citation>Fessel J (2018). Amyloid is essential but insufficient for Alzheimer causation: addition of subcellular cofactors is required for dementia. Int J Geriatr Psychiatry 33, e14&#x2013;e21.</Citation><ArticleIdList><ArticleId IdType="pubmed">28509380</ArticleId></ArticleIdList></Reference><Reference><Citation>Flamand L (2018). Chromosomal Integration by Human Herpesviruses 6A and 6B. Adv Exp Med Biol 1045, 209&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">29896669</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldschmidt-Clermont PJ, Volinsky FG, LaRosa SP, Gilbert JR, and Pericak-Vance MA (2019). Time for Well-Powered Controlled Prospective Studies to test a Causal Role for Herpes Viruses in Alzheimer Using Anti-Herpes Drugs. J Gerontol A Biol Sci Med Sci.</Citation><ArticleIdList><ArticleId IdType="pubmed">31175818</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas JG, and Lathe R (2018). Microbes and Alzheimer&#x2019;s Disease: New Findings Call for a Paradigm Change. Trends Neurosci 41, 570&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">30033181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemling N, Roytta M, Rinne J, Pollanen P, Broberg E, Tapio V, Vahlberg T, and Hukkanen V (2003). Herpesviruses in brains in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Ann Neurol 54, 267&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891684</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C (2013). Review: systemic inflammation and Alzheimer&#x2019;s disease. Neuropathol Appl Neurobiol 39, 51&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">23046210</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, and Jamieson GA (1997). Herpes simplex virus type 1 in brain and risk of Alzheimer&#x2019;s disease. Lancet 349, 241&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">9014911</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar DK, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, Lefkowitz A, McColl G, Goldstein LE, Tanzi RE, and Moir RD (2016). Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer&#x2019;s disease. Sci Transl Med 8, 340ra372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505565</ArticleId><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibovitch EC, Brunetto GS, Caruso B, Fenton K, Ohayon J, Reich DS, and Jacobson S (2014). Coinfection of human herpesviruses 6A (HHV-6A) and HHV-6B as demonstrated by novel digital droplet PCR assay. PLoS One 9, e92328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963908</ArticleId><ArticleId IdType="pubmed">24663487</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibovitch EC, and Jacobson S (2018). Viruses in chronic progressive neurologic disease. Mult Scler 24, 48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777331</ArticleId><ArticleId IdType="pubmed">29307291</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibovitch EC, Lin CM, Billioux BJ, Graves J, Waubant E, and Jacobson S (2019). Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls. Mult Scler 25, 644&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119543</ArticleId><ArticleId IdType="pubmed">29569515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CT, Leibovitch EC, Almira-Suarez MI, and Jacobson S (2016). Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls. Infect Agent Cancer 11, 32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4960850</ArticleId><ArticleId IdType="pubmed">27462365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WR, Wozniak MA, Cooper RJ, Wilcock GK, and Itzhaki RF (2002). Herpesviruses in brain and Alzheimer&#x2019;s disease. J Pathol 197, 395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">12115887</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Chyr J, Zhao W, Xu Y, Ji Z, Tan H, Soto C, Zhou X, and , f.t.A.s.D.N.I. (2018). Genome-Wide Association and Mechanistic Studies Indicate That Immune Response Contributes to Alzheimer&#x2019;s Disease Development. Frontiers in Genetics 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166008</ArticleId><ArticleId IdType="pubmed">30319691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H, Olsson J, Weidung B, Johansson A, Eriksson S, Hallmans G, and Elgh F (2018). Interaction between Cytomegalovirus and Herpes Simplex Virus Type 1 Associated with the Risk of Alzheimer&#x2019;s Disease Development. J Alzheimers Dis 61, 939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">29254081</ArticleId></ArticleIdList></Reference><Reference><Citation>Miklossy J (2015). Historic evidence to support a causal relationship between spirochetal infections and Alzheimer&#x2019;s disease. Front Aging Neurosci 7, 46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4399390</ArticleId><ArticleId IdType="pubmed">25932012</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir RD, and Tanzi RE (2019). Low Evolutionary Selection Pressure in Senescence Does Not Explain the Persistence of Abeta in the Vertebrate Genome. Front Aging Neurosci 11, 70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447958</ArticleId><ArticleId IdType="pubmed">30983989</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath A (2015). Neurologic Complications of Human Immunodeficiency Virus Infection. Continuum (Minneap Minn) 21, 1557&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">26633776</ArticleId></ArticleIdList></Reference><Reference><Citation>Piacentini R, De Chiara G, Li Puma DD, Ripoli C, Marcocci ME, Garaci E, Palamara AT, and Grassi C (2014). HSV-1 and Alzheimer&#x2019;s disease: more than a hypothesis. Front Pharmacol 5, 97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019841</ArticleId><ArticleId IdType="pubmed">24847267</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Q, and Li Y (2019). Herpesviral infections and antimicrobial protection for Alzheimer&#x2019;s disease: Implications for prevention and treatment. J Med Virol.</Citation><ArticleIdList><ArticleId IdType="pubmed">30997676</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B, Haure-Mirande JV, Funk CC, Richards MA, Shannon P, Haroutunian V, Sano M, Liang WS, Beckmann ND, Price ND, et al. (2018). Multiscale Analysis of Independent Alzheimer&#x2019;s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron 99, 64&#x2013;82 e67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551233</ArticleId><ArticleId IdType="pubmed">29937276</ArticleId></ArticleIdList></Reference><Reference><Citation>Regen F, Hellmann-Regen J, Costantini E, and Reale M (2017). Neuroinflammation and Alzheimer&#x2019;s Disease: Implications for Microglial Activation. Curr Alzheimer Res 14, 1140&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">28164764</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo R, Bortolotti D, Gentili V, Rotola A, Bolzani S, Caselli E, Tola MR, and Di Luca D (2019). KIR2DS2/KIR2DL2/HLA-C1 Haplotype Is Associated with Alzheimer&#x2019;s Disease: Implication for the Role of Herpesvirus Infections. J Alzheimers Dis 67, 1379&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">30689576</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeo MA, Faggioni A, and Cirone M (2019a). Could autophagy dysregulation link neurotropic viruses to Alzheimer&#x2019;s disease? Neural Regen Res 14, 1503&#x2013;1506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6557098</ArticleId><ArticleId IdType="pubmed">31089040</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeo MA, Masuelli L, Gaeta A, Nazzari C, Granato M, Gilardini Montani MS, Faggioni A, and Cirone M (2019b). Impact of HHV-6A and HHV-6B lytic infection on autophagy and endoplasmic reticulum stress. J Gen Virol 100, 89&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">30427305</ArticleId></ArticleIdList></Reference><Reference><Citation>Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, and Moir RD (2010). The Alzheimer&#x2019;s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5, e9505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831066</ArticleId><ArticleId IdType="pubmed">20209079</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer P, Condic M, Herrmann M, Oberstein TJ, Scharin-Mehlmann M, Gilbert DF, Friedrich O, Gromer T, Kornhuber J, Lang R, and Maler JM (2016). Amyloidogenic amyloid-beta-peptide variants induce microbial agglutination and exert antimicrobial activity. Sci Rep 6, 32228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5021948</ArticleId><ArticleId IdType="pubmed">27624303</ArticleId></ArticleIdList></Reference><Reference><Citation>Talwar P, Gupta R, Kushwaha S, Agarwal R, Saso L, Kukreti S, and Kukreti R (2019). Viral Induced Oxidative and Inflammatory Response in Alzheimer&#x2019;s Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach. Curr Neuropharmacol 17, 352&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482477</ArticleId><ArticleId IdType="pubmed">29676229</ArticleId></ArticleIdList></Reference><Reference><Citation>Virtanen JO, Wohler J, Fenton K, Reich DS, and Jacobson S (2014). Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings. Mult Scler 20, 27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001156</ArticleId><ArticleId IdType="pubmed">23722324</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker MA, Pedamallu CS, Ojesina AI, Bullman S, Sharpe T, Whelan CW, and Meyerson M (2018). GATK PathSeq: a customizable computational tool for the discovery and identification of microbial sequences in libraries from eukaryotic hosts. Bioinformatics 34, 4287&#x2013;4289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289130</ArticleId><ArticleId IdType="pubmed">29982281</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, and Selkoe DJ (2002). Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30, 552&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196135</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Beckmann ND, Roussos P, Wang E, Zhou X, Wang Q, Ming C, Neff R, Ma W, Fullard JF, et al. (2018). The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer&#x2019;s disease. Sci Data 5, 180185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132187</ArticleId><ArticleId IdType="pubmed">30204156</ArticleId></ArticleIdList></Reference><Reference><Citation>White MR, Kandel R, Tripathi S, Condon D, Qi L, Taubenberger J, and Hartshorn KL (2014). Alzheimer&#x2019;s associated beta-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. PLoS One 9, e101364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4079246</ArticleId><ArticleId IdType="pubmed">24988208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wipfler P, Dunn N, Beiki O, Trinka E, and Fogdell-Hahn A (2018). The Viral Hypothesis of Mesial Temporal Lobe Epilepsy - Is Human Herpes Virus-6 the Missing Link? A systematic review and meta-analysis. Seizure 54, 33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">29195226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak MA, Mee AP, and Itzhaki RF (2009). Herpes simplex virus type 1 DNA is located within Alzheimer&#x2019;s disease amyloid plaques. J Pathol 217, 131&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">18973185</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao K, Honarmand S, Espinosa A, Akhyani N, Glaser C, and Jacobson S (2009). Detection of human herpesvirus-6 in cerebrospinal fluid of patients with encephalitis. Ann Neurol 65, 257&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666109</ArticleId><ArticleId IdType="pubmed">19334059</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32024799</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>529</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle><i>APOE</i> genotype regulates pathology and disease progression in synucleinopathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaay3069</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aay3069</ELocationID><Abstract><AbstractText>Apolipoprotein E (<i>APOE</i>) &#x3b5;4 genotype is associated with increased risk of dementia in Parkinson's disease (PD), but the mechanism is not clear, because patients often have a mixture of &#x3b1;-synuclein (&#x3b1;Syn), amyloid-&#x3b2; (A&#x3b2;), and tau pathologies. <i>APOE</i> &#x3b5;4 exacerbates brain A&#x3b2; pathology, as well as tau pathology, but it is not clear whether <i>APOE</i> genotype independently regulates &#x3b1;Syn pathology. In this study, we generated A53T &#x3b1;Syn transgenic mice (A53T) on <i>Apoe</i> knockout (A53T/EKO) or human <i>APOE</i> knockin backgrounds (A53T/E2, E3, and E4). At 12 months of age, A53T/E4 mice accumulated higher amounts of brainstem detergent-insoluble phosphorylated &#x3b1;Syn compared to A53T/EKO and A53T/E3; detergent-insoluble &#x3b1;Syn in A53T/E2 mice was undetectable. By immunohistochemistry, A53T/E4 mice displayed a higher burden of phosphorylated &#x3b1;Syn and reactive gliosis compared to A53T/E2 mice. A53T/E2 mice exhibited increased survival and improved motor performance compared to other <i>APOE</i> genotypes. In a complementary model of &#x3b1;Syn spreading, striatal injection of &#x3b1;Syn preformed fibrils induced greater accumulation of &#x3b1;Syn pathology in the substantia nigra of A53T/E4 mice compared to A53T/E2 and A53T/EKO mice. In two separate cohorts of human patients with PD, <i>APOE</i> &#x3b5;4/&#x3b5;4 individuals showed the fastest rate of cognitive decline over time. Our results demonstrate that <i>APOE</i> genotype directly regulates &#x3b1;Syn pathology independent of its established effects on A&#x3b2; and tau, corroborate the finding that <i>APOE</i> &#x3b5;4 exacerbates pathology, and suggest that <i>APOE</i> &#x3b5;2 may protect against &#x3b1;Syn aggregation and neurodegeneration in synucleinopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Albert A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0003-2042-8445</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA. albert.a.davis@wustl.edu holtzman@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inman</LastName><ForeName>Casey E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0002-0313-1175</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wargel</LastName><ForeName>Zachary M</ForeName><Initials>ZM</Initials><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dube</LastName><ForeName>Umber</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-9324-1927</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freeberg</LastName><ForeName>Brittany M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0003-4756-5634</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galluppi</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0788-4166</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jessica N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhavale</LastName><ForeName>Dhruva D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1227-5891</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhury</LastName><ForeName>Fahim A</ForeName><Initials>FA</Initials><Identifier Source="ORCID">0000-0002-9612-4264</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0001-8402-2634</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Duke University Medical Center, Durham VAMC and Geriatric Research Clinical Center, Durham, NC 27705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0276-2899</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlmutter</LastName><ForeName>Joel S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neuroscience and Radiology, Programs in Physical and Occupational Therapy, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-4743-926X</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benitez</LastName><ForeName>Bruno A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0002-2699-3878</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotzbauer</LastName><ForeName>Paul T</ForeName><Initials>PT</Initials><Identifier Source="ORCID">0000-0001-7155-114X</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-3400-0856</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA. albert.a.davis@wustl.edu holtzman@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS101118</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075321</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097799</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS075321</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058922</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Apr;16(4):185. doi: 10.1038/s41582-020-0335-5.</RefSource><PMID Version="1">32107475</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080874" MajorTopicYN="Y">Synucleinopathies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>COMPETING INTERESTS. C.C. receives research support from: Biogen, EISAI, Alector and Parabon, none of which had any role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. C.C. is a member of the advisory board of ADx Healthcare, Halia Terapeutics and Vivid Genomics. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics, LLC. D.M.H. is on the scientific advisory board of Denali and consults for Genentech and Idorsia. All other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32024799</ArticleId><ArticleId IdType="mid">NIHMS1593444</ArticleId><ArticleId IdType="pmc">PMC7289511</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aay3069</ArticleId><ArticleId IdType="pii">12/529/eaay3069</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Obeso JA et al., Past, present, and future of Parkinson&#x2019;s disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement disorders : official journal of the Movement Disorder Society 32, 1264&#x2013;1310 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5685546</ArticleId><ArticleId IdType="pubmed">28887905</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis AW et al., Predictors of survival in patients with Parkinson disease. Archives of neurology 69, 601&#x2013;607 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3599783</ArticleId><ArticleId IdType="pubmed">22213411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG, The Sydney multicenter study of Parkinson&#x2019;s disease: the inevitability of dementia at 20 years. Movement disorders : official journal of the Movement Disorder Society 23, 837&#x2013;844 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18307261</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG et al., Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88&#x2013;100 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Bras J et al., Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human molecular genetics, (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222357</ArticleId><ArticleId IdType="pubmed">24973356</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R et al., Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet neurology 17, 64&#x2013;74 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5805394</ArticleId><ArticleId IdType="pubmed">29263008</ArticleId></ArticleIdList></Reference><Reference><Citation>Mata IF et al., APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA neurology 71, 1405&#x2013;1412 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4227942</ArticleId><ArticleId IdType="pubmed">25178429</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JF et al., Genetic influences on cognitive decline in Parkinson&#x2019;s disease. Movement disorders : official journal of the Movement Disorder Society 27, 512&#x2013;518 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323737</ArticleId><ArticleId IdType="pubmed">22344634</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H et al., Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiology of aging 24, 197&#x2013;211 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday G, Hely M, Reid W, Morris J, The progression of pathology in longitudinally followed patients with Parkinson&#x2019;s disease. Acta neuropathologica 115, 409&#x2013;415 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18231798</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Lee VM, Trojanowski JQ, Parkinson&#x2019;s disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nature reviews. Neuroscience 14, 626&#x2013;636 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4017235</ArticleId><ArticleId IdType="pubmed">23900411</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotzbauer PT et al., Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Archives of neurology 69, 1326&#x2013;1331 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616136</ArticleId><ArticleId IdType="pubmed">22825369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM, The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron 63, 287&#x2013;303 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Herz J, Bu G, Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor perspectives in medicine 2, a006312 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282491</ArticleId><ArticleId IdType="pubmed">22393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ et al., Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet neurology 16, 55&#x2013;65 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181646</ArticleId><ArticleId IdType="pubmed">27979356</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D et al., APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA neurology 70, 223&#x2013;228 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580799</ArticleId><ArticleId IdType="pubmed">23407718</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW et al., APOE epsilon4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology 91, e1182&#x2013;e1195 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6161556</ArticleId><ArticleId IdType="pubmed">30143564</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabir MS et al., Assessment of APOE in atypical parkinsonism syndromes. Neurobiology of disease 127, 142&#x2013;146 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6588472</ArticleId><ArticleId IdType="pubmed">30798004</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK et al., Human alpha-synuclein-harboring familial Parkinson&#x2019;s disease-linked Ala-53 --&gt; Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 99, 8968&#x2013;8973 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124407</ArticleId><ArticleId IdType="pubmed">12084935</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ et al., Parkinson&#x2019;s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. The Journal of neuroscience : the official journal of the Society for Neuroscience 26, 41&#x2013;50 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6381830</ArticleId><ArticleId IdType="pubmed">16399671</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al., ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC et al., Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (New York, N.Y.) 338, 949&#x2013;953 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB, A large study reveals no association between APOE and Parkinson&#x2019;s disease. Neurobiology of disease 46, 389&#x2013;392 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323723</ArticleId><ArticleId IdType="pubmed">22349451</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul KC et al., APOE, MAPT, and COMT and Parkinson&#x2019;s Disease Susceptibility and Cognitive Symptom Progression. Journal of Parkinson&#x2019;s disease, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927361</ArticleId><ArticleId IdType="pubmed">27061069</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropea TF et al., APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson&#x2019;s disease. Movement disorders : official journal of the Movement Disorder Society 33, 289&#x2013;297 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5809205</ArticleId><ArticleId IdType="pubmed">29168904</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahid M et al., An increased rate of longitudinal cognitive decline is observed in Parkinson&#x2019;s disease patients with low CSF Ass42 and an APOE epsilon4 allele. Neurobiology of disease 127, 278&#x2013;286 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6588475</ArticleId><ArticleId IdType="pubmed">30826425</ArticleId></ArticleIdList></Reference><Reference><Citation>Marek K. e. a., for the Parkinson&#x2019;s Progression Markers Initiative, The Parkinson Progression Marker Initiative (PPMI). Progress in neurobiology 95, 629&#x2013;635 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014725</ArticleId><ArticleId IdType="pubmed">21930184</ArticleId></ArticleIdList></Reference><Reference><Citation>Eusebi P et al., Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson&#x2019;s disease: A systematic review and meta-analysis. Movement disorders : official journal of the Movement Disorder Society 32, 1389&#x2013;1400 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28880418</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA, Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64, 1404&#x2013;1410 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15851731</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Pollack J, Morris JC, Clinical phenotype of Parkinson disease dementia. Neurology 67, 1605&#x2013;1611 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17101891</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtig HI et al., Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson&#x2019;s disease. Neurology 54, 1916&#x2013;1921 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10822429</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnetti L et al., Cerebrospinal fluid biomarkers in Parkinson&#x2019;s disease with dementia and dementia with Lewy bodies. Biological psychiatry 64, 850&#x2013;855 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18395699</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochimica et biophysica acta 1792, 730&#x2013;740 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18718530</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ et al., Neuropathologic substrates of Parkinson disease dementia. Annals of neurology 72, 587&#x2013;598 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484250</ArticleId><ArticleId IdType="pubmed">23037886</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L et al., Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson&#x2019;s disease diagnosis: a systematic review and meta-analysis. The International journal of neuroscience 125, 645&#x2013;654 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25202803</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV, Davis AA, Ulrich JD, Holtzman DM, Apolipoprotein E and Alzheimer&#x2019;s disease: the influence of apolipoprotein E on amyloid-beta and other amyloidogenic proteins. Journal of lipid research 58, 824&#x2013;836 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408619</ArticleId><ArticleId IdType="pubmed">28246336</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM, Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. The Journal of biological chemistry 273, 9443&#x2013;9449 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>George JM, Jin H, Woods WS, Clayton DF, Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361&#x2013;372 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7646890</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamzadeh FN, Aojula H, McHugh P, Allsop D, Effects of different isoforms of apoE on aggregation of the alpha-synuclein protein implicated in Parkinson&#x2019;s disease. Neuroscience letters, (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921451</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohn TT, Mack JM, Apolipoprotein E Fragmentation within Lewy Bodies of the Human Parkinson&#x2019;s Disease Brain. International journal of neurodegenerative disorders 1, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6159338</ArticleId><ArticleId IdType="pubmed">30272057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelmus MM et al., Apolipoprotein E and LRP1 Increase Early in Parkinson&#x2019;s Disease Pathogenesis. The American journal of pathology 179, 2152&#x2013;2156 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204035</ArticleId><ArticleId IdType="pubmed">21907175</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantini J, Yahi N, The driving force of alpha-synuclein insertion and amyloid channel formation in the plasma membrane of neural cells: key role of ganglioside- and cholesterol-binding domains. Advances in experimental medicine and biology 991, 15&#x2013;26 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23775688</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM et al., Exosomal cell-to-cell transmission of alpha synuclein oligomers. Molecular neurodegeneration 7, 42 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483256</ArticleId><ArticleId IdType="pubmed">22920859</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM et al., Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 25, 326&#x2013;336 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3005424</ArticleId><ArticleId IdType="pubmed">20876215</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmanouilidou E et al., Assessment of alpha-synuclein secretion in mouse and human brain parenchyma. PloS one 6, e22225 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136497</ArticleId><ArticleId IdType="pubmed">21779395</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Iwatsubo T, Extracellular alpha-synuclein levels are regulated by neuronal activity. Molecular neurodegeneration 13, 9 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822605</ArticleId><ArticleId IdType="pubmed">29467003</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S et al., Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis. Journal of neuroimmunology 271, 8&#x2013;17 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4042395</ArticleId><ArticleId IdType="pubmed">24794230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD et al., ApoE facilitates the microglial response to amyloid plaque pathology. The Journal of experimental medicine 215, 1047&#x2013;1058 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S et al., The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581.e569 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al., Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. The Journal of experimental medicine 216, 2546&#x2013;2561 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Movement disorders : official journal of the Movement Disorder Society 29, 1720&#x2013;1741 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25297524</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng C et al., Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies. Nature 557, 558&#x2013;563 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970994</ArticleId><ArticleId IdType="pubmed">29743672</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ et al., Apolipoprotein E e4 allele frequency in patients with multiple system atrophy. Neuroscience letters 221, 161&#x2013;164 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9121689</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogaki K et al., Multiple system atrophy and apolipoprotein E. Movement disorders : official journal of the Movement Disorder Society 33, 647&#x2013;650 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889322</ArticleId><ArticleId IdType="pubmed">29442376</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura N et al., Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein (alpha-Syn) Pathology in Synthetic alpha-Syn Fibril-Induced Mouse Models of Synucleinopathy. Journal of neuropathology and experimental neurology 78, 877&#x2013;890 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6934438</ArticleId><ArticleId IdType="pubmed">31504665</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez L et al., Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Frontiers in neuroscience 12, 230 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902712</ArticleId><ArticleId IdType="pubmed">29692703</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsian A, Racette B, Goldsmith LJ, Perlmutter JS, Parkinson&#x2019;s disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 79, 458&#x2013;461 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11863377</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C et al., CSF tau and tau/Abeta42 predict cognitive decline in Parkinson&#x2019;s disease. Parkinsonism &amp; related disorders 21, 271&#x2013;276 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603566</ArticleId><ArticleId IdType="pubmed">25596881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall S et al., CSF biomarkers and clinical progression of Parkinson disease. Neurology 84, 57&#x2013;63 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336091</ArticleId><ArticleId IdType="pubmed">25411441</ArticleId></ArticleIdList></Reference><Reference><Citation>Backstrom DC et al., Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA neurology 72, 1175&#x2013;1182 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26258692</ArticleId></ArticleIdList></Reference><Reference><Citation>Siderowf A et al., CSF amyloid {beta} 1&#x2013;42 predicts cognitive decline in Parkinson disease. Neurology 75, 1055&#x2013;1061 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942062</ArticleId><ArticleId IdType="pubmed">20720189</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ et al., CSF Abeta(42) and tau in Parkinson&#x2019;s disease with cognitive impairment. Movement disorders : official journal of the Movement Disorder Society 25, 2682&#x2013;2685 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978754</ArticleId><ArticleId IdType="pubmed">20818673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S et al., Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to the Brain Models Parkinson&#x2019;s Disease. Neuron, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6706297</ArticleId><ArticleId IdType="pubmed">31255487</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM et al., Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Proceedings of the National Academy of Sciences of the United States of America 97, 2892&#x2013;2897 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM et al., Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer&#x2019;s disease. Neurobiology of disease 9, 305&#x2013;318 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11950276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo G, Schluter OM, Sudhof TC, A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nature neuroscience 11, 301&#x2013;308 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18297066</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR et al., Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience 29, 6771&#x2013;6779 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665579</ArticleId><ArticleId IdType="pubmed">19474305</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S, WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics 9, 559 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>The Gene Ontology Resource: 20 years and still GOing strong. Nucleic acids research 47, D330&#x2013;d338 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323945</ArticleId><ArticleId IdType="pubmed">30395331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M et al., Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature genetics 25, 25&#x2013;29 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi H et al., PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic acids research 45, D183&#x2013;d189 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210595</ArticleId><ArticleId IdType="pubmed">27899595</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, Lee VM, Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nature protocols 9, 2135&#x2013;2146 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372899</ArticleId><ArticleId IdType="pubmed">25122523</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ, Accuracy of clinical diagnosis of idiopathic Parkinson&#x2019;s disease: a clinico-pathological study of 100 cases. Journal of neurology, neurosurgery, and psychiatry 55, 181&#x2013;184 (1992).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference><Reference><Citation>Racette BA, Rundle M, Parsian A, Perlmutter JS, Evaluation of a screening questionnaire for genetic studies of Parkinson&#x2019;s disease. American journal of medical genetics 88, 539&#x2013;543 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10490713</ArticleId></ArticleIdList></Reference><Reference><Citation>Factor SA et al., Postural instability/gait disturbance in Parkinson&#x2019;s disease has distinct subtypes: an exploratory analysis. Journal of neurology, neurosurgery, and psychiatry 82, 564&#x2013;568 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646086</ArticleId><ArticleId IdType="pubmed">20884673</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32024798</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>529</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>APOE4 exacerbates &#x3b1;-synuclein pathology and related toxicity independent of amyloid.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaay1809</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aay1809</ELocationID><Abstract><AbstractText>The apolipoprotein E (<i>APOE</i>) &#x3b5;4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease mainly by driving amyloid-&#x3b2; pathology. Recently, <i>APOE4</i> has also been found to be a genetic risk factor for Lewy body dementia (LBD), which includes dementia with Lewy bodies and Parkinson's disease dementia. How <i>APOE4</i> drives risk of LBD and whether it has a direct effect on &#x3b1;-synuclein pathology are not clear. Here, we generated a mouse model of synucleinopathy using an adeno-associated virus gene delivery of &#x3b1;-synuclein in human APOE-targeted replacement mice expressing APOE2, APOE3, or APOE4. We found that APOE4, but not APOE2 or APOE3, increased &#x3b1;-synuclein pathology, impaired behavioral performances, worsened neuronal and synaptic loss, and increased astrogliosis at 9 months of age. Transcriptomic profiling in APOE4-expressing &#x3b1;-synuclein mice highlighted altered lipid and energy metabolism and synapse-related pathways. We also observed an effect of <i>APOE4</i> on &#x3b1;-synuclein pathology in human postmortem brains with LBD and minimal amyloid pathology. Our data demonstrate a pathogenic role of APOE4 in exacerbating &#x3b1;-synuclein pathology independent of amyloid, providing mechanistic insights into how <i>APOE4</i> increases the risk of LBD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Na</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8648-9422</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attrebi</LastName><ForeName>Olivia N</ForeName><Initials>ON</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Yingxue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Wenhui</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonustun</LastName><ForeName>Berkiye</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martens</LastName><ForeName>Yuka A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meneses</LastName><ForeName>Axel D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0002-8915-2590</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fuyao</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3986-2412</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shue</LastName><ForeName>Francis</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1659-1952</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Jiaying</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7457-6198</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Ingelgom</LastName><ForeName>Alexandra J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Mary D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-2123-4688</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurti</LastName><ForeName>Aishe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linares</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yixing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delenclos</LastName><ForeName>Marion</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3168-951X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chen</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-7203-3926</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fryer</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asmann</LastName><ForeName>Yan W</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Owen A</ForeName><Initials>OA</Initials><Identifier Source="ORCID">0000-0003-4813-756X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3491-1016</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA. bu.guojun@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS110435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057181</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Apr;16(4):185. doi: 10.1038/s41582-020-0335-5.</RefSource><PMID Version="1">32107475</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="Y">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074085" MajorTopicYN="N">Mice, Knockout, ApoE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080874" MajorTopicYN="Y">Synucleinopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="Y">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32024798</ArticleId><ArticleId IdType="mid">NIHMS1721284</ArticleId><ArticleId IdType="pmc">PMC8309690</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aay1809</ArticleId><ArticleId IdType="pii">12/529/eaay1809</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahkonen T et al., Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 74, 720&#x2013;724 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738491</ArticleId><ArticleId IdType="pubmed">12754338</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M, Dementia associated with Parkinson&#x2019;s disease. Lancet Neurol 2, 229&#x2013;237 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12849211</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF et al., DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68, 812&#x2013;819 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17353469</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG et al., Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88&#x2013;100 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui IJ, Pervaiz N, Abbasi AA, The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication. Sci Rep 6, 24475 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832246</ArticleId><ArticleId IdType="pubmed">27080380</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E et al., Multicenter analysis of glucocerebrosidase mutations in Parkinson&#x2019;s disease. N Engl J Med 361, 1651&#x2013;1661 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856322</ArticleId><ArticleId IdType="pubmed">19846850</ArticleId></ArticleIdList></Reference><Reference><Citation>Berge G, Sando SB, Rongve A, Aarsland D, White LR, Apolipoprotein E epsilon2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry 85, 1227&#x2013;1231 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4215279</ArticleId><ArticleId IdType="pubmed">24639435</ArticleId></ArticleIdList></Reference><Reference><Citation>Bras J et al., Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 23, 6139&#x2013;6146 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222357</ArticleId><ArticleId IdType="pubmed">24973356</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R et al., Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. The Lancet Neurology 17, 64&#x2013;74 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5805394</ArticleId><ArticleId IdType="pubmed">29263008</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D et al., APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70, 223&#x2013;228 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580799</ArticleId><ArticleId IdType="pubmed">23407718</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Chen P, Kaufer DI, Troster AI, Poole C, Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 63, 189&#x2013;193 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16476806</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ et al., Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72, 587&#x2013;598 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484250</ArticleId><ArticleId IdType="pubmed">23037886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9, 106&#x2013;118 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G, Apolipoprotein E and its receptors in Alzheimer&#x2019;s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10, 333&#x2013;344 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908393</ArticleId><ArticleId IdType="pubmed">19339974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Liu CC, Qiao W, Bu G, Apolipoprotein E, Receptors, and Modulation of Alzheimer&#x2019;s Disease. Biol Psychiatry, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599322</ArticleId><ArticleId IdType="pubmed">28434655</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG et al., Alpha-synuclein in Lewy bodies. Nature 388, 839&#x2013;840 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L, Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 10, 1015&#x2013;1025 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22014436</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel HA, Overk CR, Oueslati A, Masliah E, The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14, 38&#x2013;48 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4295774</ArticleId><ArticleId IdType="pubmed">23254192</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer M et al., Low frequency of alpha-synuclein mutations in familial Parkinson&#x2019;s disease. Ann Neurol 43, 394&#x2013;397 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger R et al., Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson&#x2019;s disease. Nat Genet 18, 106&#x2013;108 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredenburg RA et al., The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46, 7107&#x2013;7118 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17530780</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC et al., Alpha-synuclein locus duplication as a cause of familial Parkinson&#x2019;s disease. Lancet 364, 1167&#x2013;1169 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15451224</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB et al., alpha-Synuclein locus triplication causes Parkinson&#x2019;s disease. Science 302, 841 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Visanji NP et al., alpha-Synuclein-Based Animal Models of Parkinson&#x2019;s Disease: Challenges and Opportunities in a New Era. Trends Neurosci 39, 750&#x2013;762 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27776749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirik D et al., Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22, 2780&#x2013;2791 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758323</ArticleId><ArticleId IdType="pubmed">11923443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N et al., APOE epsilon2 is associated with increased tau pathology in primary tauopathy. Nat Commun 9, 4388 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197187</ArticleId><ArticleId IdType="pubmed">30348994</ArticleId></ArticleIdList></Reference><Reference><Citation>Delenclos M et al., Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain. Acta Neuropathol Commun 5, 51 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5481919</ArticleId><ArticleId IdType="pubmed">28645308</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM et al., Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging 32, 791&#x2013;801 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">19577821</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG et al., Intracellular processing of disease-associated alpha-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol Dis 69, 76&#x2013;92 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24878508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG et al., An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology. Acta Neuropathol 124, 37&#x2013;50 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22370907</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H et al., alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4, 160&#x2013;164 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen I, Chesselet MF, Mouse models of cognitive deficits due to alpha-synuclein pathology. J Parkinsons Dis 1, 217&#x2013;227 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">23939303</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Beyer MK, Kurz MW, Dementia in Parkinson&#x2019;s disease. Curr Opin Neurol 21, 676&#x2013;682 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18989112</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn DJ, Cortical Lewy body disease. J Neurol Neurosurg Psychiatry 75, 175&#x2013;178 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738936</ArticleId><ArticleId IdType="pubmed">14742580</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger K, Overview of morphological changes in Parkinson&#x2019;s disease. Adv Neurol 45, 1&#x2013;18 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3825687</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR, alpha-Synuclein and neuronal cell death. Mol Neurodegener 4, 9 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646729</ArticleId><ArticleId IdType="pubmed">19193223</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN et al., Brain injection of alpha-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J Neurosci 34, 12368&#x2013;12378 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6615494</ArticleId><ArticleId IdType="pubmed">25209277</ArticleId></ArticleIdList></Reference><Reference><Citation>Burda JE, Sofroniew MV, Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81, 229&#x2013;248 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3984950</ArticleId><ArticleId IdType="pubmed">24462092</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW et al., APOE epsilon4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology 91, e1182&#x2013;e1195 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6161556</ArticleId><ArticleId IdType="pubmed">30143564</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL et al., Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141, 2181&#x2013;2193 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022546</ArticleId><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW et al., Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet 10, e1004606 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropea TF et al., APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson&#x2019;s disease. Mov Disord 33, 289&#x2013;297 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5809205</ArticleId><ArticleId IdType="pubmed">29168904</ArticleId></ArticleIdList></Reference><Reference><Citation>Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW, Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59, 102&#x2013;112 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11790237</ArticleId></ArticleIdList></Reference><Reference><Citation>Olichney JM et al., Cognitive decline is faster in Lewy body variant than in Alzheimer&#x2019;s disease. Neurology 51, 351&#x2013;357 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9710002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Liu CC, Qiao W, Bu G, Apolipoprotein E, Receptors, and Modulation of Alzheimer&#x2019;s Disease. Biol Psychiatry 83, 347&#x2013;357 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599322</ArticleId><ArticleId IdType="pubmed">28434655</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM, Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273, 9443&#x2013;9449 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucci S, Ginevrino M, Valente EM, Phenotypic spectrum of alpha-synuclein mutations: New insights from patients and cellular models. Parkinsonism Relat Disord 22 Suppl 1, S16&#x2013;20 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26341711</ArticleId></ArticleIdList></Reference><Reference><Citation>Twohig D et al., The relevance of cerebrospinal fluid alpha-synuclein levels to sporadic and familial Alzheimer&#x2019;s disease. Acta Neuropathol Commun 6, 130 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6260771</ArticleId><ArticleId IdType="pubmed">30477568</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvagnion C, The Role of Lipids Interacting with alpha-Synuclein in the Pathogenesis of Parkinson&#x2019;s Disease. J Parkinsons Dis 7, 433&#x2013;450 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28671142</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622&#x2013;630 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinohara M et al., APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations. Ann Neurol 79, 758&#x2013;774 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010530</ArticleId><ArticleId IdType="pubmed">26933942</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG et al., Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119, 689&#x2013;702 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866090</ArticleId><ArticleId IdType="pubmed">20306269</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamzadeh FN, Allsop D, alpha-Synuclein Interacts with Lipoproteins in Plasma. J Mol Neurosci 63, 165&#x2013;172 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5674120</ArticleId><ArticleId IdType="pubmed">28887769</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamzadeh FN, Role of Apolipoproteins and alpha-Synuclein in Parkinson&#x2019;s Disease. J Mol Neurosci 62, 344&#x2013;355 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5541107</ArticleId><ArticleId IdType="pubmed">28695482</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamzadeh FN, Aojula H, McHugh PC, Allsop D, Effects of different isoforms of apoE on aggregation of the alpha-synuclein protein implicated in Parkinson&#x2019;s disease. Neurosci Lett 618, 146&#x2013;151 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921451</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Bae EJ, Lee SJ, Extracellular alpha--synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol 10, 92&#x2013;98 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24468877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD et al., In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener 8, 13 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640999</ArticleId><ArticleId IdType="pubmed">23601557</ArticleId></ArticleIdList></Reference><Reference><Citation>Achariyar TM et al., Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Mol Neurodegener 11, 74 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5146863</ArticleId><ArticleId IdType="pubmed">27931262</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzeja P, Terzic A, Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int J Mol Sci 10, 1729&#x2013;1772 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680645</ArticleId><ArticleId IdType="pubmed">19468337</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Gonzalez A, Kourembanas S, Wyatt TA, Mitsialis SA, Mutation of murine adenylate kinase 7 underlies a primary ciliary dyskinesia phenotype. Am J Respir Cell Mol Biol 40, 305&#x2013;313 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2645528</ArticleId><ArticleId IdType="pubmed">18776131</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto Y et al., Possible existence of lysosome-like organella within mitochondria and its role in mitochondrial quality control. PLoS One 6, e16054 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3022026</ArticleId><ArticleId IdType="pubmed">21264221</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura N et al., Mieap, a p53-inducible protein, controls mitochondrial quality by repairing or eliminating unhealthy mitochondria. PLoS One 6, e16060 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3022033</ArticleId><ArticleId IdType="pubmed">21264228</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura Y et al., BNIP3 and NIX mediate Mieap-induced accumulation of lysosomal proteins within mitochondria. PLoS One 7, e30767 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266916</ArticleId><ArticleId IdType="pubmed">22292033</ArticleId></ArticleIdList></Reference><Reference><Citation>Roesler R, Schwartsmann G, Gastrin-releasing peptide receptors in the central nervous system: role in brain function and as a drug target. Front Endocrinol (Lausanne) 3, 159 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3523293</ArticleId><ArticleId IdType="pubmed">23251133</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Yang et al., ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg AM et al., Association of Apolipoprotein E epsilon4 With Transactive Response DNA-Binding Protein 43. JAMA Neurol. 75, 1347&#x2013;1354 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6248121</ArticleId><ArticleId IdType="pubmed">30422173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H-S et al., Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE &#x3b5;4 haplotype status: a community-based cohort study. Lancet Neurol. 17, 773&#x2013;781 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6154505</ArticleId><ArticleId IdType="pubmed">30093249</ArticleId></ArticleIdList></Reference><Reference><Citation>Koriath C et al., ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid-beta copathology. Alzheimers Dement (Amst) 11, 277&#x2013;280 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6430720</ArticleId><ArticleId IdType="pubmed">30949567</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW et al., Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol 87, 269&#x2013;276 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7912027</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamowicz DH et al., Hippocampal alpha-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and Is Consistent with Spread of Pathology. J Neurosci 37, 1675&#x2013;1684 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320602</ArticleId><ArticleId IdType="pubmed">28039370</ArticleId></ArticleIdList></Reference><Reference><Citation>Riekkinen M, Kejonen K, Jakala P, Soininen H, Riekkinen P Jr., Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson&#x2019;s disease. Eur J Neurosci 10, 1429&#x2013;1435 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9749797</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawamoto N et al., Cognitive deficits and striato-frontal dopamine release in Parkinson&#x2019;s disease. Brain 131, 1294&#x2013;1302 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18362097</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday GM, Leverenz JB, Schneider JS, Adler CH, The neurobiological basis of cognitive impairment in Parkinson&#x2019;s disease. Mov Disord 29, 634&#x2013;650 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049032</ArticleId><ArticleId IdType="pubmed">24757112</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC et al., Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer&#x2019;s disease. Neuron 84, 63&#x2013;77 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4199382</ArticleId><ArticleId IdType="pubmed">25242217</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC et al., Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer&#x2019;s disease. Sci Transl Med 8, 332ra344 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5512541</ArticleId><ArticleId IdType="pubmed">27030596</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinohara M et al., Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer&#x2019;s disease. Acta Neuropathol 132, 225&#x2013;234 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947445</ArticleId><ArticleId IdType="pubmed">27179972</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N et al., Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. Neuron 96, 115&#x2013;129 e115 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5621659</ArticleId><ArticleId IdType="pubmed">28957663</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q et al., Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci 30, 17068&#x2013;17078 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146802</ArticleId><ArticleId IdType="pubmed">21159977</ArticleId></ArticleIdList></Reference><Reference><Citation>Maejima T et al., Postnatal loss of P/Q-type channels confined to rhombic-lip-derived neurons alters synaptic transmission at the parallel fiber to purkinje cell synapse and replicates genomic Cacna1a mutation phenotype of ataxia and seizures in mice. J Neurosci 33, 5162&#x2013;5174 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3641643</ArticleId><ArticleId IdType="pubmed">23516282</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyenet SJ et al., A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp, (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121238</ArticleId><ArticleId IdType="pubmed">20495529</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu JW, Li YF, Wang ZT, Jia WQ, Xu RX, Toll-Like Receptor 4 Deficiency Impairs Motor Coordination. Front Neurosci 10, 33 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754460</ArticleId><ArticleId IdType="pubmed">26909014</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalari KR et al., MAP-RSeq: Mayo Analysis Pipeline for RNA sequencing. BMC Bioinformatics 15, 224 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4228501</ArticleId><ArticleId IdType="pubmed">24972667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen KD, Irizarry RA, Wu Z, Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics 13, 204&#x2013;216 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297825</ArticleId><ArticleId IdType="pubmed">22285995</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S, WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z et al., VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies. Nucleic Acids Res 41, W225&#x2013;231 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692070</ArticleId><ArticleId IdType="pubmed">23716640</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32032505</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>180</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains.</ArticleTitle><Pagination><StartPage>633</StartPage><EndPage>644.e12</EndPage><MedlinePgn>633-644.e12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2020.01.027</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(20)30108-2</ELocationID><Abstract><AbstractText>Tau aggregation into insoluble filaments is the defining pathological hallmark of tauopathies. However, it is not known what controls the formation and templated seeding of strain-specific structures associated with individual tauopathies. Here, we use cryo-electron microscopy (cryo-EM) to determine the structures of tau filaments from corticobasal degeneration (CBD) human brain tissue. Cryo-EM and mass spectrometry of tau filaments from CBD reveal that this conformer is heavily decorated with posttranslational modifications (PTMs), enabling us to map PTMs directly onto the structures. By comparing the structures and PTMs of tau filaments from CBD and Alzheimer's disease, it is found that ubiquitination of tau can mediate inter-protofilament interfaces. We propose a structure-based model in which cross-talk between PTMs influences tau filament structure, contributing to the structural diversity of&#xa0;tauopathy strains. Our approach establishes a framework for further elucidating the relationship between the structures of polymorphic fibrils, including their PTMs, and neurodegenerative disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arakhamia</LastName><ForeName>Tamta</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Christina E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlomagno</LastName><ForeName>Yari</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Duc M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kundinger</LastName><ForeName>Sean R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Dewight</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>John M. Cowley Center for High Resolution Electron Microscopy, Arizona State University, Tempe, AZ 85287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeTure</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Casey N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nicholas T</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA; Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA. Electronic address: petrucelli.leonard@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Anthony W P</ForeName><Initials>AWP</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: anthony.fitzpatrick@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062171</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061800</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103310</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR001209</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061357</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088689</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 GM116792</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056151</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023057</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100693</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS110438</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053960</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018111</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062077</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS099114</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Mol Cell Biol. 2020 Apr;21(4):180. doi: 10.1038/s41580-020-0233-0.</RefSource><PMID Version="1">32127686</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Cell. 2021 Dec 9;184(25):6207-6210. doi: 10.1016/j.cell.2021.11.029.</RefSource><PMID Version="1">34890553</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">acetylation</Keyword><Keyword MajorTopicYN="N">corticobasal degeneration</Keyword><Keyword MajorTopicYN="N">cryo-EM</Keyword><Keyword MajorTopicYN="N">integrated structural biology</Keyword><Keyword MajorTopicYN="N">posttranslational modifications</Keyword><Keyword MajorTopicYN="N">tau strains</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword><Keyword MajorTopicYN="N">templated seeding</Keyword><Keyword MajorTopicYN="N">ubiquitination</Keyword></KeywordList><CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32032505</ArticleId><ArticleId IdType="mid">NIHMS1569114</ArticleId><ArticleId IdType="pmc">PMC7491959</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.01.027</ArticleId><ArticleId IdType="pii">S0092-8674(20)30108-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abreha MH, Dammer EB, Ping L, Zhang T, Duong DM, Gearing M, Lah JJ, Levey AI, and Seyfried NT (2018). Quantitative Analysis of the Brain Ubiquitylome in Alzheimer&#x2019;s Disease. Proteomics 18, e1800108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6283072</ArticleId><ArticleId IdType="pubmed">30230243</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV, Poon BK, Read RJ, Sobolev OV, Terwilliger TC, Urzhumtsev A, and Adams PD (2018). Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D Struct. Biol 74, 531&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096492</ArticleId><ArticleId IdType="pubmed">29872004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B, Hales CM, Chen PC, Gozal Y, Dammer EB, Fritz JJ, Wang X, Xia Q, Duong DM, Street C, et al. (2013). U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. USA 110, 16562&#x2013;16567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799305</ArticleId><ArticleId IdType="pubmed">24023061</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, and Trojanowski JQ (2007). Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat. Rev. Neurosci 8, 663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom GS (2014). Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 71, 505&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">24493463</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer D, and Eisenberg DS (2019). A structure-based model for the electrostatic interaction of the N-terminus of protein tau with the fibril core of Alzheimer&#x2019;s disease filaments. Alzheimer&#x2019;s &amp; Dementia 15, 321.</Citation></Reference><Reference><Citation>Braak H, and Braak E. (1998). Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J. Neural. Transm 105, 801&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">9869320</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, McMullan G, Faruqi AR, Murshudov GN, Short JM, Scheres SH, and Henderson R. (2013). High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy 135, 24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, and Richardson DC (2010). MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr 66, 12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, and Lee VM (2011). The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun 2, 252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120096</ArticleId><ArticleId IdType="pubmed">21427723</ArticleId></ArticleIdList></Reference><Reference><Citation>Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, and Yang AJ (2006). Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J. Biol. Chem 281, 10825&#x2013;10838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443603</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA (1991). Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc. Natl. Acad. Sci. USA 88, 2288&#x2013;2292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51216</ArticleId><ArticleId IdType="pubmed">1706519</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, Zehr C, West G, Cao S, Clark AM, et al. (2006). Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J. Neurosci 26, 6985&#x2013;6996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673930</ArticleId><ArticleId IdType="pubmed">16807328</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Kouri N, Murray ME, and Josephs KA (2011). Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J. Mol. Neurosci 45, 384&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208128</ArticleId><ArticleId IdType="pubmed">21720721</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Yen SH, Suzuki KI, Davies P, Garcia JH, and Hirano A. (1986). Ballooned neurons in select neurodegenerative diseases contain phosphorylated neurofilament epitopes. Acta Neuropathol. 71, 216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">2432750</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D, and Jucker M. (2012). The amyloid state of proteins in human diseases. Cell 148, 1188&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, and Cowtan K. (2010). Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr 66, 486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercan E, Eid S, Weber C, Kowalski A, Bichmann M, Behrendt A, Matthes F, Krauss S, Reinhardt P, Fulle S, et al. (2017). A validated antibody panel for the characterization of tau post-translational modifications. Mol. Neurodegener 12, 87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5697095</ArticleId><ArticleId IdType="pubmed">29157277</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R, Crowther RA, Ghetti B, Scheres SHW, and Goedert M. (2018a). Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature 561, 137&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Schweighauser M, Murzin AG, Vidal R, Garringer HJ, Ghetti B, Scheres SHW, and Goedert M. (2018b). Tau filaments from multiple cases of sporadic and inherited Alzheimer&#x2019;s disease adopt a common fold. Acta Neuropathol. 136, 699&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208733</ArticleId><ArticleId IdType="pubmed">30276465</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zivanov J, Zhang W, Murzin AG, Garringer HJ, Vidal R, Crowther RA, Newell KL, Ghetti B, Goedert M, et al. (2019). Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Farid M, Corbo CP, and Alonso Adel C. (2014). Tau binds ATP and induces its aggregation. Microsc. Res. Tech 77, 133&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">24258797</ArticleId></ArticleIdList></Reference><Reference><Citation>Feany MB, and Dickson DW (1995). Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am. J. Pathol 146, 1388&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1870913</ArticleId><ArticleId IdType="pubmed">7778678</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldblum ES, and Arkin IT (2014). Strength of a bifurcated H bond. Proc. Natl. Acad. Sci. USA 111, 4085&#x2013;4090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964065</ArticleId><ArticleId IdType="pubmed">24591597</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Debelouchina GT, Bayro MJ, Clare DK, Caporini MA, Bajaj VS, Jaroniec CP, Wang L, Ladizhansky V, Muller SA, et al. (2013). Atomic structure and hierarchical assembly of a cross-beta amyloid fibril. Proc. Natl. Acad. Sci. USA 110, 5468&#x2013;5473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619355</ArticleId><ArticleId IdType="pubmed">23513222</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, and Scheres SHW (2017). Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, and Saibil HR (2019). Cryo-EM of amyloid fibrils and cellular aggregates. Curr. Opin. Struct. Biol 58, 34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778506</ArticleId><ArticleId IdType="pubmed">31200186</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Falcon B, Zhang W, Ghetti B, and Scheres SHW (2018). Distinct Conformers of Assembled Tau in Alzheimer&#x2019;s and Pick&#x2019;s Diseases. Cold Spring Harb. Symp. Quant. Biol 83, 163&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">30886056</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, Gathagan RJ, Iba M, McBride JD, Trojanowski JQ, et al. (2016). Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J. Exp. Med 213, 2635&#x2013;2654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Haj-Yahya M, Fauvet B, Herman-Bachinsky Y, Hejjaoui M, Bavikar SN, Karthikeyan SV, Ciechanover A, Lashuel HA, and Brik A. (2013). Synthetic polyubiquitinated alpha-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc. Natl. Acad. Sci. USA 110, 17726&#x2013;17731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3816408</ArticleId><ArticleId IdType="pubmed">24043770</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, and Scheres SHW (2017). Helical reconstruction in RELION. J. Struct. Biol 198, 163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Higginbotham L, Ping L, Dammer EB, Duong DM, Zhou M, Gearing M, Johnson ECB, Hajjar I, Lah JJ, Levey AI, et al. (2019). Integrated Proteomics Reveals Brain-Based Cerebrospinal Fluid Biomarkers in Asymptomatic and Symptomatic Alzheimer&#x2019;s Disease. bioRxiv, 10.1101/806752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/806752</ArticleId><ArticleId IdType="pmc">PMC7577712</ArticleId><ArticleId IdType="pubmed">33087358</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, and Radford SE (2018a). A new era for understanding amyloid structures and disease. Nat. Rev. Mol. Cell Biol 19, 755&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">30237470</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadanza MG, Silvers R, Boardman J, Smith HI, Karamanos TK, Debelouchina GT, Su Y, Griffin RG, Ranson NA, and Radford SE (2018b). The structure of a beta2-microglobulin fibril suggests a molecular basis for its amyloid polymorphism. Nat. Commun 9, 4517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6207761</ArticleId><ArticleId IdType="pubmed">30375379</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ (2016). Tauopathies as clinicopathological entities. Parkinsonism Relat. Disord 22 Suppl 1, S29&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4662611</ArticleId><ArticleId IdType="pubmed">26382841</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM, and Trojanowski JQ (2012). Acetylated tau, a novel pathological signature in Alzheimer&#x2019;s disease and other tauopathies. Brain 135, 807&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286338</ArticleId><ArticleId IdType="pubmed">22366796</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam T-I, Mao X, Park H, Chou S-C, Karuppagounder SS, Umanah GE, Yun SP, Brahmachari S, Panicker N, Chen R, et al. (2018). Poly(ADP-ribose) drives pathologic &#x3b1;-synuclein neurodegeneration in Parkinson&#x2019;s disease. Science 362, eaat8407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6431793</ArticleId><ArticleId IdType="pubmed">30385548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamieniarz K, and Schneider R. (2009). Tools to tackle protein acetylation. Chem. Biol 16, 1027&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">19875076</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, Miller TM, and Diamond MI (2016). Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron 92, 796&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392364</ArticleId><ArticleId IdType="pubmed">27974162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd M. (1963). Paired Helical Filaments in Electron Microscopy of Alzheimer&#x2019;s Disease. Nature 197, 192&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">14032480</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles TP, Vendruscolo M, and Dobson CM (2014). The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol 15, 384&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">24854788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmer M, Close W, Funk L, Rasmussen J, Bsoul A, Schierhorn A, Schmidt M, Sigurdson CJ, Jucker M, and F&#xe4;ndrich M. (2019). Cryo-EM structure and olymorphism of A&#x3b2; amyloid fibrils purified from Alzheimer&#x2019;s brain tissue. Nat. Commun 10, 4760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820800</ArticleId><ArticleId IdType="pubmed">31664019</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontaxi C, Piccardo P, and Gill AC (2017). Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer&#x2019;s Disease and Related Tauopathies. Front. Mol. Biosci 4, 56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554484</ArticleId><ArticleId IdType="pubmed">28848737</ArticleId></ArticleIdList></Reference><Reference><Citation>Krissinel E, and Henrick K. (2007). Inference of macromolecular assemblies from crystalline state. J. Mol. Biol 372, 774&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">17681537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiezak-Reding H, Tracz E, Yang LS, Dickson DW, Simon M, and Wall JS (1996). Ultrastructural instability of paired helical filaments from corticobasal degeneration as examined by scanning transmission electron microscopy. Am. J. Pathol 149, 639&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865307</ArticleId><ArticleId IdType="pubmed">8702002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuazi AD, Kito K, Abe Y, Shin R-W, Kamitani T, and Ueda N. (2003). NEDD8 protein is involved in ubiquitinated inclusion bodies. J. Pathol 199, 259&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">12533840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukelbir A, Sigworth FJ, and Tagare HD (2014). Quantifying the local resolution of cryo-EM density maps. Nat. Methods 11, 63&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903095</ArticleId><ArticleId IdType="pubmed">24213166</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MJ, Lee JH, and Rubinsztein DC (2013). Tau degradation: the ubiquitinproteasome system versus the autophagy-lysosome system. Prog. Neurobiol 105, 49&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">23528736</ArticleId></ArticleIdList></Reference><Reference><Citation>Losev Y, Paul A, Frenkel-Pinter M, Abu-Hussein M, Khalaila I, Gazit E, and Segal D. (2019). Novel model of secreted human tau protein reveals the impact of the abnormal N-glycosylation of tau on its aggregation propensity. Sci. Rep 9, 2254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6381127</ArticleId><ArticleId IdType="pubmed">30783169</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo HB, Xia YY, Shu XJ, Liu ZC, Feng Y, Liu XH, Yu G, Yin G, Xiong YS, Zeng K, et al. (2014). SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc. Natl. Acad. Sci. USA 111, 16586&#x2013;16591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4246270</ArticleId><ArticleId IdType="pubmed">25378699</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, and Mandelkow E. (2012). Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med 2, a006247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385935</ArticleId><ArticleId IdType="pubmed">22762014</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, et al. (2010). Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035103</ArticleId><ArticleId IdType="pubmed">20869593</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL, and Mucke L. (2015). Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci 18, 1183&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049446</ArticleId><ArticleId IdType="pubmed">26192747</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, and Duff KE (2016). Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat. Med 22, 46&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4787271</ArticleId><ArticleId IdType="pubmed">26692334</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Lee JH, Jeon JH, and Lee MJ (2018). Degradation or aggregation: the ramifications of post-translational modifications on tau. BMB Rep. 51, 265&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6033068</ArticleId><ArticleId IdType="pubmed">29661268</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, Inuganti A, Griss J, Mayer G, Eisenacher M, et al. (2019). The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442&#x2013;D450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323896</ArticleId><ArticleId IdType="pubmed">30395289</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, and Tycko R. (2005). Self-propagating, molecular-level polymorphism in Alzheimer&#x2019;s beta-amyloid fibrils. Science 307, 262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, et al. (2004). CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet 13, 703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, and Ferrin TE (2004). UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem 25, 1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Schr&#xf6;dinger LLC (2017). The PyMOL Molecular Graphics System, Version 2.0.</Citation></Reference><Reference><Citation>Sergeant N, Wattez A, and Delacourte A. (1999). Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively &#x201c;exon 10&#x201d; isoforms. J. Neurochem 72, 1243&#x2013;1249.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037497</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormanni P, Aprile FA, and Vendruscolo M. (2015). The CamSol method of rational design of protein mutants with enhanced solubility. J. Mol. Biol 427, 478&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">25451785</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaney DL, McAlister GC, and Coon JJ (2008). Decision tree-driven tandem mass spectrometry for shotgun proteomics. Nat. Methods 5, 959&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597439</ArticleId><ArticleId IdType="pubmed">18931669</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD (1963). The Fine Structure of Neurofibrillary Tangles in Alzheimer&#x2019;s Disease. J. Neuropathol. Exp. Neurol 22, 629&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">14069842</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracz E, Dickson DW, Hainfeld JF, and Ksiezak-Reding H. (1997). Paired helical filaments in corticobasal degeneration: the fine fibrillary structure with NanoVan. Brain Res. 773, 33&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9409702</ArticleId></ArticleIdList></Reference><Reference><Citation>Truscott RJW, Schey KL, and Friedrich MG (2016). Old Proteins in Man: A Field in its Infancy. Trends Biochem. Sci 41, 654&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5500981</ArticleId><ArticleId IdType="pubmed">27426990</ArticleId></ArticleIdList></Reference><Reference><Citation>Trzeciakiewicz H, Tseng JH, Wander CM, Madden V, Tripathy A, Yuan CX, and Cohen TJ (2017). A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy. Sci. Rep 7, 44102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5347034</ArticleId><ArticleId IdType="pubmed">28287136</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Grundke-Iqbal I, and Iqbal K. (1996). Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer&#x2019;s disease. Nat. Med 2, 871&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705855</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnecke A, Sandalova T, Achour A, and Harris RA (2014). PyTMs: a useful PyMOL plugin for modeling common post-translational modifications. BMC Bioinformatics 15, 370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256751</ArticleId><ArticleId IdType="pubmed">25431162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y, Klenerman D, and Finley D. (2019). N-Terminal Ubiquitination of Amyloidogenic Proteins Triggers Removal of Their Oligomers by the Proteasome Holoenzyme. J. Mol. Biol</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990400</ArticleId><ArticleId IdType="pubmed">31518613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Dennissen FJA, Kumar Y, Luedtke J, Biernat J, Mandelkow EM, and Mandelkow E. (2017). Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture. J. Biol. Chem 292, 12192&#x2013;12207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519369</ArticleId><ArticleId IdType="pubmed">28536263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K. (2016). Gctf: Real-time CTF determination and correction. J. Struct. Biol 193, 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Falcon B, Murzin AG, Fan J, Crowther RA, Goedert M, and Scheres SH (2019a). Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. Elife 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B, Vidal R, Garringer HJ, Shi Y, Ikeuchi T, et al. (2019b). Novel tau filament fold in corticobasal degeneration, a four-repeat tauopathy. bioRxiv 10.1101/811703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/811703</ArticleId><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ, Palovcak E, Armache JP, Verba KA, Cheng Y, and Agard DA (2017). MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32050258</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>580</Volume><Issue>7802</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Novel tau filament fold in corticobasal degeneration.</ArticleTitle><Pagination><StartPage>283</StartPage><EndPage>287</EndPage><MedlinePgn>283-287</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2043-0</ELocationID><Abstract><AbstractText>Corticobasal degeneration (CBD) is a neurodegenerative tauopathy-a class of disorders in which the tau protein forms insoluble inclusions in the brain-that is characterized by motor and cognitive disturbances<sup>1-3</sup>. The H1 haplotype of MAPT (the tau gene) is present in cases of CBD at a higher frequency than in controls<sup>4,5</sup>, and genome-wide association studies have identified additional risk factors<sup>6</sup>. By histology, astrocytic plaques are diagnostic of CBD<sup>7,8</sup>; by SDS-PAGE, so too are detergent-insoluble, 37&#xa0;kDa fragments of tau<sup>9</sup>. Like progressive supranuclear palsy, globular glial tauopathy and argyrophilic grain disease<sup>10</sup>, CBD is characterized by abundant filamentous tau inclusions that are made of isoforms with four microtubule-binding repeats<sup>11-15</sup>. This distinguishes such '4R' tauopathies from Pick's disease (the filaments of which are made of three-repeat (3R) tau isoforms) and from Alzheimer's disease and chronic traumatic encephalopathy (CTE) (in which both 3R and 4R isoforms are found in the filaments)<sup>16</sup>. Here we use cryo-electron microscopy to analyse the structures of tau filaments extracted from the brains of three individuals with CBD. These filaments were identical between cases, but distinct from those seen in Alzheimer's disease, Pick's disease and CTE<sup>17-19</sup>. The core of a CBD filament comprises residues lysine 274 to glutamate 380 of tau, spanning the last residue of the R1 repeat, the whole of the R2, R3 and R4 repeats, and 12 amino acids after R4. The core adopts a previously unseen four-layered fold, which encloses a large nonproteinaceous density. This density is surrounded by the side chains of lysine residues 290 and 294 from R2 and lysine 370 from the sequence after R4.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarutani</LastName><ForeName>Airi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newell</LastName><ForeName>Kathy L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzin</LastName><ForeName>Alexey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsubara</LastName><ForeName>Tomoyasu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcon</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garringer</LastName><ForeName>Holly J</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-1899-7676</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8828-8085</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1842-8019</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. mg@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><Identifier Source="ORCID">0000-0002-0462-6540</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. scheres@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS110437</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070627" MajorTopicYN="N">Chronic Traumatic Encephalopathy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="N">Pick Disease of the Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b> The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32050258</ArticleId><ArticleId IdType="mid">EMS85703</ArticleId><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2043-0</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-2043-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lhermitte J, L&#xe9;vy G &amp; Kyriaco N Les perturbations de la repr&#xe9;sentation spatiale chez les apraxiques. Rev. Neurol. (Paris) 2, 586&#x2013;600 (1925).</Citation></Reference><Reference><Citation>Rebeiz JJ, Kolodny EH &amp; Richardson EP Corticodentatonigral degeneration with neuronal achromasia. Arch. Neurol 18, 20&#x2013;33 (1968).</Citation><ArticleIdList><ArticleId IdType="pubmed">5634369</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibb WRG, Luthert PJ &amp; Marsden CD Corticobasal degeneration. Brain 112, 1171&#x2013;1192 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2478251</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Maria E et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann. Neurol 47, 374&#x2013;377 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10716259</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlden H et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56, 1702&#x2013;1706 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11425937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouri N et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat. Commun 6, 7247 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469997</ArticleId><ArticleId IdType="pubmed">26077951</ArticleId></ArticleIdList></Reference><Reference><Citation>Feany MB &amp; Dickson DW Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am. J. Pathol 146, 1388&#x2013;1396 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1870913</ArticleId><ArticleId IdType="pubmed">7778678</ArticleId></ArticleIdList></Reference><Reference><Citation>Komori T et al. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 96, 401&#x2013;407 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9797005</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T et al. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann. Neurol 55, 72&#x2013;79 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14705114</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;sler TW et al. Four-repeat tauopathies. Prog. Neurobiol 180, 101644 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31238088</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulus W &amp; Selim W Corticonigral degeneration with neuronal achromasia and basal neurofibrillary tangles. Acta Neuropathol. 81, 89&#x2013;94 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2085097</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K et al. Corticobasal degeneration: Etiopathological significance of the cytoskeletal alterations. Acta Neuropathol. 87, 545&#x2013;553 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8091948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiezak-Reding H et al. Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am. J. Pathol 145, 1496&#x2013;1508 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887493</ArticleId><ArticleId IdType="pubmed">7992852</ArticleId></ArticleIdList></Reference><Reference><Citation>Arima K et al. Corticonigral degeneration with neuronal achromasia presenting with primary progressive aphasia: Ultrastructural and immunocytochemical studies. J. Neurol. Sci 127, 186&#x2013;197 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7707078</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N, Wattez A &amp; Delacourte A Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: Tau pathologies with exclusively &#x201c;exon 10&#x201d; isoforms. J. Neurochem 72, 1243&#x2013;1249 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10037497</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Eisenberg DS &amp; Crowther RA Propagation of tau aggregates and neurodegeneration. Annu. Rev. Neurosci 40, 189&#x2013;210 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature 561, 137&#x2013;140 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420&#x2013;423 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 131, 267&#x2013;280 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiezak-Reding H et al. Ultrastructural instability of paired helical filaments from corticobasal degeneration as examined by scanning transmission electron microscopy. Am. J. Pathol 149, 639&#x2013;651 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865307</ArticleId><ArticleId IdType="pubmed">8702002</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141, 2181&#x2013;2193 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022546</ArticleId><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J. Neuropathol. Exp. Neurol 67, 555&#x2013;564 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali CP et al. C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathol. 138, 795&#x2013;811 (2019)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802287</ArticleId><ArticleId IdType="pubmed">31327044</ArticleId></ArticleIdList></Reference><Reference><Citation>He S &amp; Scheres SHW Helical reconstruction in RELION. J. Struct. Biol 198, 163&#x2013;176 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H et al. Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain 139, 3237&#x2013;3252 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27797812</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K et al. Perivascular orientation of astrocytic plaques and tuft-shaped astrocytes. Brain Res. 1404, 50&#x2013;54 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21722877</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M et al. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron 3, 519&#x2013;526 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. USA 110, 9535&#x2013;9540 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan S et al. Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. J. Neurosci 37, 11406&#x2013;11423 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5700423</ArticleId><ArticleId IdType="pubmed">29054878</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Bergen M et al. Assembly of &#x3c4; protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming &#x3b2; structure. Proc. Natl. Acad. Sci. USA 97, 5129&#x2013;5134 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Bergen M et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local &#x3b2;-structure. J. Biol. Chem 276, 48165&#x2013;48174 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11606569</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Conformation determines the seeding potencies of native and recombinant tau aggregates. J. Biol. Chem 290, 1049&#x2013;1065 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4294473</ArticleId><ArticleId IdType="pubmed">25406315</ArticleId></ArticleIdList></Reference><Reference><Citation>Macdonald JA et al. Assembly of transgenic human P301S Tau is necessary for neurodegeneration in murine spinal cord. Acta Neuropathol. Commun 7, 44 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6421678</ArticleId><ArticleId IdType="pubmed">30885267</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustke N et al. Domains of tau protein and interactions with microtubules. Biochemistry 33, 9511&#x2013;9522 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8068626</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. eLife 8: e43584 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan A et al. Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer&#x2019;s disease brain. Acta Neuropathol. Commun 1: 54 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893535</ArticleId><ArticleId IdType="pubmed">24252707</ArticleId></ArticleIdList></Reference><Reference><Citation>Kara E et al. The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol. Aging 33, 2231.e7&#x2013;2231.e14 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657164</ArticleId><ArticleId IdType="pubmed">22595371</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer&#x2019;s disease. Hum. Mol. Genet 21, 3500&#x2013;3512 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392107</ArticleId><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad C et al. Differences in a dinucleotide repeat polymorphism in the tau gene between Caucasian and Japanese populations: implication for progressive supranuclear palsy. Neurosci. Lett 250, 135&#x2013;137 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9697937</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans W et al. The tau H2 haplotype is almost exclusively Caucasian in origin. Neurosci. Lett 369, 183&#x2013;185 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15464261</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow JL et al. Whole-exome sequencing in familial Parkinson disease. JAMA Neurol. 73, 68&#x2013;75 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4946647</ArticleId><ArticleId IdType="pubmed">26595808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M &amp; Hakonarson H ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ &amp; Crowther RA Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8, 159&#x2013;168 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>De Silva R et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol. Appl. Neurobiol 29, 288&#x2013;302 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12787326</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercken M et al. Monoclonal antibodies with selective specificity for Alzheimer tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 84, 265&#x2013;272 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1384266</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol 64, 60&#x2013;70 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Inukai Y et al. Abnormal phosphorylation of Ser 409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett. 582, 2899&#x2013;2904 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18656473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebashi M et al. Detection of AD-specific four repeat tau with deamidated asparagine residue 279-specific fraction purified from 4R tau polyclonal antibody. Acta Neuropathol. 138, 163&#x2013;166 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570692</ArticleId><ArticleId IdType="pubmed">31006065</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S et al. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain 131, 72&#x2013;89 (2008)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702832</ArticleId><ArticleId IdType="pubmed">18065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallyas F Silver staining of Alzheimer&#x2019;s neurofibrillary changes by means of physical development. Acta Morphol. Acad. Sci. Hung 19, 1&#x2013;8 (1971).</Citation><ArticleIdList><ArticleId IdType="pubmed">4107507</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Ohm T &amp; Bohl J Silver impregnation of Alzheimer&#x2019;s neurofibrillary changes counterstained for basophilic material and lipofuscin pigment. Stain Technol. 63, 197&#x2013;200 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2464205</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Watanabe ST, Iwatsubo T, &amp; Hasegawa M Seeded aggregation and toxicity of alpha-synuclein and tau: cellular models of neurodegenerative diseases. J. Biol. Chem 285, 34885&#x2013;34898 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966103</ArticleId><ArticleId IdType="pubmed">20805224</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ et al. MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Meth 14, 331&#x2013;332 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K Gctf: Real-time CTF determination and correction. J. Struct. Biol 193, 1&#x2013;12 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol 180, 519&#x2013;530 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690530</ArticleId><ArticleId IdType="pubmed">23000701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy 135, 24&#x2013;35 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J et al. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ 6, 5&#x2013;17(2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327179</ArticleId><ArticleId IdType="pubmed">30713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG &amp; Cowtan K Features and development of Coot. Acta Crystallogr. D 66, 486&#x2013;501 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12&#x2013;21 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Vagin AA &amp; Dodson EJ Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240&#x2013;255 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213&#x2013;221 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32101309</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Longitudinal Maintenance of Cognitive Health in Centenarians in the 100-plus Study.</ArticleTitle><Pagination><StartPage>e200094</StartPage><MedlinePgn>e200094</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e200094</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2020.0094</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Some individuals who reach ages beyond 100 years in good cognitive health may be resilient against risk factors associated with cognitive decline. Exploring the processes underlying resilience may contribute to the development of therapeutic strategies that help to maintain cognitive health while aging.</AbstractText><AbstractText Label="OBJECTIVE">To identify individuals who escape cognitive decline until extreme ages and to investigate the prevalence of associated risk factors.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The 100-plus Study is a prospective observational cohort study of community-based Dutch centenarians enrolled between 2013 and 2019 who were visited annually until death or until participation was no longer possible. The centenarians self-reported their cognitive health, as confirmed by a proxy. Of the 1023 centenarians approached for study inclusion, 340 fulfilled the study criteria and were included in analyses. Data analysis was performed from April 2019 to December 2019.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Cognition was assessed using the Mini-Mental State Examination (MMSE). To identify centenarians who escape cognitive decline, this study investigated the association of baseline cognition with survivorship and cognitive trajectories for at least 2 years of follow-up using linear mixed models, adjusted for sex, age, and education. This study investigated the prevalence of apolipoprotein E (APOE) genotypes and cardiovascular disease as risk factors associated with cognitive decline.</AbstractText><AbstractText Label="RESULTS">At baseline, the median age of 340 centenarians was 100.5 years (range, 100.0-108.2 years); 245 participants (72.1%) were female. The maximum survival estimate plateaued at 82% per year (95% CI, 77% to 87%) across centenarians who scored 26 to 30 points on the baseline MMSE (hazard ratio,&#x2009;0.56; 95% CI, 0.42 to 0.75; P&#x2009;&lt;&#x2009;.001), suggesting that an MMSE score of 26 or higher is representative of both cognitive and physical health. Among the 79 centenarians who were followed up for 2 years or longer, those with baseline MMSE score less than 26 experienced a decline in MMSE score of 1.68 points per year (95% CI, -2.45 to -0.92 points per year; P&#x2009;=&#x2009;.02), whereas centenarians with MMSE scores of 26 or higher at baseline experienced a decline of 0.71 point per year (95% CI, -1.08 to -0.35 points per year). For 73% of the centenarians with baseline MMSE scores of 26 or higher, no cognitive changes were observed, which often extended to ensuing years or until death. It is estimated that this group is representative of less than 10% of Dutch centenarians. In this group, 18.6% carried at least 1 APOE-&#x3b5;4 allele, compared with 5.6% of the centenarians with lower and/or declining cognitive performance.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Most centenarians who scored 26 or higher on the MMSE at baseline maintained high levels of cognitive performance for at least 2 years, in some cases despite the presence of risk factors associated with cognitive decline. Investigation of this group might reveal the processes underlying resilience against risk factors associated with cognitive decline.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beker</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sikkes</LastName><ForeName>Sietske A M</ForeName><Initials>SAM</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Psychology, Neuropsychology, and Developmental Psychology, Faculty of Behavioural and Movement Sciences, Vrije Universiteit, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hulsman</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tesi</LastName><ForeName>Niccol&#xf2;</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Sven J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holstege</LastName><ForeName>Henne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Sikkes reported receiving grants from Zon-MW during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32101309</ArticleId><ArticleId IdType="pmc">PMC7137688</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.0094</ArticleId><ArticleId IdType="pii">2761867</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>United Nations Department of Economic and Social Affairs, Population Division  World population ageing. https://www.un.org/en/development/desa/population/publications/pdf/ageing/WPA2015_Report.pdf. Published 2015. Accessed January 15, 2020.</Citation></Reference><Reference><Citation>Robine J-M, Cubaynes S. Worldwide demography of centenarians. Mech Ageing Dev. 2017;165(Pt B):-. doi:10.1016/j.mad.2017.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2017.03.004</ArticleId><ArticleId IdType="pubmed">28315698</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol. 2010;67(1):114-121. doi:10.1002/ana.21915</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21915</ArticleId><ArticleId IdType="pmc">PMC3385995</ArticleId><ArticleId IdType="pubmed">20186856</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio B, Ostan R, Mari D, et al. . Cognitive status in the oldest old and centenarians: a condition crucial for quality of life methodologically difficult to assess. Mech Ageing Dev. 2017;165(Pt B):185-194. doi:10.1016/j.mad.2017.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2017.02.010</ArticleId><ArticleId IdType="pubmed">28286214</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Fratiglioni L. Aging without dementia is achievable: current evidence from epidemiological research. J Alzheimers Dis. 2018;62(3):933-942. doi:10.3233/JAD-171037</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-171037</ArticleId><ArticleId IdType="pmc">PMC5870011</ArticleId><ArticleId IdType="pubmed">29562544</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon LW, Woodard JL, Stephen Miller L, et al. . Understanding dementia prevalence among centenarians. J Gerontol A Biol Sci Med Sci. 2012;67(4):358-365. doi:10.1093/gerona/glr250</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glr250</ArticleId><ArticleId IdType="pmc">PMC3309877</ArticleId><ArticleId IdType="pubmed">22389466</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvert JF Jr, Hollander-Rodriguez J, Kaye J, Leahy M. Dementia-free survival among centenarians: an evidence-based review. J Gerontol A Biol Sci Med Sci. 2006;61(9):951-956. doi:10.1093/gerona/61.9.951</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/61.9.951</ArticleId><ArticleId IdType="pubmed">16960026</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen SL, Sebastiani P, Dworkis DA, Feldman L, Perls TT. Health span approximates life span among many supercentenarians: compression of morbidity at the approximate limit of life span. J Gerontol A Biol Sci Med Sci. 2012;67(4):395-405. doi:10.1093/gerona/glr223</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glr223</ArticleId><ArticleId IdType="pmc">PMC3309876</ArticleId><ArticleId IdType="pubmed">22219514</ArticleId></ArticleIdList></Reference><Reference><Citation>Robine JM, Jagger C. What do we know about the cognitive status of supercentenarians? In: Finch CE, Robine JM, Christen Y, eds. Brain and Longevity: Research and Perspectives in Longevity. Berlin, Germany: Springer; 2003:145-152. doi:10.1007/978-3-642-59356-7_9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-59356-7_9</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie K. Mental status examination of an exceptional case of longevity: J. C. aged 118 years. Br J Psychiatry. 1995;166(2):229-235. doi:10.1192/bjp.166.2.229</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.166.2.229</ArticleId><ArticleId IdType="pubmed">7728367</ArticleId></ArticleIdList></Reference><Reference><Citation>den Dunnen WF, Brouwer WH, Bijlard E, et al. . No disease in the brain of a 115-year-old woman. Neurobiol Aging. 2008;29(8):1127-1132. doi:10.1016/j.neurobiolaging.2008.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.04.010</ArticleId><ArticleId IdType="pubmed">18534718</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. Neurology. 2018;90(15):695-703. doi:10.1212/WNL.0000000000005303</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005303</ArticleId><ArticleId IdType="pmc">PMC5894932</ArticleId><ArticleId IdType="pubmed">29592885</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon LW, Jazwinski M, Green RC, et al. . Methodological considerations in studying centenarians: lessons learned from the Georgia Centenarian Studies. Annu Rev Gerontol Geriatr. 2007;27(1):231-264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156654</ArticleId><ArticleId IdType="pubmed">21852888</ArticleId></ArticleIdList></Reference><Reference><Citation>Gondo Y, Hirose N, Arai Y, et al. . Functional status of centenarians in Tokyo, Japan: developing better phenotypes of exceptional longevity. J Gerontol A Biol Sci Med Sci. 2006;61(3):305-310. doi:10.1093/gerona/61.3.305</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/61.3.305</ArticleId><ArticleId IdType="pubmed">16567382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu D, Feng Q. Frailty still matters to health and survival in centenarians: the case of China. BMC Geriatr. 2015;15:159. doi:10.1186/s12877-015-0159-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-015-0159-0</ArticleId><ArticleId IdType="pmc">PMC4669603</ArticleId><ArticleId IdType="pubmed">26634246</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu D, Dupre ME, Sautter J, Zhu H, Liu Y, Yi Z. Frailty and mortality among Chinese at advanced ages. J Gerontol B Psychol Sci Soc Sci. 2009;64(2):279-289. doi:10.1093/geronb/gbn009</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronb/gbn009</ArticleId><ArticleId IdType="pmc">PMC2655172</ArticleId><ArticleId IdType="pubmed">19196691</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte N, Teixeira L, Ribeiro O, Paul C. Frailty phenotype criteria in centenarians: findings from the Oporto Centenarian Study. Eur Geriatr Med. 2014;5(6):371-376. doi:10.1016/j.eurger.2014.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eurger.2014.09.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen-Ranberg K, Christensen K, Jeune B, Skytthe A, Vasegaard L, Vaupel JW. Declining physical abilities with age: a cross-sectional study of older twins and centenarians in Denmark. Age Ageing. 1999;28(4):373-377. doi:10.1093/ageing/28.4.373</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/28.4.373</ArticleId><ArticleId IdType="pubmed">10459791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagberg B, Samuelsson G. Survival after 100 years of age: a multivariate model of exceptional survival in Swedish centenarians. J Gerontol A Biol Sci Med Sci. 2008;63(11):1219-1226. doi:10.1093/gerona/63.11.1219</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/63.11.1219</ArticleId><ArticleId IdType="pubmed">19038837</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossakowska M, Broczek K, Wieczorowska-Tobis K, et al. . Cognitive performance and functional status are the major factors predicting survival of centenarians in Poland. J Gerontol A Biol Sci Med Sci. 2014;69(10):1269-1275. doi:10.1093/gerona/glu003</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glu003</ArticleId><ArticleId IdType="pubmed">24509978</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon L, Johnson M, Davey A, Dawson D, Siegler I, Martin P. Psycho-social predictors of survival among centenarians In: Martin P, Rott C, Hagberg B, Morgan K, eds. Autonomy Versus Independence in the Oldest Old. New York, NY: Springer Publishing; 2000:77-89.</Citation></Reference><Reference><Citation>Samuelsson SM, Alfredson BB, Hagberg B, et al. . The Swedish Centenarian Study: a multidisciplinary study of five consecutive cohorts at the age of 100. Int J Aging Hum Dev. 1997;45(3):223-253. doi:10.2190/XKG9-YP7Y-QJTK-BGPG</Citation><ArticleIdList><ArticleId IdType="doi">10.2190/XKG9-YP7Y-QJTK-BGPG</ArticleId><ArticleId IdType="pubmed">9438877</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H, Beker N, Dijkstra T, et al. . The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. Eur J Epidemiol. 2018;33(12):1229-1249. doi:10.1007/s10654-018-0451-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-018-0451-3</ArticleId><ArticleId IdType="pmc">PMC6290855</ArticleId><ArticleId IdType="pubmed">30362018</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J. 1965;14:61-65.</Citation><ArticleIdList><ArticleId IdType="pubmed">14258950</ArticleId></ArticleIdList></Reference><Reference><Citation>Post MW, van Asbeck FW, van Dijk AJ, Schrijvers AJ. Dutch interview version of the Barthel Index evaluated in patients with spinal cord injuries [in Dutch]. Ned Tijdschr Geneeskd. 1995;139(27):1376-1380.</Citation><ArticleIdList><ArticleId IdType="pubmed">7617060</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiepers OJ, Harris SE, Gow AJ, et al. . APOE E4 status predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the Lothian Birth Cohort 1921. Mol Psychiatry. 2012;17(3):315-324. doi:10.1038/mp.2010.137</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2010.137</ArticleId><ArticleId IdType="pubmed">21263443</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E, Hannequin D, Wallon D, et al. . APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16(9):903-907. doi:10.1038/mp.2011.52</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2011.52</ArticleId><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta-Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356. doi:10.1001/jama.1997.03550160069041</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03550160069041</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Lee SJ, Wolters FJ, Ikram MK, et al. . The effect of APOE and other common genetic variants on the onset of Alzheimer&#x2019;s disease and dementia: a community-based cohort study. Lancet Neurol. 2018;17(5):434-444. doi:10.1016/S1474-4422(18)30053-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30053-X</ArticleId><ArticleId IdType="pubmed">29555425</ArticleId></ArticleIdList></Reference><Reference><Citation>UNESCO  International standard classification of education or ISCED-1997. http://www.unesco.org/education/ Published 1997. Accessed January 15, 2020.</Citation></Reference><Reference><Citation>Beker N, Sikkes SA, Hulsman M, Schmand B, Scheltens P, Holstege H. Neuropsychological test performance of cognitively healthy centenarians: normative data from the Dutch 100-Plus Study. J Am Geriatr Soc. 2018;67(4):759-767.&#xa0;doi:10.1111/jgs.15729</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.15729</ArticleId><ArticleId IdType="pmc">PMC7379661</ArticleId><ArticleId IdType="pubmed">30592018</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med. 1994;24(1):145-153. doi:10.1017/S003329170002691X</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S003329170002691X</ArticleId><ArticleId IdType="pubmed">8208879</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelune GJ, Naugle RI, L&#xfc;ders H, Sedlak J, Awad IA. Individual change after epilepsy surgery: practice effects and base-rate information. Neuropsychology. 1993;7(1):41. doi:10.1037/0894-4105.7.1.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0894-4105.7.1.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Garssen J, Harmsen C Nearly 2000 centenarians in the Netherlands. https://www.cbs.nl/en-gb/news/2013/12/nearly-2-000-centenarians-in-the-netherlands. Published March 22, 2013. Accessed January 15, 2020.</Citation></Reference><Reference><Citation>Perls T. Centenarians who avoid dementia. Trends Neurosci. 2004;27(10):633-636. doi:10.1016/j.tins.2004.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2004.07.012</ArticleId><ArticleId IdType="pubmed">15374676</ArticleId></ArticleIdList></Reference><Reference><Citation>Perls T. Dementia-free centenarians. Exp Gerontol. 2004;39(11-12):1587-1593. doi:10.1016/j.exger.2004.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2004.08.015</ArticleId><ArticleId IdType="pubmed">15582273</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog J, Backman K, Ribbe M, et al. . A longitudinal study of the Mini-Mental State Examination in late nonagenarians and its relationship with dementia, mortality, and education. J Am Geriatr Soc. 2017;65(6):1296-1300. doi:10.1111/jgs.14871</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.14871</ArticleId><ArticleId IdType="pubmed">28323333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kliegel M, Moor C, Rott C. Cognitive status and development in the oldest old: a longitudinal analysis from the Heidelberg Centenarian Study. Arch Gerontol Geriatr. 2004;39(2):143-156. doi:10.1016/j.archger.2004.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2004.02.004</ArticleId><ArticleId IdType="pubmed">15249151</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol. 2015;12(5):267-277. doi:10.1038/nrcardio.2014.223</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2014.223</ArticleId><ArticleId IdType="pubmed">25583619</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakatta EG. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev. 2002;7(1):29-49. doi:10.1023/A:1013797722156</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1013797722156</ArticleId><ArticleId IdType="pubmed">11790921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaup AR, Nettiksimmons J, Harris TB, et al. ; Health, Aging, and Body Composition (Health ABC) Study . Cognitive resilience to apolipoprotein E &#x3b5;4: contributing factors in black and white older adults. JAMA Neurol. 2015;72(3):340-348. doi:10.1001/jamaneurol.2014.3978</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.3978</ArticleId><ArticleId IdType="pmc">PMC4624320</ArticleId><ArticleId IdType="pubmed">25599330</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesi N, van der Lee SJ, Hulsman M, et al. . Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer&#x2019;s disease. Eur J Hum Genet. 2019;27(2):244-253. doi:10.1038/s41431-018-0273-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-018-0273-5</ArticleId><ArticleId IdType="pmc">PMC6336855</ArticleId><ArticleId IdType="pubmed">30258121</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Lee SJ, Conway OJ, Jansen I, et al. ; Dementia Genetics Spanish Consortium; Alzheimer Disease European DNA Biobank; International FTD-Genomics Consortium; The International Parkinson Disease Genomics Consortium; Risk and Modifying Factors in Fronto-Temporal Dementia; Netherlands Brain Bank; Genetic Investigation in Frontotemporal Dementia and Alzheimer&#x2019;s Disease Study Group . A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer&#x2019;s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathol. 2019;138(2):237-250. doi:10.1007/s00401-019-02026-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02026-8</ArticleId><ArticleId IdType="pmc">PMC6660501</ArticleId><ArticleId IdType="pubmed">31131421</ArticleId></ArticleIdList></Reference><Reference><Citation>Arboleda-Velasquez JF, Lopera F, O&#x2019;Hare M, et al. . Resistance to autosomal dominant Alzheimer&#x2019;s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680-1683. doi:10.1038/s41591-019-0611-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0611-3</ArticleId><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="pubmed">31686034</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaza-Urquijo EM, Przybelski SA, Lesnick TL, et al. . The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain. 2019;142(4):1134-1147. doi:10.1093/brain/awz037</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz037</ArticleId><ArticleId IdType="pmc">PMC6439329</ArticleId><ArticleId IdType="pubmed">30851100</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrada MM, Berlau DJ, Kawas CH. A population-based clinicopathological study in the oldest-old: the 90+ study. Curr Alzheimer Res. 2012;9(6):709-717. doi:10.2174/156720512801322537</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322537</ArticleId><ArticleId IdType="pmc">PMC3409303</ArticleId><ArticleId IdType="pubmed">22471863</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Kuller LH, Klunk WE, et al. . In vivo assessment of amyloid-&#x3b2; deposition in nondemented very elderly subjects. Ann Neurol. 2013;73(6):751-761. doi:10.1002/ana.23797</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23797</ArticleId><ArticleId IdType="pmc">PMC3725727</ArticleId><ArticleId IdType="pubmed">23596051</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012;72(4):599-609. doi:10.1002/ana.23654</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23654</ArticleId><ArticleId IdType="pmc">PMC3490232</ArticleId><ArticleId IdType="pubmed">23109154</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasubramanian AB, Kawas CH, Peltz CB, Brookmeyer R, Corrada MM. Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementia. Neurology. 2012;79(9):915-921. doi:10.1212/WNL.0b013e318266fc77</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318266fc77</ArticleId><ArticleId IdType="pmc">PMC3425842</ArticleId><ArticleId IdType="pubmed">22895581</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW Jr, Buckles VD, et al. . Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026-1036. doi:10.1016/j.neurobiolaging.2009.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.04.002</ArticleId><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganz AB, Beker N, Hulsman M, et al. ; Netherlands Brain Bank . Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. Acta Neuropathol Commun. 2018;6(1):64. doi:10.1186/s40478-018-0558-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0558-5</ArticleId><ArticleId IdType="pmc">PMC6055341</ArticleId><ArticleId IdType="pubmed">30037350</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE, Chatfield M, Brayne C, Matthews FE; Medical Research Council Cognitive Function and Ageing Study Group . The reliability of assigning individuals to cognitive states using the Mini Mental-State Examination: a population-based prospective cohort study. BMC Med Res Methodol. 2011;11:127-127. doi:10.1186/1471-2288-11-127</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-11-127</ArticleId><ArticleId IdType="pmc">PMC3175206</ArticleId><ArticleId IdType="pubmed">21896187</ArticleId></ArticleIdList></Reference><Reference><Citation>Engberg H, Christensen K, Andersen-Ranberg K, Jeune B. Cohort changes in cognitive function among Danish centenarians: a comparative study of 2 birth cohorts born in 1895 and 1905. Dement Geriatr Cogn Disord. 2008;26(2):153-160. doi:10.1159/000149819</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000149819</ArticleId><ArticleId IdType="pmc">PMC2731155</ArticleId><ArticleId IdType="pubmed">18679030</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen-Ranberg K, Vasegaard L, Jeune B. Dementia is not inevitable: a population-based study of Danish centenarians. J Gerontol B Psychol Sci Soc Sci. 2001;56(3):152-159. doi:10.1093/geronb/56.3.P152</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronb/56.3.P152</ArticleId><ArticleId IdType="pubmed">11316833</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhaeghen P, Salthouse TA. Meta-analyses of age-cognition relations in adulthood: estimates of linear and nonlinear age effects and structural models. Psychol Bull. 1997;122(3):231-249. doi:10.1037/0033-2909.122.3.231</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0033-2909.122.3.231</ArticleId><ArticleId IdType="pubmed">9354147</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Stern Y, Tang M, Mayeux R. Selective decline in memory function among healthy elderly. Neurology. 1999;52(7):1392-1396. doi:10.1212/WNL.52.7.1392</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.52.7.1392</ArticleId><ArticleId IdType="pubmed">10227623</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA. Trajectories of normal cognitive aging. Psychol Aging. 2019;34(1):17-24. doi:10.1037/pag0000288</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/pag0000288</ArticleId><ArticleId IdType="pmc">PMC6367038</ArticleId><ArticleId IdType="pubmed">30211596</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinggaard M, McGue M, Jeune B, Osler M, Vaupel JW, Christensen K. Survival prognosis in very old adults. J Am Geriatr Soc. 2016;64(1):81-88. doi:10.1111/jgs.13838</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.13838</ArticleId><ArticleId IdType="pmc">PMC4749674</ArticleId><ArticleId IdType="pubmed">26782855</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y-P, Chang C-K, Hayes RD, et al. . Mini-mental state examination as a predictor of mortality among older people referred to secondary mental healthcare. PLoS One. 2014;9(9):e105312. doi:10.1371/journal.pone.0105312</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0105312</ArticleId><ArticleId IdType="pmc">PMC4153564</ArticleId><ArticleId IdType="pubmed">25184819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahle-Wrobleski K, Corrada MM, Li B, Kawas CH. Sensitivity and specificity of the mini-mental state examination for identifying dementia in the oldest-old: the 90+ study. J Am Geriatr Soc. 2007;55(2):284-289. doi:10.1111/j.1532-5415.2007.01049.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2007.01049.x</ArticleId><ArticleId IdType="pmc">PMC3373261</ArticleId><ArticleId IdType="pubmed">17302668</ArticleId></ArticleIdList></Reference><Reference><Citation>Barral S, Cosentino S, Costa R, et al. ; Long Life Family Study . Exceptional memory performance in the Long Life Family Study. Neurobiol Aging. 2013;34(11):2445-2448. doi:10.1016/j.neurobiolaging.2013.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.05.002</ArticleId><ArticleId IdType="pmc">PMC4095822</ArticleId><ArticleId IdType="pubmed">23759147</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurland BF, Johnson LL, Egleston BL, Diehr PH. Longitudinal data with follow-up truncated by death: match the analysis method to research aims. Stat Sci. 2009;24(2):211-211. doi:10.1214/09-STS293</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/09-STS293</ArticleId><ArticleId IdType="pmc">PMC2812934</ArticleId><ArticleId IdType="pubmed">20119502</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32461689</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>585</Volume><Issue>7825</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Structures of &#x3b1;-synuclein filaments from multiple system atrophy.</ArticleTitle><Pagination><StartPage>464</StartPage><EndPage>469</EndPage><MedlinePgn>464-469</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2317-6</ELocationID><Abstract><AbstractText>Synucleinopathies, which include multiple system atrophy (MSA), Parkinson's disease, Parkinson's disease with dementia and dementia with Lewy bodies (DLB), are human neurodegenerative diseases<sup>1</sup>. Existing treatments are at best symptomatic. These diseases are characterized by the presence of, and believed to be caused by the formation of, filamentous inclusions of &#x3b1;-synuclein in brain cells<sup>2,3</sup>. However, the structures of &#x3b1;-synuclein filaments from the human brain are unknown. Here, using cryo-electron microscopy, we show that &#x3b1;-synuclein inclusions&#xa0;from the brains of individuals with MSA are made of two types of filament, each of which consists of two different protofilaments. In each type of filament, non-proteinaceous molecules are present at the interface of the two protofilaments. Using two-dimensional class averaging, we show that &#x3b1;-synuclein filaments from the brains of individuals with MSA differ from those of individuals with DLB, which suggests that distinct conformers or strains characterize specific synucleinopathies. As is the case with tau assemblies<sup>4-9</sup>, the structures of &#x3b1;-synuclein filaments extracted from the brains of individuals with MSA differ from those formed in vitro using recombinant proteins, which has implications for understanding the mechanisms of aggregate propagation and neurodegeneration in the human brain. These findings have diagnostic and potential therapeutic relevance, especially because of the unmet clinical need to be able to image filamentous &#x3b1;-synuclein inclusions in the human brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Schweighauser</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1848-1610</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Shi</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-1579-7561</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarutani</LastName><ForeName>Airi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kametani</LastName><ForeName>Fuyuki</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9125-7001</Identifier><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzin</LastName><ForeName>Alexey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1842-8019</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsubara</LastName><ForeName>Tomoyasu</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7559-8284</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomita</LastName><ForeName>Taisuke</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0075-5943</Identifier><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ando</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Kazuko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Neurology, Sagamihara National Hospital, Sagamihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><Identifier Source="ORCID">0000-0002-0462-6540</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. scheres@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5214-7886</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. mg@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_EX_MR/N027892/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 NS110437</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011699" MajorTopicYN="N">Putamen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32461689</ArticleId><ArticleId IdType="mid">EMS107716</ArticleId><ArticleId IdType="pmc">PMC7116528</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2317-6</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-2317-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Jakes R, Spillantini MG. The Synucleinopathies: twenty years on. J Parkinson&#x2019;s Dis. 2017;7:S51&#x2013;S69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5345650</ArticleId><ArticleId IdType="pubmed">28282814</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. &#x3b1;-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the &#x3b1;-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature. 2017;547:185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature. 2018;561:137&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Tau filaments from multiple cases of sporadic and inherited Alzheimer&#x2019;s disease adopt a common fold. Acta Neuropathol. 2018;136:699&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208733</ArticleId><ArticleId IdType="pubmed">30276465</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568:420&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. eLife. 2019;8:e43584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. Novel tau filament fold in corticobasal degeneration, a four-repeat tauopathy. Nature. 2020 doi: 10.1038/s41586-020-2043-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2043-0</ArticleId><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, et al. &#x3b1;-synuclein locus triplication causes Parkinson&#x2019;s disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiely AP, et al. &#x3b1;-synucleinopathy associated with G51D SNCA mutation: A link between Parkinson&#x2019;s disease and multiple system atrophy? Acta Neuropathol. 2013;125:753&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681325</ArticleId><ArticleId IdType="pubmed">23404372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiely AP, et al. Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Mol Neurodeg. 2015;10:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4549856</ArticleId><ArticleId IdType="pubmed">26306801</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasanen P, et al. A novel &#x3b1;-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson&#x2019;s disease-type pathology. Neurobiol Aging. 2014;35:e2181&#x2013;e2185.</Citation><ArticleIdList><ArticleId IdType="pubmed">24746362</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nature Genet. 2014;46:989&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejerine J, Thomas A. L&#x2019;atrophie olivo-ponto-c&#xe9;r&#xe9;belleuse. Nouv Iconogr Salp&#xea;tri&#xe8;re. 1900;13:330&#x2013;370.</Citation></Reference><Reference><Citation>Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1969;32:28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC493381</ArticleId><ArticleId IdType="pubmed">5774131</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn N. Multiple system atrophy &#x2013; the nature of the beast. J Neurol Neurosurg Psychiatry. 1989;(Suppl):78&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1033311</ArticleId><ArticleId IdType="pubmed">2666581</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy. J Neurol Sci. 1989;94:79&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">2559165</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. &#x3b1;-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett. 1998;49:180&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">9682846</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Filamentous &#x3b1;-synuclein inclusions link multiple system atrophy with Parkinson&#x2019;s disease and dementia with Lewy bodies. Neurosci Lett. 1998;251:205&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9726379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu P, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brain contain insoluble &#x3b1;-synuclein. Ann Neurol. 1998;44:415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">9749615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato S, Nakamura H. Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies. Acta Neuropathol. 1990;79:584&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">2163181</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovic IN, et al. Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord. 2012;27:1184&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">22806758</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of &#x3b1;-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273:9443&#x2013;9449.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda K, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:11282&#x2013;11286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47966</ArticleId><ArticleId IdType="pubmed">8248242</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HT, Du HN, Tang L, Hu J, Hu HY. Structural transformation and aggregation of human &#x3b1;-synuclein in trifluoroethanol: Non-amyloid component sequence is essential and &#x3b2;-sheet formation is prerequisite to aggregation. Biopolymers. 2002;64:221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">12115139</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA, Jakes R, Spillantini MG, Goedert M. Synthetic filaments assembled from C-terminally truncated &#x3b1;-synuclein. FEBS Lett. 1998;436:309&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">9801138</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Harper JD, Lansbury PT. Fibrils formed in vitro from &#x3b1;-synuclein and two mutant forms linked to Parkinson&#x2019;s disease are typical amyloid. Biochemistry. 2000;39:2552&#x2013;2563.</Citation><ArticleIdList><ArticleId IdType="pubmed">10704204</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic &#x3b1;-synuclein filaments show amyloid-like cross-&#x3b2; conformation. Proc Natl Acad Sci USA. 2000;97:4897&#x2013;4902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18329</ArticleId><ArticleId IdType="pubmed">10781096</ArticleId></ArticleIdList></Reference><Reference><Citation>Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. Biochemical characterization of the core structure of &#x3b1;-synuclein filaments. J Biol Chem. 2002;277:19213&#x2013;19219.</Citation><ArticleIdList><ArticleId IdType="pubmed">11893734</ArticleId></ArticleIdList></Reference><Reference><Citation>Mougenot AL, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging. 2012;33:2225&#x2013;2228.</Citation><ArticleIdList><ArticleId IdType="pubmed">21813214</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, et al. Pathological &#x3b1;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M, et al. Prion-like spreading of pathological &#x3b1;-synuclein in brain. Brain. 2013;136:1128&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterberg VR, et al. Progressive aggregation of &#x3b1;-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 2015;10:1252&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351119</ArticleId><ArticleId IdType="pubmed">25732816</ArticleId></ArticleIdList></Reference><Reference><Citation>Peelaerts W, et al. &#x3b1;-synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522:340&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26061766</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng C, et al. Cellular milieu imparts distinct pathological &#x3b1;-synuclein strains in &#x3b1;-synucleinopathies. Nature. 2018;557:558&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970994</ArticleId><ArticleId IdType="pubmed">29743672</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, et al. Evidence for &#x3b1;-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci USA. 2015;112:E5308&#x2013;E5317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586853</ArticleId><ArticleId IdType="pubmed">26324905</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarutani A, Arai T, Murayama S, Hisanaga SI, Hasegawa M. Potent prion-like behaviors of pathogenic &#x3b1;-synuclein and evaluation of inactivation methods. Acta Neuropathol Commun. 2018;6:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5907316</ArticleId><ArticleId IdType="pubmed">29669601</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki TR, et al. Parkinson&#x2019;s disease and multiple system atrophy have distinct &#x3b1;-synuclein seed characteristics. J Biol Chem. 2019;294:1045&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6341389</ArticleId><ArticleId IdType="pubmed">30478174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavenir I, et al. Silver staining (Campbell-Switzer) of neuronal &#x3b1;-synuclein assemblies induced by multiple system atrophy and Parkinson&#x2019;s disease brain extracts in transgenic mice. Acta Neuropathol Commun. 2019;7:148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6745790</ArticleId><ArticleId IdType="pubmed">31522685</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingstedt T, et al. Luminescent conjugated oligothiophenes distinguish between &#x3b1;-synuclein assemblies of Parkinson&#x2019;s disease and multiple system atrophy. Acta Neuropathol Commun. 2019;7:193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6892142</ArticleId><ArticleId IdType="pubmed">31796099</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroh&#xe4;ker T, et al. Structural heterogeneity of &#x3b1;-synuclein fibrils amplified from patient brain extracts. Nature Commun. 2019;10:5535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6893031</ArticleId><ArticleId IdType="pubmed">31797870</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahnawaz M, et al. Discriminating &#x3b1;-synuclein strains in Parkinson&#x2019;s disease and multiple system atrophy. Nature. 2020;578:273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066875</ArticleId><ArticleId IdType="pubmed">32025029</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell BCV, et al. The solubility of &#x3b1;-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson&#x2019;s disease. J Neurochem. 2001;76:87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145981</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, et al. Alph&#x3b1;-synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biol. 2002;4:160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. &#x3b1;-synuclein in filamentous inclusions of Lewy bodies from Parkinson&#x2019;s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469&#x2013;6473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27806</ArticleId><ArticleId IdType="pubmed">9600990</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuttle MD, et al. Solid-state NMR structure of a pathogenic fibril of full-length human &#x3b1;-synuclein. Nature Struct Mol Biol. 2016;23:409&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5034296</ArticleId><ArticleId IdType="pubmed">27018801</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero-Ferreira R, et al. Cryo-EM structure of alph&#x3b1;-synuclein fibrils. eLife. 2018;7:e36402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6092118</ArticleId><ArticleId IdType="pubmed">29969391</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Amyloid fibril structure of &#x3b1;-synuclein determined by cryo-electron microscopy. Cell Res. 2018;28:897&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123497</ArticleId><ArticleId IdType="pubmed">30065316</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, et al. Cryo-EM of full-length &#x3b1;-synuclein reveals fibril polymorphs with a common structural kernel. Nature Commun. 2018;9:3609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6127345</ArticleId><ArticleId IdType="pubmed">30190461</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero-Ferreira R, et al. Two new polymorphic structures of human full-length alph&#x3b1;-synuclein fibrils solved by cryo-electron microscopy. eLife. 2019;8:e48907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6957273</ArticleId><ArticleId IdType="pubmed">31815671</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer DR, et al. Structures of fibrils formed by &#x3b1;-synuclein hereditary disease mutant H50Q reveal new polymorphs. Nature Struct Mol Biol. 2019;26:1044&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6907165</ArticleId><ArticleId IdType="pubmed">31695184</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer DR, et al. The &#x3b1;-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure. Proc Natl Acad Sci USA. 2020;117:3592&#x2013;3602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035510</ArticleId><ArticleId IdType="pubmed">32015135</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, et al. Parkinson&#x2019;s disease associated mutation E46K of &#x3b1;-synuclein triggers the formation of a novel fibril structure. bioRxiv</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250837</ArticleId><ArticleId IdType="pubmed">32457390</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangwan S, et al. Inhibition of synucleinopathic seeding by rationally designed inhibitors. eLife. 2020;9:e46775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6977966</ArticleId><ArticleId IdType="pubmed">31895037</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Falcon B, Zhang W, Ghetti B, Scheres SHW. Distinct conformers of assembled tau in Alzheimer&#x2019;s and Pick&#x2019;s diseases. Cold Spring Harbor Symp Quant Biol. 2018;83:163&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">30886056</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, et al. A panel of epitope-specific antibodies detects protein domains distributed throughout human alph&#x3b1;-synuclein in Lewy bodies of Parkinson&#x2019;s disease. J Neurosci Res. 2000;59:528&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679792</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S, et al. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain. 2008;131:72&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702832</ArticleId><ArticleId IdType="pubmed">18065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M. Seeded aggregation and toxicity of &#x3b1;-synuclein and tau. J Biol Chem. 2010;285:34885&#x2013;34898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966103</ArticleId><ArticleId IdType="pubmed">20805224</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarutani A, et al. The effect of fragmented pathogenic &#x3b1;-synuclein seeds on prion-like propagation. J Biol Chem. 2016;291:18675&#x2013;18688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009244</ArticleId><ArticleId IdType="pubmed">27382062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, et al. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci Rep. 2016;6:23281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793195</ArticleId><ArticleId IdType="pubmed">26980269</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife. 2018;7:e42166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A, Grigorieff N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015;192:216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Scheres SHW. Helical reconstruction in RELION. J Struct Biol. 2017;198:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW. Amyloid structure determination in RELION-3.1. Acta Crystallogr D. 2020;76:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008511</ArticleId><ArticleId IdType="pubmed">32038040</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D. 2010;66:486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D. 2010;66:213&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D. 2010;66:12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32123386</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.</ArticleTitle><Pagination><StartPage>387</StartPage><EndPage>397</EndPage><MedlinePgn>387-397</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-020-0762-2</ELocationID><Abstract><AbstractText>With the potential development of new disease-modifying Alzheimer's disease (AD) therapies, simple, widely available screening tests are needed to identify which individuals, who are experiencing symptoms of cognitive or behavioral decline, should be further evaluated for initiation of treatment. A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved cerebrospinal fluid or amyloid &#x3b2; positron emission tomography (PET) diagnostic tests. We examined whether plasma tau phosphorylated at residue 181 (pTau181) could differentiate between clinically diagnosed or autopsy-confirmed AD and frontotemporal lobar degeneration. Plasma pTau181 concentrations were increased by 3.5-fold in AD compared to controls and differentiated AD from both clinically diagnosed (receiver operating characteristic area under the curve of 0.894) and autopsy-confirmed frontotemporal lobar degeneration (area under the curve of 0.878). Plasma pTau181 identified individuals who were amyloid &#x3b2;-PET-positive regardless of clinical diagnosis and correlated with cortical tau protein deposition measured by <sup>18</sup>F-flortaucipir PET. Plasma pTau181 may be useful to screen for tau pathology associated with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thijssen</LastName><ForeName>Elisabeth H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Joie</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2581-8100</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strom</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iaccarino</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourakova</LastName><ForeName>Viktoriya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobigo</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuer</LastName><ForeName>Hilary</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>VandeVrede</LastName><ForeName>Lawren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8304-6711</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Xiyun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proctor</LastName><ForeName>Nicholas K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Airey</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shcherbinin</LastName><ForeName>Sergey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duggan Evans</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, University College London Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology &amp; Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dage</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-2192-1699</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Julio C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-1215-5064</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA. adam.boxer@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG045333</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG053435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG063911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG050967</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG066597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH120794</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG059888</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG052648</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062268</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG045390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG023481</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2020 Mar;26(3):314-316. doi: 10.1038/s41591-020-0797-4.</RefSource><PMID Version="1">32132715</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 May;16(5):241. doi: 10.1038/s41582-020-0347-1.</RefSource><PMID Version="1">32203395</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interest statement: E.H.T, R.L.J., A.W., A.S., P.W., L.I., V.B., Y.C., H.H., S.S., A.M.K., C.E.T., J.H.K., W.W.S., H.R., B.F.B., and B.L.M. declare no conflict of interest. J.L.D., X.C., N.K.P., D.C.A., S.S., C.D.E., and J.R.S. are employees of Eli Lilly and Company. H.Z. has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. K.B. served as a consultant or at advisory boards for Alector, Biogen, CogRx, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. L.T.G. receives research support from Avid Radiopharmaceuticals, Eli Lilly. She has received consulting fees from the Simon Foundation and Cura Sen, Inc. She serves as associate editor for Frontiers in Aging Neurosciences, Frontiers in Dementia and the Journal of Alzheimer Disease. G.D.R. receives research support from NIH, Alzheimer&#x2019;s Association, American College of Radiology, Tau Research Consortium, Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare, Life Molecular Imaging. He has served as a consultant for Eisai, Merck, Axon Neurosciences. He received speaking honoraria from GE Healthcare. He serves as Associate Editor for JAMA Neurology. J.C.R. is a site PI for clinical trials supported by Eli Lilly and receives support from NIH. A.L.B. receives research support from NIH, the Tau Research Consortium, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, Corticobasal Degeneration Solutions, the Alzheimer&#x2019;s Drug Discovery Foundation and the Alzheimer's Association. He has served as a consultant for Aeton, Abbvie, Alector, AGTC, Amgen, Arkuda, Arvinas, Asceneuron, Ionis, Lundbeck, Novartis, Passage BIO, Sangamo, Samumed, Third Rock, Toyama and UCB, and received research support from Avid, Biogen, BMS, C2N, Cortice, Eli Lilly, Forum, Genentech, Janssen, Novartis, Pfizer, Roche and TauRx.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Forsberg</LastName><ForeName>Leah</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huey</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghoshal</LastName><ForeName>Nupur</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Appleby</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendez</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordelon</LastName><ForeName>Yvette</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramos</LastName><ForeName>Eliana Marisa</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>M Carmela</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacKenzie</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Domoto-Reilly</LastName><ForeName>Kimiko</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32123386</ArticleId><ArticleId IdType="mid">NIHMS1549223</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pii">10.1038/s41591-020-0762-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Swine flu snipers, Alzheimer&#x2019;s drug push and Google&#x2019;s latest gaming bot. Nature 574 602&#x2013;603 (2019). doi:doi: 10.1038/d41586-019-03266-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-019-03266-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA - J. Am. Med. Assoc 94158, 1286&#x2013;1294 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450276</ArticleId><ArticleId IdType="pubmed">30938796</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann. Neurol 74, 826&#x2013;836 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85, 1240&#x2013;1249 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4607601</ArticleId><ArticleId IdType="pubmed">26354982</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD &amp; Miller BL Frontotemporal Lobar Degeneration: Epidemiology, Pathophysiology, Diagnosis and Management. CNS Drugs 24, 375&#x2013;398 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916644</ArticleId><ArticleId IdType="pubmed">20369906</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahia VS, Takada LT &amp; Deramecourt V Neuropathology of frontotemporal lobar degeneration: A review. Dement. Neuropsychol 7, 19&#x2013;26 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5619540</ArticleId><ArticleId IdType="pubmed">29213815</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain 129, 3035&#x2013;3041 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T et al. Cerebrospinal Fluid &#x3b2;-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain. Arch. Neurol 66, 382&#x2013;389 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M et al. Biomarkers for tau pathology. Mol. Cell. Neurosci (2018). doi:10.1016/j.mcn.2018.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2018.12.001</ArticleId><ArticleId IdType="pmc">PMC6584358</ArticleId><ArticleId IdType="pubmed">30529601</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol 78, 787&#x2013;800 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R et al. Discriminative accuracy of [ 18 F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA - J. Am. Med. Assoc 320, 1151&#x2013;1162 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron 91, 56&#x2013;66 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27292537</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LH, Kaat LD, Rohrer JD &amp; Van Swieten JC Imaging and fluid biomarkers in frontotemporal dementia. Nature Reviews Neurology 13, 406&#x2013;419 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28621768</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol 14, 577&#x2013;589 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LHH et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology 90, e1231&#x2013;e1239 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5890612</ArticleId><ArticleId IdType="pubmed">29514947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ljubenkov PA et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann. Clin. Transl. Neurol 5, 1250&#x2013;1263 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6186942</ArticleId><ArticleId IdType="pubmed">30349860</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherling CS et al. CSF neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann. Neurol 75, 116&#x2013;126 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020786</ArticleId><ArticleId IdType="pubmed">24242746</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas JC et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90, e273&#x2013;e281 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5798651</ArticleId><ArticleId IdType="pubmed">29282336</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87, 1329&#x2013;1336 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047041</ArticleId><ArticleId IdType="pubmed">27581216</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P et al. Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology 91, e1390&#x2013;e1401 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30209235</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol. 1&#x2013;14 (2019). doi:10.1001/jamaneurol.2019.1534</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1534</ArticleId><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nature Medicine 25, 277&#x2013;283 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Cullen NC, Andreasson U, Zetterberg H &amp; Blennow K Association between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients with Alzheimer Disease. JAMA Neurol. 1&#x2013;9 (2019). doi:10.1001/jamaneurol.2019.0765</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.0765</ArticleId><ArticleId IdType="pmc">PMC6583067</ArticleId><ArticleId IdType="pubmed">31009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A et al. High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature 554, 249&#x2013;254 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V et al. Amyloid &#x3b2; concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer&#x2019;s Dement. 13, 841&#x2013;849 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S et al. Plasma &#x3b2;-amyloid in Alzheimer&#x2019;s disease and vascular disease. Sci. Rep 6, 1&#x2013;11 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4886210</ArticleId><ArticleId IdType="pubmed">27241045</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic study on aging. JAMA Neurol. 74, 1073&#x2013;1080 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710182</ArticleId><ArticleId IdType="pubmed">28692710</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N et al. Plasma tau in Alzheimer disease. Neurology 87, 1827&#x2013;1835 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5089525</ArticleId><ArticleId IdType="pubmed">27694257</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 15, 487&#x2013;496 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6476313</ArticleId><ArticleId IdType="pubmed">30419228</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat. Rev. Neurol 14, 639&#x2013;652 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6211654</ArticleId><ArticleId IdType="pubmed">30297701</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM et al. Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimer&#x2019;s Dement. 14, 989&#x2013;997 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti B et al. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: A chameleon for neuropathology and neuroimaging. Neuropathol. Appl. Neurobiol 41, 24&#x2013;46 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329416</ArticleId><ArticleId IdType="pubmed">25556536</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A et al. NeuroImage Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer &#x2018; s disease. Neuroimage 157, 448&#x2013;463 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E &amp; Del Tredici K Stages of the pathologic process in alzheimer disease: Age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol 70, 960&#x2013;969 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD et al. Distinct MRI Atrophy Patterns in Autopsy-Proven Alzheimer&#x2019;s Disease and Frontotemporal Lobar Degeneration. Am J Alzheimers Dis Other Demen 22, 474&#x2013;488 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443731</ArticleId><ArticleId IdType="pubmed">18166607</ArticleId></ArticleIdList></Reference><Reference><Citation>Halabi C et al. Patterns of striatal degeneration in frontotemporal dementia. Alzheimer Dis. Assoc. Disord 27, 74&#x2013;83 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389579</ArticleId><ArticleId IdType="pubmed">22367382</ArticleId></ArticleIdList></Reference><Reference><Citation>Doraiswamy PM et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study. Mol. Psychiatry 19, 1044&#x2013;1051 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4195975</ArticleId><ArticleId IdType="pubmed">24614494</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&#x3b2; plaques&#x202f;: a prospective cohort study. Lancet Neurol. 11, 669&#x2013;678 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R et al. Multisite study of the relationships between antemortem [ 11 C]PIB-PET Centiloid values and postmortem measures of Alzheimer&#x2019;s disease neuropathology. Alzheimer&#x2019;s Dement. 15, 205&#x2013;216 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368897</ArticleId><ArticleId IdType="pubmed">30347188</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 77, (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236517</ArticleId><ArticleId IdType="pubmed">22131541</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS et al. Entorhinal cortex tau, amyloid-beta, cortical thickness and memory performance in non-demented subjects. Brain 142, 1148&#x2013;1160 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439321</ArticleId><ArticleId IdType="pubmed">30759182</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Harten AC et al. Tau and p-tau as CSF biomarkers in dementia: A meta-analysis. Clin. Chem. Lab. Med 49, 353&#x2013;366 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21342021</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivero-Santana A et al. Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer&#x2019;s Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors. J. Alzheimer&#x2019;s Dis 55, 625&#x2013;644 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27716663</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Campo M et al. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Ann. Clin. Transl. Neurol 5, 1163&#x2013;1175 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6186934</ArticleId><ArticleId IdType="pubmed">30349851</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DT et al. In vivo 18 F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology 90, e947&#x2013;e954 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858948</ArticleId><ArticleId IdType="pubmed">29440563</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 139, 2372&#x2013;2379 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995360</ArticleId><ArticleId IdType="pubmed">27357347</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R et al. Associations between [ 18 F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90, e282&#x2013;e290 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5798657</ArticleId><ArticleId IdType="pubmed">29282337</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140, 748&#x2013;763 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382945</ArticleId><ArticleId IdType="pubmed">28077397</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR et al. Longitudinal tau PET in ageing and Alzheimer&#x2019;s disease. Brain 141, 1517&#x2013;1528 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease&#x2013;Related &#x3b2;-Amyloid Status. JAMA Neurol. 1&#x2013;10 (2019). doi:10.1001/jamaneurol.2019.1632</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1632</ArticleId><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="pubmed">31233127</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE et al. Clinicopathological correlations in corticobasal degeneration. Ann. Neurol 70, 327&#x2013;340 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154081</ArticleId><ArticleId IdType="pubmed">21823158</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers. Dement 7, 263&#x2013;269 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers. Dement 7, 270&#x2013;279 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoglinger GU et al. Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria HHS Public Access Author manuscript. Mov Disord 32, 853&#x2013;864 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516529</ArticleId><ArticleId IdType="pubmed">28467028</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456&#x2013;77 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006&#x2013;14 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch CA et al. The clinical dementia rating sum of box score in mild dementia. Dement. Geriatr. Cogn. Disord 21, 40&#x2013;43 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16254429</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE &amp; McHugh PR &#x2018;Mini-mental state&#x2019;. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 12, 189&#x2013;198 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer JH et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn. Behav. Neurol 16, 211&#x2013;218 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14665820</ArticleId></ArticleIdList></Reference><Reference><Citation>Satz P, Uchiyama C &amp; White T Color Trails Test. Professional Manual. Odessa Psychol. Assess. Resour (1996).</Citation></Reference><Reference><Citation>Heaton R, Miller S, Taylor M &amp; Grant I Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults. PAR (2004).</Citation></Reference><Reference><Citation>Kaplan E, Goodglass H, Weintraub S &amp; Goodglass H Boston naming test. (Lea &amp; Febiger, 1983).</Citation></Reference><Reference><Citation>Yesavage JA et al. Development and validation of a geriatric depression screening scale: a preliminary report. J. Psychiatr. Res 17, 37&#x2013;49 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer RI, Kurosaki TT, Harrah CHJ, Chance JM &amp; Filos S Measurement of functional activities in older adults in the community. J. Gerontol 37, 323&#x2013;329 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab R &amp; England A Projection technique for evaluating surgery in Parkinson&#x2019;s disease in Billingham FH, Donaldson MC , eds. Third symposium on parkinson&#x2019;s disease. Edinburgh: Churchill Livingstone, 152&#x2013;157 (1969).</Citation></Reference><Reference><Citation>Hochberg Y Controlling the False Discovery Rate&#x202f;: A Practical and Powerful Approach to Multiple Testing Author ( s ): Yoav Benjamini and Yosef Hochberg Source&#x202f;: Journal of the Royal Statistical Society . Series B ( Methodological ), Vol . 57 , No . 1 ( 1995 ), Publi. 57, 289&#x2013;300 (1995).</Citation></Reference><Reference><Citation>Youden WJ. Index for rating diagnostic tests. Cancer 32&#x2013;35 (1950).</Citation><ArticleIdList><ArticleId IdType="pubmed">15405679</ArticleId></ArticleIdList></Reference><Reference><Citation>ADNI. ADNI2 Procedures manual. BIOFLUIDS Collect. Process. Shipm 94 doi:10.1002/ejoc.201200111</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejoc.201200111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J &amp; Friston KJ Unified segmentation. Neuroimage 26, 839&#x2013;851 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone IB et al. Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance. Neuroimage 104, 366&#x2013;372 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4265726</ArticleId><ArticleId IdType="pubmed">25255942</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J &amp; Friston KJ NeuroImage Diffeomorphic registration using geodesic shooting and Gauss &#x2013; Newton optimisation. Neuroimage 55, 954&#x2013;967 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221052</ArticleId><ArticleId IdType="pubmed">21216294</ArticleId></ArticleIdList></Reference><Reference><Citation>Southekal S et al. Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity. J. Nucl. Med 59, 944&#x2013;951 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29191858</ArticleId></ArticleIdList></Reference><Reference><Citation>Devous MD et al. Test&#x2013;Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. J. Nucl. Med 59, 937&#x2013;943 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29284675</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 138, 2020&#x2013;2033 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806716</ArticleId><ArticleId IdType="pubmed">25953778</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia M, Wang J &amp; He Y BrainNet Viewer: a network visualization tool for human brain connectomics. PLoS One 8, e68910 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701683</ArticleId><ArticleId IdType="pubmed">23861951</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32123385</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.</ArticleTitle><Pagination><StartPage>379</StartPage><EndPage>386</EndPage><MedlinePgn>379-386</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-020-0755-1</ELocationID><Abstract><AbstractText>Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased in preclinical AD and further increased at the MCI and dementia stages. It correlated with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the curve (AUC)&#x2009;=&#x2009;0.87-0.91 for different brain regions). Plasma P-tau181 differentiated AD dementia from non-AD neurodegenerative diseases with an accuracy similar to that of Tau PET and CSF P-tau181 (AUC&#x2009;=&#x2009;0.94-0.98), and detected AD neuropathology in an autopsy-confirmed cohort. High plasma P-tau181 was associated with subsequent development of AD dementia in cognitively unimpaired and MCI subjects. In conclusion, plasma P-tau181 is a noninvasive diagnostic and prognostic biomarker of AD, which may be useful in clinical practice and trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2869-8378</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Lund, Sweden. shorena.janelidze@med.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Geidy E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Xiyun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proctor</LastName><ForeName>Nicholas K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichenlaub</LastName><ForeName>Udo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-0705-3696</Identifier><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dage</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Lund, Sweden. Oskar.Hansson@med.lu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden. Oskar.Hansson@med.lu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 May;16(5):241. doi: 10.1038/s41582-020-0347-1.</RefSource><PMID Version="1">32203395</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069338" MajorTopicYN="N">Neuropathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32123385</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pii">10.1038/s41591-020-0755-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack, C. R. Jr. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pubmed">5958625</ArticleId><ArticleId IdType="pmc">5958625</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow, K., Hampel, H., Weiner, M. &amp; Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131&#x2013;144 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.4</ArticleId><ArticleId IdType="pubmed">20157306</ArticleId><ArticleId IdType="pmc">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989&#x2013;997 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId><ArticleId IdType="pmc">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebe, H. et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer&#x2019;s disease and Down Syndrome. Mol. Neurodegener. 12, 63 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0206-8</ArticleId><ArticleId IdType="pubmed">28866979</ArticleId><ArticleId IdType="pmc">28866979</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, C. C. et al. Assay of plasma phosphorylated tau protein (Threonine 181) and total tau protein in early-stage Alzheimer&#x2019;s disease. J. Alzheimers Dis. 61, 1323&#x2013;1332 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170810</ArticleId><ArticleId IdType="pubmed">29376870</ArticleId><ArticleId IdType="pmc">29376870</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouraki, V. et al. Plasma amyloid-beta and risk of Alzheimer&#x2019;s disease in the Framingham Heart Study. Alzheimers Dement. 11, 249&#x2013;257 e241 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.07.001</ArticleId><ArticleId IdType="pubmed">25217292</ArticleId><ArticleId IdType="pmc">25217292</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. &amp; Blennow, K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791&#x2013;799 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.0765</ArticleId><ArticleId IdType="pubmed">31009028</ArticleId><ArticleId IdType="pmc">31009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson, N. et al. Plasma tau in Alzheimer disease. Neurology 87, 1827&#x2013;1835 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003246</ArticleId><ArticleId IdType="pubmed">27694257</ArticleId><ArticleId IdType="pmc">27694257</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase, M. P. et al. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol. 76, 598&#x2013;606 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.4666</ArticleId><ArticleId IdType="pubmed">30830207</ArticleId><ArticleId IdType="pmc">30830207</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Lancet Neurol. 15, 673&#x2013;684 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00070-3</ArticleId><ArticleId IdType="pubmed">27068280</ArticleId><ArticleId IdType="pmc">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, R., Wibom, M., Pawlik, D., Englund, E. &amp; Hansson, O. Correlation of in vivo [18F]Flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol. 76, 310&#x2013;317 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.3692</ArticleId><ArticleId IdType="pubmed">6439731</ArticleId><ArticleId IdType="pmc">6439731</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl, M. et al. Biomarkers for tau pathology. Mol Cell Neurosci. 97, 18&#x2013;33 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2018.12.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele, R. et al. Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease. Neurology 92, e601&#x2013;e612 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006875</ArticleId><ArticleId IdType="pubmed">6382060</ArticleId><ArticleId IdType="pmc">6382060</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, R. et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 139, 2372&#x2013;2379 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww163</ArticleId><ArticleId IdType="pubmed">4995360</ArticleId><ArticleId IdType="pmc">4995360</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist, S. et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. 76, 1060&#x2013;1069 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1632</ArticleId><ArticleId IdType="pubmed">6593637</ArticleId><ArticleId IdType="pmc">6593637</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson, N. et al. The implications of different approaches to define ATN in Alzheimer&#x2019;s disease. Neurology (in the press).</Citation></Reference><Reference><Citation>Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 7, 280&#x2013;292 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pubmed">3220946</ArticleId><ArticleId IdType="pmc">3220946</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist, S. et al. Accurate risk estimation of beta-amyloid positivity to identify prodromal Alzheimer&#x2019;s disease: cross-validation study of practical algorithms. Alzheimers Dement. 15, 194&#x2013;204 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.08.014</ArticleId><ArticleId IdType="pubmed">6374284</ArticleId><ArticleId IdType="pmc">6374284</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg, H. et al. Plasma tau levels in Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 5, 9 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt163</ArticleId><ArticleId IdType="pubmed">3707015</ArticleId><ArticleId IdType="pmc">3707015</ArticleId></ArticleIdList></Reference><Reference><Citation>Randall, J. et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation 84, 351&#x2013;356 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2012.07.027</ArticleId><ArticleId IdType="pubmed">22885094</ArticleId><ArticleId IdType="pmc">22885094</ArticleId></ArticleIdList></Reference><Reference><Citation>Couchie, D. et al. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc. Natl Acad. Sci. USA 89, 4378&#x2013;4381 (1992).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.10.4378</ArticleId><ArticleId IdType="pubmed">1374898</ArticleId><ArticleId IdType="pmc">1374898</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson, N. et al. (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer&#x2019;s disease. EMBO Mol. Med. 9, 1212&#x2013;1223 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707809</ArticleId><ArticleId IdType="pubmed">28743782</ArticleId><ArticleId IdType="pmc">28743782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson, N. et al. Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology 90, e388&#x2013;e395 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004887</ArticleId><ArticleId IdType="pubmed">5791788</ArticleId><ArticleId IdType="pmc">5791788</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284&#x2013;1298 e1287 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.015</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId><ArticleId IdType="pmc">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach, T. G., Monsell, S. E., Phillips, L. E. &amp; Kukull, W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005&#x2013;2010. J. Neuropathol. Exp. Neurol. 71, 266&#x2013;273 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31824b211b</ArticleId><ArticleId IdType="pubmed">3331862</ArticleId><ArticleId IdType="pmc">3331862</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151&#x2013;1162 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.12917</ArticleId><ArticleId IdType="pubmed">6233630</ArticleId><ArticleId IdType="pmc">6233630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson, O. et al. Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228&#x2013;234 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(06)70355-6</ArticleId><ArticleId IdType="pubmed">16488378</ArticleId><ArticleId IdType="pmc">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura, A. et al. High performance plasma amyloid-beta biomarkers for Alzheimer&#x2019;s disease. Nature 554, 249&#x2013;254 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pubmed">29420472</ArticleId><ArticleId IdType="pmc">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler, S. E. et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 93, e1647&#x2013;e1659 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31371569</ArticleId><ArticleId IdType="pmc">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann, J. et al. CSF Abeta1-42 &#x2013; an excellent but complicated Alzheimer&#x2019;s biomarker &#x2013; a route to standardisation. Clin. Chim. Acta 467, 27&#x2013;33 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2016.05.014</ArticleId><ArticleId IdType="pubmed">27216941</ArticleId><ArticleId IdType="pmc">27216941</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy, N. R. et al. Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-&#x3b2; pathology. Preprint at bioRxiv https://doi.org/10.1101/226977 (2017).</Citation></Reference><Reference><Citation>Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595&#x2013;599 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1641</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId><ArticleId IdType="pmc">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183&#x2013;194 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2004.01388.x</ArticleId><ArticleId IdType="pubmed">15324362</ArticleId><ArticleId IdType="pmc">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson, N. et al. Increased amyloidogenic APP processing in APOE varepsilon4-negative individuals with cerebral beta-amyloidosis. Nat. Commun. 7, 10918 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10918</ArticleId><ArticleId IdType="pubmed">4786682</ArticleId><ArticleId IdType="pmc">4786682</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelb, D. J., Oliver, E. &amp; Gilman, S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56, 33&#x2013;39 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.56.1.33</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov. Disord. 32, 853&#x2013;864 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26987</ArticleId><ArticleId IdType="pubmed">5516529</ArticleId><ArticleId IdType="pmc">5516529</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan, I. et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele&#x2013;Richardson&#x2013;Olszewski Syndrome): report of the NINDS-SPSP International Workshop. Neurology 47, 1&#x2013;9 (1996).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.1.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496&#x2013;503 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31827f0fd1</ArticleId><ArticleId IdType="pubmed">3590050</ArticleId><ArticleId IdType="pmc">3590050</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer&#x2019;s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer&#x2019;s disease. Neurobiol. Aging 18, S1&#x2013;S2 (1997).</Citation></Reference><Reference><Citation>Palmqvist, S. et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 71, 1282&#x2013;1289 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1358</ArticleId><ArticleId IdType="pubmed">25155658</ArticleId><ArticleId IdType="pmc">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson, O. et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88, 930&#x2013;937 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003680</ArticleId><ArticleId IdType="pubmed">5333515</ArticleId><ArticleId IdType="pmc">5333515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn, A. et al. Modeling strategies for quantification of in vivo (18)F-AV-1451 binding in patients with tau pathology. J. Nucl. Med. 58, 623&#x2013;631 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.116.174508</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass, A. et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer&#x2019;s disease. Neuroimage 157, 448&#x2013;463 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.05.058</ArticleId><ArticleId IdType="pubmed">5814575</ArticleId><ArticleId IdType="pmc">5814575</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho, H. et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann. Neurol. 80, 247&#x2013;258 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24711</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen, D. C. A Population-Average, Landmark- and Surface-based (PALS) atlas of human cerebral cortex. Neuroimage 28, 635&#x2013;662 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2005.06.058</ArticleId><ArticleId IdType="pubmed">16172003</ArticleId><ArticleId IdType="pmc">16172003</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist, S. et al. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 8, 1214 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01150-x</ArticleId><ArticleId IdType="pubmed">29089479</ArticleId><ArticleId IdType="pmc">29089479</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32145376</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease.</ArticleTitle><Pagination><StartPage>104831</StartPage><MedlinePgn>104831</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2020.104831</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(20)30106-6</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Cholinergic dysfunction plays a prominent role in cognitive impairment in Parkinson's disease (PD). The aim of this study was to assess the relationship of baseline and longitudinal basal forebrain atrophy with cognitive decline and dementia in PD.</AbstractText><AbstractText Label="METHODS">We included 106 non-demented PD patients, 19 PD dementia (PDD) patients and 42 controls with longitudinal structural MRI and cognitive testing. After 4.2&#xa0;&#xb1;&#xa0;1.8&#xa0;years, 20 non-demented PD patients were diagnosed with dementia (PD-dementia converters), whereas the rest of PD patients remained non-demented (stable-PD). We compared MRI volumes of the medial septum/diagonal band (Ch1/Ch2) and nucleus basalis of Meynert (Ch4) between groups. Cox regression analyses were applied to test whether Ch1/Ch2 or Ch4 atrophy could predict future dementia and linear mixed models assessed their association with cognitive decline.</AbstractText><AbstractText Label="RESULTS">Compared to controls, we found reduced Ch4 baseline volumes in PD-dementia converters (p&#xa0;=&#xa0;.003) and those who already had PDD (p&#xa0;&lt;&#xa0;.001) but not in stable-PD. Over time, there was a greater loss in Ch1/Ch2 volumes in PD-dementia converters and PDD compared to the other groups (p&#xa0;=&#xa0;.004). Baseline and longitudinal Ch4 volumes were associated with cognition (p&#xa0;&lt;&#xa0;.002) and longitudinal Ch4 atrophy predicted future dementia (p&#xa0;=&#xa0;.009).</AbstractText><AbstractText Label="CONCLUSIONS">Atrophy of Ch4 precedes and predicts future dementia in PD and is followed by changes in Ch1/Ch2, reflecting a posterior-anterior pattern of basal forebrain atrophy. This pattern could be used to track the spread of cholinergic degeneration and identify patients at risk of developing dementia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Joana B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden; Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden. Electronic address: joana.pereira@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden; Memory Clinic, Sk&#xe5;ne University Hospital, Malmo, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jalakas</LastName><ForeName>Mattis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grothe</LastName><ForeName>Michel J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) - Rostock/Greifswald, Rostock, Germany; Unidad de Trastornos del Movimiento, Servicio de Neurolog&#xed;a y Neurofisiolog&#xed;a Cl&#xed;nica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc&#xed;o/CSIC/Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westman</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Westen</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden; Memory Clinic, Sk&#xe5;ne University Hospital, Malmo, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden; Memory Clinic, Sk&#xe5;ne University Hospital, Malmo, Sweden. Electronic address: Oskar.Hansson@med.lu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066187" MajorTopicYN="N">Basal Forebrain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Basal forebrain</Keyword><Keyword MajorTopicYN="N">Cognitive decline</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Longitudinal MRI</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2&#xa0;years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche. The rest of authors have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32145376</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2020.104831</ArticleId><ArticleId IdType="pii">S0969-9961(20)30106-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32154671</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region.</ArticleTitle><Pagination><StartPage>e11227</StartPage><MedlinePgn>e11227</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e11227</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201911227</ELocationID><Abstract><AbstractText>Triggering receptor expressed on myeloid cells 2 (TREM2) is essential for the transition of homeostatic microglia to a disease-associated microglial state. To enhance TREM2 activity, we sought to selectively increase the full-length protein on the cell surface via reducing its proteolytic shedding by A Disintegrin And Metalloproteinase (i.e., &#x3b1;-secretase) 10/17. We screened a panel of monoclonal antibodies against TREM2, with the aim to selectively compete for &#x3b1;-secretase-mediated shedding. Monoclonal antibody 4D9, which has a stalk region epitope close to the cleavage site, demonstrated dual mechanisms of action by stabilizing TREM2 on the cell surface and reducing its shedding, and concomitantly activating phospho-SYK signaling. 4D9 stimulated survival of macrophages and increased microglial uptake of myelin debris and amyloid &#x3b2;-peptide in&#xa0;vitro. In vivo target engagement was demonstrated in cerebrospinal fluid, where nearly all soluble TREM2 was 4D9-bound. Moreover, in a mouse model for Alzheimer's disease-related pathology, 4D9 reduced amyloidogenesis, enhanced microglial TREM2 expression, and reduced a homeostatic marker, suggesting a protective function by driving microglia toward a disease-associated state.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Schlepckow</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Monroe</LastName><ForeName>Kathryn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5811-8226</Identifier><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantuti-Castelvetri</LastName><ForeName>Ludovico</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parhizkar</LastName><ForeName>Samira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettkus</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xfc;lzen</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuscher</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Heike</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Xianyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Systemic Neuroscience, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feederle</LastName><ForeName>Regina</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3981-367X</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz Center Munich, German Research Center for Environmental Health, Institute for Diabetes and Obesity, Core Facility Monoclonal Antibody Development, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahirovic</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4403-9559</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Joshua I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prorok</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahon</LastName><ForeName>Cathal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Chun-Chi</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Ju</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Do Jin</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabelstr&#xf6;m</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Fen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simons</LastName><ForeName>Mikael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology (TUM-NZB), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewcock</LastName><ForeName>Joseph W</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0003-3012-7881</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>EXC 2145; ID 390857198 SyNergy</GrantID><Agency>Deutsche Forschungsgemeinschaft (DFG)</Agency><Country>International</Country></Grant><Grant><GrantID>HA1737/16-1</GrantID><Agency>Deutsche Forschungsgemeinschaft (DFG)</Agency><Country>International</Country></Grant><Grant><GrantID>ZT-0027</GrantID><Agency>Helmholtz Association</Agency><Country>International</Country></Grant><Grant><Agency>Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)</Agency><Country>International</Country></Grant><Grant><GrantID>115976</GrantID><Agency>Innovative Medicines Initiative (IMI)</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009101" MajorTopicYN="Y">Multiple Myeloma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">amyloid &#x3b2;-peptide</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">therapeutic antibody</Keyword></KeywordList><CoiStatement>C.H. collaborates with Denali Therapeutics, participated on one advisory board meeting of Biogen, and received a speaker honorarium from Novartis and Roche. C.H. is chief advisor of ISAR Bioscience. J.W.L., K.M.M., J.I.P., H.S., J.S., R.P., D.X., C.M., D.J.K., C.C.L., F.H., and G.D.P. are employees of Denali Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32154671</ArticleId><ArticleId IdType="pmc">PMC7136959</ArticleId><ArticleId IdType="doi">10.15252/emmm.201911227</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, Barres BA (2017) Diverse requirements for microglial survival, specification, and function revealed by defined&#x2010;medium cultures. Neuron 94: 759&#x2013;773.e758</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5523817</ArticleId><ArticleId IdType="pubmed">28521131</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C, Piaceri I, Archetti S, Bonvicini C et&#xa0;al (2014) Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging 35: 934.e937&#x2013;910</Citation><ArticleIdList><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury A (2010) Antibody engineering, Vol. 1 Berlin Heidelberg: Springer&#x2010;Verlag;</Citation></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE et&#xa0;al (2014) Identification of a unique TGF&#x2010;beta&#x2010;dependent molecular and functional signature in microglia. Nat Neurosci 17: 131&#x2013;143</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, Yuede CM, Galimberti D, Olivecrona G, Klein RS et&#xa0;al (2015) TREM2 regulates microglial cell activation in response to demyelination in&#xa0;vivo . Acta Neuropathol 129: 429&#x2013;447</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4667728</ArticleId><ArticleId IdType="pubmed">25631124</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, Wenk MR, Shui G, Di Paolo G (2012) Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 287: 2678&#x2013;2688</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268426</ArticleId><ArticleId IdType="pubmed">22134919</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q, Danao J, Talreja S, Wen P, Yin J, Sun N, Li CM, Chui D, Tran D, Koirala S et&#xa0;al (2018) TREM2&#x2010;activating antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant Trem 2(R47H) on murine myeloid cell function. J Biol Chem 293: 12620&#x2013;12633</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093249</ArticleId><ArticleId IdType="pubmed">29599291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochet O, Martin E, Fridman WH, Teillaud JL (1999) Selective PCR amplification of functional immunoglobulin light chain from hybridoma containing the aberrant MOPC 21&#x2010;derived V kappa by PNA&#x2010;mediated PCR clamping. Biotechniques 26: 818&#x2013;820, 822</Citation><ArticleIdList><ArticleId IdType="pubmed">10337468</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3: 445&#x2013;453</Citation><ArticleIdList><ArticleId IdType="pubmed">12776204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N et&#xa0;al (2014) Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 35: 726.e711&#x2013;729</Citation><ArticleIdList><ArticleId IdType="pubmed">24119542</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M et&#xa0;al (2019) Randomized trial of verubecestat for prodromal Alzheimer's disease. N Engl J Med 380: 1408&#x2013;1420</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776078</ArticleId><ArticleId IdType="pubmed">30970186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Franzmeier N, Suarez&#x2010;Calvet M, Morenas&#x2010;Rodriguez E, Caballero MAA, Kleinberger G, Piccio L, Cruchaga C, Deming Y, Dichgans M et&#xa0;al (2019) Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med 11: eaav6221</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7050285</ArticleId><ArticleId IdType="pubmed">31462511</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuerbach D, Schindler P, Barske C, Joller S, Beng&#x2010;Louka E, Worringer KA, Kommineni S, Kaykas A, Ho DJ, Ye C et&#xa0;al (2017) ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157. Neurosci Lett 660: 109&#x2013;114</Citation><ArticleIdList><ArticleId IdType="pubmed">28923481</ArticleId></ArticleIdList></Reference><Reference><Citation>Focke C, Blume T, Zott B, Shi Y, Deussing M, Peters F, Schmidt C, Kleinberger G, Lindner S, Gildehaus FJ et&#xa0;al (2019) Early and longitudinal microglial activation but not amyloid accumulation predicts cognitive outcome in PS2APP mice. J Nucl Med 60: 548&#x2013;554</Citation><ArticleIdList><ArticleId IdType="pubmed">30262517</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Brendel M, Werner G, Parhizkar S, Sebastian Monasor L, Kleinberger G, Colombo AV, Deussing M, Wagner M, Winkelmann J et&#xa0;al (2019) Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism. EMBO Mol Med 11: e9711</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554672</ArticleId><ArticleId IdType="pubmed">31122931</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Patel S, Federico AN, Choi SH, Innes BJ, Oram MK, Cereghetti G, McGinty D, Anselmo A, Sadreyev RI et&#xa0;al (2019) TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer's disease. Neuron 103: 820&#x2013;835</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6728215</ArticleId><ArticleId IdType="pubmed">31301936</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Bilgic B, Guven G, Bras J, Rohrer J, Lohmann E, Hanagasi H, Gurvit H, Emre M (2013) Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia&#x2010;like family. Neurobiol Aging 34: 2890.e2891&#x2013;2895</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898264</ArticleId><ArticleId IdType="pubmed">23870839</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ (1993) Cellular processing of beta&#x2010;amyloid precursor protein and the genesis of amyloid beta&#x2010;peptide. Cell 75: 1039&#x2013;1042</Citation><ArticleIdList><ArticleId IdType="pubmed">8261505</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaitin DA, Adlung L, Thaiss CA, Weiner A, Li B, Descamps H, Lundgren P, Bleriot C, Liu Z, Deczkowska A et&#xa0;al (2019) Lipid&#x2010;associated macrophages control metabolic homeostasis in a Trem2&#x2010;dependent manner. Cell 178: 686&#x2013;698</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7068689</ArticleId><ArticleId IdType="pubmed">31257031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, Tan L, Chen Q, Tan MS, Zhou JS, Zhu XC, Lu H, Wang HF, Zhang YD, Yu JT (2016) A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese. Neurobiol Aging 42: 217. e211&#x2013;213</Citation><ArticleIdList><ArticleId IdType="pubmed">27067662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson K (2013) TREM2 and neurodegenerative disease. N Engl J Med 369: 1568&#x2013;1569</Citation><ArticleIdList><ArticleId IdType="pubmed">24131183</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ et&#xa0;al (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren&#x2010;Shaul H, Spinrad A, Weiner A, Matcovitch&#x2010;Natan O, Dvir&#x2010;Szternfeld R, Ulland TK, David E, Baruch K, Lara&#x2010;Astaiso D, Toth B et&#xa0;al (2017) A unique microglia type associated with restricting development of Alzheimer's disease. Cell 169: 1276&#x2013;1290.e1217</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Lee SR, Li LH, Park HJ, Park JH, Lee KY, Kim MK, Shin BA, Choi SY (2011) High cleavage efficiency of a 2A peptide derived from porcine teschovirus&#x2010;1 in human cell lines, zebrafish and mice. PLoS ONE 6: e18556</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084703</ArticleId><ArticleId IdType="pubmed">21602908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Suarez&#x2010;Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger&#x2010;Weinzierl A, Mazaheri F et&#xa0;al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6: 243ra286</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, Focke C, Deussing M, Suarez&#x2010;Calvet M, Mazaheri F et&#xa0;al (2017) The FTD&#x2010;like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J 36: 1837&#x2013;1853</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494459</ArticleId><ArticleId IdType="pubmed">28559417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495&#x2013;497</Citation><ArticleIdList><ArticleId IdType="pubmed">1172191</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z et&#xa0;al (2017) The TREM2&#x2010;APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47: 566&#x2013;581.e569</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Colombo AV, Schusser B, Dreymueller D, Wetzel S, Schepers U, Herber J, Ludwig A, Kremmer E, Montag D et&#xa0;al (2016) Systematic substrate identification indicates a central role for the metalloprotease ADAM10 in axon targeting and synapse function. Elife 5: e12748</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786429</ArticleId><ArticleId IdType="pubmed">26802628</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschallinger JIT, Zardeneta M, Lee SE, Lehallier B, Haney MS, Pluvinage JV, Mathur V, Hahn O, Morgens DW, Kim J et&#xa0;al (2020) Lipid droplet accumulating microglia represent a dysfunctional and pro&#x2010;inflammatory state in the aging brain. Nat Neurosci 23: 194&#x2013;208</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7595134</ArticleId><ArticleId IdType="pubmed">31959936</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, Krasemann S, Capell A, Trumbach D, Wurst W et&#xa0;al (2017) TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep 18: 1186&#x2013;1198</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Monasor LSMSA, Colombo A, K&#xf6;nig J, Roth S, Liesz A, Berghofer A, Saito T, Saido TC, Herms J, Willem M et&#xa0;al (2019) Fibrillar Abeta triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. bioRxiv 10.1101/861146 [PREPRINT]</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/861146</ArticleId><ArticleId IdType="pmc">PMC7279888</ArticleId><ArticleId IdType="pubmed">32510331</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC et&#xa0;al (2014) Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81: 49&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pubmed">24411731</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, Llapashtica C, Wang J, Kim DJ, Xia D et&#xa0;al (2019) TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron 105: 837&#x2013;854</Citation><ArticleIdList><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Koren EG, Yu C, Klingeborn M, Wong AYW, Prigge CL, Mathew R, Kalnitsky J, Msallam RA, Silvin A, Kay JN et&#xa0;al (2019) Microglial function is distinct in different anatomical locations during retinal homeostasis and degeneration. Immunity 50: 723&#x2013;737.e727</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6592635</ArticleId><ArticleId IdType="pubmed">30850344</ArticleId></ArticleIdList></Reference><Reference><Citation>Page RM, Baumann K, Tomioka M, Perez&#x2010;Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H et&#xa0;al (2008) Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease&#x2010;associated presenilin mutations and gamma&#x2010;secretase modulation. J Biol Chem 283: 677&#x2013;683</Citation><ArticleIdList><ArticleId IdType="pubmed">17962197</ArticleId></ArticleIdList></Reference><Reference><Citation>Page RM, Gutsmiedl A, Fukumori A, Winkler E, Haass C, Steiner H (2010) Beta&#x2010;amyloid precursor protein mutants respond to gamma&#x2010;secretase modulators. J Biol Chem 285: 17798&#x2013;17810</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2878544</ArticleId><ArticleId IdType="pubmed">20348104</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N et&#xa0;al (2019) Loss of TREM2 function increases amyloid seeding but reduces plaque&#x2010;associated ApoE. Nat Neurosci 22: 191&#x2013;204</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353: 777&#x2013;783</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen&#x2010;Hoerth C, Kertesz A, Bigio EH et&#xa0;al (2013) TREM2 in neurodegeneration: evidence for association of the p. R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener 8: 19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC (2014) Single App knock&#x2010;in mouse models of Alzheimer's disease. Nat Neurosci 17: 661&#x2013;663</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K, Kleinberger G, Fukumori A, Feederle R, Lichtenthaler SF, Steiner H, Haass C (2017) An Alzheimer&#x2010;associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol Med 9: 1356&#x2013;1365</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623859</ArticleId><ArticleId IdType="pubmed">28855300</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y et&#xa0;al (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature 537: 50&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirotani K, Tomioka M, Kremmer E, Haass C, Steiner H (2007) Pathological activity of familial Alzheimer's disease&#x2010;associated mutant presenilin can be executed by six different gamma&#x2010;secretase complexes. Neurobiol Dis 27: 102&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pubmed">17560791</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirotani K, Hori Y, Yoshizaki R, Higuchi E, Colonna M, Saito T, Hashimoto S, Saito T, Saido TC, Iwata N (2019) Aminophospholipids are signal&#x2010;transducing TREM2 ligands on apoptotic cells. Sci Rep 9: 7508</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525155</ArticleId><ArticleId IdType="pubmed">31101881</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M (2018) Humanized TREM2 mice reveal microglia&#x2010;intrinsic and &#x2010;extrinsic effects of R47H polymorphism. J Exp Med 215: 745&#x2013;760</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez&#x2010;Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C et&#xa0;al (2016a) Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8: 369ra178</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez&#x2010;Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD et&#xa0;al (2016b) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early&#x2010;stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8: 466&#x2013;476</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez&#x2010;Calvet M, Morenas&#x2010;Rodriguez E, Kleinberger G, Schlepckow K, Araque Caballero MA, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E et&#xa0;al (2019) Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related&#x2010;neurodegeneration but not with amyloid&#x2010;beta pathology. Mol Neurodegener 14: 1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327425</ArticleId><ArticleId IdType="pubmed">30630532</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton P, Sevalle J, Deery MJ, Fraser G, Zhou Y, Stahl S, Franssen EH, Dodd RB, Qamar S, Gomez Perez&#x2010;Nievas B et&#xa0;al (2017) TREM2 shedding by cleavage at the H157&#x2010;S158 bond is accelerated for the Alzheimer's disease&#x2010;associated H157Y variant. EMBO Mol Med 9: 1366&#x2013;1378</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623839</ArticleId><ArticleId IdType="pubmed">28855301</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M (2006) Cutting edge: TREM&#x2010;2 attenuates macrophage activation. J Immunol 177: 3520&#x2013;3524</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Wang Y, Colonna M (2015) Regulation of microglial survival and proliferation in health and diseases. Semin Immunol 27: 410&#x2013;415</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084693</ArticleId><ArticleId IdType="pubmed">27033414</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A et&#xa0;al (2017) TREM2 maintains microglial metabolic fitness in Alzheimer's disease. Cell 170: 649&#x2013;663.e613</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Colonna M, Holtzman DM (2017) Elucidating the role of TREM2 in Alzheimer's disease. Neuron 94: 237&#x2013;248</Citation><ArticleIdList><ArticleId IdType="pubmed">28426958</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH et&#xa0;al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160: 1061&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, Hornburg D, Evans LD, Moore S, Daria A et&#xa0;al (2015) &#x3b7;&#x2010;Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 526: 443&#x2013;447</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570618</ArticleId><ArticleId IdType="pubmed">26322584</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J (2013) Sequential proteolytic processing of the triggering receptor expressed on myeloid cells&#x2010;2 (TREM2) protein by ectodomain shedding and gamma&#x2010;secretase&#x2010;dependent intramembranous cleavage. J Biol Chem 288: 33027&#x2013;33036</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C (2016) TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med 8: 992&#x2013;1004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009806</ArticleId><ArticleId IdType="pubmed">27402340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ et&#xa0;al (2011) Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3: 84ra44</Citation><ArticleIdList><ArticleId IdType="pubmed">21613623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Chen XF, Wang T, Wang Z, Liao C, Wang Z, Huang R, Wang D, Li X, Wu L et&#xa0;al (2017) Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med 214: 597&#x2013;607</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5339672</ArticleId><ArticleId IdType="pubmed">28209725</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, Wang D, Gao Y, Zhu Y, Sheng X et&#xa0;al (2019) Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model. Nat Commun 10: 1365</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433910</ArticleId><ArticleId IdType="pubmed">30911003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32160553</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>The FTLD Risk Factor TMEM106B Regulates the Transport of Lysosomes at the Axon Initial Segment of Motoneurons.</ArticleTitle><Pagination><StartPage>3506</StartPage><EndPage>3519.e6</EndPage><MedlinePgn>3506-3519.e6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2020.02.060</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(20)30228-X</ELocationID><Abstract><AbstractText>Genetic variations in TMEM106B, coding for a lysosomal membrane protein, affect frontotemporal lobar degeneration (FTLD) in GRN- (coding for progranulin) and C9orf72-expansion carriers and might play a role in aging. To determine the physiological function of TMEM106B, we generated TMEM106B-deficient mice. These mice develop proximal axonal swellings caused by drastically enlarged LAMP1-positive vacuoles, increased retrograde axonal transport of lysosomes, and accumulation of lipofuscin and autophagosomes. Giant vacuoles specifically accumulate at the distal end and within the axon initial segment, but not in peripheral nerves or at axon terminals, resulting in an impaired facial-nerve-dependent motor performance. These data implicate TMEM106B in mediating the axonal transport of LAMP1-positive organelles in motoneurons and axonal sorting at the initial segment. Our data provide mechanistic insight into how TMEM106B affects lysosomal proteolysis and degradative capacity in neurons.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xfc;ningschr&#xf6;r</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital Wuerzburg, University of Wuerzburg, 97078 Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stroobants</LastName><ForeName>Stijn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Biological Psychology, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakuta</LastName><ForeName>Soichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Neuropathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dombert</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital Wuerzburg, University of Wuerzburg, 97078 Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinske</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Physiological Chemistry, Ulm University, 89081 Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanner</LastName><ForeName>Renate</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Physiological Chemistry, Ulm University, 89081 Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xfc;llmann-Rauch</LastName><ForeName>Renate</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Anatomy, Kiel University, 24098 Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wefers</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany; Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wurst</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany; Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany; Technische Universit&#xe4;t M&#xfc;nchen-Weihenstephan, 85764 Neuherberg/Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Hooge</LastName><ForeName>Rudi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Biological Psychology, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchiyama</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Neuropathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sendtner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital Wuerzburg, University of Wuerzburg, 97078 Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, 81377 Munich, Germany; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saftig</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry, Kiel University, 24098 Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kn&#xf6;ll</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Physiological Chemistry, Ulm University, 89081 Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capell</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damme</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry, Kiel University, 24098 Kiel, Germany. Electronic address: mdamme@biochem.uni-kiel.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000632372">Tmem106b protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071182" MajorTopicYN="N">Autophagosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071040" MajorTopicYN="N">Axon Initial Segment</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001933" MajorTopicYN="N">Brain Stem</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005154" MajorTopicYN="N">Facial Nerve</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009132" MajorTopicYN="N">Muscles</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">TMEM106B</Keyword><Keyword MajorTopicYN="N">axon</Keyword><Keyword MajorTopicYN="N">axon initial segment</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">lysosome</Keyword><Keyword MajorTopicYN="N">motoneurons</Keyword><Keyword MajorTopicYN="N">retrograde</Keyword></KeywordList><CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32160553</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.02.060</ArticleId><ArticleId IdType="pii">S2211-1247(20)30228-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32160554</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Neuronal BIN1 Regulates Presynaptic Neurotransmitter Release and Memory Consolidation.</ArticleTitle><Pagination><StartPage>3520</StartPage><EndPage>3535.e7</EndPage><MedlinePgn>3520-3535.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2020.02.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(20)30187-X</ELocationID><Abstract><AbstractText>BIN1, a member of the BAR adaptor protein family, is a significant late-onset Alzheimer disease risk factor. Here, we investigate BIN1 function in the brain using conditional knockout (cKO) models. Loss of neuronal Bin1 expression results in the select impairment of spatial learning and memory. Examination of hippocampal CA1 excitatory synapses reveals a deficit in presynaptic release probability and slower depletion of neurotransmitters during repetitive stimulation, suggesting altered vesicle dynamics in Bin1 cKO mice. Super-resolution and immunoelectron microscopy localizes BIN1 to presynaptic sites in excitatory synapses. Bin1 cKO significantly reduces synapse density and alters presynaptic active zone protein cluster formation. Finally, 3D electron microscopy reconstruction analysis uncovers a significant increase in docked and reserve pools of synaptic vesicles at hippocampal synapses in Bin1 cKO mice. Our results demonstrate a non-redundant role for BIN1 in presynaptic regulation, thus providing significant insights into the fundamental function of BIN1 in synaptic physiology relevant to Alzheimer disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Rossi</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nomura</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrew</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masse</LastName><ForeName>Nicolas Y</ForeName><Initials>NY</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampathkumar</LastName><ForeName>Vandana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musial</LastName><ForeName>Timothy F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Neurological sciences, Rush University, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudwarts</LastName><ForeName>Ari</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA; Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recupero</LastName><ForeName>Aleksandra J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Metayer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Mitchell T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA; Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shim</LastName><ForeName>Ha-Na</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krause</LastName><ForeName>Sofia V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freedman</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bindokas</LastName><ForeName>Vytas P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>Integrated Light Microscopy Facility, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasthuri</LastName><ForeName>Narayanan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurological sciences, Rush University, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contractor</LastName><ForeName>Anis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Department of Neurobiology, Weinberg College of Arts and Sciences, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thinakaran</LastName><ForeName>Gopal</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL 60637, USA; Department of Neurology, The University of Chicago, Chicago, IL 60637, USA; Department of Pathology, The University of Chicago, Chicago, IL 60637, USA; Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613, USA. Electronic address: thinakaran@usf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S10 OD010649</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG063175</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG017139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG050767</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054223</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH099114</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG017139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056061</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C109221">Bin1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050600">SNARE Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069077" MajorTopicYN="Y">Memory Consolidation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050600" MajorTopicYN="N">SNARE Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065853" MajorTopicYN="N">Spatial Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3D EM reconstruction</Keyword><Keyword MajorTopicYN="N">Amphiphysin 2</Keyword><Keyword MajorTopicYN="N">BIN1</Keyword><Keyword MajorTopicYN="N">Morris water maze</Keyword><Keyword MajorTopicYN="N">STED</Keyword><Keyword MajorTopicYN="N">dSTORM</Keyword><Keyword MajorTopicYN="N">late-onset Alzheimer disease</Keyword><Keyword MajorTopicYN="N">release probability</Keyword><Keyword MajorTopicYN="N">super-resolution</Keyword><Keyword MajorTopicYN="N">synaptic physiology</Keyword></KeywordList><CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32160554</ArticleId><ArticleId IdType="mid">NIHMS1574783</ArticleId><ArticleId IdType="pmc">PMC7146643</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.02.026</ArticleId><ArticleId IdType="pii">S2211-1247(20)30187-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrew RJ, De Rossi P, Nguyen P, Kowalski HR, Recupero AJ, Guerbette T, Krause SV, Rice RC, Laury-Kleintop L, Wagner SL, and Thinakaran G (2019). Reduction of the expression of the late-onset Alzheimer&#x2019;s disease (AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model. J. Biol. Chem 294, 4477&#x2013;4487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433054</ArticleId><ArticleId IdType="pubmed">30692199</ArticleId></ArticleIdList></Reference><Reference><Citation>Annamneedi A, Caliskan G, M&#xfc;ller S, Montag D, Budinger E, Angenstein F, Fejtova A, Tischmeyer W, Gundelfinger ED, and Stork O (2018). Ablation of the presynaptic organizer Bassoon in excitatory neurons retards dentate gyrus maturation and enhances learning performance. Brain Struct. Funct 223, 3423&#x2013;3445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132633</ArticleId><ArticleId IdType="pubmed">29915867</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthet G, Jord&#xe0;-Siquier T, Rumi-Masante J, Bernadou F, M&#xfc;ller U, and Mulle C (2018). Presenilin-mediated cleavage of APP regulates synaptotagmin-7 and presynaptic plasticity. Nat. Commun 9, 4780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6235831</ArticleId><ArticleId IdType="pubmed">30429473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bungenberg J, Surano N, Grote A, Surges R, Pernhorst K, Hofmann A, Schoch S, Helmstaedter C, and Becker AJ (2016). Gene expression variance in hippocampal tissue of temporal lobe epilepsy patients corresponds to differential memory performance. Neurobiol. Dis 86, 121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631617</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S, Flavin W, Verstreken P, and Moechars D (2016). Loss of Bin1 Promotes the Propagation of Tau Pathology. Cell Rep. 17, 931&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">27760323</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter RJ, Morton J, and Dunnett SB (2001). Motor coordination and balance in rodents. Curr. Protoc. Neurosci Chapter 8, 12.</Citation><ArticleIdList><ArticleId IdType="pubmed">18428540</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakroborty S, Hill ES, Christian DT, Helfrich R, Riley S, Schneider C, Kapecki N, Mustaly-Kalimi S, Seiler FA, Peterson DA, et al. (2019). Reduced presynaptic vesicle stores mediate cellular and network plasticity defects in an early-stage mouse model of Alzheimer&#x2019;s disease. Mol. Neurodegener 14, 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343260</ArticleId><ArticleId IdType="pubmed">30670054</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MY, Boulden J, Katz JB, Wang L, Meyer TJ, Soler AP, Muller AJ, and Prendergast GC (2007). Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res. 67, 7605&#x2013;7612.</Citation><ArticleIdList><ArticleId IdType="pubmed">17699764</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis J, Hansmannel F, Gistelinck M, Mounier A, Van Cauwenberghe C, Kolen KV, Geller F, Sottejeau Y, Harold D, Dourlen P, et al.; GERAD Consortium (2013). Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol. Psychiatry 18, 1225&#x2013;1234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807661</ArticleId><ArticleId IdType="pubmed">23399914</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung C, Barylko B, Leitz J, Liu X, and Kavalali ET (2010). Acute dynamin inhibition dissects synaptic vesicle recycling pathways that drive spontaneous and evoked neurotransmission. J. Neurosci 30, 1363&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823378</ArticleId><ArticleId IdType="pubmed">20107062</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremona O, Di Paolo G, Wenk MR, L&#xfc;thi A, Kim WT, Takei K, Daniell L, Nemoto Y, Shears SB, Flavell RA, et al. (1999). Essential role of phosphoinositide metabolism in synaptic vesicle recycling. Cell 99, 179&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">10535736</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotti A, Sait HR, McAvoy KM, Estrada K, Ergun A, Szak S, Marsh G, Jandreski L, Peterson M, Reynolds TL, et al. (2019). BIN1 favors the spreading of Tau via extracellular vesicles. Sci. Rep 9, 9477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6603165</ArticleId><ArticleId IdType="pubmed">31263146</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rossi P, Buggia-Pr&#xe9;vot V, Clayton BL, Vasquez JB, van Sanford C, Andrew RJ, Lesnick R, Bott&#xe9; A, Deyts C, Salem S, et al. (2016a). Predominant expression of Alzheimer&#x2019;s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts. Mol. Neurodegener 11, 59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4973113</ArticleId><ArticleId IdType="pubmed">27488240</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rossi P, Harde E, Dupuis JP, Martin L, Chounlamountri N, Bardin M, Watrin C, Benetollo C, Pernet-Gallay K, Luhmann HJ, et al. (2016b). A critical role for VEGF and VEGFR2 in NMDA receptor synaptic function and fear-related behavior. Mol. Psychiatry 21, 1768&#x2013;1780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5116482</ArticleId><ArticleId IdType="pubmed">26728568</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paolo G, Sankaranarayanan S, Wenk MR, Daniell L, Perucco E, Caldarone BJ, Flavell R, Picciotto MR, Ryan TA, Cremona O, and De Camilli P (2002). Decreased synaptic vesicle recycling efficiency and cognitive deficits in amphiphysin 1 knockout mice. Neuron 33, 789&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ester M, Kriegel HP, Sander H, and Xu X (1996). A Density-Based Algorithm for Discovering Clusters in Large Spatial Datasets with Noise. In Proceedings of the 2nd International Conference on KDD, pp. 1232&#x2013;1239.</Citation></Reference><Reference><Citation>Ferguson SM, Brasnjo G, Hayashi M, W&#xf6;lfel M, Collesi C, Giovedi S, Raimondi A, Gong LW, Ariel P, Paradise S, et al. (2007). A selective activity-dependent requirement for dynamin 1 in synaptic vesicle endocytosis. Science 316, 570&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">17463283</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes HB, Riordan S, Nomura T, Remmers CL, Kraniotis S, Marshall JJ, Kukreja L, Vassar R, and Contractor A (2015). Epac2 Mediates cAMP-Dependent Potentiation of Neurotransmission in the Hippocampus. J. Neurosci 35, 6544&#x2013;6553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405561</ArticleId><ArticleId IdType="pubmed">25904804</ArticleId></ArticleIdList></Reference><Reference><Citation>Fioravante D, and Regehr WG (2011). Short-term forms of presynaptic plasticity. Curr. Opin. Neurobiol 21, 269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3599780</ArticleId><ArticleId IdType="pubmed">21353526</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogel H, Frere S, Segev O, Bharill S, Shapira I, Gazit N, O&#x2019;Malley T, Slomowitz E, Berdichevsky Y, Walsh DM, et al. (2014). APP homodimers transduce an amyloid-&#x3b2;-mediated increase in release probability at excitatory synapses. Cell Rep. 7, 1560&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">24835997</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N, Rubinski A, Neitzel J, and Ewers M; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) (2019). The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. Nat. Commun 10, 1766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6467911</ArticleId><ArticleId IdType="pubmed">30992433</ArticleId></ArticleIdList></Reference><Reference><Citation>Geis C, Weishaupt A, Hallermann S, Gr&#xfc;newald B, Wessig C, Wultsch T, Reif A, Byts N, Beck M, Jablonka S, et al. (2010). Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 133, 3166&#x2013;3180.</Citation><ArticleIdList><ArticleId IdType="pubmed">20884644</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorski JA, Talley T, Qiu M, Puelles L, Rubenstein JL, and Jones KR (2002). Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. J. Neurosci 22, 6309&#x2013;6314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758181</ArticleId><ArticleId IdType="pubmed">12151506</ArticleId></ArticleIdList></Reference><Reference><Citation>Graziano A, Petrosini L, and Bartoletti A (2003). Automatic recognition of explorative strategies in the Morris water maze. J. Neurosci. Methods 130, 33&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">14583402</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundelfinger ED, Reissner C, and Garner CC (2016). Role of Bassoon and Piccolo in Assembly and Molecular Organization of the Active Zone. Front. Synaptic Neurosci 7, 19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709825</ArticleId><ArticleId IdType="pubmed">26793095</ArticleId></ArticleIdList></Reference><Reference><Citation>Haytural H, Mermelekas G, Emre C, Nigam SM, Carroll SL, Winblad B, Bogdanovic N, Barthet G, Granholm AC, Orre LM, et al. (2020). The proteome of the dentate terminal zone of the perforant path indicates presynaptic impairment in Alzheimer disease. Mol. Cell. Proteomics 19, 128&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6944231</ArticleId><ArticleId IdType="pubmed">31699905</ArticleId></ArticleIdList></Reference><Reference><Citation>He E, Wierda K, van Westen R, Broeke JH, Toonen RF, Cornelisse LN, and Verhage M (2017). Munc13&#x2013;1 and Munc18&#x2013;1 together prevent NSF-dependent de-priming of synaptic vesicles. Nat. Commun 8, 15915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482055</ArticleId><ArticleId IdType="pubmed">28635948</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler CJ, Davis PR, Beckett TL, Platt TL, Webb RL, Head E, and Murphy MP (2014). Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer&#x2019;s disease brain and correlates with neurofibrillary tangle pathology. J. Alzheimers Dis 42, 1221&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198456</ArticleId><ArticleId IdType="pubmed">25024306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogendoorn E, Crosby KC, Leyton-Puig D, Breedijk RM, Jalink K, Gadella TW, and Postma M (2014). The fidelity of stochastic single-molecule super-resolution reconstructions critically depends upon robust background estimation. Sci. Rep 4, 3854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900998</ArticleId><ArticleId IdType="pubmed">24458236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y, Laserstein P, and Helmstaedter M (2015). Large-volume en-bloc staining for electron microscopy-based connectomics. Nat. Commun 6, 7923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4532871</ArticleId><ArticleId IdType="pubmed">26235643</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, Dammer EB, Duong DM, Yin L, Thambisetty M, Troncoso JC, Lah JJ, Levey AI, and Seyfried NT (2018). Deep proteomic network analysis of Alzheimer&#x2019;s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Mol. Neurodegener 13, 52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6172707</ArticleId><ArticleId IdType="pubmed">30286791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasthuri N, Hayworth KJ, Berger DR, Schalek RL, Conchello JA, Knowles-Barley S, Lee D, V&#xe1;zquez-Reina A, Kaynig V, Jones TR, et al. (2015). Saturated Reconstruction of a Volume of Neocortex. Cell 162, 648&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">26232230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JJ, and Jung MW (2006). Neural circuits and mechanisms involved in Pavlovian fear conditioning: a critical review. Neurosci. Biobehav. Rev 30, 188&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342048</ArticleId><ArticleId IdType="pubmed">16120461</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemmer P, Meredith RM, Holmgren CD, Klychnikov OI, Stahl-Zeng J, Loos M, van der Schors RC, Wortel J, de Wit H, Spijker S, et al. (2011). Proteomics, ultrastructure, and physiology of hippocampal synapses in a fragile X syndrome mouse model reveal presynaptic phenotype. J. Biol. Chem 286, 25495&#x2013;25504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138307</ArticleId><ArticleId IdType="pubmed">21596744</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R (2002). The neurobiological basis of spontaneous alternation. Neurosci. Biobehav. Rev 26, 91&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835987</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wang S, Li T, Zhu L, Xu Y, and Ma C (2017). A Stimulation Function of Synaptotagmin-1 in Ternary SNARE Complex Formation Dependent on Munc18 and Munc13. Front. Mol. Neurosci 10, 256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5559510</ArticleId><ArticleId IdType="pubmed">28860966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichte B, Veh RW, Meyer HE, and Kilimann MW (1992). Amphiphysin, a novel protein associated with synaptic vesicles. EMBO J. 11, 2521&#x2013;2530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556727</ArticleId><ArticleId IdType="pubmed">1628617</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou X, Fan F, Messa M, Raimondi A, Wu Y, Looger LL, Ferguson SM, and De Camilli P (2012). Reduced release probability prevents vesicle depletion and transmission failure at dynamin mutant synapses. Proc. Natl. Acad. Sci. USA 109, E515&#x2013;E523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286982</ArticleId><ArticleId IdType="pubmed">22308498</ArticleId></ArticleIdList></Reference><Reference><Citation>MacGillavry HD, Song Y, Raghavachari S, and Blanpied TA (2013). Nanoscale scaffolding domains within the postsynaptic density concentrate synaptic AMPA receptors. Neuron 78, 615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668352</ArticleId><ArticleId IdType="pubmed">23719161</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks B, and McMahon HT (1998). Calcium triggers calcineurin-dependent synaptic vesicle recycling in mammalian nerve terminals. Curr. Biol 8, 740&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">9651678</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie AT, Moyon S, Wang M, Katsyv I, Song WM, Zhou X, Dammer EB, Duong DM, Aaker J, Zhao Y, et al. (2017). Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer&#x2019;s disease. Mol. Neurodegener 12, 82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5674813</ArticleId><ArticleId IdType="pubmed">29110684</ArticleId></ArticleIdList></Reference><Reference><Citation>Meckler X, Roseman J, Das P, Cheng H, Pei S, Keat M, Kassarjian B, Golde TE, Parent AT, and Thinakaran G (2010). Reduced Alzheimer&#x2019;s disease b-amyloid deposition in transgenic mice expressing S-palmitoylation-deficient APH1aL and nicastrin. Journal of Neuroscience 30, 16160&#x2013;16169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2999009</ArticleId><ArticleId IdType="pubmed">21123562</ArticleId></ArticleIdList></Reference><Reference><Citation>Micheva KD, Kay BK, and McPherson PS (1997). Synaptojanin forms two separate complexes in the nerve terminal. Interactions with endophilin and amphiphysin. J. Biol. Chem 272, 27239&#x2013;27245.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341169</ArticleId></ArticleIdList></Reference><Reference><Citation>Milosevic I, Giovedi S, Lou X, Raimondi A, Collesi C, Shen H, Paradise S, O&#x2019;Toole E, Ferguson S, Cremona O, and De Camilli P (2011). Recruitment of endophilin to clathrin-coated pit necks is required for efficient vesicle uncoating after fission. Neuron 72, 587&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3258500</ArticleId><ArticleId IdType="pubmed">22099461</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa T, Ebinuma I, Morohashi Y, Hori Y, Young Chang M, Hattori H, Maehara T, Yokoshima S, Fukuyama T, Tsuji S, et al. (2016). BIN1 regulates BACE1 intracellular trafficking and amyloid-b production. Hum. Mol. Genet 25, 2948&#x2013;2958.</Citation><ArticleIdList><ArticleId IdType="pubmed">27179792</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair D, Hosy E, Petersen JD, Constals A, Giannone G, Choquet D, and Sibarita JB (2013). Super-resolution imaging reveals that AMPA receptors inside synapses are dynamically organized in nanodomains regulated by PSD95. J. Neurosci 33, 13204&#x2013;13224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619720</ArticleId><ArticleId IdType="pubmed">23926273</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman KM, Molina-Campos E, Musial TF, Price AL, Oh KJ, Wolke ML, Buss EW, Scheff SW, Mufson EJ, and Nicholson DA (2015). Evidence for Alzheimer&#x2019;s disease-linked synapse loss and compensation in mouse and human hippocampal CA1 pyramidal neurons. Brain Struct. Funct 220, 3143&#x2013;3165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297585</ArticleId><ArticleId IdType="pubmed">25031178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomura T, Oyamada Y, Fernandes HB, Remmers CL, Xu J, Meltzer HY, and Contractor A (2016). Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus. Neuropharmacology 100, 90&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584174</ArticleId><ArticleId IdType="pubmed">25937215</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovesn&#xfd; M, K r&#xed; zek P, Borkovec J, Svindrych Z, and Hagen GM (2014). ThunderSTORM: a comprehensive ImageJ plug-in for PALM and STORM data analysis and super-resolution imaging. Bioinformatics 30, 2389&#x2013;2390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4207427</ArticleId><ArticleId IdType="pubmed">24771516</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DJ, Wigge P, Vallis Y, Moore JD, Evans PR, and McMahon HT (1998). Crystal structure of the amphiphysin-2 SH3 domain and its role in the prevention of dynamin ring formation. EMBO J. 17, 5273&#x2013;5285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170855</ArticleId><ArticleId IdType="pubmed">9736607</ArticleId></ArticleIdList></Reference><Reference><Citation>Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, and Herms J (2006). Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci 26, 7212&#x2013;7221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673945</ArticleId><ArticleId IdType="pubmed">16822978</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokic I, Cowling BS, and Laporte J (2014). Amphiphysin 2 (BIN1) in physiology and diseases. J. Mol. Med. (Berl.) 92, 453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">24590001</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzoli SO, and Betz WJ (2005). Synaptic vesicle pools. Nat. Rev. Neurosci 6, 57&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">15611727</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueden CT, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, and Eliceiri KW (2017). ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics 18, 529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5708080</ArticleId><ArticleId IdType="pubmed">29187165</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto H, Ariyoshi T, Kimpara N, Sugao K, Taiko I, Takikawa K, Asanuma D, Namiki S, and Hirose K (2018). Synaptic weight set by Munc13&#x2013;1 supramolecular assemblies. Nat. Neurosci 21, 41&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">29230050</ArticleId></ArticleIdList></Reference><Reference><Citation>Schikorski T, and Stevens CF (1997). Quantitative ultrastructural analysis of hippocampal excitatory synapses. J. Neurosci 17, 5858&#x2013;5867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573206</ArticleId><ArticleId IdType="pubmed">9221783</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneggenburger R, Meyer AC, and Neher E (1999). Released fraction and total size of a pool of immediately available transmitter quanta at a calyx synapse. Neuron 23, 399&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">10399944</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;rmann B, Bermingham DP, Kopeikina KJ, Myczek K, Yoon S, Horan KE, Kelly CJ, Martin-de-Saavedra MD, Forrest MP, Fawcett-Patel JM, et al. (2019). A novel role for the late-onset Alzheimer&#x2019;s disease (LOAD)-associated protein Bin1 in regulating postsynaptic trafficking and glutamatergic signaling. Mol. Psychiatry 9 10.1038/s41380-019-0407-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0407-3</ArticleId><ArticleId IdType="pmc">PMC6785379</ArticleId><ArticleId IdType="pubmed">30967682</ArticleId></ArticleIdList></Reference><Reference><Citation>Singec I, Knoth R, Ditter M, Hagemeyer CE, Rosenbrock H, Frotscher M, and Volk B (2002). Synaptic vesicle protein synaptoporin is differently expressed by subpopulations of mouse hippocampal neurons. J. Comp. Neurol 452, 139&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">12271488</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;dhof TC, and Rizo J (1996). Synaptotagmins: C2-domain proteins that regulate membrane traffic. Neuron 17, 379&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">8816702</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor MJ, Perrais D, and Merrifield CJ (2011). A high precision survey of the molecular dynamics of mammalian clathrin-mediated endocytosis. PLoS Biol. 9, e1000604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3062526</ArticleId><ArticleId IdType="pubmed">21445324</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Kitt CA, Roskams AJ, Slunt HH, Masliah E, von Koch C, Ginsberg SD, Reed RR, Price DL, and Sisodia SS (1995). Distribution of an APP homolog, APLP2, in the mouse olfactory system: a potential role for APLP2 in axogenesis. Journal of Neuroscience 15, 6314&#x2013;6326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577992</ArticleId><ArticleId IdType="pubmed">7472397</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Regard JB, Bouton CML, Harris CL, Price DL, Borchelt DR, and Sisodia SS (1998). Stable association of presenilin derivatives and absence of presenilin interactions with APP. Neurobiology of Disease 4, 438&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9666482</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas KJ, Makani S, Davis T, Westphal CH, Castillo PE, and Chandra SS (2014). Synucleins regulate the kinetics of synaptic vesicle endocytosis. J. Neurosci 34, 9364&#x2013;9376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087213</ArticleId><ArticleId IdType="pubmed">25009269</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Mamer LE, Raychaudhuri S, Luvsanjav D, Eisen J, Trimbuch T, Sohl-Kielczynski B, Fenske P, Milosevic I, Rosenmund C, and Jorgensen EM (2018). Synaptojanin and Endophilin Mediate Neck Formation during Ultrafast Endocytosis. Neuron 98, 1184&#x2013;1197.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086574</ArticleId><ArticleId IdType="pubmed">29953872</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner C, Pauli M, Doose S, Weishaupt A, Haselmann H, Gr&#xfc;newald B, Sauer M, Heckmann M, Toyka KV, Asan E, et al. (2016). Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition. Brain 139, 365&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">26582558</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigge P, Vallis Y, and McMahon HT (1997). Inhibition of receptor-mediated endocytosis by the amphiphysin SH3 domain. Curr. Biol 7, 554&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">9259551</ArticleId></ArticleIdList></Reference><Reference><Citation>Winters BD, Saksida LM, and Bussey TJ (2008). Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci. Biobehav. Rev 32, 1055&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">18499253</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Nowack A, Kensel-Hammes P, Gardner RG, and Bajjalieh SM (2010). Cotrafficking of SV2 and synaptotagmin at the synapse. J. Neurosci 30, 5569&#x2013;5578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866018</ArticleId><ArticleId IdType="pubmed">20410110</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue SH, Li P, Guo JD, and Zhou SG (2004). Using Greedy algorithm: DBSCAN revisited II. J. Zhejiang Univ. Sci 5, 1405&#x2013;1412.</Citation><ArticleIdList><ArticleId IdType="pubmed">15495334</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wu B, Beglopoulos V, Wines-Samuelson M, Zhang D, Dragatsis I, S&#xfc;dhof TC, and Shen J (2009). Presenilins are essential for regulating neurotransmitter release. Nature 460, 632&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744588</ArticleId><ArticleId IdType="pubmed">19641596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Yu JT, Li J, Wang C, Tan L, Liu B, and Jiang T (2015). Bridging Integrator 1 (BIN1) Genotype Effects on Working Memory, Hippocampal Volume, and Functional Connectivity in Young Healthy Individuals. Neuropsychopharmacology 40, 1794&#x2013;1803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4915264</ArticleId><ArticleId IdType="pubmed">25630570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Romero MI, Ghosh P, Ye Z, Charnay P, Rushing EJ, Marth JD, and Parada LF (2001). Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 15, 859&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC312666</ArticleId><ArticleId IdType="pubmed">11297510</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucker RS, and Regehr WG (2002). Short-term synaptic plasticity. Annu. Rev. Physiol 64, 355&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11826273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32161412</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease.</ArticleTitle><Pagination><StartPage>398</StartPage><EndPage>407</EndPage><MedlinePgn>398-407</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-020-0781-z</ELocationID><Abstract><AbstractText>Development of tau-based therapies for Alzheimer's disease requires an understanding of the timing of disease-related changes in tau. We quantified the phosphorylation state at multiple sites of the tau protein in cerebrospinal fluid markers across four decades of disease progression in dominantly inherited Alzheimer's disease. We identified a pattern of tau staging where site-specific phosphorylation changes occur at different periods of disease progression and follow distinct trajectories over time. These tau phosphorylation state changes are uniquely associated with structural, metabolic, neurodegenerative and clinical markers of disease, and some (p-tau217 and p-tau181) begin with the initial increases in aggregate amyloid-&#x3b2; as early as two decades before the development of aggregated tau pathology. Others (p-tau205 and t-tau) increase with atrophy and hypometabolism closer to symptom onset. These findings provide insights into the pathways linking tau, amyloid-&#x3b2; and neurodegeneration, and may facilitate clinical trials of tau-based treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barth&#xe9;lemy</LastName><ForeName>Nicolas R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph-Mathurin</LastName><ForeName>Nelly</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-2109-2955</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><Identifier Source="ORCID">0000-0002-8114-0552</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-0576-2472</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-6854-5547</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allegri</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Patricio Chrem</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI) Instituto de Investigaciones Neurol&#xf3;gicas Ra&#xfa;l Correa, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Sarah B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8828-8085</Identifier><AffiliationInfo><Affiliation>Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Osaka City University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimada</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Osaka City University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoji</LastName><ForeName>Mikio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hirosaki University, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Kazushi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Tokyo University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noble</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Columbia University, College of Physicians and Surgeons, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7792-1698</Identifier><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Butler Hospital, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0003-2967-9662</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Edith Cowan University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Antoinette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9045-1072</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabelle</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Prot&#xe9;omique Clinique and CRB, INSERM-UM, CHU Montpellier, Montpellier, France, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Prot&#xe9;omique Clinique and CRB, INSERM-UM, CHU Montpellier, Montpellier, France, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA. batemanr@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6764-3866</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA. ericmcdade@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS095773</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)</Agency><Country>International</Country></Grant><Grant><GrantID>K23 AG046363</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1AG032438</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)</Agency><Country>International</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Agency>RCUK | Medical Research Council (MRC)</Agency><Country>International</Country></Grant><Grant><GrantID>MR/009076/1</GrantID><Agency>RCUK | Medical Research Council (MRC)</Agency><Country>International</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)</Agency><Country>International</Country></Grant><Grant><GrantID>R01 AG052550</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095773</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040582" MajorTopicYN="N">Inheritance Patterns</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. R.J.B. has equity ownership interest in C2N Diagnostics and receives royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. R.J.B. receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with R.J.B., E.M. and N.R.B. as co-inventors, has submitted the US nonprovisional patent application &#x2018;Cerebrospinal fluid (CSF) tau rate of phosphorylation measurement to define stages of Alzheimer&#x2019;s disease and monitor brain kinases/phosphatases activity&#x2019;. R.J.B. has received honoraria from Janssen and Pfizer as a speaker, and from Merck and Pfizer as an advisory board member. E.M. has received royalty payments for an educational program supported by Eli Lilly and as a member of a scientific advisory board for Eli Lilly.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Allegri</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randy</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bechara</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berman</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodge</LastName><ForeName>Courtney</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandon</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>William Bill</ForeName><Initials>WB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buck</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chea</LastName><ForeName>Sochenda</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chrem Mendez</LastName><ForeName>Patricio</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cinco</LastName><ForeName>Jake</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clifford</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donahue</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Douglas</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edigo</LastName><ForeName>Noelia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erekin-Taner</LastName><ForeName>Nilufer</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flynn</LastName><ForeName>Gigi</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujii</LastName><ForeName>Hisako</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gant</LastName><ForeName>Cortaiga</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardener</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gray</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groves</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoechst-Swisher</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hornbeck</LastName><ForeName>Russ</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiBari</LastName><ForeName>Siri Houeland</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Snezana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerome</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasuga</LastName><ForeName>Kensaku</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawarabayashi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klunk</LastName><ForeName>William Bill</ForeName><Initials>WB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuder-Buletta</LastName><ForeName>Elke</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Jae-Hong</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Neal Scott</ForeName><Initials>NS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maue-Dreyfus</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mori</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagamatsu</LastName><ForeName>Akem</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neimeyer</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noble</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renton</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roh</LastName><ForeName>Jee Hoon</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimada</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sigurdson</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sohrabi</LastName><ForeName>Hamid</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sparks</LastName><ForeName>Paige</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Kazushi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taddei</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiong</ForeName><Initials>X</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32161412</ArticleId><ArticleId IdType="mid">NIHMS1584278</ArticleId><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0781-z</ArticleId><ArticleId IdType="pii">10.1038/s41591-020-0781-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D &amp; Crowther RA Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron 3, 519&#x2013;526 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I et al. Abnormal phosphorylation of the microtubule-associated protein &#x3c4; (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913&#x2013;4917 (1986).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Sharma G, Ishiguro K &amp;Hisanaga S Phospho-tau bar code: analysis of phosphoisotypes of tau and its application to tauopathy. Front. Neurosci 12, 44 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5808175</ArticleId><ArticleId IdType="pubmed">29467609</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc. Natl Acad. Sci. USA 88, 2288&#x2013;2292 (1991).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51216</ArticleId><ArticleId IdType="pubmed">1706519</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Davis PB, Morris JC &amp; White DL The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer&#x2019;s disease. Neurobiol. Aging 12, 295&#x2013;312 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J, Hyman BT &amp;Betensky RA Neurofibrillary tangle stage and the rate of progression of Alzheimer symptoms: modeling using an autopsy cohort and application to clinical trial design. JAMA Neurol. 74, 540&#x2013;548 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5547572</ArticleId><ArticleId IdType="pubmed">28288263</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91, e1295&#x2013;e1306 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="pubmed">30217935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med 367, 795&#x2013;804 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM et al. Cerebrospinal fluid tau/&#x3b2;-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol 64, 343&#x2013;349 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandermeeren M et al. Detection of tau proteins in normal and Alzheimer&#x2019;s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem 61, 1828&#x2013;1834 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8228996</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori H et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci. Lett 186, 181&#x2013;183 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7777192</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE et al. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Alzheimers Dement. 15, 655&#x2013;665 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511459</ArticleId><ArticleId IdType="pubmed">30846386</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ &amp; Shaw LM Longitudinal change in CSF Tau and A&#x3b2; biomarkers for up to 48 months in ADNI. Acta Neuropathol.126, 659&#x2013;670 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr. et al. NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr. et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539&#x2013;547 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology 81, 1945&#x2013;1952 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843382</ArticleId><ArticleId IdType="pubmed">24174584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 61, 95&#x2013;102 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14706948</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R et al. Associations between AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90, e282&#x2013;e290 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5798657</ArticleId><ArticleId IdType="pubmed">29282337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N et al. 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer&#x2019;s disease. EMBO Mol. Med 9, 1212&#x2013;1223 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5582410</ArticleId><ArticleId IdType="pubmed">28743782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA et al. Tau PET in autosomal dominant Alzheimer&#x2019;s disease: relationship with cognition, dementia and other biomarkers. Brain 142, 1063&#x2013;1076 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439328</ArticleId><ArticleId IdType="pubmed">30753379</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr. et al. The bivariate distribution of amyloid-&#x3b2; and tau: relationship with established neurocognitive clinical syndromes. Brain 142, 3230&#x2013;3242 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763736</ArticleId><ArticleId IdType="pubmed">31501889</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol 79, 110&#x2013;119 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N et al. Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer&#x2019;s disease. Alzheimers Dement. 15, 570&#x2013;580 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30639421</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT et al. Association between amyloid and Tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol. 75, 548&#x2013;556 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885174</ArticleId><ArticleId IdType="pubmed">29435558</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 72, 316&#x2013;324 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="pubmed">25580592</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ &amp; Shaw LM Longitudinal change in CSF Tau and A&#x3b2; biomarkers for up to 48 months in ADNI. Acta Neuropathol.126, 659&#x2013;670 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci. Transl. Med 6, 226ra230 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL &amp; Morris JC Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann. Neurol 45, 358&#x2013;368 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM et al. Dendritic function of Tau mediates amyloid-&#x3b2; toxicity in Alzheimer&#x2019;s disease mouse models. Cell 142, 387&#x2013;397 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD et al. Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer&#x2019;s disease from late-onset amyloid deposition. Alzheimers Dement. 14, 743&#x2013;750 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5994364</ArticleId><ArticleId IdType="pubmed">29477284</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF et al. Changes in amyloid-&#x3b2; and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med 5, 194re192 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C et al. Tau kinetics in neurons and the human central nervous system. Neuron 98, 861&#x2013;864 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192252</ArticleId><ArticleId IdType="pubmed">29772204</ArticleId></ArticleIdList></Reference><Reference><Citation>Schelle J et al. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Alzheimers Dement.13, 701&#x2013;709 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27750032</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Thies E, Mandelkow E &amp;Mandelkow EM A&#x3b2; oligomers cause localized Ca2+elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci 30, 11938&#x2013;11950 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman S et al. Exosome-associated Tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem 287, 3842&#x2013;3849 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281682</ArticleId><ArticleId IdType="pubmed">22057275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M et al. Soluble amyloid &#x3b2;-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl Acad. Sci. USA 108, 5819&#x2013;5824 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer&#x2019;s disease: a longitudinal study. Lancet Neurol. 17, 241&#x2013;250 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816717</ArticleId><ArticleId IdType="pubmed">29397305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83, 253&#x2013;260 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412&#x2013;2414 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina M &amp; Avila J Further understanding of tau phosphorylation: implications for therapy. Expert Rev. Neurother 15, 115&#x2013;122 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25555397</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TL et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA 110, E4502&#x2013;E4509 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT et al. Cortical atrophy in presymptomatic Alzheimer&#x2019;s disease presenilin 1 mutation carriers. J. Neurol. Neurosurg. Psychiatry 84, 556&#x2013;561 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632663</ArticleId><ArticleId IdType="pubmed">23134660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha BH et al. Tracking atrophy progression in familial Alzheimer&#x2019;s disease: a serial MRI study. Lancet Neurol. 5, 828&#x2013;834 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16987729</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET &amp; Hyman BT Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology 42, 631&#x2013;639 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonkwo OC et al. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Arch. Neurol 68, 113&#x2013;119 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058271</ArticleId><ArticleId IdType="pubmed">21220682</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ et al. The DIAN-TU Next Generation Alzheimer&#x2019;s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 13, 8&#x2013;19 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci. Transl. Med 9, eaal2029 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5727571</ArticleId><ArticleId IdType="pubmed">28424326</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z et al. Amyloid-&#x3b2; plaques enhance Alzheimer&#x2019;s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med 24, 29&#x2013;38 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="pubmed">29200205</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain 129, 3035&#x2013;3041 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A et al. Site-specific phosphorylation of tau inhibits amyloid-&#x3b2; toxicity in Alzheimer&#x2019;s mice. Science 354, 904&#x2013;908 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27856911</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R et al. Increased in vivo amyloid-&#x3b2;42 production, exchange, and loss in presenilin mutation carriers. Sci. Transl. Med 5, 189ra177 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci 31, 13110&#x2013;13117 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Kant R et al. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-&#x3b2; in iPSC-derived Alzheimer&#x2019;s disease neurons. Cell Stem Cell 24, 363&#x2013;375.e9 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6414424</ArticleId><ArticleId IdType="pubmed">30686764</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. Clin. Investig. (Lond.) 2, 975&#x2013;984 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489185</ArticleId><ArticleId IdType="pubmed">23139856</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Balota DA, Aschenbrenner AJ &amp; Morris JC Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychology 28, 19&#x2013;29 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877741</ArticleId><ArticleId IdType="pubmed">24219606</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY et al. BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer&#x2019;s disease. Brain 139, 2766&#x2013;2777 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5815565</ArticleId><ArticleId IdType="pubmed">27521573</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 34, 939&#x2013;944 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BW et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann. Neurol 78, 439&#x2013;453 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Campo M et al. Recommendations to standardize preanalytical confounding factors in Alzheimer&#x2019;s and Parkinson&#x2019;s disease cerebrospinal fluid biomarkers: an update. Biomark. Med 6, 419&#x2013;430 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22917144</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR et al. Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J. Proteome Res 15, 667&#x2013;676 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26742856</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y et al. Partial volume correction in quantitative amyloid imaging. Neuroimage 107, 55&#x2013;64 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, D&#x2019;Angelo G, Gao F, Ding J &amp;Xiong C Bivariate correlation coefficients in family-type clustered studies. Biom. J 57, 1084&#x2013;1109 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4741284</ArticleId><ArticleId IdType="pubmed">26360805</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C et al. Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology 86, 1499&#x2013;1506 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836885</ArticleId><ArticleId IdType="pubmed">27009258</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y &amp; Hochberg Y Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289&#x2013;300 (1995).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32161102</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>534</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Neurophysiological signatures in Alzheimer's disease are distinctly associated with TAU, amyloid-&#x3b2; accumulation, and cognitive decline.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaaz4069</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaz4069</ELocationID><Abstract><AbstractText>Neural synchrony is intricately balanced in the normal resting brain but becomes altered in Alzheimer's disease (AD). To determine the neurophysiological manifestations associated with molecular biomarkers of AD neuropathology, in patients with AD, we used magnetoencephalographic imaging (MEGI) and positron emission tomography with amyloid-beta (A&#x3b2;) and TAU tracers. We found that alpha oscillations (8 to 12 Hz) were hyposynchronous in occipital and posterior temporoparietal cortices, whereas delta-theta oscillations (2 to 8 Hz) were hypersynchronous in frontal and anterior temporoparietal cortices, in patients with AD compared to age-matched controls. Regional patterns of alpha hyposynchrony were unique in each neurobehavioral phenotype of AD, whereas the regional patterns of delta-theta hypersynchrony were similar across the phenotypes. Alpha hyposynchrony strongly colocalized with TAU deposition and was modulated by the degree of TAU tracer uptake. In contrast, delta-theta hypersynchrony colocalized with both TAU and A&#x3b2; depositions and was modulated by both TAU and A&#x3b2; tracer uptake. Furthermore, alpha hyposynchrony but not delta-theta hypersynchrony was correlated with the degree of global cognitive dysfunction in patients with AD. The current study demonstrates frequency-specific neurophysiological signatures of AD pathophysiology and suggests that neurophysiological measures from MEGI are sensitive indices of network disruptions mediated by TAU and A&#x3b2; and associated cognitive decline. These findings facilitate the pursuit of novel therapeutic approaches toward normalizing network synchrony in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ranasinghe</LastName><ForeName>Kamalini G</ForeName><Initials>KG</Initials><Identifier Source="ORCID">0000-0002-4217-8785</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA. kamalini.ranasinghe@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Jungho</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1189-2051</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iaccarino</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0053-9519</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinkley</LastName><ForeName>Leighton B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beagle</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0002-4458-113X</Identifier><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, UC Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0002-2152-4220</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rankin</LastName><ForeName>Katherine P</ForeName><Initials>KP</Initials><Identifier Source="ORCID">0000-0002-3611-0848</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vossel</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-6351-6720</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, Institute for Translational Neuroscience, and Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagarajan</LastName><ForeName>Srikantan S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AG058749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052943</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062196</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS100440</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC013979</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG038357</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB022717</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS076171</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS050915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 DC015544</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG050434</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS066654</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> K.G.R., J.C., L.I., L.B.H., A.J.B., J.P., K.P.R., K.A.V., and S.S.N. declare that they have no competing interests relevant to this work. B.L.M. serves as medical director for the John Douglas French Foundation, scientific director for the Tau Consortium, director/medical advisory board of the Larry L. Hillblom Foundation, and scientific advisory board member for the National Institute for Health Research Cambridge Biomedical Research Centre. G.D.R. receives research support from Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare, and Life Molecular Imaging; has served on scientific advisory boards for Axon Neurosciences, Eisai, Genentech, and Merck; and has received honoraria for speaking engagements from GE Healthcare. W.J.J. serves as a consultant to Genentech and Novartis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32161102</ArticleId><ArticleId IdType="mid">NIHMS1577144</ArticleId><ArticleId IdType="pmc">PMC7138514</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaz4069</ArticleId><ArticleId IdType="pii">12/534/eaaz4069</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ, Alzheimer&#x2019;s disease is a synaptic failure. Science 298, 789&#x2013;791 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R, Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol 30, 572&#x2013;580 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association, 2018 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 14, 367&#x2013;425 (2018).</Citation></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold K-H, Haass C, Staufenbiel M, Konnerth A, Garaschuk O, Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer&#x2019;s disease. Science 321, 1686&#x2013;1689 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahnaou A, Moechars D, Raeymaekers L, Biermans R, Manyakov NV, Bottelbergs A, Wintmolders C, Van Kolen K, Van De Casteele T, Kemp JA, Drinkenburg WH, Emergence of early alterations in network oscillations and functional connectivity in a tau seeding mouse model of Alzheimer&#x2019;s disease pathology. Sci. Rep 7, 14189 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5660172</ArticleId><ArticleId IdType="pubmed">29079799</ArticleId></ArticleIdList></Reference><Reference><Citation>Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen D, Stern EA, Pathological tau disrupts ongoing network activity. Neuron 85, 959&#x2013;966 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25704951</ArticleId></ArticleIdList></Reference><Reference><Citation>Angulo SL, Orman R, Neymotin SA, Liu L, Buitrago L, Cepeda-Prado E, Stefanov D, Lytton WW, Stewart M, Small SA, Duff KE, Moreno H, Tau and amyloid-related pathologies in the entorhinal cortex have divergent effects in the hippocampal circuit. Neurobiol. Dis 108, 261&#x2013;276 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28860088</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Wegmann S, Dujardin S, Commins C, Schiantarelli J, Klickstein N, Kamath TV, Carlson GA, Nelken I, Hyman BT, Tau impairs neural circuits, dominating amyloid-&#x3b2; effects, in Alzheimer models in vivo. Nat. Neurosci 22, 57&#x2013;64 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6560629</ArticleId><ArticleId IdType="pubmed">30559471</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L, Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat. Rev. Neurosci 17, 777&#x2013;792 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8162106</ArticleId><ArticleId IdType="pubmed">27829687</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, O&#x2019;Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD, Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain 139, 1551&#x2013;1567 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, O&#x2019;Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ, PET imaging of tau deposition in the aging human brain. Neuron 89, 971&#x2013;982 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W, Imaging the evolution and pathophysiology of Alzheimer disease. Nat. Rev. Neurosci 19, 687&#x2013;700 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7032048</ArticleId><ArticleId IdType="pubmed">30266970</ArticleId></ArticleIdList></Reference><Reference><Citation>Osipova D, Ahveninen J, Jensen O, Ylikoski A, Pekkonen E, Altered generation of spontaneous oscillations in Alzheimer&#x2019;s disease. Neuroimage 27, 835&#x2013;841 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15961323</ArticleId></ArticleIdList></Reference><Reference><Citation>de Haan W, Stam CJ, Jones BF, Zuiderwijk IM, van Dijk BW, Scheltens P, Resting-state oscillatory brain dynamics in Alzheimer disease. J. Clin. Neurophysiol 25, 187&#x2013;193 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18677182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lizio R, Vecchio F, Frisoni GB, Ferri R, Rodriguez G, Babiloni C, Electroencephalographic rhythms in Alzheimer&#x2019;s disease. Int. J. Alzheimers Dis 2011, 927573 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100729</ArticleId><ArticleId IdType="pubmed">21629714</ArticleId></ArticleIdList></Reference><Reference><Citation>Cu&#xe9;sta P, Garces P, Castellanos NP, Lopez ME, Aurtenetxe S, Bajo R, Pineda-Pardo JA, Bru&#xf1;a R, Marin AG, Delgado M, Barabash A, Anc&#xed;n I, Cabranes JA, Fernandez A, Del Pozo F, Sancho M, Marcos A, Nakamura A, Maest&#xfa; F, Influence of the APOE &#x3b5;4 allele and mild cognitive impairment diagnosis in the disruption of the MEG resting state functional connectivity in sources space. J. Alzheimers Dis 44, 493&#x2013;505 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25281603</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Cuesta P, Fernandez A, Arahata Y, Iwata K, Kuratsubo I, Bundo M, Hattori H, Sakurai T, Fukuda K, Washimi Y, Endo H, Takeda A, Diers K, Bajo R, Maestu F, Ito K, Kato T, Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer&#x2019;s disease. Brain 141, 1470&#x2013;1485 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5920328</ArticleId><ArticleId IdType="pubmed">29522156</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Cuesta P, Kato T, Arahata Y, Iwata K, Yamagishi M, Kuratsubo I, Kato K, Bundo M, Diers K, Fernandez A, Maestu F, Ito K, Early functional network alterations in asymptomatic elders at risk for Alzheimer&#x2019;s disease. Sci. Rep 7, 6517 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5529571</ArticleId><ArticleId IdType="pubmed">28747760</ArticleId></ArticleIdList></Reference><Reference><Citation>Sami S, Williams N, Hughes LE, Cope TE, Rittman T, Coyle-Gilchrist ITS, Henson RN, Rowe JB, Neurophysiological signatures of Alzheimer&#x2019;s disease and frontotemporal lobar degeneration: Pathology versus phenotype. Brain 141, 2500&#x2013;2510 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6061803</ArticleId><ArticleId IdType="pubmed">30060017</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, Jones BF, Manshanden I, van Cappellen van Walsum AM, Montez T, Verbunt JP, de Munck JC, van Dijk BW, Berendse HW, Scheltens P, Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer&#x2019;s disease. Neuroimage 32, 1335&#x2013;1344 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16815039</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookes MJ, Woolrich M, Luckhoo H, Price D, Hale JR, Stephenson MC, Barnes GR, Smith SM, Morris PG, Investigating the electrophysiological basis of resting state networks using magnetoencephalography. Proc. Natl. Acad. Sci. U.S.A 108, 16783&#x2013;16788 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3189080</ArticleId><ArticleId IdType="pubmed">21930901</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V, Default-mode network activity distinguishes Alzheimer&#x2019;s disease from healthy aging: Evidence from functional MRI. Proc. Natl. Acad. Sci. U.S.A 101, 4637&#x2013;4642 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DT, Machulda MM, Vemuri P, McDade EM, Zeng G, Senjem ML, Gunter JL, Przybelski SA, Avula RT, Knopman DS, Boeve BF, Petersen RC, Jack CR Jr., Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology 77, 1524&#x2013;1531 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198977</ArticleId><ArticleId IdType="pubmed">21975202</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Damoiseaux JS, Goekoop R, Barkhof F, Scheltens P, Smith SM, Beckmann CF, Model-free group analysis shows altered BOLD FMRI networks in dementia. Hum. Brain Mapp 30, 256&#x2013;266 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870626</ArticleId><ArticleId IdType="pubmed">18041738</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, Sabuncu MR, Li Q, El Fakhri G, Sperling R, Johnson KA, Tau and amyloid &#x3b2; proteins distinctively associate to functional network changes in the aging brain. Alzheimers Dement. 13, 1261&#x2013;1269 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623176</ArticleId><ArticleId IdType="pubmed">28366797</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz AP, Chhatwal JP, Hedden T, Mormino EC, Hanseeuw BJ, Sepulcre J, Huijbers W, LaPoint M, Buckley RF, Johnson KA, Sperling RA, Phases of hyperconnectivity and hypoconnectivity in the default mode and salience networks track with amyloid and Tau in clinically normal individuals. J. Neurosci 37, 4323&#x2013;4331 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5413178</ArticleId><ArticleId IdType="pubmed">28314821</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Brambati SM, Ginex V, Ogar J, Dronkers NF, Marcone A, Perani D, Garibotto V, Cappa SF, Miller BL, The logopenic/phonological variant of primary progressive aphasia. Neurology 71, 1227&#x2013;1234 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676989</ArticleId><ArticleId IdType="pubmed">18633132</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Ghajarania M, Perryman KM, Posterior cortical atrophy: Clinical characteristics and differences compared to Alzheimer&#x2019;s disease. Dement. Geriatr. Cogn. Disord 14, 33&#x2013;40 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12053130</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalal SS, Zumer JM, Guggisberg AG, Trumpis M, Wong DD, Sekihara K, Nagarajan SS, MEG/EEG source reconstruction, statistical evaluation, and visualization with NUTMEG. Comput. Intell. Neurosci 2011, 758973 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061455</ArticleId><ArticleId IdType="pubmed">21437174</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH, The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 7, 263&#x2013;269 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH, The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 7, 270&#x2013;279 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolte G, Bai O, Wheaton L, Mari Z, Vorbach S, Hallett M, Identifying true brain interaction from EEG data using the imaginary part of coherency. Clin. Neurophysiol 115, 2292&#x2013;2307 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15351371</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann M, Ghosh PM, Madison C, Laforce R Jr., Corbetta-Rastelli C, Weiner MW, Greicius MD, Seeley WW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD, Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer&#x2019;s disease. Brain 136, 844&#x2013;858 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580269</ArticleId><ArticleId IdType="pubmed">23358601</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwet KL, Computing inter-rater reliability and its variance in the presence of high agreement. Br. J. Math. Stat. Psychol 61, 29&#x2013;48 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18482474</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors, NIA-AA research framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X-J, Neurophysiological and computational principles of cortical rhythms in cognition. Physiol. Rev 90, 1195&#x2013;1268 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923921</ArticleId><ArticleId IdType="pubmed">20664082</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyafil A, Giraud AL, Fontolan L, Gutkin B, Neural cross-frequency coupling: Connecting architectures, mechanisms, and functions. Trends Neurosci. 38, 725&#x2013;740 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26549886</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobier M, Palva JM, Palva S, High-alpha band synchronization across frontal, parietal and visual cortex mediates behavioral and neuronal effects of visuospatial attention. Neuroimage 165, 222&#x2013;237 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29074278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadaghiani S, Kleinschmidt A, Brain networks and &#x3b1;-oscillations: Structural and functional foundations of cognitive control. Trends Cogn. Sci 20, 805&#x2013;817 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27707588</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L, Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron 55, 697&#x2013;711 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Ranasinghe KG, Beagle AJ, Mizuiri D, Honma SM, Dowling AF, Darwish SM, Van Berlo V, Barnes DE, Mantle M, Karydas AM, Coppola G, Roberson ED, Miller BL, Garcia PA, Kirsch HE, Mucke L, Nagarajan SS, Incidence and impact of subclinical epileptiform activity in Alzheimer&#x2019;s disease. Ann. Neurol 80, 858&#x2013;870 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5177487</ArticleId><ArticleId IdType="pubmed">27696483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondadori CR, Buchmann A, Mustovic H, Schmidt CF, Boesiger P, Nitsch RM, Hock C, Streffer J, Henke K, Enhanced brain activity may precede the diagnosis of Alzheimer&#x2019;s disease by 30 years. Brain 129, 2908&#x2013;2922 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17012294</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O&#x2019;Neil JP, Gorno-Tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD, Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x2019;s disease. Brain 140, 3286&#x2013;3300 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT, Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology 42, 631&#x2013;639 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Plewnia C, Rilk AJ, Soekadar SR, Arfeller C, Huber HS, Sauseng P, Hummel F, Gerloff C, Enhancement of long-range EEG coherence by synchronous bifocal transcranial magnetic stimulation. Eur. J. Neurosci 27, 1577&#x2013;1583 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18336566</ArticleId></ArticleIdList></Reference><Reference><Citation>Thut G, Miniussi C, New insights into rhythmic brain activity from TMS-EEG studies. Trends Cogn. Sci 13, 182&#x2013;189 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19286414</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DT, Knopman DS, Gunter JL, Graff-Radford J, Vemuri P, Boeve BF, Petersen RC, Weiner MW, Jack CR Jr.; Alzheimer&#x2019;s Disease Neuroimaging Initiative, Cascading network failure across the Alzheimer&#x2019;s disease spectrum. Brain 139, 547&#x2013;562 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4805086</ArticleId><ArticleId IdType="pubmed">26586695</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ, The amyloid hypothesis of Alzheimer&#x2019;s disease: Progress and problems on the road to therapeutics. Science 297, 353&#x2013;356 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA, Alzheimer&#x2019;s disease: The amyloid cascade hypothesis. Science 256, 184&#x2013;185 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Musaeus CS, Shafi MM, Santarnecchi E, Herman ST, Press DZ, Levetiracetam alters oscillatory connectivity in Alzheimer&#x2019;s Disease. J. Alzheimers Dis 58, 1065&#x2013;1076 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28527204</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, Kim D, Hamto P, Lo I, Yu G-Q, Palop JJ, Masliah E, Mucke L, Transsynaptic progression of amyloid-&#x3b2;-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 68, 428&#x2013;441 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller EC, Teravskis PJ, Dummer BW, Zhao X, Huganir RL, Liao D, Tau phosphorylation and tau mislocalization mediate soluble A&#x3b2; oligomer-induced AMPA glutamate receptor signaling deficits. Eur. J. Neurosci 39, 1214&#x2013;1224 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123852</ArticleId><ArticleId IdType="pubmed">24713000</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzs&#xe1;ki G, Watson BO, Brain rhythms and neural syntax: Implications for efficient coding of cognitive content and neuropsychiatric disease. Dialogues Clin. Neurosci 14, 345&#x2013;367 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553572</ArticleId><ArticleId IdType="pubmed">23393413</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzsaki G, Rhythms of the Brain (Oxford Univ. Press, 2011).</Citation></Reference><Reference><Citation>Jing W, Wang Y, Fang G, Chen M, Xue M, Guo D, Yao D, Xia Y, EEG bands of wakeful rest, slow-wave and rapid-eye-movement sleep at different brain areas in rats. Front. Comput. Neurosci 10, 79 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4971061</ArticleId><ArticleId IdType="pubmed">27536231</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirota A, Csicsvari J, Buhl D, Buzs&#xe1;ki G, Communication between neocortex and hippocampus during sleep in rodents. Proc. Natl. Acad. Sci. U.S.A 100, 2065&#x2013;2069 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149959</ArticleId><ArticleId IdType="pubmed">12576550</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondrag&#xf3;n-Rodriguez S, Gu N, Manseau F, Williams S, Alzheimer&#x2019;s transgenic model is characterized by very early brain network alterations and &#x3b2;-CTF fragment accumulation: Reversal by &#x3b2;-secretase inhibition. Front. Cell. Neurosci 12, 121 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5952042</ArticleId><ArticleId IdType="pubmed">29867356</ArticleId></ArticleIdList></Reference><Reference><Citation>Das M, Maeda S, Hu B, Yu G-Q, Guo W, Lopez I, Yu X, Tai C, Wang X, Mucke L, Neuronal levels and sequence of tau modulate the power of brain rhythms. Neurobiol. Dis 117, 181&#x2013;188 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29859869</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranasinghe KG, Hinkley LB, Beagle AJ, Mizuiri D, Honma SM, Welch AE, Hubbard I, Mandelli ML, Miller ZA, Garrett C, La A, Boxer AL, Houde JF, Miller BL, Vossel KA, Gorno-Tempini ML, Nagarajan SS, Distinct spatiotemporal patterns of neuronal functional connectivity in primary progressive aphasia variants. Brain 140, 2737&#x2013;2751 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841154</ArticleId><ArticleId IdType="pubmed">28969381</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries P, A mechanism for cognitive dynamics: Neuronal communication through neuronal coherence. Trends Cogn. Sci 9, 474&#x2013;480 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16150631</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlhaas PJ, Singer W, Neural synchrony in brain disorders: Relevance for cognitive dysfunctions and pathophysiology. Neuron 52, 155&#x2013;168 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17015233</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimesch W, Sauseng P, Hanslmayr S, EEG alpha oscillations: The inhibition-timing hypothesis. Brain Res. Rev 53, 63&#x2013;88 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">16887192</ArticleId></ArticleIdList></Reference><Reference><Citation>Palva S, Palva JM, Functional roles of alpha-band phase synchronization in local and large-scale cortical networks. Front. Psychol 2, 204 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166799</ArticleId><ArticleId IdType="pubmed">21922012</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauseng P, Klimesch W, Doppelmayr M, Pecherstorfer T, Freunberger R, Hanslmayr S, EEG alpha synchronization and functional coupling during top-down processing in a working memory task. Hum. Brain Mapp 26, 148&#x2013;155 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871735</ArticleId><ArticleId IdType="pubmed">15929084</ArticleId></ArticleIdList></Reference><Reference><Citation>Freunberger R, Klimesch W, Griesmayr B, Sauseng P, Gruber W, Alpha phase coupling reflects object recognition. Neuroimage 42, 928&#x2013;935 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18595738</ArticleId></ArticleIdList></Reference><Reference><Citation>Doesburg SM, Green JJ, McDonald JJ, Ward LM, Rhythms of consciousness: Binocular rivalry reveals large-scale oscillatory network dynamics mediating visual perception. PLOS ONE 4, e6142 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702101</ArticleId><ArticleId IdType="pubmed">19582165</ArticleId></ArticleIdList></Reference><Reference><Citation>Backus AR, Schoffelen J-M, Szeb&#xe9;nyi S, Hanslmayr S, Doeller CF, Hippocampalprefrontal theta oscillations support memory integration. Curr. Biol 26, 450&#x2013;457 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26832442</ArticleId></ArticleIdList></Reference><Reference><Citation>Clouter A, Shapiro KL, Hanslmayr S, Theta phase synchronization is the glue that binds human associative memory. Curr. Biol 27, 3143&#x2013;3148.e6 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28988860</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412&#x2013;2414 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranasinghe KG, Rankin KP, Lobach IV, Kramer JH, Sturm VE, Bettcher BM, Possin K, Christine You S, Lamarre AK, Shany-Ur T, Stephens ML, Perry DC, Lee SE, Miller ZA, Gorno-Tempini ML, Rosen HJ, Boxer A, Seeley WW, Rabinovici GD, Vossel KA, Miller BL, Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology 86, 600&#x2013;610 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4762418</ArticleId><ArticleId IdType="pubmed">26802093</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalal SS, Guggisberg AG, Edwards E, Sekihara K, Findlay AM, Canolty RT, Berger MS, Knight RT, Barbaro NM, Kirsch HE, Nagarajan SS, Five-dimensional neuroimaging: Localization of the time-frequency dynamics of cortical activity. Neuroimage 40, 1686&#x2013;1700 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2426929</ArticleId><ArticleId IdType="pubmed">18356081</ArticleId></ArticleIdList></Reference><Reference><Citation>Guggisberg AG, Honma SM, Findlay AM, Dalal SS, Kirsch HE, Berger MS, Nagarajan SS, Mapping functional connectivity in patients with brain lesions. Ann. Neurol 63, 193&#x2013;203 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3646715</ArticleId><ArticleId IdType="pubmed">17894381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinkley LBN, Vinogradov S, Guggisberg AG, Fisher M, Findlay AM, Nagarajan SS, Clinical symptoms and alpha band resting-state functional connectivity imaging in patients with schizophrenia: Implications for novel approaches to treatment. Biol. Psychiatry 70, 1134&#x2013;1142 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3327723</ArticleId><ArticleId IdType="pubmed">21861988</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes GR, Hillebrand A, Fawcett IP, Singh KD, Realistic spatial sampling for MEG beamformer images. Hum. Brain Mapp 23, 120&#x2013;127 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6872013</ArticleId><ArticleId IdType="pubmed">15340934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, Huang G-F, Debnath ML, Klunk WE, Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem 46, 2740&#x2013;2754 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL, Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab 16, 834&#x2013;840 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SL, Maass A, Jagust WJ, Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data. Data Brief 15, 648&#x2013;657 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5671473</ArticleId><ArticleId IdType="pubmed">29124088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM, Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341&#x2013;355 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedrichsen J, A spatially unbiased atlas template of the human cerebellum. Neuroimage 33, 127&#x2013;138 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16904911</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32175624</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>Cell-to-cell transmission of C9orf72 poly-(Gly-Ala) triggers key features of ALS/FTD.</ArticleTitle><Pagination><StartPage>e102811</StartPage><MedlinePgn>e102811</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e102811</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/embj.2019102811</ELocationID><Abstract><AbstractText>The C9orf72 repeat expansion causes amyotrophic lateral sclerosis and frontotemporal dementia, but the poor correlation between C9orf72-specific pathology and TDP-43 pathology linked to neurodegeneration hinders targeted therapeutic development. Here, we addressed the role of the aggregating dipeptide repeat proteins resulting from unconventional translation of the repeat in all reading frames. Poly-GA promoted cytoplasmic mislocalization and aggregation of TDP-43 non-cell-autonomously, and anti-GA antibodies ameliorated TDP-43 mislocalization in both donor and receiver cells. Cell-to-cell transmission of poly-GA inhibited proteasome function in neighboring cells. Importantly, proteasome inhibition led to the accumulation of TDP-43 ubiquitinated within the nuclear localization signal (NLS) at lysine 95. Mutagenesis of this ubiquitination site completely blocked poly-GA-dependent mislocalization of TDP-43. Boosting proteasome function with rolipram reduced both poly-GA and TDP-43 aggregation. Our data from cell lines, primary neurons, transgenic mice, and patient tissue suggest that poly-GA promotes TDP-43 aggregation by inhibiting the proteasome cell-autonomously and non-cell-autonomously, which can be prevented by inhibiting poly-GA transmission with antibodies or boosting proteasome activity with rolipram.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Published under the terms of the CC BY NC ND 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khosravi</LastName><ForeName>Bahram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Systemic Neurosciences (GSN), Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>LaClair</LastName><ForeName>Kathrine D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Riemenschneider</LastName><ForeName>Henrick</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Qihui</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-5733-9820</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frottin</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mareljic</LastName><ForeName>Nikola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czuppa</LastName><ForeName>Mareike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farny</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Hannelore</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michaelsen</LastName><ForeName>Meike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arzberger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartl</LastName><ForeName>F Ulrich</ForeName><Initials>FU</Initials><Identifier Source="ORCID">0000-0002-7941-135X</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hipp</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-0497-3016</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences of Cells and Systems, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edbauer</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7186-4653</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Systemic Neurosciences (GSN), Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>NOMIS Stiftung (NOMIS Foundation)</Agency><Country>International</Country></Grant><Grant><GrantID>617198</GrantID><Agency>EC | Seventh Framework Programme (FP7)</Agency><Country>International</Country></Grant><Grant><GrantID>EXC 2145</GrantID><Agency>Deutsche Forschungsgemeinschaft (DFG)</Agency><Country>International</Country></Grant><Grant><Agency>Hans und Ilse Breuer Foundation</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019913">Nuclear Localization Signals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>926-77-2</RegistryNumber><NameOfSubstance UI="C065992">N-glycylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019913" MajorTopicYN="N">Nuclear Localization Signals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">antibody therapy</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">nucleocytoplasmic transport</Keyword><Keyword MajorTopicYN="N">proteasome</Keyword></KeywordList><CoiStatement>D.E. holds a patent on &#x201c;Dipeptide&#x2010;repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion&#x201d; (EP2948777 and US10066007).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32175624</ArticleId><ArticleId IdType="pmc">PMC7156967</ArticleId><ArticleId IdType="doi">10.15252/embj.2019102811</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akimov V, Barrio&#x2010;Hernandez I, Hansen SVF, Hallenborg P, Pedersen AK, Bekker&#x2010;Jensen DB, Puglia M, Christensen SDK, Vanselow JT, Nielsen MM et&#xa0;al (2018) UbiSite approach for comprehensive mapping of lysine and N&#x2010;terminal ubiquitination sites. Nat Struct Mol Biol 25: 631&#x2013;640</Citation><ArticleIdList><ArticleId IdType="pubmed">29967540</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksu M, Pleiner T, Karaca S, Kappert C, Dehne HJ, Seibel K, Urlaub H, Bohnsack MT, Gorlich D (2018) Xpo7 is a broad&#x2010;spectrum exportin and a nuclear import receptor. J Cell Biol 217: 2329&#x2013;2340</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6028547</ArticleId><ArticleId IdType="pubmed">29748336</ArticleId></ArticleIdList></Reference><Reference><Citation>Archbold HC, Jackson KL, Arora A, Weskamp K, Tank EM, Li X, Miguez R, Dayton RD, Tamir S, Klein RL et&#xa0;al (2018) TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci Rep 8: 4606</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854632</ArticleId><ArticleId IdType="pubmed">29545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Bogaert E, Michiels E, Gijselinck I, Sieben A, Jovicic A, De Baets G, Scheveneels W, Steyaert J, Cuijt I et&#xa0;al (2016) Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci Rep 6: 20877</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751451</ArticleId><ArticleId IdType="pubmed">26869068</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Bogaert E, Kovacs D, Konijnenberg A, Timmerman E, Volkov A, Guharoy M, De Decker M, Jaspers T, Ryan VH et&#xa0;al (2017) Phase separation of C9orf72 dipeptide repeats perturbs stress granule dynamics. Mol Cell 65: 1044&#x2013;1055.e1045</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="pubmed">28306503</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YJ, Jeng US, Chiang YL, Hwang IS, Chen YR (2016) The glycine&#x2010;alanine dipeptide repeat from C9orf72 hexanucleotide expansions forms toxic amyloids possessing cell&#x2010;to&#x2010;cell transmission properties. J Biol Chem 291: 4903&#x2013;4911</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4777828</ArticleId><ArticleId IdType="pubmed">26769963</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen BB, Mallampalli RK (2009) Masking of a nuclear signal motif by monoubiquitination leads to mislocalization and degradation of the regulatory enzyme cytidylyltransferase. Mol Cell Biol 29: 3062&#x2013;3075</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682000</ArticleId><ArticleId IdType="pubmed">19332566</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Gendron TF, Prudencio M, Sasaguri H, Zhang YJ, Castanedes&#x2010;Casey M, Lee CW, Jansen&#x2010;West K, Kurti A, Murray ME et&#xa0;al (2015) Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP&#x2010;43 pathology, neuronal loss, and behavioral deficits. Science 348: 1151&#x2013;1154</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, Liu F, Sayegh M, Donlin&#x2010;Asp PG, Chen YH, Duong DM et&#xa0;al (2018) TDP&#x2010;43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci 21: 228&#x2013;239</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG (2000) Short&#x2010;lived green fluorescent proteins for quantifying ubiquitin/proteasome&#x2010;dependent proteolysis in living cells. Nat Biotechnol 18: 538&#x2013;543</Citation><ArticleIdList><ArticleId IdType="pubmed">10802622</ArticleId></ArticleIdList></Reference><Reference><Citation>De Smet F, Saiz Rubio M, Hompes D, Naus E, De Baets G, Langenberg T, Hipp MS, Houben B, Claes F, Charbonneau S et&#xa0;al (2017) Nuclear inclusion bodies of mutant and wild&#x2010;type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. J Pathol 242: 24&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pubmed">28035683</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus&#x2010;Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J et&#xa0;al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;linked FTD and ALS. Neuron 72: 245&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus&#x2010;Hernandez M, Finch NA, Wang X, Gendron TF, Bieniek KF, Heckman MG, Vasilevich A, Murray ME, Rousseau L, Weesner R et&#xa0;al (2017) In&#x2010;depth clinico&#x2010;pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathol 134: 255&#x2013;269</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508036</ArticleId><ArticleId IdType="pubmed">28508101</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Haass C (2016) An amyloid&#x2010;like cascade hypothesis for C9orf72 ALS/FTD. Curr Opin Neurobiol 36: 99&#x2013;106</Citation><ArticleIdList><ArticleId IdType="pubmed">26555807</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Dormann D (2017) TDP&#x2010;43 and FUS en route from the nucleus to the cytoplasm. FEBS Lett 591: 1489&#x2013;1507</Citation><ArticleIdList><ArticleId IdType="pubmed">28380257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Funk C, Abou&#x2010;Ajram C, Hutten S, Funk EBE, Kehlenbach RH, Bailer SM, Dormann D (2018) Nuclear egress of TDP&#x2010;43 and FUS occurs independently of exportin&#x2010;1/CRM1. Sci Rep 8: 7084</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935713</ArticleId><ArticleId IdType="pubmed">29728564</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eersel J, Ke YD, Gladbach A, Bi M, Gotz J, Kril JJ, Ittner LM (2011) Cytoplasmic accumulation and aggregation of TDP&#x2010;43 upon proteasome inhibition in cultured neurons. PLoS ONE 6: e22850</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146516</ArticleId><ArticleId IdType="pubmed">21829535</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores BN, Dulchavsky ME, Krans A, Sawaya MR, Paulson HL, Todd PK, Barmada SJ, Ivanova MI (2016) Distinct C9orf72&#x2010;associated dipeptide repeat structures correlate with neuronal toxicity. PLoS ONE 11: e0165084</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5077081</ArticleId><ArticleId IdType="pubmed">27776165</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez&#x2010;Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC et&#xa0;al (2015) GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525: 129&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick P, Sellier C, Mackenzie IRA, Cheng CY, Tahraoui&#x2010;Bories J, Martinat C, Pasterkamp RJ, Prudlo J, Edbauer D, Oulad&#x2010;Abdelghani M et&#xa0;al (2018) Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathol Commun 6: 72</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091050</ArticleId><ArticleId IdType="pubmed">30075745</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao FB, Almeida S, Lopez&#x2010;Gonzalez R (2017) Dysregulated molecular pathways in amyotrophic lateral sclerosis&#x2010;frontotemporal dementia spectrum disorder. EMBO J 36: 2931&#x2013;2950</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641681</ArticleId><ArticleId IdType="pubmed">28916614</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Petrucelli L (2011) Rodent models of TDP&#x2010;43 proteinopathy: investigating the mechanisms of TDP&#x2010;43&#x2010;mediated neurodegeneration. J Mol Neurosci 45: 486&#x2013;499</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207125</ArticleId><ArticleId IdType="pubmed">21811811</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Martinez&#x2010;Lage M, Robinson J, Uryu K, Neumann M, Brandmeir NJ, Xie SX, Kwong LK, Elman L, McCluskey L et&#xa0;al (2009) Clinical and pathological continuum of multisystem TDP&#x2010;43 proteinopathies. Arch Neurol 66: 180&#x2013;189</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774117</ArticleId><ArticleId IdType="pubmed">19204154</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Lang CM, Haass C, Capell A (2016) Impaired protein degradation in FTLD and related disorders. Ageing Res Rev 32: 122&#x2013;139</Citation><ArticleIdList><ArticleId IdType="pubmed">27166223</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Kim HJ, Wang H, Monaghan J, Freyermuth F, Sung JC, O'Donovan K, Fare CM, Diaz Z, Singh N et&#xa0;al (2018a) Nuclear&#x2010;import receptors reverse aberrant phase transitions of RNA&#x2010;binding proteins with prion&#x2010;like domains. Cell 173: 677&#x2013;692.e620</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Lehmer C, Martinez&#x2010;Sanchez A, Rudack T, Beck F, Hartmann H, Perez&#x2010;Berlanga M, Frottin F, Hipp MS, Hartl FU et&#xa0;al (2018b) In situ structure of neuronal C9orf72 poly&#x2010;GA aggregates reveals proteasome recruitment. Cell 172: 696&#x2013;705.e612</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035389</ArticleId><ArticleId IdType="pubmed">29398115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hans F, Eckert M, von Zweydorf F, Gloeckner CJ, Kahle PJ (2018) Identification and characterization of ubiquitinylation sites in TAR DNA&#x2010;binding protein of 43&#xa0;kDa (TDP&#x2010;43). J Biol Chem 293: 16083&#x2013;16099</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6187624</ArticleId><ArticleId IdType="pubmed">30120199</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber M, Hutten S, Bourgeois B, Spreitzer E, Niedner&#x2010;Boblenz A, Schifferer M, Ruepp MD, Simons M, Niessing D, Madl T et&#xa0;al (2018) Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. Cell 173: 706&#x2013;719.e713</Citation><ArticleIdList><ArticleId IdType="pubmed">29677514</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Chen&#x2010;Plotkin A, Winton MJ, Unger TL, Xu Y, Neumann M, Trojanowski JQ, Lee VM (2009) Expression of TDP&#x2010;43 C&#x2010;terminal fragments in&#xa0;vitro recapitulates pathological features of TDP&#x2010;43 proteinopathies. J Biol Chem 284: 8516&#x2013;8524</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW 3rd, Sun S, Herdy JR, Bieri G et&#xa0;al (2015) Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci 18: 1226&#x2013;1229</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC (2018) Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci 21: 1341&#x2013;1349</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375686</ArticleId><ArticleId IdType="pubmed">30258241</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi B, Hartmann H, May S, Mohl C, Ederle H, Michaelsen M, Schludi MH, Dormann D, Edbauer D (2017) Cytoplasmic poly&#x2010;GA aggregates impair nuclear import of TDP&#x2010;43 in C9orf72 ALS/FTLD. Hum Mol Genet 26: 790&#x2013;800</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409121</ArticleId><ArticleId IdType="pubmed">28040728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A, Sowa ME, Rad R, Rush J, Comb MJ et&#xa0;al (2011) Systematic and quantitative assessment of the ubiquitin&#x2010;modified proteome. Mol Cell 44: 325&#x2013;340</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200427</ArticleId><ArticleId IdType="pubmed">21906983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraut DA (2013) Slippery substrates impair ATP&#x2010;dependent protease function by slowing unfolding. J Biol Chem 288: 34729&#x2013;34735</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843084</ArticleId><ArticleId IdType="pubmed">24151080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, Baskaran P, Gomez&#x2010;Deza J, Chen HJ, Nishimura AL, Smith BN, Troakes C, Adachi Y, Stepto A, Petrucelli L et&#xa0;al (2017) C9orf72 poly GA RAN&#x2010;translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity. Hum Mol Genet 26: 4765&#x2013;4777</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886201</ArticleId><ArticleId IdType="pubmed">28973350</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG (1997) Inhibition of ubiquitin/proteasome&#x2010;dependent protein degradation by the Gly&#x2010;Ala repeat domain of the Epstein&#x2010;Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 94: 12616&#x2013;12621</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25057</ArticleId><ArticleId IdType="pubmed">9356498</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79: 416&#x2013;438</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR, Yachnis AT, Ranum LP (2016) C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron 90: 521&#x2013;534</Citation><ArticleIdList><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokireddy S, Kukushkin NV, Goldberg AL (2015) cAMP&#x2010;induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc Natl Acad Sci USA 112: E7176&#x2013;E7185</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702992</ArticleId><ArticleId IdType="pubmed">26669444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumpkin RJ, Gu H, Zhu Y, Leonard M, Ahmad AS, Clauser KR, Meyer JG, Bennett EJ, Komives EA (2017) Site&#x2010;specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8: 1171</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5660086</ArticleId><ArticleId IdType="pubmed">29079793</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenzl S, Mori K, Weng SM, Haass C, Kretzschmar HA, Edbauer D et&#xa0;al (2013) Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico&#x2010;pathological correlations. Acta Neuropathol 126: 859&#x2013;879</Citation><ArticleIdList><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Frick P, Grasser FA, Gendron TF, Petrucelli L, Cashman NR, Edbauer D, Kremmer E, Prudlo J, Troost D et&#xa0;al (2015) Quantitative analysis and clinico&#x2010;pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol 130: 845&#x2013;861</Citation><ArticleIdList><ArticleId IdType="pubmed">26374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchenko ND, Hanel W, Li D, Becker K, Reich N, Moll UM (2010) Stress&#x2010;mediated nuclear stabilization of p53 is regulated by ubiquitination and importin&#x2010;alpha3 binding. Cell Death Differ 17: 255&#x2013;267</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419752</ArticleId><ArticleId IdType="pubmed">19927155</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, Schwenk BM, Grasser FA, Mori K, Kremmer E, Banzhaf&#x2010;Strathmann J et&#xa0;al (2014) C9orf72 FTLD/ALS&#x2010;associated Gly&#x2010;Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol 128: 485&#x2013;503</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C et&#xa0;al (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide&#x2010;repeat proteins in FTLD/ALS. Science 339: 1335&#x2013;1338</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, Duff KE (2016) Tau&#x2010;driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP&#x2010;PKA signaling. Nat Med 22: 46&#x2013;53</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4787271</ArticleId><ArticleId IdType="pubmed">26692334</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM et&#xa0;al (2006) Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, Montrasio F, Pattamatta A, Tusi SK, Bardhi O, Meyer KD, Hayes L, Nakamura K, Banez&#x2010;Coronel M, Coyne A et&#xa0;al (2020) Antibody therapy targeting RAN proteins rescues C9 ALS/FTD phenotypes in C9orf72 mouse model. Neuron 105: 645&#x2013;662.e11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391607</ArticleId><ArticleId IdType="pubmed">31831332</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, Zupunski V, Troakes C, Kathe C, Fratta P, Howell M, Gallo JM, Hortobagyi T, Shaw CE, Rogelj B (2010) Nuclear import impairment causes cytoplasmic trans&#x2010;activation response DNA&#x2010;binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain 133: 1763&#x2013;1771</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Masuda&#x2010;Suzukake M, Hosokawa M, Shimozawa A, Hirai S, Okado H, Hasegawa M (2018) C9ORF72 dipeptide repeat poly&#x2010;GA inclusions promote intracellular aggregation of phosphorylated TDP&#x2010;43. Hum Mol Genet 27: 2658&#x2013;2670</Citation><ArticleIdList><ArticleId IdType="pubmed">29750243</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier&#x2010;Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C et&#xa0;al (2011) Long pre&#x2010;mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP&#x2010;43. Nat Neurosci 14: 459&#x2013;468</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK (2019) Molecular mechanisms of TDP&#x2010;43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci 12: 25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon&#x2010;Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L et&#xa0;al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron 72: 257&#x2013;268</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Jiang J, Garcia SD, Taylor AE, Schulte D, Ohkubo T, Schloffman CL, Maldonado M, Baughn M et&#xa0;al (2018) Sense&#x2010;encoded poly&#x2010;GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co&#x2010;localize with TDP&#x2010;43 in dendrites of repeat&#x2010;expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathol 135: 459&#x2013;474</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935138</ArticleId><ArticleId IdType="pubmed">29196813</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH, May S, Grasser FA, Rentzsch K, Kremmer E, Kupper C, Klopstock T; German Consortium for Frontotemporal Lobar Degeneration; Bavarian Brain Banking Alliance , Arzberger T et&#xa0;al (2015) Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol 130: 537&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575390</ArticleId><ArticleId IdType="pubmed">26085200</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH, Becker L, Garrett L, Gendron TF, Zhou Q, Schreiber F, Popper B, Dimou L, Strom TM, Winkelmann J et&#xa0;al (2017) Spinal poly&#x2010;GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. Acta Neuropathol 134: 241&#x2013;254</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508040</ArticleId><ArticleId IdType="pubmed">28409281</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen HJ, Shaw CE (2015) TDP&#x2010;43 proteinopathy and ALS: insights into disease mechanisms and therapeutic targets. Neurotherapeutics 12: 352&#x2013;363</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Shcherbakova DM, Verkhusha VV (2013) Near&#x2010;infrared fluorescent proteins for multicolor in&#xa0;vivo imaging. Nat Methods 10: 751&#x2013;754</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3737237</ArticleId><ArticleId IdType="pubmed">23770755</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon DA, Stepto A, Au WH, Adachi Y, Diaper DC, Hall R, Rekhi A, Boudi A, Tziortzouda P, Lee YB et&#xa0;al (2018) A feedback loop between dipeptide&#x2010;repeat protein, TDP&#x2010;43 and karyopherin&#x2010;alpha mediates C9orf72&#x2010;related neurodegeneration. Brain 141: 2908&#x2013;2924</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6158706</ArticleId><ArticleId IdType="pubmed">30239641</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro Y, Urushitani M, Inoue H, Koike M, Uchiyama Y, Komatsu M, Tanaka K, Yamazaki M, Abe M, Misawa H et&#xa0;al (2012) Motor neuron&#x2010;specific disruption of proteasomes, but not autophagy, replicates amyotrophic lateral sclerosis. J Biol Chem 287: 42984&#x2013;42994</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522293</ArticleId><ArticleId IdType="pubmed">23095749</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, Konig J, Hortobagyi T, Nishimura AL, Zupunski V et&#xa0;al (2011) Characterizing the RNA targets and position&#x2010;dependent splicing regulation by TDP&#x2010;43. Nat Neurosci 14: 452&#x2013;458</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A, Pribadi M, Phillips JJ, Gaus SE, Hixson JD et&#xa0;al (2016) Timing and significance of pathological features in C9orf72 expansion&#x2010;associated frontotemporal dementia. Brain 139: 3202&#x2013;3216</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790143</ArticleId><ArticleId IdType="pubmed">27797809</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilchez D, Boyer L, Morantte I, Lutz M, Merkwirth C, Joyce D, Spencer B, Page L, Masliah E, Berggren WT et&#xa0;al (2012) Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature 489: 304&#x2013;308</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215918</ArticleId><ArticleId IdType="pubmed">22972301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA (2011) An AlphaScreen(R)&#x2010;based assay for high&#x2010;throughput screening for specific inhibitors of nuclear import. J Biomol Screen 16: 192&#x2013;200</Citation><ArticleIdList><ArticleId IdType="pubmed">21297106</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Spiller KJ, Ge G, Zheng A, Xu Y, Zhou M, Tripathy K, Kwong LK, Trojanowski JQ, Lee VM (2015) Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP&#x2010;43. Acta Neuropathol 130: 643&#x2013;660</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB et&#xa0;al (2014) Antisense proline&#x2010;arginine RAN dipeptides linked to C9ORF72&#x2010;ALS/FTD form toxic nuclear aggregates that initiate in&#xa0;vitro and in&#xa0;vivo neuronal death. Neuron 84: 1213&#x2013;1225</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergard T, Jensen BK, Wen X, Cai J, Kropf E, Iacovitti L, Pasinelli P, Trotti D (2016) Cell&#x2010;to&#x2010;cell transmission of dipeptide repeat proteins linked to C9orf72&#x2010;ALS/FTD. Cell Rep 17: 645&#x2013;652</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5078984</ArticleId><ArticleId IdType="pubmed">27732842</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM (2008) Disturbance of nuclear and cytoplasmic TAR DNA&#x2010;binding protein (TDP&#x2010;43) induces disease&#x2010;like redistribution, sequestration, and aggregate formation. J Biol Chem 283: 13302&#x2013;13309</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin P, Guo X, Yang W, Yan S, Yang S, Zhao T, Sun Q, Liu Y, Li S, Li XJ (2019) Caspase&#x2010;4 mediates cytoplasmic accumulation of TDP&#x2010;43 in the primate brains. Acta Neuropathol 137: 919&#x2013;937</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6531422</ArticleId><ArticleId IdType="pubmed">30810811</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, Lin WL, Tong J, Castanedes&#x2010;Casey M, Ash P et&#xa0;al (2009) Aberrant cleavage of TDP&#x2010;43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci USA 106: 7607&#x2013;7612</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S et&#xa0;al (2015) The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525: 56&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen&#x2010;West K, Xu YF, Katzman RB, Gass J, Murray ME, Shinohara M et&#xa0;al (2016) C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci 19: 668&#x2013;677</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Lehmer C, Michaelsen M, Mori K, Alterauge D, Baumjohann D, Schludi MH, Greiling J, Farny D, Flatley A et&#xa0;al (2017) Antibodies inhibit transmission and aggregation of C9orf72 poly&#x2010;GA dipeptide repeat proteins. EMBO Mol Med 9: 687&#x2013;702</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5412769</ArticleId><ArticleId IdType="pubmed">28351931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Mareljic N, Michaelsen M, Parhizkar S, Heindl S, Nuscher B, Farny D, Czuppa M, Schludi C, Graf A et&#xa0;al (2020) Active poly&#x2010;GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. EMBO Mol Med 12: e10919</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7005532</ArticleId><ArticleId IdType="pubmed">31858749</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Banez&#x2010;Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH et&#xa0;al (2013) RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci USA 110: E4968&#x2013;E4977</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32184288</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1937-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>623</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Science signaling</Title><ISOAbbreviation>Sci Signal</ISOAbbreviation></Journal><ArticleTitle>SERP1 is an assembly regulator of &#x3b3;-secretase in metabolic stress conditions.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaax8949</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scisignal.aax8949</ELocationID><Abstract><AbstractText>The enzyme &#x3b3;-secretase generates &#x3b2;-amyloid (A&#x3b2;) peptides by cleaving amyloid protein precursor (APP); the aggregation of these peptides is associated with Alzheimer's disease (AD). Despite the development of various &#x3b3;-secretase regulators, their clinical use is limited by coincident disruption of other &#x3b3;-secretase-regulated substrates, such as Notch. Using a genome-wide functional screen of &#x3b3;-secretase activity in cells and a complementary DNA expression library, we found that SERP1 is a previously unknown &#x3b3;-secretase activator that stimulates A&#x3b2; generation in cells experiencing endoplasmic reticulum (ER) stress, such as is seen with diabetes. SERP1 interacted with a subcomplex of &#x3b3;-secretase (APH1A/NCT) through its carboxyl terminus to enhance the assembly and, consequently, the activity of the &#x3b3;-secretase holoenzyme complex. In response to ER stress, SERP1 preferentially recruited APP rather than Notch into the &#x3b3;-secretase complex and enhanced the subcellular localization of the complex into lipid rafts, increasing A&#x3b2; production. Moreover, SERP1 abundance, &#x3b3;-secretase assembly, and A&#x3b2; production were increased both in cells exposed to high amounts of glucose and in diabetic AD model mice. Conversely, A&#x3b2; production was decreased by knocking down SERP1 in cells or in the hippocampi of mice. Compared to postmortem samples from control individuals, those from patients with AD showed increased SERP1 expression in the hippocampus and parietal lobe. Together, our findings suggest that SERP1 is an APP-biased regulator of &#x3b3;-secretase function in the context of cell stress, providing a possible molecular explanation for the link between diabetes and sporadic AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Sunmin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7665-0371</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyun</LastName><ForeName>Junho</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4546-4100</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nah</LastName><ForeName>Jihoon</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2254-2233</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Jonghee</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seo-Hyun</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-5112-0104</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jaesang</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9270-4723</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Yoonseo</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9715-2585</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gwon</LastName><ForeName>Youngdae</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5618-9370</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Seowon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3361-7587</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Dong-Gyu</ForeName><Initials>DG</Initials><Identifier Source="ORCID">0000-0003-2271-1076</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Yong-Keun</ForeName><Initials>YK</Initials><Identifier Source="ORCID">0000-0002-9686-3120</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea. ykjung@snu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Signal</MedlineTA><NlmUniqueID>101465400</NlmUniqueID><ISSNLinking>1945-0877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C575068">SERP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013312" MajorTopicYN="Y">Stress, Physiological</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32184288</ArticleId><ArticleId IdType="doi">10.1126/scisignal.aax8949</ArticleId><ArticleId IdType="pii">13/623/eaax8949</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32183883</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification.</ArticleTitle><Pagination><StartPage>26</StartPage><MedlinePgn>26</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">26</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13195-020-00596-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cerebrospinal fluid biomarker profiles characterized by decreased amyloid-beta peptide levels and increased total and phosphorylated tau levels at threonine 181 (pT181) are currently used to discriminate between Alzheimer's disease and other neurodegenerative diseases. However, these changes are not entirely specific to Alzheimer's disease, and it is noteworthy that other phosphorylated isoforms of tau, possibly more specific for the disease process, have been described in the brain parenchyma of patients. The precise detection of these isoforms in biological fluids remains however a challenge.</AbstractText><AbstractText Label="METHODS">In the present study, we used the latest quantitative mass spectrometry approach, which achieves a sensitive detection in cerebrospinal fluid biomarker of two phosphorylated tau isoforms, pT181 and pT217, and first analyzed a cohort of probable Alzheimer's disease patients and patients with other neurological disorders, including tauopathies, and a set of cognitively normal controls. We then checked the validity of our results on a second cohort comprising cognitively normal individuals and patients with mild cognitive impairments and AD stratified in terms of their amyloid status based on PiB-PET imaging methods.</AbstractText><AbstractText Label="RESULTS">In the first cohort, pT217 but not pT181 differentiated between Alzheimer's disease patients and those with other neurodegenerative diseases and control subjects much more specificity and sensitivity than pT181. T217 phosphorylation was increased by 6.0-fold in patients with Alzheimer's disease whereas T181 phosphorylation was only increased by 1.3-fold, when compared with control subjects. These results were confirmed in the case of a second cohort, in which the pT217 cerebrospinal fluid levels marked out amyloid-positive patients with a sensitivity and a specificity of more than 90% (AUC 0.961; CI 0.874 to 0.995). The pT217 concentrations were also highly correlated with the PiB-PET values (correlation coefficient 0.72; P&#x2009;&lt;&#x2009;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">Increased cerebrospinal fluid pT217 levels, more than those of pT181, are highly specific biomarkers for detecting both the preclinical and advanced forms of Alzheimer's disease. This finding should greatly improve the diagnosis of Alzheimer's disease, along with the correlations found to exist between pT217 levels and PiB-PET data. It also suggests that pT217 is a promising potential target for therapeutic applications and that a link exists between amyloid and tau pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barth&#xe9;lemy</LastName><ForeName>Nicolas R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie Prot&#xe9;omique Clinique, Plateforme de Prot&#xe9;omique Clinique, CHU de Montpellier, INSERM, Universit&#xe9; de Montpellier, Montpellier, France. barthelemy.nicolas@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint-Louis, MO, USA. barthelemy.nicolas@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint-Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirtz</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie Prot&#xe9;omique Clinique, Plateforme de Prot&#xe9;omique Clinique, CHU de Montpellier, INSERM, Universit&#xe9; de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut de G&#xe9;nomique Fonctionnelle, CNRS UMR5203, INSERM U1191, Universit&#xe9; de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becher</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service de Pharmacologie et d'Immunoanalyse (SPI), Laboratoire d'Etude du M&#xe9;tabolisme des M&#xe9;dicaments (LEMM), CEA, INRA, Universit&#xe9; Paris Saclay, F-91191, Gif-sur-Yvette cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint-Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabelle</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory Resources and Research Center of Montpellier, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France. audreygabelle@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie Prot&#xe9;omique Clinique, Plateforme de Prot&#xe9;omique Clinique, CHU de Montpellier, INSERM, Universit&#xe9; de Montpellier, Montpellier, France. s-lehmann@chu-montpellier.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS095773</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS065667</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095773</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="Y">tau Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">Tau proteins</Keyword></KeywordList><CoiStatement>Dr. Nicolas Barth&#xe9;lemy is a recipient of the Alzheimer&#x2019;s Association Research Fellowship which supported this work. He declares that there are no conflicts of interest involved. Pr Sylvain Lehmann received institutional support from Montpellier University Hospital and the French National Research Agency for biomarker research. He received honoraria from Thermo Fisher, Roche, and Fujirebio for serving on scientific advisory boards. He is a shareholder at the Spot-to-Lab start-up company, which was not involved in this particular research. Dr. Audrey Gabelle received funds from the Fondation Philippe Chatrier. She declares that there are no conflicts of interest involved in this paper. Dr. Randall Bateman has received honoraria from Janssen, Pfizer, and Roche as a speaker; from Eisai as a consultant; and from Merck and Pfizer as an Advisory Board member. Washington University has submitted the US nonprovisional patent applications &#x201c;Methods of Diagnosing and Treating Based on Site-Specific Tau Phosphorylation&#x201d; (co-inventors RJB, NB) and &#x201c;Central Nervous System Tau Kinetic Measurements as Diagnostic and Theragnostic Biomarkers&#x201d; (co-inventors RJB, CS) and the provisional patent application &#x201c;Quantification of Tau Isoforms, Modification, and Truncation for Assessment of Tauopathies&#x201d; (co-inventors RJB, CS). Dr. Philippe Marin, Fran&#xe7;ois Becher, Christophe Hirtz, and Chihiro Sato (pr&#xe9;ciser Dr. ou Professor avant chaque nom) also declare that there are no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32183883</ArticleId><ArticleId IdType="pmc">PMC7079453</ArticleId><ArticleId IdType="doi">10.1186/s13195-020-00596-4</ArticleId><ArticleId IdType="pii">10.1186/s13195-020-00596-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Association As 2018 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2018;14(3):367&#x2013;429. doi: 10.1016/j.jalz.2018.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Piton M, Hirtz C, Desmetz C, Milhau J, Lajoix AD, Bennys K, et al. Alzheimer&#x2019;s disease: advances in drug development. Journal of Alzheimer's disease : JAD. 2018;65(1):3&#x2013;13. doi: 10.3233/JAD-180145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180145</ArticleId><ArticleId IdType="pubmed">30040716</ArticleId></ArticleIdList></Reference><Reference><Citation>Duits FH, Prins ND, Lemstra AW, Pijnenburg YA, Bouwman FH, Teunissen CE, et al. Diagnostic impact of CSF biomarkers for Alzheimer&#x2019;s disease in a tertiary memory clinic. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer's Association. 2015;11(5):523&#x2013;532. doi: 10.1016/j.jalz.2014.05.1753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.05.1753</ArticleId><ArticleId IdType="pubmed">25156643</ArticleId></ArticleIdList></Reference><Reference><Citation>Gooblar J, Carpenter BD, Coats MA, Morris JC, Snider BJ. The influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluations. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer's Association. 2015;11(5):533&#x2013;40 e2 Epub 2014/07/16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287458</ArticleId><ArticleId IdType="pubmed">25022536</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton-Liger F, Wallon D, Troussiere AC, Yatimi R, Dumurgier J, Magnin E, et al. Impact of cerebro-spinal fluid biomarkers of Alzheimer&#x2019;s disease in clinical practice: a multicentric study. J Neurol. 2014;261(1):144&#x2013;151. doi: 10.1007/s00415-013-7160-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-013-7160-3</ArticleId><ArticleId IdType="pubmed">24162039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann S, Schraen S, Paquet C, Bombois S, Delaby C, Dorey A, et al. A diagnostic scale for Alzheimer&#x2019;s disease based on cerebrospinal fluid biomarker profiles. Alzheimers Res Ther. 2014;6:38. doi: 10.1186/alzrt267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt267</ArticleId><ArticleId IdType="pmc">PMC4255520</ArticleId><ArticleId IdType="pubmed">25478015</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1):98&#x2013;106. doi: 10.1001/archgenpsychiatry.2011.155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.155</ArticleId><ArticleId IdType="pubmed">22213792</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Gardoni F, Parnetti L, Magno L, Malinverno M, Saggese E, et al. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging. 2009;30(1):34&#x2013;40. doi: 10.1016/j.neurobiolaging.2007.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.05.009</ArticleId><ArticleId IdType="pubmed">17709155</ArticleId></ArticleIdList></Reference><Reference><Citation>Marelli C, Gutierrez LA, Menjot de Champfleur N, Charroud C, De Verbizier D, Touchon J, et al. Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer&#x2019;s disease: interest of cerebrospinal fluid biomarker ratios. Alzheimers Dement (Amst) 2015;1(3):371&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878372</ArticleId><ArticleId IdType="pubmed">27239517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61(1):95&#x2013;102. doi: 10.1001/archpsyc.61.1.95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.61.1.95</ArticleId><ArticleId IdType="pubmed">14706948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. JAD: Journal of Alzheimer's disease; 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22710920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair W, Muntel J, Tepper K, Tang S, Biernat J, Seeley WW, et al. FLEXITau: quantifying post-translational modifications of tau protein in vitro and in human disease. Anal Chem. 2016;88(7):3704&#x2013;3714. doi: 10.1021/acs.analchem.5b04509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.5b04509</ArticleId><ArticleId IdType="pmc">PMC5808556</ArticleId><ArticleId IdType="pubmed">26877193</ArticleId></ArticleIdList></Reference><Reference><Citation>Dammer EB, Lee AK, Duong DM, Gearing M, Lah JJ, Levey AI, et al. Quantitative phosphoproteomics of Alzheimer&#x2019;s disease reveals cross-talk between kinases and small heat shock proteins. Proteomics. 2015;15(2&#x2013;3):508&#x2013;519. doi: 10.1002/pmic.201400189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201400189</ArticleId><ArticleId IdType="pmc">PMC4404162</ArticleId><ArticleId IdType="pubmed">25332170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem. 2007;282(32):23645&#x2013;23654. doi: 10.1074/jbc.M703269200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M703269200</ArticleId><ArticleId IdType="pubmed">17562708</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Hanger DP, Miller CC, Lovestone S. The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol. 2013;4:83. doi: 10.3389/fneur.2013.00083.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2013.00083</ArticleId><ArticleId IdType="pmc">PMC3696910</ArticleId><ArticleId IdType="pubmed">23847585</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, Buee L. Normal and pathological Tau proteins as factors for microtubule assembly. Int Rev Cytol. 1997;171:167&#x2013;224. doi: 10.1016/S0074-7696(08)62588-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0074-7696(08)62588-7</ArticleId><ArticleId IdType="pubmed">9066128</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, et al. Biochemistry of Tau in Alzheimer&#x2019;s disease and related neurological disorders. Expert review of proteomics. 2008;5(2):207&#x2013;224. doi: 10.1586/14789450.5.2.207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14789450.5.2.207</ArticleId><ArticleId IdType="pubmed">18466052</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;2010 Epub 2010/08/04.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090074</ArticleId><ArticleId IdType="pubmed">20678074</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59(4):627&#x2013;629. doi: 10.1212/WNL.59.4.627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.59.4.627</ArticleId><ArticleId IdType="pubmed">12196665</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos JRF, Bauer C, Schuchhardt J, Wedekind D, Waniek K, Lachmann I, et al. Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer&#x2019;s disease. J Neural Transm (Vienna) 2019;126(3):339&#x2013;348. doi: 10.1007/s00702-019-01982-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-019-01982-5</ArticleId><ArticleId IdType="pubmed">30767082</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato Chihiro, Barth&#xe9;lemy Nicolas R., Mawuenyega Kwasi G., Patterson Bruce W., Gordon Brian A., Jockel-Balsarotti Jennifer, Sullivan Melissa, Crisp Matthew J., Kasten Tom, Kirmess Kristopher M., Kanaan Nicholas M., Yarasheski Kevin E., Baker-Nigh Alaina, Benzinger Tammie L.S., Miller Timothy M., Karch Celeste M., Bateman Randall J. Tau Kinetics in Neurons and the Human Central Nervous System. Neuron. 2018;97(6):1284-1298.e7. doi: 10.1016/j.neuron.2018.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.015</ArticleId><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR, Mallipeddi N, Moiseyev P, Sato C, Bateman RJ. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer&#x2019;s disease. Frontiers in aging neuroscience. 2019;11:121. doi: 10.3389/fnagi.2019.00121.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00121</ArticleId><ArticleId IdType="pmc">PMC6537657</ArticleId><ArticleId IdType="pubmed">31178717</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association. 2011;7(3):263&#x2013;269. doi: 10.1016/j.jalz.2011.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick&#x2019;s Disease. Arch Neurol. 2001;58(11):1803&#x2013;1809. doi: 10.1001/archneur.58.11.1803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.58.11.1803</ArticleId><ArticleId IdType="pubmed">11708987</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Journal of Alzheimer's disease : JAD. 2006;9(3 Suppl):417&#x2013;423. doi: 10.3233/JAD-2006-9S347.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2006-9S347</ArticleId><ArticleId IdType="pubmed">16914880</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer&#x2019;s and Parkinson&#x2019;s disease cerebrospinal fluid biomarkers: an update. Biomark Med. 2012;6(4):419&#x2013;430. doi: 10.2217/bmm.12.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm.12.46</ArticleId><ArticleId IdType="pubmed">22917144</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumurgier J, Vercruysse O, Paquet C, Bombois S, Chaulet C, Laplanche JL, et al. Intersite variability of CSF Alzheimer&#x2019;s disease biomarkers in clinical setting. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association. 2013;9(4):406&#x2013;413. doi: 10.1016/j.jalz.2012.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.06.006</ArticleId><ArticleId IdType="pubmed">23141384</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol. 2015;78(3):439&#x2013;453. doi: 10.1002/ana.24454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24454</ArticleId><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, et al. Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J Proteome Res. 2016;15(2):667&#x2013;676. doi: 10.1021/acs.jproteome.5b01001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.5b01001</ArticleId><ArticleId IdType="pubmed">26742856</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019; Epub 2019/08/03.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida H, Goedert M. Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope. J Neurochem. 2006;99(1):154&#x2013;164. doi: 10.1111/j.1471-4159.2006.04052.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04052.x</ArticleId><ArticleId IdType="pubmed">16987243</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Shi J, Chu D, Hu W, Guan Z, Gong CX, et al. Relevance of phosphorylation and truncation of tau to the etiopathogenesis of Alzheimer&#x2019;s disease. Front Aging Neurosci. 2018;10:27. doi: 10.3389/fnagi.2018.00027.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00027</ArticleId><ArticleId IdType="pmc">PMC5810298</ArticleId><ArticleId IdType="pubmed">29472853</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasorsa A, Malki I, Cantrelle FX, Merzougui H, Boll E, Lambert JC, et al. Structural basis of tau interaction with BIN1 and regulation by tau phosphorylation. Front Mol Neurosci. 2018;11:421. doi: 10.3389/fnmol.2018.00421.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00421</ArticleId><ArticleId IdType="pmc">PMC6246682</ArticleId><ArticleId IdType="pubmed">30487734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009;15(3):112&#x2013;119. doi: 10.1016/j.molmed.2009.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2009.01.003</ArticleId><ArticleId IdType="pubmed">19246243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer&#x2019;s disease: original data and review of the literature. J Mol Neurosci. 2004;23(1&#x2013;2):115&#x2013;122. doi: 10.1385/JMN:23:1-2:115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:23:1-2:115</ArticleId><ArticleId IdType="pubmed">15126697</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer&#x2019;s disease. Mol Neurobiol. 2001;24(1&#x2013;3):87&#x2013;97. doi: 10.1385/MN:24:1-3:087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/MN:24:1-3:087</ArticleId><ArticleId IdType="pubmed">11831556</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association. 2018;14(8):989&#x2013;997. doi: 10.1016/j.jalz.2018.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, et al. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. Journal of Alzheimer's disease : JAD. 2013;34(1):297&#x2013;305. doi: 10.3233/JAD-121549.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-121549</ArticleId><ArticleId IdType="pubmed">23186986</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, et al. CSF biomarkers for the differential diagnosis of Alzheimer&#x2019;s disease: a large-scale international multicenter study. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association. 2015;11(11):1306&#x2013;1315. doi: 10.1016/j.jalz.2014.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.12.006</ArticleId><ArticleId IdType="pubmed">25804998</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012;78(1):47&#x2013;54. doi: 10.1212/WNL.0b013e31823ed0f0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31823ed0f0</ArticleId><ArticleId IdType="pubmed">22170879</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol. 2012;69(7):856&#x2013;867. doi: 10.1001/archneurol.2011.3405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.3405</ArticleId><ArticleId IdType="pmc">PMC3595157</ArticleId><ArticleId IdType="pubmed">22409939</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. The Lancet Neurology. 2013;12(10):957&#x2013;965. doi: 10.1016/S1474-4422(13)70194-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70194-7</ArticleId><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A, Alcolea D, Martinez-Lage P, Scheltens P, Parnetti L, Poirier J, et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer&#x2019;s disease continuum in the BIOMARKAPD study. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association. 2019; Epub 2019/04/11.</Citation><ArticleIdList><ArticleId IdType="pubmed">30967340</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA neurology. 2015;72(9):1029&#x2013;1042. doi: 10.1001/jamaneurol.2015.1285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1285</ArticleId><ArticleId IdType="pmc">PMC4570860</ArticleId><ArticleId IdType="pubmed">26147946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez F&#xe9;lix, G&#xf3;mez de Barreda Elena, Fuster-Matanzo Almudena, Lucas Jos&#xe9; J., Avila Jes&#xfa;s. GSK3: A possible link between beta amyloid peptide and tau protein. Experimental Neurology. 2010;223(2):322&#x2013;325. doi: 10.1016/j.expneurol.2009.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.09.011</ArticleId><ArticleId IdType="pubmed">19782073</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108(14):5819&#x2013;5824. doi: 10.1073/pnas.1017033108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017033108</ArticleId><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32203580</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>143</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration.</ArticleTitle><Pagination><StartPage>993</StartPage><EndPage>1009</EndPage><MedlinePgn>993-1009</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awaa012</ELocationID><Abstract><AbstractText>Alzheimer's disease neurodegeneration is thought to spread across anatomically and functionally connected brain regions. However, the precise sequence of spread remains ambiguous. The prevailing model used to guide in vivo human neuroimaging and non-human animal research assumes that Alzheimer's degeneration starts in the entorhinal cortices, before spreading to the temporoparietal cortex. Challenging this model, we previously provided evidence that in vivo markers of neurodegeneration within the nucleus basalis of Meynert (NbM), a subregion of the basal forebrain heavily populated by cortically projecting cholinergic neurons, precedes and predicts entorhinal degeneration. There have been few systematic attempts at directly comparing staging models using in vivo longitudinal biomarker data, and none to our knowledge testing if comparative evidence generalizes across independent samples. Here we addressed the sequence of pathological staging in Alzheimer's disease using two independent samples of the Alzheimer's Disease Neuroimaging Initiative (n1 = 284; n2 = 553) with harmonized CSF assays of amyloid-&#x3b2; and hyperphosphorylated tau (pTau), and longitudinal structural MRI data over 2 years. We derived measures of grey matter degeneration in a priori NbM and the entorhinal cortical regions of interest. To examine the spreading of degeneration, we used a predictive modelling strategy that tests whether baseline grey matter volume in a seed region accounts for longitudinal change in a target region. We demonstrated that predictive spread favoured the NbM&#x2192;entorhinal over the entorhinal&#x2192;NbM model. This evidence generalized across the independent samples. We also showed that CSF concentrations of pTau/amyloid-&#x3b2; moderated the observed predictive relationship, consistent with evidence in rodent models of an underlying trans-synaptic mechanism of pathophysiological spread. The moderating effect of CSF was robust to additional factors, including clinical diagnosis. We then applied our predictive modelling strategy to an exploratory whole-brain voxel-wise analysis to examine the spatial specificity of the NbM&#x2192;entorhinal model. We found that smaller baseline NbM volumes predicted greater degeneration in localized regions of the entorhinal and perirhinal cortices. By contrast, smaller baseline entorhinal volumes predicted degeneration in the medial temporal cortex, recapitulating a prior influential staging model. Our findings suggest that degeneration of the basal forebrain cholinergic projection system is a robust and reliable upstream event of entorhinal and neocortical degeneration, calling into question a prevailing view of Alzheimer's disease pathogenesis.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Cabello</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Cognitive Neuroscience, University of Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kronbichler</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Cognitive Neuroscience, University of Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute, Christian-Doppler Medical Centre, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Dijk</LastName><ForeName>Koene R A</ForeName><Initials>KRA</Initials><AffiliationInfo><Affiliation>Clinical and Translational Imaging, Early Clinical Development, Pfizer Inc, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodman</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Clinical and Translational Imaging, Early Clinical Development, Pfizer Inc, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spreng</LastName><ForeName>R Nathan</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Laboratory of Brain and Cognition, Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Psychiatry and Psychology, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Verdun, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitz</LastName><ForeName>Taylor W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Brain and Mind Institute, Western University, London, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Western University, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R03 AG060263</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>W 1233</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066187" MajorTopicYN="N">Basal Forebrain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020532" MajorTopicYN="N">Basal Nucleus of Meynert</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">NbM</Keyword><Keyword MajorTopicYN="N">basal forebrain</Keyword><Keyword MajorTopicYN="N">entorhinal cortex</Keyword><Keyword MajorTopicYN="N">nucleus basalis of Meynert</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32203580</ArticleId><ArticleId IdType="pmc">PMC7092749</ArticleId><ArticleId IdType="doi">10.1093/brain/awaa012</ArticleId><ArticleId IdType="pii">5811050</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, et al.Quantification of brain cholinergic denervation in Alzheimer&#x2019;s disease using PET imaging with [18F]-FEOBV. Mol Psychiatry 2017; 11: 1531&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28894304</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Petersen RC, Donohue M, Weiner MW. Alzheimer&#x2019;s disease neuroimaging I. Alzheimer&#x2019;s disease neuroimaging initiative 2 clinical core: progress and plans. Alzheimers Dement 2015; 11: 734&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643840</ArticleId><ArticleId IdType="pubmed">26194309</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, et al.Clinical core of the Alzheimer&#x2019;s disease neuroimaging initiative: progress and plans. Alzheimers Dement 2010; 6: 239&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867843</ArticleId><ArticleId IdType="pubmed">20451872</ArticleId></ArticleIdList></Reference><Reference><Citation>Amunts K, Kedo O, Kindler M, Pieperhoff P, Mohlberg H, Shah NJ, et al.Cytoarchitectonic mapping of the human amygdala, hippocampal region and entorhinal cortex: intersubject variability and probability maps. Anat Embryol (Berl) 2005; 210: 343&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16208455</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Bigl V, Tennstedt A, Arendt A. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer&#x2019;s disease. Neuroscience 1985; 14: 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">3974875</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Bruckner MK, Morawski M, Jager C, Gertz HJ. Early neurone loss in Alzheimer&#x2019;s disease: cortical or subcortical? Acta Neuropathol Commun 2015; 3: 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359478</ArticleId><ArticleId IdType="pubmed">25853173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007; 38: 95&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Ridgway GR. Symmetric diffeomorphic modeling of longitudinal structural MRI. Front Neurosci 2012; 6: 197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564017</ArticleId><ArticleId IdType="pubmed">23386806</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker-Nigh A, Vahedi S, Davis EG, Weintraub S, Bigio EH, Klein WL, et al.Neuronal amyloid-beta accumulation within cholinergic basal forebrain in ageing and Alzheimer&#x2019;s disease. Brain 2015; 138: 1722&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542619</ArticleId><ArticleId IdType="pubmed">25732182</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci A, Luccarini I, Scali C, Prosperi C, Giovannini MG, Pepeu G, et al.Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol Dis 2006; 23: 260&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16766197</ArticleId></ArticleIdList></Reference><Reference><Citation>Botly LC, De Rosa E. Cholinergic deafferentation of the neocortex using 192 IgG-saporin impairs feature binding in rats. J Neurosci 2009; 29: 4120&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665388</ArticleId><ArticleId IdType="pubmed">19339607</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The pathological process underlying Alzheimer&#x2019;s disease in individuals under thirty. Acta Neuropathol 2011; 121: 171&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">21170538</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer&#x2019;s disease. Brain 2015; 138: 2814&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">26283673</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011; 70: 960&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantero JL, Zaborszky L, Atienza M. Volume loss of the nucleus basalis of meynert is associated with atrophy of innervated regions in mild cognitive impairment. Cereb Cortex 2017; 27: 3881&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6059249</ArticleId><ArticleId IdType="pubmed">27371762</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavedo E, Grothe MJ, Colliot O, Lista S, Chupin M, Dormont D, et al.Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer&#x2019;s disease. Sci Rep 2017; 7: 11706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5601919</ArticleId><ArticleId IdType="pubmed">28916821</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science 1993; 261: 921&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al.Development and assessment of a composite score for memory in the Alzheimer&#x2019;s disease neuroimaging initiative (ADNI). Brain Imaging Behav 2012; 6: 502&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer&#x2019;s disease. Lancet 1976; 2: 1403.</Citation><ArticleIdList><ArticleId IdType="pubmed">63862</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al.Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 2012; 73: 685&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lacalle S, Cooper JD, Svendsen CN, Dunnett SB, Sofroniew MV. Reduced retrograde labelling with fluorescent tracer accompanies neuronal atrophy of basal forebrain cholinergic neurons in aged rats. Neuroscience 1996; 75: 19&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">8923519</ArticleId></ArticleIdList></Reference><Reference><Citation>de Toledo-Morrell L, Goncharova I, Dickerson B, Wilson RS, Bennett DA. From healthy aging to early Alzheimer&#x2019;s disease: in vivo detection of entorhinal cortex atrophy. Ann N Y Acad Sci 2000; 911: 240&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">10911878</ArticleId></ArticleIdList></Reference><Reference><Citation>de Toledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, et al.MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 2004; 25: 1197&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312965</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, et al.MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer&#x2019;s disease. Neurobiol Aging 2001; 22: 747&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedenhofen B, Musch J. cocor: a comprehensive solution for the statistical comparison of correlations. PLoS One 2015; 10: e0121945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383486</ArticleId><ArticleId IdType="pubmed">25835001</ArticleId></ArticleIdList></Reference><Reference><Citation>Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, et al.Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry 2001; 71: 441&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1763497</ArticleId><ArticleId IdType="pubmed">11561025</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al.Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010; 6: 67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938772</ArticleId><ArticleId IdType="pubmed">20139996</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerardin E, Chetelat G, Chupin M, Cuingnet R, Desgranges B, Kim HS, et al.Multidimensional classification of hippocampal shape features discriminates Alzheimer&#x2019;s disease and mild cognitive impairment from normal aging. Neuroimage 2009; 47: 1476&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001345</ArticleId><ArticleId IdType="pubmed">19463957</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula C, Nagykery N, Nicholas A, Wu CK. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J Neuropathol Exp Neurol 2008; 67: 309&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243760</ArticleId><ArticleId IdType="pubmed">18379437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Torraville SE, Mukherjee B, Walling SG, Martin GM, Harley CW, et al.An experimental model of Braak&#x2019;s pretangle proposal for the origin of Alzheimer&#x2019;s disease: the role of locus coeruleus in early symptom development. Alzheimers Res Ther 2019; 11: 59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6607586</ArticleId><ArticleId IdType="pubmed">31266535</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al.A composite score for executive functioning, validated in Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 2012; 6: 517&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684181</ArticleId><ArticleId IdType="pubmed">22644789</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Scahill RI, Fox NC, Ashburner J, Friston KJ, Chan D, et al.Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage 2002; 17: 29&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482066</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe M, Heinsen H, Teipel S. Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer&#x2019;s disease. Neurobiol Aging 2013; 34: 1210&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4058576</ArticleId><ArticleId IdType="pubmed">23158764</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe M, Heinsen H, Teipel SJ. Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer&#x2019;s disease. Biol Psychiatry 2012; 71: 805&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701122</ArticleId><ArticleId IdType="pubmed">21816388</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, Scholl M, Hansson O, et al.Molecular properties underlying regional vulnerability to Alzheimer&#x2019;s disease pathology. Brain 2018; 141: 2755&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6113636</ArticleId><ArticleId IdType="pubmed">30016411</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe M, Zaborszky L, Atienza M, Gil-Neciga E, Rodriguez-Romero R, Teipel SJ, et al.Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer&#x2019;s disease. Cereb Cortex 2010; 20: 1685&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912653</ArticleId><ArticleId IdType="pubmed">19889714</ArticleId></ArticleIdList></Reference><Reference><Citation>Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer&#x2019;s disease. Neurobiol Aging 2007; 28: 327&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">16574280</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z, Yakel JL. Timing-dependent septal cholinergic induction of dynamic hippocampal synaptic plasticity. Neuron 2011; 71: 155&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134790</ArticleId><ArticleId IdType="pubmed">21745645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna Al-Shaikh FS, Duara R, Crook JE, Lesser ER, Schaeverbeke J, Hinkle KM, et al.Selective vulnerability of the nucleus basalis of Meynert among neuropathologic subtypes of Alzheimer disease. JAMA Neurol 2019. doi: 10.1001/jamaneurol.2019.3606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820048</ArticleId><ArticleId IdType="pubmed">31657834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al.Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol 2019. doi: 10.1001/jamaneurol.2019.1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547132</ArticleId><ArticleId IdType="pubmed">31157827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al.CSF biomarkers of Alzheimer&#x2019;s disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 2018; 14: 1470&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, et al.Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 2010; 68: 428&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, La Joie R, Maass A, Baker SL, Swinnerton K, Fenton L, et al.Longitudinal tau accumulation and atrophy in aging and Alzheimer disease. Ann Neurol 2019; 85: 229&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579738</ArticleId><ArticleId IdType="pubmed">30597624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasselmo ME. The role of acetylcholine in learning and memory. Curr Opin Neurobiol 2006; 16: 710&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659740</ArticleId><ArticleId IdType="pubmed">17011181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes AF. Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. 2nd edn. New York, NY: The Guilford Press; 2017.</Citation></Reference><Reference><Citation>Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, et al.Locus ceruleus controls Alzheimer&#x2019;s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A 2010; 107: 6058&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851853</ArticleId><ArticleId IdType="pubmed">20231476</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T, et al.Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 2006; 26: 1343&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675491</ArticleId><ArticleId IdType="pubmed">16452658</ArticleId></ArticleIdList></Reference><Reference><Citation>Hett K, Ta VT, Catheline G, Tourdias T, Manjon JV, Coupe P, et al.Multimodal hippocampal subfield grading for Alzheimer&#x2019;s disease classification. Sci Rep 2019; 9: 13845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6761169</ArticleId><ArticleId IdType="pubmed">31554909</ArticleId></ArticleIdList></Reference><Reference><Citation>Heys JG, Giocomo LM, Hasselmo ME. Cholinergic modulation of the resonance properties of stellate cells in layer II of medial entorhinal cortex. J Neurophysiol 2010; 104: 258&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904208</ArticleId><ArticleId IdType="pubmed">20445030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirata Y, Matsuda H, Nemoto K, Ohnishi T, Hirao K, Yamashita F, et al.Voxel-based morphometry to discriminate early Alzheimer&#x2019;s disease from controls. Neurosci Lett 2005; 382: 269&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">15925102</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Perez JM, Evans AC. Early role of vascular dysregulation on late-onset Alzheimer&#x2019;s disease based on multifactorial data-driven analysis. Nat Commun 2016; 7: 11934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4919512</ArticleId><ArticleId IdType="pubmed">27327500</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al.Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicich J, Czanner S, Han X, Salat D, van der Kouwe A, Quinn B, et al.MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage 2009; 46: 177&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866077</ArticleId><ArticleId IdType="pubmed">19233293</ArticleId></ArticleIdList></Reference><Reference><Citation>Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC, et al.Global and local gray matter loss in mild cognitive impairment and Alzheimer&#x2019;s disease. Neuroimage 2004; 23: 708&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerbler GM, Hamlin AS, Pannek K, Kurniawan ND, Keller MD, Rose SE, et al.Diffusion-weighted magnetic resonance imaging detection of basal forebrain cholinergic degeneration in a mouse model. Neuroimage 2013; 66: 133&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23128077</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren NI, Lozar CT, Harris KC, Morgan PS, Eckert MA. In vivo mapping of the human locus coeruleus. Neuroimage 2009; 47: 1261&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3671394</ArticleId><ArticleId IdType="pubmed">19524044</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, et al.Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer&#x2019;s disease. Nat Neurosci 2014; 17: 304&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044925</ArticleId><ArticleId IdType="pubmed">24362760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilimann I, Grothe M, Heinsen H, Alho EJ, Grinberg L, Amaro E Jr, et al.Subregional basal forebrain atrophy in Alzheimer&#x2019;s disease: a multicenter study. J Alzheimer's Dis 2014; 40: 687&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120953</ArticleId><ArticleId IdType="pubmed">24503619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilimann I, Hausner L, Fellgiebel A, Filippi M, Wurdemann TJ, Heinsen H, et al.Parallel atrophy of cortex and basal forebrain cholinergic system in mild cognitive impairment. Cereb Cortex 2017; 27: 1841&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26879092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kloppel S, Stonnington CM, Chu C, Draganski B, Scahill RI, Rohrer JD, et al.Automatic classification of MR scans in Alzheimer&#x2019;s disease. Brain 2008; 131: 681&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2579744</ArticleId><ArticleId IdType="pubmed">18202106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolisnyk B, Al-Onaizi M, Soreq L, Barbash S, Bekenstein U, Haberman N, et al.Cholinergic surveillance over hippocampal RNA metabolism and Alzheimer&#x2019;s-like pathology. Cereb Cortex 2016; 36: 6287&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">27312991</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruggel F, Turner J, Muftuler LT. Alzheimer&#x2019;s Disease Neuroimaging I. Impact of scanner hardware and imaging protocol on image quality and compartment volume precision in the ADNI cohort. Neuroimage 2010; 49: 2123&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951115</ArticleId><ArticleId IdType="pubmed">19913626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert C, Chowdhury R, Fitzgerald TH, Fleming SM, Lutti A, Hutton C, et al.Characterizing aging in the human brainstem using quantitative multimodal MRI analysis. Front Hum Neurosci 2013a; 7: 462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747448</ArticleId><ArticleId IdType="pubmed">23970860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert C, Lutti A, Helms G, Frackowiak R, Ashburner J. Multiparametric brainstem segmentation using a modified multivariate mixture of Gaussians. Neuroimage Clin 2013b; 2: 684&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777756</ArticleId><ArticleId IdType="pubmed">24179820</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Yu B, Sun Q, Zhang Y, Ren M, Zhang X, et al.Generation of a whole-brain atlas for the cholinergic system and mesoscopic projectome analysis of basal forebrain cholinergic neurons. Proc Natl Acad Sci U S A 2018; 115: 415&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777024</ArticleId><ArticleId IdType="pubmed">29259118</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al.Trans-synaptic spread of tau pathology in vivo. PLoS One 2012; 7: e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma D, Popuri K, Bhalla M, Sangha O, Lu D, Cao J, et al.Quantitative assessment of field strength, total intracranial volume, sex, and age effects on the goodness of harmonization for volumetric analysis on the ADNI database. Hum Brain Mapp 2019; 40: 1507&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449147</ArticleId><ArticleId IdType="pubmed">30431208</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone IB, Leung KK, Clegg S, Barnes J, Whitwell JL, Ashburner J, et al.Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance. Neuroimage 2015; 104: 366&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4265726</ArticleId><ArticleId IdType="pubmed">25255942</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci 2006; 7: 278&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710114</ArticleId><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli A, Price CJ, Friston KJ, Ashburner J. Voxel-based morphometry of the human brain: methods and applications. Curr Med Imaging Rev 2005; 1: 1&#x2013;10.</Citation></Reference><Reference><Citation>Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 2004; 55: 815&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">15174015</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. Neuroplasticity failure in Alzheimer&#x2019;s disease: bridging the gap between plaques and tangles. Neuron 1999; 24: 521&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988; 275: 216&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">3220975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983a; 214: 170&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">6841683</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Mufson EJ, Wainer BH, Levey AI. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 1983b; 10: 1185&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">6320048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsushima D, Sano A, Takahashi T. A cholinergic trigger drives learning-induced plasticity at hippocampal synapses. Nat Commun 2013; 4: 2760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831287</ArticleId><ArticleId IdType="pubmed">24217681</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al.Ways toward an early diagnosis in Alzheimer&#x2019;s disease: the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 2005; 1: 55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1864941</ArticleId><ArticleId IdType="pubmed">17476317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002; 15: 1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871862</ArticleId><ArticleId IdType="pubmed">11747097</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 1992; 89: 1671&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48514</ArticleId><ArticleId IdType="pubmed">1311847</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al.Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010; 74: 201&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Pigino G, Morfini G, Atagi Y, Deshpande A, Yu C, Jungbauer L, et al.Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci U S A 2009; 106: 5907&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667037</ArticleId><ArticleId IdType="pubmed">19321417</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer&#x2019;s disease. Trends Neurosci 1994; 17: 525&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">7532337</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer&#x2019;s disease. Lancet 1993; 342: 697&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103819</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, et al.Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92: 12260&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40336</ArticleId><ArticleId IdType="pubmed">8618881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray NJ, Metzler-Baddeley C, Khondoker MR, Grothe MJ, Teipel S, Wright P, et al.Cholinergic basal forebrain structure influences the reconfiguration of white matter connections to support residual memory in mild cognitive impairment. J Neurosci 2015; 35: 739&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293419</ArticleId><ArticleId IdType="pubmed">25589767</ArticleId></ArticleIdList></Reference><Reference><Citation>Roussarie JP, Yao V, Plautz Z, Kasturia S, Albornoz C, Schmidt EF, et al.Selective neuronal vulnerability in Alzheimer&#x2019;s disease: a network-based analysis. bioRxiv 2019. doi: 10.1101/499897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7580783</ArticleId><ArticleId IdType="pubmed">32603655</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarter M, Bruno JP, Givens B. Attentional functions of cortical cholinergic inputs: what does it mean for learning and memory? Neurobiol Learn Mem 2003; 80: 245&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">14521867</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 2011; 71: 35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">21745636</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S, et al.Alzheimer&#x2019;s disease neuroimaging initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement 2010; 6: 265&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868595</ArticleId><ArticleId IdType="pubmed">20451875</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, et al.Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement 2018; 14: 1460&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119652</ArticleId><ArticleId IdType="pubmed">29501462</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz TW, Duncan J. Normalization and the cholinergic microcircuit: a unified basis for attention. Trends Cogn Sci 2018; 22: 422&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">29576464</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz TW, Mur M, Aghourian M, Bedard MA, Spreng RN. Alzheimer&#x2019;s disease neuroimaging I. Longitudinal Alzheimer&#x2019;s degeneration reflects the spatial topography of cholinergic basal forebrain projections. Cell Rep 2018; 24: 38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8840819</ArticleId><ArticleId IdType="pubmed">29972789</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz TW, Spreng RN. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer&#x2019;s pathology. Nat Commun 2016; 7: 13249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5097157</ArticleId><ArticleId IdType="pubmed">27811848</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz LA, Luo L. Organization of the locus coeruleus-norepinephrine system. Curr Biol 2015; 25: R1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">26528750</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz LA, Miyamichi K, Gao XJ, Beier KT, Weissbourd B, DeLoach KE, et al.Viral-genetic tracing of the input-output organization of a central noradrenaline circuit. Nature 2015; 524: 88&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4587569</ArticleId><ArticleId IdType="pubmed">26131933</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, Grothe MJ, d&#x2019;Oleire Uquillas F, Ortiz-Teran L, Diez I, Yang HS, et al.Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat Med 2018; 24: 1910&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6518398</ArticleId><ArticleId IdType="pubmed">30374196</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al.Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen L, Igel C, Liv Hansen N, Osler M, Lauritzen M, Rostrup E, et al.Early detection of Alzheimer&#x2019;s disease using MRI hippocampal texture. Hum Brain Mapp 2016; 37: 1148&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6867374</ArticleId><ArticleId IdType="pubmed">26686837</ArticleId></ArticleIdList></Reference><Reference><Citation>Stonnington CM, Tan G, Kloppel S, Chu C, Draganski B, Jack CR Jr, et al.Interpreting scan data acquired from multiple scanners: a study with Alzheimer&#x2019;s disease. Neuroimage 2008; 39: 1180&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2225446</ArticleId><ArticleId IdType="pubmed">18032068</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al.Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 1977&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamamaki N, Nojyo Y. Projection of the entorhinal layer II neurons in the rat as revealed by intracellular pressure-injection of neurobiotin. Hippocampus 1993; 3: 471&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8269038</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Flatz W, Ackl N, Grothe M, Kilimann I, Bokde AL, et al.Brain atrophy in primary progressive aphasia involves the cholinergic basal forebrain and Ayala&#x2019;s nucleus. Psychiatry Res 2014; 221: 187&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086659</ArticleId><ArticleId IdType="pubmed">24434193</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Flatz WH, Heinsen H, Bokde AL, Schoenberg SO, Stockel S, et al.Measurement of basal forebrain atrophy in Alzheimer&#x2019;s disease using MRI. Brain 2005; 128: 2626&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16014654</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Keller F, Thyrian JR, Strohmaier U, Altiner A, Hoffmann W, et al.Hippocampus and basal forebrain volumetry for dementia and mild cognitive impairment diagnosis: could it be useful in primary care? J Alzheimer&#x2019;s Dis 2017; 55: 1379&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">27834778</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Meindl T, Grinberg L, Grothe M, Cantero JL, Reiser MF, et al.The cholinergic system in mild cognitive impairment and Alzheimer&#x2019;s disease: an in vivo MRI and DTI study. Hum Brain Mapp 2011; 32: 1349&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899896</ArticleId><ArticleId IdType="pubmed">20672311</ArticleId></ArticleIdList></Reference><Reference><Citation>Tona KD, Keuken MC, de Rover M, Lakke E, Forstmann BU, Nieuwenhuis S, et al.In vivo visualization of the locus coeruleus in humans: quantifying the test-retest reliability. Brain Struct Funct 2017; 222: 4203&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5686260</ArticleId><ArticleId IdType="pubmed">28647901</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Diamond MI, Duff KE, Hyman BT. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 2013; 70: 304&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665718</ArticleId><ArticleId IdType="pubmed">23599928</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren JD, Rohrer JD, Schott JM, Fox NC, Hardy J, Rossor MN. Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends Neurosci 2013; 36: 561&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3794159</ArticleId><ArticleId IdType="pubmed">23876425</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7283399</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, et al.Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci 2016; 19: 1085&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Williams J, Nathans J. Complete morphologies of basal forebrain cholinergic neurons in the mouse. Elife 2014; 3: e02444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038840</ArticleId><ArticleId IdType="pubmed">24894464</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurtman RJ. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. Trends Neurosci 1992; 15: 117&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">1374967</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurtman RJ, Blusztajn JK, Ulus IH, Coviella IL, Buyukuysal RL, Growdon JH, et al.Choline metabolism in cholinergic neurons: implications for the pathogenesis of neurodegenerative diseases. Adv Neurol 1990; 51: 117&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">2403709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyman BT, Harvey DJ, Crawford K, Bernstein MA, Carmichael O, Cole PE, et al.Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimers Dement 2013; 9: 332&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891834</ArticleId><ArticleId IdType="pubmed">23110865</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H, Pang P, Chen W, Zhu H, Henok KA, Li H, et al.The lesion analysis of cholinergic neurons in 5XFAD mouse model in the three-dimensional level of whole brain. Mol Neurobiol 2018; 55: 4115&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">28597200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaborszky L, Hoemke L, Mohlberg H, Schleicher A, Amunts K, Zilles K. Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage 2008; 42: 1127&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577158</ArticleId><ArticleId IdType="pubmed">18585468</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003; 60: 337&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633144</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32213642</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>21</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.</ArticleTitle><Pagination><StartPage>e320</StartPage><EndPage>e331</EndPage><MedlinePgn>e320-e331</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000009277</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals.</AbstractText><AbstractText Label="METHODS">Aspirin in Reducing Events in the Elderly (ASPREE) was a double-blind, placebo-controlled trial of low-dose aspirin. In the United States and Australia, community-dwelling individuals aged &#x2265;70 years (US minorities &#x2265;65 years) and free of cardiovascular disease, physical disability, and diagnosed dementia were enrolled. Participants were randomized 1:1-100 mg daily aspirin or placebo. The Modified Mini-Mental State Examination, Hopkins Verbal Learning Test-Revised, Symbol Digit Modalities Test, and Controlled Oral Word Association Test assessed cognition at baseline and over follow-up. Additional cognitive testing was performed in participants with suspected dementia ("trigger") based on within-study assessments or clinical history. Dementia was adjudicated according to DSM-IV criteria. National Institute on Aging-Alzheimer's Association criteria were used for AD and MCI subclassification.</AbstractText><AbstractText Label="RESULTS">A total of 19,114 participants were followed over a median 4.7 years and 964 triggered further dementia assessments. There were 575 adjudicated dementia cases, and 41% were classified as clinically probable AD. There was no substantial difference in the risk of all dementia triggers (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.91-1.17), probable AD (HR, 0.96; 95% CI, 0.74-1.24), or MCI (HR, 1.12; 95% CI, 0.92-1.37) between aspirin and placebo. Cognitive change over time was similar in the aspirin and placebo groups.</AbstractText><AbstractText Label="CONCLUSIONS">There was no evidence that aspirin was effective in reducing risk of dementia, MCI, or cognitive decline. Follow-up of these outcomes after initial exposure is ongoing.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE">This study provides Class II evidence that for healthy older individuals, low-dose aspirin does not significantly reduce the incidence of dementia, probable AD, MCI, or cognitive decline.</AbstractText><AbstractText Label="CLINICALTRIALSGOV IDENTIFIER">NCT01038583.</AbstractText><CopyrightInformation>&#xa9; 2020 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7039-6325</Identifier><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL. elsdon.storey@monash.edu joanne.ryan@monash.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Storey</LastName><ForeName>Elsdon</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL. elsdon.storey@monash.edu joanne.ryan@monash.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woods</LastName><ForeName>Robyn L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Rory</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reid</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Trevor T J</ForeName><Initials>TTJ</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lockery</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orchard</LastName><ForeName>Suzanne G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trevaks</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirpach</LastName><ForeName>Brenda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>Anne B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ernst</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNeil</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ASPREE Investigator Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01038583</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG024827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG029824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG024824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG044271</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG024832</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2020 Jul 21;95(3):105-106. doi: 10.1212/WNL.0000000000009278.</RefSource><PMID Version="1">32213641</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32213642</ArticleId><ArticleId IdType="pmc">PMC7455352</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000009277</ArticleId><ArticleId IdType="pii">WNL.0000000000009277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Piepoli MF, Hoes AW, Agewall S, et al. . 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Atherosclerosis 2016;252:207&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">27664503</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement 2018;4:575&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6214864</ArticleId><ArticleId IdType="pubmed">30406177</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Jana M, Pahan K. Aspirin induces lysosomal biogenesis and attenuates amyloid plaque pathology in a mouse model of Alzheimer's disease via PPARalpha. J Neurosci 2018;38:6682&#x2013;6699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6067079</ArticleId><ArticleId IdType="pubmed">29967008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachinski V, Einhaupl K, Ganten D, et al. . Preventing dementia by preventing stroke: the Berlin Manifesto. Alzheimers Dement 2019;15:961&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7001744</ArticleId><ArticleId IdType="pubmed">31327392</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Rogers J, McGeer EG. Inflammation, antiinflammatory agents, and Alzheimer's disease: the last 22 years. J Alzheimers Dis 2016;54:853&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">27716676</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink HA, Jutkowitz E, McCarten JR, et al. . Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann Intern Med 2018;168:39&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">29255847</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil JJ, Woods RL, Nelson MR, et al. . Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med 2018;379:1499&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426126</ArticleId><ArticleId IdType="pubmed">30221596</ArticleId></ArticleIdList></Reference><Reference><Citation>ASPREE IG. Study design of Aspirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials 2013;36:555&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3919683</ArticleId><ArticleId IdType="pubmed">24113028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockery JE, Collyer TA, Abhayaratna WP, et al. . Recruiting general practice patients for large clinical trials: lessons from the Aspirin in Reducing Events in the Elderly (ASPREE) study. Med J Aust 2019;210:168&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6456041</ArticleId><ArticleId IdType="pubmed">30835844</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan J, Woods RL, Britt C, et al. . Normative performance of healthy older individuals on the Modified Mini-Mental State (3MS) examination according to ethno-racial group, gender, age, and education level. Clin Neuropsychol 2018;33:779&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810645</ArticleId><ArticleId IdType="pubmed">29976121</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test&#x2013;Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 2001;12:43&#x2013;55.</Citation></Reference><Reference><Citation>Ross TP. The reliability of cluster and switch scores for the Controlled Oral Word Association Test. Arch Clin Neuropsychol 2003;18:153&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">14591467</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith A. Symbol Digit Modalities Test (SDMT) Manual (Revised). Los Angeles: Western Psychological Services; 1982.</Citation></Reference><Reference><Citation>Bland RC, Newman SC. Mild dementia or cognitive impairment: the Modified Mini-Mental State Examination (3MS) as a screen for dementia. Can J Psychiatry 2001;46:506&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">11526806</ArticleId></ArticleIdList></Reference><Reference><Citation>Tombaugh TN. Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS. Arch Clin Neuropsychol 2005;20:485&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">15896562</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham DP, Cully JA, Snow AL, Massman P, Doody R. The Alzheimer's Disease Assessment Scale&#x2013;Cognitive Subscale: normative data for older adult controls. Alzheimer Dis Assoc Disord 2004;18:236&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592137</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Elia L. Color Trails Test: Professional Manual. Odessa, FL: Psychological Assessment Resources; 1996.</Citation></Reference><Reference><Citation>Alegret M, Boada-Rovira M, Vinyes-Junque G, et al. . Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease. J Clin Exp Neuropsychol 2009;31:860&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834652</ArticleId><ArticleId IdType="pubmed">19142775</ArticleId></ArticleIdList></Reference><Reference><Citation>J. F. Alzheimer's Disease. Cooperative Study ADL Scale. In: Encyclopedia of Clinical Neuropsychology. New York: Springer; 2011.</Citation></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington, DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe R, Murray AM, Woods RL, et al. . The Aspirin in Reducing Events in the Elderly Trial: statistical analysis plan. Int J Stroke 2018;13:335&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380180</ArticleId><ArticleId IdType="pubmed">29111960</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol 2012;41:861&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396320</ArticleId><ArticleId IdType="pubmed">22253319</ArticleId></ArticleIdList></Reference><Reference><Citation>Jutten RJ, Harrison JE, Lee Meeuw Kjoe PR, et al. . Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. Alzheimers Res Ther 2019;11:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6521452</ArticleId><ArticleId IdType="pubmed">31092277</ArticleId></ArticleIdList></Reference><Reference><Citation>Naka H, Nomura E, Kitamura J, Imamura E, Wakabayashi S, Matsumoto M. Antiplatelet therapy as a risk factor for microbleeds in intracerebral hemorrhage patients: analysis using specific antiplatelet agents. J Stroke Cerebrovasc Dis 2013;22:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">22784819</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Ramirez S, Greenberg SM, Viswanathan A. Cerebral microbleeds: overview and implications in cognitive impairment. Alzheimers Res Ther 2014;6:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4075149</ArticleId><ArticleId IdType="pubmed">24987468</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAID exposure and risk of Alzheimer's disease: an updated meta-analysis from cohort studies. Front Aging Neurosci 2018;10:83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5882872</ArticleId><ArticleId IdType="pubmed">29643804</ArticleId></ArticleIdList></Reference><Reference><Citation>de Craen AJ, Gussekloo J, Vrijsen B, Westendorp RG. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol 2005;161:114&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">15632261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Cook N, Manson J, Buring JE, Grodstein F. Low dose aspirin and cognitive function in the Women's Health Study cognitive cohort. BMJ 2007;334:987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867896</ArticleId><ArticleId IdType="pubmed">17468120</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JF, Stewart MC, Deary IJ, et al. . Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ 2008;337:a1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527654</ArticleId><ArticleId IdType="pubmed">18762476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargiulo G, Capodanno D, Longo G, Capranzano P, Tamburino C. Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Rev Cardiovasc Ther 2014;12:1185&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pubmed">25220474</ArticleId></ArticleIdList></Reference><Reference><Citation>ADAPT. Results of a follow-up study to the randomized Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). Alzheimers Dement 2013;9:714&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3823756</ArticleId><ArticleId IdType="pubmed">23562431</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer PF, Tremblay-Mercier J, Leoutsakos J, et al. . INTREPAD: a randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology 2019;92:e2070&#x2013;e2080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6512884</ArticleId><ArticleId IdType="pubmed">30952794</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta KM, Yeo GW. Systematic review of dementia prevalence and incidence in United States race/ethnic populations. Alzheimers Dement 2017;13:72&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">27599209</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. . The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology 2012;78:342&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280046</ArticleId><ArticleId IdType="pubmed">22282647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol 2008;7:41&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">18068522</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Gottesman RF, Sharrett AR, et al. . Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: the Atherosclerosis Risk in Communities Study. Alzheimers Dement 2018;14:1406&#x2013;1415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6231996</ArticleId><ArticleId IdType="pubmed">29763593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32246036</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>03</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1683</StartPage><MedlinePgn>1683</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1683</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-020-15436-0</ELocationID><Abstract><AbstractText>Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer's disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate the performance of CSF p-tau217 as a biomarker of AD in comparison to p-tau181. In the Swedish BioFINDER cohort (n&#x2009;=&#x2009;194), p-tau217 shows stronger correlations with the tau positron emission tomography (PET) tracer [<sup>18</sup>F]flortaucipir, and more accurately identifies individuals with abnormally increased [<sup>18</sup>F]flortaucipir retention. Furthermore, longitudinal increases in p-tau217 are higher compared to p-tau181 and better correlate with [<sup>18</sup>F]flortaucipir uptake. P-tau217 correlates better than p-tau181 with CSF and PET measures of neocortical amyloid-&#x3b2; burden and more accurately distinguishes AD dementia from non-AD neurodegenerative disorders. Higher correlations between p-tau217 and [<sup>18</sup>F]flortaucipir are corroborated in an independent EXPEDITION3 trial cohort (n&#x2009;=&#x2009;32). The main results are validated using a different p-tau217 immunoassay. These findings suggest that p-tau217 might be more useful than p-tau181 in the diagnostic work up of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, S&#xf6;lvegatan 18, Lund, Sweden. shorena.janelidze@med.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, S&#xf6;lvegatan 18, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7147-0112</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, S&#xf6;lvegatan 18, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Entr&#xe9;gatan 7, 222 42, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, S&#xf6;lvegatan 18, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Entr&#xe9;gatan 7, 222 42, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-8885-7724</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, S&#xf6;lvegatan 18, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Entr&#xe9;gatan 7, 222 42, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Center for Molecular Medicine, Lund University, Klinikgatan 32, 221 84, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Airey</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proctor</LastName><ForeName>Nicholas K</ForeName><Initials>NK</Initials><Identifier Source="ORCID">0000-0003-1525-3580</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Xiyun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shcherbinin</LastName><ForeName>Sergey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triana-Baltzer</LastName><ForeName>Gallen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroscience Biomarkers, Janssen Research &amp; Development, 3210 Merryfield Row, San Diego, CA, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theunis</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slemmon</LastName><ForeName>Randy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuroscience Biomarkers, Janssen Research &amp; Development, 3210 Merryfield Row, San Diego, CA, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercken</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolb</LastName><ForeName>Hartmuth</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroscience Biomarkers, Janssen Research &amp; Development, 3210 Merryfield Row, San Diego, CA, CA 92121, USA. HKolb1@ITS.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dage</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-2192-1699</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, 46285, USA. Jeffrey.Dage@Lilly.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, S&#xf6;lvegatan 18, Lund, Sweden. Oskar.Hansson@med.lu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Simrisbanv&#xe4;gen 14, 205 02, Malm&#xf6;, Sweden. Oskar.Hansson@med.lu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>S.J., E.S., S.P., N.M. declare no competing interests. Ru.S. has served as a non-paid consultant for Roche. O.H. has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche. J.L.D., N.K.P., X.C., D.C.A., J.R.S., S.S. are employees of Eli Lilly and Company. G.T.B., C.T., Ra.S., M.M., H.K. are employees of Janssen R&amp;D.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32246036</ArticleId><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-15436-0</ArticleId><ArticleId IdType="pii">10.1038/s41467-020-15436-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scheltens P, et al. Alzheimer&#x2019;s disease. Lancet. 2016;388:505&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso AD, Beharry C, Corbo CP, Cohen LS. Molecular mechanism of prion-like tau-induced neurodegeneration. Alzheimers Dement. 2016;12:1090&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">27126544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 2009;15:112&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">19246243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez F, Avila J. Tauopathies. Cell Mol. Life Sci. 2007;64:2219&#x2013;2233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11136052</ArticleId><ArticleId IdType="pubmed">17604998</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, et al. CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., et al. NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:535&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, et al. Advancing research diagnostic criteria for Alzheimer&#x2019;s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinuevo JL, et al. Current state of Alzheimer&#x2019;s fluid biomarkers. Acta Neuropathol. 2018;136:821&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280827</ArticleId><ArticleId IdType="pubmed">30488277</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchhave P, et al. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry. 2012;69:98&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">22213792</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, et al. Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12:957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A, et al. A 2-Step cerebrospinal algorithm for the selection of frontotemporal lobar degeneration subtypes. JAMA Neurol. 2018;75:738&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885205</ArticleId><ArticleId IdType="pubmed">29554190</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoonenboom NS, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012;78:47&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">22170879</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129:3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 2009;66:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, et al. Tau and Abeta imaging, CSF measures, and cognition in Alzheimer&#x2019;s disease. Sci. Transl. Med. 2016;8:338ra366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal JP, et al. Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology. 2016;87:920&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035159</ArticleId><ArticleId IdType="pubmed">27473132</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, et al. (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer&#x2019;s disease. EMBO Mol. Med. 2017;9:1212&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5582410</ArticleId><ArticleId IdType="pubmed">28743782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, et al. Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology. 2018;90:e388&#x2013;e395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5791788</ArticleId><ArticleId IdType="pubmed">29321235</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain. 2016;139:2249&#x2013;2260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958902</ArticleId><ArticleId IdType="pubmed">27286736</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry. 2004;61:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">14706948</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97:1284&#x2013;1298 e1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildsmith KR, et al. TAU BURDEN MEASURED USING [18F]GTP1 CORRELATES WITH CSF TAU PHOSPHORYLATION AT SITES T217 AND T205 MORE CLOSELY THAN T181. Alzheimer&#x2019;s Dement.: J. Alzheimer&#x2019;s Assoc. 2018;14:1059&#x2013;1060.</Citation></Reference><Reference><Citation>Ossenkoppele R, et al. Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92:e601&#x2013;e612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382060</ArticleId><ArticleId IdType="pubmed">30626656</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320:1151&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74:1492&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822196</ArticleId><ArticleId IdType="pubmed">29114726</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CF, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer&#x2019;s disease. Alzheimers Dement. 2013;9:666&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol. Commun. 2016;4:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4906968</ArticleId><ArticleId IdType="pubmed">27296779</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie, M. et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 78, 787&#x2013;800 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander K, et al. Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer&#x2019;s disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016;12:1116&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">26892233</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith Ruben, Wibom Moa, Pawlik Daria, Englund Elisabet, Hansson Oskar. Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology. JAMA Neurology. 2019;76(3):310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439731</ArticleId><ArticleId IdType="pubmed">30508025</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng-Fischhofer Q, et al. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur. J. Biochem. 1998;252:542&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem. 2007;282:23645&#x2013;23654.</Citation><ArticleIdList><ArticleId IdType="pubmed">17562708</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida H, Goedert M. Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope. J. Neurochem. 2006;99:154&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987243</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Crowther RA, Goedert M. Comparison of the neurofibrillary pathology in Alzheimer&#x2019;s disease and familial presenile dementia with tangles. Acta Neuropathol. 1996;92:42&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">8811124</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer&#x2019;s disease. Trends Pharm. Sci. 2015;36:297&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">25840462</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy, N. R. et al. Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-&#x3b2; pathology. bioRxiv, 10.1101/226977 (2017).</Citation></Reference><Reference><Citation>Hansson O, et al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer&#x2019;s disease diagnosis: a review. Alzheimers Dement. 2018;14:1313&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pubmed">29940161</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:1505&#x2013;1521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10013957</ArticleId><ArticleId IdType="pubmed">30316776</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 1999;56:33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9923759</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M, et al. Clinical diagnostic criteria for dementia associated with Parkinson&#x2019;s disease. Mov. Disord. 2007;22:1689&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">17542011</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710059</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology. 1999;53:902&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang, A. E., Riley D. E., Bergeron C. Cortical-basal ganglionic degeneration. in Neurodegenerative Diseases (ed. Calne D. B.). (W.B. Saunders, 1994).</Citation></Reference><Reference><Citation>Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig LS, et al. Trial of Solanezumab for mild dementia due to Alzheimer&#x2019;s disease. N. Engl. J. Med. 2018;378:321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">29365294</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71:1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn A, et al. Modeling strategies for quantification of in vivo (18)F-AV-1451 binding in patients with Tau pathology. J. Nucl. Med. 2017;58:623&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">27765859</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer&#x2019;s disease. Neuroimage. 2017;157:448&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann. Neurol. 2016;80:247&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DC. A population-average, landmark- and surface-based (PALS) atlas of human cerebral cortex. Neuroimage. 2005;28:635&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">16172003</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 2017;8:1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663717</ArticleId><ArticleId IdType="pubmed">29089479</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Accurate risk estimation of beta-amyloid positivity to identify prodromal Alzheimer&#x2019;s disease: cross-validation study of practical algorithms. Alzheimers Dement. 2019;15:194&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6374284</ArticleId><ArticleId IdType="pubmed">30365928</ArticleId></ArticleIdList></Reference><Reference><Citation>Southekal S, et al. Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity. J. Nucl. Med. 2018;59:944&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pubmed">29191858</ArticleId></ArticleIdList></Reference><Reference><Citation>Devous MD, Sr., et al. Test-retest reproducibility for the Tau PET imaging agent Flortaucipir F 18. J. Nucl. Med. 2018;59:937&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">29284675</ArticleId></ArticleIdList></Reference><Reference><Citation>Team, R. C. R.: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, 2014). http://www.R-project.org/.</Citation></Reference><Reference><Citation>Rosner B, Wang W, Eliassen H, Hibert E. Comparison of dependent pearson and spearman correlation coefficients with and without correction for measurement error. J. Biom. Biostat. 2015;6:1&#x2013;9.</Citation></Reference><Reference><Citation>Robin X, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 2011;12:77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Benaglia T, Chauveau D, Hunter DR, Young D. S. mixtools: an R package for analyzing finite mixture models. J. Stat. Softw. 2009;32:1&#x2013;29.</Citation></Reference><Reference><Citation>Triana-Baltzer, G., et al. Development and validation of a high sensitivity assay for measuring p217+Tau in CSF. J. Alzheimers Dis.62, 737&#x2013;744 (2018)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158165</ArticleId><ArticleId IdType="pubmed">34095436</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32250387</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.</ArticleTitle><Pagination><StartPage>735</StartPage><EndPage>745</EndPage><MedlinePgn>735-745</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.0387</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The Anti-Amyloid Treatment in Asymptomatic Alzheimer disease (A4) Study is an ongoing prevention trial in clinically normal older individuals with evidence of elevated brain amyloid. The large number of participants screened with amyloid positron emission tomography (PET) and standardized assessments provides an unprecedented opportunity to evaluate factors associated with elevated brain amyloid.</AbstractText><AbstractText Label="OBJECTIVE">To investigate the association of elevated amyloid with demographic and lifestyle factors, apolipoprotein E (APOE), neuropsychological testing, and self- and study partner reports of cognitive function.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study included screening data in the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease (A4) Study collected from April 2014 to December 2017 and classified by amyloid status. Data were was analyzed from 2018 to 2019 across 67 sites in the US, Canada, Australia, and Japan and included 4486 older individuals (age 65-85 years) who were eligible for amyloid PET (clinically normal [Clinical Dementia Rating&#x2009;=&#x2009;0] and cognitively unimpaired [Mini-Mental State Examination score, &#x2265;25; logical memory IIa 6-18]).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Screening demographics, lifestyle variables, APOE genotyping, and cognitive testing (Preclinical Alzheimer Cognitive Composite), self- and study partner reports of high-level daily cognitive function (Cognitive Function Index). Florbetapir amyloid PET imaging was used to classify participants as having elevated amyloid (A&#x3b2;+) or not having elevated amyloid (A&#x3b2;-).</AbstractText><AbstractText Label="RESULTS">Amyloid PET results were acquired for 4486 participants (mean [SD] age, 71.29 [4.67] years; 2647 women [59%]), with 1323 (29.5%) classified as A&#x3b2;+. A&#x3b2;+ participants were slightly older than A&#x3b2;-, with no observed differences in sex, education, marital or retirement status, or any self-reported lifestyle factors. A&#x3b2;+ participants were more likely to have a family history of dementia (3320 A&#x3b2;+ [74%] vs 3050 A&#x3b2;- [68%]) and at least 1 APOE &#x3b5;4 allele (2602 A&#x3b2;+ [58%] vs 1122 A&#x3b2;- [25%]). A&#x3b2;+ participants demonstrated worse performance on screening Preclinical Alzheimer Cognitive Composite results and reported higher change scores on the Cognitive Function Index.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Among a large group of older individuals screening for an Alzheimer disease (AD) prevention trial, elevated brain amyloid was associated with family history and APOE &#x3b5;4 allele but not with multiple other previously reported risk factors for AD. Elevated amyloid was associated with lower test performance results and increased reports of subtle recent declines in daily cognitive function. These results support the hypothesis that elevated amyloid represents an early stage in the Alzheimer continuum and demonstrate the feasibility of enrolling these high-risk participants in secondary prevention trials aimed at slowing cognitive decline during the preclinical stages of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Rema</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Chung-Kai</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaari</LastName><ForeName>Roy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Eli Lilly &amp; Co, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holdridge</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Eli Lilly &amp; Co, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siemers</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Eli Lilly &amp; Co, Indianapolis, Indiana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Siemers Integration LLC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>A4 Study Team</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG063689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Sperling reported grant support from the National Institutes of Health (NIH), Eli Lilly, Alzheimer's Association, GHR Foundation, Fidelity, and Gates Ventures; nonfinancial support from CogState, and Mount Sinai; grants and personal fees from Janssen; and personal fees from AC Immune, Biogen, Neurocentria, Eisai, Roche, Takeda, and Novartis. Dr Donohue reported grants from the NIH, a spouse&#x2019;s employment with Janssen, and personal fees from Roche and Biogen. Dr Raman reported grants from the NIH, Eli Lilly, and Janssen. Dr Siemers reported being an employee of Eli Lilly from November 1998 until December 31, 2017; consulting fees from Acelot, Acumen Pharmaceuticals, Aquestive Therapeutics, Athira Pharma Inc, Biogen, Cogstate, Cortexyme, Gates Ventures LLC, Hoffman La-Roche, Indiana University, LuMind Research Down Syndrome Foundation, Partner Therapeutics, Pinteon Therapeutics, Prothena, Servier, Sangamo Therapeutics, Takeda Development Center Americas, Vaccinex, Washington University (St. Louis), and Weston Foundation; being a shareholder in Eli Lilly; and owning stock options in Acumen Pharmaceuticals. Dr Johnson reported grants from the NIH and Lilly and personal fees from AC Immune, Novartis, Janssen, and Takeda. Dr Aisen reported grants from Lilly and personal fees from Merck, Roche, Biogen, ImmunoBrain Checkpoint, and Samus. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32250387</ArticleId><ArticleId IdType="pmc">PMC7136861</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.0387</ArticleId><ArticleId IdType="pii">2763540</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45(3):358-368. doi:10.1002/1531-8249(199903)45:3&lt;358::AID-ANA12&gt;3.0.CO;2-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199903)45:3&lt;358::AID-ANA12&gt;3.0.CO;2-X</ArticleId><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280-292. doi:10.1016/j.jalz.2011.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. ; Contributors . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Maruff P, Pietrzak RH, et al. ; AIBL Research Group . Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer&#x2019;s disease. Brain. 2014;137(pt 1):221-231. doi:10.1093/brain/awt286</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt286</ArticleId><ArticleId IdType="pubmed">24176981</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Wiste HJ, Weigand SD, et al. . Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol. 2016;73(1):85-92. doi:10.1001/jamaneurol.2015.3098</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.3098</ArticleId><ArticleId IdType="pmc">PMC4710552</ArticleId><ArticleId IdType="pubmed">26595683</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Papp KV, Rentz DM, et al. . Early and late change on the preclinical Alzheimer&#x2019;s cognitive composite in clinically normal older individuals with elevated amyloid &#x3b2;. Alzheimers Dement. 2017;13(9):1004-1012. doi:10.1016/j.jalz.2017.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.01.018</ArticleId><ArticleId IdType="pmc">PMC5573651</ArticleId><ArticleId IdType="pubmed">28253478</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317(22):2305-2316. doi:10.1001/jama.2017.6669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.6669</ArticleId><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Therneau TM, et al. . Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321(23):2316-2325. doi:10.1001/jama.2019.7437</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.7437</ArticleId><ArticleId IdType="pmc">PMC6582267</ArticleId><ArticleId IdType="pubmed">31211344</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Amariglio RE, van Boxtel M, et al. ; Subjective Cognitive Decline Initiative (SCD-I) Working Group . A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer&#x2019;s disease. Alzheimers Dement. 2014;10(6):844-852. doi:10.1016/j.jalz.2014.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.01.001</ArticleId><ArticleId IdType="pmc">PMC4317324</ArticleId><ArticleId IdType="pubmed">24798886</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Buckley RF, Mormino EC, et al. . Amyloid-associated increases in longitudinal report of subjective cognitive complaints. Alzheimers Dement (N Y). 2018;4:444-449. doi:10.1016/j.trci.2018.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2018.08.005</ArticleId><ArticleId IdType="pmc">PMC6153378</ArticleId><ArticleId IdType="pubmed">30258973</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. . Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965. doi:10.1016/S1474-4422(13)70194-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70194-7</ArticleId><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Hansson O, Mackin RS, Weiner M, Mattsson N; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Amyloid pathology in the progression to mild cognitive impairment. Neurobiol Aging. 2018;64:76-84. doi:10.1016/j.neurobiolaging.2017.12.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.12.018</ArticleId><ArticleId IdType="pmc">PMC5820200</ArticleId><ArticleId IdType="pubmed">29353101</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Thomas RG, Farlow M, et al. ; Alzheimer&#x2019;s Disease Cooperative Study Steering Committee; Solanezumab Study Group . Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med. 2014;370(4):311-321. doi:10.1056/NEJMoa1312889</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1312889</ArticleId><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology. 2013;80(14):1341-1348. doi:10.1212/WNL.0b013e31828ab35d</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828ab35d</ArticleId><ArticleId IdType="pmc">PMC3656457</ArticleId><ArticleId IdType="pubmed">23547267</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13. doi:10.1126/scitranslmed.3007941</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007941</ArticleId><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkins K, Sankar P, Sperling R, et al. . Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7(1):26. doi:10.1186/s13195-015-0112-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0112-7</ArticleId><ArticleId IdType="pmc">PMC4428104</ArticleId><ArticleId IdType="pubmed">25969699</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Donohue MC, Marshall GA, et al. ; Alzheimer&#x2019;s Disease Cooperative Study . Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer&#x2019;s Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015;72(4):446-454. doi:10.1001/jamaneurol.2014.3375</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.3375</ArticleId><ArticleId IdType="pmc">PMC4397164</ArticleId><ArticleId IdType="pubmed">25706191</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Arora AK, Devine M, et al. . Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. Eur J Nucl Med Mol Imaging. 2017;44(5):825-837. doi:10.1007/s00259-016-3601-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-016-3601-4</ArticleId><ArticleId IdType="pubmed">28064343</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Sperling RA, Gidicsin CM, et al. ; AV45-A11 study group . Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer&#x2019;s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9(5)(suppl):S72-S83. doi:10.1016/j.jalz.2012.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.10.007</ArticleId><ArticleId IdType="pmc">PMC3800236</ArticleId><ArticleId IdType="pubmed">23375563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward A, Crean S, Mercaldi CJ, et al. . Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38(1):1-17. doi:10.1159/000334607</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000334607</ArticleId><ArticleId IdType="pubmed">22179327</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Walker D, Sue L, Sabbagh M, Beach T. Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett. 2010;473(3):168-171. doi:10.1016/j.neulet.2010.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.02.016</ArticleId><ArticleId IdType="pmc">PMC2851172</ArticleId><ArticleId IdType="pubmed">20153809</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Knopman DS, Lesnick TG, et al. . Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals. JAMA Neurol. 2017;74(6):718-726. doi:10.1001/jamaneurol.2017.0244</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0244</ArticleId><ArticleId IdType="pmc">PMC5649401</ArticleId><ArticleId IdType="pubmed">28418521</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider AL, Zhou Y, et al. . Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443-1450. doi:10.1001/jama.2017.3090</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.3090</ArticleId><ArticleId IdType="pmc">PMC5921896</ArticleId><ArticleId IdType="pubmed">28399252</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Mormino EC, Amariglio RE, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Australian Imaging, Biomarker and Lifestyle study of ageing; Harvard Aging Brain Study . Sex, amyloid, and APOE &#x3b5;4 and risk of cognitive decline in preclinical Alzheimer&#x2019;s disease: findings from three well-characterized cohorts. Alzheimers Dement. 2018;14(9):1193-1203. doi:10.1016/j.jalz.2018.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.04.010</ArticleId><ArticleId IdType="pmc">PMC6131023</ArticleId><ArticleId IdType="pubmed">29803541</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS, Klein H, Kirn DR, et al. . Associations of physical activity and &#x3b2;-amyloid with longitudinal cognition and neurodegeneration in clinically normal older adults. JAMA Neurol. 2019. doi:10.1001/jamaneurol.2019.1879</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1879</ArticleId><ArticleId IdType="pmc">PMC6635892</ArticleId><ArticleId IdType="pubmed">31312836</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider AL, Zhou Y, et al. . The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE. Neurology. 2016;87(5):473-480. doi:10.1212/WNL.0000000000002914</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002914</ArticleId><ArticleId IdType="pmc">PMC4970663</ArticleId><ArticleId IdType="pubmed">27371485</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahodne LB, Manly JJ, Narkhede A, et al. . Structural MRI predictors of late-life cognition differ across African Americans, Hispanics, and whites. Curr Alzheimer Res. 2015;12(7):632-639. doi:10.2174/1567205012666150530203214</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205012666150530203214</ArticleId><ArticleId IdType="pmc">PMC4872300</ArticleId><ArticleId IdType="pubmed">26027808</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Leurgans S, Aggarwal NT, et al. . Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85(6):528-534. doi:10.1212/WNL.0000000000001834</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001834</ArticleId><ArticleId IdType="pmc">PMC4540250</ArticleId><ArticleId IdType="pubmed">26180136</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Mormino EC, Schultz AP, et al. . The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019;85(2):181-193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402593</ArticleId><ArticleId IdType="pubmed">30549303</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS, Schultz AP, Hedden T, et al. . Interactive associations of vascular risk and &#x3b2;-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the Harvard Aging Brain Study. JAMA Neurol. 2018;75(9):1124-1131. doi:10.1001/jamaneurol.2018.1123</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.1123</ArticleId><ArticleId IdType="pmc">PMC6143121</ArticleId><ArticleId IdType="pubmed">29799986</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Knopman DS, et al. . Amyloid, vascular, and resilience pathways associated with cognitive aging. Ann Neurol. 2019;86(6):866-877. doi:10.1002/ana.25600</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25600</ArticleId><ArticleId IdType="pmc">PMC6899909</ArticleId><ArticleId IdType="pubmed">31509621</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldan A, Pettigrew C, Fagan AM, et al. . ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology. 2019;92(14):e1567-e1579. doi:10.1212/WNL.0000000000007248</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007248</ArticleId><ArticleId IdType="pmc">PMC6448449</ArticleId><ArticleId IdType="pubmed">30842300</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. ; Amyloid Biomarker Study Group . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938. doi:10.1001/jama.2015.4668</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age-specific and sex-specific prevalence of cerebral &#x3b2;-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017;16(6):435-444. doi:10.1016/S1474-4422(17)30077-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30077-7</ArticleId><ArticleId IdType="pmc">PMC5516534</ArticleId><ArticleId IdType="pubmed">28456479</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Epelbaum S, Nyasse F, et al. ; INSIGHT-preAD study group . Cognitive and neuroimaging features and brain &#x3b2;-amyloidosis in individuals at risk of Alzheimer&#x2019;s disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 2018;17(4):335-346. doi:10.1016/S1474-4422(18)30029-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30029-2</ArticleId><ArticleId IdType="pubmed">29500152</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32255447</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2040-3372</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>15</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>21</Day></PubDate></JournalIssue><Title>Nanoscale</Title><ISOAbbreviation>Nanoscale</ISOAbbreviation></Journal><ArticleTitle>Real-time nanoscale organization of amyloid precursor protein.</ArticleTitle><Pagination><StartPage>8200</StartPage><EndPage>8215</EndPage><MedlinePgn>8200-8215</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d0nr00052c</ELocationID><Abstract><AbstractText>Despite an intuitive understanding of the role of APP in health and disease, there exist few attempts to dissect its molecular localization at excitatory synapses. Though the biochemistry involved in the enzymatic processing of APP is well understood, there is a void in understanding the nonuniformity of the product formation in vivo. Here, we employed multiple paradigms of single molecules and ensemble based nanoscopic imaging to reveal that APP molecules are organized into regulatory nanodomains that are differentially compartmentalized in the functional zones of an excitatory synapse. Furthermore, with the aid of high density single particle tracking, we show that the lateral diffusion of APP in live cells dictates an equilibrium between these nanodomains and their nano-environment, which is affected in a detrimental variant of APP. Additionally, we incorporate this spatio-temporal detail 'in silico' to generate a realistic nanoscale topography of APP in dendrites and synapses. This approach uncovers a nanoscale heterogeneity in the molecular organization of APP, depicting a locus for differential APP processing. This holistic paradigm, to decipher the real-time heterogeneity of the substrate molecules on the nanoscale, could enable us to better evaluate the molecular constraints overcoming the ensemble approaches used traditionally to understand the kinetics of product formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kedia</LastName><ForeName>Shekhar</ForeName><Initials>S</Initials><Suffix/><AffiliationInfo><Affiliation>Centre for Neuroscience, Indian Institute of Science, Bangalore 560012, India. deepak@iisc.ac.in.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramakrishna</LastName><ForeName>Pratyush</ForeName><Initials>P</Initials><Suffix/></Author><Author ValidYN="Y"><LastName>Netrakanti</LastName><ForeName>Pallavi Rao</ForeName><Initials>PR</Initials><Suffix/></Author><Author ValidYN="Y"><LastName>Jose</LastName><ForeName>Mini</ForeName><Initials>M</Initials><Suffix/></Author><Author ValidYN="Y"><LastName>Sibarita</LastName><ForeName>Jean-Baptiste</ForeName><Initials>JB</Initials><Suffix/></Author><Author ValidYN="Y"><LastName>Nadkarni</LastName><ForeName>Suhita</ForeName><Initials>S</Initials><Suffix/></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Deepak</ForeName><Initials>D</Initials><Suffix/></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nanoscale</MedlineTA><NlmUniqueID>101525249</NlmUniqueID><ISSNLinking>2040-3364</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072760" MajorTopicYN="N">Single Molecule Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32255447</ArticleId><ArticleId IdType="doi">10.1039/d0nr00052c</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32282020</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.</ArticleTitle><Pagination><StartPage>849</StartPage><EndPage>862</EndPage><MedlinePgn>849-862</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.0414</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Identification of genetic factors that interact with the apolipoprotein e4 (APOE4) allele to reduce risk for Alzheimer disease (AD) would accelerate the search for new AD drug targets. Klotho-VS heterozygosity (KL-VSHET+ status) protects against aging-associated phenotypes and cognitive decline, but whether it protects individuals who carry APOE4 from AD remains unclear.</AbstractText><AbstractText Label="OBJECTIVES">To determine if KL-VSHET+ status is associated with reduced AD risk and &#x3b2;-amyloid (A&#x3b2;) pathology in individuals who carry APOE4.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This study combined 25 independent case-control, family-based, and longitudinal AD cohorts that recruited referred and volunteer participants and made data available through public repositories. Analyses were stratified by APOE4 status. Three cohorts were used to evaluate conversion risk, 1 provided longitudinal measures of A&#x3b2; CSF and PET, and 3 provided cross-sectional measures of A&#x3b2; CSF. Genetic data were available from high-density single-nucleotide variant microarrays. All data were collected between September 2015 and September 2019 and analyzed between April 2019 and December 2019.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The risk of AD was evaluated through logistic regression analyses under a case-control design. The risk of conversion to mild cognitive impairment (MCI) or AD was evaluated through competing risks regression. Associations with A&#x3b2;, measured from cerebrospinal fluid (CSF) or brain positron emission tomography (PET), were evaluated using linear regression and mixed-effects modeling.</AbstractText><AbstractText Label="RESULTS">Of 36&#x202f;530 eligible participants, 13&#x202f;782 were excluded for analysis exclusion criteria or refusal to participate. Participants were men and women aged 60 years and older who were non-Hispanic and of Northwestern European ancestry and had been diagnosed as being cognitively normal or having MCI or AD. The sample included 20&#x202f;928 participants in case-control studies, 3008 in conversion studies, 556 in A&#x3b2; CSF regression analyses, and 251 in PET regression analyses. The genotype KL-VSHET+ was associated with reduced risk for AD in individuals carrying APOE4 who were 60 years or older (odds ratio, 0.75 [95% CI, 0.67-0.84]; P&#x2009;=&#x2009;7.4&#x2009;&#xd7;&#x2009;10-7), and this was more prominent at ages 60 to 80 years (odds ratio, 0.69 [95% CI, 0.61-0.79]; P&#x2009;=&#x2009;3.6&#x2009;&#xd7;&#x2009;10-8). Additionally, control participants carrying APOE4 with KL-VS heterozygosity were at reduced risk of converting to MCI or AD (hazard ratio, 0.64 [95% CI, 0.44-0.94]; P&#x2009;=&#x2009;.02). Finally, in control participants who carried APOE4 and were aged 60 to 80 years, KL-VS heterozygosity was associated with higher A&#x3b2; in CSF (&#x3b2;, 0.06 [95% CI, 0.01-0.10]; P&#x2009;=&#x2009;.03) and lower A&#x3b2; on PET scans (&#x3b2;, -0.04 [95% CI, -0.07 to -0.00]; P&#x2009;=&#x2009;.04).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The genotype KL-VSHET+ is associated with reduced AD risk and A&#x3b2; burden in individuals who are aged 60 to 80 years, cognitively normal, and carrying APOE4. Molecular pathways associated with KL merit exploration for novel AD drug targets. The KL-VS genotype should be considered in conjunction with the APOE genotype to refine AD prediction models used in clinical trial enrichment and personalized genetic counseling.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Belloy</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Functional Imaging in Neuropsychiatric Disorders (FIND) Lab, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Napolioni</LastName><ForeName>Valerio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Functional Imaging in Neuropsychiatric Disorders (FIND) Lab, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Summer S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Stanford University, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quantitative Sciences Unit, Stanford Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Guen</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Functional Imaging in Neuropsychiatric Disorders (FIND) Lab, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greicius</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Functional Imaging in Neuropsychiatric Disorders (FIND) Lab, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG060747</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D005966">Glucuronidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D000090265">Klotho Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2020 Jul 1;77(7):798-800. doi: 10.1001/jamaneurol.2020.0112.</RefSource><PMID Version="1">32282012</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005966" MajorTopicYN="N">Glucuronidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090265" MajorTopicYN="N">Klotho Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None
reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32282020</ArticleId><ArticleId IdType="pmc">PMC7154955</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.0414</ArticleId><ArticleId IdType="pii">2763599</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kurosu H, Yamamoto M, Clark JD, et al. . Suppression of aging in mice by the hormone Klotho. Science. 2005;309(5742):1829-1833. doi:10.1126/science.1112766</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1112766</ArticleId><ArticleId IdType="pmc">PMC2536606</ArticleId><ArticleId IdType="pubmed">16123266</ArticleId></ArticleIdList></Reference><Reference><Citation>Arking DE, Krebsova A, Macek M Sr, et al. . Association of human aging with a functional variant of klotho. Proc Natl Acad Sci U S A. 2002;99(2):856-861. doi:10.1073/pnas.022484299</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.022484299</ArticleId><ArticleId IdType="pmc">PMC117395</ArticleId><ArticleId IdType="pubmed">11792841</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Yokoyama JS, Zhu L, et al. . Life extension factor klotho enhances cognition. Cell Rep. 2014;7(4):1065-1076. doi:10.1016/j.celrep.2014.03.076</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.076</ArticleId><ArticleId IdType="pmc">PMC4176932</ArticleId><ArticleId IdType="pubmed">24813892</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama JS, Sturm VE, Bonham LW, et al. . Variation in longevity gene KLOTHO is associated with greater cortical volumes. Ann Clin Transl Neurol. 2015;2(3):215-230. doi:10.1002/acn3.161</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.161</ArticleId><ArticleId IdType="pmc">PMC4369272</ArticleId><ArticleId IdType="pubmed">25815349</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries CF, Staff RT, Harris SE, et al. . Klotho, APOE&#x3b5;4, cognitive ability, brain size, atrophy, and survival: a study in the Aberdeen Birth Cohort of 1936. Neurobiol Aging. 2017;55:91-98. doi:10.1016/j.neurobiolaging.2017.02.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.02.019</ArticleId><ArticleId IdType="pubmed">28431289</ArticleId></ArticleIdList></Reference><Reference><Citation>Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer&#x2019;s disease: progress to date and the path forward. Neuron. 2019;101(5):820-838. doi:10.1016/j.neuron.2019.01.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.056</ArticleId><ArticleId IdType="pmc">PMC6407643</ArticleId><ArticleId IdType="pubmed">30844401</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. . Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512-519. doi:10.1002/ana.20730</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20730</ArticleId><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. . APOE predicts amyloid-&#x3b2; but not tau Alzheimer&#x2019;s pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122-131. doi:10.1002/ana.21843</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21843</ArticleId><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185. doi:10.1126/science.1566067</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1566067</ArticleId><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216. doi:10.1016/S1474-4422(12)70291-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC, Bourgeat P, Dor&#xe9; V, et al. ; AIBL Research Group . Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer&#x2019;s disease pathophysiology (SNAP) or Alzheimer&#x2019;s disease pathology: a longitudinal study. Lancet Neurol. 2016;15(10):1044-1053. doi:10.1016/S1474-4422(16)30125-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30125-9</ArticleId><ArticleId IdType="pubmed">27450471</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJB, Xiong C, Visser PJ, et al. . Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965. doi:10.1016/S1474-4422(13)70194-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70194-7</ArticleId><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Zetterberg H, van Harten AC, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Alzheimer&#x2019;s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain. 2015;138(pt 9):2701-2715. doi:10.1093/brain/awv199</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv199</ArticleId><ArticleId IdType="pmc">PMC4643624</ArticleId><ArticleId IdType="pubmed">26220940</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutphen CL, Jasielec MS, Shah AR, et al. . Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol. 2015;72(9):1029-1042. doi:10.1001/jamaneurol.2015.1285</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1285</ArticleId><ArticleId IdType="pmc">PMC4570860</ArticleId><ArticleId IdType="pubmed">26147946</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. ; Amyloid PET Study Group . Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939-1949. doi:10.1001/jama.2015.4669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4669</ArticleId><ArticleId IdType="pmc">PMC4517678</ArticleId><ArticleId IdType="pubmed">25988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Kalinowski P, Pietrzak RH, et al. . Association of &#x3b2;-amyloid and apolipoprotein E &#x3b5;4 with memory decline in preclinical Alzheimer disease. JAMA Neurol. 2018;75(4):488-494. doi:10.1001/jamaneurol.2017.4325</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.4325</ArticleId><ArticleId IdType="pmc">PMC5933393</ArticleId><ArticleId IdType="pubmed">29356823</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu SC, Pa J, Kukull W, et al. . Apolipoprotein E genotype and sex risk factors for alzheimer disease: a meta-analysis. JAMA Neurol. 2017;74(10):1178-1189. doi:10.1001/jamaneurol.2017.2188</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2188</ArticleId><ArticleId IdType="pmc">PMC5759346</ArticleId><ArticleId IdType="pubmed">28846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356. doi:10.1001/jama.1997.03550160069041</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03550160069041</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Bickeb&#xf6;ller H, Campion D, Brice A, et al. . Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet. 1997;60(2):439-446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1712413</ArticleId><ArticleId IdType="pubmed">9012418</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer&#x2019;s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698-712. doi:10.1038/nrd3505</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3505</ArticleId><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson CM, Schultz SA, Oh JM, et al. . KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD. Neurology. 2019;92(16):e1878-e1889. doi:10.1212/WNL.0000000000007323</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007323</ArticleId><ArticleId IdType="pmc">PMC6550504</ArticleId><ArticleId IdType="pubmed">30867273</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter T, Burnham SC, Milicic L, et al. . Klotho allele status is not associated with A&#x3b2; and APOE &#x3b5;4-related cognitive decline in preclinical Alzheimer&#x2019;s disease. Neurobiol Aging. 2019;76:162-165. doi:10.1016/j.neurobiolaging.2018.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.12.014</ArticleId><ArticleId IdType="pubmed">30716541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo MT, Kauppi K, Fan CC, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium . Identification of genetic heterogeneity of Alzheimer&#x2019;s disease across age. Neurobiol Aging. 2019;84:243.e1-243.e9. doi:10.1016/j.neurobiolaging.2019.02.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.02.022</ArticleId><ArticleId IdType="pmc">PMC6783343</ArticleId><ArticleId IdType="pubmed">30979435</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Aisen PS, Jack CR Jr, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . The Alzheimer&#x2019;s disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010;6(3):202-11.e7. doi:10.1016/j.jalz.2010.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.03.007</ArticleId><ArticleId IdType="pmc">PMC2927112</ArticleId><ArticleId IdType="pubmed">20451868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res. 2012;9(6):646-663. doi:10.2174/156720512801322663</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322663</ArticleId><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Graff-Radford N, Foroud T, Mayeux R; National Institute on Aging Late-Onset Alzheimer&#x2019;s Disease Family Study Group . Analyses of the National Institute on Aging Late-Onset Alzheimer&#x2019;s Disease Family Study: implication of additional loci. Arch Neurol. 2008;65(11):1518-1526. doi:10.1001/archneur.65.11.1518</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.11.1518</ArticleId><ArticleId IdType="pmc">PMC2694670</ArticleId><ArticleId IdType="pubmed">19001172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Minster RL, Demirci FY, et al. . Association of CLU and PICALM variants with Alzheimer&#x2019;s disease. Neurobiol Aging. 2012;33(3):518-521. doi:10.1016/j.neurobiolaging.2010.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.04.015</ArticleId><ArticleId IdType="pmc">PMC3010357</ArticleId><ArticleId IdType="pubmed">20570404</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Hayes J, et al. ; Department of Defense Alzheimer&#x2019;s Disease Neuroimaging Initiative . Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer&#x2019;s disease in veterans, using the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimers Dement. 2014;10(3)(suppl):S226-S235. doi:10.1016/j.jalz.2014.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.04.005</ArticleId><ArticleId IdType="pmc">PMC4392759</ArticleId><ArticleId IdType="pubmed">24924673</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wetten S, Li L, et al. . Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol. 2008;65(1):45-53. doi:10.1001/archneurol.2007.3</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2007.3</ArticleId><ArticleId IdType="pubmed">17998437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovestone S, Francis P, Kloszewska I, et al. . AddNeuroMed Consortium. AddNeuroMed&#x2014;the European collaboration for the discovery of novel biomarkers for Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2009;1180:36-46. doi:10.1111/j.1749-6632.2009.05064.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.05064.x</ArticleId><ArticleId IdType="pubmed">19906259</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Carrasquillo MM, Funk C, et al. . Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Sci Data. 2016;3:160089. doi:10.1038/sdata.2016.89</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.89</ArticleId><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Zou F, Pankratz VS, et al. . Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer&#x2019;s disease. Nat Genet. 2009;41(2):192-198. doi:10.1038/ng.305</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.305</ArticleId><ArticleId IdType="pmc">PMC2873177</ArticleId><ArticleId IdType="pubmed">19136949</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser L, Kukull W, Knopman DS, et al. ; Neuropsychology Work Group . Directors, and Clinical Core leaders of the National Institute on Aging-funded US Alzheimer&#x2019;s Disease Centers. Version 3 of the national Alzheimer&#x2019;s coordinating center&#x2019;s uniform data set. Alzheimer Dis Assoc Disord. 2018;32(4):351-358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6249084</ArticleId><ArticleId IdType="pubmed">30376508</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et al. . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):436-441. doi:10.1038/ng.801</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Martin ER, Li YJ, et al. . Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009;84(1):35-43. doi:10.1016/j.ajhg.2008.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2008.12.008</ArticleId><ArticleId IdType="pmc">PMC2668056</ArticleId><ArticleId IdType="pubmed">19118814</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukull WA, Higdon R, Bowen JD, et al. . Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59(11):1737-1746. doi:10.1001/archneur.59.11.1737</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.11.1737</ArticleId><ArticleId IdType="pubmed">12433261</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Cupples LA, Go R, et al. ; MIRAGE Study Group . Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287(3):329-336. doi:10.1001/jama.287.3.329</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.287.3.329</ArticleId><ArticleId IdType="pubmed">11790212</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, et al. ; Alzheimer Disease Genetics Consortium (ADGC) . European Alzheimer&#x2019;s Disease Initiative (EADI); Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE); Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer&#x2019;s Disease Consortium (GERAD/PERADES). Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414-430. doi:10.1038/s41588-019-0358-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413. doi:10.1002/ana.21610</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21610</ArticleId><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Bandy D, Chen K, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . The Alzheimer&#x2019;s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6(3):221-229. doi:10.1016/j.jalz.2010.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.03.003</ArticleId><ArticleId IdType="pmc">PMC2920531</ArticleId><ArticleId IdType="pubmed">20451870</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207-1218. doi:10.1016/j.neurobiolaging.2009.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.07.002</ArticleId><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578-586. doi:10.1002/ana.23650</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23650</ArticleId><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Kauwe JSK, Harari O, et al. . GERAD Consortium; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetic Consortium (ADGC). GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer&#x2019;s disease. Neuron. 2013;78(2):256-268. doi:10.1016/j.neuron.2013.02.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.026</ArticleId><ArticleId IdType="pmc">PMC3664945</ArticleId><ArticleId IdType="pubmed">23562540</ArticleId></ArticleIdList></Reference><Reference><Citation>Auton A, Brooks LD, Durbin RM, et al. . 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526(7571):68-74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Pollack S, Hunter DJ, Hirschhorn JN, Kraft P, Price AL. Improved ancestry inference using weights from external reference panels. Bioinformatics. 2013;29(11):1399-1406. doi:10.1093/bioinformatics/btt144</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt144</ArticleId><ArticleId IdType="pmc">PMC3661048</ArticleId><ArticleId IdType="pubmed">23539302</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, Forer L, Sch&#xf6;nherr S, et al. . Next-generation genotype imputation service and methods. Nat Genet. 2016;48(10):1284-1287. doi:10.1038/ng.3656</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3656</ArticleId><ArticleId IdType="pmc">PMC5157836</ArticleId><ArticleId IdType="pubmed">27571263</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509. doi:10.1080/01621459.1999.10474144</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1999.10474144</ArticleId></ArticleIdList></Reference><Reference><Citation>Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant. 2010;45(9):1388-1395. doi:10.1038/bmt.2009.359</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2009.359</ArticleId><ArticleId IdType="pubmed">20062101</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJB, Verhey F, Fr&#xf6;lich L, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Prevalence and prognosis of Alzheimer&#x2019;s disease at the mild cognitive impairment stage. Brain. 2015;138(Pt 5):1327-1338. doi:10.1093/brain/awv029</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv029</ArticleId><ArticleId IdType="pmc">PMC5013930</ArticleId><ArticleId IdType="pubmed">25693589</ArticleId></ArticleIdList></Reference><Reference><Citation>Belleville S, Fouquet C, Hudon C, Zomahoun HTV, Croteau J. Consortium for the Early Identification of Alzheimer&#x2019;s disease-Quebec. Neuropsychological measures that predict progression from mild cognitive impairment to Alzheimer&#x2019;s type dementia in older adults: a systematic review and meta-analysis. Neuropsychol Rev. 2017;27(4):328-353. doi:10.1007/s11065-017-9361-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11065-017-9361-5</ArticleId><ArticleId IdType="pmc">PMC5754432</ArticleId><ArticleId IdType="pubmed">29019061</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Reisberg B, Zaudig M, et al. . International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet. 2006;367(9518):1262-1270. doi:10.1016/S0140-6736(06)68542-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)68542-5</ArticleId><ArticleId IdType="pubmed">16631882</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama JS, Marx G, Brown JA, et al. . Systemic klotho is associated with KLOTHO variation and predicts intrinsic cortical connectivity in healthy human aging. Brain Imaging Behav. 2017;11(2):391-400. doi:10.1007/s11682-016-9598-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-016-9598-2</ArticleId><ArticleId IdType="pmc">PMC5382127</ArticleId><ArticleId IdType="pubmed">27714549</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Ibrahim-Verbaas CA, Vronskaya M, et al. . IGAP Consortium. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry. 2016;21(1):108-117. doi:10.1038/mp.2015.23</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.23</ArticleId><ArticleId IdType="pmc">PMC4573764</ArticleId><ArticleId IdType="pubmed">25778476</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve in ageing and Alzheimer&#x2019;s disease. Lancet Neurol. 2012;11(11):1006-1012. doi:10.1016/S1474-4422(12)70191-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70191-6</ArticleId><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, Harris SE, Fox HC, et al. . KLOTHO genotype and cognitive ability in childhood and old age in the same individuals. Neurosci Lett. 2005;378(1):22-27. doi:10.1016/j.neulet.2004.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2004.12.005</ArticleId><ArticleId IdType="pubmed">15763166</ArticleId></ArticleIdList></Reference><Reference><Citation>van Maurik IS, Vos SJ, Bos I, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol. 2019;18(11):1034-1044. doi:10.1016/S1474-4422(19)30283-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30283-2</ArticleId><ArticleId IdType="pubmed">31526625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Atri A, Boneva N, et al. . Enrichment factors for clinical trials in mild-to-moderate Alzheimer&#x2019;s disease. Alzheimers Dement (N Y). 2019;5:164-174. doi:10.1016/j.trci.2019.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2019.04.001</ArticleId><ArticleId IdType="pmc">PMC6527908</ArticleId><ArticleId IdType="pubmed">31193334</ArticleId></ArticleIdList></Reference><Reference><Citation>Semba RD, Moghekar AR, Hu J, et al. . Klotho in the cerebrospinal fluid of adults with and without Alzheimer&#x2019;s disease. Neurosci Lett. 2014;558:37-40. doi:10.1016/j.neulet.2013.10.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.10.058</ArticleId><ArticleId IdType="pmc">PMC4037850</ArticleId><ArticleId IdType="pubmed">24211693</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wang B, Wang Z, et al. . Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci U S A. 2010;107(40):17362-17367. doi:10.1073/pnas.1012568107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1012568107</ArticleId><ArticleId IdType="pmc">PMC2951422</ArticleId><ArticleId IdType="pubmed">20855613</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer&#x2019;s disease. Annu Rev Neurosci. 2011;34:185-204. doi:10.1146/annurev-neuro-061010-113613</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-061010-113613</ArticleId><ArticleId IdType="pmc">PMC3174086</ArticleId><ArticleId IdType="pubmed">21456963</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C-D, Podvin S, Gillespie E, Leeman SE, Abraham CR. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A. 2007;104(50):19796-19801. doi:10.1073/pnas.0709805104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0709805104</ArticleId><ArticleId IdType="pmc">PMC2148378</ArticleId><ArticleId IdType="pubmed">18056631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch L, Sineshchekova O, Reichenbach D, et al. . Klotho is a substrate for &#x3b1;-, &#x3b2;- and &#x3b3;-secretase. FEBS Lett. 2009;583(19):3221-3224. doi:10.1016/j.febslet.2009.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2009.09.009</ArticleId><ArticleId IdType="pmc">PMC2757472</ArticleId><ArticleId IdType="pubmed">19737556</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng CY, Yang TT, Zhou HJ, et al. . Lentiviral vector-mediated overexpression of Klotho in the brain improves Alzheimer&#x2019;s disease-like pathology and cognitive deficits in mice. Neurobiol Aging. 2019;78:18-28. doi:10.1016/j.neurobiolaging.2019.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.02.003</ArticleId><ArticleId IdType="pubmed">30851437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuang X, Zhou HJ, Thorne AH, Chen XN, Li LJ, Du JR. Neuroprotective effect of ligustilide through induction of &#x3b1;-secretase processing of both APP and Klotho in a mouse model of Alzheimer&#x2019;s disease. Front Aging Neurosci. 2017;9:353. doi:10.3389/fnagi.2017.00353</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00353</ArticleId><ArticleId IdType="pmc">PMC5673635</ArticleId><ArticleId IdType="pubmed">29163135</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Zhu L, Sanchez PE, et al. . Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. J Neurosci. 2015;35(6):2358-2371. doi:10.1523/JNEUROSCI.5791-12.2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5791-12.2015</ArticleId><ArticleId IdType="pmc">PMC4323521</ArticleId><ArticleId IdType="pubmed">25673831</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham CR, Mullen PC, Tucker-Zhou T, Chen CD, Zeldich E. Klotho is a neuroprotective and cognition-enhancing protein. Vitam Horm. 2016;101:215-238. doi:10.1016/bs.vh.2016.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.vh.2016.02.004</ArticleId><ArticleId IdType="pubmed">27125744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf EJ, Morrison FG, Sullivan DR, et al. . The goddess who spins the thread of life: Klotho, psychiatric stress, and accelerated aging. Brain Behav Immun. 2019;80:193-203. doi:10.1016/j.bbi.2019.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2019.03.007</ArticleId><ArticleId IdType="pmc">PMC6660403</ArticleId><ArticleId IdType="pubmed">30872092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah M, Sun Z. Klotho deficiency accelerates stem cells aging by impairing telomerase activity. J Gerontol A Biol Sci Med Sci. 2019;74(9):1396-1407. doi:10.1093/gerona/gly261</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/gly261</ArticleId><ArticleId IdType="pmc">PMC6696722</ArticleId><ArticleId IdType="pubmed">30452555</ArticleId></ArticleIdList></Reference><Reference><Citation>Invidia L, Salvioli S, Altilia S, et al. . The frequency of Klotho KL-VS polymorphism in a large Italian population, from young subjects to centenarians, suggests the presence of specific time windows for its effect. Biogerontology. 2010;11(1):67-73. doi:10.1007/s10522-009-9229-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10522-009-9229-z</ArticleId><ArticleId IdType="pubmed">19421891</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32284590</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation.</ArticleTitle><Pagination><StartPage>769</StartPage><EndPage>780</EndPage><MedlinePgn>769-780</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-020-0815-6</ELocationID><Abstract><AbstractText>Our understanding of Alzheimer's disease (AD) pathophysiology remains incomplete. Here we used quantitative mass spectrometry and coexpression network analysis to conduct the largest proteomic study thus far on AD. A protein network module linked to sugar metabolism emerged as one of the modules most significantly associated with AD pathology and cognitive impairment. This module was enriched in AD genetic risk factors and in microglia and astrocyte protein markers associated with an anti-inflammatory state, suggesting that the biological functions it represents serve a protective role in AD. Proteins from this module were elevated in cerebrospinal fluid in early stages of the disease. In this study of &gt;2,000 brains and nearly 400 cerebrospinal fluid samples by quantitative proteomics, we identify proteins and biological processes in AD brains that may serve as therapeutic targets and fluid biomarkers for the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Johnson</LastName><ForeName>Erik C B</ForeName><Initials>ECB</Initials><Identifier Source="ORCID">0000-0002-0604-2944</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA. erik.c.b.johnson@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. erik.c.b.johnson@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Dammer</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0003-2947-7606</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Duc M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ping</LastName><ForeName>Lingyan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Maotian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Luming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higginbotham</LastName><ForeName>Lenora A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guajardo</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Bartholomew</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thambisetty</LastName><ForeName>Madhav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0002-4589-1180</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><Identifier Source="ORCID">0000-0002-9239-8794</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Pathology, Banner Sun Health Research Institute, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-0705-3696</Identifier><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Arizona State University and University of Arizona, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5860-2512</Identifier><AffiliationInfo><Affiliation>Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>JJ Peters VA Medical Center MIRECC, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Minghui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schadt</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7892-8808</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nil&#xfc;fer</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petyuk</LastName><ForeName>Vladislav A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-8057-2505</Identifier><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Taub Institute, Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wingo</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials><Identifier Source="ORCID">0000-0002-7679-6282</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rangaraju</LastName><ForeName>Srikant</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2765-1500</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajjar</LastName><ForeName>Ihab</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shulman</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Departments of Neurology, Neuroscience and Molecular &amp; Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurologic Research Institute, Texas Children's Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0002-3153-502X</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA. alevey@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. alevey@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nicholas T</ForeName><Initials>NT</Initials><Identifier Source="ORCID">0000-0002-4507-624X</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA. nseyfri@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. nseyfri@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA. nseyfri@emory.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053960</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051633</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG075827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057339</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057471</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061800</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054014</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG072120</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG050631</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056533</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057907</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX003853</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS114130</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061357</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061796</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057470</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS099474</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Metab. 2020 Jul 7;32(1):11-12. doi: 10.1016/j.cmet.2020.06.001.</RefSource><PMID Version="1">32640242</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="Y">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32284590</ArticleId><ArticleId IdType="mid">NIHMS1606876</ArticleId><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0815-6</ArticleId><ArticleId IdType="pii">10.1038/s41591-020-0815-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince M , et al. World Alzheimer Report 2015: The Global Impact of Dementia. (Alzheimer&#x2019;s Disease International, London, 2015).</Citation></Reference><Reference><Citation>Jack CR Jr., et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Oldham MC &amp; Geschwind DH A systems level analysis of transcriptional changes in Alzheimer&#x2019;s disease and normal aging. J Neurosci 28, 1410&#x2013;1420 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902235</ArticleId><ArticleId IdType="pubmed">18256261</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldham MC, et al. Functional organization of the transcriptome in human brain. Nat Neurosci 11, 1271&#x2013;1282 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756411</ArticleId><ArticleId IdType="pubmed">18849986</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke C, et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis 34, 2300&#x2013;2308 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23740839</ArticleId></ArticleIdList></Reference><Reference><Citation>Barabasi AL, Gulbahce N &amp; Loscalzo J Network medicine: a network-based approach to human disease. Nat Rev Genet 12, 56&#x2013;68 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140052</ArticleId><ArticleId IdType="pubmed">21164525</ArticleId></ArticleIdList></Reference><Reference><Citation>Huan T, et al. Integrative network analysis reveals molecular mechanisms of blood pressure regulation. Mol Syst Biol 11, 799 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4422556</ArticleId><ArticleId IdType="pubmed">25882670</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran LM, et al. Inferring causal genomic alterations in breast cancer using gene expression data. BMC Syst Biol 5, 121 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162519</ArticleId><ArticleId IdType="pubmed">21806811</ArticleId></ArticleIdList></Reference><Reference><Citation>Huan T, et al. A systems biology framework identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol 33, 1427&#x2013;1434 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752786</ArticleId><ArticleId IdType="pubmed">23539213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami E, Demir E, Schultz N, Taylor BS &amp; Sander C Automated network analysis identifies core pathways in glioblastoma. PLoS One 5, e8918 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820542</ArticleId><ArticleId IdType="pubmed">20169195</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Z, et al. Repositioning drugs by targeting network modules: a Parkinson&#x2019;s disease case study. BMC Bioinformatics 18, 532 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5751600</ArticleId><ArticleId IdType="pubmed">29297292</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, et al. Metabolic network failures in Alzheimer&#x2019;s disease: A biochemical road map. Alzheimers Dement 13, 965&#x2013;984 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866045</ArticleId><ArticleId IdType="pubmed">28341160</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Sun T, He Z &amp; Xiong B Identification of two novel biomarkers of rectal carcinoma progression and prognosis via co-expression network analysis. Oncotarget 8, 69594&#x2013;69609 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642502</ArticleId><ArticleId IdType="pubmed">29050227</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, et al. Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis. Oncotarget 8, 27904&#x2013;27914 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5438617</ArticleId><ArticleId IdType="pubmed">28427189</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41, 479&#x2013;486 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Woltjer RL, Goodenbour JM, Horvath S &amp; Geschwind DH Genes and pathways underlying regional and cell type changes in Alzheimer&#x2019;s disease. Genome Med 5, 48 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706780</ArticleId><ArticleId IdType="pubmed">23705665</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfried NT, et al. A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer&#x2019;s Disease. Cell Syst 4, 60&#x2013;72 e64 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269514</ArticleId><ArticleId IdType="pubmed">27989508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z &amp; Wilson RS Overview and findings from the religious orders study. Curr Alzheimer Res 9, 628&#x2013;645 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res 9, 646&#x2013;663 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology 25, 163&#x2013;175 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping L, et al. Global quantitative analysis of the human brain proteome in Alzheimer&#x2019;s and Parkinson&#x2019;s Disease. Sci Data 5, 180036 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5848788</ArticleId><ArticleId IdType="pubmed">29533394</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauniyar N &amp; Yates JR 3rd. Isobaric labeling-based relative quantification in shotgun proteomics. J Proteome Res 13, 5293&#x2013;5309 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4261935</ArticleId><ArticleId IdType="pubmed">25337643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting L, Rad R, Gygi SP &amp; Haas W MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. Nat Methods 8, 937&#x2013;940 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205343</ArticleId><ArticleId IdType="pubmed">21963607</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson AC, Russell JD, Bailey DJ, Westphall MS &amp; Coon JJ Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics 11, 1475&#x2013;1488 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3494192</ArticleId><ArticleId IdType="pubmed">22865924</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Mooij JM, Heskes T &amp; Posthuma D MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol 11, e1004219 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401657</ArticleId><ArticleId IdType="pubmed">25885710</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL, et al. Genomic analysis of reactive astrogliosis. J Neurosci 32, 6391&#x2013;6410 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangaraju S, et al. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer&#x2019;s disease. Mol Neurodegener 13, 24 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5963076</ArticleId><ArticleId IdType="pubmed">29784049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM &amp; Perry VH Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27, 119&#x2013;145 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19302036</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci 17, 131&#x2013;143 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtman IR, et al. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis. Acta Neuropathol Commun 3, 31 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489356</ArticleId><ArticleId IdType="pubmed">26001565</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR, et al. Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 50, 253&#x2013;271 e256 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M, et al. Isolation of glia from Alzheimer&#x2019;s mice reveals inflammation and dysfunction. Neurobiol Aging 35, 2746&#x2013;2760 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25002035</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, et al. Mouse and human microglial phenotypes in Alzheimer&#x2019;s disease are controlled by amyloid plaque phagocytosis through Hif1&#x3b1;. bioRxiv (2019).</Citation></Reference><Reference><Citation>Jack CR Jr., et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539&#x2013;547 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B, et al. Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer&#x2019;s Disease Progression. Neuron (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7322979</ArticleId><ArticleId IdType="pubmed">32437656</ArticleId></ArticleIdList></Reference><Reference><Citation>Higginbotham L, et al. Integrated Proteomics Reveals Brain-Based Cerebrospinal Fluid Biomarkers in Asymptomatic and Symptomatic Alzheimer&#x2019;s Disease. bioRxiv (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577712</ArticleId><ArticleId IdType="pubmed">33087358</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, et al. Deep proteomic network analysis of Alzheimer&#x2019;s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Mol Neurodegener 13, 52 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6172707</ArticleId><ArticleId IdType="pubmed">30286791</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo AP, et al. Cerebral atherosclerosis contributes to Alzheimer&#x2019;s dementia independently of its hallmark amyloid and tau pathologies. bioRxiv (2019).</Citation></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med 368, 107&#x2013;116 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916&#x2013;919 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920&#x2013;924 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S, Izzy S, Sen P, Morsett L &amp; El Khoury J Microglia in neurodegeneration. Nat Neurosci 21, 1359&#x2013;1369 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, et al. Identification of conserved proteomic networks in neurodegenerative dementia. bioRxiv (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221021</ArticleId><ArticleId IdType="pubmed">32579933</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E, et al. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer&#x2019;s disease. Acta Neuropathol 133, 933&#x2013;954 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5503748</ArticleId><ArticleId IdType="pubmed">28258398</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamelin L, et al. Early and protective microglial activation in Alzheimer&#x2019;s disease: a prospective study using 18F-DPA-714 PET imaging. Brain 139, 1252&#x2013;1264 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26984188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan VK, et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer&#x2019;s disease implicates microglial activation gene IL1RAP. Brain 138, 3076&#x2013;3088 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4671479</ArticleId><ArticleId IdType="pubmed">26268530</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur R, et al. A reduced astrocyte response to beta-amyloid plaques in the ageing brain associates with cognitive impairment. PLoS One 10, e0118463 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338046</ArticleId><ArticleId IdType="pubmed">25707004</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, et al. Asymmetric dimethylarginine exacerbates Abeta-induced toxicity and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free Radic Biol Med 79, 117&#x2013;126 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25499850</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JH, et al. Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer&#x2019;s disease pathology. Acta Neuropathol 115, 611&#x2013;622 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386158</ArticleId><ArticleId IdType="pubmed">18386021</ArticleId></ArticleIdList></Reference><Reference><Citation>Clements CM, McNally RS, Conti BJ, Mak TW &amp; Ting JP DJ-1, a cancer- and Parkinson&#x2019;s disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A 103, 15091&#x2013;15096 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1586179</ArticleId><ArticleId IdType="pubmed">17015834</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayon L, et al. Alzheimer disease pathology and the cerebrospinal fluid proteome. Alzheimers Res Ther 10, 66 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052524</ArticleId><ArticleId IdType="pubmed">30021611</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathe G, et al. Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer&#x2019;s Disease. Proteomics Clin Appl 13, e1800105 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6639119</ArticleId><ArticleId IdType="pubmed">30578620</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayon L, et al. Proteomes of Paired Human Cerebrospinal Fluid and Plasma: Relation to Blood-Brain Barrier Permeability in Older Adults. J Proteome Res 18, 1162&#x2013;1174 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30702894</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien RJ, et al. Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J Alzheimers Dis 18, 665&#x2013;675 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978421</ArticleId><ArticleId IdType="pubmed">19661626</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, et al. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology 35, 354&#x2013;389 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593391</ArticleId><ArticleId IdType="pubmed">25619230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis 64, S161&#x2013;S189 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ince PG, Ince PG, Lowe J &amp; Shaw PJ Review. Neuropathology and Applied Neurobiology 24, 104&#x2013;117 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9634206</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsis S, Benge JF, Lowe DA, Geraci L &amp; Doody RS How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond? Clin Neuropsychol 29, 1002&#x2013;1009 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26617181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics 13, 2513&#x2013;2526 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159666</ArticleId><ArticleId IdType="pubmed">24942700</ArticleId></ArticleIdList></Reference><Reference><Citation>Luber CA, et al. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity 32, 279&#x2013;289 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20171123</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertins P, et al. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. Nat Protoc 13, 1632&#x2013;1661 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6211289</ArticleId><ArticleId IdType="pubmed">29988108</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo TS, et al. Integrating Next-Generation Genomic Sequencing and Mass Spectrometry To Estimate Allele-Specific Protein Abundance in Human Brain. J Proteome Res 16, 3336&#x2013;3347 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5698003</ArticleId><ArticleId IdType="pubmed">28691493</ArticleId></ArticleIdList></Reference><Reference><Citation>Petyuk VA, Qian WJ, Smith RD &amp; Smith DJ Mapping protein abundance patterns in the brain using voxelation combined with liquid chromatography and mass spectrometry. Methods 50, 77&#x2013;84 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818068</ArticleId><ArticleId IdType="pubmed">19654045</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulstaert F, et al. Improved discrimination of AD patients using beta-amyloid(1&#x2013;42) and tau levels in CSF. Neurology 52, 1555&#x2013;1562 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10331678</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol 65, 403&#x2013;413 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, et al. Boosting to Amplify Signal with Isobaric Labeling (BASIL) Strategy for Comprehensive Quantitative Phosphoproteomic Characterization of Small Populations of Cells. Anal Chem 91, 5794&#x2013;5801 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6596310</ArticleId><ArticleId IdType="pubmed">30843680</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukey JW Exploratory data analysis. (1977).</Citation></Reference><Reference><Citation>McKenzie AT, et al. Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer&#x2019;s disease. Mol Neurodegener 12, 82 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5674813</ArticleId><ArticleId IdType="pubmed">29110684</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Chen L &amp; Qu H CSGene: a literature-based database for cell senescence genes and its application to identify critical cell aging pathways and associated diseases. Cell Death Dis 7, e2053 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4816187</ArticleId><ArticleId IdType="pubmed">26775705</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, et al. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 10, 48&#x2013;62 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760858</ArticleId><ArticleId IdType="pubmed">29191947</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Luo R, Oldham MC &amp; Horvath S Is my network module preserved and reproducible? PLoS Comput Biol 7, e1001057 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024255</ArticleId><ArticleId IdType="pubmed">21283776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32296178</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>580</Volume><Issue>7803</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>LRP1 is a master regulator of tau uptake and spread.</ArticleTitle><Pagination><StartPage>381</StartPage><EndPage>385</EndPage><MedlinePgn>381-385</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2156-5</ELocationID><Abstract><AbstractText>The spread of protein aggregates during disease progression is a common theme underlying many neurodegenerative diseases. The microtubule-associated protein tau has a central role in the pathogenesis of several forms of dementia known as tauopathies-including Alzheimer's disease, frontotemporal dementia and chronic traumatic encephalopathy<sup>1</sup>. Progression of these diseases is characterized by the sequential spread and deposition of protein aggregates in a predictable pattern that correlates with clinical severity<sup>2</sup>. This observation and complementary experimental studies<sup>3,4</sup> have suggested that tau can spread in a prion-like manner, by passing to naive cells in which it templates misfolding and aggregation. However, although the propagation of tau has been extensively studied, the underlying cellular mechanisms remain poorly understood. Here we show that the low-density lipoprotein receptor-related protein 1 (LRP1) controls the endocytosis of tau and its subsequent spread. Knockdown of LRP1 significantly reduced tau uptake in H4 neuroglioma cells and in induced pluripotent stem cell-derived neurons. The interaction between tau and LRP1 is mediated by lysine residues in the microtubule-binding repeat region of tau. Furthermore, downregulation of LRP1 in an in vivo mouse model of tau spread was found to effectively reduce the propagation of tau between neurons. Our results identify LRP1 as a key regulator of tau spread in the brain, and therefore a potential target for the treatment of diseases that involve tau spread and aggregation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rauch</LastName><ForeName>Jennifer N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luna</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzman</LastName><ForeName>Elmer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Audouard</LastName><ForeName>Morgane</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Challis</LastName><ForeName>Collin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sibih</LastName><ForeName>Youssef E</ForeName><Initials>YE</Initials><Identifier Source="ORCID">0000-0002-0839-5428</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leshuk</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Israel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegmann</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5388-2479</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><Identifier Source="ORCID">0000-0002-7959-9401</Identifier><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gradinaru</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5868-348X</Identifier><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3819-7019</Identifier><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, The California Institute for Quantitative Biomedical Research, Quantitative Biosciences Institute, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA, USA. kenneth.kosik@lifesci.ucsb.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG062479</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023100</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG057528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059789</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 GM119139</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG064116</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100717</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062359</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475476">LRP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026503">Low Density Lipoprotein Receptor-Related Protein-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2020 Apr;580(7803):326-327. doi: 10.1038/d41586-020-00874-z.</RefSource><PMID Version="1">32238893</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Jun;16(6):298. doi: 10.1038/s41582-020-0360-4.</RefSource><PMID Version="1">32300227</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2020 Jul;35(7):1136. doi: 10.1002/mds.28107.</RefSource><PMID Version="1">32445197</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Front Neurol. 2020 Dec 23;11:557509. doi: 10.3389/fneur.2020.557509.</RefSource><PMID Version="1">33424736</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026503" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32296178</ArticleId><ArticleId IdType="mid">NIHMS1568257</ArticleId><ArticleId IdType="pmc">PMC7687380</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2156-5</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-2156-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Eisenberg DS &amp; Crowther RA Propagation of Tau Aggregates and Neurodegeneration. Annu Rev Neurosci 40, 189&#x2013;210, doi:10.1146/annurev-neuro-072116-031153 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-072116-031153</ArticleId><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239&#x2013;259, doi:10.1007/bf00308809 (1991).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A et al. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697, doi:10.1016/j.neuron.2011.11.033 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL et al. Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J Exp Med 213, 2635&#x2013;2654, doi:10.1084/jem.20160833 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20160833</ArticleId><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN et al. Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs). Sci Rep 8, 6382, doi:10.1038/s41598-018-24904-z (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-24904-z</ArticleId><ArticleId IdType="pmc">PMC5913225</ArticleId><ArticleId IdType="pubmed">29686391</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A 110, E3138&#x2013;3147, doi:10.1073/pnas.1301440110 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301440110</ArticleId><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T et al. Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake. J Neurosci 31, 1644&#x2013;1651, doi:10.1523/JNEUROSCI.5491-10.2011 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5491-10.2011</ArticleId><ArticleId IdType="pmc">PMC3272839</ArticleId><ArticleId IdType="pubmed">21289173</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans LD et al. Extracellular Monomeric and Aggregated Tau Efficiently Enter Human Neurons through Overlapping but Distinct Pathways. Cell Rep 22, 3612&#x2013;3624, doi:10.1016/j.celrep.2018.03.021 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.03.021</ArticleId><ArticleId IdType="pmc">PMC5896171</ArticleId><ArticleId IdType="pubmed">29590627</ArticleId></ArticleIdList></Reference><Reference><Citation>De Nardis C et al. Recombinant Expression of the Full-length Ectodomain of LDL Receptor-related Protein 1 (LRP1) Unravels pH-dependent Conformational Changes and the Stoichiometry of Binding with Receptor-associated Protein (RAP). J Biol Chem 292, 912&#x2013;924, doi:10.1074/jbc.M116.758862 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.758862</ArticleId><ArticleId IdType="pmc">PMC5247663</ArticleId><ArticleId IdType="pubmed">27956551</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolmer K, Campos A &amp; Gettins PG Quantitative dissection of the binding contributions of ligand lysines of the receptor-associated protein (RAP) to the low density lipoprotein receptor-related protein (LRP1). J Biol Chem 288, 24081&#x2013;24090, doi:10.1074/jbc.M113.473728 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.473728</ArticleId><ArticleId IdType="pmc">PMC3745351</ArticleId><ArticleId IdType="pubmed">23798683</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolic J et al. Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein. Nat Commun 9, 1029, doi:10.1038/s41467-018-03432-4 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03432-4</ArticleId><ArticleId IdType="pmc">PMC5847621</ArticleId><ArticleId IdType="pubmed">29531262</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher C, Beglova N &amp; Blacklow SC Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors. Mol Cell 22, 277&#x2013;283, doi:10.1016/j.molcel.2006.02.021 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2006.02.021</ArticleId><ArticleId IdType="pubmed">16630895</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillis AP, Van Duyn LB, Murphy-Ullrich JE &amp; Strickland DK LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 88, 887&#x2013;918, doi:10.1152/physrev.00033.2007 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00033.2007</ArticleId><ArticleId IdType="pmc">PMC2744109</ArticleId><ArticleId IdType="pubmed">18626063</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190, doi:10.1038/nature23002 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23002</ArticleId><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420&#x2013;423, doi:10.1038/s41586-019-1026-5 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1026-5</ArticleId><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing P et al. Roles of low-density lipoprotein receptor-related protein 1 in tumors. Chin J Cancer 35, 6, doi:10.1186/s40880-015-0064-0 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40880-015-0064-0</ArticleId><ArticleId IdType="pmc">PMC4704379</ArticleId><ArticleId IdType="pubmed">26738504</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM &amp; Willnow TE Lipoprotein receptors in Alzheimer&#x2019;s disease. Trends Neurosci 29, 687&#x2013;694, doi:10.1016/j.tins.2006.09.002 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2006.09.002</ArticleId><ArticleId IdType="pubmed">17000013</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima C et al. Low density lipoprotein receptor-related protein 1 (LRP1) modulates N-methyl-D-aspartate (NMDA) receptor-dependent intracellular signaling and NMDA-induced regulation of postsynaptic protein complexes. J Biol Chem 288, 21909&#x2013;21923, doi:10.1074/jbc.M112.444364 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.444364</ArticleId><ArticleId IdType="pmc">PMC3724646</ArticleId><ArticleId IdType="pubmed">23760271</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S et al. Experimental evidence for the age dependence of tau protein spread in the brain. Sci Adv 5, eaaw6404, doi:10.1126/sciadv.aaw6404 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaw6404</ArticleId><ArticleId IdType="pmc">PMC6594764</ArticleId><ArticleId IdType="pubmed">31249873</ArticleId></ArticleIdList></Reference><Reference><Citation>Szymczak AL et al. Correction of multi-gene deficiency in vivo using a single &#x2018;self-cleaving&#x2019; 2A peptide-based retroviral vector. Nat Biotechnol 22, 589&#x2013;594, doi:10.1038/nbt957 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt957</ArticleId><ArticleId IdType="pubmed">15064769</ArticleId></ArticleIdList></Reference><Reference><Citation>Auderset L, Cullen CL &amp; Young KM Low Density Lipoprotein-Receptor Related Protein 1 Is Differentially Expressed by Neuronal and Glial Populations in the Developing and Mature Mouse Central Nervous System. PLoS One 11, e0155878, doi:10.1371/journal.pone.0155878 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0155878</ArticleId><ArticleId IdType="pmc">PMC4900551</ArticleId><ArticleId IdType="pubmed">27280679</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinohara M, Tachibana M, Kanekiyo T &amp; Bu G Role of LRP1 in the pathogenesis of Alzheimer&#x2019;s disease: evidence from clinical and preclinical studies. J Lipid Res 58, 1267&#x2013;1281, doi:10.1194/jlr.R075796 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R075796</ArticleId><ArticleId IdType="pmc">PMC5496044</ArticleId><ArticleId IdType="pubmed">28381441</ArticleId></ArticleIdList></Reference><Reference><Citation>Tachibana M et al. APOE4-mediated amyloid-beta pathology depends on its neuronal receptor LRP1. J Clin Invest 129, 1272&#x2013;1277, doi:10.1172/JCI124853 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124853</ArticleId><ArticleId IdType="pmc">PMC6391135</ArticleId><ArticleId IdType="pubmed">30741718</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527, doi:10.1038/nature24016 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism. Arterioscler Thromb Vasc Biol 36, 1305&#x2013;1315, doi:10.1161/ATVBAHA.116.307023 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.116.307023</ArticleId><ArticleId IdType="pmc">PMC4942259</ArticleId><ArticleId IdType="pubmed">27174096</ArticleId></ArticleIdList></Reference><Reference><Citation>Christianson HC &amp; Belting M Heparan sulfate proteoglycan as a cell-surface endocytosis receptor. Matrix Biol 35, 51&#x2013;55, doi:10.1016/j.matbio.2013.10.004 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2013.10.004</ArticleId><ArticleId IdType="pubmed">24145152</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Additional References</Title><Reference><Citation>Horlbeck MA et al. Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. Elife 5, doi:10.7554/eLife.19760 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.19760</ArticleId><ArticleId IdType="pmc">PMC5094855</ArticleId><ArticleId IdType="pubmed">27661255</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermoeller-McCormick LM et al. Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J Cell Sci 114, 899&#x2013;908 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11181173</ArticleId></ArticleIdList></Reference><Reference><Citation>Despres C et al. Identification of the Tau phosphorylation pattern that drives its aggregation. Proc Natl Acad Sci U S A 114, 9080&#x2013;9085, doi:10.1073/pnas.1708448114 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708448114</ArticleId><ArticleId IdType="pmc">PMC5576827</ArticleId><ArticleId IdType="pubmed">28784767</ArticleId></ArticleIdList></Reference><Reference><Citation>Usenovic M et al. Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells. The Journal of neuroscience : the official journal of the Society for Neuroscience 35, 14234&#x2013;14250, doi:10.1523/JNEUROSCI.1523-15.2015 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1523-15.2015</ArticleId><ArticleId IdType="pmc">PMC6605424</ArticleId><ArticleId IdType="pubmed">26490863</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian R et al. CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons. Neuron, doi:10.1016/j.neuron.2019.07.014 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.07.014</ArticleId><ArticleId IdType="pmc">PMC6813890</ArticleId><ArticleId IdType="pubmed">31422865</ArticleId></ArticleIdList></Reference><Reference><Citation>Challis RC et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat Protoc 14, 379&#x2013;414, doi:10.1038/s41596-018-0097-3 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-018-0097-3</ArticleId><ArticleId IdType="pubmed">30626963</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KY et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci 20, 1172&#x2013;1179, doi:10.1038/nn.4593 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4593</ArticleId><ArticleId IdType="pmc">PMC5529245</ArticleId><ArticleId IdType="pubmed">28671695</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna G et al. The effects of transient retinal detachment on cavity size and glial and neural remodeling in a mouse model of X-linked retinoschisis. Invest Ophthalmol Vis Sci 50, 3977&#x2013;3984, doi:10.1167/iovs.08-2910 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.08-2910</ArticleId><ArticleId IdType="pmc">PMC2735860</ArticleId><ArticleId IdType="pubmed">19387072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32330418</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6605</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>07</Day></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Non-coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases.</ArticleTitle><Pagination><StartPage>632</StartPage><EndPage>645</EndPage><MedlinePgn>632-645</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajhg.2020.03.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9297(20)30086-0</ELocationID><Abstract><AbstractText>We conducted genome sequencing to search for rare variation contributing to early-onset Alzheimer's disease (EOAD) and frontotemporal dementia (FTD). Discovery analysis was conducted on 435 cases and 671 controls of European ancestry. Burden testing for rare variation associated with disease was conducted using filters based on variant rarity (less than one in 10,000 or private), computational prediction of deleteriousness (CADD) (10 or 15 thresholds), and molecular function (protein loss-of-function [LoF] only, coding alteration only, or coding plus non-coding variants in experimentally predicted regulatory regions). Replication analysis was conducted on 16,434 independent cases and 15,587 independent controls. Rare variants in TET2 were enriched in the discovery combined EOAD and FTD cohort (p = 4.6&#xa0;&#xd7; 10<sup>-8</sup>, genome-wide corrected p = 0.0026). Most of these variants were canonical LoF or non-coding in predicted regulatory regions. This enrichment replicated across several cohorts of Alzheimer's disease (AD) and FTD (replication only p = 0.0029). The combined analysis odds ratio was 2.3 (95% confidence interval [CI] 1.6-3.4) for AD and FTD. The odds ratio for qualifying non-coding variants considered independently from coding variants was 3.7 (95% CI 1.7-9.4). For LoF variants, the combined odds ratio (for AD, FTD, and amyotrophic lateral sclerosis, which shares clinicopathological overlap with FTD) was 3.1 (95% CI 1.9-5.2). TET2 catalyzes DNA demethylation. Given well-defined changes in DNA methylation that occur during aging, rare variation in TET2 may confer risk for neurodegeneration by altering the homeostasis of key aging-related processes. Additionally, our study emphasizes the relevance of non-coding variation in genetic studies of complex disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cochran</LastName><ForeName>J Nicholas</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geier</LastName><ForeName>Ethan G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonham</LastName><ForeName>Luke W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newberry</LastName><ForeName>J Scott</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amaral</LastName><ForeName>Michelle D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Michelle L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasseigne</LastName><ForeName>Brittany N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, United States; Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Departments of Neurology and Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Gregory M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, United States; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94158, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, United States; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94158, United States. Electronic address: jennifer.yokoyama@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG049152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062588</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I 904</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.11.-</RegistryNumber><NameOfSubstance UI="D049308">Dioxygenases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.11.-</RegistryNumber><NameOfSubstance UI="C541081">TET2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Hum Genet. 2020 Sep 3;107(3):575-576. doi: 10.1016/j.ajhg.2020.07.011.</RefSource><PMID Version="1">32888507</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Am J Hum Genet. 2020 Sep 3;107(3):577-578. doi: 10.1016/j.ajhg.2020.07.012.</RefSource><PMID Version="1">32888508</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049308" MajorTopicYN="N">Dioxygenases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073658" MajorTopicYN="N">Loss of Function Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AD</Keyword><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Alzheimer</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">TET2</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">genome sequencing</Keyword><Keyword MajorTopicYN="N">non-coding</Keyword></KeywordList><CoiStatement>The authors declare competing interests. G.D.R. industry relationships: Research support from Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare, and Life Molecular Imaging. Consultant/scientific advisory board member for Axon Neurosciences, Eisai, and Merck. Speaking honorarium from GE Healthcare. Associate Editor for JAMA Neurology.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32330418</ArticleId><ArticleId IdType="pmc">PMC7212268</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2020.03.010</ArticleId><ArticleId IdType="pii">S0002-9297(20)30086-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lambert M.A., Bickel H., Prince M., Fratiglioni L., Von Strauss E., Frydecka D., Kiejna A., Georges J., Reynish E.L. Estimating the burden of early onset dementia; systematic review of disease prevalence. Eur. J. Neurol. 2014;21:563&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">24418291</ArticleId></ArticleIdList></Reference><Reference><Citation>Loy C.T., Schofield P.R., Turner A.M., Kwok J.B. Genetics of dementia. Lancet. 2014;383:828&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">23927914</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman J.S., Farmer J.M., Wood E.M., Johnson J.K., Boxer A., Neuhaus J., Lomen-Hoerth C., Wilhelmsen K.C., Lee V.M., Grossman M., Miller B.L. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005;65:1817&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo T.S., Lah J.J., Levey A.I., Cutler D.J. Autosomal recessive causes likely in early-onset Alzheimer&#x2019;s disease. Arch. Neurol. 2012;69:59&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3332307</ArticleId><ArticleId IdType="pubmed">21911656</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R., Hernandez D.G., Nalls M.A., Rohrer J.D., Ramasamy A., Kwok J.B., Dobson-Stone C., Brooks W.S., Schofield P.R., Halliday G.M. Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol. 2014;13:686&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112126</ArticleId><ArticleId IdType="pubmed">24943344</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott J.M., Crutch S.J., Carrasquillo M.M., Uphill J., Shakespeare T.J., Ryan N.S., Yong K.X., Lehmann M., Ertekin-Taner N., Graff-Radford N.R. Genetic risk factors for the posterior cortical atrophy variant of Alzheimer&#x2019;s disease. Alzheimers Dement. 2016;12:862&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4982482</ArticleId><ArticleId IdType="pubmed">26993346</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas G., Charbonnier C., Campion D. From Common to Rare Variants: The Genetic Component of Alzheimer&#x2019;s disease. Hum. Hered. 2016;81:129&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">28002825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Lasseigne B.N., Petrovski S., Sapp P.C., Dion P.A., Leblond C.S., Couthouis J., Lu Y.F., Wang Q., Krueger B.J., FALS Sequencing Consortium Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Geier E.G., Bourdenx M., Storm N.J., Cochran J.N., Sirkis D.W., Hwang J.H., Bonham L.W., Ramos E.M., Diaz A., Van Berlo V. Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia. Acta Neuropathol. 2019;137:71&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6371791</ArticleId><ArticleId IdType="pubmed">30382371</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C., Ren Y., Perkerson R.B., 3rd, Baker M., Jenkins G.D., van Blitterswijk M., DeJesus-Hernandez M., van Rooij J.G.J., Murray M.E., Christopher E. Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathol. 2019;137:879&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6533145</ArticleId><ArticleId IdType="pubmed">30739198</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch C.M., Wen N., Fan C.C., Yokoyama J.S., Kouri N., Ross O.A., H&#xf6;glinger G., M&#xfc;ller U., Ferrari R., Hardy J., International Frontotemporal Dementia (FTD)&#x2013;Genomics Consortium, International Collaboration for Frontotemporal Dementia, Progressive Supranuclear Palsy (PSP) Genetics Consortium, and International Parkinson&#x2019;s Disease Genomics Consortium Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. JAMA Neurol. 2018;75:860&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6043387</ArticleId><ArticleId IdType="pubmed">29630712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R., Wang Y., Vandrovcova J., Guelfi S., Witeolar A., Karch C.M., Schork A.J., Fan C.C., Brewer J.B., Momeni P., International FTD-Genomics Consortium (IFGC) International Parkinson&#x2019;s Disease Genomics Consortium (IPDGC) International Genomics of Alzheimer&#x2019;s Project (IGAP) Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. J.&#xa0;Neurol. Neurosurg. Psychiatry. 2017;88:152&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237405</ArticleId><ArticleId IdType="pubmed">27899424</ArticleId></ArticleIdList></Reference><Reference><Citation>Broce I., Karch C.M., Wen N., Fan C.C., Wang Y., Tan C.H., Kouri N., Ross O.A., H&#xf6;glinger G.U., Muller U., International FTD-Genomics Consortium Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Med. 2018;15:e1002487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760014</ArticleId><ArticleId IdType="pubmed">29315334</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama J.S., Wang Y., Schork A.J., Thompson W.K., Karch C.M., Cruchaga C., McEvoy L.K., Witoelar A., Chen C.H., Holland D., Alzheimer&#x2019;s Disease Neuroimaging Initiative Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer&#x2019;s disease. JAMA Neurol. 2016;73:691&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4905783</ArticleId><ArticleId IdType="pubmed">27088644</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan R.S., Schork A.J., Wang Y., Witoelar A., Sharma M., McEvoy L.K., Holland D., Brewer J.B., Chen C.H., Thompson W.K., ADNI, ADGC, GERAD, CHARGE and IPDGC Investigators Genetic overlap between Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease at the MAPT locus. Mol. Psychiatry. 2015;20:1588&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539304</ArticleId><ArticleId IdType="pubmed">25687773</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochran J.N., McKinley E.C., Cochran M., Amaral M.D., Moyers B.A., Lasseigne B.N., Gray D.E., Lawlor J.M.J., Prokop J.W., Geier E.G. Genome sequencing for early-onset or atypical dementia: high diagnostic yield and frequent observation of multiple contributory alleles. Cold Spring Harb. Mol. Case Stud. 2019;5:a003491. doi: 10.1101/mcs.a003491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/mcs.a003491</ArticleId><ArticleId IdType="pmc">PMC6913143</ArticleId><ArticleId IdType="pubmed">31836585</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowling K.M., Thompson M.L., Amaral M.D., Finnila C.R., Hiatt S.M., Engel K.L., Cochran J.N., Brothers K.B., East K.M., Gray D.E. Genomic diagnosis for children with intellectual disability and/or developmental delay. Genome Med. 2017;9:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5448144</ArticleId><ArticleId IdType="pubmed">28554332</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasov A., Vilella A.J., Cuppen E., Nijman I.J., Prins P. Sambamba: fast processing of NGS alignment formats. Bioinformatics. 2015;31:2032&#x2013;2034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765878</ArticleId><ArticleId IdType="pubmed">25697820</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A., Hanna M., Banks E., Sivachenko A., Cibulskis K., Kernytsky A., Garimella K., Altshuler D., Gabriel S., Daly M., DePristo M.A. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Danecek P., Auton A., Abecasis G., Albers C.A., Banks E., DePristo M.A., Handsaker R.E., Lunter G., Marth G.T., Sherry S.T., 1000 Genomes Project Analysis Group The variant call format and VCFtools. Bioinformatics. 2011;27:2156&#x2013;2158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137218</ArticleId><ArticleId IdType="pubmed">21653522</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics. 2011;27:2987&#x2013;2993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198575</ArticleId><ArticleId IdType="pubmed">21903627</ArticleId></ArticleIdList></Reference><Reference><Citation>Paila U., Chapman B.A., Kirchner R., Quinlan A.R. GEMINI: integrative exploration of genetic variation and genome annotations. PLoS Comput. Biol. 2013;9:e1003153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715403</ArticleId><ArticleId IdType="pubmed">23874191</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen B.S., Collins R.L., Talkowski M.E., Quinlan A.R. Indexcov: fast coverage quality control for whole-genome sequencing. Gigascience. 2017;6:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5737511</ArticleId><ArticleId IdType="pubmed">29048539</ArticleId></ArticleIdList></Reference><Reference><Citation>Manichaikul A., Mychaleckyj J.C., Rich S.S., Daly K., Sale M., Chen W.M. Robust relationship inference in genome-wide association studies. Bioinformatics. 2010;26:2867&#x2013;2873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025716</ArticleId><ArticleId IdType="pubmed">20926424</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Auton A., Brooks L.D., Durbin R.M., Garrison E.P., Kang H.M., Korbel J.O., Marchini J.L., McCarthy S., McVean G.A., Abecasis G.R., 1000 Genomes Project Consortium A global reference for human genetic variation. Nature. 2015;526:68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander D.H., Novembre J., Lange K. Fast model-based estimation of ancestry in unrelated individuals. Genome Res. 2009;19:1655&#x2013;1664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752134</ArticleId><ArticleId IdType="pubmed">19648217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A., Abecasis G.R., Kang H.M. Unified representation of genetic variants. Bioinformatics. 2015;31:2202&#x2013;2204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4481842</ArticleId><ArticleId IdType="pubmed">25701572</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher M., Witten D.M., Jain P., O&#x2019;Roak B.J., Cooper G.M., Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 2014;46:310&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992975</ArticleId><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Cingolani P., Platts A., Wang L., Coon M., Nguyen T., Wang L., Land S.J., Lu X., Ruden D.M. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 2012;6:80&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679285</ArticleId><ArticleId IdType="pubmed">22728672</ArticleId></ArticleIdList></Reference><Reference><Citation>NHLBI. University of Michigan  . University of Michigan; 2018. The NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. BRAVO variant browser.https://bravo.sph.umich.edu/freeze5/hg38/</Citation></Reference><Reference><Citation>Zhao H., Sun Z., Wang J., Huang H., Kocher J.-P., Wang L. CrossMap: a versatile tool for coordinate conversion between genome assemblies. Bioinformatics. 2014;30:1006&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3967108</ArticleId><ArticleId IdType="pubmed">24351709</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., White S., Peng B., Johnson A.D., Brody J.A., Li A.H., Huang Z., Carroll A., Wei P., Gibbs R. WGSA: an annotation pipeline for human genome sequencing studies. J.&#xa0;Med. Genet. 2016;53:111&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5124490</ArticleId><ArticleId IdType="pubmed">26395054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., O&#x2019;Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Exome Aggregation Consortium Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski K.J., Francioli L.C., Tiao G., Cummings B.B., Alf&#xf6;ldi J., Wang Q., Collins R.L., Laricchia K.M., Ganna A., Birnbaum D.P. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv. 2019 doi: 10.1101/531210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/531210</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry S.T., Ward M.H., Kholodov M., Baker J., Phan L., Smigielski E.M., Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC29783</ArticleId><ArticleId IdType="pubmed">11125122</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q., Powles R.L., Abdallah S., Ou D., Wang Q., Hu Y., Lu Y., Liu W., Li B., Mukherjee S. Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer&#x2019;s disease. PLoS Genet. 2017;13:e1006933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546707</ArticleId><ArticleId IdType="pubmed">28742084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M.C., Lee S., Cai T., Li Y., Boehnke M., Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am. J. Hum. Genet. 2011;89:82&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135811</ArticleId><ArticleId IdType="pubmed">21737059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Fuchsberger C., Kim S., Scott L. An efficient resampling method for calibrating single and gene-based rare variant association analysis in case-control studies. Biostatistics. 2016;17:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692986</ArticleId><ArticleId IdType="pubmed">26363037</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner S.D. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. bioRxiv. 2014 doi: 10.1101/005165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/005165</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner M.W., Veitch D.P., Aisen P.S., Beckett L.A., Cairns N.J., Cedarbaum J., Green R.C., Harvey D., Jack C.R., Jagust W., Alzheimer&#x2019;s Disease Neuroimaging Initiative 2014&#xa0;Update of the Alzheimer&#x2019;s Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2015;11:e1&#x2013;e120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5469297</ArticleId><ArticleId IdType="pubmed">26073027</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin A.J., Shen L., Foroud T.M., Potkin S.G., Swaminathan S., Kim S., Risacher S.L., Nho K., Huentelman M.J., Craig D.W., Alzheimer&#x2019;s Disease Neuroimaging Initiative Alzheimer&#x2019;s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement. 2010;6:265&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868595</ArticleId><ArticleId IdType="pubmed">20451875</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen R.C., Aisen P.S., Beckett L.A., Donohue M.C., Gamst A.C., Harvey D.J., Jack C.R., Jr., Jagust W.J., Shaw L.M., Toga A.W. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams M.M., Storandt M., Roe C.M., Morris J.C. Progression of Alzheimer&#x2019;s disease as measured by Clinical Dementia Rating Sum of Boxes scores. Alzheimers Dement. 2013;9(1, Suppl):S39&#x2013;S44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660405</ArticleId><ArticleId IdType="pubmed">22858530</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Bryant S.E., Lacritz L.H., Hall J., Waring S.C., Chan W., Khodr Z.G., Massman P.J., Hobson V., Cullum C.M. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer&#x2019;s coordinating center database. Arch. Neurol. 2010;67:746&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2888493</ArticleId><ArticleId IdType="pubmed">20558394</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S., Ciura S., Rouleau G.A., Kabashi E. Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD) Trends Genet. 2015;31:263&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">25869998</ArticleId></ArticleIdList></Reference><Reference><Citation>Project MinE ALS Sequencing Consortium Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur. J. Hum. Genet. 2018;26:1537&#x2013;1546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6138692</ArticleId><ArticleId IdType="pubmed">29955173</ArticleId></ArticleIdList></Reference><Reference><Citation>Bis J.C., Jian X., Kunkle B.W., Chen Y., Hamilton-Nelson K.L., Bush W.S., Salerno W.J., Lancour D., Ma Y., Renton A.E., Alzheimer&#x2019;s Disease Sequencing Project Whole exome sequencing study identifies novel rare and common Alzheimer&#x2019;s-Associated variants involved in immune response and transcriptional regulation. Mol. Psychiatry. 2018 doi: 10.1038/s41380-018-0112-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0112-7</ArticleId><ArticleId IdType="pmc">PMC6375806</ArticleId><ArticleId IdType="pubmed">30108311</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M.F., Folstein S.E., McHugh P.R. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J.&#xa0;Psychiatr. Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle B.W., Grenier-Boley B., Sims R., Bis J.C., Damotte V., Naj A.C., Boland A., Vronskaya M., van der Lee S.J., Amlie-Wolf A., Alzheimer&#x2019;s disease Genetics Consortium (ADGC) European Alzheimer&#x2019;s Disease Initiative (EADI) Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE) Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer&#x2019;s Disease Consortium (GERAD/PERADES) Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet. 2019;51:414&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath S., Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat. Rev. Genet. 2018;19:371&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">29643443</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyward F.D., Sweatt J.D. DNA Methylation in Memory Formation: Emerging Insights. Neuroscientist. 2015;21:475&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4770785</ArticleId><ArticleId IdType="pubmed">25832671</ArticleId></ArticleIdList></Reference><Reference><Citation>Antunes C., Sousa N., Pinto L., Marques C.J. TET enzymes in neurophysiology and brain function. Neurosci. Biobehav. Rev. 2019;102:337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">31078565</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransquet P.D., Wrigglesworth J., Woods R.L., Ernst M.E., Ryan J. The epigenetic clock as a predictor of disease and mortality risk: a systematic review and meta-analysis. Clin. Epigenetics. 2019;11:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6458841</ArticleId><ArticleId IdType="pubmed">30975202</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessop P., Toledo-Rodriguez M. Hippocampal TET1 and TET2 Expression and DNA Hydroxymethylation Are Affected by Physical Exercise in Aged Mice. Front. Cell Dev. Biol. 2018;6:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5922180</ArticleId><ArticleId IdType="pubmed">29732371</ArticleId></ArticleIdList></Reference><Reference><Citation>Gontier G., Iyer M., Shea J.M., Bieri G., Wheatley E.G., Ramalho-Santos M., Villeda S.A. Tet2 Rescues Age-Related Regenerative Decline and Enhances Cognitive Function in the Adult Mouse Brain. Cell Rep. 2018;22:1974&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5870899</ArticleId><ArticleId IdType="pubmed">29466726</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Yao B., Chen L., Kang Y., Li Y., Cheng Y., Li L., Lin L., Wang Z., Wang M. Ten-eleven translocation 2 interacts with forkhead box O3 and regulates adult neurogenesis. Nat. Commun. 2017;8:15903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5493768</ArticleId><ArticleId IdType="pubmed">28660881</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi Y., Gao X., Dai J., Ma Y., Xu L., Jin W. A Novel Function of TET2 in CNS: Sustaining Neuronal Survival. Int. J. Mol. Sci. 2015;16:21846&#x2013;21857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4613284</ArticleId><ArticleId IdType="pubmed">26378518</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck D.B., Petracovici A., He C., Moore H.W., Louie R.J., Ansar M., Douzgou S., Sithambaram S., Cottrell T., Santos-Cortez R.L.P. Delineation of a Human Mendelian Disorder of the DNA Demethylation Machinery: TET3 Deficiency. Am. J. Hum. Genet. 2020;106:234&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7010978</ArticleId><ArticleId IdType="pubmed">31928709</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo-Jimenez A., Deniz &#xd6;., Niklison-Chirou M.V., Ruiz R., Bezerra-Salom&#xe3;o K., Stratoulias V., Amouroux R., Yip P.K., Vilalta A., Cheray M. TET2 Regulates the Neuroinflammatory Response in Microglia. Cell Rep. 2019;29:697&#x2013;713.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31618637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M., Franzmeier N., Su&#xe1;rez-Calvet M., Morenas-Rodriguez E., Caballero M.A.A., Kleinberger G., Piccio L., Cruchaga C., Deming Y., Dichgans M., Alzheimer&#x2019;s Disease Neuroimaging Initiative Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer&#x2019;s disease. Sci. Transl. Med. 2019;11:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7050285</ArticleId><ArticleId IdType="pubmed">31462511</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Qiu Y., Miao M., Liu Z., Li W., Zhu Y., Wang Q. Reduction of Tet2 exacerbates early stage Alzheimer&#x2019;s pathology and cognitive impairments in 2 x Tg-ad mice. Hum. Mol. Genet. 2020 doi: 10.1093/hmg/ddz282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz282</ArticleId><ArticleId IdType="pubmed">31943063</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C., Wallon D., Rousseau S., Rovelet-Lecrux A., Richard A.C., Rollin-Sillaire A., Frebourg T., Campion D., Hannequin D. TREM2 R47H variant as a risk factor for early-onset Alzheimer&#x2019;s disease. J.&#xa0;Alzheimers Dis. 2013;35:45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">23380991</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E., Bettens K., Philtjens S., Van Langenhove T., Gijselinck I., van der Zee J., Engelborghs S., Vandenbulcke M., Van Dongen J., Geerts N., BELNEU consortium Investigating the role of rare heterozygous TREM2 variants in Alzheimer&#x2019;s disease and frontotemporal dementia. Neurobiol. Aging. 2014;35:726.e11&#x2013;726.e19.</Citation><ArticleIdList><ArticleId IdType="pubmed">24119542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H.P., Van Broeckhoven C., van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet. 2018;34:404&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Orme T., Guerreiro R., Bras J. The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions. Curr. Neurol. Neurosci. Rep. 2018;18:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097049</ArticleId><ArticleId IdType="pubmed">30097731</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M., Mullen B., Wojtas A., Heckman M.G., Diehl N.N., Baker M.C., DeJesus-Hernandez M., Brown P.H., Murray M.E., Hsiung G.Y. Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol. Neurodegener. 2014;9:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4190282</ArticleId><ArticleId IdType="pubmed">25239657</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M., Theuns J., Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 2012;33:1340&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465795</ArticleId><ArticleId IdType="pubmed">22581678</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Dermaut B., Peeters K., Cruts M., Heutink P., Goate A., Van Broeckhoven C. Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer&#x2019;s disease does not share a common founder in Western Europe. Hum. Mutat. 2003;22:409&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">14517953</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L.A., Grabowski T.J., Schmidt M.L., Morris J.C., Goate A., Solodkin A., Van Hoesen G.W., Schelper R.L., Talbot C.J., Wragg M.A., Trojanowski J.Q. Autosomal dominant dementia with widespread neurofibrillary tangles. Ann. Neurol. 1997;42:564&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">9382467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok J.B., Teber E.T., Loy C., Hallupp M., Nicholson G., Mellick G.D., Buchanan D.D., Silburn P.A., Schofield P.R. Tau haplotypes regulate transcription and are associated with Parkinson&#x2019;s disease. Ann. Neurol. 2004;55:329&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991810</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D.A., Buchman A.S., Boyle P.A., Barnes L.L., Wilson R.S., Schneider J.A. Religious Orders Study and Rush Memory and Aging Project. J.&#xa0;Alzheimers Dis. 2018;64(s1):S161&#x2013;S189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M., Carrasquillo M.M., Funk C., Heavner B.D., Zou F., Younkin C.S., Burgess J.D., Chai H.S., Crook J., Eddy J.A. Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Sci. Data. 2016;3:160089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32338734</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.</ArticleTitle><Pagination><StartPage>829</StartPage><EndPage>839</EndPage><MedlinePgn>829-839</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.0528</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Positron emission tomography (PET) may increase the diagnostic accuracy and confirm the underlying neuropathologic changes of Alzheimer disease (AD).</AbstractText><AbstractText Label="OBJECTIVE">To determine the accuracy of antemortem [18F]flortaucipir PET images for predicting the presence of AD-type tau pathology at autopsy.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This diagnostic study (A16 primary cohort) was conducted from October 2015 to June 2018 at 28 study sites (27 in US sites and 1 in Australia). Individuals with a terminal illness who were older than 50 years and had a projected life expectancy of less than 6 months were enrolled. All participants underwent [18F]flortaucipir PET imaging, and scans were interpreted by 5 independent nuclear medicine physicians or radiologists. Supplemental autopsy [18F]flortaucipir images and pathological samples were also collected from 16 historically collected cases. A second study (FR01 validation study) was conducted from March 26 to April 26, 2019, in which 5 new readers assessed the original PET images for comparison to autopsy.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">[18F]flortaucipir PET images were visually assessed and compared with immunohistochemical tau pathology. An AD tau pattern of flortaucipir retention was assessed for correspondence with a postmortem B3-level (Braak stage V or VI) pathological pattern of tau accumulation and to the presence of amyloid-&#x3b2; plaques sufficient to meet the criteria for high levels of AD neuropathological change. Success was defined as having at least 3 of the 5 readers above the lower bounds of the 95% CI for both sensitivity and specificity of 50% or greater.</AbstractText><AbstractText Label="RESULTS">A total of 156 patients were enrolled in the A16 study and underwent [18F]flortaucipir PET imaging. Of these, 73 died during the study, and valid autopsies were performed for 67 of these patients. Three autopsies were evaluated as test cases and removed from the primary cohort (n&#x2009;=&#x2009;64). Of the 64 primary cohort patients, 34 (53%) were women and 62 (97%) were white; mean (SD) age was 82.5 (9.6) years; and 49 (77%) had dementia, 1 (2%) had mild cognitive impairment, and 14 (22%) had normal cognition. Prespecified success criteria were met for the A16 primary cohort. The flortaucipir PET scans predicted a B3 level of tau pathology, with sensitivity ranging from 92.3% (95% CI, 79.7%-97.3%) to 100.0% (95% CI, 91.0%-100.0%) and specificity ranging from 52.0% (95% CI, 33.5%-70.0%) to 92.0% (95% CI, 75.0%-97.8%). A high level of AD neuropathological change was predicted with sensitivity of 94.7% (95% CI, 82.7%-98.5%) to 100.0% (95% CI, 90.8%-100.0%) and specificity of 50.0% (95% CI, 32.1%-67.9%) to 92.3% (95% CI, 75.9%-97.9%). The FR01 validation study also met prespecified success criteria. Addition of the supplemental autopsy data set and 3 test cases, which comprised a total of 82 patients and autopsies for both the A16 and FR01 studies, resulted in improved specificity and comparable overall accuracy. Among the 156 enrolled participants, 14 (9%) experienced at least 1 treatment-emergent adverse event.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study's findings suggest that PET imaging with [18F]flortaucipir could be used to identify the density and distribution of AD-type tau pathology and the presence of high levels of AD neuropathological change, supporting a neuropathological diagnosis of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devous</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Suffix>Sr</Suffix><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Anupa K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truocchio</LastName><ForeName>Stephen P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldea</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flitter</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locascio</LastName><ForeName>Tricia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devine</LastName><ForeName>Marybeth</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siderowf</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Sun City, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Geidy E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Sun City, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Waypoint Research, Windermere, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Butler Hospital, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniel</LastName><ForeName>Misty</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pacific Research Network, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wellman</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospice of the Western Reserve, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Abhinay D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Imaginab, Inglewood, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Val J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Milos D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>University of Pittsburgh, Pittsburgh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masdeu</LastName><ForeName>Joseph C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Houston Methodist Institute for Academic Medicine, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navitsky</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Southekal</LastName><ForeName>Sudeepti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>A16 Study Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089757</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG066597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS094489</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089544</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097495</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2020 Jul 1;77(7):796-797. doi: 10.1001/jamaneurol.2020.0520.</RefSource><PMID Version="1">32338712</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2023 Aug 1;80(8):873. doi: 10.1001/jamaneurol.2023.1911.</RefSource><PMID Version="1">37306990</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Fleisher reported being a full-time employee of Avid Radiopharmaceuticals and being a minor shareholder in Eli Lilly and Company. Dr Pontecorvo reported receiving other from Eli Lilly and Company and being a full-time employee of Avid Radiopharmaceuticals during the conduct of the study. Dr Devous reported being a full-time employee of Avid Radiopharmaceuticals during the conduct of the study. Dr Lu reported being a full-time employee of Avid Radiopharmaceuticals during the conduct of the study. Dr Arora reported being a full-time employee of Avid Radiopharmaceuticals during the conduct of the study. Mr Truocchio reported being a full-time employee of Avid Radiopharmaceuticals during the conduct of the study. Ms Aldea reported receiving other from Eli Lilly and Company during the conduct of the study. Mr Flitter reported receiving other from Eli Lilly and Company during the conduct of the study and being a full-time employee of Avid Radiopharmaceuticals. Ms Devine reported being a full-time employee of Avid Radiopharmaceuticals during the conduct of the study. Dr Siderowf reported receiving personal fees from Avid Radiopharmaceuticals during the conduct of the study and being a former employee of Avid Radiopharmaceuticals. Dr Beach reported receiving grants from Avid Radiopharmaceuticals during the conduct of the study and personal fees from Vivid Genomics and Prothena Biosciences, and holding stock options with Vivid Genomics. Dr Montine reported receiving personal fees and consulting fees from Avid Radiopharmaceuticals during the conduct of the study. Dr Serrano reported being a full-time employee of Avid Radiopharmaceuticals during the conduct of the study. Dr Perrin reported receiving other from Banner Alzheimer's Institute during the conduct of the study. Mr Joshi reported being a former employee of Avid Radiopharmaceuticals. Dr Irwin reported receiving grants from the National Institutes of Health (NIH) and from Avid Radiopharmaceuticals during the conduct of the study. Dr Lowe reported receiving nonfinancial support from Avid Radiopharmaceuticals, grants from GE Healthcare, and grants from Seimens Molecular Imaging outside the submitted work. Dr Ikonomovic reported receiving grants from the NIH during the conduct of the study. Dr Masdeu reported receiving grants from Eli Lilly and Company during the conduct of the study as well as grants and personal fees from GE Healthcare outside the submitted work. Mr Kennedy reported being a full-time employee of Avid Radiopharmaceuticals during the conduct of the study. Mr Harris reported being a full-time employee of Avid Radiopharmaceuticals during the conduct of the study. Dr Southekal reported being a full-time employee of Avid Radiopharmaceuticals during the conduct of the study and being an employee of and minor stockholder in Eli Lilly and Company. Dr Mintun reported being an employee of Eli Lilly and Company. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32338734</ArticleId><ArticleId IdType="pmc">PMC7186920</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.0528</ArticleId><ArticleId IdType="pii">2764329</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739(2-3):240-250. doi:10.1016/j.bbadis.2004.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2004.08.007</ArticleId><ArticleId IdType="pubmed">15615642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd M. Paired helical filaments in electron microscopy of Alzheimer&#x2019;s disease. Nature. 1963;197:192-193. doi:10.1038/197192b0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/197192b0</ArticleId><ArticleId IdType="pubmed">14032480</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer&#x2019;s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985;4(11):2757-2763. doi:10.1002/j.1460-2075.1985.tb04000.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1985.tb04000.x</ArticleId><ArticleId IdType="pmc">PMC554575</ArticleId><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT. The neuropathological diagnosis of Alzheimer&#x2019;s disease: clinical-pathological studies. Neurobiol Aging. 1997;18(4)(suppl):S27-S32. doi:10.1016/S0197-4580(97)00066-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(97)00066-3</ArticleId><ArticleId IdType="pubmed">9330982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. . National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8(1):1-13. doi:10.1016/j.jalz.2011.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. ; Contributors . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. . Revising the definition of Alzheimer&#x2019;s disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127. doi:10.1016/S1474-4422(10)70223-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70223-4</ArticleId><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Petersen RC, Jack CR Jr. A brief history of &#x201c;Alzheimer disease&#x201d;: multiple meanings separated by a common name. Neurology. 2019;92(22):1053-1059. doi:10.1212/WNL.0000000000007583</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007583</ArticleId><ArticleId IdType="pmc">PMC6556090</ArticleId><ArticleId IdType="pubmed">31028129</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004;84(2):361-384. doi:10.1152/physrev.00024.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00024.2003</ArticleId><ArticleId IdType="pubmed">15044677</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer&#x2019;s disease. N Engl J Med. 2010;362(4):329-344. doi:10.1056/NEJMra0909142</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0909142</ArticleId><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson TC, Saunders HL, Vickers JC. Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer&#x2019;s disease. Neuropathol Appl Neurobiol. 1997;23(6):483-491. doi:10.1111/j.1365-2990.1997.tb01325.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1997.tb01325.x</ArticleId><ArticleId IdType="pubmed">9460714</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Brion JP, Hauw JJ, Flament-Durand J. Quantitative assessment of the density of neurofibrillary tangles and senile plaques in senile dementia of the Alzheimer type. Comparison of immunocytochemistry with a specific antibody and Bodian&#x2019;s protargol method. Acta Neuropathol. 1987;73(2):167-170. doi:10.1007/BF00693783</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00693783</ArticleId><ArticleId IdType="pubmed">2440224</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-381. doi:10.1097/NEN.0b013e31825018f7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong DF, Rosenberg PB, Zhou Y, et al. . In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913-920. doi:10.2967/jnumed.109.069088</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.109.069088</ArticleId><ArticleId IdType="pmc">PMC3101877</ArticleId><ArticleId IdType="pubmed">20501908</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Pontecorvo MJ, Beach TG, et al. ; AV-45-A16 Study Group . Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&#x3b2; plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669-678. doi:10.1016/S1474-4422(12)70142-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70142-4</ArticleId><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis C, Gamez JE, Singh U, et al. . Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72(3):287-294. doi:10.1001/jamaneurol.2014.4144</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4144</ArticleId><ArticleId IdType="pubmed">25622185</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabri O, Sabbagh MN, Seibyl J, et al. ; Florbetaben Phase 3 Study Group . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer&#x2019;s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964-974. doi:10.1016/j.jalz.2015.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.02.004</ArticleId><ArticleId IdType="pubmed">25824567</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, et al. . Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457-468. doi:10.3233/JAD-122059</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-122059</ArticleId><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CF, Arteaga J, Chen G, et al. . [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer&#x2019;s disease. Alzheimers Dement. 2013;9(6):666-676. doi:10.1016/j.jalz.2012.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.11.008</ArticleId><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Fleisher AS, Devous MD, et al. . Baseline tau accumulation, as evidenced by visual interpretation of flortaucipir PET, and longitudinal cognitive change in three trials with MCI and AD dementia subjects. Paper presented at: 14th International Conference on Alzheimer&#x2019;s &amp; Parkinson&#x2019;s Diseases; March 27, 2019; Lisbon, Portugal.</Citation></Reference><Reference><Citation>Southekal S, Devous MD Sr, Kennedy I, et al. . Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity. J Nucl Med. 2018;59(6):944-951. doi:10.2967/jnumed.117.200006</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.117.200006</ArticleId><ArticleId IdType="pubmed">29191858</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Devous MD Sr, Navitsky M, et al. ; 18F-AV-1451-A05 investigators . Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140(3):748-763. doi:10.1093/brain/aww334</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww334</ArticleId><ArticleId IdType="pmc">PMC5382945</ArticleId><ArticleId IdType="pubmed">28077397</ArticleId></ArticleIdList></Reference><Reference><Citation>Devous MD Sr, Joshi AD, Navitsky M, et al. . Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18. J Nucl Med. 2018;59(6):937-943. doi:10.2967/jnumed.117.200691</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.117.200691</ArticleId><ArticleId IdType="pubmed">29284675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Lundt ES, Albertson SM, et al. . Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16(3):561-571. doi:10.1016/j.jalz.2019.09.079</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.09.079</ArticleId><ArticleId IdType="pmc">PMC7067654</ArticleId><ArticleId IdType="pubmed">31784374</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Tacik P, et al. . [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132(6):931-933. doi:10.1007/s00401-016-1618-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1618-1</ArticleId><ArticleId IdType="pmc">PMC5107140</ArticleId><ArticleId IdType="pubmed">27645292</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Meltzer AC, et al. . Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. Ann Neurol. 2017;81(1):117-128. doi:10.1002/ana.24844</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24844</ArticleId><ArticleId IdType="pmc">PMC5319193</ArticleId><ArticleId IdType="pubmed">27997036</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Verwer EE, Meltzer AC, et al. . Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson&#x2019;s case. Acta Neuropathol Commun. 2017;5(1):75. doi:10.1186/s40478-017-0482-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0482-0</ArticleId><ArticleId IdType="pmc">PMC5648451</ArticleId><ArticleId IdType="pubmed">29047416</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan CT, Irwin DJ, Nasrallah I, et al. . Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132(6):935-937. doi:10.1007/s00401-016-1640-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1640-3</ArticleId><ArticleId IdType="pmc">PMC5154298</ArticleId><ArticleId IdType="pubmed">27815633</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Puschmann A, Sch&#xf6;ll M, et al. . 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016;139(pt 9):2372-2379. doi:10.1093/brain/aww163</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww163</ArticleId><ArticleId IdType="pmc">PMC4995360</ArticleId><ArticleId IdType="pubmed">27357347</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Sch&#xf6;ll M, Honer M, Nilsson CF, Englund E, Hansson O. Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathol. 2017;133(1):149-151. doi:10.1007/s00401-016-1650-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1650-1</ArticleId><ArticleId IdType="pmc">PMC5209394</ArticleId><ArticleId IdType="pubmed">27900460</ArticleId></ArticleIdList></Reference><Reference><Citation>Day GS, Gordon BA, Perrin RJ, et al. . In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology. 2018;90(10):e896-e906. doi:10.1212/WNL.0000000000005064</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005064</ArticleId><ArticleId IdType="pmc">PMC5863493</ArticleId><ArticleId IdType="pubmed">29438042</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Wibom M, Pawlik D, Englund E, Hansson O. Correlation of in vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol. 2019;76(3):310-317. doi:10.1001/jamaneurol.2018.3692</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.3692</ArticleId><ArticleId IdType="pmc">PMC6439731</ArticleId><ArticleId IdType="pubmed">30508025</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389-404. doi:10.1007/s00401-006-0127-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon JR Jr. The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur. 1998;6(2):65-74. doi:10.1080/105294199277860</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/105294199277860</ArticleId><ArticleId IdType="pubmed">10386329</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med. 1994;24(1):145-153. doi:10.1017/S003329170002691X</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S003329170002691X</ArticleId><ArticleId IdType="pubmed">8208879</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdi H, Williams LJ, Beaton D, et al. . Analysis of regional cerebral blood flow data to discriminate among Alzheimer&#x2019;s disease, frontotemporal dementia, and elderly controls: a multi-block barycentric discriminant analysis (MUBADA) methodology. J Alzheimers Dis. 2012;31(suppl 3):S189-S201. doi:10.3233/JAD-2012-112111</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-112111</ArticleId><ArticleId IdType="pmc">PMC3725397</ArticleId><ArticleId IdType="pubmed">22785390</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. ; National Institute on Aging; Alzheimer&#x2019;s Association . National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123(1):1-11. doi:10.1007/s00401-011-0910-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0910-3</ArticleId><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791-1800. doi:10.1212/WNL.58.12.1791</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.12.1791</ArticleId><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. . The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479-486. doi:10.1212/WNL.41.4.479</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.41.4.479</ArticleId><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D, Tractenberg R, Schneider JA, Crane PK, Bennett DA. A 2-process model for neuropathology of Alzheimer&#x2019;s disease. Neurobiol Aging. 2014;35(2):301-308. doi:10.1016/j.neurobiolaging.2013.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.08.007</ArticleId><ArticleId IdType="pmc">PMC3977862</ArticleId><ArticleId IdType="pubmed">24080173</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsell SE, Mock C, Roe CM, et al. . Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology. 2013;80(23):2121-2129. doi:10.1212/WNL.0b013e318295d7a1</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318295d7a1</ArticleId><ArticleId IdType="pmc">PMC3716351</ArticleId><ArticleId IdType="pubmed">23645594</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119. doi:10.1002/ana.24546</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Schmitt FA, et al. . Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol. 2009;68(7):774-784. doi:10.1097/NEN.0b013e3181aacbe9</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181aacbe9</ArticleId><ArticleId IdType="pmc">PMC2725359</ArticleId><ArticleId IdType="pubmed">19535994</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Alafuzoff I, Attems J, et al. . PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 2015;129(5):757-762. doi:10.1007/s00401-015-1407-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1407-2</ArticleId><ArticleId IdType="pmc">PMC4534004</ArticleId><ArticleId IdType="pubmed">25778618</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61(3):378-384. doi:10.1001/archneur.61.3.378</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.61.3.378</ArticleId><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64(5):834-841. doi:10.1212/01.WNL.0000152982.47274.9E</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000152982.47274.9E</ArticleId><ArticleId IdType="pubmed">15753419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Rabinovici GD, Smith R, et al. . Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320(11):1151-1162. doi:10.1001/jama.2018.12917</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.12917</ArticleId><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Devous MD, Kennedy I, et al. . A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer&#x2019;s disease dementia. Brain. 2019;142(6):1723-1735. doi:10.1093/brain/awz090</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz090</ArticleId><ArticleId IdType="pmc">PMC6536847</ArticleId><ArticleId IdType="pubmed">31009046</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Pontecorvo MJ, Devous MD, et al. . Tau PET imaging as a screening tool for clinical trials of disease modifying therapies. J Prev Alzheimers Dis. 2018;5(S1):S17.</Citation></Reference><Reference><Citation>Siderowf AD, Keene CD, Beach TG, et al. . Comparison of regional flortaucipir PET to quantitative tau and amyloid immunoassay in patients with Alzheimer&#x2019;s disease pathology: a pilot clinico-pathological study. Alzheimers Dement. 2017;13(7):776. doi:10.1016/j.jalz.2017.06.1038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.1038</ArticleId></ArticleIdList></Reference><Reference><Citation>Southekal S, Kotari V, Devous MD Sr, et al. . Temporal lobe quantitation of flortaucipir PET images may improve detection of intermediate neurofibrillary tangle pathology in autopsy-validated cases. Alzheimers Dement. 2019;15(7):P1486-P1487. doi:10.1016/j.jalz.2019.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.08.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotari V, Navitsky M, Southekal S, et al. . Early tau detection and implications for disease progression. Alzheimers Dement. 2019;15(7):P1614-P1615. doi:10.1016/j.jalz.2019.06.4839</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.06.4839</ArticleId><ArticleId IdType="pmc">PMC9972744</ArticleId><ArticleId IdType="pubmed">36855201</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickstein DL, Pullman MY, Fernandez C, et al. . Cerebral [18&#x2009;F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy. Transl Psychiatry. 2016;6(9):e900. doi:10.1038/tp.2016.175</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2016.175</ArticleId><ArticleId IdType="pmc">PMC5048212</ArticleId><ArticleId IdType="pubmed">27676441</ArticleId></ArticleIdList></Reference><Reference><Citation>Schonhaut DR, McMillan CT, Spina S, et al. . 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol. 2017;82(4):622-634. doi:10.1002/ana.25060</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25060</ArticleId><ArticleId IdType="pmc">PMC5665658</ArticleId><ArticleId IdType="pubmed">28980714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32321864</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>540</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>22</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaav0820</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aav0820</ELocationID><Abstract><AbstractText>The kinase-activating mutation G2019S in leucine-rich repeat kinase 2 (LRRK2) is one of the most common genetic causes of Parkinson's disease (PD) and has spurred development of LRRK2 inhibitors. Preclinical studies have raised concerns about the safety of LRRK2 inhibitors due to histopathological changes in the lungs of nonhuman primates treated with two of these compounds. Here, we investigated whether these lung effects represented on-target pharmacology and whether they were reversible after drug withdrawal in macaques. We also examined whether treatment was associated with pulmonary function deficits. We conducted a 2-week repeat-dose toxicology study in macaques comparing three different LRRK2 inhibitors: GNE-7915 (30 mg/kg, twice daily as a positive control), MLi-2 (15 and 50 mg/kg, once daily), and PFE-360 (3 and 6 mg/kg, once daily). Subsets of animals dosed with GNE-7915 or MLi-2 were evaluated 2 weeks after drug withdrawal for lung function. All compounds induced mild cytoplasmic vacuolation of type II lung pneumocytes without signs of lung degeneration, implicating on-target pharmacology. At low doses of PFE-360 or MLi-2, there was ~50 or 100% LRRK2 inhibition in brain tissue, respectively, but histopathological lung changes were either absent or minimal. The lung effect was reversible after dosing ceased. Lung function tests demonstrated that the histological changes in lung tissue induced by MLi-2 and GNE-7915 did not result in pulmonary deficits. Our results suggest that the observed lung effects in nonhuman primates in response to LRRK2 inhibitors should not preclude clinical testing of these compounds for PD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baptista</LastName><ForeName>Marco A S</ForeName><Initials>MAS</Initials><Identifier Source="ORCID">0000-0002-5915-4894</Identifier><AffiliationInfo><Affiliation>The Michael J. Fox Foundation for Parkinson's Research, Grand Central Station, P.O. Box 4777, New York, NY 10001, USA. mbaptista@michaeljfox.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merchant</LastName><ForeName>Kalpana</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Northwestern University School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Ted</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0521-0683</Identifier><AffiliationInfo><Affiliation>Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhargava</LastName><ForeName>Sakshi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3837-1224</Identifier><AffiliationInfo><Affiliation>Pfizer Inc., Neuroscience Research Unit, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryce</LastName><ForeName>Dianne K</ForeName><Initials>DK</Initials><Identifier Source="ORCID">0000-0002-2249-2240</Identifier><AffiliationInfo><Affiliation>Merck Research Laboratories, Early Discovery Neuroscience, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-4303-3972</Identifier><AffiliationInfo><Affiliation>Merck Research Laboratories, Early Discovery Neuroscience, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrada</LastName><ForeName>Anthony A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fell</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Merck Research Laboratories, Early Discovery Neuroscience, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiske</LastName><ForeName>Brian K</ForeName><Initials>BK</Initials><Identifier Source="ORCID">0000-0002-8797-2042</Identifier><AffiliationInfo><Affiliation>The Michael J. Fox Foundation for Parkinson's Research, Grand Central Station, P.O. Box 4777, New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>Reina N</ForeName><Initials>RN</Initials><Identifier Source="ORCID">0000-0002-8294-5782</Identifier><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galatsis</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0505-9058</Identifier><AffiliationInfo><Affiliation>Pfizer Inc., Neuroscience Research Unit, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Anastasia G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0002-8124-5477</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Sue</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5905-4749</Identifier><AffiliationInfo><Affiliation>Merck Research Laboratories, Early Discovery Neuroscience, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirst</LastName><ForeName>Warren</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Pfizer Inc., Neuroscience Research Unit, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houle</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0586-6044</Identifier><AffiliationInfo><Affiliation>Pfizer Inc., Neuroscience Research Unit, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-4842-4529</Identifier><AffiliationInfo><Affiliation>Merck Research Laboratories, Early Discovery Neuroscience, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xingrong</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-0749-1469</Identifier><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maddess</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0002-7273-528X</Identifier><AffiliationInfo><Affiliation>Merck Research Laboratories, Early Discovery Neuroscience, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markgraf</LastName><ForeName>Carrie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Merck Research Laboratories, Early Discovery Neuroscience, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Hong</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2335-9986</Identifier><AffiliationInfo><Affiliation>Merck Research Laboratories, Early Discovery Neuroscience, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meier</LastName><ForeName>William A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Covance Laboratories, Inc., Madison, WI 53704, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Needle</LastName><ForeName>Elie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pfizer Inc., Neuroscience Research Unit, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ploch</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9511-4275</Identifier><AffiliationInfo><Affiliation>Covance Laboratories, Inc., Madison, WI 53704, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Royer</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4085-7987</Identifier><AffiliationInfo><Affiliation>Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudolph</LastName><ForeName>Karin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-3606-1983</Identifier><AffiliationInfo><Affiliation>Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Alok K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Covance Laboratories, Inc., Madison, WI 53704, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stepan</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pfizer Inc., Neuroscience Research Unit, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steyn</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0061-5350</Identifier><AffiliationInfo><Affiliation>Pfizer Inc., Neuroscience Research Unit, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trost</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Covance Laboratories, Inc., Madison, WI 53704, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Zhizhang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Merck Research Laboratories, Early Discovery Neuroscience, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hongshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Merck Research Laboratories, Early Discovery Neuroscience, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-5134-1292</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherer</LastName><ForeName>Todd B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>The Michael J. Fox Foundation for Parkinson's Research, Grand Central Station, P.O. Box 4777, New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009025">Morpholines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000709230">PFE-360</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="N">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011323" MajorTopicYN="N">Primates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32321864</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aav0820</ArticleId><ArticleId IdType="pii">12/540/eaav0820</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32341526</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease.</ArticleTitle><Pagination><StartPage>482</StartPage><EndPage>493</EndPage><MedlinePgn>482-493</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-020-0610-9</ELocationID><Abstract><AbstractText>Genome-wide association studies have discovered hundreds of loci associated with complex brain disorders, but it remains unclear in which cell types these loci are active. Here we integrate genome-wide association study results with single-cell transcriptomic data from the entire mouse nervous system to systematically identify cell types underlying brain complex traits. We show that psychiatric disorders are predominantly associated with projecting excitatory and inhibitory neurons. Neurological diseases were associated with different cell types, which is consistent with other lines of evidence. Notably, Parkinson's disease was genetically associated not only with cholinergic and monoaminergic neurons (which include dopaminergic neurons) but also with enteric neurons and oligodendrocytes. Using post-mortem brain transcriptomic data, we confirmed alterations in these cells, even at the earliest stages of disease progression. Our study provides an important framework for understanding the cellular basis of complex brain maladies, and reveals an unexpected role of oligodendrocytes in Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bryois</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Skene</LastName><ForeName>Nathan G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Brain Sciences, Department of Medicine, Imperial College, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Imperial College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Thomas Folkmann</ForeName><Initials>TF</Initials><Identifier Source="ORCID">0000-0001-6703-7762</Identifier><AffiliationInfo><Affiliation>Danish Headache Center, Dept of Neurology, Copenhagen University Hospital, Glostrup, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biological Psychiatry, Copenhagen University Hospital MHC Sct Hans, Roskilde, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Novo Nordic Foundations Center for Protein Research, Copenhagen University, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kogelman</LastName><ForeName>Lisette J A</ForeName><Initials>LJA</Initials><AffiliationInfo><Affiliation>Danish Headache Center, Dept of Neurology, Copenhagen University Hospital, Glostrup, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Hunna J</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0001-8405-381X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Psychology, Curtin University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Paediatrics, School of Medicine, The University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zijing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Brain Sciences, Department of Medicine, Imperial College, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Imperial College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Eating Disorders Working Group of the Psychiatric Genomics Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>International Headache Genetics Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>23andMe Research Team</CollectiveName></Author><Author ValidYN="Y"><LastName>Brueggeman</LastName><ForeName>Leo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breen</LastName><ForeName>Gerome</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2053-1792</Identifier><AffiliationInfo><Affiliation>Institute of Psychiatry, MRC Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Biomedical Research Centre, South London and Maudsley National Health Service Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bulik</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arenas</LastName><ForeName>Ernest</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0197-6577</Identifier><AffiliationInfo><Affiliation>Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hjerling-Leffler</LastName><ForeName>Jens</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4539-1776</Identifier><AffiliationInfo><Affiliation>Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. jens.hjerling-leffler@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick F</ForeName><Initials>PF</Initials><Identifier Source="ORCID">0000-0002-6619-873X</Identifier><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. patrick.sullivan@ki.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. patrick.sullivan@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>108726</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 MH077139</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>108726/Z/15/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 MH124871</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007337</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>819540</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>U01 MH109528</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>165049</GrantID><Acronym>SNSF_</Acronym><Agency>Swiss National Science Foundation</Agency><Country>Switzerland</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Potential conflicts of interest. P.F.S. reports the following potentially competing financial interests. Current: Lundbeck (advisory committee, grant recipient). Past three years: Pfizer (scientific advisory board), Element Genomics (consultation fee), and Roche (speaker reimbursement). C.M. Bulik reports: Shire (grant recipient, Scientific Advisory Board member); Pearson and Walker (author, royalty recipient).</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Adan</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alfredsson</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ando</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergen</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berrettini</LastName><ForeName>Wade</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Birgeg&#xe5;rd</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boden</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boehm</LastName><ForeName>Ilka</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boni</LastName><ForeName>Claudette</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boraska Perica</LastName><ForeName>Vesna</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandt</LastName><ForeName>Harry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breen</LastName><ForeName>Gerome</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bryois</LastName><ForeName>Julien</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buehren</LastName><ForeName>Katharina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bulik</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burghardt</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cassina</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cichon</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clementi</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coleman</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cone</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Courtet</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crow</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crowley</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danner</LastName><ForeName>Unna</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Zwaan</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dedoussis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Degortes</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeSocio</LastName><ForeName>Janiece</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dick</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dikeos</LastName><ForeName>Dimitris</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dina</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dmitrzak-Weglarz</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Docampo Martinez</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duncan</LastName><ForeName>Laramie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Egberts</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ehrlich</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escaram&#xed;s</LastName><ForeName>Ge&#xf2;rgia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esko</LastName><ForeName>T&#xf5;nu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Estivill</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farmer</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Favaro</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fern&#xe1;ndez-Aranda</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fichter</LastName><ForeName>Manfred</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fischer</LastName><ForeName>Krista</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>F&#xf6;cker</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foretova</LastName><ForeName>Lenka</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forstner</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forzan</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallinger</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaspar</LastName><ForeName>H&#xe9;l&#xe9;na</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giegling</LastName><ForeName>Ina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giuranna</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giusti-Rodr&#xed;quez</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonidakis</LastName><ForeName>Fragiskos</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorwood</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gratacos Mayora</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grove</LastName><ForeName>Jakob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillaume</LastName><ForeName>S&#xe9;bastien</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guo</LastName><ForeName>Yiran</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Halmi</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanscombe</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hatzikotoulas</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hauser</LastName><ForeName>Joanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hebebrand</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Helder</LastName><ForeName>Sietske</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henders</LastName><ForeName>Anjali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herms</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herpertz-Dahlmann</LastName><ForeName>Beate</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herzog</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinney</LastName><ForeName>Anke</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horwood</LastName><ForeName>L John</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xfc;bel</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huckins</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Imgart</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Inoko</LastName><ForeName>Hidetoshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janout</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jim&#xe9;nez-Murcia</LastName><ForeName>Susana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Craig</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jordan</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juli&#xe0;</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jur&#xe9;us</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalsi</LastName><ForeName>Gursharan</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaminsk&#xe1;</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaprio</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karhunen</LastName><ForeName>Leila</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karwautz</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kas</LastName><ForeName>Martien</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keski-Rahkonen</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiezebrink</LastName><ForeName>Kirsty</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Youl-Ri</ForeName><Initials>YR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirk</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klareskog</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klump</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knudsen</LastName><ForeName>Gun Peggy</ForeName><Initials>GP</Initials></Investigator><Investigator ValidYN="Y"><LastName>La Via</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Land&#xe9;n</LastName><ForeName>Mikael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larsen</LastName><ForeName>Janne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Hellard</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepp&#xe4;</LastName><ForeName>Virpi</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levitan</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Dong</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lichtenstein</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lilenfeld</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Bochao Danae</ForeName><Initials>BD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lissowska</LastName><ForeName>Jolanta</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luykx</LastName><ForeName>Jurjen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Magistretti</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maj</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mannik</LastName><ForeName>Katrin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsal</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mattheisen</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mattingsdal</LastName><ForeName>Morten</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDevitt</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGuffin</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Medland</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Metspalu</LastName><ForeName>Andres</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meulenbelt</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Micali</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitchell</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monteleone</LastName><ForeName>Palmiero</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monteleone</LastName><ForeName>Alessio Maria</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Grant</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mortensen</LastName><ForeName>Preben Bo</ForeName><Initials>PB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munn-Chernoff</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Navratilova</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norring</LastName><ForeName>Claes</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ntalla</LastName><ForeName>Ioanna</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olsen</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ophoff</LastName><ForeName>Roel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Toole</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padyukov</LastName><ForeName>Leonid</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palotie</LastName><ForeName>Aarno</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pantel</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papezova</LastName><ForeName>Hana</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parker</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearson</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Liselotte</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinto</LastName><ForeName>Dalila</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Purves</LastName><ForeName>Kirstin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabionet</LastName><ForeName>Raquel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raevuori</LastName><ForeName>Anu</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramoz</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reichborn-Kjennerud</LastName><ForeName>Ted</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ricca</LastName><ForeName>Valdo</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ripatti</LastName><ForeName>Samuli</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ripke</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ritschel</LastName><ForeName>Franziska</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Marion</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rotondo</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rujescu</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>Filip</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santonastaso</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scherag</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scherer</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schork</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schosser</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seitz</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slachtova</LastName><ForeName>Lenka</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slagboom</LastName><ForeName>P Eline</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slof-Op 't Landt</LastName><ForeName>Margarita</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slopien</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strober</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stuber</LastName><ForeName>Garret</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#x15a;wi&#x105;tkowska</LastName><ForeName>Beata</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Szatkiewicz</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tachmazidou</LastName><ForeName>Ioanna</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tenconi</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thornton</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tortorella</LastName><ForeName>Alfonso</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tozzi</LastName><ForeName>Federica</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Treasure</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsitsika</LastName><ForeName>Artemis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tyszkiewicz-Nwafor</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tziouvas</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Elburg</LastName><ForeName>Annemarie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Furth</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wade</LastName><ForeName>Tracey</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wagner</LastName><ForeName>Gudrun</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walton</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>Hunna</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Werge</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whiteman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Widen</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woodside</LastName><ForeName>D Blake</ForeName><Initials>DB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yao</LastName><ForeName>Shuyang</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yilmaz</LastName><ForeName>Zeynep</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zeggini</LastName><ForeName>Eleftheria</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zerwas</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zipfel</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anttila</LastName><ForeName>Verneri</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Artto</LastName><ForeName>Ville</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belin</LastName><ForeName>Andrea Carmine</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Boer</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boomsma</LastName><ForeName>Dorret I</ForeName><Initials>DI</Initials></Investigator><Investigator ValidYN="Y"><LastName>B&#xf8;rte</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chasman</LastName><ForeName>Daniel I</ForeName><Initials>DI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cherkas</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christensen</LastName><ForeName>Anne Francke</ForeName><Initials>AF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cormand</LastName><ForeName>Bru</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuenca-Leon</LastName><ForeName>Ester</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davey-Smith</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dichgans</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esko</LastName><ForeName>Tonu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esserlind</LastName><ForeName>Ann Louise</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frants</LastName><ForeName>Rune R</ForeName><Initials>RR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freilinger</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furlotte</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gormley</LastName><ForeName>Padhraig</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffiths</LastName><ForeName>Lyn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamalainen</LastName><ForeName>Eija</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hansen</LastName><ForeName>Thomas Folkmann</ForeName><Initials>TF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hiekkala</LastName><ForeName>Marjo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingason</LastName><ForeName>Andres</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xe4;rvelin</LastName><ForeName>Marjo-Riitta</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kajanne</LastName><ForeName>Risto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kallela</LastName><ForeName>Mikko</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaprio</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaunisto</LastName><ForeName>Mari</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kogelman</LastName><ForeName>Lisette J A</ForeName><Initials>LJA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kubisch</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurki</LastName><ForeName>Mitja</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurth</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehtimaki</LastName><ForeName>Terho</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lessel</LastName><ForeName>Davor</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ligthart</LastName><ForeName>Lannie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Litterman</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maagdenberg</LastName><ForeName>Arn van den</ForeName><Initials>AVD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macaya</LastName><ForeName>Alfons</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malik</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mangino</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMahon</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muller-Myhsok</LastName><ForeName>Bertram</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neale</LastName><ForeName>Benjamin M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Northover</LastName><ForeName>Carrie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nyholt</LastName><ForeName>Dale R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olesen</LastName><ForeName>Jes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palotie</LastName><ForeName>Aarno</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palta</LastName><ForeName>Priit</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Posthuma</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pozo-Rosich</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pressman</LastName><ForeName>Alice</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raitakari</LastName><ForeName>Olli</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xfc;rks</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sintas</LastName><ForeName>Celia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Kari</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Hreinn</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strachan</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terwindt</LastName><ForeName>Gisela</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vila-Pueyo</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wessman</LastName><ForeName>Maija</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winsvold</LastName><ForeName>Bendik S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>Huiying</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zwart</LastName><ForeName>John Anker</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agee</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alipanahi</LastName><ForeName>Babak</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auton</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bryc</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elson</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fontanillas</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furlotte</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heilbron</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinds</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huber</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleinman</LastName><ForeName>Aaron</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Litterman</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCreight</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mountain</LastName><ForeName>Joanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noblin</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Northover</LastName><ForeName>Carrie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pitts</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sathirapongsasuti</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sazonova</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shelton</LastName><ForeName>Janie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shringarpure</LastName><ForeName>Suyash</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tian</LastName><ForeName>Chao</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tung</LastName><ForeName>Joyce</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vacic</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32341526</ArticleId><ArticleId IdType="mid">NIHMS1672179</ArticleId><ArticleId IdType="pmc">PMC7930801</ArticleId><ArticleId IdType="doi">10.1038/s41588-020-0610-9</ArticleId><ArticleId IdType="pii">10.1038/s41588-020-0610-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polderman TJC et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. Nat. Genet. 47, 702&#x2013;709 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25985137</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi&#xf1;as AF et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 50, 381&#x2013;389 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5918692</ArticleId><ArticleId IdType="pubmed">29483656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JJ, Wedow R &amp; Okbay. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat. Genet. 50, 1112&#x2013;1121 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393768</ArticleId><ArticleId IdType="pubmed">30038396</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel M et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. Nat. Genet. 50, 920&#x2013;927 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29942085</ArticleId></ArticleIdList></Reference><Reference><Citation>Yengo L et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. Hum. Mol. Genet. 27, 3641&#x2013;3649 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6488973</ArticleId><ArticleId IdType="pubmed">30124842</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurano MT et al. Systematic localization of common disease-associated variation in regulatory DNA. Science (80-. ). 337, 1190&#x2013;1195 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771521</ArticleId><ArticleId IdType="pubmed">22955828</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbarian S et al. The PsychENCODE project. Nature Neuroscience 18, 1707&#x2013;1712 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675669</ArticleId><ArticleId IdType="pubmed">26605881</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguet F et al. Genetic effects on gene expression across human tissues. Nature 550, 204&#x2013;213 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5776756</ArticleId><ArticleId IdType="pubmed">29022597</ArticleId></ArticleIdList></Reference><Reference><Citation>Roadmap Epigenomics Consortium et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317&#x2013;329 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530010</ArticleId><ArticleId IdType="pubmed">25693563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongen H et al. Estimating the causal tissues for complex traits and diseases. Nat. Genet. 49, 1676&#x2013;1683 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29058715</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene NG &amp; Grant SGN Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment. Front. Neurosci. 10, 1&#x2013;11 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730103</ArticleId><ArticleId IdType="pubmed">26858593</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene NG et al. Genetic identification of brain cell types underlying schizophrenia. Nat. Genet. 50, 825&#x2013;833 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6477180</ArticleId><ArticleId IdType="pubmed">29785013</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane HK et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nat. Genet. 50, 621&#x2013;629 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5896795</ArticleId><ArticleId IdType="pubmed">29632380</ArticleId></ArticleIdList></Reference><Reference><Citation>Calderon D et al. Inferring relevant cell types for complex traits by using single-cell gene expression. Am. J. Hum. Genet. 101, 686&#x2013;699 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5673624</ArticleId><ArticleId IdType="pubmed">29106824</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage JE et al. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nat. Genet. 50, 912&#x2013;919 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6411041</ArticleId><ArticleId IdType="pubmed">29942086</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman JRI et al. Biological annotation of genetic loci associated with intelligence in a meta-analysis of 87, 740 individuals.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6330082</ArticleId><ArticleId IdType="pubmed">29520040</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat. Genet. doi:10.1038/s41588-018-0311-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0311-9</ArticleId><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA et al. Expanding Parkinson&#x2019;s disease genetics: novel risk loci, genomic context, causal insights and heritable risk. bioRxiv 388165 (2019). doi:10.1101/388165</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/388165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nat. Genet. 46, 989&#x2013;993 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet. 47, 1236&#x2013;1241 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4797329</ArticleId><ArticleId IdType="pubmed">26414676</ArticleId></ArticleIdList></Reference><Reference><Citation>Anttila V et al. Analysis of shared heritability in common disorders of the brain. Science (80-.) 360, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097237</ArticleId><ArticleId IdType="pubmed">29930110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45, 984&#x2013;994 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800159</ArticleId><ArticleId IdType="pubmed">23933821</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Mooij JM, Heskes T &amp; Posthuma D MAGMA: Generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 11, (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401657</ArticleId><ArticleId IdType="pubmed">25885710</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane HK et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228&#x2013;1235 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626285</ArticleId><ArticleId IdType="pubmed">26414678</ArticleId></ArticleIdList></Reference><Reference><Citation>Jevtic S, Sengar AS, Salter MW &amp; McLaurin JA The role of the immune system in Alzheimer disease: Etiology and treatment. Ageing Research Reviews 40, 84&#x2013;94 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28941639</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nature Genetics 51, 404&#x2013;413 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet. 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Leary DH et al. Carotid-Artery Intima and Media Thickness as a Risk Factor for Myocardial Infarction and Stroke in Older Adults. N. Engl. J. Med. 340, 14&#x2013;22 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9878640</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PF &amp; Geschwind DH Defining the Genetic, Genomic, Cellular, and Diagnostic Architectures of Psychiatric Disorders. Cell 177, 162&#x2013;183 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6432948</ArticleId><ArticleId IdType="pubmed">30901538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A et al. Molecular architecture of the mouse nervous system. Cell 174, 999&#x2013;1014.e22 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086934</ArticleId><ArticleId IdType="pubmed">30096314</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A unique microglia type associated with restricting development of alzheimer&#x2019;s disease. Cell 169, (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H et al. Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiol. Aging 24, 197&#x2013;211 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D &amp; Surmeier DJ Neuronal vulnerability, pathogenesis, and Parkinson&#x2019;s disease. Movement Disorders 28, 41&#x2013;50 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578396</ArticleId><ArticleId IdType="pubmed">22791686</ArticleId></ArticleIdList></Reference><Reference><Citation>Poewe W et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28332488</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday GM et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson&#x2019;s disease. Ann. Neurol. 27, 373&#x2013;385 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">1972319</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaville C, de Deurwaerd&#xe8;re P &amp; Benazzouz A Noradrenaline and Parkinson&#x2019;s disease. Frontiers in Systems Neuroscience (2011). doi:10.3389/fnsys.2011.00031</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnsys.2011.00031</ArticleId><ArticleId IdType="pmc">PMC3103977</ArticleId><ArticleId IdType="pubmed">21647359</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Ma SY, Lee MS, Collan Y &amp; R&#xf6;ytt&#xe4; M Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson&#x2019;s disease is related to disability of the patients. Park. Relat. Disord. (2008). doi:10.1016/j.parkreldis.2008.01.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2008.01.006</ArticleId><ArticleId IdType="pubmed">18329941</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, R&#xfc;b U, Gai WP &amp; Del Tredici K Idiopathic Parkinson&#x2019;s disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. (2003). doi:10.1007/s00702-002-0808-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-002-0808-2</ArticleId><ArticleId IdType="pubmed">12721813</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddle RA Parkinson&#x2019;s disease from the gut. Brain Research (2018). doi:10.1016/j.brainres.2018.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.01.010</ArticleId><ArticleId IdType="pmc">PMC6003841</ArticleId><ArticleId IdType="pubmed">29360467</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrett RM, Alexopoulou Z &amp; Tofaris GK The endosomal pathway in Parkinson&#x2019;s disease. Molecular and Cellular Neuroscience 66, 21&#x2013;28 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25701813</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A et al. Molecular diversity and specializations among the cells of the adult mouse brain. Cell 174, 1015&#x2013;1030.e16 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods 14, 955 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature (2019). doi:10.1038/s41586-019-1195-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A et al. Molecular Diversity and Specializations among the Cells of the Adult Mouse Brain. Cell 174, 1015&#x2013;1030.e16 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat. Biotechnol. 36, 70&#x2013;80 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesnick TG et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet. 3, 0984&#x2013;0995 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1904362</ArticleId><ArticleId IdType="pubmed">17571925</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran LB et al. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson&#x2019;s disease. Neurogenetics (2006). doi:10.1007/s10048-005-0020-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-005-0020-2</ArticleId><ArticleId IdType="pubmed">16344956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannarkat GT, Boss JM &amp; Tansey MG The role of innate and adaptive immunity in parkinson&#x2019;s disease. Journal of Parkinson&#x2019;s Disease 3, 493&#x2013;514 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102262</ArticleId><ArticleId IdType="pubmed">24275605</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliano SA et al. Genomics implicates adaptive and innate immunity in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Ann. Clin. Transl. Neurol. 3, 924&#x2013;933 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5224821</ArticleId><ArticleId IdType="pubmed">28097204</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijkstra AA et al. Evidence for immune response, axonal dysfunction and reduced endocytosis in the substantia nigra in early stage Parkinson&#x2019;s disease. PLoS One 10, (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4472235</ArticleId><ArticleId IdType="pubmed">26087293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science (80-. ). 352, 1586&#x2013;1590 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5038589</ArticleId><ArticleId IdType="pubmed">27339989</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathyamurthy A et al. Massively Parallel Single Nucleus Transcriptional Profiling Defines Spinal Cord Neurons and Their Activity during Behavior. Cell Rep. 22, 2216&#x2013;2225 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5849084</ArticleId><ArticleId IdType="pubmed">29466745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB et al. A comparative strategy for single-nucleus and single-cell transcriptomes confirms accuracy in predicted cell-type expression from nuclear RNA. Sci. Rep. 7, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519641</ArticleId><ArticleId IdType="pubmed">28729663</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryois J et al. Evaluation of chromatin accessibility in prefrontal cortex of individuals with schizophrenia. Nat. Commun. 9, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6081462</ArticleId><ArticleId IdType="pubmed">30087329</ArticleId></ArticleIdList></Reference><Reference><Citation>Fullard JF et al. An atlas of chromatin accessibility in the adult human brain. Genome Res. 28, 1243&#x2013;1252 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6071637</ArticleId><ArticleId IdType="pubmed">29945882</ArticleId></ArticleIdList></Reference><Reference><Citation>Hook PW &amp; McCallion AS Heritability enrichment in open chromatin reveals cortical layer contributions to schizophrenia. bioRxiv (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197474</ArticleId><ArticleId IdType="pubmed">32303558</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspi A et al. The p factor: One general psychopathology factor in the structure of psychiatric disorders? Clin. Psychol. Sci. 2, 119&#x2013;137 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4209412</ArticleId><ArticleId IdType="pubmed">25360393</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PF &amp; Geschwind DH Defining the genetic, genomic, cellular, and diagnostic architectures of psychiatric disorders. Submitted</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6432948</ArticleId><ArticleId IdType="pubmed">30901538</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller AH &amp; Raison CL The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nature Reviews Immunology 16, 22&#x2013;34 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5542678</ArticleId><ArticleId IdType="pubmed">26711676</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller N, Weidinger E, Leitner B &amp; Schwarz MJ The role of inflammation in schizophrenia. Frontiers in Neuroscience 9, (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4612505</ArticleId><ArticleId IdType="pubmed">26539073</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds RH et al. Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson&#x2019;s disease heritability. bioRxiv 442152 (2018). doi:10.1101/442152</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/442152</ArticleId><ArticleId IdType="pmc">PMC6470136</ArticleId><ArticleId IdType="pubmed">31016231</ArticleId></ArticleIdList></Reference><Reference><Citation>Recasens A &amp; Dehay B Alpha-synuclein spreading in Parkinson&#x2019;s disease. Front. Neuroanat. 8, (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270285</ArticleId><ArticleId IdType="pubmed">25565982</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelender S &amp; Isacson O The threshold theory for Parkinson&#x2019;s disease. Trends in Neurosciences 40, 4&#x2013;14 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27894611</ArticleId></ArticleIdList></Reference><Reference><Citation>Surmeier DJ, Obeso JA &amp; Halliday GM Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience 18, 101&#x2013;113 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5564322</ArticleId><ArticleId IdType="pubmed">28104909</ArticleId></ArticleIdList></Reference><Reference><Citation>Singaram C et al. Dopaminergic defect of enteric nervous system in Parkinson&#x2019;s disease patients with chronic constipation. Lancet (1995). doi:10.1016/S0140-6736(95)92707-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(95)92707-7</ArticleId><ArticleId IdType="pubmed">7564669</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Takahashi H, Takeda S, Ohama E &amp; Ikuta F Lewy Bodies in the Enteric Nervous System in Parkinson&#x2019;s Disease. Arch. Histol. Cytol. (1989). doi:10.1679/aohc.52.Suppl_191</Citation><ArticleIdList><ArticleId IdType="doi">10.1679/aohc.52.Suppl_191</ArticleId><ArticleId IdType="pubmed">2554944</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ &amp; Borghammer P Pathological &#x3b1;-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. (2016). doi:10.1002/ana.24648</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24648</ArticleId><ArticleId IdType="pubmed">27015771</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson E et al. Vagotomy and subsequent risk of Parkinson&#x2019;s disease. Ann. Neurol. (2015). doi:10.1002/ana.24448</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24448</ArticleId><ArticleId IdType="pubmed">26031848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670&#x2013;676 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676993</ArticleId><ArticleId IdType="pubmed">18725592</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorsey ER et al. Virtual research visits and direct-to-consumer genetic testing in Parkinson&#x2019;s disease. Digit. Heal. 1, 205520761559299 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5999055</ArticleId><ArticleId IdType="pubmed">29942542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H &amp; Takahashi H NACP/&#x3b1;-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson&#x2019;s disease brains. Acta Neuropathol. 99, 14&#x2013;20 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10651022</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidel K et al. The brainstem pathologies of Parkinson&#x2019;s disease and dementia with lewy bodies. Brain Pathol. 25, 121&#x2013;135 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397912</ArticleId><ArticleId IdType="pubmed">24995389</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl E et al. Genomewide association study identifies 30 loci associated with bipolar disorder. bioRxiv 173062 (2017). doi:10.1101/173062</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/173062</ArticleId><ArticleId IdType="pmc">PMC6956732</ArticleId><ArticleId IdType="pubmed">31043756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray N, Sullivan PF &amp; PGC MDDWG of the. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat. Genet. 50, 668&#x2013;681 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5934326</ArticleId><ArticleId IdType="pubmed">29700475</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry JRB et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature 514, 92&#x2013;97 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185210</ArticleId><ArticleId IdType="pubmed">25231870</ArticleId></ArticleIdList></Reference><Reference><Citation>Grove J et al. Common risk variants identified in autism spectrum disorder. bioRxiv 33, 42 (2017).</Citation></Reference><Reference><Citation>Gormley P et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat. Genet. 48, 1296 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27681292</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen W et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 48, 1043&#x2013;1048 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Demontis D et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat. Genet. (2018). doi:10.1038/s41588-018-0269-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0269-7</ArticleId><ArticleId IdType="pmc">PMC6481311</ArticleId><ArticleId IdType="pubmed">30478444</ArticleId></ArticleIdList></Reference><Reference><Citation>Day FR et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat. Genet. 47, 1294&#x2013;1303 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4661791</ArticleId><ArticleId IdType="pubmed">26414677</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CP et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. Nature Genetics 49, (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28714975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler E et al. Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations. PLoS Med. 14, 1&#x2013;30 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5595282</ArticleId><ArticleId IdType="pubmed">28898252</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibar DP et al. Novel genetic loci associated with hippocampal volume. Nat. Commun. 8, 13624 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5253632</ArticleId><ArticleId IdType="pubmed">28098162</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lange KM et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256&#x2013;261 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5289481</ArticleId><ArticleId IdType="pubmed">28067908</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams HHH et al. Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nat. Neurosci. 19, 1569&#x2013;1582 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5227112</ArticleId><ArticleId IdType="pubmed">27694991</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik R et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat. Genet. 50, 524&#x2013;537 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5968830</ArticleId><ArticleId IdType="pubmed">29531354</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott RA et al. An expanded genome-wide association study of type 2 diabetes in europeans. Diabetes 66, 2888&#x2013;2902 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5652602</ArticleId><ArticleId IdType="pubmed">28566273</ArticleId></ArticleIdList></Reference><Reference><Citation>Shungin D et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 518, 187&#x2013;196 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338562</ArticleId><ArticleId IdType="pubmed">25673412</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson HJ et al. Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. Nat. Genet. (2019). doi:10.1038/s41588-019-0439-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0439-2</ArticleId><ArticleId IdType="pmc">PMC6779477</ArticleId><ArticleId IdType="pubmed">31308545</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y &amp; Abecasis GR METAL: Fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190&#x2013;2191 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A et al. Molecular diversity and specializations among the cells of the adult mouse brain. Cell 174, 1015&#x2013;1030.e16 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Auton A et al. A global reference for human genetic variation. Nature 526, 68&#x2013;74 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A et al. Molecular Architecture of the Mouse Nervous System. Cell 174, 999&#x2013;1014.e22 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086934</ArticleId><ArticleId IdType="pubmed">30096314</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K, Umi&#x107;evi&#x107; Mirkov M, de Leeuw CA, van den Heuvel MP &amp; Posthuma D Genetic mapping of cell type specificity for complex traits. Nat. Commun. (2019). doi:10.1038/s41467-019-11181-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11181-1</ArticleId><ArticleId IdType="pmc">PMC6642112</ArticleId><ArticleId IdType="pubmed">31324783</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane HK et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228&#x2013;1235 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626285</ArticleId><ArticleId IdType="pubmed">26414678</ArticleId></ArticleIdList></Reference><Reference><Citation>Cajigas IJ et al. The Local Transcriptome in the Synaptic Neuropil Revealed by Deep Sequencing and High-Resolution Imaging. Neuron 74, 453&#x2013;466 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3627340</ArticleId><ArticleId IdType="pubmed">22578497</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexa A &amp; Rahnenfuhrer J topGO: Enrichment analysis for gene ontology. (2016).</Citation></Reference><Reference><Citation>Gautier L, Cope L, Bolstad BM &amp; Irizarry RA Affy - Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307&#x2013;315 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14960456</ArticleId></ArticleIdList></Reference><Reference><Citation>Durinck S, Spellman PT, Birney E &amp; Huber W Mapping identifiers for the integration of genomic datasets with the R/ Bioconductor package biomaRt. Nat. Protoc. 4, 1184&#x2013;1191 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159387</ArticleId><ArticleId IdType="pubmed">19617889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 47, 291&#x2013;295 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32376954</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>581</Volume><Issue>7806</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.</ArticleTitle><Pagination><StartPage>71</StartPage><EndPage>76</EndPage><MedlinePgn>71-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2247-3</ELocationID><Abstract><AbstractText>Vascular contributions to dementia and Alzheimer's disease are increasingly recognized<sup>1-6</sup>. Recent studies have suggested that breakdown of the blood-brain barrier (BBB) is an early biomarker of human cognitive dysfunction<sup>7</sup>, including the early clinical stages of Alzheimer's disease<sup>5,8-10</sup>. The E4 variant of apolipoprotein E (APOE4), the main susceptibility gene for Alzheimer's disease<sup>11-14</sup>, leads to accelerated breakdown of the BBB and degeneration of brain capillary pericytes<sup>15-19</sup>, which maintain BBB integrity<sup>20-22</sup>. It is unclear, however, whether the cerebrovascular effects of APOE4 contribute to cognitive impairment. Here we show that individuals bearing APOE4 (with the &#x3b5;3/&#x3b5;4 or &#x3b5;4/&#x3b5;4 alleles) are distinguished from those without APOE4 (&#x3b5;3/&#x3b5;3) by breakdown of the BBB in the hippocampus and medial temporal lobe. This finding is apparent in cognitively unimpaired APOE4 carriers and more severe in those with cognitive impairment, but is not related to amyloid-&#x3b2; or tau pathology measured in cerebrospinal fluid or by positron emission tomography<sup>23</sup>. High baseline levels of the BBB pericyte injury biomarker soluble PDGFR&#x3b2;<sup>7,8</sup> in the cerebrospinal fluid predicted future cognitive decline in APOE4 carriers but not in non-carriers, even after controlling for amyloid-&#x3b2; and tau status, and were correlated with increased activity of the BBB-degrading cyclophilin A-matrix metalloproteinase-9 pathway<sup>19</sup> in cerebrospinal fluid. Our findings suggest that breakdown of the BBB contributes to APOE4-associated cognitive decline independently of Alzheimer's disease pathology, and might be a therapeutic target in APOE4 carriers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Montagne</LastName><ForeName>Axel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5564-985X</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nation</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychological Science, University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Memory Disorders and Neurological Impairments, University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sagare</LastName><ForeName>Abhay P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Barisano</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5598-1369</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sweeney</LastName><ForeName>Melanie D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakhoyan</LastName><ForeName>Ararat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pachicano</LastName><ForeName>Maricarmen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joe</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Amy R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Orazio</LastName><ForeName>Lina M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buennagel</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Huntington Medical Research Institutes, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Huntington Medical Research Institutes, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Hope Center for Neurodegenerative Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>The Hope Center for Neurodegenerative Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-0705-3696</Identifier><AffiliationInfo><Affiliation>Banner Alzheimer Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tcw</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3054-9374</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yining</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pa</LastName><ForeName>Judy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conti</LastName><ForeName>Peter S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Radiology, Monash University, Alfred Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials><Identifier Source="ORCID">0000-0002-6802-8232</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. zlokovic@usc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. zlokovic@usc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064228</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG062683</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS100459</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB009352</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG058780</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG052350</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG058780</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG060049</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS090904</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066530</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054434</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020797">Receptor, Platelet-Derived Growth Factor beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="C579270">MMP9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.2.1.-</RegistryNumber><NameOfSubstance UI="D021984">Cyclophilin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2020 May;581(7806):31-32. doi: 10.1038/d41586-020-01152-8.</RefSource><PMID Version="1">32350425</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Jul;16(7):350. doi: 10.1038/s41582-020-0367-x.</RefSource><PMID Version="1">32393877</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Cereb Blood Flow Metab. 2020 Sep;40(9):1912-1914. doi: 10.1177/0271678X20938146.</RefSource><PMID Version="1">32600092</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021984" MajorTopicYN="N">Cyclophilin A</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020534" MajorTopicYN="N">Parahippocampal Gyrus</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020286" MajorTopicYN="N">Pericytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020797" MajorTopicYN="N">Receptor, Platelet-Derived Growth Factor beta</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32376954</ArticleId><ArticleId IdType="mid">NIHMS1581356</ArticleId><ArticleId IdType="pmc">PMC7250000</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2247-3</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-2247-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wardlaw JM et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 12, 822&#x2013;838 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714437</ArticleId><ArticleId IdType="pubmed">23867200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapasi A, DeCarli C &amp; Schneider JA Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. (Berl.) 134, 171&#x2013;186 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663642</ArticleId><ArticleId IdType="pubmed">28488154</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron 96, 17&#x2013;42 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657612</ArticleId><ArticleId IdType="pubmed">28957666</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y et al. Early role of vascular dysregulation on late-onset Alzheimer&#x2019;s disease based on multifactorial data-driven analysis. Nat. Commun 7, 11934 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4919512</ArticleId><ArticleId IdType="pubmed">27327500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD, Sagare AP &amp; Zlokovic BV Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol 14, 133&#x2013;150 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD et al. Vascular dysfunction-The disregarded partner of Alzheimer&#x2019;s disease. Alzheimers Dement. J. Alzheimers Assoc 15, 158&#x2013;167 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6338083</ArticleId><ArticleId IdType="pubmed">30642436</ArticleId></ArticleIdList></Reference><Reference><Citation>Nation DA et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat. Med 25, 270&#x2013;276 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367058</ArticleId><ArticleId IdType="pubmed">30643288</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296&#x2013;302 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4350773</ArticleId><ArticleId IdType="pubmed">25611508</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Haar HJ et al. Neurovascular unit impairment in early Alzheimer&#x2019;s disease measured with magnetic resonance imaging. Neurobiol. Aging 45, 190&#x2013;196 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27459939</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Haar HJ et al. Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease. Radiology 281, 527&#x2013;535 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27243267</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science 261, 921&#x2013;923 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD Apolipoprotein E alleles as risk factors in Alzheimer&#x2019;s disease. Annu. Rev. Med 47, 387&#x2013;400 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8712790</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349&#x2013;1356 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol. Psychiatry 16, 903&#x2013;907 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hultman K, Strickland S &amp; Norris EH The APOE &#x25b;4/&#x25b;4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer&#x2019;s disease patients. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab 33, 1251&#x2013;1258 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3734776</ArticleId><ArticleId IdType="pubmed">23652625</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday MR et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer&#x2019;s disease. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab 36, 216&#x2013;227 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758554</ArticleId><ArticleId IdType="pubmed">25757756</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S et al. Effect of APOE genotype on microvascular basement membrane in Alzheimer&#x2019;s disease. J. Neurol. Sci 203&#x2013;204, 183&#x2013;187 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12417381</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipser BD Microvascular injury and blood-brain barrier leakage in Alzheimer/&#x2019;s disease. Neurobiol Aging 28, 977&#x2013;986 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">16782234</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512&#x2013;516 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A et al. Pericytes regulate the blood-brain barrier. Nature 468, 557&#x2013;561 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68, 409&#x2013;427 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056408</ArticleId><ArticleId IdType="pubmed">21040844</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolakopoulou AM et al. Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. Nat. Neurosci 22, 1089&#x2013;1098 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6668719</ArticleId><ArticleId IdType="pubmed">31235908</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. J. Alzheimers Assoc 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan C et al. Diagnostic Values of Cerebrospinal Fluid T-Tau and A&#x3b2;&#x2084;&#x2082; using Meso Scale Discovery Assays for Alzheimer&#x2019;s Disease. J. Alzheimers Dis. JAD 45, 709&#x2013;719 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517668</ArticleId><ArticleId IdType="pubmed">25613100</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80, 1784&#x2013;1791 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A, Zhao Z &amp; Zlokovic BV Alzheimer&#x2019;s disease: A matter of blood-brain barrier dysfunction? J. Exp. Med 214, 3151&#x2013;3169 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5679168</ArticleId><ArticleId IdType="pubmed">29061693</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett RE et al. Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A 115, E1289&#x2013;E1298 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819390</ArticleId><ArticleId IdType="pubmed">29358399</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouquet M, Besson FL, Gonneaud J, La Joie R &amp; Ch&#xe9;telat G Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan. Neuropsychol. Rev 24, 290&#x2013;299 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25146994</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz SA et al. Widespread distribution of tauopathy in preclinical Alzheimer&#x2019;s disease. Neurobiol. Aging 72, 177&#x2013;185 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6422832</ArticleId><ArticleId IdType="pubmed">30292840</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners JS, Kehoe PG, Love S, Zetterberg H &amp; Blennow K CSF evidence of pericyte damage in Alzheimer&#x2019;s disease is associated with markers of blood-brain barrier dysfunction and disease pathology. Alzheimers Res. Ther 11, 81 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6745071</ArticleId><ArticleId IdType="pubmed">31521199</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanciu C, Trifan A, Muzica C &amp; Sfarti C Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opin. Pharmacother 20, 379&#x2013;384 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30576256</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis. Assoc. Disord 20, 210&#x2013;216 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412&#x2013;2414 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Nation DA et al. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer&#x2019;s disease. J. Alzheimers Dis. JAD 30, 595&#x2013;603 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370943</ArticleId><ArticleId IdType="pubmed">22451309</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangen KJ et al. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer&#x2019;s disease. Alzheimers Dement. J. Alzheimers Assoc 11, 394&#x2013;403.e1 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287462</ArticleId><ArticleId IdType="pubmed">25022538</ArticleId></ArticleIdList></Reference><Reference><Citation>Jak AJ et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry 17, 368&#x2013;375 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743175</ArticleId><ArticleId IdType="pubmed">19390294</ArticleId></ArticleIdList></Reference><Reference><Citation>Jak AJ et al. Neuropsychological Criteria for Mild Cognitive Impairment and Dementia Risk in the Framingham Heart Study. J. Int. Neuropsychol. Soc. JINS 22, 937&#x2013;943 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5045758</ArticleId><ArticleId IdType="pubmed">27029348</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S et al. The Alzheimer&#x2019;s Disease Centers&#x2019; Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis. Assoc. Disord 23, 91&#x2013;101 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743984</ArticleId><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser L et al. Version 3 of the National Alzheimer&#x2019;s Coordinating Center&#x2019;s Uniform Data Set. Alzheimer Dis. Assoc. Disord 32, 351&#x2013;358 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6249084</ArticleId><ArticleId IdType="pubmed">30376508</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis D, Kramer J, Kaplan E &amp; Ober B California Verbal Learning Test. (PsychCorp, 2000).</Citation></Reference><Reference><Citation>Montagne A et al. Undetectable gadolinium brain retention in individuals with an age-dependent blood-brain barrier breakdown in the hippocampus and mild cognitive impairment. Alzheimers Dement. J. Alzheimers Assoc 15, 1568&#x2013;1575 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927478</ArticleId><ArticleId IdType="pubmed">31862169</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B FreeSurfer. NeuroImage 62, 774&#x2013;781 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341&#x2013;355 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage 31, 968&#x2013;980 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B &amp; Dale AM Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. U. S. A 97, 11050&#x2013;11055 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27146</ArticleId><ArticleId IdType="pubmed">10984517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Sereno MI, Tootell RB &amp; Dale AM High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum. Brain Mapp 8, 272&#x2013;284 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6873338</ArticleId><ArticleId IdType="pubmed">10619420</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinov I et al. Neuroimaging study designs, computational analyses and data provenance using the LONI pipeline. PloS One 5, (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946935</ArticleId><ArticleId IdType="pubmed">20927408</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepehrband F et al. Neuroanatomical morphometric characterization of sex differences in youth using statistical learning. NeuroImage 172, 217&#x2013;227 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5967879</ArticleId><ArticleId IdType="pubmed">29414494</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabeen RP, Laidlaw DH &amp; Toga AW Quantitative imaging toolkit: Software for interactive 3D visualization, data exploration, and computational analysis of neuroimaging datasets. in Proceedings of the International Society for Magnetic Resonance in Medicine (ISMRM) vol. 2854 (2018).</Citation></Reference><Reference><Citation>Jenkinson M, Bannister P, Brady M &amp; Smith S Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage 17, 825&#x2013;841 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12377157</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullich S et al. Optimal Reference Region to Measure Longitudinal Amyloid-&#x3b2; Change with 18F-Florbetaben PET. J. Nucl. Med. Off. Publ. Soc. Nucl. Med 58, 1300&#x2013;1306 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28183994</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M et al. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson&#x2019;s case. Acta Neuropathol. Commun 5, 75 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5648451</ArticleId><ArticleId IdType="pubmed">29047416</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. NeuroImage 161, 171&#x2013;178 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5696044</ArticleId><ArticleId IdType="pubmed">28756238</ArticleId></ArticleIdList></Reference><Reference><Citation>TCW J et al. Cholesterol and matrisome pathways dysregulated in human &#x3b5;4 glia. bioRxiv (2019) doi:10.1101/713362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/713362</ArticleId></ArticleIdList></Reference><Reference><Citation>Faal T et al. Induction of Mesoderm and Neural Crest-Derived Pericytes from Human Pluripotent Stem Cells to Study Blood-Brain Barrier Interactions. Stem Cell Rep. 12, 451&#x2013;460 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6409424</ArticleId><ArticleId IdType="pubmed">30745035</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal CC Outlier analysis. (Springer, 2013).</Citation></Reference><Reference><Citation>Sagare AP, Sweeney MD, Makshanoff J &amp; Zlokovic BV Shedding of soluble platelet-derived growth factor receptor-&#x3b2; from human brain pericytes. Neurosci. Lett 607, 97&#x2013;101 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631673</ArticleId><ArticleId IdType="pubmed">26407747</ArticleId></ArticleIdList></Reference><Reference><Citation>Glickman ME, Rao SR &amp; Schultz MR False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. J. Clin. Epidemiol 67, 850&#x2013;857 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24831050</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32392471</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>SEQUIN Multiscale Imaging of Mammalian Central Synapses Reveals Loss of Synaptic Connectivity Resulting from Diffuse Traumatic Brain Injury.</ArticleTitle><Pagination><StartPage>257</StartPage><EndPage>273.e5</EndPage><MedlinePgn>257-273.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2020.04.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(20)30281-6</ELocationID><Abstract><AbstractText>The brain's complex microconnectivity underlies its computational abilities and vulnerability to injury and disease. It has been challenging to illuminate the features of this synaptic network due to the small size and dense packing of its elements. Here, we describe a rapid, accessible super-resolution imaging and analysis workflow-SEQUIN-that quantifies central synapses in human tissue and animal models, characterizes their nanostructural and molecular features, and enables volumetric imaging of mesoscale synaptic networks without the production of large histological arrays. Using SEQUIN, we identify cortical synapse loss resulting from diffuse traumatic brain injury, a highly prevalent connectional disorder. Similar synapse loss is observed&#xa0;in three murine models of Alzheimer-related neurodegeneration, where SEQUIN mesoscale mapping identifies regional synaptic vulnerability. These results establish an easily implemented and robust nano-to-mesoscale synapse quantification and characterization method. They furthermore identify a shared mechanism-synaptopathy-between Alzheimer neurodegeneration and its best-established epigenetic risk factor, brain trauma.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sauerbeck</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gangolli</LastName><ForeName>Mihika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>McKelvey School of Engineering, Washington University, St. Louis, MO 63130, USA; Currently, Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Sydney J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salyards</LastName><ForeName>Maverick H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Samuel H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemingway</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen, Munich 82152, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gratuze</LastName><ForeName>Maud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makkapati</LastName><ForeName>Tejaswi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerschensteiner</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen, Munich 82152, Germany; Munich Cluster of Systems Neurology (SyNergy), Munich 81377, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brody</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Currently, Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kummer</LastName><ForeName>Terrance T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: kummert@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 NS094760</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS102983</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021629</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="N">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049329" MajorTopicYN="N">Nanostructures</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">SEQUIN</Keyword><Keyword MajorTopicYN="N">TBI</Keyword><Keyword MajorTopicYN="N">imaging</Keyword><Keyword MajorTopicYN="N">microconnectivity</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">super-resolution microscopy</Keyword><Keyword MajorTopicYN="N">synapse</Keyword><Keyword MajorTopicYN="N">synaptome</Keyword><Keyword MajorTopicYN="N">traumatic brain injury</Keyword></KeywordList><CoiStatement>Declaration of Interests D.M.H. co-founded C2N Diagnostics, LLC, and advises/consults for C2N, Genentech, Denali, and Idorsia.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32392471</ArticleId><ArticleId IdType="mid">NIHMS1586788</ArticleId><ArticleId IdType="pmc">PMC7381374</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2020.04.012</ArticleId><ArticleId IdType="pii">S0896-6273(20)30281-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen P, Silfvenius H, Sundberg SH, and Sveen O. (1980). A comparison of distal and proximal dendritic synapses on CA1 pyramids in guinea-pig hippocampal slices in vitro. J Physiol 307, 273&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283045</ArticleId><ArticleId IdType="pubmed">7205666</ArticleId></ArticleIdList></Reference><Reference><Citation>Anton-Sanchez L, Bielza C, Merch&#xc3;&#xa1;n-P&#xc3;&#xa9;rez A, Rodr&#xc3;-guez J-R, DeFelipe J, and Larra&#xc3;&#xb1;aga P. (2014). Three-dimensional distribution of cortical synapses: a replicated point pattern-based analysis. Frontiers in Neuroanatomy 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4143965</ArticleId><ArticleId IdType="pubmed">25206325</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddeley Adrian, Rubak Ege, and Turner Rolf Spatial Point Patterns: Methodology and Applications with R.</Citation></Reference><Reference><Citation>Bartol TM Jr, Bromer C, Kinney J, Chirillo MA, Bourne JN, Harris KM, and Sejnowski TJ (2015). Nanoconnectomic upper bound on the variability of synaptic plasticity. ELife 4, e10778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4737657</ArticleId><ArticleId IdType="pubmed">26618907</ArticleId></ArticleIdList></Reference><Reference><Citation>Bay&#xe9;s &#xc0;, van de Lagemaat LN, Collins MO, Croning MDR, Whittle IR, Choudhary JS, and Grant SGN (2011). Characterization of the proteome, diseases and evolution of the human postsynaptic density. Nature Neuroscience 14, 19&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040565</ArticleId><ArticleId IdType="pubmed">21170055</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Bauer AQ, Stewart FR, White BR, Cirrito JR, Raichle ME, Culver JP, and Holtzman DM (2012). Bidirectional Relationship between Functional Connectivity and Amyloid-Deposition in Mouse Brain. Journal of Neuroscience 32, 4334&#x2013;4340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326343</ArticleId><ArticleId IdType="pubmed">22457485</ArticleId></ArticleIdList></Reference><Reference><Citation>Betzig E, Patterson GH, Sougrat R, Lindwasser OW, Olenych S, Bonifacino JS, Davidson MW, Lippincott-Schwartz J, and Hess HF (2006). Imaging Intracellular Fluorescent Proteins at Nanometer Resolution. Science 313, 1642&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bierbaum M, Leahy BD, Alemi AA, Cohen I, and Sethna JP (2017). Light Microscopy at Maximal Precision. Phys. Rev. X 7, 041007.</Citation></Reference><Reference><Citation>Bigler ED (2013). Traumatic brain injury, neuroimaging, and neurodegeneration. Front Hum Neurosci 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3734373</ArticleId><ArticleId IdType="pubmed">23964217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohland JW, Wu C, Barbas H, Bokil H, Bota M, Breiter HC, Cline HT, Doyle JC, Freed PJ, Greenspan RJ, et al. (2009). A Proposal for a Coordinated Effort for the Determination of Brainwide Neuroanatomical Connectivity in Model Organisms at a Mesoscopic Scale. PLOS Computational Biology 5, e1000334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655718</ArticleId><ArticleId IdType="pubmed">19325892</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada C-M, Kim G, Seekins S, Yager D, et al. (1996). Familial Alzheimer&#x2019;s Disease&#x2013;Linked Presenilin 1 Variants Elevate A&#x3b2;1&#x2013;42/1&#x2013;40 Ratio In Vitro and In Vivo. Neuron 17, 1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne JN, Chirillo MA, and Harris KM (2013). Presynaptic Ultrastructural Plasticity Along CA3&#x2192;CA1 Axons During Long-Term Potentiation in Mature Hippocampus. Journal of Comparative Neurology 521, 3898&#x2013;3912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838200</ArticleId><ArticleId IdType="pubmed">23784793</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggman KL, and Bock DD (2012). Volume electron microscopy for neuronal circuit reconstruction. Current Opinion in Neurobiology 22, 154&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">22119321</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadhead MJ, Horrocks MH, Zhu F, Muresan L, Benavides-Piccione R, DeFelipe J, Fricker D, Kopanitsa MV, Duncan RR, Klenerman D, et al. (2016). PSD95 nanoclusters are postsynaptic building blocks in hippocampus circuits. Scientific Reports 6, 24626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842999</ArticleId><ArticleId IdType="pubmed">27109929</ArticleId></ArticleIdList></Reference><Reference><Citation>Castej&#xf2;n OJ, Valero C, and D&#xec;az M. (1995). Synaptic degenerative changes in human traumatic brain edema. An electron microscopic study of cerebral cortical biopsies. J Neurosurg Sci 39, 47&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">8568555</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesca F, Baldelli P, Valtorta F, and Benfenati F. (2010). The synapsins: Key actors of synapse function and plasticity. Progress in Neurobiology 91, 313&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">20438797</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan NB (2014). Chronic neurodegenerative consequences of traumatic brain injury. Restorative Neurology and Neuroscience 32, 337&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">24398724</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole JH, Jolly A, de Simoni S, Bourke N, Patel MC, Scott G, and Sharp DJ (2018). Spatial patterns of progressive brain volume loss after moderate-severe traumatic brain injury. Brain 141, 822&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837530</ArticleId><ArticleId IdType="pubmed">29309542</ArticleId></ArticleIdList></Reference><Reference><Citation>Collman F, Buchanan J, Phend KD, Micheva KD, Weinberg RJ, and Smith SJ (2015). Mapping Synapses by Conjugate Light-Electron Array Tomography. J. Neurosci 35, 5792&#x2013;5807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388933</ArticleId><ArticleId IdType="pubmed">25855189</ArticleId></ArticleIdList></Reference><Reference><Citation>Crocker JC, and Grier DG (1996). Methods of Digital Video Microscopy for Colloidal Studies. Journal of Colloid and Interface Science 179, 298&#x2013;310.</Citation></Reference><Reference><Citation>Dani A, Huang B, Bergan J, Dulac C, and Zhuang X. (2010). Superresolution Imaging of Chemical Synapses in the Brain. Neuron 68, 843&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057101</ArticleId><ArticleId IdType="pubmed">21144999</ArticleId></ArticleIdList></Reference><Reference><Citation>Danielson NB, Zaremba JD, Kaifosh P, Bowler J, Ladow M, and Losonczy A. (2016). Sublayer-specific coding dynamics during spatial navigation and learning in hippocampal area CA1. Neuron 91, 652&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4975984</ArticleId><ArticleId IdType="pubmed">27397517</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies CA, Mann DMA, Sumpter PQ, and Yates PO (1987). A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer&#x2019;s disease. Journal of the Neurological Sciences 78, 151&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">3572454</ArticleId></ArticleIdList></Reference><Reference><Citation>Deerinck TJ, Bushong E, Thor A, Ellisman M, Deerinck T, Thor A, Deerinck TJ, Bushong EA, Thor CA, and Ellisman MH (2010). NCMIR methods for 3D EM: A new protocol for preparation of biological specimens for serial block face scanning electron microscopy.</Citation></Reference><Reference><Citation>DeKosky ST, and Scheff SW (1990). Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: Correlation with cognitive severity. Ann Neurol. 27, 457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Denk W, and Horstmann H. (2004). Serial Block-Face Scanning Electron Microscopy to Reconstruct Three-Dimensional Tissue Nanostructure. PLOS Biology 2, e329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524270</ArticleId><ArticleId IdType="pubmed">15514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Martin MV, Chambers S, and Csernansky JG (2007). Spatial relationship between synapse loss and &#x3b2;-amyloid deposition in Tg2576 mice. Journal of Comparative Neurology 500, 311&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1661843</ArticleId><ArticleId IdType="pubmed">17111375</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenstein M. (2015). Super-resolve me: from micro to nano. Nature 526, 459&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">26469055</ArticleId></ArticleIdList></Reference><Reference><Citation>Emes RD, and Grant SGN (2012). Evolution of Synapse Complexity and Diversity. Annual Review of Neuroscience 35, 111&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">22715880</ArticleId></ArticleIdList></Reference><Reference><Citation>Faden AI, and Loane DJ (2015). Chronic Neurodegeneration After Traumatic Brain Injury: Alzheimer Disease, Chronic Traumatic Encephalopathy, or Persistent Neuroinflammation? Neurotherapeutics 12, 143&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322076</ArticleId><ArticleId IdType="pubmed">25421001</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, Lichtman JW, and Sanes JR (2000). Imaging Neuronal Subsets in Transgenic Mice Expressing Multiple Spectral Variants of GFP. Neuron 28, 41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro M, Lamanna J, Ripamonti M, Racchetti G, Arena A, Spadini S, Montesano G, Cortese R, Zimarino V, and Malgaroli A. (2017). Functional mapping of brain synapses by the enriching activity-marker SynaptoZip. Nat Commun 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663910</ArticleId><ArticleId IdType="pubmed">29089485</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, and Giora A. (2003). Head injury as a risk factor for Alzheimer&#x2019;s disease: the evidence 10 years on; a partial replication. Journal of Neurology, Neurosurgery &amp; Psychiatry 74, 857&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738550</ArticleId><ArticleId IdType="pubmed">12810767</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortin DA, Tillo SE, Yang G, Rah J-C, Melander JB, Bai S, Soler-Cedeno O, Qin M, Zemelman BV, Guo C, et al. (2014). Live Imaging of Endogenous PSD-95 Using ENABLED: A Conditional Strategy to Fluorescently Label Endogenous Proteins. Journal of Neuroscience 34, 16698&#x2013;16712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4261096</ArticleId><ArticleId IdType="pubmed">25505322</ArticleId></ArticleIdList></Reference><Reference><Citation>Fremeau RT, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, Bellocchio EE, Fortin D, Storm-Mathisen J, and Edwards RH (2001). The Expression of Vesicular Glutamate Transporters Defines Two Classes of Excitatory Synapse. Neuron 31, 247&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">11502256</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerth F, J&#xe4;pel M, Pechstein A, Kochlamazashvili G, Lehmann M, Puchkov D, Onofri F, Benfenati F, Nikonenko AG, Fredrich K, et al. (2017). Intersectin associates with synapsin and regulates its nanoscale localization and function. PNAS 114, 12057&#x2013;12062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5692602</ArticleId><ArticleId IdType="pubmed">29078407</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregor I, and Enderlein J. (2019). Image scanning microscopy. Current Opinion in Chemical Biology 51, 74&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">31203139</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;rcan &#xd6; (2014). Effective connectivity at synaptic level in humans: a review and future prospects. Biol Cybern 108, 713&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">25128317</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM, and Stevens JK (1989). Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: serial electron microscopy with reference to their biophysical characteristics. J. Neurosci 9, 2982&#x2013;2997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569708</ArticleId><ArticleId IdType="pubmed">2769375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hell SW, and Wichmann J. (1994). Breaking the diffraction resolution limit by stimulated emission: stimulated-emission-depletion fluorescence microscopy. Opt. Lett., OL 19, 780&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">19844443</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Pickett E, and Spires-Jones TL (2016). Synaptic pathology: A shared mechanism in neurological disease. Ageing Research Reviews 28, 72&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">27108053</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess ST, Girirajan TPK, and Mason MD (2006). Ultra-High Resolution Imaging by Fluorescence Photoactivation Localization Microscopy. Biophysical Journal 91, 4258&#x2013;4272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1635685</ArticleId><ArticleId IdType="pubmed">16980368</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill CS, Coleman MP, and Menon DK (2016). Traumatic Axonal Injury: Mechanisms and Translational Opportunities. Trends in Neurosciences 39, 311&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5405046</ArticleId><ArticleId IdType="pubmed">27040729</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, and Goate AM (2011). Alzheimer&#x2019;s Disease: The Challenge of the Second Century. Science Translational Medicine 3, 77sr1&#x2013;77sr1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Nikolakopoulou AM, and Cohen-Cory S. (2005). BDNF stabilizes synapses and maintains the structural complexity of optic axons in vivo. Development 132, 4285&#x2013;4298.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141221</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff J. (2015). The Airyscan detector from ZEISS: confocal imaging with improved signal-to-noise ratio and super-resolution. Nat Meth 12.</Citation></Reference><Reference><Citation>Huff J, Bergter A, Birkenbeil J, Kleppe I, and Engelmann R. The New 2D Superresolution Mode for ZEISS Airyscan &#x2013; 120 nm Lateral Resolution without Acquiring a Z-stack. 6.</Citation></Reference><Reference><Citation>Igarashi KM, Ito HT, Moser EI, and Moser M-B (2014). Functional diversity along the transverse axis of hippocampal area CA1. FEBS Letters 588, 2470&#x2013;2476.</Citation><ArticleIdList><ArticleId IdType="pubmed">24911200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Mi Z, and Abrahamson EE (2017). Disordered APP metabolism and neurovasculature in trauma and aging: Combined risks for chronic neurodegenerative disorders. Ageing Res Rev 34, 51&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5315701</ArticleId><ArticleId IdType="pubmed">27829172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, and Borchelt DR (2001). Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng 17, 157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasthuri N, Hayworth KJ, Berger DR, Schalek RL, Conchello JA, Knowles-Barley S, Lee D, V&#xe1;zquez-Reina A, Kaynig V, Jones TR, et al. (2015). Saturated Reconstruction of a Volume of Neocortex. Cell 162, 648&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">26232230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke M-T, Nakai Y, Fujimoto S, Takayama R, Yoshida S, Kitajima TS, Sato M, and Imai T. (2016). Super-Resolution Mapping of Neuronal Circuitry With an Index-Optimized Clearing Agent. Cell Reports 14, 2718&#x2013;2732.</Citation><ArticleIdList><ArticleId IdType="pubmed">26972009</ArticleId></ArticleIdList></Reference><Reference><Citation>Keith D, and El-Husseini A. (2008). Excitation Control: Balancing PSD-95 Function at the Synapse. Front Mol Neurosci 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2526002</ArticleId><ArticleId IdType="pubmed">18946537</ArticleId></ArticleIdList></Reference><Reference><Citation>Knott G, Marchman H, Wall D, and Lich B. (2008). Serial Section Scanning Electron Microscopy of Adult Brain Tissue Using Focused Ion Beam Milling. J. Neurosci 28, 2959&#x2013;2964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670719</ArticleId><ArticleId IdType="pubmed">18353998</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, et al. (2009). Oligomeric amyloid &#x3b2; associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. PNAS 106, 4012&#x2013;4017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Hyman BT, and Spires-Jones TL (2011). Alzheimer&#x2019;s disease: synapses gone cold. Molecular Neurodegeneration 6, 63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3178498</ArticleId><ArticleId IdType="pubmed">21871088</ArticleId></ArticleIdList></Reference><Reference><Citation>Korogod N, Petersen CC, and Knott GW Ultrastructural analysis of adult mouse neocortex comparing aldehyde perfusion with cryo fixation. ELife 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530226</ArticleId><ArticleId IdType="pubmed">26259873</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuljis RO, Xu Y, Aguila MC, and Baltimore D. (1997). Degeneration of neurons, synapses, and neuropil and glial activation in a murine Atm knockout model of ataxia&#x2013;telangiectasia. PNAS 94, 12688&#x2013;12693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25086</ArticleId><ArticleId IdType="pubmed">9356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer TT, Magnoni S, MacDonald CL, Dikranian K, Milner E, Sorrell J, Conte V, Benetatos JJ, Zipfel GJ, and Brody DL (2015). Experimental subarachnoid haemorrhage results in multifocal axonal injury. Brain 138, 2608&#x2013;2618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4564022</ArticleId><ArticleId IdType="pubmed">26115676</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert TJ, and Waters JC (2016). Navigating challenges in the application of superresolution microscopy. J Cell Biol jcb.201610011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5223610</ArticleId><ArticleId IdType="pubmed">27920217</ArticleId></ArticleIdList></Reference><Reference><Citation>Langlois JAS, Rutland-Brown W, and Wald MMM (2006). The Epidemiology and Impact of Traumatic Brain Injury: A Brief Overview. Journal of Head Trauma Rehabilitation Highlights From the 2nd Federal TBI Interagency Conference 21, 375&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">16983222</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassmann H, Fischer P, and Jellinger K. (1993). Synaptic Pathology of Alzheimer&#x2019;s Diseasea. Annals of the New York Academy of Sciences 695, 59&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239314</ArticleId></ArticleIdList></Reference><Reference><Citation>Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, et al. (2007). Genome-wide atlas of gene expression in the adult mouse brain. Nature 445, 168&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">17151600</ArticleId></ArticleIdList></Reference><Reference><Citation>Leranth C, Hajszan T, Szigeti-Buck K, Bober J, and MacLusky NJ (2008). Bisphenol A prevents the synaptogenic response to estradiol in hippocampus and prefrontal cortex of ovariectomized nonhuman primates. Proc. Natl. Acad. Sci. U.S.A 105, 14187&#x2013;14191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544599</ArticleId><ArticleId IdType="pubmed">18768812</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM, and Holtzman DM (2019). Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell 179, 312&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lujan R, Roberts JDB, Shigemoto R, Ohishi H, and Somogyi P. (1997). Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1h, mGluR2 and mGluR5, relative to neurotransmitter release sites. Journal of Chemical Neuroanatomy 23.</Citation><ArticleIdList><ArticleId IdType="pubmed">9412905</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallucci GR (2009). Prion neurodegeneration. Prion 3, 195&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807691</ArticleId><ArticleId IdType="pubmed">19887910</ArticleId></ArticleIdList></Reference><Reference><Citation>Masch J-M, Steffens H, Fischer J, Engelhardt J, Hubrich J, Keller-Findeisen J, D&#x2019;Este E, Urban NT, Grant SGN, Sahl SJ, et al. (2018). Robust nanoscopy of a synaptic protein in living mice by organic-fluorophore labeling. PNAS 115, E8047&#x2013;E8056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112726</ArticleId><ArticleId IdType="pubmed">30082388</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Terry RD, DeTeresa RM, and Hansen LA (1989). Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neuroscience Letters 103, 234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">2505201</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Albright T, Mallory M, and Terry RD (1991). Immunoelectron microscopic study of synaptic pathology in Alzheimer&#x2019;s disease. Acta Neuropathol 81, 428&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">1903014</ArticleId></ArticleIdList></Reference><Reference><Citation>Matti U, Pattu V, Halimani M, Schirra C, Krause E, Liu Y, Weins L, Fang Chang H, Guzman R, Olausson J, et al. (2013). Synaptobrevin2 is the v-SNARE required for cytotoxic T-lymphocyte lytic granule fusion. Nature Communications 4, 1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">23385584</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Stein TD, Nowinski CJ, Stern RA, Daneshvar DH, Alvarez VE, Lee H-S, Hall G, Wojtowicz SM, Baugh CM, et al. (2012). The spectrum of disease in chronic traumatic encephalopathy. Brain.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Stein TD, Kiernan PT, and Alvarez VE (2015). The Neuropathology of Chronic Traumatic Encephalopathy. Brain Pathology 25, 350&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526170</ArticleId><ArticleId IdType="pubmed">25904048</ArticleId></ArticleIdList></Reference><Reference><Citation>Micheva KD, and Smith SJ (2007). Array Tomography: A New Tool for Imaging the Molecular Architecture and Ultrastructure of Neural Circuits. Neuron 55, 25&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2080672</ArticleId><ArticleId IdType="pubmed">17610815</ArticleId></ArticleIdList></Reference><Reference><Citation>Micheva KD, Busse B, Weiler NC, O&#x2019;Rourke N, and Smith SJ (2010). Single-Synapse Analysis of a Diverse Synapse Population: Proteomic Imaging Methods and Markers. Neuron 68, 639&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995697</ArticleId><ArticleId IdType="pubmed">21092855</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison JH, and Baxter MG (2012). The Aging Cortical Synapse: Hallmarks and Implications for Cognitive Decline. Nat Rev Neurosci 13, 240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592200</ArticleId><ArticleId IdType="pubmed">22395804</ArticleId></ArticleIdList></Reference><Reference><Citation>Namjoshi DR, Cheng WH, McInnes KA, Martens KM, Carr M, Wilkinson A, Fan J, Robert J, Hayat A, Cripton PA, et al. (2014). Merging pathology with biomechanics using CHIMERA (Closed-Head Impact Model of Engineered Rotational Acceleration): a novel, surgery-free model of traumatic brain injury. Molecular Neurodegeneration 9, 55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4269957</ArticleId><ArticleId IdType="pubmed">25443413</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstr&#xf6;m A, and Nordstr&#xf6;m P. (2018). Traumatic brain injury and the risk of dementia diagnosis: A nationwide cohort study. PLOS Medicine 15, e1002496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790223</ArticleId><ArticleId IdType="pubmed">29381704</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke NA, Weiler NC, Micheva KD, and Smith SJ (2012). Deep molecular diversity of mammalian synapses: why it matters and how to measure it. Nature Reviews Neuroscience 13, 365&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3670986</ArticleId><ArticleId IdType="pubmed">22573027</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquet M, and Smith Y. (2003). Group I Metabotropic Glutamate Receptors in the Monkey Striatum: Subsynaptic Association with Glutamatergic and Dopaminergic Afferents. J. Neurosci 23, 7659&#x2013;7669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740746</ArticleId><ArticleId IdType="pubmed">12930805</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez EJ, Cepero ML, Perez SU, Coyle JT, Sick TJ, and Liebl DJ (2016). EphB3 signaling propagates synaptic dysfunction in the traumatic injured brain. Neurobiology of Disease 94, 73&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5662938</ArticleId><ArticleId IdType="pubmed">27317833</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Alvarez A, Fearey B, Schulze C, O&#x2019;Toole RJ, Moeyaert B, Mohr MA, Arganda-Carreras I, Yang W, Wiegert JS, Schreiter ER, et al. (2019). Freeze-frame imaging of synaptic activity using SynTagMA. BioRxiv 538041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7235013</ArticleId><ArticleId IdType="pubmed">32424147</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, Phillips C, Gau BA, Welsh&#x2013;Bohmer KA, Burke JR, et al. (2000). Documented head injury in early adulthood and risk of Alzheimer&#x2019;s disease and other dementias. Neurology 55, 1158&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">11071494</ArticleId></ArticleIdList></Reference><Reference><Citation>Przekwas A, Somayaji MR, and Gupta RK (2016). Synaptic Mechanisms of Blast-Induced Brain Injury. Front. Neurol 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4720734</ArticleId><ArticleId IdType="pubmed">26834697</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiner A, and Levitz J. (2018). Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert. Neuron 98, 1080&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484838</ArticleId><ArticleId IdType="pubmed">29953871</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, and Triller A. (2010). Deleterious Effects of Amyloid &#x3b2; Oligomers Acting as an Extracellular Scaffold for mGluR5. Neuron 66, 739&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111138</ArticleId><ArticleId IdType="pubmed">20547131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro FM, Vieira LB, Pires RGW, Olmo RP, and Ferguson SSG (2017). Metabotropic glutamate receptors and neurodegenerative diseases. Pharmacological Research 115, 179&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">27872019</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson DS, and Lichtman JW (2015). Clarifying Tissue Clearing. Cell 162, 246&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4537058</ArticleId><ArticleId IdType="pubmed">26186186</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues SM, Bauer EP, Farb CR, Schafe GE, and LeDoux JE (2002). The Group I Metabotropic Glutamate Receptor mGluR5 Is Required for Fear Memory Formation and Long-Term Potentiation in the Lateral Amygdala. J. Neurosci 22, 5219&#x2013;5229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757718</ArticleId><ArticleId IdType="pubmed">12077217</ArticleId></ArticleIdList></Reference><Reference><Citation>Rollenhagen A, and L&#xfc;bke JHR (2010). The Mossy Fiber Bouton: the &#x201c;Common&#x201d; or the &#x201c;Unique&#x201d; Synapse? Front Synaptic Neurosci 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059708</ArticleId><ArticleId IdType="pubmed">21423488</ArticleId></ArticleIdList></Reference><Reference><Citation>Rust MJ, Bates M, and Zhuang X. (2006). Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM). Nature Methods 3, 793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700296</ArticleId><ArticleId IdType="pubmed">16896339</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, and Saido TC (2014). Single App knock-in mouse models of Alzheimer&#x2019;s disease. Nat Neurosci 17, 661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Santuy A, Rodriguez JR, DeFelipe J, and Merchan-Perez A. (2018). Volume electron microscopy of the distribution of synapses in the neuropil of the juvenile rat somatosensory cortex. Brain Struct Funct 223, 77&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5772167</ArticleId><ArticleId IdType="pubmed">28721455</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauerbeck AD, Fanizzi C, Kim JH, Gangolli M, Bayly PV, Wellington CL, Brody DL, and Kummer TT (2018). modCHIMERA: a novel murine closed-head model of moderate traumatic brain injury. Scientific Reports 8, 7677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5955903</ArticleId><ArticleId IdType="pubmed">29769541</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff S. (2003). Synaptic pathology in Alzheimer&#x2019;s disease: a review of ultrastructural studies. Neurobiology of Aging 24, 1029&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643375</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, and Price DA (1993). Synapse loss in the temporal lobe in Alzheimer&#x2019;s disease. Annals of Neurology 33, 190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">8434881</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff S. w., Price D. a., Hicks R. r., Baldwin S. a., Robinson S, and Brackney C. (2005). Synaptogenesis in the Hippocampal CA1 Field following Traumatic Brain Injury. Journal of Neurotrauma 22, 719&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">16004576</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, DeKosky ST, and Mufson EJ (2007). Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68, 1501&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Schikorski T, and Stevens CF (1997). Quantitative Ultrastructural Analysis of Hippocampal Excitatory Synapses. J. Neurosci 17, 5858&#x2013;5867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573206</ArticleId><ArticleId IdType="pubmed">9221783</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2002). Alzheimer&#x2019;s Disease Is a Synaptic Failure. Science 298, 789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahim P, Tegner Y, Marklund N, H&#xf6;glund K, Portelius E, Brody DL, Blennow K, and Zetterberg H. (2017). Astroglial activation and altered amyloid metabolism in human repetitive concussion. Neurology 88, 1400&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5386435</ArticleId><ArticleId IdType="pubmed">28283595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheppard CJR (1988). Super-resolution in confocal imaging. Optik (Jena) 80, 53&#x2013;54.</Citation></Reference><Reference><Citation>Shostak Y, Wenger A, Mavity-Hudson J, and Casagrande VA (2014). Metabotropic glutamate receptor 5 shows different patterns of localization within the parallel visual pathways in macaque and squirrel monkeys. Eye Brain 6, 29&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356996</ArticleId><ArticleId IdType="pubmed">25774086</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Tononi G, and K&#xf6;tter R. (2005). The human connectome: A structural description of the human brain. PLoS Comput. Biol 1, e42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239902</ArticleId><ArticleId IdType="pubmed">16201007</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson LW, and Lichtman JW (2016). From Cajal to Connectome and Beyond. Annual Review of Neuroscience 39, 197&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">27442070</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamori S, Holt M, Stenius K, Lemke EA, Gr&#xf8;nborg M, Riedel D, Urlaub H, Schenck S, Br&#xfc;gger B, Ringler P, et al. (2006). Molecular Anatomy of a Trafficking Organelle. Cell 127, 831&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">17110340</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang A-H, Chen H, Li TP, Metzbower SR, MacGillavry HD, and Blanpied TA (2016). A trans-synaptic nanocolumn aligns neurotransmitter release to receptors. Nature 536, 210&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5002394</ArticleId><ArticleId IdType="pubmed">27462810</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, and Katzman R. (1991). Physical basis of cognitive alterations in alzheimer&#x2019;s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 30, 572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiel G. (1993). Synapsin I, Synapsin II, and Synaptophysin: Marker Proteins of Synaptic Vesicles. Brain Pathology 3, 87&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">7903586</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran HT, LaFerla FM, Holtzman DM, and Brody DL (2011a). Controlled Cortical Impact Traumatic Brain Injury in 3xTg-AD Mice Causes Acute Intra-axonal Amyloid-beta Accumulation and Independently Accelerates the Development of Tau Abnormalities. J Neurosci 31, 9513&#x2013;9525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146343</ArticleId><ArticleId IdType="pubmed">21715616</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran HT, Sanchez L, Esparza TJ, and Brody DL (2011b). Distinct Temporal and Anatomical Distributions of Amyloid-&#x3b2; and Tau Abnormalities following Controlled Cortical Impact in Transgenic Mice. PLoS One 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183029</ArticleId><ArticleId IdType="pubmed">21980472</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, et al. (2013). Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer A&#x3b2; Oligomer Bound to Cellular Prion Protein. Neuron 79, 887&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3768018</ArticleId><ArticleId IdType="pubmed">24012003</ArticleId></ArticleIdList></Reference><Reference><Citation>Vascak M, Sun J, Baer M, Jacobs KM, and Povlishock JT (2017). Mild Traumatic Brain Injury Evokes Pyramidal Neuron Axon Initial Segment Plasticity and Diffuse Presynaptic Inhibitory Terminal Loss. Front. Cell. Neurosci 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5459898</ArticleId><ArticleId IdType="pubmed">28634442</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker KR, and Tesco G. (2013). Molecular mechanisms of cognitive dysfunction following traumatic brain injury. Front Aging Neurosci 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3705200</ArticleId><ArticleId IdType="pubmed">23847533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C-C, Held RG, Chang S-C, Yang L, Delpire E, Ghosh A, and Hall BJ (2011). A Critical Role for GluN2B-Containing NMDA Receptors in Cortical Development and Function. Neuron 72, 789&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">22153375</ArticleId></ArticleIdList></Reference><Reference><Citation>Winston CN, Chellappa D, Wilkins T, Barton DJ, Washington PM, Loane DJ, Zapple DN, and Burns MP (2013). Controlled Cortical Impact Results in an Extensive Loss of Dendritic Spines that Is Not Mediated by Injury-Induced Amyloid-Beta Accumulation. Journal of Neurotrauma 30, 1966&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837436</ArticleId><ArticleId IdType="pubmed">23879560</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang S-M, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, and Lee VM-Y (2007). Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model. Neuron 53, 337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Cizeron M, Qiu Z, Benavides-Piccione R, Kopanitsa MV, Skene NG, Koniaris B, DeFelipe J, Frans&#xe9;n E, Komiyama NH, et al. (2018). Architecture of the Mouse Brain Synaptome. Neuron 99, 781&#x2013;799.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6117470</ArticleId><ArticleId IdType="pubmed">30078578</ArticleId></ArticleIdList></Reference><Reference><Citation>(2002). Ripley&#x2019;s K function. Encyclopedia of Environmetrics.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32391858</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.</ArticleTitle><Pagination><StartPage>955</StartPage><EndPage>965</EndPage><MedlinePgn>955-965</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.0989</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The diagnostic performance of second-generation tau positron emission tomographic (PET) tracers is not yet known.</AbstractText><AbstractText Label="OBJECTIVE">To examine the novel tau PET tracer RO948 F 18 ([18F]RO948) performance in discriminating Alzheimer disease (AD) from non-AD neurodegenerative disorders.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this diagnostic study, 613 participants in the Swedish BioFINDER-2 study were consecutively enrolled in a prospective cross-sectional study from September 4, 2017, to August 28, 2019. Participants included 257 cognitively unimpaired controls, 154 patients with mild cognitive impairment, 100 patients with AD dementia, and 102 with non-AD neurodegenerative disorders. Evaluation included a comparison of tau PET tracer [18F]RO948 with magnetic resonance imaging (MRI) and cerebrospinal fluid and a head-to-head comparison between [18F]RO948 and flortaucipir F 18 ([18F]flortaucipir) in patients with semantic variant primary progressive aphasia (svPPA).</AbstractText><AbstractText Label="EXPOSURES">[18F]RO948 (all patients) and [18F]flortaucipir (3 patients with svPPA) tau PET; MRI (hippocampal volume, composite temporal lobe cortical thickness, whole-brain cortical thickness) and cerebrospinal fluid measures (p-tau181 and amyloid A&#x3b2;42 and A&#x3b2;40 ratio[A&#x3b2;42/A&#x3b2;40], and A&#x3b2;42/p-tau181 ratio).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Standard uptake value ratios (SUVRs) in 4 predefined regions of interest (ROIs) reflecting Braak staging scheme for tau pathology and encompass I-II (entorhinal cortex), III-IV (inferior/middle temporal, fusiform gyrus, parahippocampal cortex, and amygdala), I-IV, and V-VI (widespread neocortical areas), area under the receiver operating characteristic curve (AUC) values, and subtraction images between [18F]RO948 and [18F]flortaucipir.</AbstractText><AbstractText Label="RESULTS">Diagnostic groups among the 613 participants included cognitively unimpaired (mean [SD] age, 65.8 [12.1] years; 117 men [46%]), mild cognitive impairment (age, 70.8 [8.3] years; 82 men [53%]), AD dementia (age, 73.5 [6.7] years; 57 men [57%]), and non-AD disorders (age, 70.5 [8.6] years; 41 men [40%]). Retention of [18F]RO948 was higher in AD dementia compared with all other diagnostic groups. [18F]RO948 could distinguish patients with AD dementia from individuals without cognitive impairment and those with non-AD disorders, and the highest AUC was obtained using the I-IV ROI (AUC&#x2009;=&#x2009;0.98; 95% CI, 0.96-0.99 for AD vs no cognitive impairment and AUC&#x2009;=&#x2009;0.97; 95% CI, 0.95-0.99 for AD vs non-AD disorders), which outperformed MRI (highest AUC&#x2009;=&#x2009;0.91 for AD vs no cognitive impairment using whole-brain thickness, and AUC&#x2009;=&#x2009;0.80 for AD vs non-AD disorders using temporal lobe thickness) and cerebrospinal fluid measures (highest AUC&#x2009;=&#x2009;0.94 for AD vs no cognitive impairment using A&#x3b2;42/p-tau181, and AUC&#x2009;=&#x2009;0.93 for AD vs non-AD disorders using A&#x3b2;42/A&#x3b2;40). Generally, tau PET positivity using [18F]RO948 was observed only in A&#x3b2;-positive cases or in MAPT R406W mutation carriers. Retention of [18F]RO948 was not pronounced in patients with svPPA, and head-to-head comparison revealed lower temporal lobe uptake than with [18F]flortaucipir.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this study, elevated [18F]RO948 SUVRs were most often seen among A&#x3b2;-positive cases, which suggests that [18F]RO948 has high specificity for AD-type tau and highlights its potential as a diagnostic marker in the differential diagnosis of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leuzy</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santillo</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Edilio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohlsson</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiation Physics, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;gi</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sk&#xe5;ne University Hospital, Department of Clinical Physiology and Nuclear Medicine, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson-Carlgren</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019028" MajorTopicYN="N">Magnetic Resonance Imaging, Cine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Santillo reported receiving grants from the Swedish Society for Medical Research and the Bente Rexhed Gerstedts Foundation for Medical Research during the conduct of the study. Dr Klein reported receiving personal fees from F. Hoffmann-La Roche Ltd during the conduct of the study. Dr Hansson reported receiving grants from Roche during the conduct of the study as well as grants from Roche, nonfinancial support from GE Healthcare, and grants from Biogen outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32391858</ArticleId><ArticleId IdType="pmc">PMC7215644</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.0989</ArticleId><ArticleId IdType="pii">2765841</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer&#x2019;s disease. Lancet. 2006;368(9533):387-403. doi:10.1016/S0140-6736(06)69113-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)69113-7</ArticleId><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Bancher C. Neuropathology of Alzheimer&#x2019;s disease: a critical update. J Neural Transm Suppl. 1998;54:77-95. doi:10.1007/978-3-7091-7508-8_8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-7091-7508-8_8</ArticleId><ArticleId IdType="pubmed">9850917</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;7(8):656-664. doi:10.2174/156720510793611592</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720510793611592</ArticleId><ArticleId IdType="pmc">PMC3090074</ArticleId><ArticleId IdType="pubmed">20678074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121-1159. doi:10.1146/annurev.neuro.24.1.1121</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.24.1.1121</ArticleId><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Tau filaments in neurodegenerative diseases. FEBS Lett. 2018;592(14):2383-2391. doi:10.1002/1873-3468.13108</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.13108</ArticleId><ArticleId IdType="pubmed">29790176</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C; Medical Research Council Cognitive Function and Ageing Study . Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302-2309. doi:10.1056/NEJMoa0806142</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0806142</ArticleId><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114-124. doi:10.1016/S1474-4422(14)70252-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70252-2</ArticleId><ArticleId IdType="pubmed">25496902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Maass A, Mattsson N, et al. . Biomarkers for tau pathology. Mol Cell Neurosci. 2019;97:18-33. doi:10.1016/j.mcn.2018.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2018.12.001</ArticleId><ArticleId IdType="pmc">PMC6584358</ArticleId><ArticleId IdType="pubmed">30529601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Rabinovici GD, Smith R, et al. . Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320(11):1151-1162. doi:10.1001/jama.2018.12917</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.12917</ArticleId><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Harada R, Ishiki A, Kikuchi A, Nakamura T, Kudo Y. The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging. 2018;6(4):305-316. doi:10.1007/s40336-018-0290-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40336-018-0290-y</ArticleId><ArticleId IdType="pmc">PMC6096533</ArticleId><ArticleId IdType="pubmed">30148121</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Santillo AF, Wald&#xf6; ML, et al. . 18F-flortaucipir in TDP-43 associated frontotemporal dementia. Sci Rep. 2019;9(1):6082. doi:10.1038/s41598-019-42625-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-42625-9</ArticleId><ArticleId IdType="pmc">PMC6465310</ArticleId><ArticleId IdType="pubmed">30988363</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DMA, Snowden JS. Frontotemporal lobar degeneration: pathogenesis, pathology and pathways to phenotype. Brain Pathol. 2017;27(6):723-736. doi:10.1111/bpa.12486</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12486</ArticleId><ArticleId IdType="pmc">PMC8029341</ArticleId><ArticleId IdType="pubmed">28100023</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, et al. . A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122(1):111-113. doi:10.1007/s00401-011-0845-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanabria Boh&#xf3;rquez S, Marik J, Ogasawara A, et al. . [18F]GTP1 (Genentech tau probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2019;46(10):2077-2089. doi:10.1007/s00259-019-04399-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-019-04399-0</ArticleId><ArticleId IdType="pubmed">31254035</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, Shin M, Kang MS, et al. . In vivo quantification of neurofibrillary tangles with [18F]MK-6240. Alzheimers Res Ther. 2018;10(1):74. doi:10.1186/s13195-018-0402-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0402-y</ArticleId><ArticleId IdType="pmc">PMC6069775</ArticleId><ArticleId IdType="pubmed">30064520</ArticleId></ArticleIdList></Reference><Reference><Citation>Betthauser TJ, Cody KA, Zammit MD, et al. . In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60(1):93-99. doi:10.2967/jnumed.118.209650</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.118.209650</ArticleId><ArticleId IdType="pmc">PMC6354223</ArticleId><ArticleId IdType="pubmed">29777006</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Chiotis K, Lemoine L, et al. . Tau PET imaging in neurodegenerative tauopathies&#x2014;still a challenge. Mol Psychiatry. 2019;24(8):1112-1134. doi:10.1038/s41380-018-0342-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0342-8</ArticleId><ArticleId IdType="pmc">PMC6756230</ArticleId><ArticleId IdType="pubmed">30635637</ArticleId></ArticleIdList></Reference><Reference><Citation>Honer M, Gobbi L, Knust H, et al. . Preclinical evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer disease. J Nucl Med. 2018;59(4):675-681. doi:10.2967/jnumed.117.196741</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.117.196741</ArticleId><ArticleId IdType="pmc">PMC5932750</ArticleId><ArticleId IdType="pubmed">28970331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong DF, Comley RA, Kuwabara H, et al. . Characterization of 3 novel tau radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in healthy controls and in Alzheimer subjects. J Nucl Med. 2018;59(12):1869-1876. doi:10.2967/jnumed.118.209916</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.118.209916</ArticleId><ArticleId IdType="pmc">PMC6278896</ArticleId><ArticleId IdType="pubmed">29728519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobbi LC, Knust H, K&#xf6;rner M, et al. . Identification of three novel radiotracers for imaging aggregated tau in Alzheimer&#x2019;s disease with positron emission tomography. J Med Chem. 2017;60(17):7350-7370. doi:10.1021/acs.jmedchem.7b00632</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.7b00632</ArticleId><ArticleId IdType="pubmed">28654263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwabara H, Comley RA, Borroni E, et al. . Evaluation of 18F-RO-948 PET for quantitative assessment of tau accumulation in the human brain. J Nucl Med. 2018;59(12):1877-1884. doi:10.2967/jnumed.118.214437</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.118.214437</ArticleId><ArticleId IdType="pmc">PMC6278898</ArticleId><ArticleId IdType="pubmed">30097505</ArticleId></ArticleIdList></Reference><Reference><Citation>The Swedish BioFINDER 2 Study (BioFINDER2). ClinicalTrials.gov Identifier: NCT03174938. Updated April 18, 2018. Accessed February 1, 2020. https://clinicaltrials.gov/ct2/show/NCT03174938</Citation></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Sch&#xf6;ll M, Leuzy A, et al. . Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. Eur J Nucl Med Mol Imaging. 2020;47(2):342-354. doi:10.1007/s00259-019-04496-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-019-04496-0</ArticleId><ArticleId IdType="pmc">PMC6974501</ArticleId><ArticleId IdType="pubmed">31612245</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn A, Schain M, Erlandsson M, et al. . Modeling strategies for quantification of in vivo 18F-AV-1451 binding in patients with tau pathology. J Nucl Med. 2017;58(4):623-631. doi:10.2967/jnumed.116.174508</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.116.174508</ArticleId><ArticleId IdType="pubmed">27765859</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data. Data Brief. 2017;15:648-657. doi:10.1016/j.dib.2017.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dib.2017.10.024</ArticleId><ArticleId IdType="pmc">PMC5671473</ArticleId><ArticleId IdType="pubmed">29124088</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904-911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, et al. . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247-258. doi:10.1002/ana.24711</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24711</ArticleId><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259. doi:10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age-specific and sex-specific prevalence of cerebral &#x3b2;-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017;16(6):435-444. doi:10.1016/S1474-4422(17)30077-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30077-7</ArticleId><ArticleId IdType="pmc">PMC5516534</ArticleId><ArticleId IdType="pubmed">28456479</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Defining imaging biomarker cut points for brain aging and Alzheimer&#x2019;s disease. Alzheimers Dement. 2017;13(3):205-216. doi:10.1016/j.jalz.2016.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.08.005</ArticleId><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain. 2015;138(pt 12):3747-3759. doi:10.1093/brain/awv283</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv283</ArticleId><ArticleId IdType="pmc">PMC4655341</ArticleId><ArticleId IdType="pubmed">26428666</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Pannee J, Mikulskis A, et al. . Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74(12):1492-1501. doi:10.1001/jamaneurol.2017.2814</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2814</ArticleId><ArticleId IdType="pmc">PMC5822196</ArticleId><ArticleId IdType="pubmed">29114726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, et al. ; Swedish BioFINDER Study Group; Alzheimer&#x2019;s Disease Neuroimaging Initiative . CSF biomarkers of Alzheimer&#x2019;s disease concord with amyloid-&#x3b2; PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470-1481. doi:10.1016/j.jalz.2018.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.01.010</ArticleId><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Navitsky M, Kotari V, Southekal S, et al. Association between APOE isoform and 18-month tau accumulation. Presentation at: Alzheimer&#x2019;s Association International Conference; July 16, 2019; Los Angeles, CA.</Citation></Reference><Reference><Citation>Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839-843. doi:10.1148/radiology.148.3.6878708</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.148.3.6878708</ArticleId><ArticleId IdType="pubmed">6878708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29-36. doi:10.1148/radiology.143.1.7063747</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.143.1.7063747</ArticleId><ArticleId IdType="pubmed">7063747</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin X, Turck N, Hainard A, et al. . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. doi:10.1186/1471-2105-12-77</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-77</ArticleId><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan-Jones WR, Cope TE, Jones PS, et al. . [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018;89(10):1032-1037. doi:10.1136/jnnp-2017-316402</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316402</ArticleId><ArticleId IdType="pmc">PMC6166613</ArticleId><ArticleId IdType="pubmed">28912300</ArticleId></ArticleIdList></Reference><Reference><Citation>Makaretz SJ, Quimby M, Collins J, et al. . Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018;89(10):1024-1031. doi:10.1136/jnnp-2017-316409</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316409</ArticleId><ArticleId IdType="pmc">PMC5964045</ArticleId><ArticleId IdType="pubmed">28986472</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai RM, Bejanin A, Lesman-Segev O, et al. . 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther. 2019;11(1):13. doi:10.1186/s13195-019-0470-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0470-7</ArticleId><ArticleId IdType="pmc">PMC6357510</ArticleId><ArticleId IdType="pubmed">30704514</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci. 2007;257(1-2):80-87. doi:10.1016/j.jns.2007.01.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.01.045</ArticleId><ArticleId IdType="pubmed">17324442</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Alafuzoff I, Attems J, et al. . PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 2015;129(5):757-762. doi:10.1007/s00401-015-1407-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1407-2</ArticleId><ArticleId IdType="pmc">PMC4534004</ArticleId><ArticleId IdType="pubmed">25778618</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LA, Grabowski TJ, Schmidt ML, et al. . Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol. 1997;42(4):564-572. doi:10.1002/ana.410420406</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410420406</ArticleId><ArticleId IdType="pubmed">9382467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. ; Amyloid PET Study Group . Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939-1949. doi:10.1001/jama.2015.4669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4669</ArticleId><ArticleId IdType="pmc">PMC4517678</ArticleId><ArticleId IdType="pubmed">25988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid &#x3b2;-protein and &#x3b1;-synuclein. J Neurochem. 2012;122(5):883-890. doi:10.1111/j.1471-4159.2012.07847.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2012.07847.x</ArticleId><ArticleId IdType="pubmed">22734715</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Covell DJ, Daniels JP, et al. . Distinct &#x3b1;-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013;154(1):103-117. doi:10.1016/j.cell.2013.05.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.05.057</ArticleId><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. ; Dominantly Inherited Alzheimer Network . Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795-804. doi:10.1056/NEJMoa1202753</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of &#x3b2;-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1):98-106. doi:10.1001/archgenpsychiatry.2011.155</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.155</ArticleId><ArticleId IdType="pubmed">22213792</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Minoshima S, Bohnen NI, et al. . Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med. 2013;54(7):1011-1013. doi:10.2967/jnumed.113.127068</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.113.127068</ArticleId><ArticleId IdType="pubmed">23753186</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Sperling RA, Norton DJ, et al. . Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol. 2018;75(5):548-556. doi:10.1001/jamaneurol.2017.4907</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.4907</ArticleId><ArticleId IdType="pmc">PMC5885174</ArticleId><ArticleId IdType="pubmed">29435558</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Graff-Radford J, Tosakulwong N, et al. . Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(8):1005-1014. doi:10.1016/j.jalz.2018.02.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.020</ArticleId><ArticleId IdType="pmc">PMC6097955</ArticleId><ArticleId IdType="pubmed">29605222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain. 2016;139(pt 5):1551-1567. doi:10.1093/brain/aww027</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww027</ArticleId><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Sch&#xf6;ll M, Strandberg O, et al. . 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer&#x2019;s disease. EMBO Mol Med. 2017;9(9):1212-1223. doi:10.15252/emmm.201707809</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707809</ArticleId><ArticleId IdType="pmc">PMC5582410</ArticleId><ArticleId IdType="pubmed">28743782</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216. doi:10.1016/S1474-4422(12)70291-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E, Bateman RJ. Tau positron emission tomography in autosomal dominant Alzheimer disease: small windows, big picture. JAMA Neurol. 2018;75(5):536-538. doi:10.1001/jamaneurol.2017.4026</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.4026</ArticleId><ArticleId IdType="pmc">PMC5970084</ArticleId><ArticleId IdType="pubmed">29435570</ArticleId></ArticleIdList></Reference><Reference><Citation>Chare L, Hodges JR, Leyton CE, et al. . New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. J Neurol Neurosurg Psychiatry. 2014;85(8):865-870. doi:10.1136/jnnp-2013-306948</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306948</ArticleId><ArticleId IdType="pubmed">24421286</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodges JR, Mitchell J, Dawson K, et al. . Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain. 2010;133(pt 1):300-306. doi:10.1093/brain/awp248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp248</ArticleId><ArticleId IdType="pubmed">19805492</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron D, Gorno-Tempini ML, Rabinovici GD, et al. . Prevalence of amyloid-&#x3b2; pathology in distinct variants of primary progressive aphasia. Ann Neurol. 2018;84(5):729-740. doi:10.1002/ana.25333</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25333</ArticleId><ArticleId IdType="pmc">PMC6354051</ArticleId><ArticleId IdType="pubmed">30255971</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Vanderburg CR, et al. . Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787-800. doi:10.1002/ana.24517</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24517</ArticleId><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Curran G, Fang P, et al. . An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58. doi:10.1186/s40478-016-0315-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0315-6</ArticleId><ArticleId IdType="pmc">PMC4906968</ArticleId><ArticleId IdType="pubmed">27296779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander K, Lashley T, Gami P, et al. . Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer&#x2019;s disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016;12(11):1116-1124. doi:10.1016/j.jalz.2016.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.01.003</ArticleId><ArticleId IdType="pubmed">26892233</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ZA, Rankin KP, Graff-Radford NR, et al. . TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry. 2013;84(9):956-962. doi:10.1136/jnnp-2012-304644</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304644</ArticleId><ArticleId IdType="pmc">PMC3840954</ArticleId><ArticleId IdType="pubmed">23543794</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldridge GM, Birnschein A, Denburg NL, Narayanan NS. Parkinson&#x2019;s disease dementia and dementia with lewy bodies have similar neuropsychological profiles. Front Neurol. 2018;9:123. doi:10.3389/fneur.2018.00123</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00123</ArticleId><ArticleId IdType="pmc">PMC5857567</ArticleId><ArticleId IdType="pubmed">29593630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen AK, Brooks DJ, Borghammer P. MAO-B inhibitors do not block in vivo flortaucipir([18F]-AV-1451) binding. Mol Imaging Biol. 2018;20(3):356-360. doi:10.1007/s11307-017-1143-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11307-017-1143-1</ArticleId><ArticleId IdType="pubmed">29127552</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71(4):266-273. doi:10.1097/NEN.0b013e31824b211b</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31824b211b</ArticleId><ArticleId IdType="pmc">PMC3331862</ArticleId><ArticleId IdType="pubmed">22437338</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Mattsson N, Sch&#xf6;ll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer&#x2019;s disease. Trends Pharmacol Sci. 2015;36(5):297-309. doi:10.1016/j.tips.2015.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2015.03.002</ArticleId><ArticleId IdType="pubmed">25840462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32483373</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>582</Volume><Issue>7810</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>C9orf72 suppresses systemic and neural inflammation induced by gut bacteria.</ArticleTitle><Pagination><StartPage>89</StartPage><EndPage>94</EndPage><MedlinePgn>89-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2288-7</ELocationID><Abstract><AbstractText>A hexanucleotide-repeat expansion in C9ORF72 is the most common genetic variant that contributes to amyotrophic lateral sclerosis and frontotemporal dementia<sup>1,2</sup>. The C9ORF72 mutation acts through gain- and loss-of-function mechanisms to induce pathways that are implicated in neural degeneration<sup>3-9</sup>. The expansion is transcribed into a long repetitive RNA, which negatively sequesters RNA-binding proteins<sup>5</sup> before its non-canonical translation into neural-toxic dipeptide proteins<sup>3,4</sup>. The failure of RNA polymerase to read through the mutation also reduces the abundance of the endogenous C9ORF72 gene product, which functions in endolysosomal pathways and suppresses systemic and neural inflammation<sup>6-9</sup>. Notably, the effects of the repeat expansion act with incomplete penetrance in families with a high prevalence of amyotrophic lateral sclerosis or frontotemporal dementia, indicating that either genetic or environmental factors modify the risk of disease for each individual. Identifying disease modifiers is of considerable translational interest, as it could suggest strategies to diminish the risk of developing amyotrophic lateral sclerosis or frontotemporal dementia, or to slow progression. Here we report that an environment with reduced abundance of immune-stimulating bacteria<sup>10,11</sup> protects C9orf72-mutant mice from premature mortality and significantly ameliorates their underlying systemic inflammation and autoimmunity. Consistent with C9orf72 functioning to prevent microbiota from inducing a pathological inflammatory response, we found that reducing the microbial burden in mutant mice with broad spectrum antibiotics-as well as transplanting gut microflora from a protective environment-attenuated inflammatory phenotypes, even after their onset. Our studies provide further evidence that the microbial composition of our gut has an important role in brain health and can interact in surprising ways with well-known genetic risk factors for disorders of the nervous system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burberry</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1552-8695</Identifier><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wells</LastName><ForeName>Michael F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limone</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubrecht Institute for Developmental Biology and Stem Cell Research, Royal Netherlands Academy of Arts and Sciences, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couto</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Kevin S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keaney</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuroscience Therapeutic Area, New Medicines, UCB Biopharma SPRL, Braine-l'Alleud, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillet</LastName><ForeName>Ga&#xeb;lle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroscience Therapeutic Area, New Medicines, UCB Biopharma SPRL, Braine-l'Alleud, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gastel</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jin-Yuan</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietilainen</LastName><ForeName>Olli</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Menglu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggan</LastName><ForeName>Pierce</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantrell</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Joanie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadiu</LastName><ForeName>Irena</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuroscience Therapeutic Area, New Medicines, UCB Biopharma SPRL, Braine-l'Alleud, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scadden</LastName><ForeName>David T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4436-8467</Identifier><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA. Eggan@mcb.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. Eggan@mcb.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA. Eggan@mcb.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS089742</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 MH119327</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01NS089742</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG057808</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL131477</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 MH119327</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG057808</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1K99MH119327-01</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5K99AG057808-02</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606498">C9orf72 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2020 Jun;582(7810):34-35. doi: 10.1038/d41586-020-01335-3.</RefSource><PMID Version="1">32405038</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Trends Immunol. 2020 Sep;41(9):755-757. doi: 10.1016/j.it.2020.07.012.</RefSource><PMID Version="1">32800706</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="Y">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069467" MajorTopicYN="N">Fecal Microbiota Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="Y">Gliosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073658" MajorTopicYN="N">Loss of Function Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="Y">Spinal Cord</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087502" MajorTopicYN="Y">Brain-Gut Axis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflicts of interest. KE is a co-founder of Q-State Biosciences, Quralis and Endear Therapies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32483373</ArticleId><ArticleId IdType="mid">NIHMS1607883</ArticleId><ArticleId IdType="pmc">PMC7416879</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2288-7</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-2288-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C90RF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 11, 323&#x2013;330 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K et al. The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS. Science 339, 1335&#x2013;1338 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA et al. Unconventional translation of C90RF72 GGGGCC expansion generates insoluble polypeptides specific to C9FTD/ALS. Neuron 77, 639&#x2013;646 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ et al. RNA Toxicity from the ALS/FTD C90RF72 Expansion Is Mitigated by Antisense Intervention. Neuron 80, 415&#x2013;428 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG et al. C9orf72 is required for proper macrophage and microglial function in mice. Science 351, 1324&#x2013;1329 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A et al. Loss-of-function mutations in the C90RF72 mouse ortholog cause fatal autoiimnune disease. Sci. Transl. Med 8, 347ra93 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassif M&#x201e; Woehlbier U &amp; Manque PA. The Enigmatic Role of C90RF72 in Autophagy. Front. Neurosci 11, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5541066</ArticleId><ArticleId IdType="pubmed">28824365</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al. Haploinsufficiency leads to neurodegeneration in C90RF72 ALS/FTD human induced motor neurons. Nat. Med 24, 313&#x2013;325 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Whary &#x39c;T &amp; Fox JG
Natural and Experimental Helicobacter Infections. https://www.ingentaconnect.corn/content/aalas/cm/2004/00000054/00000002/art00002%3bjsessionidMhkpa2iwdtskb.x-ic-live-02# (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15134359</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannigan KL &amp; Denning TL Segmented filamentous bacteria-induced iimnune responses: a balancing act between host protection and autoimmunity. Immunology 154, 537&#x2013;546 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050222</ArticleId><ArticleId IdType="pubmed">29771448</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugolino J et al. Loss of C9orf72 Enhances Autophagic Activity via Deregulated mTOR and TFEB Signaling. PLOS Genet. 12,el006443 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119725</ArticleId><ArticleId IdType="pubmed">27875531</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C90RF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron 90, 535&#x2013;550 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci. Rep 6, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ZA et al. Increased prevalence of autoiimnune disease within C9 and FTD/MND cohorts. Neurol. Neuroimmunol. Neuroinflammation 3, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5087253</ArticleId><ArticleId IdType="pubmed">27844039</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredi M et al. C9orf72 Intennediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. NeuroMolecular Med. (2019) doi:10.1007/sl2017-019-08528-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/sl2017-019-08528-8</ArticleId><ArticleId IdType="pubmed">30859373</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine JG &amp; Lewis JH Hepatotoxicity of antibiotics: a review and update for the clinician. Clin. Liver Dis 17, 609&#x2013;642, ix (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24099021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM How neuroinflammation contributes to neurodegeneration. Science 353, 777&#x2013;783 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley &#x39c;E &amp; Baloh RH Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. (Berl.) 137, 715&#x2013;730 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR &amp; Appel SH Immune-mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral Sclerosis. J. Neuroimmune Pharmacol. Off. J. Soc. Neurolmmune Pharmacol 8, 888&#x2013;899 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. (Berl.) 132, 391&#x2013;411 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang GX, Li J, Ventura E &amp; Rostami A Parenchymal microglia of naive adult C57BL/6J mice express high levels of B7.1, B7.2, and MHC class II. Exp. Mol. Pathol 73, 35&#x2013;45 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12127052</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D &amp; Baloh RH Microglia and C9orf72 in nemoinflammation and ALS and frontotemporal dementia. J. Clin. Invest 127, 3250&#x2013;3258 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669558</ArticleId><ArticleId IdType="pubmed">28737506</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y et al. The C9orf72-interacting protein Smcr8 is a negative regulator of autoimmunity and lysosomal exocytosis. Genes Dev. 32, 929&#x2013;943 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075033</ArticleId><ArticleId IdType="pubmed">29950492</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H et al. Different Neurotropic Pathogens Elicit Neurotoxic CCR9- or Neurosupportive CXCR3-Expressing Microglia. J. Immunol 177, 3644&#x2013;3656 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16951324</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566&#x2013;581.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H el al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.el7 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson H-O et al. High Prevalence of Helicobacter Species Detected in Laboratory Mouse Strains by Multiplex PCR-Denaturing Gradient Gel Electrophoresis and Pyrosequencing. J. Clin. Microbiol 42, 3781&#x2013;3788 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC497606</ArticleId><ArticleId IdType="pubmed">15297530</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 572, 474&#x2013;480 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zliai R et al. Strain-Specific Anti-inflammatory Properties of Two Akkennansia muciniphila Strains on Chronic Colitis in Mice. Front. Cell. Infect. Microbiol 9, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6624636</ArticleId><ArticleId IdType="pubmed">31334133</ArticleId></ArticleIdList></Reference><Reference><Citation>Emy D et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 18, 965&#x2013;977 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5528863</ArticleId><ArticleId IdType="pubmed">26030851</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson CA el al. The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. Cell 173, 1728&#x2013;1741.el3 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6003870</ArticleId><ArticleId IdType="pubmed">29804833</ArticleId></ArticleIdList></Reference><Reference><Citation>Harach T et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci. Rep 7, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5297247</ArticleId><ArticleId IdType="pubmed">28176819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson TR et al. Gut Microbiota Regulate Motor Deficits and Neuroinflaimnation in a Model of Parkinson&#x2019;s Disease. Cell 167, 1469&#x2013;1480.el2 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremlett H, Bauer KC, Appel-Cresswell S, Finlay BB &amp; Waubant E The gut microbiome in human neurological disease: A review. Ann. Neurol 81, 369&#x2013;382 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28220542</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X et al. Evaluation of the Microbial Diversity in Amyotrophic Lateral Sclerosis Using Fhgh-Throughput Sequencing. Front. Microbiol 7, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5028383</ArticleId><ArticleId IdType="pubmed">27703453</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D et al. The fecal microbiome of ALS patients. Neurobiol. Aging 61, 132&#x2013;137 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29065369</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32470423</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study.</ArticleTitle><Pagination><StartPage>513</StartPage><EndPage>521</EndPage><MedlinePgn>513-521</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(20)30137-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(20)30137-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Neurofilament light chain (NfL) is a promising biomarker of active axonal injury and neuronal degeneration. We aimed to characterise cross-sectional and longitudinal plasma NfL measurements and determine the age at which NfL concentrations begin to differentiate between carriers of the presenilin 1 (PSEN1) E280A (Glu280Ala) mutation and age-matched non-carriers from the Colombian autosomal dominant Alzheimer's disease kindred.</AbstractText><AbstractText Label="METHODS">In this cross-sectional and longitudinal cohort study, members of the familial Alzheimer's disease Colombian kindred aged 8-75 years with no other neurological or health conditions were recruited from the Alzheimer's Prevention Initiative Registry at the University of Antioquia (Medell&#xed;n, Colombia) between Aug 1, 1995, and Dec 15, 2018. We used a single molecule array immunoassay and log-transformed data to examine the relationship between plasma NfL concentrations and age, and establish the earliest age at which NfL concentrations begin to diverge between mutation carriers and non-carriers.</AbstractText><AbstractText Label="FINDINGS">We enrolled a cohort of 1070 PSEN1 E280A mutation carriers and 1074 non-carriers with baseline assessments; of these participants, longitudinal measures (with a mean follow-up of 6 years) were available for 242 mutation carriers and 262 non-carriers. Plasma NfL measurements increased with age in both groups (p&lt;0&#xb7;0001), and began to differentiate carriers from non-carriers when aged 22 years (22 years before the estimated median age at mild cognitive impairment onset of 44 years), although the ability of plasma NfL to discriminate between carriers and non-carriers only reached high sensitivity close to the age of clinical onset.</AbstractText><AbstractText Label="INTERPRETATION">Our findings further support the promise of plasma NfL as a biomarker of active neurodegeneration in the detection and tracking of Alzheimer's disease and the evaluation of disease-modifying therapies.</AbstractText><AbstractText Label="FUNDING">National Institute on Aging, National Institute of Neurological Disorders and Stroke, Banner Alzheimer's Foundation, COLCIENCIAS, the Torsten S&#xf6;derberg Foundation, the Swedish Research Council, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, and the Swedish state under the ALF-agreement.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medell&#xed;n, Colombia. Electronic address: yquiroz@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA; University of Arizona College of Medicine, Phoenix AZ, USA; Arizona State University, Tempe, AZ, USA; Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yinghua</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox-Fuller</LastName><ForeName>Joshua T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Psychological and Brain Sciences, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villegas</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulveda-Falla</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medell&#xed;n, Colombia; Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villada</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arboleda-Velasquez</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass, Eye and Ear, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzm&#xe1;n-V&#xe9;lez</LastName><ForeName>Edmarie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vila-Castelar</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Protas</LastName><ForeName>Hillary D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghisays</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giraldo</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tirado</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baena</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munoz</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rios-Romenets</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA; University of Arizona College of Medicine, Phoenix AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG055444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS110048</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG062158</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP5 OD019833</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG061276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C564622">Alzheimer Disease 8</SupplMeshName><SupplMeshName Type="Disease" UI="C536594">Alzheimer disease type 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2020 Jun;19(6):475-476. doi: 10.1016/S1474-4422(20)30155-1.</RefSource><PMID Version="1">32470411</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflicts of Interest. All other co-authors have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32470423</ArticleId><ArticleId IdType="mid">NIHMS1600196</ArticleId><ArticleId IdType="pmc">PMC7417082</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(20)30137-X</ArticleId><ArticleId IdType="pii">S1474-4422(20)30137-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018; 14(10): 577&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Leuzy A, Lim YM, et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun 2019; 7(1): 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327431</ArticleId><ArticleId IdType="pubmed">30626432</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol 2019; 76(7): 791&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583067</ArticleId><ArticleId IdType="pubmed">31009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Skillback T, Farahmand B, Bartlett JW, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 2014; 83(21): 1945&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">25339208</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer&#x2019;s Disease Neuroimaging I. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol 2017; 74(5): 557&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 2013; 8(9): e75091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 2019; 92(10): e1007&#x2013;e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6442011</ArticleId><ArticleId IdType="pubmed">30737333</ArticleId></ArticleIdList></Reference><Reference><Citation>Gisslen M, Price RW, Andreasson U, et al. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine 2016; 3: 135&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M, Maia LF, Preische O, et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron 2016; 91(2): 494&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477021</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nat Med 2019; 25(2): 277&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston PSJ, Poole T, O&#x2019;Connor A, et al. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer&#x2019;s disease. Alzheimers Res Ther 2019; 11(1): 19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6383280</ArticleId><ArticleId IdType="pubmed">30786919</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston PSJ, Poole T, Ryan NS, et al. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology 2017; 89(21): 2167&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5696646</ArticleId><ArticleId IdType="pubmed">29070659</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Baena N, Sepulveda-Falla D, Lopera-G&#xf3;mez CM, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer&#x2019;s disease: a retrospective cohort study. Lancet Neurol 2011; 10(3): 213&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296022</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller JT, Cronin-Golomb A, Gatchel JR, et al. Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer&#x2019;s Disease: A Comprehensive Review of the Colombian Kindred. J Prev Alzheimers Dis 2019; 6(2): 112&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6925534</ArticleId><ArticleId IdType="pubmed">30756118</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Lopera F, Langbaum JB, et al. The Alzheimer&#x2019;s Prevention Initiative Autosomal-Dominant Alzheimer&#x2019;s Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer&#x2019;s disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y) 2018; 4: 150&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6021543</ArticleId><ArticleId IdType="pubmed">29955659</ArticleId></ArticleIdList></Reference><Reference><Citation>Rios-Romenets S, Acosta-Baena N, Lopez L, et al. Adherence/Retention Alzheimer&#x2019;s Prevention Initiative Colombia Plan. Alzheimers Dement (N Y) 2018; 4: 283&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077834</ArticleId><ArticleId IdType="pubmed">30090848</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B Functional assessment staging (FAST). Psychopharmacol Bull 1988; 24(4): 653&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249767</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre-Acevedo DC, G&#xf3;mez RD, Moreno S, et al. [Validity and reliability of the CERAD-Col neuropsychological battery]. Rev Neurol 2007; 45(11): 655&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">18050096</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement 2011; 7(3): 270&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA. Opportunities for and obstacles to treatments for dementias. J Am Geriatr Soc 1983; 31(1): 59&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6848578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendon CL, Martinez A, Behrens IM, et al. E280A PS-1 mutation causes Alzheimer&#x2019;s disease but age of onset is not modified by ApoE alleles. Hum Mutat 1997; 10(3): 186&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">9298817</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol 2015; 72(3): 316&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="pubmed">25580592</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Sperling RA, Norton DJ, et al. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurol 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885174</ArticleId><ArticleId IdType="pubmed">29435558</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer&#x2019;s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011; 26 Suppl 3: 321&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343739</ArticleId><ArticleId IdType="pubmed">21971471</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32456694</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Partial reduction of amyloid &#x3b2; production by &#x3b2;-secretase inhibitors does not decrease synaptic transmission.</ArticleTitle><Pagination><StartPage>63</StartPage><MedlinePgn>63</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">63</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13195-020-00635-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Alzheimer's disease (AD) is the most common form of age-related neurodegenerative diseases. Cerebral deposition of A&#x3b2; peptides, especially A&#x3b2;42, is considered the major neuropathological hallmark of AD and the putative cause of AD-related neurotoxicity. A&#x3b2; peptides are produced by sequential proteolytic processing of APP, with &#x3b2;-secretase (BACE) being the initiating enzyme. Therefore, BACE has been considered an attractive therapeutic target in AD research and several BACE inhibitors have been tested in clinical trials, but so far, all have had negative outcomes or even led to worsening of cognitive function. AD can be triggered by A&#x3b2; years before the first symptoms appear and one reason for the failures could be that the clinical trials were initiated too late in the disease process. Another possible explanation could be that BACE inhibition alters physiological APP processing in a manner that impairs synaptic function, causing cognitive deterioration.</AbstractText><AbstractText Label="METHODS">The aim of this study was to investigate if partial BACE inhibition, mimicking the putative protective effect of the Icelandic mutation in the APP gene, could reduce A&#x3b2; generation without affecting synaptic transmission. To investigate this, we used an optical electrophysiology platform, in which effects of compounds on synaptic transmission in cultured neurons can be monitored. We employed this method on primary cortical rat neuronal cultures treated with three different BACE inhibitors (BACE inhibitor IV, LY2886721, and lanabecestat) and monitored A&#x3b2; secretion into the cell media.</AbstractText><AbstractText Label="RESULTS">We found that all three BACE inhibitors tested decreased synaptic transmission at concentrations leading to significantly reduced A&#x3b2; secretion. However, low-dose BACE inhibition, resulting in less than a 50% decrease in A&#x3b2; secretion, did not affect synaptic transmission for any of the inhibitors tested.</AbstractText><AbstractText Label="CONCLUSION">Our results indicate that A&#x3b2; production can be reduced by up to 50%, a level of reduction of relevance to the protective effect of the Icelandic mutation, without causing synaptic dysfunction. We therefore suggest that future clinical trials aimed at prevention of A&#x3b2; build-up in the brain should aim for a moderate CNS exposure of BACE inhibitors to avoid side effects on synaptic function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Satir</LastName><ForeName>Tugce Munise</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, S-415 30, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agholme</LastName><ForeName>Lotta</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3816-7474</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, S-415 30, Gothenburg, Sweden. lotta.agholme@gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlsson</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cellectricon AB, Neongatan 4B, S-431 53, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlsson</LastName><ForeName>Mattias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cellectricon AB, Neongatan 4B, S-431 53, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karila</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cellectricon AB, Neongatan 4B, S-431 53, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Illes</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cellectricon AB, Neongatan 4B, S-431 53, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergstr&#xf6;m</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, S-415 30, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, S-431 80, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Institute of Neurology, University College London Queen Square, WC1N 3BG, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, WC1E 6BT, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="Y">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Amyloid beta</Keyword><Keyword MajorTopicYN="N">BACE inhibition</Keyword><Keyword MajorTopicYN="N">Beta-secretase</Keyword><Keyword MajorTopicYN="N">Synaptic transmission</Keyword></KeywordList><CoiStatement>HZ has served at scientific advisory boards for Samumed, CogRx, Roche Diagnostics, Denali, and Wave, has given lectures in symposia sponsored by Fujirebio, AlzeCure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. AK, MK, PK, and SI were all employed by Cellectricon AB at the time for the experiments. All other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32456694</ArticleId><ArticleId IdType="pmc">PMC7251689</ArticleId><ArticleId IdType="doi">10.1186/s13195-020-00635-0</ArticleId><ArticleId IdType="pii">10.1186/s13195-020-00635-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer&#x2019;s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">26987701</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer&#x2019;s disease. Trends Pharmacol Sci. 1991;12(10):383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med. 2016;8(6):595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011;32(6):1090&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">19604603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer&#x2019;s disease: clinical trials and drug development. Lancet Neurol. 2010;9(7):702&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">20610346</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Haass C, Finucane T. Semagacestat&#x2019;s fall: where next for AD therapies? Nat Med. 2013;19(10):1214&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">24100981</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Lindholm K, Yang L-B, Yue X, Citron M, Yan R, et al. Amyloid &#x3b2; peptide load is correlated with increased &#x3b2;-secretase activity in sporadic Alzheimer&#x2019;s disease patients. Proc Natl Acad Sci U S A. 2004;101(10):3632&#x2013;3637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373514</ArticleId><ArticleId IdType="pubmed">14978286</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. &#x3b2;-Secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol. 2004;164(2):719&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602259</ArticleId><ArticleId IdType="pubmed">14742275</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008;65(8):1102&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695061</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, et al. The Swedish mutation causes early-onset Alzheimer&#x2019;s disease by &#x3b2;-secretase cleavage within the secretory pathway. Nat Med. 1995;1(12):1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488(7409):96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Martiskainen H, Herukka S-K, Stan&#x10d;&#xe1;kov&#xe1; A, Paananen J, Soininen H, Kuusisto J, et al. Decreased plasma &#x3b2;-amyloid in the Alzheimer&#x2019;s disease APP A673T variant carriers. Ann Neurol. 2017;82(1):128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">28556232</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman M, Palcza J, Tseng J, Leempoels J, Ramael S, Han D, et al. The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid A&#x3b2; peptides in healthy subjects following single- and multiple-dose administration. Alzheimers Dement. 2012;8(4):P704.</Citation></Reference><Reference><Citation>Zhu K, Peters F, Filser S, Herms J. Consequences of pharmacological BACE inhibition on synaptic structure and function. Biol Psychiatry. 2018;84(7):478&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">29945719</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid &#x3b2;-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359(6393):322&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">1383826</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Sunderland T, Roth GS, Wolozin B. Physiological levels of &#x3b2;-amyloid peptide promote PC12 cell proliferation. Neurosci Lett. 1996;217(2):125&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">8916088</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Dong C. A&#x3b2;40 promotes neuronal cell fate in neural progenitor cells. Cell Death Differ. 2009;16(3):386&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">18566600</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP processing and synaptic function. Neuron. 2003;37(6):925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JE, Farr SA, Banks WA, Johnson SN, Yamada KA, Xu L. A physiological role for amyloid-beta protein:enhancement of learning and memory. J Alzheimers Dis. 2010;19(2):441&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">19749407</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidders B, Karlsson A, Kitching L, Torella R, Karila P, Phelan A. Network-based drug discovery: coupling network pharmacology with phenotypic screening for neuronal excitability. J Mol Biol. 2018;430(18, Part A):3005&#x2013;3015.</Citation><ArticleIdList><ArticleId IdType="pubmed">30030026</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan B, Cottrell JR, Li B, Larson KC, Ashford CJ, Levenson JM, et al. Development of a high-throughput AlphaScreen assay for modulators of synapsin I phosphorylation in primary neurons. J Biomol Screen. 2014;19(2):205&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">24088370</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, et al. BACE1 inhibition induces a specific cerebrospinal fluid &#x3b2;-amyloid pattern that identifies drug effects in the central nervous system. PLoS One. 2012;7(2):e31084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3273469</ArticleId><ArticleId IdType="pubmed">22328928</ArticleId></ArticleIdList></Reference><Reference><Citation>May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015;35(3):1199&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605527</ArticleId><ArticleId IdType="pubmed">25609634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri DK, Maloney B, Long JM, Greig NH. Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimer&#x2019;s Dementia. 2014;10(5, Supplement):S411&#x2013;S419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205206</ArticleId><ArticleId IdType="pubmed">24530026</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto K, Matsuki S, Matsuguma K, Yoshihara T, Uchida N, Azuma F, et al. BACE1 inhibitor lanabecestat (AZD3293) in a phase 1 study of healthy Japanese subjects: pharmacokinetics and effects on plasma and cerebrospinal fluid Abeta peptides. J Clin Pharmacol. 2017;57(11):1460&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pubmed">28618005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels Alette M., Tariot Pierre N., Zimmer Jennifer A., Selzler Katherine J., Bragg Sonja M., Andersen Scott W., Landry John, Krull James H., Downing AnnCatherine M., Willis Brian A., Shcherbinin Sergey, Mullen Jamie, Barker Peter, Schumi Jennifer, Shering Craig, Matthews Brandy R., Stern Robert A., Vellas Bruno, Cohen Sharon, MacSweeney Emer, Boada Merc&#xe8;, Sims John R. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease. JAMA Neurology. 2020;77(2):199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902191</ArticleId><ArticleId IdType="pubmed">31764959</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, et al. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1) J Med Chem. 2004;47(26):6447&#x2013;6450.</Citation><ArticleIdList><ArticleId IdType="pubmed">15588077</ArticleId></ArticleIdList></Reference><Reference><Citation>Neff R, Lindwall-Blom C, J&#xe4;gervall &#xc5;, Balana B, Karlsson M, Karila P, et al., Development of a moderate throughput assay to detect novel modulators of synaptic efficacy in neuronal cultures in Society for Neuroscience 2015: Washington, DC.</Citation></Reference><Reference><Citation>Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, et al. Eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature. 2015;526(7573):443&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570618</ArticleId><ArticleId IdType="pubmed">26322584</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo BP, Watling M. Investigational BACE inhibitors for the treatment of Alzheimer&#x2019;s disease. Expert Opin Investig Drugs. 2019;28(11):967&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">31661331</ArticleId></ArticleIdList></Reference><Reference><Citation>Filser S, Ovsepian SV, Masana M, Blazquez-Llorca L, Brandt Elvang A, Volbracht C, et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol Psychiatry. 2015;77(8):729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">25599931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu K, Xiang X, Filser S, Marinkovi&#x107; P, Dorostkar MM, Crux S, et al. Beta-site amyloid precursor protein cleaving enzyme 1 inhibition impairs synaptic plasticity via seizure protein 6. Biol Psychiatry. 2018;83(5):428&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">28129943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamikubo Y, Takasugi N, Niisato K, Hashimoto Y, Sakurai T. Consecutive analysis of BACE1 function on developing and developed neuronal cells. J Alzheimer&#x2019;s Disease. 2017;56(2):641&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">28035928</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Megill A, Wong PC, Kirkwood A, Lee H-K. Postsynaptic target specific synaptic dysfunctions in the CA3 area of BACE1 knockout mice. PLoS One. 2014;9(3):e92279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956924</ArticleId><ArticleId IdType="pubmed">24637500</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25(50):11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmers M, Van Broeck B, Ramael S, Slemmon J, De Waepenaert K, Russu A, et al. Profiling the dynamics of CSF and plasma A&#x3b2; reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimers Dement. 2016;2(3):202&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651349</ArticleId><ArticleId IdType="pubmed">29067308</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts SB, Ripellino JA, Ingalls KM, Robakis NK, Felsenstein KM. Non-amyloidogenic cleavage of the beta-amyloid precursor protein by an integral membrane metalloendopeptidase. J Biol Chem. 1994;269(4):3111&#x2013;3116.</Citation><ArticleIdList><ArticleId IdType="pubmed">8300647</ArticleId></ArticleIdList></Reference><Reference><Citation>Mockett BG, Richter M, Abraham WC, and M&#xfc;ller UC. Therapeutic potential of secreted amyloid precursor protein APPs&#x3b1;. Front Molecular Neurosci. 2017;10(30):1&#x2013;14. 10.3389/fnmol.2017.00030eCollection%202017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5293819</ArticleId><ArticleId IdType="pubmed">28223920</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kovacs DM, Yan R, Wong PC. The &#x3b2;-secretase enzyme BACE in health and Alzheimer&#x2019;s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009;29(41):12787&#x2013;12794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879048</ArticleId><ArticleId IdType="pubmed">19828790</ArticleId></ArticleIdList></Reference><Reference><Citation>Das B, Yan R. Role of BACE1 in Alzheimer&#x2019;s synaptic function. Transl Neurodegener. 2017;6:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5575945</ArticleId><ArticleId IdType="pubmed">28855981</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt B, Riordan SM, Kukreja L, Eimer WA, Rajapaksha TW, Vassar R. &#x3b2;-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem. 2012;287(46):38408&#x2013;38425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493884</ArticleId><ArticleId IdType="pubmed">22988240</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Lammich S, Haass C. Function, regulation and therapeutic properties of &#x3b2;-secretase (BACE1) Semin Cell Dev Biol. 2009;20(2):175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">19429494</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleck D, Garratt AN, Haass C, Willem M. BACE1 dependent neuregulin processing: review. Curr Alzheimer Res. 2012;9(2):178&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">22455478</ArticleId></ArticleIdList></Reference><Reference><Citation>Agholme L, Clarin M, Gkanatsiou E, Kettunen P, Chebli J, Brinkmalm G, et al. Low-dose gamma-secretase inhibition increases secretion of Abeta peptides and intracellular oligomeric Abeta. Mol Cell Neurosci. 2017;85:211&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">29104140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther. 2006;319(2):924&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920992</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer&#x2019;s disease. J Neurosci. 2007;27(4):796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32461332</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>545</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaay1359</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aay1359</ELocationID><Abstract><AbstractText>Effective delivery of protein therapeutics to the central nervous system (CNS) has been greatly restricted by the blood-brain barrier (BBB). We describe the development of a BBB transport vehicle (TV) comprising an engineered Fc fragment that exploits receptor-mediated transcytosis for CNS delivery of biotherapeutics by binding a highly expressed brain endothelial cell target. TVs were engineered using directed evolution to bind the apical domain of the human transferrin receptor (hTfR) without the use of amino acid insertions, deletions, or unnatural appendages. A crystal structure of the TV-TfR complex revealed the TV binding site to be away from transferrin and FcRn binding sites, which was further confirmed experimentally in vitro and in vivo. Recombinant expression of TVs fused to anti-&#x3b2;-secretase (BACE1) Fabs yielded antibody transport vehicle (ATV) molecules with native immunoglobulin G (IgG) structure and stability. Peripheral administration of anti-BACE1 ATVs to hTfR-engineered mice and cynomolgus monkeys resulted in substantially improved CNS uptake and sustained pharmacodynamic responses. The TV platform readily accommodates numerous additional configurations, including bispecific antibodies and protein fusions, yielding a highly modular CNS delivery platform.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kariolis</LastName><ForeName>Mihalis S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0003-2067-4013</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA. kariolis@dnli.com zuchero@dnli.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wells</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><Identifier Source="ORCID">0000-0002-2713-2201</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Getz</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-1777-8401</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwan</LastName><ForeName>Wanda</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahon</LastName><ForeName>Cathal S</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0001-6898-2264</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Raymond</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7915-1850</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Do Jin</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-7078-3915</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Ankita</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7022-3371</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedard</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5671-9255</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henne</LastName><ForeName>Kirk R</ForeName><Initials>KR</Initials><Identifier Source="ORCID">0000-0003-0370-2094</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giese</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assimon</LastName><ForeName>Victoria A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaocheng</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-1292-7084</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solanoy</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-4211-9064</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Pascal E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kane</LastName><ForeName>Lesley</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9631-3471</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Kylie S</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0003-4752-009X</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pizzo</LastName><ForeName>Michelle E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-4219-5996</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0757-3787</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvert</LastName><ForeName>Meredith E K</ForeName><Initials>MEK</Initials><Identifier Source="ORCID">0000-0003-2893-959X</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeVos</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baskaran</LastName><ForeName>Sulochanadevi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Sejal</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6036-8788</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>Zachary K</ForeName><Initials>ZK</Initials><Identifier Source="ORCID">0000-0002-9852-1802</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thorne</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials><Identifier Source="ORCID">0000-0002-1671-5700</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-4973-5089</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennis</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0003-3581-2917</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>Adam P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0003-1749-6607</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuchero</LastName><ForeName>Y Joy Yu</ForeName><Initials>YJY</Initials><Identifier Source="ORCID">0000-0001-5183-7968</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA. kariolis@dnli.com zuchero@dnli.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007141">Immunoglobulin Fc Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2020 Jul;19(7):444. doi: 10.1038/d41573-020-00102-3.</RefSource><PMID Version="1">32504057</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Aug;16(8):404. doi: 10.1038/s41582-020-0380-0.</RefSource><PMID Version="1">32561823</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="Y">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="Y">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000882" MajorTopicYN="N">Haplorhini</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007141" MajorTopicYN="N">Immunoglobulin Fc Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32461332</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aay1359</ArticleId><ArticleId IdType="pii">12/545/eaay1359</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32492427</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Depletion of the AD Risk Gene SORL1 Selectively Impairs Neuronal Endosomal Traffic Independent of Amyloidogenic APP Processing.</ArticleTitle><Pagination><StartPage>107719</StartPage><MedlinePgn>107719</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2020.107719</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(20)30696-3</ELocationID><Abstract><AbstractText>SORL1/SORLA is a sorting receptor involved in retromer-related endosomal traffic and an Alzheimer's disease (AD) risk gene. Using CRISPR-Cas9, we deplete SORL1 in hiPSCs to ask if loss of SORL1 contributes to AD pathogenesis by endosome dysfunction. SORL1-deficient hiPSC neurons show early endosome enlargement, a hallmark cytopathology of AD. There is no effect of SORL1 depletion on endosome size in hiPSC microglia, suggesting a selective effect on neuronal endosomal trafficking. We validate defects in neuronal endosomal traffic by showing altered localization of amyloid precursor protein (APP) in early endosomes, a site of APP cleavage by the &#x3b2;-secretase (BACE). Inhibition of BACE does not rescue endosome enlargement in SORL1-deficient neurons, suggesting that this phenotype is independent of amyloidogenic APP processing. Our data, together with recent findings, underscore how sporadic AD pathways regulating endosomal trafficking and autosomal-dominant AD pathways regulating APP cleavage independently converge on the defining cytopathology of AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Knupp</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Swati</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Refugio</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braggin</LastName><ForeName>Jacquelyn E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szabo</LastName><ForeName>Marcell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Chizuru</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hailey</LastName><ForeName>Dale W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayadev</LastName><ForeName>Suman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, WA 98195, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA 98109, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA. Electronic address: jeyoung@uw.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062148</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG052354</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000094704">RNA, Guide, CRISPR-Cas Systems</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="N">CRISPR-Cas Systems</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="N">Gene Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094704" MajorTopicYN="N">RNA, Guide, CRISPR-Cas Systems</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">SORL1</Keyword><Keyword MajorTopicYN="N">early endosomes</Keyword><Keyword MajorTopicYN="N">human induced pluripotent stem cells</Keyword></KeywordList><CoiStatement>Declaration of Interests S.A.S. is on the Scientific Advisory Board of Meira GTX and holds Equity in Imij Technologies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32492427</ArticleId><ArticleId IdType="mid">NIHMS1600581</ArticleId><ArticleId IdType="pmc">PMC7409533</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.107719</ArticleId><ArticleId IdType="pii">S2211-1247(20)30696-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association (2019). 2019 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 15, 321&#x2013;387.</Citation></Reference><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, et al. (2005). Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U S A 102, 13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis D, McKinstry WJ, Parker MW, Masters CL, Hyman BT, et al. (2006). Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry 45, 2618&#x2013;2628.</Citation><ArticleIdList><ArticleId IdType="pubmed">16489755</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, and Sleegers K (2008). SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum. Mutat. 29, 769&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolte S, and Cordeli&#xe8;res FP (2006). A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210054</ArticleId></ArticleIdList></Reference><Reference><Citation>Caglayan S, Takagi-Niidome S, Liao F, Carlo AS, Schmidt V, Burgert T, Kitago Y, F&#xfc;chtbauer EM, F&#xfc;chtbauer A, Holtzman DM, et al. (2014). Lysosomal sorting of amyloid-&#x3b2; by the SORLA receptor is impaired by a familial Alzheimer&#x2019;s disease mutation. Sci. Transl. Med. 6, 223ra20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24523320</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, and Nixon RA (2000). Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157, 277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Gearing M, Lippa CF, Montine TJ, Levey AI, and Lah JJ (2006). LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J. Neuropathol. Exp. Neurol. 65, 866&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663339</ArticleId><ArticleId IdType="pubmed">16957580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanis SB, Burgert T, Caglayan S, F&#xfc;chtbauer A, F&#xfc;chtbauer EM, Schmidt V, and Willnow TE (2015). Distinct functions for anterograde and retrograde sorting of SORLA in amyloidogenic processes in the brain. J. Neurosci. 35, 12703&#x2013;12713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6795211</ArticleId><ArticleId IdType="pubmed">26377460</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjorback AW, Seaman M, Gustafsen C, Mehmedbasic A, Gokool S, Wu C, Militz D, Schmidt V, Madsen P, Nyengaard JR, et al. (2012). Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing. J. Neurosci. 32, 1467&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6796259</ArticleId><ArticleId IdType="pubmed">22279231</ArticleId></ArticleIdList></Reference><Reference><Citation>Glerup S, Lume M, Olsen D, Nyengaard JR, Vaegter CB, Gustafsen C, Christensen EI, Kjolby M, Hay-Schmidt A, Bender D, et al. (2013). SorLA controls neurotrophic activity by sorting of GDNF and its receptors GFR&#x3b1;1 and RET. Cell Rep. 3, 186&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">23333276</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermans-Borgmeyer I, Hampe W, Schinke B, Methner A, Nykjaer A, S&#xfc;sens U, Fenger U, Herbarth B, and Schaller HC (1998). Unique expression pattern of a novel mosaic receptor in the developing cerebral cortex. Mech. Dev. 70, 65&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">9510025</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz JH, Offe K, Deshpande A, Kahn RA, Levey AI, and Lah JJ (2012). GGA1-mediated endocytic traffic of LR11/SorLA alters APP intracellular distribution and amyloid-&#x3b2; production. Mol. Biol. Cell 23, 2645&#x2013;2657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3395654</ArticleId><ArticleId IdType="pubmed">22621900</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JG, Weiss M, Louwersheimer E, Wolters FJ, Amin N, Uitterlinden AG, et al. (2017). Characterization of pathogenic SORL1 genetic variants for association with Alzheimer&#x2019;s disease: a clinical interpretation strategy. Eur. J. Hum. Genet. 25, 973&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567154</ArticleId><ArticleId IdType="pubmed">28537274</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, et al. (2012). Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature 482, 216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, and Goate AM (2015). Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry 77, 43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur G, and Lakkaraju A (2018). Early endosome morphology in health and disease. Adv. Exp. Med. Biol. 1074, 335&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6563932</ArticleId><ArticleId IdType="pubmed">29721961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Sato Y, Mohan PS, Peterhoff C, Pensalfini A, Rigoglioso A, Jiang Y, and Nixon RA (2016). Evidence that the rab5 effector APPL1 mediates APP-&#x3b2;CTF-induced dysfunction of endosomes in Down syndrome and Alzheimer&#x2019;s disease. Mol. Psychiatry 21, 707&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721948</ArticleId><ArticleId IdType="pubmed">26194181</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinger SC, Glerup S, Raarup MK, Mari MC, Nyegaard M, Koster G, Prabakaran T, Nilsson SK, Kjaergaard MM, Bakke O, et al. (2011). SorLA regulates the activity of lipoprotein lipase by intracellular trafficking. J. Cell Sci. 124, 1095&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">21385844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwart D, Gregg A, Scheckel C, Murphy EA, Paquet D, Duffield M, Fak J, Olsen O, Darnell RB, and Tessier-Lavigne M (2019). A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP &#x3b2;-CTFs, not A&#x3b2;. Neuron 104, 1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">31805257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritzen I, Pardossi-Piquard R, Bourgeois A, Pagnotta S, Biferi MG, Barkats M, Lacor P, Klein W, Bauer C, and Checler F (2016). Intraneuronal aggregation of the &#x3b2;-CTF fragment of APP (C99) induces A&#x3b2;-independent lysosomal-autophagic pathology. Acta Neuropathol. 132, 257&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947121</ArticleId><ArticleId IdType="pubmed">27138984</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, et al. (2007). The diploid genome sequence of an individual human. PLoS Biol. 5, e254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1964779</ArticleId><ArticleId IdType="pubmed">17803354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J, Cam HP, Gjoneska E, Raja WK, Cheng J, et al. (2018). APOE4 causes widespread molecular and cellular alterations associated with Alzheimer&#x2019;s disease phenotypes in human iPSC-derived brain cell types. Neuron 98, 1141&#x2013;1154.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ubeda OJ, Rosario ER, Teter B, Frautschy SA, and Cole GM (2009). Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid. Arch. Neurol. 66, 448&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742778</ArticleId><ArticleId IdType="pubmed">19364929</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini AC, Gomez-Arboledas A, Forner S, Rodriguez-Ortiz CJ, McQuade A, Danhash E, Phan J, Javonillo D, Ha JV, Tram M, et al. (2019). Amyloid-beta impairs TOM1-mediated IL-1R1 signaling. Proc. Natl. Acad. Sci. U S A 116, 21198&#x2013;21206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800331</ArticleId><ArticleId IdType="pubmed">31570577</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, and Blurton-Jones M (2018). Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol. Neurodegener. 13, 67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuin C, Goodman A, Chernyshev V, Kamentsky L, Cimini BA, Karhohs KW, Doan M, Ding L, Rafelski SM, Thirstrup D, et al. (2018). Cell-Profiler 3.0: Next-generation image processing for biology. PLoS Biol. 16, e2005970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029841</ArticleId><ArticleId IdType="pubmed">29969450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecozzi VJ, Berman DE, Simoes S, Vetanovetz C, Awal MR, Patel VM, Schneider RT, Petsko GA, Ringe D, and Small SA (2014). Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol. 10, 443&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076047</ArticleId><ArticleId IdType="pubmed">24747528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehmedbasic A, Christensen SK, Nilsson J, R&#xfc;etschi U, Gustafsen C, Poulsen AS, Rasmussen RW, Fjorback AN, Larson G, and Andersen OM (2015). SorLA complement-type repeat domains protect the amyloid precursor protein against processing. J. Biol. Chem. 290, 3359&#x2013;3376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4319007</ArticleId><ArticleId IdType="pubmed">25525276</ArticleId></ArticleIdList></Reference><Reference><Citation>Netzer WJ, Bettayeb K, Sinha SC, Flajolet M, Greengard P, and Bustos V (2017). Gleevec shifts APP processing from a &#x3b2;-cleavage to a nonamyloidogenic cleavage. Proc. Natl. Acad. Sci. U S A 114, 1389&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5307477</ArticleId><ArticleId IdType="pubmed">28115709</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MS, Gustafsen C, Madsen P, Nyengaard JR, Hermey G, Bakke O, Mari M, Schu P, Pohlmann R, Dennes A, and Petersen CM (2007). Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor SorLA. Mol. Cell. Biol. 27, 6842&#x2013;6851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099242</ArticleId><ArticleId IdType="pubmed">17646382</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI, and Lah JJ (2006). The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J. Neurosci. 26, 1596&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A, Wallon D, Rousseau S, Legallic S, Paquet C, Bombois S, Pariente J, et al.; PHRC GMAJ Collaborators (2012). High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol. Psychiatry 17, 875&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">22472873</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan NS, Brickman AM, Andrews H, Manly JJ, Schupf N, Lantigua R, Wolock CJ, Kamalakaran S, Petrovski S, Tosto G, et al.; Alzheimer&#x2019;s Disease Sequencing Project (2018). Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer&#x2019;s disease. Ann. Clin. Transl. Neurol. 5, 832&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6043775</ArticleId><ArticleId IdType="pubmed">30009200</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja WK, Mungenast AE, Lin YT, Ko T, Abdurrob F, Seo J, and Tsai LH (2016). Self-Organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer&#x2019;s disease phenotypes. PLoS ONE 11, e0161969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5021368</ArticleId><ArticleId IdType="pubmed">27622770</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Cheng R, Rogaeva E, Lee JH, Tokuhiro S, Zou F, Bettens K, Sleegers K, Tan EK, Kimura R, et al.; Genetic and Environmental Risk in Alzheimer Disease 1 Consortium (2011). Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch. Neurol. 68, 99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086666</ArticleId><ArticleId IdType="pubmed">21220680</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, et al. (2007). The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39, 168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose SE, Frankowski H, Knupp A, Berry BJ, Martinez R, Dinh SQ, Bruner LT, Willis SL, Crane PK, Larson EB, et al. (2018). Leptomeninges-derived induced pluripotent stem cells and directly converted neurons from autopsy cases with varying neuropathologic backgrounds. J. Neuropathol. Exp. Neurol. 77, 353&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6018913</ArticleId><ArticleId IdType="pubmed">29474672</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager KL, Wuu J, Leurgans SE, Rees HD, Gearing M, Mufson EJ, Levey AI, and Lah JJ (2007). Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Ann. Neurol. 62, 640&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669325</ArticleId><ArticleId IdType="pubmed">17721864</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Moore DB, Milla ME, Doms RW, and Lee VM (2000). Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J. Biol. Chem. 275, 2568&#x2013;2575.</Citation><ArticleIdList><ArticleId IdType="pubmed">10644715</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, and Gandy S (2006). Sorting through the cell biology of Alzheimer&#x2019;s disease: intracellular pathways to pathogenesis. Neuron 52, 15&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820242</ArticleId><ArticleId IdType="pubmed">17015224</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol&#xe9;-Dom&#xe8;nech S, Cruz DL, Capetillo-Zarate E, and Maxfield FR (2016). The endocytic pathway in microglia during health, aging and Alzheimer&#x2019;s disease. Ageing Res. Rev. 32, 89&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127718</ArticleId><ArticleId IdType="pubmed">27421577</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamayev R, Matsuda S, Arancio O, and D&#x2019;Adamio L (2012). &#x3b2;- but not &#x3b3;-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol. Med. 4, 171&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3376850</ArticleId><ArticleId IdType="pubmed">22170863</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagnozzi AN, and Pratic&#xf2; D (2019). Endosomal sorting and trafficking, the retromer complex and neurodegeneration. Mol. Psychiatry 24, 857&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378136</ArticleId><ArticleId IdType="pubmed">30120416</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Acker ZP, Bretou M, and Annaert W (2019). Endo-lysosomal dysregulations and late-onset Alzheimer&#x2019;s disease: impact of genetic risk factors. Mol. Neurodegener. 14, 20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547588</ArticleId><ArticleId IdType="pubmed">31159836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, Jaenisch R, and Jacks T (2004). Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl. Acad. Sci. U S A 101, 10380&#x2013;10385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC478580</ArticleId><ArticleId IdType="pubmed">15240889</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME, Yoon SY, Yuan H, Li G, Miller ZA, et al. (2018). Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat. Med. 24, 647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948154</ArticleId><ArticleId IdType="pubmed">29632371</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Weissmiller AM, White JA 2nd, Fang F, Wang X, Wu Y, Pearn ML, Zhao X, Sawa M, Chen S, et al. (2016). Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J. Clin. Invest. 126, 1815&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4855914</ArticleId><ArticleId IdType="pubmed">27064279</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JE, Boulanger-Weill J, Williams DA, Woodruff G, Buen F, Revilla AC, Herrera C, Israel MA, Yuan SH, Edland SD, and Goldstein LS (2015). Elucidating molecular phenotypes caused by the SORL1 Alzheimer&#x2019;s disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell 16, 373&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388804</ArticleId><ArticleId IdType="pubmed">25772071</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JE, Fong LK, Frankowski H, Petsko GA, Small SA, and Goldstein LSB (2018). Stabilizing the retromer complex in a human stem cell model of Alzheimer&#x2019;s disease reduces TAU phosphorylation independently of amyloid precursor protein. Stem Cell Reports 10, 1046&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919412</ArticleId><ArticleId IdType="pubmed">29503090</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan SH, Martin J, Elia J, Flippin J, Paramban RI, Hefferan MP, Vidal JG, Mu Y, Killian RL, Israel MA, et al. (2011). Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS ONE 6, e17540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047583</ArticleId><ArticleId IdType="pubmed">21407814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. (2014). An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32514169</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Reconstruction of the human blood-brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes.</ArticleTitle><Pagination><StartPage>952</StartPage><EndPage>963</EndPage><MedlinePgn>952-963</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-020-0886-4</ELocationID><Abstract><AbstractText>In Alzheimer's disease, amyloid deposits along the brain vasculature lead to a condition known as cerebral amyloid angiopathy (CAA), which impairs blood-brain barrier (BBB) function and accelerates cognitive degeneration. Apolipoprotein (APOE4) is the strongest risk factor for CAA, yet the mechanisms underlying this genetic susceptibility are unknown. Here we developed an induced pluripotent stem cell-based three-dimensional model that recapitulates anatomical and physiological properties of the human BBB in vitro. Similarly to CAA, our in vitro BBB displayed significantly more amyloid accumulation in APOE4 compared to APOE3. Combinatorial experiments revealed that dysregulation of calcineurin-nuclear factor of activated T cells (NFAT) signaling and APOE in pericyte-like mural cells induces APOE4-associated CAA pathology. In the human brain, APOE and NFAT are selectively dysregulated in pericytes of APOE4 carriers, and inhibition of calcineurin-NFAT signaling reduces APOE4-associated CAA pathology in vitro and in vivo. Our study reveals the role of pericytes in APOE4-mediated CAA and highlights calcineurin-NFAT signaling as a therapeutic target in CAA and Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blanchard</LastName><ForeName>Joel W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bula</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davila-Velderrain</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akay</LastName><ForeName>Leyla Anne</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-5944-2466</Identifier><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0056-0174</Identifier><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Victor</LastName><ForeName>Matheus B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonner</LastName><ForeName>Julia Maeve</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathys</LastName><ForeName>Hansruedi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yuan-Ta</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Tak</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cam</LastName><ForeName>Hugh P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7113-9630</Identifier><AffiliationInfo><Affiliation>MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0003-1262-0592</Identifier><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA. lhtsai@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA. lhtsai@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA, USA. lhtsai@mit.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UG3 NS115064</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048056</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG008097</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C118125">NFAT5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050778">NFATC Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494003">NFATC1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D019703">Calcineurin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Med. 2021 Feb;27(2):356. doi: 10.1038/s41591-021-01250-8.</RefSource><PMID Version="1">33514950</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019703" MajorTopicYN="N">Calcineurin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050778" MajorTopicYN="N">NFATC Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020286" MajorTopicYN="N">Pericytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081246" MajorTopicYN="N">RNA-Seq</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32514169</ArticleId><ArticleId IdType="mid">NIHMS1631046</ArticleId><ArticleId IdType="pmc">PMC7704032</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0886-4</ArticleId><ArticleId IdType="pii">10.1038/s41591-020-0886-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andreone BJ, Lacoste B &amp; Gu C Neuronal and vascular interactions. Annu. Rev. Neurosci 38, 25&#x2013;46 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5729758</ArticleId><ArticleId IdType="pubmed">25782970</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28, 202&#x2013;208 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15808355</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron 96, 17&#x2013;42 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657612</ArticleId><ArticleId IdType="pubmed">28957666</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain 138, 761&#x2013;771 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339775</ArticleId><ArticleId IdType="pubmed">25595145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM How neuroinflammation contributes to neurodegeneration. Science 353, 777&#x2013;783 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nation DA et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat. Med 1 (2019). doi:10.1038/s41591-018-0297-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0297-y</ArticleId><ArticleId IdType="pmc">PMC6367058</ArticleId><ArticleId IdType="pubmed">30643288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM et al. Clinical Predictors of Severe Cerebral Amyloid Angiopathy and Influence of APOE Genotype in Persons With Pathologically Verified Alzheimer Disease. JAMA Neurol 71, 878&#x2013;883 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4101018</ArticleId><ArticleId IdType="pubmed">24797962</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Neurology JGNR 2012. 
Dementia in 2011: microbleeds in dementia&#x2014;singing a different ARIA. nature.com </Citation><ArticleIdList><ArticleId IdType="pubmed">22231195</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C The Pathobiology of Vascular Dementia. Neuron 80, 844&#x2013;866 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842016</ArticleId><ArticleId IdType="pubmed">24267647</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Rebeck GW, Vonsattel JPG, Isla TG &amp; Hyman BT Apolipoprotein E &#x3f5;4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol 38, 254&#x2013;259 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7654074</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar DR, Cohen DL, Hedera P, Friedland RP &amp; Kalaria RN Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer&#x2019;s disease. Am. J. Pathol 148, 2083 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861657</ArticleId><ArticleId IdType="pubmed">8669492</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinohara M et al. Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer's disease. Acta Neuropathol. 132, 225&#x2013;234 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947445</ArticleId><ArticleId IdType="pubmed">27179972</ArticleId></ArticleIdList></Reference><Reference><Citation>Janzer RC &amp; Raff MC Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325, 253&#x2013;257 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3543687</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A et al. Pericytes regulate the blood?brain barrier. Nature 468, 557&#x2013;561 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Zhou L, Kebede AA &amp; Barres BA Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 468, 562&#x2013;566 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241506</ArticleId><ArticleId IdType="pubmed">20944625</ArticleId></ArticleIdList></Reference><Reference><Citation>The Molecular Constituents of the Blood&#x2013;Brain Barrier. Trends Neurosci. 38, 598&#x2013;608 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4597316</ArticleId><ArticleId IdType="pubmed">26442694</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian T et al. Directed differentiation of human pluripotent stem cells to blood-brain barrier endothelial cells. Sci Adv 3, e1701679 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5677350</ArticleId><ArticleId IdType="pubmed">29134197</ArticleId></ArticleIdList></Reference><Reference><Citation>Patsch C et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat. Cell Biol 17, 994&#x2013;1003 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4566857</ArticleId><ArticleId IdType="pubmed">26214132</ArticleId></ArticleIdList></Reference><Reference><Citation>TCW J et al. An Efficient Platform for Astrocyte Differentiation from Human Induced Pluripotent Stem Cells. Stem Cell Reports 9, 600&#x2013;614 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5550034</ArticleId><ArticleId IdType="pubmed">28757165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A et al. Specification and Diversification of Pericytes and Smooth Muscle Cells from Mesenchymoangioblasts. Cell Rep 19, 1902&#x2013;1916 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6428685</ArticleId><ArticleId IdType="pubmed">28564607</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, Genov&#xe9; G &amp; Betsholtz C Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises. Dev Cell 21, 193&#x2013;215 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21839917</ArticleId></ArticleIdList></Reference><Reference><Citation>Attwell D, Mishra A, Hall CN, O&#x2019;Farrell FM &amp; Dalkara T What is a pericyte?:. Journal of Cerebral Blood Flow &amp; Metabolism (2015). doi:10.1177/0271678X15610340</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X15610340</ArticleId><ArticleId IdType="pmc">PMC4759679</ArticleId><ArticleId IdType="pubmed">26661200</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandewijck M et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature 554, 475&#x2013;480 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29443965</ArticleId></ArticleIdList></Reference><Reference><Citation>He L et al. Single-cell RNA sequencing of mouse brain and lung vascular and vessel-associated cell types. Scientific Data 2018 5 5, 180160 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6103262</ArticleId><ArticleId IdType="pubmed">30129931</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonomini F, Francesca B &amp; Rezzani R Aquaporin and blood brain barrier. Curr Neuropharmacol 8, 92&#x2013;96 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923372</ArticleId><ArticleId IdType="pubmed">21119879</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam J, Zhang X &amp; Yao Y The role of pericytic laminin in blood brain barrier integrity maintenance. Sci. Rep 6, 36450 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5093438</ArticleId><ArticleId IdType="pubmed">27808256</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brown NM, Pfau SJ &amp; Gu C Bridging barriers: a comparative look at the blood&#x2013;brain barrier across organisms. Genes &amp; Development 32, 466&#x2013;478 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959231</ArticleId><ArticleId IdType="pubmed">29692355</ArticleId></ArticleIdList></Reference><Reference><Citation>Urich E, Lazic SE, Molnos J, Wells I &amp; Freskg&#xe5;rd P-O Transcriptional Profiling of Human Brain Endothelial Cells Reveals Key Properties Crucial for Predictive In Vitro Blood-Brain Barrier Models. PLoS ONE 7, e38149 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364980</ArticleId><ArticleId IdType="pubmed">22675443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Nelson AR, Betsholtz C &amp; Zlokovic BV Establishment and Dysfunction of the Blood-Brain Barrier. Cell 163, 1064&#x2013;1078 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655822</ArticleId><ArticleId IdType="pubmed">26590417</ArticleId></ArticleIdList></Reference><Reference><Citation>Strickland LA et al. Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). J. Pathol 206, 466&#x2013;475 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15971170</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan B et al. TEER Measurement Techniques for In Vitro Barrier Model Systems:. Journal of Laboratory Automation 20, 107&#x2013;126 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4652793</ArticleId><ArticleId IdType="pubmed">25586998</ArticleId></ArticleIdList></Reference><Reference><Citation>Deli MA, &#xc1;brah&#xe1;m CS, Kataoka Y &amp; Niwa M Permeability Studies on In Vitro Blood&#x2013;Brain Barrier Models: Physiology, Pathology, and Pharmacology. Cell Mol Neurobiol 25, 59&#x2013;127 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11529645</ArticleId><ArticleId IdType="pubmed">15962509</ArticleId></ArticleIdList></Reference><Reference><Citation>Seetharaman S, Barrand MA, Maskell L &amp; Scheper RJ Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. Journal of Neurochemistry 70, 1151&#x2013;1159 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9489736</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482, 216&#x2013;220 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers SM et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat Biotechnol 30, 715&#x2013;720 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516136</ArticleId><ArticleId IdType="pubmed">22750882</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Kirwan P &amp; Livesey FJ Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc 7, 1836&#x2013;1846 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22976355</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-T et al. APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron (2018). doi:10.1016/j.neuron.2018.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.05.008</ArticleId><ArticleId IdType="pmc">PMC6048952</ArticleId><ArticleId IdType="pubmed">29953873</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q et al. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci 26, 4985&#x2013;4994 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674234</ArticleId><ArticleId IdType="pubmed">16687490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 1, 1 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD et al. Apolipoprotein E Markedly Facilitates Age-Dependent Cerebral Amyloid Angiopathy and Spontaneous Hemorrhage in Amyloid Precursor Protein Transgenic Mice. J. Neurosci 23, 7889&#x2013;7896 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740607</ArticleId><ArticleId IdType="pubmed">12944519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J et al. Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-&#x3b2; Amyloidosis. J. Neurosci 31, 18007&#x2013;18012 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257514</ArticleId><ArticleId IdType="pubmed">22159114</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney B, Ge Y-W, Alley GM &amp; Lahiri DK Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease. Journal of Neurochemistry 103, 1237&#x2013;1257 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17854398</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese LC &amp; Taglialatela G A role for calcineurin in Alzheimer's disease. Curr Neuropharmacol 9, 685&#x2013;692 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3263462</ArticleId><ArticleId IdType="pubmed">22654726</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwack Y et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 441, 646&#x2013;650 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16511445</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulero MC, Aubareda A, Schl&#xfc;ter A &amp; P&#xe9;rez-Riba M RCAN3, a novel calcineurin inhibitor that down-regulates NFAT-dependent cytokine gene expression. Biochim. Biophys. Acta 1773, 330&#x2013;341 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17270291</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MY, Garvey SM, Ripley ML &amp; Wamhoff BR Genome-wide microarray analyses identify the protein C receptor as a novel calcineurin/nuclear factor of activated T cells-dependent gene in vascular smooth muscle cell phenotypic modulation. Arterioscler. Thromb. Vasc. Biol 31, 2665&#x2013;2675 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245683</ArticleId><ArticleId IdType="pubmed">21903947</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr AW, Hastings NE, Blackman BR &amp; Wamhoff BR Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J. Vasc. Res 47, 168&#x2013;180 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842170</ArticleId><ArticleId IdType="pubmed">19851078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapturczak MH, Meier-Kriesche HU &amp; Kaplan B Pharmacology of calcineurin antagonists. Transplant. Proc 36, 25S&#x2013;32S (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15041303</ArticleId></ArticleIdList></Reference><Reference><Citation>Boroujerdi A, Tigges U, Welser-Alves JV &amp; Milner R in Cerebral Angiogenesis 383&#x2013;392 (Humana Press, New York, NY, 2014). doi:10.1007/978-1-4939-0320-7_31</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-0320-7_31</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Stebbins MJ et al. Human pluripotent stem cell-derived brain pericyte-like cells induce blood-brain barrier properties. Sci Adv 5, eaau7375 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6415958</ArticleId><ArticleId IdType="pubmed">30891496</ArticleId></ArticleIdList></Reference><Reference><Citation>Taglialatela G, Rastellini C &amp; Cicalese L Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors. J. Alzheimers Dis 47, 329&#x2013;333 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4923720</ArticleId><ArticleId IdType="pubmed">26401556</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Bioinformatics WS 2013. 
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features &#x2223; Bioinformatics &#x2223; Oxford Academic. academic.oup.com doi:10.1093/bioinformatics/btt656","inLanguage":"en","copyrightHolder':&#x2019;Oxford</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt656</ArticleId><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 7, 562&#x2013;578 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334321</ArticleId><ArticleId IdType="pubmed">22383036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Religious Orders Study and Rush Memory and Aging Project. Journal of Alzheimer's Disease 64, S161&#x2013;S189 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J et al. Gene expression distribution deconvolution in single-cell RNA sequencing. Proc. Natl. Acad. Sci. U.S.A 115, E6437&#x2013;E6446 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6048536</ArticleId><ArticleId IdType="pubmed">29946020</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerebral Angiogenesis. (Humana Press, New York, NY: ).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32514138</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's-associated PLC&#x3b3;2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia.</ArticleTitle><Pagination><StartPage>927</StartPage><EndPage>938</EndPage><MedlinePgn>927-938</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-020-0650-6</ELocationID><Abstract><AbstractText>Human genetic data indicate that microglial dysfunction contributes to the pathology of Alzheimer's disease (AD), exemplified by the identification of coding variants in triggering receptor expressed on myeloid cells 2 (TREM2) and, more recently, in PLCG2, a phospholipase-encoding gene expressed in microglia. Although studies in mouse models have implicated specific Trem2-dependent microglial functions in AD, the underlying molecular mechanisms and translatability to human disease remain poorly defined. In this study, we used genetically engineered human induced pluripotent stem cell-derived microglia-like cells to show that TREM2 signals through PLC&#x3b3;2 to mediate cell survival, phagocytosis, processing of neuronal debris, and lipid metabolism. Loss of TREM2 or PLC&#x3b3;2 signaling leads to a shared signature of transcriptional dysregulation that underlies these phenotypes. Independent of TREM2, PLC&#x3b3;2 also signals downstream of Toll-like receptors to mediate inflammatory responses. Therefore, PLC&#x3b3;2 activity regulates divergent microglial functions via distinct TREM2-dependent and -independent signaling and might be involved in the transition to a microglial state associated with neurodegenerative disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Andreone</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Przybyla</LastName><ForeName>Laralynne</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8598-4779</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA. laralynne.przybyla@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llapashtica</LastName><ForeName>Ceyda</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rana</LastName><ForeName>Anil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Sonnet S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Lengerich</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Ju</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Astarita</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monroe</LastName><ForeName>Kathryn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewcock</LastName><ForeName>Joseph W</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0003-3012-7881</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, California, CA, USA. lewcock@dnli.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.3</RegistryNumber><NameOfSubstance UI="D051966">Phospholipase C gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051966" MajorTopicYN="N">Phospholipase C gamma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32514138</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-0650-6</ArticleId><ArticleId IdType="pii">10.1038/s41593-020-0650-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Efthymiou, A. G. &amp; Goate, A. M. Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 12, 43 (2017).</Citation></Reference><Reference><Citation>Hansen, D. V., Hanson, J. E. &amp; Sheng, M. Microglia in Alzheimer&#x2019;s disease. J. Cell Biol. 217, 459&#x2013;472 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29196460</ArticleId><ArticleId IdType="pmc">5800817</ArticleId><ArticleId IdType="doi">10.1083/jcb.201709069</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello, C., Yuan, P., Schain, A. &amp; Grutzendler, J. Microglia constitute a barrier that prevents neurotoxic protofibrillar &#x391;&#x3b2;42 hotspots around plaques. Nat. Commun. 6, 6176 (2015).</Citation></Reference><Reference><Citation>Nugent, A. A. et al. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron 105, 837&#x2013;854 (2020).</Citation></Reference><Reference><Citation>Heppner, F. L., Ransohoff, R. M. &amp; Becher, B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16, 358&#x2013;372 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25991443</ArticleId><ArticleId IdType="doi">10.1038/nrn3880</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro, R. et al. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 368, 117&#x2013;127 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23150934</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med. 368, 107&#x2013;116 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23150908</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich, J. D., Ulland, T. K., Colonna, M. &amp; Holtzman, D. M. Elucidating the role of TREM2 in Alzheimer&#x2019;s disease. Neuron 94 (2017).</Citation></Reference><Reference><Citation>Kober, D. L. et al. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. eLife 5, e20391 (2016).</Citation></Reference><Reference><Citation>Sudom, A. et al. Molecular basis for the loss-of-function effects of the Alzheimer&#x2019;s disease-associated R47H variant of the immune receptor TREM2. J. Biol. Chem. 293, 12634&#x2013;12646 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29794134</ArticleId><ArticleId IdType="pmc">6093241</ArticleId><ArticleId IdType="doi">10.1074/jbc.RA118.002352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25728668</ArticleId><ArticleId IdType="pmc">4477963</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland, T. K. &amp; Colonna, M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat. Rev. Neurol. 14, 667&#x2013;675 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30266932</ArticleId><ArticleId IdType="doi">10.1038/s41582-018-0072-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290 (2017).</Citation></Reference><Reference><Citation>Jay, T. R. et al. Disease progression-dependent effects of trem2 deficiency in a mouse model of Alzheimer&#x2019;s disease. J. Neurosci. 37, 637&#x2013;647 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28100745</ArticleId><ArticleId IdType="pmc">5242410</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2110-16.2016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213, 667&#x2013;675 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27091843</ArticleId><ArticleId IdType="pmc">4854736</ArticleId><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann, S. et al. The TREM2&#x2013;APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566&#x2013;581 (2017).</Citation></Reference><Reference><Citation>Kadamur, G. &amp; Ross, E. M. Mammalian phospholipase C. Annu. Rev. Physiol. 75, 127&#x2013;154 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23140367</ArticleId><ArticleId IdType="doi">10.1146/annurev-physiol-030212-183750</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims, R. et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat. Genet. 49, 1373&#x2013;1384 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28714976</ArticleId><ArticleId IdType="pmc">5669039</ArticleId><ArticleId IdType="doi">10.1038/ng.3916</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25186741</ArticleId><ArticleId IdType="pmc">4152602</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1860-14.2014</ArticleId></ArticleIdList></Reference><Reference><Citation>Magno, L. et al. Alzheimer&#x2019;s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimers Res. Ther. 11, 16 (2019).</Citation></Reference><Reference><Citation>Mao, D., Epple, H., Uthgenannt, B., Novack, D. V. &amp; Faccio, R. PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J. Clin. Invest. 116, 2869&#x2013;2879 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17053833</ArticleId><ArticleId IdType="pmc">1616195</ArticleId><ArticleId IdType="doi">10.1172/JCI28775</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde, J. I. &amp; Watson, S. P. Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other? Cell Signal 13, 691&#x2013;701 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11602179</ArticleId><ArticleId IdType="doi">10.1016/S0898-6568(01)00191-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang, C. Y., Veckman, V., Limmer, K. &amp; David, M. Phospholipase Cgamma-2 and intracellular calcium are required for lipopolysaccharide-induced Toll-like receptor 4 (TLR4) endocytosis and interferon regulatory factor 3 (IRF3) activation. J. Biol. Chem. 287 (2012).</Citation></Reference><Reference><Citation>Zhou, Q. et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am. J. Hum. Genet. 91, 713&#x2013;720 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23000145</ArticleId><ArticleId IdType="pmc">3484656</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2012.08.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman, B. A. et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer&#x2019;s disease not evident in mouse models. Cell Rep. 22, 832&#x2013;847 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29346778</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.12.066</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro, T. F. et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat. Neurosci. 20, 1162&#x2013;1171 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28671693</ArticleId><ArticleId IdType="doi">10.1038/nn.4597</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda, T. et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566, 388&#x2013;392 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30760929</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-0924-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah, M. et al. A transcriptomic atlas of aged human microglia. Nat. Commun. 9, 539 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29416036</ArticleId><ArticleId IdType="pmc">5803269</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-02926-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Abud, E. M. et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron 94, 278&#x2013;293 (2017).</Citation></Reference><Reference><Citation>Muffat, J. et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat. Med. 22, 1358&#x2013;1367 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27668937</ArticleId><ArticleId IdType="pmc">5101156</ArticleId><ArticleId IdType="doi">10.1038/nm.4189</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya, H. et al. Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. Nat. Neurosci. 20, 753&#x2013;759 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28253233</ArticleId><ArticleId IdType="pmc">5404968</ArticleId><ArticleId IdType="doi">10.1038/nn.4534</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade, A. et al. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol. Neurodegener. 13, 67 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30577865</ArticleId><ArticleId IdType="pmc">6303871</ArticleId><ArticleId IdType="doi">10.1186/s13024-018-0297-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi, K., Rochford, C. D. &amp; Neumann, H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 201, 647&#x2013;657 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15728241</ArticleId><ArticleId IdType="pmc">2213053</ArticleId><ArticleId IdType="doi">10.1084/jem.20041611</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland, T. K. et al. TREM2 maintains microglial metabolic fitness in Alzheimer&#x2019;s disease. Cell 170, 649&#x2013;663 (2017).</Citation></Reference><Reference><Citation>Chae, J. J. et al. Connecting two pathways through Ca<sup>2+</sup> signaling: NLRP3 inflammasome activation induced by a hypermorphic PLCG2 mutation. Arthritis Rheumatol. 67, 563&#x2013;567 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25418813</ArticleId><ArticleId IdType="pmc">4369162</ArticleId><ArticleId IdType="doi">10.1002/art.38961</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliani, P. L. et al. TREM2 sustains microglial expansion during aging and response to demyelination. J. Clin. Invest. 125, 2161&#x2013;2170 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25893602</ArticleId><ArticleId IdType="pmc">4463196</ArticleId><ArticleId IdType="doi">10.1172/JCI77983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh, S. Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization. Expert Rev. Cardiovasc. Ther. 9, 329&#x2013;340 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21438812</ArticleId><ArticleId IdType="pmc">3098044</ArticleId><ArticleId IdType="doi">10.1586/erc.11.16</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng-Hathaway, P. J. et al. The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer&#x2019;s disease. Mol. Neurodegener. 13, 29 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29859094</ArticleId><ArticleId IdType="pmc">5984804</ArticleId><ArticleId IdType="doi">10.1186/s13024-018-0262-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, J. et al. Pathological axonal death through a MAPK cascade that triggers a local energy deficit. Cell 160, 161&#x2013;176 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25594179</ArticleId><ArticleId IdType="pmc">4306654</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.11.053</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae, Y. S., Lee, H. Y., Jung, Y. S., Lee, M. &amp; Suh, P. G. Phospholipase Cgamma in Toll-like receptor-mediated inflammation and innate immunity. Adv. Biol. Regul. 63, 92&#x2013;97 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27707630</ArticleId><ArticleId IdType="doi">10.1016/j.jbior.2016.09.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, L., Jones, C. &amp; Zhang, G. The role of phospholipase C signaling in macrophage-mediated inflammatory response. J. Immunol. Res. 2018 (2018).</Citation></Reference><Reference><Citation>Marschallinger, J. et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat. Neurosci. 23, 194&#x2013;208 (2020).</Citation></Reference><Reference><Citation>Kober, D. L. &amp; Brett, T. J. TREM2-ligand interactions in health and disease. J. Mol. Biol. 429, 1607&#x2013;1629 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28432014</ArticleId><ArticleId IdType="pmc">5485854</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2017.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantoni, C. et al. TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathol. 129, 429&#x2013;447 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25631124</ArticleId><ArticleId IdType="pmc">4667728</ArticleId><ArticleId IdType="doi">10.1007/s00401-015-1388-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluvinage, J. V. et al. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature 568, 187&#x2013;192 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30944478</ArticleId><ArticleId IdType="pmc">6574119</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1088-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka, M. T. et al. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature 493, 674&#x2013;678 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23254930</ArticleId><ArticleId IdType="doi">10.1038/nature11729</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka, M. T., Kummer, M. P. &amp; Latz, E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14, 463&#x2013;477 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24962261</ArticleId><ArticleId IdType="doi">10.1038/nri3705</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley, P. Lipids in Alzheimer&#x2019;s disease: a century-old story. Biochim. Biophys. Acta 1801, 750&#x2013;753 (2010).</Citation></Reference><Reference><Citation>Lue, L. F. et al. Inflammatory repertoire of Alzheimer&#x2019;s disease and nondemented elderly microglia in vitro. Glia 35, 72&#x2013;79 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11424194</ArticleId><ArticleId IdType="doi">10.1002/glia.1072</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow, K. et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol. Med. 12, e11227 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32154671</ArticleId><ArticleId IdType="pmc">7136959</ArticleId><ArticleId IdType="doi">10.15252/emmm.201911227</ArticleId></ArticleIdList></Reference><Reference><Citation>Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR&#x2013;Cas9. Nat. Biotechnol. 34, 184&#x2013;191 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26780180</ArticleId><ArticleId IdType="pmc">4744125</ArticleId><ArticleId IdType="doi">10.1038/nbt.3437</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntwork-Rodriguez, S. et al. JNK-mediated phosphorylation of DLK suppresses its ubiquitination to promote neuronal apoptosis. J. Cell Biol. 202, 747&#x2013;763 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23979718</ArticleId><ArticleId IdType="pmc">3760612</ArticleId><ArticleId IdType="doi">10.1083/jcb.201303066</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan, S. et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat. Neurosci. 19, 995&#x2013;998 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27294511</ArticleId><ArticleId IdType="doi">10.1038/nn.4325</ArticleId><ArticleId IdType="pmc">7116794</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966&#x2013;968 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20147306</ArticleId><ArticleId IdType="pmc">2844992</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btq054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukural, A., Yukselen, O., Ozata, D. M., Moore, M. J. &amp; Garber, M. DEBrowser: interactive differential expression analysis and visualization tool for count data. BMC Genomics 20, 6 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30611200</ArticleId><ArticleId IdType="pmc">6321710</ArticleId><ArticleId IdType="doi">10.1186/s12864-018-5362-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Babicki, S. et al. Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 44, W147&#x2013;153 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27190236</ArticleId><ArticleId IdType="pmc">4987948</ArticleId><ArticleId IdType="doi">10.1093/nar/gkw419</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. &amp; Zhang, B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 47, W199&#x2013;W205 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31114916</ArticleId><ArticleId IdType="pmc">6602449</ArticleId><ArticleId IdType="doi">10.1093/nar/gkz401</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, H., Lei, R., Ding, S. W. &amp; Zhu, S. Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. BMC Bioinforma. 15, 182 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-15-182</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23104886</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, Y., Smyth, G. K. &amp; Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923&#x2013;930 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btt656</ArticleId></ArticleIdList></Reference><Reference><Citation>Durinck, S. et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics 21, 3439&#x2013;3440 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16082012</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/bti525</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, R. et al. Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses. Nucleic Acids Res. 43, e97 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25925576</ArticleId><ArticleId IdType="pmc">4551905</ArticleId><ArticleId IdType="doi">10.1093/nar/gkv412</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32526197</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Genetics of Gene Expression in the Aging Human Brain Reveal TDP-43 Proteinopathy Pathophysiology.</ArticleTitle><Pagination><StartPage>496</StartPage><EndPage>508.e6</EndPage><MedlinePgn>496-508.e6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2020.05.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(20)30356-1</ELocationID><Abstract><AbstractText>Here, we perform a genome-wide screen for variants that regulate the expression of gene co-expression modules in the aging human brain; we discover and replicate such variants in the TMEM106B and RBFOX1 loci. The TMEM106B haplotype is known to influence the accumulation of TAR DNA-binding protein 43&#xa0;kDa (TDP-43) proteinopathy, and the haplotype's large-scale transcriptomic effects include the dysregulation of lysosomal genes and alterations in synaptic gene splicing that are also seen in the pathophysiology of TDP-43 proteinopathy. Further, a variant near GRN, another TDP-43 proteinopathy susceptibility gene, shows concordant effects with the TMEM106B haplotype. Leveraging neuropathology data from the same participants, we also show that TMEM106B and APOE-amyloid-&#x3b2; effects converge to alter myelination and lysosomal gene expression, which then contributes to TDP-43 accumulation. These results advance our mechanistic understanding of the TMEM106B TDP-43 risk haplotype and uncover a transcriptional program that mediates the converging effects of APOE-amyloid-&#x3b2; and TMEM106B on TDP-43 aggregation in older adults.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hyun-Sik</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Hans-Ulrich</ForeName><Initials>HU</Initials><AffiliationInfo><Affiliation>The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaiteri</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yiyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felsky</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mostafavi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Statistics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada; Canadian Institute for Advanced Research, Toronto, ON M5G 1M1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petyuk</LastName><ForeName>Vladislav A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Pacific Northwest National Laboratory, Richland, WA 99354, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nil&#xfc;fer</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: pld2115@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042210</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG067482</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061796</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG062750</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C455479">RBFOX1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072260">RNA Splicing Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556915">TMEM106B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072260" MajorTopicYN="N">RNA Splicing Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Amyloid-&#x3b2;</Keyword><Keyword MajorTopicYN="N">GRN</Keyword><Keyword MajorTopicYN="N">RBFOX1</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">TMEM106B</Keyword><Keyword MajorTopicYN="N">co-expression module</Keyword><Keyword MajorTopicYN="N">cognitive resilience</Keyword><Keyword MajorTopicYN="N">eQTL</Keyword><Keyword MajorTopicYN="N">expression quantitative trait loci</Keyword><Keyword MajorTopicYN="N">sQTL</Keyword><Keyword MajorTopicYN="N">splicing quantitative trait loci</Keyword></KeywordList><CoiStatement>Declaration of Interests P.L.D. serves on a scientific advisory board for Neuroimmunology Newco, Roche, Biogen, and Celgene; has a sponsored research agreement with Biogen and Roche; and has fellowship funding through Genentech, outside the submitted work. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32526197</ArticleId><ArticleId IdType="mid">NIHMS1595466</ArticleId><ArticleId IdType="pmc">PMC7416464</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2020.05.010</ArticleId><ArticleId IdType="pii">S0896-6273(20)30356-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert FW, and Kruglyak L (2015). The role of regulatory variation in complex traits and disease. Nature reviews Genetics 16, 197&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">25707927</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Carrasquillo MM, Funk C, Heavner BD, Zou F, Younkin CS, Burgess JD, Chai HS, Crook J, Eddy JA, et al. (2016). Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Scientific data 3, 160089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Wang X, Burgess JD, Watzlawik J, Serie DJ, Younkin CS, Nguyen T, Malphrus KG, Lincoln S, Carrasquillo MM, et al. (2018a). Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association 14, 352&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866744</ArticleId><ArticleId IdType="pubmed">29107053</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Wang X, Serie DJ, Strickland SL, Burgess JD, Koga S, Younkin CS, Nguyen TT, Malphrus KG, Lincoln SJ, et al. (2018b). Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy. Acta neuropathologica 136, 709&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208732</ArticleId><ArticleId IdType="pubmed">30136084</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer's Association (2018). 2018 Alzheimer's disease facts and figures. Alzheimer's &amp; Dementia 14, 367&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">21414557</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Capuano AW, Leurgans SE, Buchman AS, Bennett DA, and Schneider JA (2017). The Relationship of Cerebral Vessel Pathology to Brain Microinfarcts. Brain Pathol 27, 77&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974145</ArticleId><ArticleId IdType="pubmed">26844934</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, et al. (2006). Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, and Schneider JA (2018). Religious Orders Study and Rush Memory and Aging Project. Journal of Alzheimer's disease : JAD 64, S161&#x2013;S189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, and Wilson RS (2012a). Overview and findings from the religious orders study. Current Alzheimer research 9, 628&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, and Wilson RS (2012b). Overview and findings from the rush Memory and Aging Project. Current Alzheimer research 9, 646&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Yu L, and De Jager PL (2014). Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. Biochemical pharmacology 88, 617&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4054869</ArticleId><ArticleId IdType="pubmed">24508835</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Nag S, Leurgans S, Wilson RS, Bennett DA, and Schneider JA (2015). Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology 85, 1930&#x2013;1936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664125</ArticleId><ArticleId IdType="pubmed">26537052</ArticleId></ArticleIdList></Reference><Reference><Citation>Brynedal B, Choi J, Raj T, Bjornson R, Stranger BE, Neale BM, Voight BF, and Cotsapas C (2017). Large-Scale trans-eQTLs Affect Hundreds of Transcripts and Mediate Patterns of Transcriptional Co-regulation. American journal of human genetics 100, 581&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5384037</ArticleId><ArticleId IdType="pubmed">28285767</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley L, Busch JI, Akle S, Grossman M, Van Deerlin V, et al. (2012). TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. The Journal of neuroscience : the official journal of the Society for Neuroscience 32, 11213&#x2013;11227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446826</ArticleId><ArticleId IdType="pubmed">22895706</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, et al. (2006). Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Ma Y, McCabe C, Xu J, Vardarajan BN, Felsky D, Klein HU, White CC, Peters MA, Lodgson B, et al. (2018). A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research. Scientific data 5, 180142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiteri C, Chen M, Szymanski B, Kuzmin K, Xie J, Lee C, Blanche T, Chaibub Neto E, Huang SC, Grabowski T, et al. (2015). Identifying robust communities and multi-community nodes by combining top-down and bottom-up approaches to clustering. Scientific reports 5, 16361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4637843</ArticleId><ArticleId IdType="pubmed">26549511</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Posavi M, Huang P, Unger TL, Berlyand Y, Gruenewald AL, Chesi A, Manduchi E, Wells AD, Grant SFA, et al. (2017). A Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and Gene Expression. American journal of human genetics 101, 643&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5673619</ArticleId><ArticleId IdType="pubmed">29056226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, Won H, van Bakel H, Varghese M, Wang Y, et al. (2018). Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science 362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6443102</ArticleId><ArticleId IdType="pubmed">30545856</ArticleId></ArticleIdList></Reference><Reference><Citation>Golab L, Korn F, Li F, Saha B, and Srivastava D (2015). Size-constrained weighted set cover. 2015 IEEE 31st International Conference on Data Engineering, 879&#x2013;890.</Citation></Reference><Reference><Citation>GTEx Consortium (2017). Genetic effects on gene expression across human tissues. Nature 550, 204&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5776756</ArticleId><ArticleId IdType="pubmed">29022597</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe AE, Hyde T, Kleinman J, Weinbergern DR, Chenoweth JG, McKay RD, Leek JT, and Colantuoni C (2015). Practical impacts of genomic data "cleaning" on biological discovery using surrogate variable analysis. BMC Bioinformatics 16, 372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4636836</ArticleId><ArticleId IdType="pubmed">26545828</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapasi A, DeCarli C, and Schneider JA (2017). Impact of multiple pathologies on the threshold for clinically overt dementia. Acta neuropathologica 134, 171&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663642</ArticleId><ArticleId IdType="pubmed">28488154</ArticleId></ArticleIdList></Reference><Reference><Citation>Klarin D, Damrauer SM, Cho K, Sun YV, Teslovich TM, Honerlaw J, Gagnon DR, DuVall SL, Li J, Peloso GM, et al. (2018). Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nature genetics 50, 1514&#x2013;1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6521726</ArticleId><ArticleId IdType="pubmed">30275531</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT, and Strittmatter SM (2017). Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice. Neuron 95, 281&#x2013;296 e286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558861</ArticleId><ArticleId IdType="pubmed">28728022</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Trapnell C, Pop M, and Salzberg SL (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome biology 10, R25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690996</ArticleId><ArticleId IdType="pubmed">19261174</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Johnson WE, Parker HS, Fertig EJ, Jaffe AE, Storey JD, Zhang Y, and Torres LC (2019). sva: Surrogate Variable Analysis. R package version 3340.</Citation></Reference><Reference><Citation>Leek JT, and Storey JD (2007). Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS genetics 3, 1724&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994707</ArticleId><ArticleId IdType="pubmed">17907809</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YI, Knowles DA, Humphrey J, Barbeira AN, Dickinson SP, Im HK, and Pritchard JK (2018). Annotation-free quantification of RNA splicing using LeafCutter. Nature genetics 50, 151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742080</ArticleId><ArticleId IdType="pubmed">29229983</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Farias FHG, Dube U, Del-Aguila JL, Mihindukulasuriya KA, Fernandez MV, Ibanez L, Budde JP, Wang F, Lake AM, et al. (2020). The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta neuropathologica 139, 45&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942643</ArticleId><ArticleId IdType="pubmed">31456032</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Wang J, Jaehnig EJ, Shi Z, and Zhang B (2019). WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic acids research 47, W199&#x2013;W205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602449</ArticleId><ArticleId IdType="pubmed">31114916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, and Wong PC (2015). TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon BA, Perumal TM, Swarup V, Wang M, Funk C, Gaiteri C, Allen M, Wang X, Dammer E, Srivastava G, et al. (2019). Meta-analysis of the human brain transcriptome identifies heterogeneity across human AD coexpression modules robust to sample collection and methodological approach. bioRxiv 10.1101/510420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/510420</ArticleId></ArticleIdList></Reference><Reference><Citation>Magis AT, Funk CC, and Price ND (2015). SNAPR: a bioinformatics pipeline for efficient and accurate RNA-seq alignment and analysis. IEEE life sciences letters 1, 22&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736311</ArticleId><ArticleId IdType="pubmed">29270443</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, Gaiteri C, Sullivan SE, White CC, Tasaki S, Xu J, Taga M, Klein HU, Patrick E, Komashko V, et al. (2018). A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer's disease. Nature neuroscience 21, 811&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, and Schneider JA (2018). TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer's disease. Acta neuropathologica communications 6, 33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928580</ArticleId><ArticleId IdType="pubmed">29716643</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, et al. (2019). Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain : a journal of neurology 142, 1503&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng B, White CC, Klein HU, Sieberts SK, McCabe C, Patrick E, Xu J, Yu L, Gaiteri C, Bennett DA, et al. (2017). An xQTL map integrates the genetic architecture of the human brain's transcriptome and epigenome. Nature neuroscience 20, 1418&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785926</ArticleId><ArticleId IdType="pubmed">28869584</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Finch NA, Wojtas A, Baker MC, Perkerson RB 3rd, Castanedes-Casey M, Rousseau L, Benussi L, Binetti G, Ghidoni R, et al. (2013). TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. Journal of neurochemistry 126, 781&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766501</ArticleId><ArticleId IdType="pubmed">23742080</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, and Rademakers R (2016). What we know about TMEM106B in neurodegeneration. Acta neuropathologica 132, 639&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5074873</ArticleId><ArticleId IdType="pubmed">27543298</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikshak NN, Gandal MJ, and Geschwind DH (2015). Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. Nature reviews Genetics 16, 441&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4699316</ArticleId><ArticleId IdType="pubmed">26149713</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsana P, Ruberman C, Jaffe AE, Schatz MC, Battle A, and Leek JT (2019). Addressing confounding artifacts in reconstruction of gene co-expression networks. Genome biology 20, 94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6521369</ArticleId><ArticleId IdType="pubmed">31097038</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick E, Rajagopal S, Wong HA, McCabe C, Xu J, Tang A, Imboywa SH, Schneider JA, Pochet N, Krichevsky AM, et al. (2017). Dissecting the role of non-coding RNAs in the accumulation of amyloid and tau neuropathologies in Alzheimer's disease. Molecular neurodegeneration 12, 51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494142</ArticleId><ArticleId IdType="pubmed">28668092</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick E, Taga M, Ergun A, Ng B, Casazza W, Cimpean M, Yung C, Schneider JA, Bennett DA, Gaiteri C, et al. (2019). Deconvolving the contributions of cell-type heterogeneity on cortical gene expression. bioRxiv doi: 10.1101/566307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/566307</ArticleId><ArticleId IdType="pmc">PMC7451979</ArticleId><ArticleId IdType="pubmed">32804935</ArticleId></ArticleIdList></Reference><Reference><Citation>Paushter DH, Du H, Feng T, and Hu F (2018). The lysosomal function of progranulin, a guardian against neurodegeneration. Acta neuropathologica 136, 1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6117207</ArticleId><ArticleId IdType="pubmed">29744576</ArticleId></ArticleIdList></Reference><Reference><Citation>Piovesan A, Caracausi M, Ricci M, Strippoli P, Vitale L, and Pelleri MC (2015). Identification of minimal eukaryotic introns through GeneBase, a user-friendly tool for parsing the NCBI Gene databank. DNA Res 22, 495&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675715</ArticleId><ArticleId IdType="pubmed">26581719</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, et al. (2011). Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nature neuroscience 14, 459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, and Willer CJ (2010). LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935401</ArticleId><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, Li YI, Wong G, Humphrey J, Wang M, Ramdhani S, Wang YC, Ng B, Gupta I, Haroutunian V, et al. (2018). Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer's disease susceptibility. Nature genetics 50, 1584&#x2013;1592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354244</ArticleId><ArticleId IdType="pubmed">30297968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, van Blitterswijk M, Allen M, Carrasquillo MM, Reddy JS, Wang X, Beach TG, Dickson DW, Ertekin-Taner N, Asmann YW, et al. (2018). TMEM106B haplotypes have distinct gene expression patterns in aged brain. Molecular neurodegeneration 13, 35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029036</ArticleId><ArticleId IdType="pubmed">29970152</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, and Abeliovich A (2017). Differential Aging Analysis in Human Cerebral Cortex Identifies Variants in TMEM106B and GRN that Regulate Aging Phenotypes. Cell systems 4, 404&#x2013;415 e405.</Citation><ArticleIdList><ArticleId IdType="pubmed">28330615</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha A, and Battle A (2018). False positives in trans-eQTL and co-expression analyses arising from RNA-sequencing alignment errors. F1000Research 7, 1860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6305209</ArticleId><ArticleId IdType="pubmed">30613398</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, and Bennett DA (2012). Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain : a journal of neurology 135, 3005&#x2013;3014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3470712</ArticleId><ArticleId IdType="pubmed">23065790</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, Fraldi A, Medina DL, and Ballabio A (2013). Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nature reviews Molecular cell biology 14, 283&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4387238</ArticleId><ArticleId IdType="pubmed">23609508</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons C, Dyment D, Bent SJ, Crawford J, D'Hooghe M, Kohlschutter A, Venkateswaran S, Helman G, Poll-The BT, Makowski CC, et al. (2017). A recurrent de novo mutation in TMEM106B causes hypomyelinating leukodystrophy. Brain : a journal of neurology 140, 3105&#x2013;3111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841038</ArticleId><ArticleId IdType="pubmed">29186371</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF, et al. (2012). Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. American journal of human genetics 90, 1102&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegle O, Parts L, Durbin R, and Winn J (2010). A Bayesian framework to account for complex non-genetic factors in gene expression levels greatly increases power in eQTL studies. PLoS Comput Biol 6, e1000770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865505</ArticleId><ArticleId IdType="pubmed">20463871</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Bell W, LaClair KD, Ling JP, Han H, Kageyama Y, Pletnikova O, Troncoso JC, Wong PC, and Chen LL (2017). Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. Acta neuropathologica 133, 923&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444385</ArticleId><ArticleId IdType="pubmed">28332094</ArticleId></ArticleIdList></Reference><Reference><Citation>The 1000 Genomes Project Consortium. (2012). An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Tingley D, Yamamoto T, Hirose K, Keele L, and Imai K (2014). mediation: R package for causal mediation analysis. Journal of Statistical Software 59.</Citation></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, Konig J, Hortobagyi T, Nishimura AL, Zupunski V, et al. (2011). Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nature neuroscience 14, 452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, et al. (2010). Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature genetics 42, 234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward LD, and Kellis M (2012). HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic acids research 40, D930&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245002</ArticleId><ArticleId IdType="pubmed">22064851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg AM, Tosakulwong N, Lesnick TG, Murray ME, Whitwell JL, Liesinger AM, Petrucelli L, Boeve BF, Parisi JE, Knopman DS, et al. (2018). Association of Apolipoprotein E epsilon4 With Transactive Response DNA-Binding Protein 43. JAMA neurology 75, 1347&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6248121</ArticleId><ArticleId IdType="pubmed">30422173</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, Christiansen MW, Fairfax BP, Schramm K, Powell JE, et al. (2013). Systematic identification of trans eQTLs as putative drivers of known disease associations. Nature genetics 45, 1238&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3991562</ArticleId><ArticleId IdType="pubmed">24013639</ArticleId></ArticleIdList></Reference><Reference><Citation>White CC, Yang HS, Yu L, Chibnik LB, Dawe RJ, Yang J, Klein HU, Felsky D, Ramos-Miguel A, Arfanakis K, et al. (2017). Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data. PLoS medicine 14, e1002287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404753</ArticleId><ArticleId IdType="pubmed">28441426</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, Adams MJ, Agerbo E, Air TM, Andlauer TMF, et al. (2018). Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature genetics 50, 668&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5934326</ArticleId><ArticleId IdType="pubmed">29700475</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, Yu L, White CC, Chibnik LB, Chhatwal JP, Sperling RA, Bennett DA, Schneider JA, and De Jager PL (2018). Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE epsilon4 haplotype status: a community-based cohort study. The Lancet Neurology, 17, 773&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6154505</ArticleId><ArticleId IdType="pubmed">30093249</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, De Jager PL, Yang J, Trojanowski JQ, Bennett DA, and Schneider JA (2015). The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology 84, 927&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351662</ArticleId><ArticleId IdType="pubmed">25653292</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Petyuk VA, Gaiteri C, Mostafavi S, Young-Pearse T, Shah RC, Buchman AS, Schneider JA, Piehowski PD, Sontag RL, et al. (2018). Targeted brain proteomics uncover multiple pathways to Alzheimer's dementia. Annals of neurology 84, 78&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119500</ArticleId><ArticleId IdType="pubmed">29908079</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32544086</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration.</ArticleTitle><Pagination><StartPage>4954</StartPage><EndPage>4968</EndPage><MedlinePgn>4954-4968</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI138179</ELocationID><ELocationID EIdType="pii" ValidYN="Y">138179</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by plaques containing amyloid-&#x3b2; (A&#x3b2;) and neurofibrillary tangles composed of aggregated, hyperphosphorylated tau. Beyond tau and A&#x3b2;, evidence suggests that microglia play an important role in AD pathogenesis. Rare variants in the microglia-expressed triggering receptor expressed on myeloid cells 2 (TREM2) gene increase AD risk 2- to 4-fold. It is likely that these TREM2 variants increase AD risk by decreasing the response of microglia to A&#x3b2; and its local toxicity. However, neocortical A&#x3b2; pathology occurs many years before neocortical tau pathology in AD. Thus, it will be important to understand the role of TREM2 in the context of tauopathy. We investigated the impact of the AD-associated TREM2 variant (R47H) on tau-mediated neuropathology in the PS19 mouse model of tauopathy. We assessed PS19 mice expressing human TREM2CV (common variant) or human TREM2R47H. PS19-TREM2R47H mice had significantly attenuated brain atrophy and synapse loss versus PS19-TREM2CV mice. Gene expression analyses and CD68 immunostaining revealed attenuated microglial reactivity in PS19-TREM2R47H versus PS19-TREM2CV mice. There was also a decrease in phagocytosis of postsynaptic elements by microglia expressing TREM2R47H in the PS19 mice and in human AD brains. These findings suggest that impaired TREM2 signaling reduces microglia-mediated neurodegeneration in the setting of tauopathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gratuze</LastName><ForeName>Maud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyns</LastName><ForeName>Cheryl Eg</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauerbeck</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St-Pierre</LastName><ForeName>Marie-Kim</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Axe Neurosciences, Centre de Recherche, Centre Hospitalier Universitaire (CHU) de Qu&#xe9;bec-Universit&#xe9; Laval, Qu&#xe9;bec City, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Nayeon</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Javier Remolina</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tremblay</LastName><ForeName>Marie-&#xc8;ve</ForeName><Initials>M&#xc8;</Initials><AffiliationInfo><Affiliation>Axe Neurosciences, Centre de Recherche, Centre Hospitalier Universitaire (CHU) de Qu&#xe9;bec-Universit&#xe9; Laval, Qu&#xe9;bec City, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kummer</LastName><ForeName>Terrance T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA091842</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021629</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Trends Neurosci. 2020 Oct;43(10):739-740. doi: 10.1016/j.tins.2020.08.002.</RefSource><PMID Version="1">32863043</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="Y">Gliosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="Y">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="Y">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="Y">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Innate immunity</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Neuroscience</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> DMH and JDU are listed as inventors on a provisional patent from Washington University on TREM2 antibodies. DMH and CEGL are listed as inventors on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. CEGL is currently an employee at Merck. MC receives research funding from Alector, Amgen, and Ono. DMH cofounded and is on the scientific advisory board of C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. DMH is on the scientific advisory board of Denali and consults for Genentech and Idorsia.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32544086</ArticleId><ArticleId IdType="pmc">PMC7456230</ArticleId><ArticleId IdType="doi">10.1172/JCI138179</ArticleId><ArticleId IdType="pii">138179</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association. Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2016;12(4):459&#x2013;509. doi: 10.1016/j.jalz.2016.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.03.001</ArticleId><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: the challenge of the second century. Sci Transl Med. 2011;3(77):77sr1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon. 2010;56(9):484&#x2013;546. doi: 10.1016/j.disamonth.2010.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.disamonth.2010.06.001</ArticleId><ArticleId IdType="pmc">PMC2941917</ArticleId><ArticleId IdType="pubmed">20831921</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener. 2017;12(1):50. doi: 10.1186/s13024-017-0192-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0192-x</ArticleId><ArticleId IdType="pmc">PMC5492997</ArticleId><ArticleId IdType="pubmed">28662669</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169(7):1276&#x2013;1290.e17. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47(3):566&#x2013;581.e9. doi: 10.1016/j.immuni.2017.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZG, Li Y, Ng CT, Song YQ. Inflammation in Alzheimer&#x2019;s disease and molecular genetics: recent update. Arch Immunol Ther Exp (Warsz) 2015;63(5):333&#x2013;344. doi: 10.1007/s00005-015-0351-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-015-0351-0</ArticleId><ArticleId IdType="pubmed">26232392</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):117&#x2013;127. doi: 10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):107&#x2013;116. doi: 10.1056/NEJMoa1211103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid CD, et al. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem. 2002;83(6):1309&#x2013;1320. doi: 10.1046/j.1471-4159.2002.01243.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.01243.x</ArticleId><ArticleId IdType="pmc">PMC2637869</ArticleId><ArticleId IdType="pubmed">12472885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchon A, Hern&#xe1;ndez-Munain C, Cella M, Colonna M. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med. 2001;194(8):1111&#x2013;1122. doi: 10.1084/jem.194.8.1111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.194.8.1111</ArticleId><ArticleId IdType="pmc">PMC2193511</ArticleId><ArticleId IdType="pubmed">11602640</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer&#x2019;s disease. Mol Neurodegener. 2018;13(1):66. doi: 10.1186/s13024-018-0298-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0298-9</ArticleId><ArticleId IdType="pmc">PMC6302500</ArticleId><ArticleId IdType="pubmed">30572908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160(6):1061&#x2013;1071. doi: 10.1016/j.cell.2015.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med. 2018;215(3):745&#x2013;760. doi: 10.1084/jem.20171529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171529</ArticleId><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, et al. Altered microglial response to A&#x3b2; plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener. 2014;9:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med. 2015;212(3):287&#x2013;295. doi: 10.1084/jem.20142322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng-Hathaway PJ, et al. The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer&#x2019;s disease. Mol Neurodegener. 2018;13(1):29. doi: 10.1186/s13024-018-0262-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0262-8</ArticleId><ArticleId IdType="pmc">PMC5984804</ArticleId><ArticleId IdType="pubmed">29859094</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312&#x2013;339. doi: 10.1016/j.cell.2019.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.09.001</ArticleId><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131(6):925&#x2013;933. doi: 10.1007/s00401-016-1533-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1533-5</ArticleId><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer&#x2019;s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8(5):466&#x2013;476. doi: 10.15252/emmm.201506123.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201506123</ArticleId><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill CM, et al. The role of TREM2 R47H as a risk factor for Alzheimer&#x2019;s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson&#x2019;s disease. Alzheimers Dement. 2015;11(12):1407&#x2013;1416. doi: 10.1016/j.jalz.2014.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.12.009</ArticleId><ArticleId IdType="pmc">PMC4627856</ArticleId><ArticleId IdType="pubmed">25936935</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer&#x2019;s disease. Neuron. 2013;78(2):256&#x2013;268. doi: 10.1016/j.neuron.2013.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.026</ArticleId><ArticleId IdType="pmc">PMC3664945</ArticleId><ArticleId IdType="pubmed">23562540</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129(pt 11):3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A. 2017;114(43):11524&#x2013;11529. doi: 10.1073/pnas.1710311114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1710311114</ArticleId><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed FA, et al. Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proc Natl Acad Sci U S A. 2018;115(40):10172&#x2013;10177. doi: 10.1073/pnas.1811411115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1811411115</ArticleId><ArticleId IdType="pmc">PMC6176614</ArticleId><ArticleId IdType="pubmed">30232263</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemiller SM, et al. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener. 2017;12(1):74. doi: 10.1186/s13024-017-0216-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0216-6</ArticleId><ArticleId IdType="pmc">PMC5644120</ArticleId><ArticleId IdType="pubmed">29037207</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216(11):2546&#x2013;2561. doi: 10.1084/jem.20190980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190980</ArticleId><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337&#x2013;351. doi: 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, et al. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain. 2019;142(10):3243&#x2013;3264. doi: 10.1093/brain/awz241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz241</ArticleId><ArticleId IdType="pmc">PMC6794948</ArticleId><ArticleId IdType="pubmed">31504240</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y, et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer&#x2019;s disease risk. Sci Transl Med. 2019;11(505):eaau2291. doi: 10.1126/scitranslmed.aau2291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau2291</ArticleId><ArticleId IdType="pmc">PMC6697053</ArticleId><ArticleId IdType="pubmed">31413141</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481&#x2013;487. doi: 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523&#x2013;527. doi: 10.1038/nature24016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejanovic B, et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron. 2018;100(6):1322&#x2013;1336.e7. doi: 10.1016/j.neuron.2018.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.10.014</ArticleId><ArticleId IdType="pubmed">30392797</ArticleId></ArticleIdList></Reference><Reference><Citation>Collman F, Buchanan J, Phend KD, Micheva KD, Weinberg RJ, Smith SJ. Mapping synapses by conjugate light-electron array tomography. J Neurosci. 2015;35(14):5792&#x2013;5807. doi: 10.1523/JNEUROSCI.4274-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4274-14.2015</ArticleId><ArticleId IdType="pmc">PMC4388933</ArticleId><ArticleId IdType="pubmed">25855189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauerbeck AD, et al. SEQUIN multiscale imaging of mammalian central synapses reveals loss of synaptic connectivity resulting from diffuse traumatic brain injury. Neuron. 2020;107(2):257&#x2013;273.e5. doi: 10.1016/j.neuron.2020.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.04.012</ArticleId><ArticleId IdType="pmc">PMC7381374</ArticleId><ArticleId IdType="pubmed">32392471</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201(4):647&#x2013;657. doi: 10.1084/jem.20041611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041611</ArticleId><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009;109(4):1144&#x2013;1156. doi: 10.1111/j.1471-4159.2009.06042.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06042.x</ArticleId><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipello F, et al. The microglial innate immune receptor TREM2 is required for synapse elimination and normal brain connectivity. Immunity. 2018;48(5):979&#x2013;991.e8. doi: 10.1016/j.immuni.2018.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.04.016</ArticleId><ArticleId IdType="pubmed">29752066</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, et al. Coding variants in TREM2 increase risk for Alzheimer&#x2019;s disease. Hum Mol Genet. 2014;23(21):5838&#x2013;5846. doi: 10.1093/hmg/ddu277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu277</ArticleId><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat Genet. 2017;49(9):1373&#x2013;1384. doi: 10.1038/ng.3916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3916</ArticleId><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, et al. TREM2 function impedes tau seeding in neuritic plaques. Nat Neurosci. 2019;22(8):1217&#x2013;1222. doi: 10.1038/s41593-019-0433-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0433-0</ArticleId><ArticleId IdType="pmc">PMC6660358</ArticleId><ArticleId IdType="pubmed">31235932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat Med. 2020;26(1):131&#x2013;142. doi: 10.1038/s41591-019-0695-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18(11):1584&#x2013;1593. doi: 10.1038/nn.4132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4132</ArticleId><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Maphis N, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015;138(pt 6):1738&#x2013;1755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542622</ArticleId><ArticleId IdType="pubmed">25833819</ArticleId></ArticleIdList></Reference><Reference><Citation>van Olst L, et al. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model. Neurobiol Aging. 2020;89:89&#x2013;98. doi: 10.1016/j.neurobiolaging.2020.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.01.003</ArticleId><ArticleId IdType="pubmed">32008854</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann NA, Dorostkar MM, Blumenstock S, Goedert M, Herms J. Impaired plasticity of cortical dendritic spines in P301S tau transgenic mice. Acta Neuropathol Commun. 2013;1:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880070</ArticleId><ArticleId IdType="pubmed">24344647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopeikina KJ, et al. Synaptic alterations in the rTg4510 mouse model of tauopathy. J Comp Neurol. 2013;521(6):1334&#x2013;1353. doi: 10.1002/cne.23234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.23234</ArticleId><ArticleId IdType="pmc">PMC3725804</ArticleId><ArticleId IdType="pubmed">23047530</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, O&#x2019;Connor T, Vassar R. The contribution of activated astrocytes to A&#x3b2; production: implications for Alzheimer&#x2019;s disease pathogenesis. J Neuroinflammation. 2011;8:150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216000</ArticleId><ArticleId IdType="pubmed">22047170</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker D, Zahn N, Deller T, Vlachos A. Tumor necrosis factor alpha maintains denervation-induced homeostatic synaptic plasticity of mouse dentate granule cells. Front Cell Neurosci. 2013;7:257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3866521</ArticleId><ArticleId IdType="pubmed">24385951</ArticleId></ArticleIdList></Reference><Reference><Citation>Tachida Y, et al. Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. J Neurochem. 2008;104(5):1387&#x2013;1393. doi: 10.1111/j.1471-4159.2007.05127.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05127.x</ArticleId><ArticleId IdType="pubmed">18021299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazawa M, et al. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal &#x3b2;-catenin pathway function in an Alzheimer&#x2019;s disease model. J Immunol. 2011;187(12):6539&#x2013;6549. doi: 10.4049/jimmunol.1100620.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1100620</ArticleId><ArticleId IdType="pmc">PMC4072218</ArticleId><ArticleId IdType="pubmed">22095718</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, et al. TREM2 promotes microglial survival by activating Wnt/&#x3b2;-catenin pathway. J Neurosci. 2017;37(7):1772&#x2013;1784. doi: 10.1523/JNEUROSCI.2459-16.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2459-16.2017</ArticleId><ArticleId IdType="pmc">PMC5320608</ArticleId><ArticleId IdType="pubmed">28077724</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawabori M, et al. Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke. J Neurosci. 2015;35(8):3384&#x2013;3396. doi: 10.1523/JNEUROSCI.2620-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2620-14.2015</ArticleId><ArticleId IdType="pmc">PMC4339351</ArticleId><ArticleId IdType="pubmed">25716838</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2) J Biol Chem. 2015;290(43):26043&#x2013;26050. doi: 10.1074/jbc.M115.679043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.679043</ArticleId><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng L, et al. Microglial Trem2 induces synaptic impairment at early stage and prevents amyloidosis at late stage in APP/PS1 mice. FASEB J. 2019;33(9):10425&#x2013;10442. doi: 10.1096/fj.201900527R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201900527R</ArticleId><ArticleId IdType="pubmed">31219699</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, et al. Alzheimer&#x2019;s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement. 2017;13(4):381&#x2013;387. doi: 10.1016/j.jalz.2016.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.07.004</ArticleId><ArticleId IdType="pmc">PMC5299056</ArticleId><ArticleId IdType="pubmed">27520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, et al. Coding variants in TREM2 increase risk for Alzheimer&#x2019;s disease. Hum Mol Genet. 2014;23(21):5838&#x2013;5846. doi: 10.1093/hmg/ddu277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu277</ArticleId><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352(6286):712&#x2013;716. doi: 10.1126/science.aad8373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71(3):656&#x2013;662. doi: 10.1086/342259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/342259</ArticleId><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchin MM, et al. Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol Neurobiol. 2004;24(1):1&#x2013;24. doi: 10.1023/B:CEMN.0000012721.08168.ee.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:CEMN.0000012721.08168.ee</ArticleId><ArticleId IdType="pmc">PMC11529946</ArticleId><ArticleId IdType="pubmed">15049507</ArticleId></ArticleIdList></Reference><Reference><Citation>Slattery CF, et al. R47H TREM2 variant increases risk of typical early-onset Alzheimer&#x2019;s disease but not of prion or frontotemporal dementia. Alzheimers Dement. 2014;10(6):602&#x2013;608.e4. doi: 10.1016/j.jalz.2014.05.1751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.05.1751</ArticleId><ArticleId IdType="pmc">PMC4627504</ArticleId><ArticleId IdType="pubmed">25160042</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 2012;32(11):3601&#x2013;3611. doi: 10.1523/JNEUROSCI.4922-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4922-11.2012</ArticleId><ArticleId IdType="pmc">PMC3321513</ArticleId><ArticleId IdType="pubmed">22423084</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402&#x2013;414. doi: 10.1016/j.neuron.2013.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.046</ArticleId><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligorio M, Descarries L, Warren RA. Cholinergic innervation and thalamic input in rat nucleus accumbens. J Chem Neuroanat. 2009;37(1):33&#x2013;45. doi: 10.1016/j.jchemneu.2008.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2008.08.003</ArticleId><ArticleId IdType="pubmed">18773952</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay ME, Riad M, Majewska A. Preparation of mouse brain tissue for immunoelectron microscopy. J Vis Exp. 2010;(41):2021. doi: 10.3791/2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2021</ArticleId><ArticleId IdType="pmc">PMC3156065</ArticleId><ArticleId IdType="pubmed">20689505</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KBJ. Paxinos and Franklin&#x2019;s the Mouse Brain in Stereotaxic Coordinates. 4th ed. Academic Press; 2012.</Citation></Reference><Reference><Citation>Bisht K, et al. Dark microglia: A new phenotype predominantly associated with pathological states. Glia. 2016;64(5):826&#x2013;839. doi: 10.1002/glia.22966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22966</ArticleId><ArticleId IdType="pmc">PMC4949554</ArticleId><ArticleId IdType="pubmed">26847266</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay M&#xc8;, Zettel ML, Ison JR, Allen PD, Majewska AK. Effects of aging and sensory loss on glial cells in mouse visual and auditory cortices. Glia. 2012;60(4):541&#x2013;558. doi: 10.1002/glia.22287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22287</ArticleId><ArticleId IdType="pmc">PMC3276747</ArticleId><ArticleId IdType="pubmed">22223464</ArticleId></ArticleIdList></Reference><Reference><Citation>El Hajj H, et al. Ultrastructural evidence of microglial heterogeneity in Alzheimer&#x2019;s disease amyloid pathology. J Neuroinflammation. 2019;16(1):87. doi: 10.1186/s12974-019-1473-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1473-9</ArticleId><ArticleId IdType="pmc">PMC6469225</ArticleId><ArticleId IdType="pubmed">30992040</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A, Palay SL, Webster HdeF. The fine structure of the nervous system: The neurons and supporting cells. 3rd ed. Oxford University Press; 1991.</Citation></Reference><Reference><Citation>Johnson JE. The occurrence of dark neurons in the normal and deafferentated lateral vestibular nucleus in the rat: observations by light and electron microscopy. Acta Neuropathol. 1975;31(2):117&#x2013;127. doi: 10.1007/BF00688146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00688146</ArticleId><ArticleId IdType="pubmed">1136711</ArticleId></ArticleIdList></Reference><Reference><Citation>St-Pierre MK, Bordeleau M, Tremblay M&#xc8;. Visualizing dark microglia. Methods Mol Biol. 2019;2034:97&#x2013;110. doi: 10.1007/978-1-4939-9658-2_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9658-2_8</ArticleId><ArticleId IdType="pubmed">31392680</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PY, et al. miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum Mol Genet. 2015;24(23):6721&#x2013;6735. doi: 10.1093/hmg/ddv377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv377</ArticleId><ArticleId IdType="pmc">PMC4634376</ArticleId><ArticleId IdType="pubmed">26362250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32572268</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1256</StartPage><EndPage>1263</EndPage><MedlinePgn>1256-1263</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-020-0938-9</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) causes unrelenting, progressive cognitive impairments, but its course is heterogeneous, with a broad range of rates of cognitive decline<sup>1</sup>. The spread of tau aggregates (neurofibrillary tangles) across the cerebral cortex parallels symptom severity<sup>2,3</sup>. We hypothesized that the kinetics of tau spread may vary if the properties of the propagating tau proteins vary across individuals. We carried out biochemical, biophysical, MS and both cell- and animal-based-bioactivity assays to characterize tau in 32 patients with AD. We found striking patient-to-patient heterogeneity in the hyperphosphorylated species of soluble, oligomeric, seed-competent tau. Tau seeding activity correlates with the aggressiveness of the clinical disease, and some post-translational modification (PTM) sites appear to be associated with both enhanced seeding activity and worse clinical outcomes, whereas others are not. These data suggest that different individuals with 'typical' AD may have distinct biochemical features of tau. These data are consistent with the possibility that individuals with AD, much like people with cancer, may have multiple molecular drivers of an otherwise common phenotype, and emphasize the potential for personalized therapeutic approaches for slowing clinical progression of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dujardin</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5614-341X</Identifier><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Commins</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lathuiliere</LastName><ForeName>Aurelien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beerepoot</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3721-3213</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Analiese R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamath</LastName><ForeName>Tarun V</ForeName><Initials>TV</Initials><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Los Santos</LastName><ForeName>Mark B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0002-7195-5141</Identifier><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klickstein</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corjuc</LastName><ForeName>Diana L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corjuc</LastName><ForeName>Bianca T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dooley</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viode</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oakley</LastName><ForeName>Derek H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Benjamin D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aquinnah Pharmaceuticals, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullin</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jean-Gilles</LastName><ForeName>Dinorah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Merck &amp; Co., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Merck &amp; Co., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atchison</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Merck &amp; Co., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Renee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Merck &amp; Co., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chibnik</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-7032-1454</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano-Pozo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0899-7530</Identifier><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elwood</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Merck &amp; Co., Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steen</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Merck &amp; Co., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><Identifier Source="ORCID">0000-0002-7959-9401</Identifier><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA. bhyman@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA. bhyman@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AG064039</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1RF1AG059789</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)</Agency><Country>International</Country></Grant><Grant><GrantID>RF1 AG058674</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1K08AG064039</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)</Agency><Country>International</Country></Grant><Grant><GrantID>2018-AARF-591935</GrantID><Agency>Alzheimer's Association</Agency><Country>International</Country></Grant><Grant><GrantID>R56 AG061196</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1P30AG062421</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)</Agency><Country>International</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059789</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1RF1AG058674</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)</Agency><Country>International</Country></Grant><Grant><GrantID>P2ELP3_184403</GrantID><Agency>Schweizerischer Nationalfonds zur F&#xf6;rderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Med. 2021 Feb;27(2):356. doi: 10.1038/s41591-021-01251-7.</RefSource><PMID Version="1">33514949</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018740" MajorTopicYN="N">Genetic Heterogeneity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. This work was supported in part by a research agreement to Massachusetts General Hospital from Merck &amp; Co. D.J.-G, R.C., R.M., K.A., F.E., and M.E.K. are/were full time employees of Merck &amp; Co. Inc. during the course of the work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32572268</ArticleId><ArticleId IdType="mid">NIHMS1631801</ArticleId><ArticleId IdType="pmc">PMC7603860</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0938-9</ArticleId><ArticleId IdType="pii">10.1038/s41591-020-0938-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Komarova NL &amp; Thalhauser CJ High degree of heterogeneity in Alzheimer&#x2019;s disease progression patterns. PLoS Comput. Biol 7, e1002251 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207941</ArticleId><ArticleId IdType="pubmed">22072952</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer&#x2019;s disease. Neurology 60, 1495&#x2013;1500 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET &amp; Hyman BT Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology 42, 631&#x2013;639 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Arakhamia T et al. Posttranslational modifications mediate the structural diversity of tauopathy strains. Cell 180, 633&#x2013;644 e612 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491959</ArticleId><ArticleId IdType="pubmed">32032505</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420&#x2013;423 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W et al. Novel tau filament fold in corticobasal degeneration. Nature 580, 283&#x2013;287 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG Invited review: neuropathology of tauopathies: principles and practice. Neuropathol. Appl. Neurobiol 41, 3&#x2013;23 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25495175</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature 561, 137&#x2013;140 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl Acad. Sci. USA 111, E4376&#x2013;E4385 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Colin M et al. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol. 139, 3&#x2013;25 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942016</ArticleId><ArticleId IdType="pubmed">31686182</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S et al. Different tau species lead to heterogeneous tau pathology propagation and misfolding. Acta Neuropathol. Commun 6, 132 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6263555</ArticleId><ArticleId IdType="pubmed">30497516</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S &amp; Hyman BT Tau prion-like propagation: state of the art and current challenges. Adv. Exp. Med. Biol 1184, 305&#x2013;325 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">32096046</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Conformation determines the seeding potencies of native and recombinant tau aggregates. J. Biol. Chem 290, 1049&#x2013;1065 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4294473</ArticleId><ArticleId IdType="pubmed">25406315</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl Acad. Sci. USA 110, 9535&#x2013;9540 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD &amp; Lansbury PT Jr. Models of amyloid seeding in Alzheimer&#x2019;s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem 66, 385&#x2013;407 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9242912</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem 86, 582&#x2013;590 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Boluda S et al. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer&#x2019;s disease or corticobasal degeneration brains. Acta Neuropathol. 129, 221&#x2013;237 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4305460</ArticleId><ArticleId IdType="pubmed">25534024</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z et al. Amyloid-&#x3b2; plaques enhance Alzheimer&#x2019;s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med 24, 29&#x2013;38 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="pubmed">29200205</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J. Neurosci 33, 1024&#x2013;1037 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Bielefeld-Sevigny M AlphaLISA immunoassay platform&#x2014;the &#x2018;no-wash&#x2019; high-throughput alternative to ELISA. Assay Drug Dev. Technol 7, 90&#x2013;92 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19382891</ArticleId></ArticleIdList></Reference><Reference><Citation>Usenovic M et al. Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells. J. Neurosci 35, 14234&#x2013;14250 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605424</ArticleId><ArticleId IdType="pubmed">26490863</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer&#x2019;s disease brain. Nat. Commun 6, 8490 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4608380</ArticleId><ArticleId IdType="pubmed">26458742</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep 2, 700 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463004</ArticleId><ArticleId IdType="pubmed">23050084</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett RE et al. Enhanced tau aggregation in the presence of amyloid beta. Am. J. Pathol 187, 1601&#x2013;1612 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5500829</ArticleId><ArticleId IdType="pubmed">28500862</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL et al. Tau reduction in the presence of amyloid-&#x3b2; prevents tau pathology and neuronal death in vivo. Brain 141, 2194&#x2013;2212 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022692</ArticleId><ArticleId IdType="pubmed">29733334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Grundke-Iqbal I &amp; Iqbal K Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci 25, 59&#x2013;68 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191918</ArticleId><ArticleId IdType="pubmed">17241267</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S, Flavin W, Verstreken P &amp; Moechars D Loss of Bin1 promotes the propagation of tau pathology. Cell Rep. 17, 931&#x2013;940 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27760323</ArticleId></ArticleIdList></Reference><Reference><Citation>Courade JP et al. Epitope determines efficacy of therapeutic anti-tau antibodies in a functional assay with human Alzheimer tau. Acta Neuropathol. 136, 729&#x2013;745 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208734</ArticleId><ArticleId IdType="pubmed">30238240</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobuhara CK et al. Tau antibody targeting pathological species blocks neuronal uptake and interneuron propagation of tau in vitro. Am. J. Pathol 187, 1399&#x2013;1412 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5455060</ArticleId><ArticleId IdType="pubmed">28408124</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402&#x2013;414 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiris E et al. Combinatorial Tau pseudophosphorylation: markedly different regulatory effects on microtubule assembly and dynamic instability than the sum of the individual parts. J. Biol. Chem 286, 14257&#x2013;14270 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077627</ArticleId><ArticleId IdType="pubmed">21288907</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahani N, Subramaniam S, Wolf T, Tackenberg C &amp; Brandt R Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer&#x2019;s disease-relevant tau constructs in organotypic hippocampal slices. J. Neurosci 26, 6103&#x2013;6114 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675219</ArticleId><ArticleId IdType="pubmed">16738255</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E et al. Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo. J. Neurosci 28, 12798&#x2013;12807 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2610528</ArticleId><ArticleId IdType="pubmed">19036972</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, Biernat J, von Bergen M, Mandelkow E &amp; Mandelkow EM Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38, 3549&#x2013;3558 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10090741</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh TJ et al. Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Lett. 387, 145&#x2013;148 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8674537</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K et al. Subgroups of Alzheimer&#x2019;s disease based on cerebrospinal fluid molecular markers. Ann. Neurol 58, 748&#x2013;757 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16247771</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A et al. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J. Neuropathol. Exp. Neurol 72, 1182&#x2013;1192 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962953</ArticleId><ArticleId IdType="pubmed">24226270</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL et al. Synaptic tau seeding precedes tau pathology in human Alzheimer&#x2019;s disease brain. Front. Neurosci 12, 267 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928393</ArticleId><ArticleId IdType="pubmed">29740275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT et al. National Institute on Aging&#x2014;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 8, 1&#x2013;13 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ et al. National Institute on Aging&#x2014;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 123, 1&#x2013;11 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Arganda-Carreras I et al. Trainable Weka Segmentation: a machine learning tool for microscopy pixel classification. Bioinformatics 33, 2424&#x2013;2426 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28369169</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer&#x2019;s disease. Am. J. Pathol 179, 1373&#x2013;1384 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157187</ArticleId><ArticleId IdType="pubmed">21777559</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski JR, Zougman A, Nagaraj N &amp; Mann M Universal sample preparation method for proteome analysis. Nat. Methods 6, 359&#x2013;362 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19377485</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller T &amp; Winter D Systematic evaluation of protein reduction and alkylation reveals massive unspecific side effects by iodine-containing reagents. Mol. Cell Proteomics 16, 1173&#x2013;1187 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5500753</ArticleId><ArticleId IdType="pubmed">28539326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J &amp; Mann M MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol 26, 1367&#x2013;1372 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling B et al. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol. Cell Proteomics 11, 202&#x2013;214 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418851</ArticleId><ArticleId IdType="pubmed">22454539</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomathinayagam S et al. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris. J. Biotechnol 208, 13&#x2013;21 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26015261</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Riverol Y et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442&#x2013;D450 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323896</ArticleId><ArticleId IdType="pubmed">30395289</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. Rapid alteration of protein phosphorylation during postmortem: implication in the study of protein phosphorylation. Sci. Rep 5, 15709 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625177</ArticleId><ArticleId IdType="pubmed">26511732</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi A et al. Abeta and tau prion-like activities decline with longevity in the Alzheimer&#x2019;s disease human brain. Sci. Transl. Med 11, eaat8462 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640844</ArticleId><ArticleId IdType="pubmed">31043574</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Colle MA, Dessi F, Piette F &amp; Hauw JJ Progression of Alzheimer histopathological changes. Acta Neurol. Belg 98, 180&#x2013;185 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9686277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925&#x2013;931 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32568366</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease.</ArticleTitle><Pagination><StartPage>1288</StartPage><EndPage>1298</EndPage><MedlinePgn>1288-1298</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.1760</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Genetic studies of Alzheimer disease have focused on the clinical or pathologic diagnosis as the primary outcome, but little is known about the genetic basis of the preclinical phase of the disease.</AbstractText><AbstractText Label="OBJECTIVE">To examine the underlying genetic basis for brain amyloidosis in the preclinical phase of Alzheimer disease.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In the first stage of this genetic association study, a meta-analysis was conducted using genetic and imaging data acquired from 6 multicenter cohort studies of healthy older individuals between 1994 and 2019: the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease Study, the Berkeley Aging Cohort Study, the Wisconsin Registry for Alzheimer's Prevention, the Biomarkers of Cognitive Decline Among Normal Individuals cohort, the Baltimore Longitudinal Study of Aging, and the Alzheimer Disease Neuroimaging Initiative, which included Alzheimer disease and mild cognitive impairment. The second stage was designed to validate genetic observations using pathologic and clinical data from the Religious Orders Study and Rush Memory and Aging Project. Participants older than 50 years with amyloid positron emission tomographic (PET) imaging data and DNA from the 6 cohorts were included. The largest cohort, the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease Study (n&#x2009;=&#x2009;3154), was the PET screening cohort used for a secondary prevention trial designed to slow cognitive decline associated with brain amyloidosis. Six smaller, longitudinal cohort studies (n&#x2009;=&#x2009;1160) provided additional amyloid PET imaging data with existing genetic data. The present study was conducted from March 29, 2019, to February 19, 2020.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">A genome-wide association study of PET imaging amyloid levels.</AbstractText><AbstractText Label="RESULTS">From the 4314 analyzed participants (age, 52-96 years; 2478 participants [57%] were women), a novel locus for amyloidosis was noted within RBFOX1 (&#x3b2;&#x2009;=&#x2009;0.61, P&#x2009;=&#x2009;3&#x2009;&#xd7;&#x2009;10-9) in addition to APOE. The RBFOX1 protein localized around plaques, and reduced expression of RBFOX1 was correlated with higher amyloid-&#x3b2; burden (&#x3b2;&#x2009;=&#x2009;-0.008, P&#x2009;=&#x2009;.002) and worse cognition (&#x3b2;&#x2009;=&#x2009;0.007, P&#x2009;=&#x2009;.006) during life in the Religious Orders Study and Rush Memory and Aging Project cohort.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">RBFOX1 encodes a neuronal RNA-binding protein known to be expressed in neuronal tissues and may play a role in neuronal development. The findings of this study suggest that RBFOX1 is a novel locus that may be involved in the pathogenesis of Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raghavan</LastName><ForeName>Neha S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The New York Presbyterian Hospital, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and The Aging Brain, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute for Genomic Medicine, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumitrescu</LastName><ForeName>Logan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Vanderbilt Memory and Alzheimer's Center, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahoney</LastName><ForeName>Emily R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Vanderbilt Memory and Alzheimer's Center, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Annie J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The New York Presbyterian Hospital, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and The Aging Brain, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yizhe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The New York Presbyterian Hospital, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and The Aging Brain, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilgel</LastName><ForeName>Murat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The New York Presbyterian Hospital, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and The Aging Brain, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelman</LastName><ForeName>Corinne D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, University of Wisconsin, School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Center for Neuroimaging, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whelan</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Research and Early Development, Biogen Inc, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jimmy Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Research and Early Development, Biogen Inc, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hyun-Sik</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resnick</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The New York Presbyterian Hospital, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and The Aging Brain, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schrag</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vanderbilt Memory and Alzheimer's Center, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The New York Presbyterian Hospital, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and The Aging Brain, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute for Genomic Medicine, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hohman</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Vanderbilt Memory and Alzheimer's Center, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The New York Presbyterian Hospital, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and The Aging Brain, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute for Genomic Medicine, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG059941</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS100980</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG063689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG062750</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG046373</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062715</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG051718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG033655</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054047</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056534</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059869</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034962</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG049164</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C455479">RBFOX1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072260">RNA Splicing Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072260" MajorTopicYN="N">RNA Splicing Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Mormino reported receiving funding from National Institutes of Health (NIH) grant K01AG051718 during the conduct of the study, personal fees from Roche, and grants from the NIH outside the submitted work. Dr Goldstein reported other support from Q State-Pairnomix, other support from Praxis Therapeutics, other support from Apostle Inc, and personal fees from AstraZeneca, Gilead Sciences, and GoldFinch Bio outside the submitted work. Dr Engelman reported receiving grants from the NIH during the conduct of the study. Dr Saykin reported receiving grants from the NIH during the conduct of the study; other support from Springer-Nature outside the submitted work, and F18-flortaucipir precursor as in-kind support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly. Dr Whelan reported other support from Biogen during the conduct of the study and is an employee of Biogen. Dr Albert reported receiving grants from the National Institute on Aging (NIA) during the conduct of the study and is a consultant for Eli Lilly. Dr S. C. Johnson reported receiving grants from the NIH during the conduct of the study, personal fees from Roche Diagnostics, and grants and nonfinancial support from Cerveau Technologies outside the submitted work. Dr Aisen reported receiving grants from Eli Lilly and the NIH during the conduct of the study, as well as personal fees from Merck, Roche, Biogen, ImmunoBrain Checkpoint, and Samus outside the submitted work. Dr Sperling reported receiving grants from Eli Lilly and the Alzheimer's Association during the conduct of the study, as well as personal fees from AC Immune, Eisai, Roche, Neurocentria, and Takeda and grants from Janssen outside the submitted work. Dr Schneider reported receiving grants from the NIH during the conduct of the study. Dr Bennett reported receiving grants from the NIH and Illinois during the conduct of the study. Dr Schrag reported receiving grant K76AG060001 from the NIH/NIA and grant R03NS111486 from the NIH/National Institute of Neurological Disorders and Stroke during the conduct of the study, as well as grants from the NIH and a loan repayment grant outside the submitted work. Dr Hohman reported receiving grants from the NIH during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32568366</ArticleId><ArticleId IdType="pmc">PMC7309575</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.1760</ArticleId><ArticleId IdType="pii">2767374</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jansen IE, Savage JE, Watanabe K, et al. . Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat Genet. 2019;51(3):404-413. doi:10.1038/s41588-018-0311-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0311-9</ArticleId><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, et al. ; Alzheimer Disease Genetics Consortium (ADGC); European Alzheimer&#x2019;s Disease Initiative (EADI); Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE); Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer&#x2019;s Disease Consortium (GERAD/PERADES) . Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414-430. doi:10.1038/s41588-019-0358-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers JC, Mitew S, Woodhouse A, et al. . Defining the earliest pathological changes of Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2016;13(3):281-287. doi:10.2174/1567205013666151218150322</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205013666151218150322</ArticleId><ArticleId IdType="pmc">PMC4917817</ArticleId><ArticleId IdType="pubmed">26679855</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh compound-B. Ann Neurol. 2004;55(3):306-319. doi:10.1002/ana.20009</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20009</ArticleId><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Rieves D, Ganley C. Brain amyloid imaging&#x2014;FDA approval of florbetapir F18 injection. N Engl J Med. 2012;367(10):885-887. doi:10.1056/NEJMp1208061</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1208061</ArticleId><ArticleId IdType="pubmed">22931256</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216. doi:10.1016/S1474-4422(12)70291-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacher M, Porter T, Villemagne VL, et al. . Validation of a priori candidate Alzheimer&#x2019;s disease SNPs with brain amyloid-beta deposition. Sci Rep. 2019;9(1):17069. doi:10.1038/s41598-019-53604-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-53604-5</ArticleId><ArticleId IdType="pmc">PMC6863876</ArticleId><ArticleId IdType="pubmed">31745181</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Nho K, Del-Aguila JL, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) . Genome-wide association study of brain amyloid deposition as measured by Pittsburgh compound-B (PiB)-PET imaging. Mol Psychiatry. 2018. Published online October 25, 2018. doi:10.1038/s41380-018-0246-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0246-7</ArticleId><ArticleId IdType="pmc">PMC6219464</ArticleId><ArticleId IdType="pubmed">30361487</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Zhang Q, Chen F, et al. . Genetic interactions explain variance in cingulate amyloid burden: an AV-45 PET genome-wide association and interaction study in the ADNI Cohort. Biomed Res Int. 2015;2015:647389. doi:10.1155/2015/647389</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/647389</ArticleId><ArticleId IdType="pmc">PMC4573220</ArticleId><ArticleId IdType="pubmed">26421299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan VK, Risacher SL, Nho K, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) . GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer&#x2019;s disease implicates microglial activation gene IL1RAP. Brain. 2015;138(pt 10):3076-3088. doi:10.1093/brain/awv231</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv231</ArticleId><ArticleId IdType="pmc">PMC4671479</ArticleId><ArticleId IdType="pubmed">26268530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan VK, Risacher SL, Nho K, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry. 2014;19(3):351-357. doi:10.1038/mp.2013.19</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2013.19</ArticleId><ArticleId IdType="pmc">PMC3661739</ArticleId><ArticleId IdType="pubmed">23419831</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 Study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13. doi:10.1126/scitranslmed.3007941</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007941</ArticleId><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Donohue MC, Raman R, et al. ; A4 Study Team . 
Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. Published online April 6, 2020. 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136861</ArticleId><ArticleId IdType="pubmed">32250387</ArticleId></ArticleIdList></Reference><Reference><Citation>Little J, Higgins JP, Ioannidis JP, et al. ; Strengthening the Reporting of Genetic Association Studies . Strengthening the Reporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med. 2009;6(2):e22. doi:10.1371/journal.pmed.1000022</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000022</ArticleId><ArticleId IdType="pmc">PMC2634792</ArticleId><ArticleId IdType="pubmed">19192942</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer&#x2019;s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer&#x2019;s Prevention. J Geriatr Psychiatry Neurol. 2005;18(4):245-249. doi:10.1177/0891988705281882</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988705281882</ArticleId><ArticleId IdType="pubmed">16306248</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Koscik RL, Jonaitis EM, et al. . The Wisconsin Registry for Alzheimer&#x2019;s Prevention: a review of findings and current directions. Alzheimers Dement (Amst). 2017;10:130-142. doi:10.1016/j.dadm.2017.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2017.11.007</ArticleId><ArticleId IdType="pmc">PMC5755749</ArticleId><ArticleId IdType="pubmed">29322089</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Soldan A, Gottesman R, et al. . Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype. Curr Alzheimer Res. 2014;11(8):773-784. doi:10.2174/156720501108140910121920</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720501108140910121920</ArticleId><ArticleId IdType="pmc">PMC4163954</ArticleId><ArticleId IdType="pubmed">25212916</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Goldszal AF, Davatzikos C, et al. . One-year age changes in MRI brain volumes in older adults. Cereb Cortex. 2000;10(5):464-472. doi:10.1093/cercor/10.5.464</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/10.5.464</ArticleId><ArticleId IdType="pubmed">10847596</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J, Zhou Y, et al. . Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010;74(10):807-815. doi:10.1212/WNL.0b013e3181d3e3e9</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181d3e3e9</ArticleId><ArticleId IdType="pmc">PMC2839197</ArticleId><ArticleId IdType="pubmed">20147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2018;64(s1):S161-S189. doi:10.3233/JAD-179939</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-179939</ArticleId><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Darst BF, Lu Q, Johnson SC, Engelman CD. Integrated analysis of genomics, longitudinal metabolomics, and Alzheimer&#x2019;s risk factors among 1,111 cohort participants. Genet Epidemiol. 2019;43(6):657-674. doi:10.1002/gepi.22211</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.22211</ArticleId><ArticleId IdType="pmc">PMC6687539</ArticleId><ArticleId IdType="pubmed">31104335</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, Forer L, Sch&#xf6;nherr S, et al. . Next-generation genotype imputation service and methods. Nat Genet. 2016;48(10):1284-1287. doi:10.1038/ng.3656</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3656</ArticleId><ArticleId IdType="pmc">PMC5157836</ArticleId><ArticleId IdType="pubmed">27571263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study . Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760-1767. doi:10.1212/WNL.0000000000000431</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000431</ArticleId><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Properzi MJ, Buckley RF, Chhatwal JP, et al. . Nonlinear distributional mapping (NoDiM) for harmonization across amyloid-PET radiotracers. Neuroimage. 2019;186:446-454. doi:10.1016/j.neuroimage.2018.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2018.11.019</ArticleId><ArticleId IdType="pmc">PMC6338495</ArticleId><ArticleId IdType="pubmed">30458305</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Ma Y, McCabe C, et al. . A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Sci Data. 2018;5:180142. doi:10.1038/sdata.2018.142</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2018.142</ArticleId><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS. The effect of social networks on the relation between Alzheimer&#x2019;s disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol. 2006;5(5):406-412. doi:10.1016/S1474-4422(06)70417-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(06)70417-3</ArticleId><ArticleId IdType="pubmed">16632311</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Petyuk VA, Tasaki S, et al. . Association of cortical &#x3b2;-amyloid protein in the absence of insoluble deposits with Alzheimer disease. JAMA Neurol. 2019;76(7):818-826. doi:10.1001/jamaneurol.2019.0834</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.0834</ArticleId><ArticleId IdType="pmc">PMC6583061</ArticleId><ArticleId IdType="pubmed">31009033</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueden CT, Schindelin J, Hiner MC, et al. . ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics. 2017;18(1):529. doi:10.1186/s12859-017-1934-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-017-1934-z</ArticleId><ArticleId IdType="pmc">PMC5708080</ArticleId><ArticleId IdType="pubmed">29187165</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-675. doi:10.1038/nmeth.2089</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2089</ArticleId><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, et al. . PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575. doi:10.1086/519795</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/519795</ArticleId><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190-2191. doi:10.1093/bioinformatics/btq340</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq340</ArticleId><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler TW, Kutalik Z, Gorski M, Lottaz C, Kronenberg F, Heid IM. EasyStrata: evaluation and visualization of stratified genome-wide association meta-analysis data. Bioinformatics. 2015;31(2):259-261. doi:10.1093/bioinformatics/btu621</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu621</ArticleId><ArticleId IdType="pmc">PMC4287944</ArticleId><ArticleId IdType="pubmed">25260699</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and Manhattan plots. Preprint. bioRxiv 005165. Posted online May 14, 2014. doi:10.1101/005165</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/005165</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1-48. doi:10.18637/jss.v036.i03</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v036.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruim RJ, Welch RP, Sanna S, et al. . LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26(18):2336-2337. doi:10.1093/bioinformatics/btq419</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq419</ArticleId><ArticleId IdType="pmc">PMC2935401</ArticleId><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold C, Hooli BV, Mullin K, et al. . Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer&#x2019;s disease with OSBPL6, PTPRG, and PDCL3. Mol Psychiatry. 2016;21(11):1608-1612. doi:10.1038/mp.2015.218</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.218</ArticleId><ArticleId IdType="pmc">PMC4970971</ArticleId><ArticleId IdType="pubmed">26830138</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong LL, Miao D, Tan L, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Genome-wide association study identifies RBFOX1 locus influencing brain glucose metabolism. Ann Transl Med. 2018;6(22):436. doi:10.21037/atm.2018.07.05</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2018.07.05</ArticleId><ArticleId IdType="pmc">PMC6281526</ArticleId><ArticleId IdType="pubmed">30596066</ArticleId></ArticleIdList></Reference><Reference><Citation>Auweter SD, Fasan R, Reymond L, et al. . Molecular basis of RNA recognition by the human alternative splicing factor Fox-1. EMBO J. 2006;25(1):163-173. doi:10.1038/sj.emboj.7600918</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600918</ArticleId><ArticleId IdType="pmc">PMC1356361</ArticleId><ArticleId IdType="pubmed">16362037</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamada N, Ito H, Iwamoto I, Morishita R, Tabata H, Nagata K. Role of the cytoplasmic isoform of RBFOX1/A2BP1 in establishing the architecture of the developing cerebral cortex. Mol Autism. 2015;6:56. doi:10.1186/s13229-015-0049-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13229-015-0049-5</ArticleId><ArticleId IdType="pmc">PMC4617638</ArticleId><ArticleId IdType="pubmed">26500751</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogel BL, Wexler E, Wahnich A, et al. . RBFOX1 regulates both splicing and transcriptional networks in human neuronal development. Hum Mol Genet. 2012;21(19):4171-4186. doi:10.1093/hmg/dds240</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds240</ArticleId><ArticleId IdType="pmc">PMC3441119</ArticleId><ArticleId IdType="pubmed">22730494</ArticleId></ArticleIdList></Reference><Reference><Citation>Lal D, Trucks H, M&#xf8;ller RS, et al. ; EMINet Consortium; EPICURE Consortium . Rare exonic deletions of the RBFOX1 gene increase risk of idiopathic generalized epilepsy. Epilepsia. 2013;54(2):265-271. doi:10.1111/epi.12084</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.12084</ArticleId><ArticleId IdType="pubmed">23350840</ArticleId></ArticleIdList></Reference><Reference><Citation>Bill BR, Lowe JK, Dybuncio CT, Fogel BL. Orchestration of neurodevelopmental programs by RBFOX1: implications for autism spectrum disorder. Int Rev Neurobiol. 2013;113:251-267. doi:10.1016/B978-0-12-418700-9.00008-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-418700-9.00008-3</ArticleId><ArticleId IdType="pmc">PMC4318517</ArticleId><ArticleId IdType="pubmed">24290388</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe0;ndez-Castillo N, Gan G, van Donkelaar MMJ, et al. . RBFOX1, encoding a splicing regulator, is a candidate gene for aggressive behavior. Eur Neuropsychopharmacol. 2020;30:44-55. doi:10.1016/j.euroneuro.2017.11.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2017.11.012</ArticleId><ArticleId IdType="pmc">PMC10975801</ArticleId><ArticleId IdType="pubmed">29174947</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkallas R, Fish L, Goodarzi H, Najafabadi HS. Inference of RNA decay rate from transcriptional profiling highlights the regulatory programs of Alzheimer&#x2019;s disease. Nat Commun. 2017;8(1):909. doi:10.1038/s41467-017-00867-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00867-z</ArticleId><ArticleId IdType="pmc">PMC5714957</ArticleId><ArticleId IdType="pubmed">29030541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JA, Damianov A, Lin C-H, et al. . Cytoplasmic Rbfox1 regulates the expression of synaptic and autism-related genes. Neuron. 2016;89(1):113-128. doi:10.1016/j.neuron.2015.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.025</ArticleId><ArticleId IdType="pmc">PMC4858412</ArticleId><ArticleId IdType="pubmed">26687839</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam S, Suzuki H, Tsukahara T. Alternative splicing regulation of APP exon 7 by RBFox proteins. Neurochem Int. 2014;78:7-17. doi:10.1016/j.neuint.2014.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2014.08.001</ArticleId><ArticleId IdType="pubmed">25125370</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. . Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130-133. doi:10.1126/science.1134108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Hamilton K, Naj AC, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium (ADGC) . Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet. 2014;10(9):e1004606. doi:10.1371/journal.pgen.1004606</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004606</ArticleId><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y, Li Z, Kapoor M, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetic Consortium (ADGC) . Genome-wide association study identifies four novel loci associated with Alzheimer&#x2019;s endophenotypes and disease modifiers. Acta Neuropathol. 2017;133(5):839-856. doi:10.1007/s00401-017-1685-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1685-y</ArticleId><ArticleId IdType="pmc">PMC5613285</ArticleId><ArticleId IdType="pubmed">28247064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32579671</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>217</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e20200785</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20200785</ELocationID><Abstract><AbstractText>TREM2 is a receptor for lipids expressed in microglia. The R47H variant of human TREM2 impairs ligand binding and increases Alzheimer's disease (AD) risk. In mouse models of amyloid &#x3b2; (A&#x3b2;) accumulation, defective TREM2 function affects microglial response to A&#x3b2; plaques, exacerbating tissue damage, whereas TREM2 overexpression attenuates pathology. Thus, AD may benefit from TREM2 activation. Here, we examined the impact of an anti-human TREM2 agonistic mAb, AL002c, in a mouse AD model expressing either the common variant (CV) or the R47H variant of TREM2. Single-cell RNA-seq of microglia after acute systemic administration of AL002c showed induction of proliferation in both CV- and R47H-transgenic mice. Prolonged administration of AL002c reduced filamentous plaques and neurite dystrophy, impacted behavior, and tempered microglial inflammatory response. We further showed that a variant of AL002c is safe and well tolerated in a first-in-human phase I clinical trial and engages TREM2 based on cerebrospinal fluid biomarkers. We conclude that AL002 is a promising candidate for AD therapy.</AbstractText><CopyrightInformation>&#xa9; 2020 Wang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shoutang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mustafa</LastName><ForeName>Meer</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuede</LastName><ForeName>Carla M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salazar</LastName><ForeName>Santiago Viveros</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Omer</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilfillan</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Adiljan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhinn</LastName><ForeName>Herv&#xe9;</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tassi</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Arnon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwabe</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Alector LLC, South San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG059176</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059082</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506896">Spp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>106441-73-0</RegistryNumber><NameOfSubstance UI="D053495">Osteopontin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053495" MajorTopicYN="N">Osteopontin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: M. Mustafa, S.V. Salazar, P. Kong, H. Long, M. Ward, O. Siddiqui, R. Paul, A. Ibrahim, H. Rhinn, I. Tassi, A. Rosenthal, and T. Schwabe reported "other" from Alector, Inc. during the conduct of the study. The authors are employees of Alector LLC and may have an equity interest in Alector, Inc. Alector and AbbVie are parties to an agreement relating to the development and commercialization of AL002. M. Colonna reported "other" from Alector and grants from Alector, Amgen, and Ono during the conduct of the study. In addition, Alector LLC has pending patent applications and M. Colonna has a patent to TREM2 pending. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32579671</ArticleId><ArticleId IdType="pmc">PMC7478730</ArticleId><ArticleId IdType="doi">10.1084/jem.20200785</ArticleId><ArticleId IdType="pii">151887</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braun D., and Feinstein D.L.. 2019. The locus coeruleus neuroprotective drug vindeburnol normalizes behavior in the 5xFAD transgenic mouse model of Alzheimer&#x2019;s disease. Brain Res. 1702:29&#x2013;37. 10.1016/j.brainres.2017.12.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2017.12.028</ArticleId><ArticleId IdType="pubmed">29274883</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruhns P., and J&#xf6;nsson F.. 2015. Mouse and human FcR effector functions. Immunol. Rev. 268:25&#x2013;51. 10.1111/imr.12350</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12350</ArticleId><ArticleId IdType="pubmed">26497511</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A., Hoffman P., Smibert P., Papalexi E., and Satija R.. 2018. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36:411&#x2013;420. 10.1038/nbt.4096</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W.-T., Lu A., Craessaerts K., Pavie B., Frigerio C.S., Mancuso R., Qian X., Lalakova J., K&#xfc;hnemund M., Voytyuk I., et al. . 2019. Spatial and temporal transcriptomics reveal microglia-astroglia crosstalk in the amyloid-&#x3b2; plaque cell niche of Alzheimer&#x2019;s disease. bioRxiv 10.1101/719930 (Preprint posted August 12, 2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/719930</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q., Danao J., Talreja S., Wen P., Yin J., Sun N., Li C.M., Chui D., Tran D., Koirala S., et al. . 2018. TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer&#x2019;s disease variant Trem2R47H on murine myeloid cell function. J. Biol. Chem. 293:12620&#x2013;12633. 10.1074/jbc.RA118.001848</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.001848</ArticleId><ArticleId IdType="pmc">PMC6093249</ArticleId><ArticleId IdType="pubmed">29599291</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D., Grutzendler J., Yang G., Kim J.V., Zuo Y., Jung S., Littman D.R., Dustin M.L., and Gan W.B.. 2005. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8:752&#x2013;758. 10.1038/nn1472</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1472</ArticleId><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuerbach D., Schindler P., Barske C., Joller S., Beng-Louka E., Worringer K.A., Kommineni S., Kaykas A., Ho D.J., Ye C., et al. . 2017. ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157. Neurosci. Lett. 660:109&#x2013;114. 10.1016/j.neulet.2017.09.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.09.034</ArticleId><ArticleId IdType="pubmed">28923481</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S.K., Younkin S., et al. ; Alzheimer Genetic Analysis Group . 2013. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 368:117&#x2013;127. 10.1056/NEJMoa1211851</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;ttenrauch M., Walter S., Kaufmann M., Weggen S., and Wirths O.. 2017. Limited Effects of Prolonged Environmental Enrichment on the Pathology of 5XFAD Mice. Mol. Neurobiol. 54:6542&#x2013;6555. 10.1007/s12035-016-0167-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0167-x</ArticleId><ArticleId IdType="pubmed">27734334</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A.I., Lah J.J., et al. . 2013. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med. 368:107&#x2013;116. 10.1056/NEJMoa1211103</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch C.M., and Goate A.M.. 2015. Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry. 77:43&#x2013;51. 10.1016/j.biopsych.2014.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2014.05.006</ArticleId><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T.K., David E., Baruch K., Lara-Astaiso D., Toth B., et al. . 2017. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 169:1276&#x2013;1290.e17. 10.1016/j.cell.2017.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., DeStafano A.L., Bis J.C., Beecham G.W., Grenier-Boley B., et al. ; Cohorts for Heart and Aging Research in Genomic Epidemiology . 2013. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 45:1452&#x2013;1458. 10.1038/ng.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.Y.D., Daggett A., Gu X., Jiang L.L., Langfelder P., Li X., Wang N., Zhao Y., Park C.S., Cooper Y., et al. . 2018. Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer&#x2019;s Disease Models. Neuron. 97:1032&#x2013;1048.e5. 10.1016/j.neuron.2018.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.002</ArticleId><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo J.A., Stern E.A., McLellan M.E., Kajdasz S.T., Hickey G.A., Bacskai B.J., and Hyman B.T.. 2003. Amyloid-&#x3b2; antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 23:10879&#x2013;10883. 10.1523/JNEUROSCI.23-34-10879.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-34-10879.2003</ArticleId><ArticleId IdType="pmc">PMC6740984</ArticleId><ArticleId IdType="pubmed">14645482</ArticleId></ArticleIdList></Reference><Reference><Citation>Long J.M., and Holtzman D.M.. 2019. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 179:312&#x2013;339. 10.1016/j.cell.2019.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.09.001</ArticleId><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H., Adaikkan C., Gao F., Young J.Z., Manet E., Hemberg M., De Jager P.L., Ransohoff R.M., Regev A., and Tsai L.H.. 2017. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep. 21:366&#x2013;380. 10.1016/j.celrep.2017.09.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.039</ArticleId><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H., Davila-Velderrain J., Peng Z., Gao F., Mohammadi S., Young J.Z., Menon M., He L., Abdurrob F., Jiang X., et al. . 2019. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 570:332&#x2013;337. 10.1038/s41586-019-1195-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A., Schmidt H., Nitsche M., Merkler D., Hanisch U.K., Mack M., Heikenwalder M., Br&#xfc;ck W., Priller J., and Prinz M.. 2007. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci. 10:1544&#x2013;1553. 10.1038/nn2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2015</ArticleId><ArticleId IdType="pubmed">18026096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L., and Selkoe D.J.. 2012. Neurotoxicity of amyloid &#x3b2;-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2 a006338 10.1101/cshperspect.a006338</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006338</ArticleId><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A., Kirchhoff F., and Helmchen F.. 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 308:1314&#x2013;1318. 10.1126/science.1110647</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1110647</ArticleId><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., et al. . 2006. Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26:10129&#x2013;10140. 10.1523/JNEUROSCI.1202-06.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero K., Turnbull I.R., Poliani P.L., Vermi W., Cerutti E., Aoshi T., Tassi I., Takai T., Stanley S.L., Miller M., et al. . 2009. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and &#x3b2;-catenin. Nat. Immunol. 10:734&#x2013;743. 10.1038/ni.1744</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1744</ArticleId><ArticleId IdType="pmc">PMC4004764</ArticleId><ArticleId IdType="pubmed">19503107</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L., Buonsanti C., Cella M., Tassi I., Schmidt R.E., Fenoglio C., Rinker J. II, Naismith R.T., Panina-Bordignon P., Passini N., et al. . 2008. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 131:3081&#x2013;3091. 10.1093/brain/awn217</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn217</ArticleId><ArticleId IdType="pmc">PMC2577803</ArticleId><ArticleId IdType="pubmed">18790823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C., Wolfs L., Fattorelli N., Thrupp N., Voytyuk I., Schmidt I., Mancuso R., Chen W.T., Woodbury M.E., Srivastava G., et al. . 2019. The Major Risk Factors for Alzheimer&#x2019;s Disease: Age, Sex, and Genes Modulate the Microglia Response to A&#x3b2; Plaques. Cell Rep. 27:1293&#x2013;1306.e6. 10.1016/j.celrep.2019.03.099</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.03.099</ArticleId><ArticleId IdType="pmc">PMC7340153</ArticleId><ArticleId IdType="pubmed">31018141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlus H., and Heneka M.T.. 2017. Microglia in Alzheimer&#x2019;s disease. J. Clin. Invest. 127:3240&#x2013;3249. 10.1172/JCI90606</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90606</ArticleId><ArticleId IdType="pmc">PMC5669553</ArticleId><ArticleId IdType="pubmed">28862638</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K., Kleinberger G., Fukumori A., Feederle R., Lichtenthaler S.F., Steiner H., and Haass C.. 2017. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol. Med. 9:1356&#x2013;1365. 10.15252/emmm.201707672</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707672</ArticleId><ArticleId IdType="pmc">PMC5623859</ArticleId><ArticleId IdType="pubmed">28855300</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K., Monroe K.M., Kleinberger G., Cantuti-Castelvetri L., Parhizkar S., Xia D., Willem M., Werner G., Pettkus N., Brunner B., et al. . 2020. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol. Med. 12 e11227 10.15252/emmm.201911227</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911227</ArticleId><ArticleId IdType="pmc">PMC7136959</ArticleId><ArticleId IdType="pubmed">32154671</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A., William C.M., Ferrer I., Uro-Coste E., Delisle M.B., Maurage C.A., Hock C., Nitsch R.M., Masliah E., Growdon J.H., et al. . 2010. Beneficial effect of human anti-amyloid-&#x3b2; active immunization on neurite morphology and tau pathology. Brain. 133:1312&#x2013;1327. 10.1093/brain/awq056</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq056</ArticleId><ArticleId IdType="pmc">PMC2859150</ArticleId><ArticleId IdType="pubmed">20360050</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., Hooli B., Mullin K., Jin S.C., Cella M., Ulland T.K., Wang Y., Tanzi R.E., and Colonna M.. 2017. Alzheimer&#x2019;s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement. 13:381&#x2013;387. 10.1016/j.jalz.2016.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.07.004</ArticleId><ArticleId IdType="pmc">PMC5299056</ArticleId><ArticleId IdType="pubmed">27520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W.M., Joshita S., Zhou Y., Ulland T.K., Gilfillan S., and Colonna M.. 2018. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. Med. 215:745&#x2013;760. 10.1084/jem.20171529</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171529</ArticleId><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirosh I., Izar B., Prakadan S.M., Wadsworth M.H. II, Treacy D., Trombetta J.J., Rotem A., Rodman C., Lian C., Murphy G., et al. . 2016. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 352:189&#x2013;196. 10.1126/science.aad0501</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad0501</ArticleId><ArticleId IdType="pmc">PMC4944528</ArticleId><ArticleId IdType="pubmed">27124452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland T.K., Song W.M., Huang S.C.C., Ulrich J.D., Sergushichev A., Beatty W.L., Loboda A.A., Zhou Y., Cairns N.J., Kambal A., et al. . 2017. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer&#x2019;s Disease. Cell. 170:649&#x2013;663.e13. 10.1016/j.cell.2017.07.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.023</ArticleId><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hove H., Martens L., Scheyltjens I., De Vlaminck K., Pombo Antunes A.R., De Prijck S., Vandamme N., De Schepper S., Van Isterdael G., Scott C.L., et al. . 2019. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci. 22:1021&#x2013;1035. 10.1038/s41593-019-0393-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0393-4</ArticleId><ArticleId IdType="pubmed">31061494</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cella M., Mallinson K., Ulrich J.D., Young K.L., Robinette M.L., Gilfillan S., Krishnan G.M., Sudhakar S., Zinselmeyer B.H., et al. . 2015. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 160:1061&#x2013;1071. 10.1016/j.cell.2015.01.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Ulland T.K., Ulrich J.D., Song W., Tzaferis J.A., Hole J.T., Yuan P., Mahan T.E., Shi Y., Gilfillan S., et al. . 2016. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213:667&#x2013;675. 10.1084/jem.20151948</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak D.F., Diggs-Andrews K.A., Conyers S., Yuede C.M., Dearborn J.T., Brown J.A., Tokuda K., Izumi Y., Zorumski C.F., and Gutmann D.H.. 2013. Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice. PLoS One. 8 e66024 10.1371/journal.pone.0066024</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0066024</ArticleId><ArticleId IdType="pmc">PMC3677926</ArticleId><ArticleId IdType="pubmed">23762458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P., Glebov K., Kemmerling N., Tien N.T., Neumann H., and Walter J.. 2013. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and &#x3b3;-secretase-dependent intramembranous cleavage. J. Biol. Chem. 288:33027&#x2013;33036. 10.1074/jbc.M113.517540</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.517540</ArticleId><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P., Condello C., Keene C.D., Wang Y., Bird T.D., Paul S.M., Luo W., Colonna M., Baddeley D., and Grutzendler J.. 2016. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron. 90:724&#x2013;739. 10.1016/j.neuron.2016.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuede C.M., Zimmerman S.D., Dong H., Kling M.J., Bero A.W., Holtzman D.M., Timson B.F., and Csernansky J.G.. 2009. Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer&#x2019;s disease. Neurobiol. Dis. 35:426&#x2013;432. 10.1016/j.nbd.2009.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.06.002</ArticleId><ArticleId IdType="pmc">PMC2745233</ArticleId><ArticleId IdType="pubmed">19524672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Song W.M., Andhey P.S., Swain A., Levy T., Miller K.R., Poliani P.L., Cominelli M., Grover S., Gilfillan S., et al. . 2020. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med. 26:131&#x2013;142. 10.1038/s41591-019-0695-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32637606</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>26</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Astrocytes and microglia play orchestrated roles and respect phagocytic territories during neuronal corpse removal in vivo.</ArticleTitle><Pagination><StartPage>eaba3239</StartPage><MedlinePgn>eaba3239</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eaba3239</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.aba3239</ELocationID><Abstract><AbstractText>Cell death is prevalent throughout life; however, the coordinated interactions and roles of phagocytes during corpse removal in the live brain are poorly understood. We developed photochemical and viral methodologies to induce death in single cells and combined this with intravital optical imaging. This approach allowed us to track multicellular phagocytic interactions with precise spatiotemporal resolution. Astrocytes and microglia engaged with dying neurons in an orchestrated and synchronized fashion. Each glial cell played specialized roles: Astrocyte processes rapidly polarized and engulfed numerous small dendritic apoptotic bodies, while microglia migrated and engulfed the soma and apical dendrites. The relative involvement and phagocytic specialization of each glial cell was plastic and controlled by the receptor tyrosine kinase <i>Mertk</i>. In aging, there was a marked delay in apoptotic cell removal. Thus, a precisely orchestrated response and cross-talk between glial cells during corpse removal may be critical for maintaining brain homeostasis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Damisah</LastName><ForeName>Eyiyemisi C</ForeName><Initials>EC</Initials><Identifier Source="ORCID">0000-0001-8854-1335</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0001-6080-8712</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, Dartmouth College, Hanover, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rai</LastName><ForeName>Anupama</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2596-5154</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fuyi</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-8883-5739</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothlin</LastName><ForeName>Carla V</ForeName><Initials>CV</Initials><Identifier Source="ORCID">0000-0002-5693-5572</Identifier><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Sourav</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5990-8708</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grutzendler</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5000-243X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS099469</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA212376</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM051384</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI089824</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058257</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089734</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 NS099469</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="Y">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002102" MajorTopicYN="N">Cadaver</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010586" MajorTopicYN="N">Phagocytes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32637606</ArticleId><ArticleId IdType="pmc">PMC7319765</ArticleId><ArticleId IdType="doi">10.1126/sciadv.aba3239</ArticleId><ArticleId IdType="pii">aba3239</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fuchs Y., Steller H., Programmed cell death in animal development and disease. Cell 147, 742&#x2013;758 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4511103</ArticleId><ArticleId IdType="pubmed">22078876</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J., Yankner B. A., Apoptosis in the nervous system. Nature 407, 802&#x2013;809 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11048732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis R. E., Yuan J. Y., Horvitz H. R., Mechanisms and functions of cell death. Annu. Rev. Cell Biol. 7, 663&#x2013;698 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1809356</ArticleId></ArticleIdList></Reference><Reference><Citation>Danthi P., Viruses and the diversity of cell death. Annu. Rev. Virol. 3, 533&#x2013;553 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27501259</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson M. D., Weil M., Raff M. C., Programmed cell death in animal development. Cell 88, 347&#x2013;354 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9039261</ArticleId></ArticleIdList></Reference><Reference><Citation>Southwell D. G., Paredes M. F., Galvao R. P., Jones D. L., Froemke R. C., Sebe J. Y., Alfaro-Cervello C., Tang Y., Garcia-Verdugo J. M., Rubenstein J. L., Baraban S. C., Alvarez-Buylla A., Intrinsically determined cell death of developing cortical interneurons. Nature 491, 109&#x2013;113 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726009</ArticleId><ArticleId IdType="pubmed">23041929</ArticleId></ArticleIdList></Reference><Reference><Citation>Tufail Y., Cook D., Fourgeaud L., Powers C. J., Merten K., Clark C. L., Hoffman E., Ngo A., Sekiguchi K. J., O&#x2019;Shea C. C., Lemke G., Nimmerjahn A., Phosphatidylserine exposure controls viral innate immune responses by microglia. Neuron 93, 574&#x2013;586.e8 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5600182</ArticleId><ArticleId IdType="pubmed">28111081</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadok V. A., Bratton D. L., Rose D. M., Pearson A., Ezekewitz R. A. B., Henson P. M., A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405, 85&#x2013;90 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10811223</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnaik R., Raff M. C., Scholes J., Differences between the clearance of apoptotic cells by professional and non-professional phagocytes. Curr. Biol. 10, 857&#x2013;860 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10899007</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood W., Turmaine M., Weber R., Camp V., Maki R. A., McKercher S. R., Martin P., Mesenchymal cells engulf and clear apoptotic footplate cells in macrophageless PU.1 null mouse embryos. Development 127, 5245&#x2013;5252 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11076747</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata S., Hanayama R., Kawane K., Autoimmunity and the clearance of dead cells. Cell 140, 619&#x2013;630 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20211132</ArticleId></ArticleIdList></Reference><Reference><Citation>Arandjelovic S., Ravichandran K. S., Phagocytosis of apoptotic cells in homeostasis. Nat. Immunol. 16, 907&#x2013;917 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826466</ArticleId><ArticleId IdType="pubmed">26287597</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochreiter-Hufford A. E., Lee C. S., Kinchen J. M., Sokolowski J. D., Arandjelovic S., Call J. A., Klibanov A. L., Yan Z., Mandell J. W., Ravichandran K. S., Phosphatidylserine receptor BAI1 and apoptotic cells as new promoters of myoblast fusion. Nature 497, 263&#x2013;267 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773542</ArticleId><ArticleId IdType="pubmed">23615608</ArticleId></ArticleIdList></Reference><Reference><Citation>Etchegaray J. I., Elguero E. J., Tran J. A., Sinatra V., Feany M. B., McCall K., Defective phagocytic corpse processing results in neurodegeneration and can be rescued by TORC1 activation. J. Neurosci. 36, 3170&#x2013;3183 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4792933</ArticleId><ArticleId IdType="pubmed">26985028</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M., Priller J., Microglia and brain macrophages in the molecular age: From origin to neuropsychiatric disease. Nat. Rev. Neurosci. 15, 300&#x2013;312 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24713688</ArticleId></ArticleIdList></Reference><Reference><Citation>Morizawa Y. M., Hirayama Y., Ohno N., Shibata S., Shigetomi E., Sui Y., Nabekura J., Sato K., Okajima F., Takebayashi H., Okano H., Koizumi S., Reactive astrocytes function as phagocytes after brain ischemia via ABCA1-mediated pathway. Nat. Commun. 8, 28 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5481424</ArticleId><ArticleId IdType="pubmed">28642575</ArticleId></ArticleIdList></Reference><Reference><Citation>Iram T., Ramirez-Ortiz Z., Byrne M. H., Coleman U. A., Kingery N. D., Means T. K., Frenkel D., el Khoury J., Megf10 is a receptor for C1Q that mediates clearance of apoptotic cells by astrocytes. J. Neurosci. 36, 5185&#x2013;5192 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4863057</ArticleId><ArticleId IdType="pubmed">27170117</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Baker M., Nicholson A. M., Rutherford N. J., Finch N., Soto-Ortolaza A., Lash J., Wider C., Wojtas A., DeJesus-Hernandez M., Adamson J., Kouri N., Sundal C., Shuster E. A., Aasly J., MacKenzie J., Roeber S., Kretzschmar H. A., Boeve B. F., Knopman D. S., Petersen R. C., Cairns N. J., Ghetti B., Spina S., Garbern J., Tselis A. C., Uitti R., Das P., van Gerpen J. A., Meschia J. F., Levy S., Broderick D. F., Graff-Radford N., Ross O. A., Miller B. B., Swerdlow R. H., Dickson D. W., Wszolek Z. K., Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat. Genet. 44, 200&#x2013;205 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3267847</ArticleId><ArticleId IdType="pubmed">22197934</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J. S. K., Younkin S., Hazrati L., Collinge J., Pocock J., Lashley T., Williams J., Lambert J.-C., Amouyel P., Goate A., Rademakers R., Morgan K., Powell J., St George-Hyslop P., Singleton A., Hardy J.; Alzheimer Genetic Analysis Group , TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 368, 117&#x2013;127 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P. V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A. I., Lah J. J., Rujescu D., Hampel H., Giegling I., Andreassen O. A., Engedal K., Ulstein I., Djurovic S., Ibrahim-Verbaas C., Hofman A., Ikram M. A., van Duijn C. M., Thorsteinsdottir U., Kong A., Stefansson K., Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med. 368, 107&#x2013;116 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal A., Li Y., Thompson D. A., Weir J., Orth U., Jacobson S. G., Apfelstedt-Sylla E., Vollrath D., Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat. Genet. 26, 270&#x2013;271 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11062461</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown G. C., Neher J. J., Microglial phagocytosis of live neurons. Nat. Rev. Neurosci. 15, 209&#x2013;216 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24646669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kl&#xfc;nemann H. H., Ridha B. H., Magy L., Wherrett J. R., Hemelsoet D. M., Keen R. W., De Bleecker J. L., Rossor M. N., Marienhagen J., Klein H. E., Peltonen L., Paloneva J., The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology 64, 1502&#x2013;1507 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15883308</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourgeaud L., Trav&#xe9;s P. G., Tufail Y., Leal-Bailey H., Lew E. D., Burrola P. G., Callaway P., Zag&#xf3;rska A., Rothlin C. V., Nimmerjahn A., Lemke G., TAM receptors regulate multiple features of microglial physiology. Nature 532, 240&#x2013;244 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358512</ArticleId><ArticleId IdType="pubmed">27049947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C., Lemke G., An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 6, 691&#x2013;704 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2025425</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahoy J. D., Emery B., Kaushal A., Foo L. C., Zamanian J. L., Christopherson K. S., Xing Y., Lubischer J. L., Krieg P. A., Krupenko S. A., Thompson W. J., Barres B. A., A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function. J. Neurosci. 28, 264&#x2013;278 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671143</ArticleId><ArticleId IdType="pubmed">18171944</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Chen K., Sloan S. A., Bennett M. L., Scholze A. R., O'Keeffe S., Phatnani H. P., Guarnieri P., Caneda C., Ruderisch N., Deng S., Liddelow S. A., Zhang C., Daneman R., Maniatis T., Barres B. A., Wu J. Q., An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill R. A., Damisah E. C., Chen F., Kwan A. C., Grutzendler J., Targeted two-photon chemical apoptotic ablation of defined cell types in vivo. Nat. Commun. 8, 15837 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501159</ArticleId><ArticleId IdType="pubmed">28621306</ArticleId></ArticleIdList></Reference><Reference><Citation>Watakabe A., Ohtsuka M., Kinoshita M., Takaji M., Isa K., Mizukami H., Ozawa K., Isa T., Yamamori T., Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci. Res. 93, 144&#x2013;157 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25240284</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyanishi M., Tada K., Koike M., Uchiyama Y., Kitamura T., Nagata S., Identification of Tim4 as a phosphatidylserine receptor. Nature 450, 435&#x2013;439 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17960135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanayama R., Tanaka M., Miwa K., Shinohara A., Iwamatsu A., Nagata S., Identification of a factor that links apoptotic cells to phagocytes. Nature 417, 182&#x2013;187 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12000961</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama M., Akiba H., Takeda K., Kojima Y., Hashiguchi M., Azuma M., Yagita H., Okumura K., Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113, 3821&#x2013;3830 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19224762</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott R. S., McMahon E. J., Pop S. M., Reap E. A., Caricchio R., Cohen P. L., Earp H. S., Matsushima G. K., Phagocytosis and clearance of apoptotic cells is mediated by MERTK. Nature 411, 207&#x2013;211 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11346799</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung W.-S., Clarke L. E., Wang G. X., Stafford B. K., Sher A., Chakraborty C., Joung J., Foo L. C., Thompson A., Chen C., Smith S. J., Barres B. A., Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504, 394&#x2013;400 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969024</ArticleId><ArticleId IdType="pubmed">24270812</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore M. R. P., Najafi A. R., Koike M. A., Dagher N. N., Spangenberg E. E., Rice R. A., Kitazawa M., Matusow B., Nguyen H., West B. L., Green K. N., Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82, 380&#x2013;397 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Joly E., Hudrisier D., What is trogocytosis and what is its purpose? Nat. Immunol. 4, 815 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12942076</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A., Kemper T., A review of the structural alterations in the cerebral hemispheres of the aging rhesus monkey. Neurobiol. Aging 33, 2357&#x2013;2372 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337968</ArticleId><ArticleId IdType="pubmed">22192242</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D. E., Rapp P. R., McKay H. M., Roberts J. A., Tuszynski M. H., Memory impairment in aged primates is associated with focal death of cortical neurons and atrophy of subcortical neurons. J. Neurosci. 24, 4373&#x2013;4381 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729447</ArticleId><ArticleId IdType="pubmed">15128851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond T. R., Dufort C., Dissing-Olesen L., Giera S., Young A., Wysoker A., Walker A. J., Gergits F., Segel M., Nemesh J., Marsh S. E., Saunders A., Macosko E., Ginhoux F., Chen J., Franklin R. J. M., Piao X., McCarroll S. A., Stevens B., Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity 50, 253&#x2013;271.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponath G., Ramanan S., Mubarak M., Housley W., Lee S., Sahinkaya F. R., Vortmeyer A., Raine C. S., Pitt D., Myelin phagocytosis by astrocytes after myelin damage promotes lesion pathology. Brain 140, 399&#x2013;413 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841057</ArticleId><ArticleId IdType="pubmed">28007993</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus T., Chan A., Linker R. A., Toyka K. V., Gold R., Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: Implications for the role of glial cells in the inflamed central nervous system. J. Neuropathol. Exp. Neurol. 61, 760&#x2013;766 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12230322</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer D. P., Lehrman E. K., Kautzman A. G., Koyama R., Mardinly A. R., Yamasaki R., Ransohoff R. M., Greenberg M. E., Barres B. A., Stevens B., Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691&#x2013;705 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu&#xf1;al V. M., Paisley C. E., Brecha F. S., Lee M. A., Perelli R. M., Wang J., O&#x2019;Koren E. G., Ackley C. R., Saban D. R., Reese B. E., Kay J. N., Large-scale death of retinal astrocytes during normal development is non-apoptotic and implemented by microglia. PLOS Biol. 17, e3000492 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6821132</ArticleId><ArticleId IdType="pubmed">31626642</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels B. P., Jujjavarapu H., Durrant D. M., Williams J. L., Green R. R., White J. P., Lazear H. M., Gale M. Jr., Diamond M. S., Klein R. S., Regional astrocyte IFN signaling restricts pathogenesis during neurotropic viral infection. J. Clin. Invest. 127, 843&#x2013;856 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5330728</ArticleId><ArticleId IdType="pubmed">28134626</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D., Grutzendler J., Yang G., Kim J. V., Zuo Y., Jung S., Littman D. R., Dustin M. L., Gan W.-B., ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8, 752&#x2013;758 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A., Kirchhoff F., Helmchen F., Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314&#x2013;1318 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasdemir-Yilmaz O. E., Freeman M. R., Astrocytes engage unique molecular programs to engulf pruned neuronal debris from distinct subsets of neurons. Genes Dev. 28, 20&#x2013;33 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3894410</ArticleId><ArticleId IdType="pubmed">24361692</ArticleId></ArticleIdList></Reference><Reference><Citation>Robel S., Bardehle S., Lepier A., Brakebusch C., G&#xf6;tz M., Genetic deletion of Cdc42 reveals a crucial role for astrocyte recruitment to the injury site in vitro and in vivo. J. Neurosci. 31, 12471&#x2013;12482 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6703275</ArticleId><ArticleId IdType="pubmed">21880909</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q., Gore M., Zhang Q., Camenisch T., Boast S., Casagranda F., Lai C., Skinner M. K., Klein R., Matsushima G. K., Earp H. S., Goff S. P., Lemke G., Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 398, 723&#x2013;728 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10227296</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C., Yuan P., Schain A., Grutzendler J., Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat. Commun. 6, 6176 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F., Maher B. J., LoTurco J. J., PiggyBac transposon-mediated cellular transgenesis in mammalian forebrain by in utero electroporation. Cold Spring Harb. Protoc. 2014, 741&#x2013;749 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24987137</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A., Kirchhoff F., Kerr J. N. D., Helmchen F., Sulforhodamine 101 as a specific marker of astroglia in the neocortex in vivo. Nat. Methods 1, 31&#x2013;37 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15782150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill R. A., Grutzendler J., In vivo imaging of oligodendrocytes with sulforhodamine 101. Nat. Methods 11, 1081&#x2013;1082 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539948</ArticleId><ArticleId IdType="pubmed">25357236</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32591829</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>143</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Sex-dependent autosomal effects on clinical progression of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>2272</StartPage><EndPage>2280</EndPage><MedlinePgn>2272-2280</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awaa164</ELocationID><Abstract><AbstractText>Sex differences in the manifestations of Alzheimer's disease are under intense investigation. Despite the emerging importance of polygenic predictions for Alzheimer's disease, sex-dependent polygenic effects have not been demonstrated. Here, using a sex crossover analysis, we show that sex-dependent autosomal genetic effects on Alzheimer's disease can be revealed by characterizing disease progress via the hazard function. We first performed sex-stratified genome-wide associations, and then applied derived sex-dependent weights to two independent cohorts. Relative to sex-mismatched scores, sex-matched polygenic hazard scores showed significantly stronger associations with age-at-disease-onset, clinical progression, amyloid deposition, neurofibrillary tangles, and composite neuropathological scores, independent of apolipoprotein E. Models without using hazard weights, i.e. polygenic risk scores, showed lower predictive power than polygenic hazard scores with no evidence for sex differences. Our results indicate that revealing sex-dependent genetic architecture requires the consideration of temporal processes of Alzheimer's disease. This has strong implications not only for the genetic underpinning of Alzheimer's disease but also for how we estimate sex-dependent polygenic effects for clinical use.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Chun Chieh</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Center for Human Development, University of California, San Diego, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banks</LastName><ForeName>Sarah J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California, San Diego, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Wesley K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Family Medicine and Public Health, University of California, San Diego, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chi-Hua</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEvoy</LastName><ForeName>Linda K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Family Medicine and Public Health, University of California, San Diego, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Chin Hong</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Psychology, Nanyang Technological University, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Washington, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurological Science, Rush Medical College, Chicago, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Biomedical Genetics, Boston University, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and the Taub Institute at Columbia University, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desikan</LastName><ForeName>Rahul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Multimodal Imaging and Genetics, University of California, San Diego, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066088</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG072122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG067501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG061163</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG063260</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020412" MajorTopicYN="N">Multifactorial Inheritance</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">cognitive decline</Keyword><Keyword MajorTopicYN="N">hazard score</Keyword><Keyword MajorTopicYN="N">polygenic scores</Keyword><Keyword MajorTopicYN="N">sex differences</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32591829</ArticleId><ArticleId IdType="pmc">PMC7364740</ArticleId><ArticleId IdType="doi">10.1093/brain/awaa164</ArticleId><ArticleId IdType="pii">5863662</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altmann A, Tian L, Henderson VW, Greicius MD.. Sex modifies the APOE -related risk of developing Alzheimer disease. Ann Neurol 2014; 75: 563&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117990</ArticleId><ArticleId IdType="pubmed">24623176</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA.. Religious orders study and rush memory and aging project. J Alzheimers Dis 2018; 64: S161&#x2013;S189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell JZK, Berg J-L, Cummings JL, Banks SJ.. Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume. Alzheimers Res Ther 2017; 9: 72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5596932</ArticleId><ArticleId IdType="pubmed">28899422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellini E, Tedde A, Bagnoli S, Pradella S, Piacentini S, Sorbi S, et al.Implication of sex and SORL1 variants in Italian patients with Alzheimer disease. Arch Neurol 2009; 66: 1260&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19822782</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis J, Flaig A, Grenier-Boley B, Eysert F, Pottiez V, Deloison G, et al.Genome-wide, high-content siRNA screening identifies the Alzheimer&#x2019;s genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathol 2017; 133: 955&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427165</ArticleId><ArticleId IdType="pubmed">27933404</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Lumley T, Brody J, Heard-Costa NL, Fox CS, Cupples LA, et al.Sequence kernel association test for survival traits. Genet Epidemiol 2014; 38: 191&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4158946</ArticleId><ArticleId IdType="pubmed">24464521</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Pollack S, Hunter DJ, Hirschhorn JN, Kraft P, Price AL.. Improved ancestry inference using weights from external reference panels. Bioinformatics 2013; 29: 1399&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661048</ArticleId><ArticleId IdType="pubmed">23539302</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, et al.Gender modulates the APOE &#x3b5;4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci 2012; 32: 8254&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394933</ArticleId><ArticleId IdType="pubmed">22699906</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y, Dumitrescu L, Barnes LL, Thambisetty M, Kunkle B, Gifford KA, et al.Sex-specific genetic predictors of Alzheimer&#x2019;s disease biomarkers. Acta Neuropathol 2018; 136: 857&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280657</ArticleId><ArticleId IdType="pubmed">29967939</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Fan CC, Wang Y, Schork AJ, Cabral HJ, Cupples LA, et al.Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. PLoS Med 2017; 14: e1002258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360219</ArticleId><ArticleId IdType="pubmed">28323831</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al.Common polygenic variation enhances risk prediction for Alzheimer&#x2019;s disease. Brain 2015; 138: 3673&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006219</ArticleId><ArticleId IdType="pubmed">26490334</ArticleId></ArticleIdList></Reference><Reference><Citation>Falconer DS. The inheritance of liability to certain diseases, estimated from the incidence among relatives. Ann Human Genet 1965; 29: 51&#x2013;76.</Citation></Reference><Reference><Citation>Farrer LA. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA J Am Med Assoc 1997; 278: 1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Schumacher Dimech A, Santuccione Chadha A, et al.Sex differences in Alzheimer disease&#x2014;the gateway to precision medicine. Nat Rev Neurol 2018; 14: 457&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">29985474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al.Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006; 63: 168.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge T, Sabuncu MR, Smoller JW, Sperling RA, Mormino EC.. Dissociable influences of APOE &#x3b5;4 and polygenic risk of AD dementia on amyloid and cognition. Neurology 2018; 90: e1605&#x2013;e1612. 10.1212/WNL.0000000000005415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005415</ArticleId><ArticleId IdType="pmc">PMC5931806</ArticleId><ArticleId IdType="pubmed">29592889</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al.Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet 2011; 43: 429&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Ma Y, McCabe C, Xu J, Vardarajan BN, Felsky D, et al.A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Sci Data 2018; 5: 180142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al.Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 2018; 50: 1219&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128408</ArticleId><ArticleId IdType="pubmed">30104762</ArticleId></ArticleIdList></Reference><Reference><Citation>Khramtsova EA, Davis LK, Stranger BE.. The role of sex in the genomics of human complex traits. Nat Rev Genet 2019; 20: 173&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">30581192</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al.Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat Genet 2019; 51: 414&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al.Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet 2013; 45: 1452&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamparter D, Marbach D, Rueedi R, Kutalik Z, Bergmann S.. Fast and rigorous computation of gene and pathway scores from SNP-based summary statistics. PLoS Comput Biol 2016; 12: e1004714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4726509</ArticleId><ArticleId IdType="pubmed">26808494</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G-D, Bi R, Zhang D-F, Xu M, Luo R, Wang D, et al.Female-specific effect of the BDNF gene on Alzheimer&#x2019;s disease. Neurobiol Aging 2017; 53: 192.e11&#x2013;192.e19.</Citation><ArticleIdList><ArticleId IdType="pubmed">28202203</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazure CM, Swendsen J.. Sex differences in Alzheimer&#x2019;s disease and other dementias. Lancet Neurol 2016; 15: 451&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4864429</ArticleId><ArticleId IdType="pubmed">26987699</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok S-A, Condello C, Freilich R, Gillies A, Arhar T, Oroz J, et al.Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nat Struct Mol Biol 2018; 25: 384&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942583</ArticleId><ArticleId IdType="pubmed">29728653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, et al.Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology 2016; 87: 481&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970660</ArticleId><ArticleId IdType="pubmed">27385740</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, et al.Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet 2011; 43: 436&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Nebel RA, Aggarwal NT, Barnes LL, Gallagher A, Goldstein JM, Kantarci K, et al.Understanding the impact of sex and gender in Alzheimer&#x2019;s disease: a call to action. Alzheimer&#x2019;s Dement 2018; 14: 1171&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6400070</ArticleId><ArticleId IdType="pubmed">29907423</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan S, Arvanitakis Z, Yu L, Farfel J, Schneider JA, Bennett DA.. Sex differences in Alzheimer&#x2019;s disease and common neuropathologies of aging. Acta Neuropathol 2018; 136: 887&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6279593</ArticleId><ArticleId IdType="pubmed">30334074</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler M.. Incidence of dementia: does gender make a difference? Neurobiol Aging 2001; 22: 575&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabuncu MR, Buckner RL, Smoller JW, Lee PH, Fischl B, Sperling RA.. The Association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. Cereb Cortex 2012; 22: 2653&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464416</ArticleId><ArticleId IdType="pubmed">22169231</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, et al.Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ 2018; 360: j5757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759091</ArticleId><ArticleId IdType="pubmed">29321194</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CH, Bonham LW, Fan CC, Mormino EC, Sugrue LP, Broce IJ, et al.Polygenic hazard score, amyloid deposition and Alzheimer&#x2019;s neurodegeneration. Brain 2019; 142: 460&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351776</ArticleId><ArticleId IdType="pubmed">30689776</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CH, Fan CC, Mormino EC, Sugrue LP, Broce IJ, Hess CP, et al.Polygenic hazard score: an enrichment marker for Alzheimer&#x2019;s associated amyloid and tau deposition. Acta Neuropathol 2018; 135: 85&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5758038</ArticleId><ArticleId IdType="pubmed">29177679</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau TM, Grambsch PM, Fleming TR.. Martingale-based residuals for survival models. Biometrika 1990; 77: 147&#x2013;60.</Citation></Reference><Reference><Citation>Torkamani A, Wineinger NE, Topol EJ.. The personal and clinical utility of polygenic risk scores. Nat Rev Genet 2018; 19: 581&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">29789686</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al.Defeating Alzheimer&#x2019;s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15: 455&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">26987701</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32597941</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Early-Life Cognitive Enrichment With Alzheimer Disease Pathological Changes and Cognitive Decline.</ArticleTitle><Pagination><StartPage>1217</StartPage><EndPage>1224</EndPage><MedlinePgn>1217-1224</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.1941</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Indicators of early-life cognitive enrichment (ELCE) have been associated with slower cognitive decline and decreased dementia in late life. However, the mechanisms underlying this association have not been elucidated.</AbstractText><AbstractText Label="OBJECTIVE">To examine the association of ELCE with late-life Alzheimer disease (AD) and other common dementia-related pathological changes.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This clinical-pathological community-based cohort study, the Rush Memory and Aging Project, followed up participants before death for a mean (SD) of 7.0 (3.8) years with annual cognitive and clinical assessments. From January 1, 1997, through June 30, 2019, 2044 participants enrolled, of whom 1018 died. Postmortem data were leveraged from 813 participants. Data were analyzed from April 12, 2019, to February 20, 2020.</AbstractText><AbstractText Label="EXPOSURES">Four indicators of ELCE (early-life socioeconomic status, availability of cognitive resources at 12 years of age, frequency of participation in cognitively stimulating activities, and early-life foreign language instruction) were obtained by self-report at the study baseline, from which a composite measure of ELCE was derived.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">A continuous global AD pathology score derived from counts of diffuse plaques, neuritic plaques, and neurofibrillary tangles.</AbstractText><AbstractText Label="RESULTS">The 813 participants included in the analysis had a mean (SD) age of 90.1 (6.3) years at the time of death, and 562 (69%) were women. In a linear regression model controlled for age at death, sex, and educational level, a higher level of ELCE was associated with a lower global AD pathology score (estimate, -0.057; standard error, 0.022; P&#x2009;=&#x2009;.01). However, ELCE was not associated with any other dementia-related pathological changes. In addition, a higher level of ELCE was associated with less cognitive decline (mean [SD], -0.13 [0.19] units per year; range, -1.74 to 0.85). An indirect effect through AD pathological changes constituted 20% of the association between ELCE and the rate of late-life cognitive decline, and 80% was a direct association.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">These findings suggest that ELCE was associated with better late-life cognitive health, in part through an association with fewer AD pathological changes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oveisgharan</LastName><ForeName>Shahram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2020 Oct 1;77(10):1207-1209. doi: 10.1001/jamaneurol.2020.1114.</RefSource><PMID Version="1">32597936</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002657" MajorTopicYN="N">Child Development</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Oveisgharan reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Yu reported receiving grants from the National Institute on Aging during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32597941</ArticleId><ArticleId IdType="pmc">PMC7325069</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.1941</ArticleId><ArticleId IdType="pii">2767582</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bezerra AB, Coutinho ES, Barca ML, Engedal K, Engelhardt E, Laks J. School attainment in childhood is an independent risk factor of dementia in late life: results from a Brazilian sample. Int Psychogeriatr. 2012;24(1):55-61. doi:10.1017/S1041610211001554</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610211001554</ArticleId><ArticleId IdType="pubmed">21813041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan GA, Turrell G, Lynch JW, Everson SA, Helkala EL, Salonen JT. Childhood socioeconomic position and cognitive function in adulthood. Int J Epidemiol. 2001;30(2):256-263. doi:10.1093/ije/30.2.256</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/30.2.256</ArticleId><ArticleId IdType="pubmed">11369724</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer&#x2019;s disease in late life: findings from the Nun Study. JAMA. 1996;275(7):528-532. doi:10.1001/jama.1996.03530310034029</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1996.03530310034029</ArticleId><ArticleId IdType="pubmed">8606473</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley KP, Snowdon DA, Desrosiers MF, Markesbery WR. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiol Aging. 2005;26(3):341-347. doi:10.1016/j.neurobiolaging.2004.06.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.06.019</ArticleId><ArticleId IdType="pubmed">15639312</ArticleId></ArticleIdList></Reference><Reference><Citation>Field TS, Doubal FN, Johnson W, et al. . Early life characteristics and late life burden of cerebral small vessel disease in the Lothian Birth Cohort 1936. Aging (Albany NY). 2016;8(9):2039-2061. doi:10.18632/aging.101043</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101043</ArticleId><ArticleId IdType="pmc">PMC5076451</ArticleId><ArticleId IdType="pubmed">27652981</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko K, Byun MS, Yi D, Lee JH, Kim CH, Lee DY. Early-life cognitive activity is related to reduced neurodegeneration in Alzheimer signature regions in late life. Front Aging Neurosci. 2018;10:70. doi:10.3389/fnagi.2018.00070</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00070</ArticleId><ArticleId IdType="pmc">PMC5875443</ArticleId><ArticleId IdType="pubmed">29623037</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Wilson RS, de Leon CF, Bennett DA. The relation of lifetime cognitive activity and lifetime access to resources to late-life cognitive function in older African Americans. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2006;13(3-4):516-528. doi:10.1080/138255890969519</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/138255890969519</ArticleId><ArticleId IdType="pubmed">16887787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Boyle PA, Yang J, James BD, Bennett DA. Early life instruction in foreign language and music and incidence of mild cognitive impairment. Neuropsychology. 2015;29(2):292-302. doi:10.1037/neu0000129</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/neu0000129</ArticleId><ArticleId IdType="pmc">PMC4324380</ArticleId><ArticleId IdType="pubmed">25110933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Boyle PA, Yu L, Barnes LL, Schneider JA, Bennett DA. Life-span cognitive activity, neuropathologic burden, and cognitive aging. Neurology. 2013;81(4):314-321. doi:10.1212/WNL.0b013e31829c5e8a</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31829c5e8a</ArticleId><ArticleId IdType="pmc">PMC3772831</ArticleId><ArticleId IdType="pubmed">23825173</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Scherr PA, Hoganson G, Bienias JL, Evans DA, Bennett DA. Early life socioeconomic status and late life risk of Alzheimer&#x2019;s disease. Neuroepidemiology. 2005;25(1):8-14. doi:10.1159/000085307</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000085307</ArticleId><ArticleId IdType="pubmed">15855799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2018;64(s1):S161-S189. doi:10.3233/JAD-179939</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-179939</ArticleId><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Uniform Law Commission  National Conference of Commissioners on Uniform State Laws. Uniform Anatomical Gift Act (2006). Published 2017. Accessed May 21, 2020. https://www.uniformlaws.org/HigherLogic/System/DownloadDocumentFile.ashx?DocumentFileKey=0e0c3a55-52cf-2082-704f-6185187a21fc&amp;forceDialog=0</Citation></Reference><Reference><Citation>Coste J, Bou&#xe9;e S, Ecosse E, Lepl&#xe8;ge A, Pouchot J. Methodological issues in determining the dimensionality of composite health measures using principal component analysis: case illustration and suggestions for practice. Qual Life Res. 2005;14(3):641-654. doi:10.1007/s11136-004-1260-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-004-1260-6</ArticleId><ArticleId IdType="pubmed">16022058</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Ma Y, McCabe C, et al. . A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Sci Data. 2018;5(1):180142. doi:10.1038/sdata.2018.142</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2018.142</ArticleId><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, et al. . Apolipoprotein E &#x3b5;4 allele, AD pathology, and the clinical expression of Alzheimer&#x2019;s disease. Neurology. 2003;60(2):246-252. doi:10.1212/01.WNL.0000042478.08543.F7</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000042478.08543.F7</ArticleId><ArticleId IdType="pubmed">12552039</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61(3):378-384. doi:10.1001/archneur.61.3.378</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.61.3.378</ArticleId><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan S, Arvanitakis Z, Yu L, Farfel J, Schneider JA, Bennett DA. Sex differences in Alzheimer&#x2019;s disease and common neuropathologies of aging. Acta Neuropathol. 2018;136(6):887-900. doi:10.1007/s00401-018-1920-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1920-1</ArticleId><ArticleId IdType="pmc">PMC6279593</ArticleId><ArticleId IdType="pubmed">30334074</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Beckett LA, Barnes LL, et al. . Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging. 2002;17(2):179-193. doi:10.1037/0882-7974.17.2.179</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0882-7974.17.2.179</ArticleId><ArticleId IdType="pubmed">12061405</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Bienias JL, Berry-Kravis E, Evans DA, Bennett DA. The apolipoprotein E &#x3b5; 2 allele and decline in episodic memory. J Neurol Neurosurg Psychiatry. 2002;73(6):672-677. doi:10.1136/jnnp.73.6.672</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.73.6.672</ArticleId><ArticleId IdType="pmc">PMC1757351</ArticleId><ArticleId IdType="pubmed">12438469</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Leurgans S, Aggarwal NT, et al. . Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85(6):528-534. doi:10.1212/WNL.0000000000001834</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001834</ArticleId><ArticleId IdType="pmc">PMC4540250</ArticleId><ArticleId IdType="pubmed">26180136</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Scherr PA, Schneider JA, Tang Y, Bennett DA. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology. 2007;69(20):1911-1920. doi:10.1212/01.wnl.0000271087.67782.cb</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000271087.67782.cb</ArticleId><ArticleId IdType="pubmed">17596582</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan S, Buchman AS, Yu L, et al. . APOE &#x3b5;2&#x3b5;4 genotype, incident AD and MCI, cognitive decline, and AD pathology in older adults. Neurology. 2018;90(24):e2127-e2134. doi:10.1212/WNL.0000000000005677</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005677</ArticleId><ArticleId IdType="pmc">PMC5996834</ArticleId><ArticleId IdType="pubmed">29752306</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards M, James S-N, Sizer A, et al. . Identifying the lifetime cognitive and socioeconomic antecedents of cognitive state: seven decades of follow-up in a British birth cohort study. BMJ Open. 2019;9(4):e024404. doi:10.1136/bmjopen-2018-024404</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-024404</ArticleId><ArticleId IdType="pmc">PMC6502022</ArticleId><ArticleId IdType="pubmed">31023749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekhtyar S, Wang HX, Fratiglioni L, Herlitz A. Childhood school performance, education and occupational complexity: a life-course study of dementia in the Kungsholmen Project. Int J Epidemiol. 2016;45(4):1207-1215. doi:10.1093/ije/dyw008</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw008</ArticleId><ArticleId IdType="pmc">PMC5841626</ArticleId><ArticleId IdType="pubmed">26968481</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ TC, Hannah J, Batty GD, Booth CC, Deary IJ, Starr JM Childhood cognitive ability and incident dementia: the 1932 Scottish Mental Survey cohort into their 10th decade. Epidemiology. 2017;28(3):361-364. doi:10.1097/EDE.0000000000000626</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000626</ArticleId><ArticleId IdType="pmc">PMC5381709</ArticleId><ArticleId IdType="pubmed">28151744</ArticleId></ArticleIdList></Reference><Reference><Citation>Osler M, Christensen GT, Garde E, Mortensen EL, Christensen K. Cognitive ability in young adulthood and risk of dementia in a cohort of Danish men, brothers, and twins. Alzheimers Dement. 2017;13(12):1355-1363. doi:10.1016/j.jalz.2017.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.04.003</ArticleId><ArticleId IdType="pubmed">28531378</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrissey TW, Hutchison L, Winsler A. Family income, school attendance, and academic achievement in elementary school. Dev Psychol. 2014;50(3):741-753. doi:10.1037/a0033848</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0033848</ArticleId><ArticleId IdType="pubmed">23914750</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Yang R, Qi X, et al. . Association of lifespan cognitive reserve indicator with dementia risk in the presence of brain pathologies. JAMA Neurol. 2019;(July). doi:10.1001/jamaneurol.2019.2455</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.2455</ArticleId><ArticleId IdType="pmc">PMC6628596</ArticleId><ArticleId IdType="pubmed">31302677</ArticleId></ArticleIdList></Reference><Reference><Citation>Everson-Rose SA, Mendes de Leon CF, Bienias JL, Wilson RS, Evans DA. Early life conditions and cognitive functioning in later life. Am J Epidemiol. 2003;158(11):1083-1089. doi:10.1093/aje/kwg263</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwg263</ArticleId><ArticleId IdType="pubmed">14630604</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff RT, Hogan MJ, Whalley LJ. The influence of childhood intelligence, social class, education and social mobility on memory and memory decline in late life. Age Ageing. 2018;47(6):847-852. doi:10.1093/ageing/afy111</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afy111</ArticleId><ArticleId IdType="pmc">PMC6904326</ArticleId><ArticleId IdType="pubmed">30084877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gow AJ, Johnson W, Mishra G, Richards M, Kuh D, Deary IJ; HALCyon Study Team . Is age kinder to the initially more able? yes, and no. Intelligence. 2012;40(1):49-59. doi:10.1016/j.intell.2011.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intell.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3657153</ArticleId><ArticleId IdType="pubmed">23690652</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaza-Urquijo EM, Bejanin A, Gonneaud J, et al. . Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation. Neurobiol Aging. 2017;59:72-79. doi:10.1016/j.neurobiolaging.2017.06.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.06.016</ArticleId><ArticleId IdType="pubmed">28764930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu K, Nicholas JM, Collins JD, et al. . Cognition at age 70: life course predictors and associations with brain pathologies. Neurology. 2019;93(23):e2144-e2156. doi:10.1212/WNL.0000000000008534</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008534</ArticleId><ArticleId IdType="pmc">PMC6937487</ArticleId><ArticleId IdType="pubmed">31666352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchard TJ Jr, McGue M. Familial studies of intelligence: a review. Science. 1981;212(4498):1055-1059. doi:10.1126/science.7195071</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7195071</ArticleId><ArticleId IdType="pubmed">7195071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y-S, Long N, Pigino G, Brady ST, Lazarov O. Molecular mechanisms of environmental enrichment: impairments in Akt/GSK3&#x3b2;, neurotrophin-3 and CREB signaling. PLoS One. 2013;8(5):e64460. doi:10.1371/journal.pone.0064460</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064460</ArticleId><ArticleId IdType="pmc">PMC3660250</ArticleId><ArticleId IdType="pubmed">23700479</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer&#x2019;s disease. Brain. 2015;138(pt 10):2814-2833. doi:10.1093/brain/awv236</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv236</ArticleId><ArticleId IdType="pubmed">26283673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampit A, Hallock H, Valenzuela M. Computerized cognitive training in cognitively healthy older adults: a systematic review and meta-analysis of effect modifiers. PLoS Med. 2014;11(11):e1001756. doi:10.1371/journal.pmed.1001756</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001756</ArticleId><ArticleId IdType="pmc">PMC4236015</ArticleId><ArticleId IdType="pubmed">25405755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie SJ, Tucker-Drob EM. How much does education improve intelligence? a meta-analysis. Psychol Sci. 2018;29(8):1358-1369. doi:10.1177/0956797618774253</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0956797618774253</ArticleId><ArticleId IdType="pmc">PMC6088505</ArticleId><ArticleId IdType="pubmed">29911926</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaschke AC, Honing H, Scherder EJA. Longitudinal analysis of music education on executive functions in primary school children. Front Neurosci. 2018;12:103. doi:10.3389/fnins.2018.00103</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00103</ArticleId><ArticleId IdType="pmc">PMC5835523</ArticleId><ArticleId IdType="pubmed">29541017</ArticleId></ArticleIdList></Reference><Reference><Citation>Daley M. Head start: program and legislative update. J Pediatr Nurs. 1999;14(3):186-188. doi:10.1016/S0882-5963(99)80007-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0882-5963(99)80007-4</ArticleId><ArticleId IdType="pubmed">10394222</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips D, Gormley W, Anderson S. The effects of Tulsa&#x2019;s CAP Head Start program on middle-school academic outcomes and progress. Dev Psychol. 2016;52(8):1247-1261. doi:10.1037/dev0000151</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/dev0000151</ArticleId><ArticleId IdType="pubmed">27455186</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32612231</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>583</Volume><Issue>7816</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Physiological blood-brain transport is impaired with age by a shift in transcytosis.</ArticleTitle><Pagination><StartPage>425</StartPage><EndPage>430</EndPage><MedlinePgn>425-430</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2453-z</ELocationID><Abstract><AbstractText>The vascular interface&#xa0;of the brain, known as the blood-brain barrier (BBB), is understood to maintain brain function in part via its low transcellular permeability<sup>1-3</sup>. Yet, recent studies have demonstrated that brain ageing is sensitive to circulatory proteins<sup>4,5</sup>. Thus, it is unclear whether permeability to individually injected exogenous tracers-as is&#xa0;standard in BBB studies-fully represents blood-to-brain transport. Here we label hundreds of proteins constituting the mouse blood plasma proteome, and upon their systemic administration, study the BBB with its physiological ligand. We find that plasma proteins readily permeate the healthy brain parenchyma, with transport maintained by BBB-specific transcriptional programmes. Unlike IgG antibody, plasma protein uptake diminishes in the aged brain, driven by an age-related shift in transport from ligand-specific receptor-mediated to non-specific caveolar transcytosis. This age-related shift occurs alongside a specific loss of pericyte coverage. Pharmacological inhibition of the age-upregulated phosphatase ALPL, a predicted negative regulator of transport, enhances brain uptake of therapeutically relevant transferrin, transferrin receptor antibody and plasma. These findings reveal the extent of physiological protein transcytosis to the healthy brain, a mechanism of widespread BBB dysfunction with age and a strategy for enhanced drug delivery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-6756-4746</Identifier><AffiliationInfo><Affiliation>Department of Bioengineering, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ChEM-H, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Marc Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Michelle B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Davis P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xe4;hli</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gate</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0481-9657</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contrepois</LastName><ForeName>K&#xe9;vin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9678-5161</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Winnie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iram</LastName><ForeName>Tal</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lichao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vest</LastName><ForeName>Ryan T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical Engineering, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaney</LastName><ForeName>Aisling</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehallier</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Niclas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9746-0542</Identifier><AffiliationInfo><Affiliation>Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Calico Life Sciences LLC, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>du Bois</LastName><ForeName>Haley</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cropper</LastName><ForeName>Haley C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berdnik</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7452-3785</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lulin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Elizabeth Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traber</LastName><ForeName>Gavin M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0003-3494-9196</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertozzi</LastName><ForeName>Carolyn R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>ChEM-H, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2064-8467</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Administration Palo Alto Healthcare System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0003-0784-7987</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elias</LastName><ForeName>Joshua E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quake</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0002-1613-0809</Identifier><AffiliationInfo><Affiliation>Department of Bioengineering, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Michelle L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5893-0831</Identifier><AffiliationInfo><Affiliation>ChEM-H, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA200423</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HG007735</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 AG053015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG047126</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD025091</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM059907</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1RF1AG059694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>3P50HG00773505S1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM099608</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014168">Transferrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.1</RegistryNumber><NameOfSubstance UI="C510878">ALPL protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.1</RegistryNumber><NameOfSubstance UI="D000469">Alkaline Phosphatase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2020 Jul;583(7816):362-363. doi: 10.1038/d41586-020-01791-x.</RefSource><PMID Version="1">32661413</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000469" MajorTopicYN="N">Alkaline Phosphatase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006262" MajorTopicYN="N">Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057900" MajorTopicYN="Y">Transcytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014168" MajorTopicYN="N">Transferrin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b> C.R.B. is a co-founder and Scientific Advisory Board member of Palleon Pharmaceuticals, Enable Bioscience, InterVenn Bio and Redwood Bioscience (a subsidiary of Catalent), and a member of the Board of Directors of Eli Lilly and Company. T.W.-C. is a co-founder and scientific advisor of Alkahest Inc. T.W.-C. and A.C.Y. are co-inventors on a patent application related to the work published in this paper. N.O. is affiliated with Calico Life Sciences and has no financial interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32612231</ArticleId><ArticleId IdType="mid">NIHMS1700821</ArticleId><ArticleId IdType="pmc">PMC8331074</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2453-z</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-2453-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Obermeier B, Daneman R &amp; Ransohoff RM Development, maintenance and disruption of the blood&#x2013;brain barrier. Nat. Med 19, 1584&#x2013;1596 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4080800</ArticleId><ArticleId IdType="pubmed">24309662</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow BW &amp; Gu C The molecular constituents of the blood&#x2013;brain barrier. Trends Neurosci 38, 598&#x2013;608 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4597316</ArticleId><ArticleId IdType="pubmed">26442694</ArticleId></ArticleIdList></Reference><Reference><Citation>Profaci CP, Munji RN, Pulido RS &amp; Daneman R The blood&#x2013;brain barrier in health and disease: important unanswered questions. J. Exp. Med 217, e20190062 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144528</ArticleId><ArticleId IdType="pubmed">32211826</ArticleId></ArticleIdList></Reference><Reference><Citation>Conboy IM et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433, 760&#x2013;764 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15716955</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90&#x2013;94 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="pubmed">21886162</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders NR, Daneman R, Dziegielewska KM &amp; Liddelow SA Transporters of the blood&#x2013;brain and blood&#x2013;CSF interfaces in development and in the adult. Mol. Aspects Med 34, 742&#x2013;752 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23506907</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders NR et al. The rights and wrongs of blood&#x2013;brain barrier permeability studies: a walk through 100 years of history. Front. Neurosci 8, 404 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267212</ArticleId><ArticleId IdType="pubmed">25565938</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese TS &amp; Karnovsky MJ Fine structural localization of a blood&#x2013;brain barrier to exogenous peroxidase. J. Cell Biol 34, 207&#x2013;217 (1967).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2107213</ArticleId><ArticleId IdType="pubmed">6033532</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo JF, Curran GL &amp; Berg CT Macromolecular permeability across the blood&#x2013;nerve and blood&#x2013;brain barriers. Proc. Natl Acad. Sci. USA 91, 5705&#x2013;5709 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44065</ArticleId><ArticleId IdType="pubmed">8202551</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu YJ &amp; Watts RJ Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 10, 459&#x2013;472 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701773</ArticleId><ArticleId IdType="pubmed">23549647</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuchero YJY et al. Discovery of novel blood&#x2013;brain barrier targets to enhance brain uptake of therapeutic antibodies. Neuron 89, 70&#x2013;82 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26687840</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewoehner J et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49&#x2013;60 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24411731</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512&#x2013;516 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Zvi A et al. Mfsd2a is critical for the formation and function of the blood&#x2013;brain barrier. Nature 509, 507&#x2013;511 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134871</ArticleId><ArticleId IdType="pubmed">24828040</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R et al. The mouse blood&#x2013;brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS ONE 5, e13741 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966423</ArticleId><ArticleId IdType="pubmed">21060791</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandewijck M et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature 554, 475&#x2013;480 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29443965</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A et al. Blood&#x2013;brain barrier breakdown in the aging human hippocampus. Neuron 85, 296&#x2013;302 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4350773</ArticleId><ArticleId IdType="pubmed">25611508</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef H et al. Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Nat. Med 25, 988&#x2013;1000 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642642</ArticleId><ArticleId IdType="pubmed">31086348</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreone BJ et al. Blood&#x2013;brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis. Neuron 94, 581&#x2013;594.e5 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5474951</ArticleId><ArticleId IdType="pubmed">28416077</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A et al. Pericytes regulate the blood&#x2013;brain barrier. Nature 468, 557&#x2013;561 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller A et al. Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat. Genet 45, 1077&#x2013;1082 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23913003</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarb Y et al. Ossified blood vessels in primary familial brain calcification elicit a neurotoxic astrocyte response. Brain 142, 885&#x2013;902 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439320</ArticleId><ArticleId IdType="pubmed">30805583</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshed M, Harmey D, Millan JL, McKee MD &amp; Karsenty G Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 19, 1093&#x2013;1104 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1091743</ArticleId><ArticleId IdType="pubmed">15833911</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahl R et al. Discovery and validation of a series of aryl sulfonamides as selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP). J. Med. Chem 52, 6919&#x2013;6925 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783186</ArticleId><ArticleId IdType="pubmed">19821572</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A, Zhao Z &amp; Zlokovic BV Alzheimer&#x2019;s disease: a matter of blood&#x2013;brain barrier dysfunction? J. Exp. Med 214, 3151&#x2013;3169 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5679168</ArticleId><ArticleId IdType="pubmed">29061693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nat. Rev. Neurosci 12, 723&#x2013;738 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MA, Ryu JK &amp; Akassoglou K Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat. Rev. Neurosci 19, 283&#x2013;301 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6743980</ArticleId><ArticleId IdType="pubmed">29618808</ArticleId></ArticleIdList></Reference><Reference><Citation>Erd&#x151; F, Denes L &amp; de Lange E Age-associated physiological and pathological changes at the blood&#x2013;brain barrier: a review. J. Cereb. Blood Flow Metab 37, 4&#x2013;24 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363756</ArticleId><ArticleId IdType="pubmed">27837191</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Zhou L, Kebede AA &amp; Barres BA Pericytes are required for blood&#x2013;brain barrier integrity during embryogenesis. Nature 468, 562&#x2013;566 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241506</ArticleId><ArticleId IdType="pubmed">20944625</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CN et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature 508, 55&#x2013;60 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976267</ArticleId><ArticleId IdType="pubmed">24670647</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardy ERLC, Kellett KAB, Cocklin SL &amp; Hooper NM Alkaline phosphatase is increased in both brain and plasma in Alzheimer&#x2019;s disease. Neurodegener. Dis 9, 31&#x2013;37 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22024719</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Deane R, Sagare AP, Bell RD &amp; Winkler EA Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer&#x2019;s amyloid &#x3b2;-peptide elimination from the brain. J. Neurochem 115, 1077&#x2013;1089 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972355</ArticleId><ArticleId IdType="pubmed">20854368</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC et al. Multiple click-selective tRNA synthetases expand mammalian cell-specific proteomics. J. Am. Chem. Soc 140, 7046&#x2013;7051 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6598694</ArticleId><ArticleId IdType="pubmed">29775058</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CS et al. Ultrasensitive proteome analysis using paramagnetic bead technology. Mol. Syst. Biol 10, 757 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299378</ArticleId><ArticleId IdType="pubmed">25358341</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J &amp; Mann M MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol 26, 1367&#x2013;1372 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyanova S, Temu T &amp; Cox J The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat. Protoc 11, 2301&#x2013;2319 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27809316</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM et al. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature 544, 488&#x2013;492 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5586222</ArticleId><ArticleId IdType="pubmed">28424512</ArticleId></ArticleIdList></Reference><Reference><Citation>Treweek JB et al. Whole-body tissue stabilization and selective extractions via tissue-hydrogel hybrids for high-resolution intact circuit mapping and phenotyping. Nat. Protoc 10, 1860&#x2013;1896 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4917295</ArticleId><ArticleId IdType="pubmed">26492141</ArticleId></ArticleIdList></Reference><Reference><Citation>Tournoux F et al. Validation of noninvasive measurements of cardiac output in mice using echocardiography. J. Am. Soc. Echocardiogr 24, 465&#x2013;470 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077062</ArticleId><ArticleId IdType="pubmed">21315557</ArticleId></ArticleIdList></Reference><Reference><Citation>Dom&#xed;nguez E et al. Non-invasive in vivo measurement of cardiac output in C57BL/6 mice using high frequency transthoracic ultrasound: evaluation of gender and body weight effects. Int. J. Cardiovasc. Imaging 30, 1237&#x2013;1244 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24852337</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat. Med 20, 659&#x2013;663 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell SA, Staines WA &amp; Wessendorf MW Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J. Histochem. Cytochem 47, 719&#x2013;730 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10330448</ArticleId></ArticleIdList></Reference><Reference><Citation>Triguero D, Buciak J &amp; Pardridge WM Capillary depletion method for quantification of blood&#x2013;brain barrier transport of circulating peptides and plasma proteins. J. Neurochem 54, 1882&#x2013;1888 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2338547</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh I et al. Low levels of copper disrupt brain amyloid-&#x3b2; homeostasis by altering its production and clearance. Proc. Natl Acad. Sci. USA 110, 14771&#x2013;14776 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3767519</ArticleId><ArticleId IdType="pubmed">23959870</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris-Robidas S, Brouard D, Emond V, Parent M &amp; Calon F Internalization of targeted quantum dots by brain capillary endothelial cells in vivo. J. Cereb. Blood Flow Metab 36, 731&#x2013;742 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820005</ArticleId><ArticleId IdType="pubmed">26661181</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston JE, al-Sarraf H &amp; Segal MB Permeability of the developing blood&#x2013;brain barrier to 14C-mannitol using the rat in situ brain perfusion technique. Brain Res. Dev. Brain Res 87, 69&#x2013;76 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7554234</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan M, Cochran DB, Yokel RA &amp; Dziubla TD Binding, transcytosis and biodistribution of anti-PECAM-1 iron oxide nanoparticles for brain-targeted delivery. PLoS ONE 8, e81051 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3835573</ArticleId><ArticleId IdType="pubmed">24278373</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulay AC, Saubam&#xe9;a B, Decl&#xe8;ves X &amp; Cohen-Salmon M Purification of mouse brain vessels. J. Vis. Exp 105, e53208 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692710</ArticleId><ArticleId IdType="pubmed">26574794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira CL et al. Comparison of bifunctional chelates for 64Cu antibody imaging. Eur. J. Nucl. Med. Mol. Imaging 37, 2117&#x2013;2126 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20552190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilovich O et al. Development and validation of an immuno-PET tracer as a companion diagnostic agent for antibody&#x2013;drug conjugate therapy to target the CA6 epitope. Radiology 276, 191&#x2013;198 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4570559</ArticleId><ArticleId IdType="pubmed">25734548</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaney A et al. 11C-DPA-713 versus 18F-GE-180: a preclinical comparison of translocator protein 18 kDa PET tracers to visualize acute and chronic neuroinflammation in a mouse model of ischemic stroke. J. Nucl. Med 60, 122&#x2013;128 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354224</ArticleId><ArticleId IdType="pubmed">29976695</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaney AM, Johnson EM, Cropper HC &amp; James ML PET imaging of neuroinflammation using [11C]DPA-713 in a mouse model of ischemic stroke. J. Vis. Exp 136, 57243 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6101726</ArticleId><ArticleId IdType="pubmed">29985311</ArticleId></ArticleIdList></Reference><Reference><Citation>James ML et al. New positron emission tomography (PET) radioligand for imaging &#x3c3;-1 receptors in living subjects. J. Med. Chem 55, 8272&#x2013;8282 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106900</ArticleId><ArticleId IdType="pubmed">22853801</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabula Muris Consortium. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature 562, 367&#x2013;372 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642641</ArticleId><ArticleId IdType="pubmed">30283141</ArticleId></ArticleIdList></Reference><Reference><Citation>Picelli S et al. Full-length RNA-seq from single cells using Smart-seq2. Nat. Protoc 9, 171&#x2013;181 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24385147</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu AR et al. Quantitative assessment of single-cell RNA-sequencing methods. Nat. Methods 11, 41&#x2013;46 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022966</ArticleId><ArticleId IdType="pubmed">24141493</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MB et al. Brain endothelial cells are exquisite sensors of age-related circulatory cues. Cell Rep 30, 4418&#x2013;4432.e4 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292569</ArticleId><ArticleId IdType="pubmed">32234477</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q et al. Developmental heterogeneity of microglia and brain myeloid cells revealed by deep single-cell RNA sequencing. Neuron 101, 207&#x2013;223.e10 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsafrir D et al. Sorting points into neighborhoods (SPIN): data analysis and visualization by ordering distance matrices. Bioinformatics 21, 2301&#x2013;2308 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15722375</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagida K et al. Size-selective opening of the blood&#x2013;brain barrier by targeting endothelial sphingosine 1-phosphate receptor 1. Proc. Natl Acad. Sci. USA 114, 4531&#x2013;4536 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5410849</ArticleId><ArticleId IdType="pubmed">28396408</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E &amp; Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluvinage JV et al. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature 568, 187&#x2013;192 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6574119</ArticleId><ArticleId IdType="pubmed">30944478</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;. Sci. Transl. Med 4, 147ra111 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Xavier ALR et al. Cannula implantation into the cisterna magna of rodents. J. Vis. Exp 135, 57378 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6101354</ArticleId><ArticleId IdType="pubmed">29889209</ArticleId></ArticleIdList></Reference><Reference><Citation>Renier N et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159, 896&#x2013;910 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25417164</ArticleId></ArticleIdList></Reference><Reference><Citation>Cajka T, Smilowitz JT &amp; Fiehn O Validating quantitative untargeted lipidomics across nine liquid chromatography-high-resolution mass spectrometry platforms. Anal. Chem 89, 12360&#x2013;12368 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29064229</ArticleId></ArticleIdList></Reference><Reference><Citation>Contrepois K et al. Cross-platform comparison of untargeted and targeted lipidomics approaches on aging mouse plasma. Sci. Rep 8, 17747 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6288111</ArticleId><ArticleId IdType="pubmed">30532037</ArticleId></ArticleIdList></Reference><Reference><Citation>Zemski Berry KA, Murphy RC, Kosmider B &amp; Mason RJ Lipidomic characterization and localization of phospholipids in the human lung. J. Lipid Res 58, 926&#x2013;933 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408611</ArticleId><ArticleId IdType="pubmed">28280112</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J et al. Long-term cognitive impairments and pathological alterations in a mouse model of repetitive mild traumatic brain injury. Front. Neurol 5, 12 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912443</ArticleId><ArticleId IdType="pubmed">24550885</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadakkuzha BM et al. Transcriptome analyses of adult mouse brain reveal enrichment of lncRNAs in specific brain regions and neuronal populations. Front. Cell. Neurosci 9, 63 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351618</ArticleId><ArticleId IdType="pubmed">25798087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K et al. Cell type- and brain region-resolved mouse brain proteome. Nat. Neurosci 18, 1819&#x2013;1831 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116867</ArticleId><ArticleId IdType="pubmed">26523646</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougherty JD, Schmidt EF, Nakajima M &amp; Heintz N Analytical approaches to RNA profiling data for the identification of genes enriched in specific cells. Nucleic Acids Res 38, 4218&#x2013;4230 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910036</ArticleId><ArticleId IdType="pubmed">20308160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M et al. Gene Ontology: tool for the unification of biology. Nat. Genet 25, 25&#x2013;29 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris MA et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 32, D258&#x2013;D261 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308770</ArticleId><ArticleId IdType="pubmed">14681407</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XD et al. Traumatic brain injury imaging in the second near-infrared window with a molecular fluorophore. Adv. Mater 28, 6872&#x2013;6879 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5293734</ArticleId><ArticleId IdType="pubmed">27253071</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiick KL, Saxon E, Tirrell DA &amp; Bertozzi CR Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation. Proc. Natl Acad. Sci. USA 99, 19&#x2013;24 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117506</ArticleId><ArticleId IdType="pubmed">11752401</ArticleId></ArticleIdList></Reference><Reference><Citation>Calve S, Witten AJ, Ocken AR &amp; Kinzer-Ursem TL Incorporation of non-canonical amino acids into the developing murine proteome. Sci. Rep 6, 32377 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5004113</ArticleId><ArticleId IdType="pubmed">27572480</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu AP, Aguet F, Danuser G &amp; Schmid SL Local clustering of transferrin receptors promotes clathrin-coated pit initiation. J. Cell Biol 191, 1381&#x2013;1393 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010081</ArticleId><ArticleId IdType="pubmed">21187331</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K et al. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89&#x2013;93 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer&#x2019;s disease. Nature 560, 185&#x2013;191 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085146</ArticleId><ArticleId IdType="pubmed">30046111</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs SBA et al. GeneAnalytics: an integrative gene set analysis tool for next generation sequencing, RNAseq and microarray data. OMICS 20, 139&#x2013;151 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4799705</ArticleId><ArticleId IdType="pubmed">26983021</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden E, Navon R, Steinfeld I, Lipson D &amp; Yakhini Z GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10, 48 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644678</ArticleId><ArticleId IdType="pubmed">19192299</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders NR, Dziegielewska KM, M&#xf8;llg&#xe5;rd K &amp; Habgood MD Physiology and molecular biology of barrier mechanisms in the fetal and neonatal brain. J. Physiol. (Lond.) 596, 5723&#x2013;5756 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6265560</ArticleId><ArticleId IdType="pubmed">29774535</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Nelson AR, Betsholtz C &amp; Zlokovic BV Establishment and dysfunction of the blood&#x2013;brain barrier. Cell 163, 1064&#x2013;1078 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655822</ArticleId><ArticleId IdType="pubmed">26590417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ximerakis M et al. Single-cell transcriptomic profiling of the aging mouse brain. Nat. Neurosci 22, 1696&#x2013;1708 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31551601</ArticleId></ArticleIdList></Reference><Reference><Citation>Simionescu M et al. The cerebral microvasculature of the rat: structure and luminal surface properties during early development. J. Submicrosc. Cytol. Pathol 20, 243&#x2013;261 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3395964</ArticleId></ArticleIdList></Reference><Reference><Citation>Herv&#xe9; F, Ghinea N &amp; Scherrmann J-M CNS delivery via adsorptive transcytosis. AAPS J 10, 455&#x2013;472 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761699</ArticleId><ArticleId IdType="pubmed">18726697</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbagh MF et al. Transcriptional and epigenomic landscapes of CNS and non-CNS vascular endothelial cells. eLife 7, e36187 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6126923</ArticleId><ArticleId IdType="pubmed">30188322</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37&#x2013;53 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Thul PJ et al. A subcellular map of the human proteome. Science 356, eaal3321 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28495876</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat. Genet 41, 1088&#x2013;1093 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32615087</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>182</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Microglial Remodeling of the Extracellular Matrix Promotes Synapse Plasticity.</ArticleTitle><Pagination><StartPage>388</StartPage><EndPage>403.e15</EndPage><MedlinePgn>388-403.e15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2020.05.050</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(20)30683-8</ELocationID><Abstract><AbstractText>Synapse remodeling is essential to encode experiences into neuronal circuits. Here, we define a molecular interaction between neurons and microglia that drives experience-dependent synapse remodeling in the hippocampus. We find that the cytokine interleukin-33 (IL-33) is expressed by adult hippocampal neurons in an experience-dependent manner and defines a neuronal subset primed for synaptic plasticity. Loss of neuronal IL-33 or the microglial IL-33 receptor leads to impaired spine plasticity, reduced newborn neuron integration, and diminished precision of remote fear memories. Memory precision and neuronal IL-33 are decreased in aged mice, and IL-33 gain of function mitigates age-related decreases in spine plasticity. We find that neuronal IL-33 instructs microglial engulfment of the extracellular matrix (ECM) and that its loss leads to impaired ECM engulfment and a concomitant accumulation of ECM proteins in contact with synapses. These data define a cellular mechanism through which microglia regulate experience-dependent synapse remodeling and promote memory consolidation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Phi T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorman</LastName><ForeName>Leah C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vainchtein</LastName><ForeName>Ilia D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Rafael T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakao-Inoue</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taloma</LastName><ForeName>Sunrae E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barron</LastName><ForeName>Jerika J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molofsky</LastName><ForeName>Ari B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kheirbek</LastName><ForeName>Mazen A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; Kavli Institute for Fundamental Neuroscience, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molofsky</LastName><ForeName>Anna V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; Kavli Institute for Fundamental Neuroscience, University of California, San Francisco, San Francisco, CA, USA. Electronic address: anna.molofsky@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH108623</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH117961</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 MH116507</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH119349</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH111754</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072179">Interleukin-1 Receptor-Like 1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067596">Interleukin-33</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2020 Jul 23;182(2):265-267. doi: 10.1016/j.cell.2020.06.042.</RefSource><PMID Version="1">32707091</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2020 Sep;21(9):449. doi: 10.1038/s41583-020-0356-5.</RefSource><PMID Version="1">32733063</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005109" MajorTopicYN="N">Extracellular Matrix</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072179" MajorTopicYN="N">Interleukin-1 Receptor-Like 1 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067596" MajorTopicYN="N">Interleukin-33</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">microglia, hippocampus, extracellular matrix, aging, memory, dendrite remodeling, interleukin-33</Keyword></KeywordList><CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32615087</ArticleId><ArticleId IdType="mid">NIHMS1599965</ArticleId><ArticleId IdType="pmc">PMC7497728</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.05.050</ArticleId><ArticleId IdType="pii">S0092-8674(20)30683-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alvarez DD, Giacomini D, Yang SM, Trinchero MF, Temprana SG, B&#xfc;ttner KA, Beltramone N, and Schinder AF (2016). A disynaptic feed-back network activated by experience promotes the integration of new granule cells. Science 354, 459&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">27789840</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Pyl PT, and Huber W (2015). HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287950</ArticleId><ArticleId IdType="pubmed">25260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbolina MV, and Stack MS (2008). Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin. Cell Dev. Biol. 19, 24&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685078</ArticleId><ArticleId IdType="pubmed">17702616</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al. (2013). NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 41,D991&#x2013;D995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu R, Duan X, Taylor MR, Martin EA, Muralidhar S, Wang Y, Gangi-Wellman L, Das SC, Yamagata M, West PJ, et al. (2017). Heterophilic Type II Cadherins Are Required for High-Magnitude Synaptic Potentiation in the Hippocampus. Neuron 96, 160&#x2013;176.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5634529</ArticleId><ArticleId IdType="pubmed">28957665</ArticleId></ArticleIdList></Reference><Reference><Citation>Bednarek E, and Caroni P (2011). &#x3b2;-Adducin is required for stable assembly of new synapses and improved memory upon environmental enrichment. Neuron 69, 11321146.</Citation><ArticleIdList><ArticleId IdType="pubmed">21435558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett FC, and Molofsky AV (2019). The immune system and psychiatric disease: a basic science perspective. Clin. Exp. Immunol. 197, 294&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6693968</ArticleId><ArticleId IdType="pubmed">31125426</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergami M, Masserdotti G, Temprana SG, Motori E, Eriksson TM, G&#xf6;bel J, Yang SM, Conzelmann K-K, Schinder AF, G&#xf6;tz M, and Berninger B (2015). A critical period for experience-dependent remodeling of adult-born neuron connectivity. Neuron 85, 710&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">25661179</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessa J, Meyer CA, deVera Mudry MC, Schlicht S, Smith SH, Iglesias A , and Cote-Sierra J (2014). Altered subcellular localization of IL-33 leads to nonresolving lethal inflammation. J. Autoimmun. 55, 33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">24786898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol&#xf3;s M, Perea JR, Terreros-Roncal J, Pallas-Bazarra N, Jurado-Arjona J, &#xc1;vila J, and Llorens-Mart&#xed;n M (2018). Absence of microglial CX3CR1 impairs the synaptic integration of adult-born hippocampal granule neurons. Brain Behav. Immun. 68, 76&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">29017970</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnans C, Chou J, and Werb Z (2014). Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 15, 786&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4316204</ArticleId><ArticleId IdType="pubmed">25415508</ArticleId></ArticleIdList></Reference><Reference><Citation>Breton-Provencher V, Bakhshetyan K, Hardy D, Bammann RR, Cavarretta F, Snapyan M, C&#xf4;t&#xe9; D, Migliore M, and Saghatelyan A (2016). Principal cell activity induces spine relocation of adult-born interneurons in the olfactory bulb. Nat. Commun. 7, 12659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013674</ArticleId><ArticleId IdType="pubmed">27578235</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, and Satija R (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai DJ, Aharoni D, Shuman T, Shobe J, Biane J, Song W, Wei B, Veshkini M, La-Vu M, Lou J, et al. (2016). A shared neural ensemble links distinct contextual memories encoded close in time. Nature 534, 115&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5063500</ArticleId><ArticleId IdType="pubmed">27251287</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W-Y, Hong J, Gannon J, Kakkar R, and Lee RT (2015). Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proc. Natl. Acad. Sci. USA 112, 7249&#x2013;7254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4466705</ArticleId><ArticleId IdType="pubmed">25941360</ArticleId></ArticleIdList></Reference><Reference><Citation>Danielson NBB, Kaifosh P, Zaremba JDD, Lovett-Barron M, Tsai J, Denny CA, Balough EM, Goldberg AR, Drew LJ, Hen R, et al. (2016). Distinct Contribution of Adult-Born Hippocampal Granule Cells to Context Encoding. Neuron 90, 101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962695</ArticleId><ArticleId IdType="pubmed">26971949</ArticleId></ArticleIdList></Reference><Reference><Citation>deVivo L, Landi S, Panniello M, Baroncelli L, Chierzi S, Mariotti L, Spolidoro M, Pizzorusso T, Maffei L, and Ratto GM (2013). Extracellular matrix inhibits structural and functional plasticity of dendritic spines in the adult visual cortex. Nat. Commun. 4, 1484.</Citation><ArticleIdList><ArticleId IdType="pubmed">23403561</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny CA, Kheirbek MA, Alba EL, Tanaka KF, Brachman RA, Laugh-man KB, Tomm NK, Turi GF, Losonczy A, and Hen R (2014). Hippocampal memory traces are differentially modulated by experience, time, and adult neurogenesis. Neuron 83, 189&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169172</ArticleId><ArticleId IdType="pubmed">24991962</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Dranovsky A, Picchini AM, Moadel T, Sisti AC, Yamada A, Kimura S, Leonardo ED, and Hen R (2011). Experience dictates stem cell fate in the adult hippocampus. Neuron 70, 908&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124009</ArticleId><ArticleId IdType="pubmed">21658584</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan X, Krishnaswamy A, Laboulaye MA, Liu J, Peng YR, Yamagata M, Toma K, and Sanes JR (2018). Cadherin Combinations Recruit Dendrites of Distinct Retinal Neurons to a Shared Interneuronal Scaffold. Neuron 99, 1145&#x2013;1154.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6284407</ArticleId><ArticleId IdType="pubmed">30197236</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyo UB, Peng J, Swiatkowski P, Mukherjee A, Bispo A, and Wu L-J (2014). Neuronal hyperactivity recruits microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus. J. Neurosci. 34, 10528&#x2013;10540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4200107</ArticleId><ArticleId IdType="pubmed">25100587</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyo UB, Gu N, De S, Dong H, Richardson JR, and Wu LJ (2015). Modulation of microglial process convergence toward neuronal dendrites by extracellular calcium. J. Neurosci. 35, 2417&#x2013;2422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4323526</ArticleId><ArticleId IdType="pubmed">25673836</ArticleId></ArticleIdList></Reference><Reference><Citation>Favuzzi E, Marques-Smith A, Deogracias R, Winterflood CM, S&#xe1;nchez-Aguilera A, Mantoan L, Maeso P, Fernandes C, Ewers H, and Rico B (2017). Activity-Dependent Gating of Parvalbumin Interneuron Function by the Perineuronal Net Protein Brevican. Neuron 95, 639&#x2013;655.e10.</Citation><ArticleIdList><ArticleId IdType="pubmed">28712654</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, Slichter CK, Miller HW, McElrath MJ, Prlic M, et al. (2015). MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Frischknecht R, Heine M, Perrais D, Seidenbecher CI, Choquet D, and Gundelfinger ED (2009). Brain extracellular matrix affects AMPA receptor lateral mobility and short-term synaptic plasticity. Nat. Neurosci. 12, 897&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">19483686</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu AKYY, Hung K-WW, Yuen MYFF, Zhou X, Mak DSYY, Chan ICWW, Cheung TH, Zhang B, Fu W-YY, Liew FY, and Ip NY (2016). IL-33 ameliorates Alzheimer&#x2019;s disease-like pathology and cognitive decline. Proc. Natl. Acad. Sci. USA 113, E2705&#x2013;E2713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4868478</ArticleId><ArticleId IdType="pubmed">27091974</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF, Vainchtein ID, Brouwer N, Boddeke EWGM, and Eggen BJL (2017). Isolation of Microglia and Immune Infiltrates from Mouse and Primate Central Nervous System. Methods Mol. Biol. 1559, 333&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">28063055</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak NJ, Joyner A, Leblanc G, Hatten ME, and Heintz N (2003). A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425, 917&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">14586460</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo N, Soden ME, Herber C, Kim MT, Besnard A, Lin P, Ma X, Cepko CL, Zweifel LS, and Sahay A (2018). Dentate granule cell recruitment of feedforward inhibition governs engram maintenance and remote memory generalization. Nat. Med. 24, 438&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893385</ArticleId><ArticleId IdType="pubmed">29529016</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J-H, Kushner SA, Yiu AP, Cole CJ, Matynia A, Brown RA, Neve RL, Guzowski JF, Silva AJ, and Josselyn SA (2007). Neuronal Competition and Selection During Memory Formation. Science 316, 457&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">17446403</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanawa-Suetsugu K, Itoh Y, Ab Fatah M, Nishimura T, Takemura K, Takeshita K, Kubota S, Miyazaki N, Wan Mohamad Noor WNI, Inaba T, et al. (2019). Phagocytosis is mediated by two-dimensional assemblies of the F-BAR protein GAS7. Nat. Commun. 10, 4763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802115</ArticleId><ArticleId IdType="pubmed">31628328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibi D, Takuma K, Koike H, Mizoguchi H, Tsuritani K, Kuwahara Y, Kamei H, Nagai T, Yoneda Y, Nabeshima T, and Yamada K (2008). Social isolation rearinginduced impairment of the hippocampal neurogenesis is associated with deficits in spatial memory and emotion-related behaviors in juvenile mice. J. Neurochem. 105, 921&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">18182044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ippolito DM, and Eroglu C (2010). Quantifying synapses: an immunocyto-chemistrybased assay to quantify synapse number. J. Vis. Exp. (45), 2270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159596</ArticleId><ArticleId IdType="pubmed">21113117</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger BN, Linker SB, Parylak SL, Barron JJ, Gallina IS, Saavedra CD, Fitzpatrick C, Lim CK, Schafer ST, Lacar B, et al. (2018). A novel environment-evoked transcriptional signature predicts reactivity in single dentate granule neurons. Nat. Commun. 9, 3084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6079101</ArticleId><ArticleId IdType="pubmed">30082781</ArticleId></ArticleIdList></Reference><Reference><Citation>Josselyn SA, and Tonegawa S (2020). Memory engrams: Recalling the past and imagining the future. Science 367, eaaw4325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577560</ArticleId><ArticleId IdType="pubmed">31896692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko M, Stellwagen D, Malenka RC, and Stryker MP (2008). Tumor necrosis factor-&#x3b1; mediates one component of competitive, experience-dependent plasticity in developing visual cortex. Neuron 58, 673&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884387</ArticleId><ArticleId IdType="pubmed">18549780</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley KW, Nakao-Inoue H, Molofsky AV, and Oldham MC (2018). Variation among intact tissue samples reveals the core transcriptional features of human CNS cell classes. Nat. Neurosci. 21, 1171&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192711</ArticleId><ArticleId IdType="pubmed">30154505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelwick R, Desanlis I, Wheeler GN, and Edwards DR (2015). The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family. Genome Biol. 16, 113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4448532</ArticleId><ArticleId IdType="pubmed">26025392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG, and Gage FH (1997). More hippocampal neurons in adult mice living in an enriched environment. Nature 386, 493&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">9087407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheirbek MA, Tannenholz L, and Hen R (2012). NR2B-dependent plasticity of adult-born granule cells is necessary for context discrimination. J. Neurosci. 32, 8696&#x2013;8702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388607</ArticleId><ArticleId IdType="pubmed">22723709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura T, Ogawa SK, Roy DS, Okuyama T, Morrissey MD, Smith LM, Redondo RL, and Tonegawa S (2017). Engrams and circuits crucial for systems consolidation of a memory. Science 356, 73&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5493329</ArticleId><ArticleId IdType="pubmed">28386011</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoferle J, Yoon SY, Walker D, Leung L, Gillespie AK, Tong LM, Bien-Ly N, and Huang Y (2014). Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice. J. Neurosci. 34, 14069&#x2013;14078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198545</ArticleId><ArticleId IdType="pubmed">25319703</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Brott BK, Kirkby LA, Adelson JD, Cheng S, Feller MB, Datwani A, and Shatz CJ (2014). Synapse elimination and learning rules co-regulated by MHC class I H2-Db. Nature 509, 195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016165</ArticleId><ArticleId IdType="pubmed">24695230</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy AD, Omar MH, and Koleske AJ (2014). Extracellular matrix control of dendritic spine and synapse structure and plasticity in adulthood. Front. Neuroanat. 8, 116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4202714</ArticleId><ArticleId IdType="pubmed">25368556</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Du X-FF, Liu C-SS, Wen Z-LL, and Du J-LL (2012). Reciprocal regulation between resting microglial dynamics and neuronal activity in vivo. Dev. Cell 23, 1189&#x2013;1202.</Citation><ArticleIdList><ArticleId IdType="pubmed">23201120</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Ramirez S, Pang PT, Puryear CB, Govindarajan A, Deisseroth K, and Tonegawa S (2012). Optogenetic stimulation of a hippocampal engram activates fear memory recall. Nature 484, 381&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331914</ArticleId><ArticleId IdType="pubmed">22441246</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, and Anders S (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Madry C, Kyrargyri V, Arancibia-Carcamo IL, Jolivet R, Kohsaka S, Bryan RM, and Attwell D (2018). Microglial Ramification, Surveillance, and Interleukin-1&#x3b2; Release Are Regulated by the Two-Pore Domain K+ Channel THIK-1. Neuron 97, 299312.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783715</ArticleId><ArticleId IdType="pubmed">29290552</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer J, Hamel MG, and Gottschall PE (2005). Evidence for proteolytic cleavage of brevican by the ADAMTSs in the dentate gyrus after excitotoxic lesion of the mouse entorhinal cortex. BMC Neurosci. 6, 52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1199600</ArticleId><ArticleId IdType="pubmed">16122387</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh TJ, Jones MW, Quinn JJ, Balthasar N, Coppari R, Elmquist JK, Lowell BB, Fanselow MS, Wilson MA, and Tonegawa S (2007). Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network. Science 317, 94&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556551</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SM, and Sahay A (2019). Functions of adult-born neurons in hippocampal memory interference and indexing. Nat. Neurosci. 22, 1565&#x2013;1575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7397477</ArticleId><ArticleId IdType="pubmed">31477897</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto A, Wake H, Ishikawa AW, Eto K, Shibata K, Murakoshi H, Koizumi S, Moorhouse AJ, Yoshimura Y, and Nabekura J (2016). Microglia contact induces synapse formation in developing somatosensory cortex. Nat. Commun. 7, 12540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007295</ArticleId><ArticleId IdType="pubmed">27558646</ArticleId></ArticleIdList></Reference><Reference><Citation>Molofsky AV, Kelley KW, Tsai H-H, Redmond SA, Chang SM, Madireddy L, Chan JR, Baranzini SE, Ullian EM, and Rowitch DH (2014). Astrocyte-encoded positional cues maintain sensorimotor circuit integrity. Nature 509, 189&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057936</ArticleId><ArticleId IdType="pubmed">24776795</ArticleId></ArticleIdList></Reference><Reference><Citation>Molofsky AB, Savage AK, and Locksley RM (2015). Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation. Immunity 42, 1005&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4471869</ArticleId><ArticleId IdType="pubmed">26084021</ArticleId></ArticleIdList></Reference><Reference><Citation>Naba A, Clauser KR, Ding H, Whittaker CA, Carr SA, and Hynes RO (2016). The extracellular matrix: Tools and insights for the &#x201c;omics&#x201d; era. Matrix Biol. 49, 10&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013529</ArticleId><ArticleId IdType="pubmed">26163349</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashiba T, Cushman JD, Pelkey KA, Renaudineau S, Buhl DL, McHugh TJ, Rodriguez Barrera V, Chittajallu R, Iwamoto KS, McBain CJ, et al. (2012). Young dentate granule cells mediate pattern separation, whereas old granule cells facilitate pattern completion. Cell 149, 188&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319279</ArticleId><ArticleId IdType="pubmed">22365813</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh MM, Oliveira FA, and Disterhoft JF (2010). Learning and aging related changes in intrinsic neuronal excitability. Front. Aging Neurosci. 2, 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874400</ArticleId><ArticleId IdType="pubmed">20552042</ArticleId></ArticleIdList></Reference><Reference><Citation>Oray S, Majewska A, and Sur M (2004). Dendritic spine dynamics are regulated by monocular deprivation and extracellular matrix degradation. Neuron 44, 1021&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">15603744</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlando C, Ster J, Gerber U, Fawcett JW, and Raineteau O (2012). Perisynaptic chondroitin sulfate proteoglycans restrict structural plasticity in an integrin-dependent manner. J. Neurosci. 32, 18009&#x2013;18017, 18017a.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621736</ArticleId><ArticleId IdType="pubmed">23238717</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer G, and Gabay C (2011). Interleukin-33 biology with potential insights into human diseases. Nat. Rev. Rheumatol. 7, 321&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">21519352</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan S, Mayoral SR, Choi HS, Chan JR, and Kheirbek MA (2020). Preservation of a remote fear memory requires new myelin formation. Nat. Neurosci. 23, 487&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7213814</ArticleId><ArticleId IdType="pubmed">32042175</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, et al. (2011). Synaptic pruning by microglia is necessary for normal brain development. Science 333,1456&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Kramer EE, Mercaldo V, Rashid AJ, Insel N, Frankland PW, and Josselyn SA (2016). Neuronal Allocation to a Hippocampal Engram. Neuropsychopharmacology 41, 2987&#x2013;2993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5101572</ArticleId><ArticleId IdType="pubmed">27187069</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR 3rd, Lafaille JJ, Hempstead BL, Littman DR, and Gan W-B (2013). Microglia promote learningdependent synapse formation through brain-derived neurotrophic factor. Cell 155, 15961609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Pikkarainen T, Br&#xe4;nnstr&#xf6;m A, and Tryggvason K (1999). Expression of macrophage MARCO receptor induces formation of dendritic plasma membrane processes. J. Biol. Chem. 274, 10975&#x2013;10982.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196178</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzorusso T, Medini P, Landi S, Baldini S, Berardi N, and Maffei L (2006). Structural and functional recovery from early monocular deprivation in adult rats. Proc. Natl. Acad. Sci. USA 103, 8517&#x2013;8522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1482523</ArticleId><ArticleId IdType="pubmed">16709670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan KR, Ressler RL, Jin J, and Maren S (2018). Nucleus reuniens is required for encoding and retrieving precise, hippocampal-dependent contextual fear memories in rats. J. Neurosci. 38, 9925&#x2013;9933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234294</ArticleId><ArticleId IdType="pubmed">30282726</ArticleId></ArticleIdList></Reference><Reference><Citation>Rempe D, Vangeison G, Hamilton J, Li Y, Jepson M, and Federoff HJ (2006). Synapsin I Cre transgene expression in male mice produces germline recombination in progeny. Genesis 44, 44&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">16419044</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards DA, Mateos JM, Hugel S, de Paola V, Caroni P, G&#xe4;hwiler BH, and McKinney RA (2005). Glutamate induces the rapid formation of spine head protrusions in hippocampal slice cultures. Proc. Natl. Acad. Sci. USA 102,6166&#x2013;6171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556130</ArticleId><ArticleId IdType="pubmed">15831587</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowlands D, Lensj0 KK Dinh T, Yang S, Andrews MR, Hafting T, Fyhn M, Fawcett JW, and Dick G (2018). Aggrecan directs extracellular matrix-mediated neuronal plasticity. J. Neurosci. 38, 10102&#x2013;10113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6596198</ArticleId><ArticleId IdType="pubmed">30282728</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy DS, Arons A, Mitchell TI, Pignatelli M, Ryan TJ, and Tonegawa S (2016). Memory retrieval by activating engram cells in mouse models of early Alzheimer&#x2019;s disease. Nature 531, 508&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4847731</ArticleId><ArticleId IdType="pubmed">26982728</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy DS, Muralidhar S, Smith LM, and Tonegawa S (2017). Silent memory engrams as the basis for retrograde amnesia. Proc. Natl. Acad. Sci. USA 114, E9972E9979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5699085</ArticleId><ArticleId IdType="pubmed">29078397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan TJ, Roy DS, Pignatelli M, Arons A, and Tonegawa S (2015). Memory. Engram cells retain memory under retrograde amnesia. Science 348, 1007&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5583719</ArticleId><ArticleId IdType="pubmed">26023136</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahay A, Scobie KN, Hill AS, O&#x2019;Carroll CM, Kheirbek MA, Burghardt NS, Fenton AA, Dranovsky A, and Hen R (2011). Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature 472, 466&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084370</ArticleId><ArticleId IdType="pubmed">21460835</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija R, Farrell JA, Gennert D, Schier AF, and Regev A (2015). Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430369</ArticleId><ArticleId IdType="pubmed">25867923</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, and Stevens B (2012). Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipe GO, Lowery RL, Tremblay ME, Kelly EA, Lamantia CE, and Majewska AK (2016). Microglial P2Y12 is necessary for synaptic plasticity in mouse visual cortex. Nat. Commun. 7, 10905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786684</ArticleId><ArticleId IdType="pubmed">26948129</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K, Friedman BA, Larson JL, Lauffer BE, Goldstein LD, Appling LL, Borneo J, Poon C, Ho T, Cai F, et al. (2016). Untangling the brain&#x2019;s neuroinflammatory and neurodegenerative transcriptional responses. Nat. Commun. 7, 11295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4844685</ArticleId><ArticleId IdType="pubmed">27097852</ArticleId></ArticleIdList></Reference><Reference><Citation>Steadman PE, Xia F, Ahmed M, Mocle AJ, Penning ARA, Geraghty AC, Steenland HW, Monje M, Josselyn SA, and Frankland PW (2020). Disruption of Oligodendrogenesis Impairs Memory Consolidation in Adult Mice. Neuron 105, 150&#x2013;164.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7579726</ArticleId><ArticleId IdType="pubmed">31753579</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, et al. (2007). The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Bernstein MJ, Meng M, Rao S, S0rensen AT, Yao L, Zhang X, Anikeeva PO, and Lin Y (2020). Functionally Distinct Neuronal Ensembles within the Memory Engram. Cell 181, 410&#x2013;423.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166195</ArticleId><ArticleId IdType="pubmed">32187527</ArticleId></ArticleIdList></Reference><Reference><Citation>Susuki K, Chang K-J, Zollinger DR, Liu Y, Ogawa Y, Eshed-Eisenbach Y, Dours-Zimmermann MT, Oses-Prieto JA, Burlingame AL, Seidenbecher CI, et al. (2013). Three mechanisms assemble central nervous system nodes of Ranvier. Neuron 78, 469&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756512</ArticleId><ArticleId IdType="pubmed">23664614</ArticleId></ArticleIdList></Reference><Reference><Citation>Talabot-Ayer D, Calo N, Vigne S, Lamacchia C, Gabay C, and Palmer G (2012). The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters. J. Leukoc. Biol. 91, 119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">22013230</ArticleId></ArticleIdList></Reference><Reference><Citation>Toni N, Teng EM, Bushong EA, Aimone JB, Zhao C, Consiglio A, van Praag H, Martone ME, Ellisman MH, and Gage FH (2007). Synapse formation on neurons born in the adult hippocampus. Nat. Neurosci. 10,727&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">17486101</ArticleId></ArticleIdList></Reference><Reference><Citation>T0nnesen J, Inavalli VVGK, and Nagerl UV (2018). Super-Resolution Imaging of the Extracellular Space in Living Brain Tissue. Cell 172, 1108&#x2013;1121.e15.</Citation><ArticleIdList><ArticleId IdType="pubmed">29474910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay M-&#xc8;, Lowery RL, and Majewska AK (2010). Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 8, e1000527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2970556</ArticleId><ArticleId IdType="pubmed">21072242</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsien RY (2013). Very long-term memories may be stored in the pattern of holes in the perineuronal net. Proc. Natl. Acad. Sci. USA 110, 12456&#x2013;12461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725115</ArticleId><ArticleId IdType="pubmed">23832785</ArticleId></ArticleIdList></Reference><Reference><Citation>Vainchtein ID, Chin G, Cho FS, Kelley KW, Miller JG, Chien EC, Liddelow SA, Nguyen PT, Nakao-Inoue H, Dorman LC, et al. (2018). Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. Science 359, 1269&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6070131</ArticleId><ArticleId IdType="pubmed">29420261</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela JC, Heise C, Franken G, Singh J, Schweitzer B, Seidenbecher CI, and Frischknecht R (2014). Hyaluronan-based extracellular matrix under conditions of homeostatic plasticity. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369, 20130606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4173291</ArticleId><ArticleId IdType="pubmed">25225099</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Laan LJ, Dopp EA, Haworth R, Pikkarainen T, Kangas M, Elomaa O, Dijkstra CD, Gordon S, Tryggvason K, and Kraal G (1999). Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. J. Immunol. 162, 939&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">9916718</ArticleId></ArticleIdList></Reference><Reference><Citation>Vegh MJ, Rausell A, Loos M, Heldring CM, Jurkowski W, van Nierop P, Paliukhovich I, Li KW, del Sol A, Smit AB, et al. (2014a). Hippocampal extracellular matrix levels and stochasticity in synaptic protein expression increase with age and are associated with age-dependent cognitive decline. Mol. Cell. Proteomics 13, 2975&#x2013;2985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223485</ArticleId><ArticleId IdType="pubmed">25044018</ArticleId></ArticleIdList></Reference><Reference><Citation>Vegh MJ, Heldring CM, Kamphuis W, Hijazi S, Timmerman AJ, Li KW, van Nierop P, Mansvelder HD, Hol EM, Smit AB, and van Kesteren RE (2014b). Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 2, 76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4149201</ArticleId><ArticleId IdType="pubmed">24974208</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, Smith LK, Bieri G, Lin K, Berdnik D, et al. (2014). Young blood reverses agerelated impairments in cognitive function and synaptic plasticity in mice. Nat. Med. 20, 659&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wake H, Moorhouse AJ, Jinno S, Kohsaka S, and Nabekura J (2009). Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. Neurosci. 29, 3974&#x2013;3980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665392</ArticleId><ArticleId IdType="pubmed">19339593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Yue H, Hu Z, Shen Y, Ma J, Li J, Wang XD, Wang L, Sun B, Shi P, et al. (2020). Microglia mediate forgetting via complement-dependent synaptic elimination. Science 367, 688&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">32029629</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinhard L, di Bartolomei G, Bolasco G, Machado P, Schieber NL, Neniskyte U, Exiga M, Vadisiute A, Raggioli A, Schertel A, et al. (2018). Microglia remodel synapses by presynaptic trogocytosis and spine head filopodia induction. Nat. Commun. 9, 1228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964317</ArticleId><ArticleId IdType="pubmed">29581545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T (2016). Ageing, neurodegeneration and brain rejuvenation. Nature 539, 180&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5172605</ArticleId><ArticleId IdType="pubmed">27830812</ArticleId></ArticleIdList></Reference><Reference><Citation>Yona S, Kim K-W, Wolf Y, Mildner A, Varol D, Breker M, Strauss-Ayali D, Viukov S, Guilliams M, Misharin A, et al. (2013). Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 79&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3908543</ArticleId><ArticleId IdType="pubmed">23273845</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Romero MI, Ghosh P, Ye Z, Charnay P, Rushing EJ, Marth JD, and Parada LF (2001). Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 15, 859&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC312666</ArticleId><ArticleId IdType="pubmed">11297510</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu A, Ibrahim JG, and Love MI (2019). Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics 35, 2084&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6581436</ArticleId><ArticleId IdType="pubmed">30395178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32631487</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-084X</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2020</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>eLife</Title><ISOAbbreviation>Elife</ISOAbbreviation></Journal><ArticleTitle>Super-resolution microscopy reveals majorly mono- and dimeric presenilin1/&#x3b3;-secretase at the cell surface.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e56679</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7554/eLife.56679</ELocationID><Abstract><AbstractText>&#x3b3;-Secretase is a multi-subunit enzyme whose aberrant activity is associated with Alzheimer's disease and cancer. While its structure is atomically resolved, &#x3b3;-secretase localization in the membrane in situ relies mostly on biochemical data. Here, we combined fluorescent tagging of &#x3b3;-secretase subunits with super-resolution microscopy in fibroblasts. Structured illumination microscopy revealed single &#x3b3;-secretase complexes with a monodisperse distribution and in a 1:1 stoichiometry of PSEN1 and nicastrin subunits. In living cells, sptPALM revealed PSEN1/&#x3b3;-secretase mainly with directed motility and frequenting 'hotspots' or high track-density areas that are sensitive to &#x3b3;-secretase inhibitors. We visualized &#x3b3;-secretase association with substrates like amyloid precursor protein and N-cadherin, but not with its sheddases ADAM10 or BACE1 at the cell surface, arguing against pre-formed megadalton complexes. Nonetheless, in living cells PSEN1/&#x3b3;-secretase transiently visits ADAM10 hotspots. Our results highlight the power of super-resolution microscopy for the study of &#x3b3;-secretase distribution and dynamics in the membrane.</AbstractText><CopyrightInformation>&#xa9; 2020, Escamilla-Ayala et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Escamilla-Ayala</LastName><ForeName>Abril Ang&#xe9;lica</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-5761-0999</Identifier><AffiliationInfo><Affiliation>Laboratory for Membrane Trafficking, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sannerud</LastName><ForeName>Ragna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Membrane Trafficking, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mondin</LastName><ForeName>Magali</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bordeaux Imaging Center, UMS 3420, CNRS-University of Bordeaux, US4 INSERM, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poersch</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Biology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeire</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory for Membrane Trafficking, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paparelli</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory for Membrane Trafficking, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB Bio Imaging Core, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berlage</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Einstein Center for Neurosciences, NeuroCure Cluster of Excellence, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koenig</LastName><ForeName>Marcelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>PicoQuant GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavez-Gutierrez</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Proteolytic Mechanisms in Neurodegeneration, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulbrich</LastName><ForeName>Maximilian H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0001-8123-1668</Identifier><AffiliationInfo><Affiliation>Institute of Internal Medicine IV, Medical Center of the University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munck</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB Bio Imaging Core, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuno</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Biomolecular Network Dynamics, Biochemistry, Molecular and Structural Biology Section, KU Leuven, Heverlee, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Annaert</LastName><ForeName>Wim</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-0150-9661</Identifier><AffiliationInfo><Affiliation>Laboratory for Membrane Trafficking, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IDO/12/020</GrantID><Agency>KU Leuven</Agency><Country>International</Country></Grant><Grant><GrantID>C16/15/073</GrantID><Agency>KU Leuven</Agency><Country>International</Country></Grant><Grant><GrantID>S006617N</GrantID><Agency>Fonds Wetenschappelijk Onderzoek</Agency><Country>International</Country></Grant><Grant><GrantID>G078117N</GrantID><Agency>Fonds Wetenschappelijk Onderzoek</Agency><Country>International</Country></Grant><Grant><GrantID>G056017N</GrantID><Agency>Fonds Wetenschappelijk Onderzoek</Agency><Country>International</Country></Grant><Grant><GrantID>AKUL/08/58</GrantID><Agency>Fonds Wetenschappelijk Onderzoek</Agency><Country>International</Country></Grant><Grant><GrantID>AKUL/11/30</GrantID><Agency>Fonds Wetenschappelijk Onderzoek</Agency><Country>International</Country></Grant><Grant><GrantID>AKUL/13/39</GrantID><Agency>Fonds Wetenschappelijk Onderzoek</Agency><Country>International</Country></Grant><Grant><GrantID>ANR-10-INBS-04</GrantID><Agency>Agence Nationale de la Recherche</Agency><Country>International</Country></Grant><Grant><GrantID>#8358</GrantID><Agency>European Molecular Biology Organization</Agency><Country>International</Country></Grant><Grant><GrantID>#14017</GrantID><Agency>SAO-FRA</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Elife</MedlineTA><NlmUniqueID>101579614</NlmUniqueID><ISSNLinking>2050-084X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C469349">PSENEN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C580804">presenilin 1, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008853" MajorTopicYN="N">Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">cell biology</Keyword><Keyword MajorTopicYN="N">gamma-secretase</Keyword><Keyword MajorTopicYN="N">human</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">presenilin1</Keyword><Keyword MajorTopicYN="N">single-particle tracking</Keyword><Keyword MajorTopicYN="N">super-resolution microscopy</Keyword></KeywordList><CoiStatement>AE, RS, MM, KP, WV, LP, LC, MU, SM, HM, WA No competing interests declared, CB Associated to PicoQuant, MK Works for PicoQuant</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32631487</ArticleId><ArticleId IdType="pmc">PMC7340497</ArticleId><ArticleId IdType="doi">10.7554/eLife.56679</ArticleId><ArticleId IdType="pii">56679</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguayo-Ortiz R, Dominguez L. Simulating the &#x3b3;-secretase enzyme: recent advances and future directions. Biochimie. 2018;147:130&#x2013;135. doi: 10.1016/j.biochi.2018.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2018.01.007</ArticleId><ArticleId IdType="pubmed">29410204</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JO. qSR: a software for quantitative analysis of single molecule and super-resolution data. bioRxiv. 2017 doi: 10.1101/146241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/146241</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert WG, Levesque L, Craessaerts K, Dierinck I, Snellings G, Westaway D, George-Hyslop PS, Cordell B, Fraser P, De Strooper B. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. Journal of Cell Biology. 1999;147:277&#x2013;294. doi: 10.1083/jcb.147.2.277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.147.2.277</ArticleId><ArticleId IdType="pmc">PMC2174229</ArticleId><ArticleId IdType="pubmed">10525535</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W, De Strooper B. A cell biological perspective on Alzheimer's disease. Annual Review of Cell and Developmental Biology. 2002;18:25&#x2013;51. doi: 10.1146/annurev.cellbio.18.020402.142302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cellbio.18.020402.142302</ArticleId><ArticleId IdType="pubmed">12142279</ArticleId></ArticleIdList></Reference><Reference><Citation>Arant RJ, Ulbrich MH. Deciphering the subunit composition of multimeric proteins by counting photobleaching steps. ChemPhysChem. 2014;15:600&#x2013;605. doi: 10.1002/cphc.201301092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphc.201301092</ArticleId><ArticleId IdType="pubmed">24481650</ArticleId></ArticleIdList></Reference><Reference><Citation>Bademosi AT, Lauwers E, Padmanabhan P, Odierna L, Chai YJ, Papadopulos A, Goodhill GJ, Verstreken P, van Swinderen B, Meunier FA. In vivo single-molecule imaging of syntaxin1A reveals polyphosphoinositide- and activity-dependent trapping in presynaptic nanoclusters. Nature Communications. 2016;7:13660. doi: 10.1038/ncomms13660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13660</ArticleId><ArticleId IdType="pmc">PMC5171881</ArticleId><ArticleId IdType="pubmed">28045048</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai XC, Rajendra E, Yang G, Shi Y, Scheres SH. Sampling the conformational space of the catalytic subunit of human &#x3b3;-secretase. eLife. 2015a;4:e11182. doi: 10.7554/eLife.11182.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.11182</ArticleId><ArticleId IdType="pmc">PMC4718806</ArticleId><ArticleId IdType="pubmed">26623517</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai XC, Yan C, Yang G, Lu P, Ma D, Sun L, Zhou R, Scheres SHW, Shi Y. An atomic structure of human &#x3b3;-secretase. Nature. 2015b;525:212&#x2013;217. doi: 10.1038/nature14892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14892</ArticleId><ArticleId IdType="pmc">PMC4568306</ArticleId><ArticleId IdType="pubmed">26280335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates IR, H&#xe9;bert B, Luo Y, Liao J, Bachir AI, Kolin DL, Wiseman PW, Hanrahan JW. Membrane lateral diffusion and capture of CFTR within transient confinement zones. Biophysical Journal. 2006;91:1046&#x2013;1058. doi: 10.1529/biophysj.106.084830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.106.084830</ArticleId><ArticleId IdType="pmc">PMC1563763</ArticleId><ArticleId IdType="pubmed">16714353</ArticleId></ArticleIdList></Reference><Reference><Citation>Belyy V, Shih SM, Bandaria J, Huang Y, Lawrence RE, Zoncu R, Yildiz A. PhotoGate microscopy to track single molecules in crowded environments. Nature Communications. 2017;8:1&#x2013;10. doi: 10.1038/ncomms13978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13978</ArticleId><ArticleId IdType="pmc">PMC5234080</ArticleId><ArticleId IdType="pubmed">28071667</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi F, Syga &#x141;, Moiset G, Spakman D, Schavemaker PE, Punter CM, Seinen AB, van Oijen AM, Robinson A, Poolman B. Steric exclusion and protein conformation determine the localization of plasma membrane transporters. Nature Communications. 2018;9:501. doi: 10.1038/s41467-018-02864-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-02864-2</ArticleId><ArticleId IdType="pmc">PMC5799302</ArticleId><ArticleId IdType="pubmed">29402931</ArticleId></ArticleIdList></Reference><Reference><Citation>Boncompain G, Divoux S, Gareil N, de Forges H, Lescure A, Latreche L, Mercanti V, Jollivet F, Raposo G, Perez F. Synchronization of secretory protein traffic in populations of cells. Nature Methods. 2012;9:493&#x2013;498. doi: 10.1038/nmeth.1928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1928</ArticleId><ArticleId IdType="pubmed">22406856</ArticleId></ArticleIdList></Reference><Reference><Citation>Calebiro D, Rieken F, Wagner J, Sungkaworn T, Zabel U, Borzi A, Cocucci E, Z&#xfc;rn A, Lohse MJ. Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. PNAS. 2013;110:743&#x2013;748. doi: 10.1073/pnas.1205798110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1205798110</ArticleId><ArticleId IdType="pmc">PMC3545784</ArticleId><ArticleId IdType="pubmed">23267088</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervantes S, Saura CA, Pomares E, Gonz&#xe0;lez-Duarte R, Marfany G. Functional implications of the presenilin dimerization. Journal of Biological Chemistry. 2004;279:36519&#x2013;36529. doi: 10.1074/jbc.M404832200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M404832200</ArticleId><ArticleId IdType="pubmed">15220354</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaney LK, Jacobson BS. Coating cells with colloidal silica for high yield isolation of plasma membrane sheets and identification of transmembrane proteins. The Journal of Biological Chemistry. 1983;258:10062&#x2013;10072.</Citation><ArticleIdList><ArticleId IdType="pubmed">6309765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L, Tolia A, Maes E, Li T, Wong PC, de Strooper B. Glu(332) in the nicastrin ectodomain is essential for gamma-secretase complex maturation but not for its activity. The Journal of Biological Chemistry. 2008;283:20096&#x2013;20105. doi: 10.1074/jbc.M803040200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M803040200</ArticleId><ArticleId IdType="pubmed">18502756</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AC, Kim S, Shepardson N, Patel S, Hong S, Selkoe DJ. Physical and functional interaction between the &#x3b1;- and &#x3b3;-secretases: a new model of regulated intramembrane proteolysis. Journal of Cell Biology. 2015;211:1157&#x2013;1176. doi: 10.1083/jcb.201502001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201502001</ArticleId><ArticleId IdType="pmc">PMC4687875</ArticleId><ArticleId IdType="pubmed">26694839</ArticleId></ArticleIdList></Reference><Reference><Citation>Constals A, Penn AC, Compans B, Toulm&#xe9; E, Phillipat A, Marais S, Retailleau N, Hafner AS, Coussen F, Hosy E, Choquet D. Glutamate-induced AMPA receptor desensitization increases their mobility and modulates short-term plasticity through unbinding from stargazin. Neuron. 2015;85:787&#x2013;803. doi: 10.1016/j.neuron.2015.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.01.012</ArticleId><ArticleId IdType="pubmed">25661182</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Wang X, Li X, Wang X, Zhang C, Li W, Zhang Y, Gu H, Xie X, Nan F, Zhao J, Pei G. Targeting the &#x3b3;-/&#x3b2;-secretase interaction reduces &#x3b2;-amyloid generation and ameliorates Alzheimer's disease-related pathogenesis. Cell Discovery. 2015;1:15021. doi: 10.1038/celldisc.2015.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/celldisc.2015.21</ArticleId><ArticleId IdType="pmc">PMC4860824</ArticleId><ArticleId IdType="pubmed">27462420</ArticleId></ArticleIdList></Reference><Reference><Citation>Das U, Wang L, Ganguly A, Saikia JM, Wagner SL, Koo EH, Roy S. Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. Nature Neuroscience. 2016;19:55&#x2013;64. doi: 10.1038/nn.4188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4188</ArticleId><ArticleId IdType="pmc">PMC4782935</ArticleId><ArticleId IdType="pubmed">26642089</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-Secretase complex. Neuron. 2003;38:9&#x2013;12. doi: 10.1016/S0896-6273(03)00205-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00205-8</ArticleId><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. Novel Research Horizons for Presenilins and &#x3b3;-Secretases in Cell Biology and Disease. Annual Review of Cell and Developmental Biology. 2010;26:235&#x2013;260. doi: 10.1146/annurev-cellbio-100109-104117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100109-104117</ArticleId><ArticleId IdType="pubmed">20604710</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedecker P, Neely RK. Localizer: fast, accurate, open-source, and modular software package for super resolution microscopy. Journal of Biomedical Optics. 2012;12:126008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3512108</ArticleId><ArticleId IdType="pubmed">23208219</ArticleId></ArticleIdList></Reference><Reference><Citation>Elad N, De Strooper B, Lismont S, Hagen W, Veugelen S, Arimon M, Horr&#xe9; K, Berezovska O, Sachse C, Ch&#xe1;vez-Guti&#xe9;rrez L. The dynamic conformational landscape of gamma-secretase. Journal of Cell Science. 2015;128:589&#x2013;598. doi: 10.1242/jcs.164384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.164384</ArticleId><ArticleId IdType="pmc">PMC4311135</ArticleId><ArticleId IdType="pubmed">25501811</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, Wolfe MS. Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. PNAS. 2002;99:2720&#x2013;2725. doi: 10.1073/pnas.052436599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.052436599</ArticleId><ArticleId IdType="pmc">PMC122414</ArticleId><ArticleId IdType="pubmed">11867728</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselens C, Oorschot V, Baert V, Raemaekers T, Spittaels K, Serneels L, Zheng H, Saftig P, De Strooper B, Klumperman J, Annaert W. Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. Journal of Cell Biology. 2004;166:1041&#x2013;1054. doi: 10.1083/jcb.200406060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200406060</ArticleId><ArticleId IdType="pmc">PMC2172014</ArticleId><ArticleId IdType="pubmed">15452145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ester M. A Density-Based algorithm for discovering clusters in large spatial databases with noise. KDD : Proceedings. 1996;96:226&#x2013;231. doi: 10.5120/739-1038.</Citation><ArticleIdList><ArticleId IdType="doi">10.5120/739-1038</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, Ostaszewski BL, van Dorsselaer A, Wang R, Selkoe DJ, Wolfe MS. Purification and characterization of the human gamma-secretase complex. Biochemistry. 2004;43:9774&#x2013;9789. doi: 10.1021/bi0494976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0494976</ArticleId><ArticleId IdType="pubmed">15274632</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman SA, Vega A, Riedl M, Collins RF, Ostrowski PP, Woods EC, Bertozzi CR, Tammi MI, Lidke DS, Johnson P, Mayor S, Jaqaman K, Grinstein S. Transmembrane pickets connect cyto- and pericellular skeletons forming barriers to receptor engagement. Cell. 2018;172:305&#x2013;317. doi: 10.1016/j.cell.2017.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.12.023</ArticleId><ArticleId IdType="pmc">PMC5929997</ArticleId><ArticleId IdType="pubmed">29328918</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA, Smith HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nature Methods. 2009;6:343&#x2013;345. doi: 10.1038/nmeth.1318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1318</ArticleId><ArticleId IdType="pubmed">19363495</ArticleId></ArticleIdList></Reference><Reference><Citation>Gru&#xdf;mayer KS, Herten DP. Time-resolved molecule counting by photon statistics across the visible spectrum. Physical Chemistry Chemical Physics. 2017;19:8962&#x2013;8969. doi: 10.1039/C7CP00363C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C7CP00363C</ArticleId><ArticleId IdType="pubmed">28300271</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Zhang SX, Sokol N, Cooley L, Boulianne GL. Physical and genetic interaction of filamin with presenilin in&#xa0;Drosophila&#xa0;rsquo. Journal of Cell Science. 2000;113 Pt 19:3499&#x2013;3508.</Citation><ArticleIdList><ArticleId IdType="pubmed">10984440</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo A, Kovacs DM. The many substrates of presenilin/&#x3b3;-secretase. Journal of Alzheimer's Disease. 2011;25:3&#x2013;28. doi: 10.3233/JAD-2011-101065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-101065</ArticleId><ArticleId IdType="pmc">PMC3281584</ArticleId><ArticleId IdType="pubmed">21335653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie P, Ulbrich MH, Wang HL, Arant RJ, Lau AG, Zhang Z, Isacoff EY, Chen L. AMPA receptor/TARP stoichiometry visualized by single-molecule subunit counting. PNAS. 2013;110:5163&#x2013;5168. doi: 10.1073/pnas.1218765110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1218765110</ArticleId><ArticleId IdType="pmc">PMC3612642</ArticleId><ArticleId IdType="pubmed">23479622</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert SS, Godin C, Tomiyama T, Mori H, L&#xe9;vesque G. Dimerization of presenilin-1 in vivo: suggestion of novel regulatory mechanisms leading to higher order complexes. Biochemical and Biophysical Research Communications. 2003;301:119&#x2013;126. doi: 10.1016/S0006-291X(02)02984-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(02)02984-4</ArticleId><ArticleId IdType="pubmed">12535650</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, Umans L, Schrijvers V, Checler F, Vanderstichele H, Baekelandt V, Dressel R, Cupers P, Huylebroeck D, Zwijsen A, Van Leuven F, De Strooper B. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. PNAS. 1999;96:11872&#x2013;11877. doi: 10.1073/pnas.96.21.11872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.21.11872</ArticleId><ArticleId IdType="pmc">PMC18379</ArticleId><ArticleId IdType="pubmed">10518543</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nature Cell Biology. 2000;2:461&#x2013;462. doi: 10.1038/35017105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35017105</ArticleId><ArticleId IdType="pubmed">10878813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitzenberger M, Zacharias M. Uncovering the binding mode of &#x3b3; -Secretase inhibitors. ACS Chemical Neuroscience. 2019;10:3398&#x2013;3403. doi: 10.1021/acschemneuro.9b00272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00272</ArticleId><ArticleId IdType="pubmed">31244051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur JY, Welander H, Behbahani H, Aoki M, Fr&#xe5;nberg J, Winblad B, Frykman S, Tjernberg LO. Active gamma-secretase is localized to detergent-resistant membranes in human brain. FEBS Journal. 2008;275:1174&#x2013;1187. doi: 10.1111/j.1742-4658.2008.06278.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2008.06278.x</ArticleId><ArticleId IdType="pubmed">18266764</ArticleId></ArticleIdList></Reference><Reference><Citation>Izeddin I, Boulanger J, Racine V, Specht CG, Kechkar A, Nair D, Triller A, Choquet D, Dahan M, Sibarita JB. Wavelet analysis for single molecule localization microscopy. Optics Express. 2012;20:2081. doi: 10.1364/OE.20.002081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1364/OE.20.002081</ArticleId><ArticleId IdType="pubmed">22330449</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon AH, B&#xf6;hm C, Chen F, Huo H, Ruan X, Ren CH, Ho K, Qamar S, Mathews PM, Fraser PE, Mount HT, St George-Hyslop P, Schmitt-Ulms G. Interactome analyses of mature &#x3b3;-secretase complexes reveal distinct molecular environments of presenilin (PS) paralogs and preferential binding of signal peptide peptidase to PS2. Journal of Biological Chemistry. 2013;288:15352&#x2013;15366. doi: 10.1074/jbc.M112.441840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.441840</ArticleId><ArticleId IdType="pmc">PMC3663554</ArticleId><ArticleId IdType="pubmed">23589300</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurisch-Yaksi N, Sannerud R, Annaert W. A fast growing spectrum of biological functions of &#x3b3;-secretase in development and disease. Biochimica Et Biophysica Acta (BBA) - Biomembranes. 2013;1828:2815&#x2013;2827. doi: 10.1016/j.bbamem.2013.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2013.04.016</ArticleId><ArticleId IdType="pubmed">24099003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, Lammich S, Edbauer D, Ertl M, Rietdorf J, Capell A, Steiner H, Haass C. Presenilin-1 affects trafficking and processing of betaAPP and is targeted in a complex with nicastrin to the plasma membrane. Journal of Cell Biology. 2002;158:551&#x2013;561. doi: 10.1083/jcb.200201123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200201123</ArticleId><ArticleId IdType="pmc">PMC2173840</ArticleId><ArticleId IdType="pubmed">12147673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, Haass C, Steiner H. Assembly, trafficking and function of gamma-secretase. Neurodegenerative Diseases. 2006;3:275&#x2013;283. doi: 10.1159/000095267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000095267</ArticleId><ArticleId IdType="pubmed">17047368</ArticleId></ArticleIdList></Reference><Reference><Citation>Kechkar A, Nair D, Heilemann M, Choquet D, Sibarita JB. Real-time analysis and visualization for single-molecule based super-resolution microscopy. PLOS ONE. 2013;8:e62918. doi: 10.1371/journal.pone.0062918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0062918</ArticleId><ArticleId IdType="pmc">PMC3639901</ArticleId><ArticleId IdType="pubmed">23646160</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandelwal A, Chandu D, Roe CM, Kopan R, Quatrano RS. Moonlighting activity of presenilin in plants is independent of gamma-secretase and evolutionarily conserved. PNAS. 2007;104:13337&#x2013;13342. doi: 10.1073/pnas.0702038104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0702038104</ArticleId><ArticleId IdType="pmc">PMC1948938</ArticleId><ArticleId IdType="pubmed">17684101</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, Nicastrin, Aph-1, and Pen-2. PNAS. 2003;100:6382&#x2013;6387. doi: 10.1073/pnas.1037392100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1037392100</ArticleId><ArticleId IdType="pmc">PMC164455</ArticleId><ArticleId IdType="pubmed">12740439</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreutzberger AJB, Ji M, Aaron J, Mihaljevi&#x107; L, Urban S. Rhomboid distorts lipids to break the viscosity-imposed speed limit of membrane diffusion. Science. 2019;363:eaao0076. doi: 10.1126/science.aao0076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao0076</ArticleId><ArticleId IdType="pmc">PMC6368390</ArticleId><ArticleId IdType="pubmed">30705155</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusumi A, Sako Y, Yamamoto M. Confined lateral diffusion of membrane receptors as studied by single particle tracking (nanovid microscopy). Effects of calcium-induced differentiation in cultured epithelial cells. Biophysical Journal. 1993;65:2021&#x2013;2040. doi: 10.1016/S0006-3495(93)81253-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3495(93)81253-0</ArticleId><ArticleId IdType="pmc">PMC1225938</ArticleId><ArticleId IdType="pubmed">8298032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagache T, Grassart A, Dallongeville S, Faklaris O, Sauvonnet N, Dufour A, Danglot L, Olivo-Marin JC. Mapping molecular assemblies with fluorescence microscopy and object-based spatial statistics. Nature Communications. 2018;9:102&#x2013;108. doi: 10.1038/s41467-018-03053-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03053-x</ArticleId><ArticleId IdType="pmc">PMC5814551</ArticleId><ArticleId IdType="pubmed">29449608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A, Tsekouras K, Calderon C, Bustamante C, Press&#xe9; S. Unraveling the thousand word picture: an introduction to Super-Resolution data analysis. Chemical Reviews. 2017;117:7276&#x2013;7330. doi: 10.1021/acs.chemrev.6b00729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.6b00729</ArticleId><ArticleId IdType="pmc">PMC5487374</ArticleId><ArticleId IdType="pubmed">28414216</ArticleId></ArticleIdList></Reference><Reference><Citation>Levet F, Hosy E, Kechkar A, Butler C, Beghin A, Choquet D, Sibarita JB. SR-Tesseler: a method to segment and quantify localization-based super-resolution microscopy data. Nature Methods. 2015;12:1065&#x2013;1071. doi: 10.1038/nmeth.3579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3579</ArticleId><ArticleId IdType="pubmed">26344046</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi V, Gratton E. Exploring dynamics in living cells by tracking single particles. Cell Biochemistry and Biophysics. 2007;48:1&#x2013;15. doi: 10.1007/s12013-007-0010-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12013-007-0010-0</ArticleId><ArticleId IdType="pubmed">17703064</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Ding L, Rovere M, Wolfe MS, Selkoe DJ. A cellular complex of BACE1 and &#x3b3;-secretase sequentially generates a&#x3b2; from its full-length precursor. Journal of Cell Biology. 2019;218:644&#x2013;663. doi: 10.1083/jcb.201806205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201806205</ArticleId><ArticleId IdType="pmc">PMC6363461</ArticleId><ArticleId IdType="pubmed">30626721</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo WJ, Wang H, Li H, Kim BS, Shah S, Lee HJ, Thinakaran G, Kim TW, Yu G, Xu H. PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. The Journal of Biological Chemistry. 2003;278:7850&#x2013;7854. doi: 10.1074/jbc.C200648200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C200648200</ArticleId><ArticleId IdType="pubmed">12522139</ArticleId></ArticleIdList></Reference><Reference><Citation>Madl J, Weghuber J, Fritsch R, Derler I, Fahrner M, Frischauf I, Lackner B, Romanin C, Sch&#xfc;tz GJ. Resting state Orai1 diffuses as homotetramer in the plasma membrane of live mammalian cells. Journal of Biological Chemistry. 2010;285:41135&#x2013;41142. doi: 10.1074/jbc.M110.177881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.177881</ArticleId><ArticleId IdType="pmc">PMC3003411</ArticleId><ArticleId IdType="pubmed">20961852</ArticleId></ArticleIdList></Reference><Reference><Citation>Manley S, Gillette JM, Patterson GH, Shroff H, Hess HF, Betzig E, Lippincott-Schwartz J. High-density mapping of single-molecule trajectories with photoactivated localization microscopy. Nature Methods. 2008;5:155&#x2013;157. doi: 10.1038/nmeth.1176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1176</ArticleId><ArticleId IdType="pubmed">18193054</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo C, Garcia-Parajo MF. A review of progress in single particle tracking: from methods to biophysical insights. Reports on Progress in Physics. 2015;78:124601. doi: 10.1088/0034-4885/78/12/124601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/0034-4885/78/12/124601</ArticleId><ArticleId IdType="pubmed">26511974</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Mu&#xf1;oz L, Rodr&#xed;guez-Frade JM, Barroso R, Sorzano C&#xd3;S, Torre&#xf1;o-Pina JA, Santiago CA, Manzo C, Lucas P, Garc&#xed;a-Cuesta EM, Gutierrez E, Barrio L, Vargas J, Cascio G, Carrasco YR, S&#xe1;nchez-Madrid F, Garc&#xed;a-Parajo MF, Mellado M. Separating Actin-Dependent chemokine receptor nanoclustering from dimerization indicates a role for clustering in CXCR4 signaling and function. Molecular Cell. 2018;71:873. doi: 10.1016/j.molcel.2018.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.08.012</ArticleId><ArticleId IdType="pubmed">30193101</ArticleId></ArticleIdList></Reference><Reference><Citation>Milenkovic L, Weiss LE, Yoon J, Roth TL, Su YS, Sahl SJ, Scott MP, Moerner WE. Single-molecule imaging of hedgehog pathway protein smoothened in primary cilia reveals binding events regulated by Patched1. PNAS. 2015;112:8320&#x2013;8325. doi: 10.1073/pnas.1510094112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510094112</ArticleId><ArticleId IdType="pmc">PMC4500289</ArticleId><ArticleId IdType="pubmed">26100903</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair D, Hosy E, Petersen JD, Constals A, Giannone G, Choquet D, Sibarita JB. Super-resolution imaging reveals that AMPA receptors inside synapses are dynamically organized in Nanodomains regulated by PSD95. Journal of Neuroscience. 2013;33:13204&#x2013;13224. doi: 10.1523/JNEUROSCI.2381-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2381-12.2013</ArticleId><ArticleId IdType="pmc">PMC6619720</ArticleId><ArticleId IdType="pubmed">23926273</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajo K, Ulbrich MH, Kubo Y, Isacoff EY. Stoichiometry of the KCNQ1 - KCNE1 ion channel complex. PNAS. 2010;107:18862&#x2013;18867. doi: 10.1073/pnas.1010354107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1010354107</ArticleId><ArticleId IdType="pmc">PMC2973890</ArticleId><ArticleId IdType="pubmed">20962273</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicovich PR, Owen DM, Gaus K. Turning single-molecule localization microscopy into a quantitative bioanalytical tool. Nature Protocols. 2017;12:453&#x2013;460. doi: 10.1038/nprot.2016.166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.166</ArticleId><ArticleId IdType="pubmed">28151466</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyabi O, Pype S, Mercken M, Herreman A, Saftig P, Craessaerts K, Serneels L, Annaert W, De Strooper B. No endogenous A&#x3b2; production in presenilin-deficient fibroblasts. Nature Cell Biology. 2002;4:E164. doi: 10.1038/ncb0702-e164a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb0702-e164a</ArticleId><ArticleId IdType="pubmed">12105423</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura T, Mio K, Hayashi I, Miyashita H, Fukuda R, Kopan R, Kodama T, Hamakubo T, Iwatsubo T, Iwastubo T, Tomita T, Sato C. Three-dimensional structure of the gamma-secretase complex. Biochemical and Biophysical Research Communications. 2006;343:525&#x2013;534. doi: 10.1016/j.bbrc.2006.02.158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.02.158</ArticleId><ArticleId IdType="pubmed">16546128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovesn&#xfd; M, K&#x159;&#xed;&#x17e;ek P, Borkovec J, Svindrych Z, Hagen GM. ThunderSTORM: a comprehensive ImageJ plug-in for PALM and STORM data analysis and super-resolution imaging. Bioinformatics. 2014;30:2389&#x2013;2390. doi: 10.1093/bioinformatics/btu202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu202</ArticleId><ArticleId IdType="pmc">PMC4207427</ArticleId><ArticleId IdType="pubmed">24771516</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan P, Mart&#xed;nez-M&#xe1;rmol R, Xia D, G&#xf6;tz J, Meunier FA. Frontotemporal dementia mutant tau promotes aberrant fyn nanoclustering in hippocampal dendritic spines. eLife. 2019;8:e45040. doi: 10.7554/eLife.45040.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.45040</ArticleId><ArticleId IdType="pmc">PMC6592683</ArticleId><ArticleId IdType="pubmed">31237563</ArticleId></ArticleIdList></Reference><Reference><Citation>Paparelli L, Corthout N, Pavie B, Wakefield DL, Sannerud R, Jovanovic-Talisman T, Annaert W, Munck S. Inhomogeneity based characterization of distribution patterns on the plasma membrane. PLOS Computational Biology. 2016;12:e1005095. doi: 10.1371/journal.pcbi.1005095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1005095</ArticleId><ArticleId IdType="pmc">PMC5014321</ArticleId><ArticleId IdType="pubmed">27603951</ArticleId></ArticleIdList></Reference><Reference><Citation>Priller C, Dewachter I, Vassallo N, Paluch S, Pace C, Kretzschmar HA, Van Leuven F, Herms J. Mutant presenilin 1 alters synaptic transmission in cultured hippocampal neurons. Journal of Biological Chemistry. 2007;282:1119&#x2013;1127. doi: 10.1074/jbc.M605066200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M605066200</ArticleId><ArticleId IdType="pubmed">17088253</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine V, Sachse M, Salamero J, Fraisier V, Trubuil A, Sibarita JB. Visualization and quantification of vesicle trafficking on a three-dimensional cytoskeleton network in living cells. Journal of Microscopy. 2007;225:214&#x2013;228. doi: 10.1111/j.1365-2818.2007.01723.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2818.2007.01723.x</ArticleId><ArticleId IdType="pubmed">17371444</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. PNAS. 2006;103:11172&#x2013;11177. doi: 10.1073/pnas.0603838103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0603838103</ArticleId><ArticleId IdType="pmc">PMC1544060</ArticleId><ArticleId IdType="pubmed">16837572</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xe9;chards M, Xia W, Oorschot VM, Selkoe DJ, Klumperman J. Presenilin-1 exists in both pre- and post-Golgi compartments and recycles via COPI-coated membranes. Traffic. 2003;4:553&#x2013;565. doi: 10.1034/j.1600-0854.2003.t01-1-00114.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0854.2003.t01-1-00114.x</ArticleId><ArticleId IdType="pubmed">12839498</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossier O, Octeau V, Sibarita JB, Leduc C, Tessier B, Nair D, Gatterdam V, Destaing O, Albig&#xe8;s-Rizo C, Tamp&#xe9; R, Cognet L, Choquet D, Lounis B, Giannone G. Integrins &#x3b2;1 and &#x3b2;3 exhibit distinct dynamic nanoscale organizations inside focal adhesions. Nature Cell Biology. 2012;14:1057&#x2013;1067. doi: 10.1038/ncb2588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2588</ArticleId><ArticleId IdType="pubmed">23023225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sako Y, Kusumi A. Compartmentalized structure of the plasma membrane for receptor movements as revealed by a nanometer-level motion analysis. The Journal of Cell Biology. 1994;125:1251&#x2013;1264. doi: 10.1083/jcb.125.6.1251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.125.6.1251</ArticleId><ArticleId IdType="pmc">PMC2290914</ArticleId><ArticleId IdType="pubmed">8207056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sannerud R, Declerck I, Peric A, Raemaekers T, Menendez G, Zhou L, Veerle B, Coen K, Munck S, De Strooper B, Schiavo G, Annaert W. ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1. PNAS. 2011;108:E559&#x2013;E568. doi: 10.1073/pnas.1100745108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1100745108</ArticleId><ArticleId IdType="pmc">PMC3161548</ArticleId><ArticleId IdType="pubmed">21825135</ArticleId></ArticleIdList></Reference><Reference><Citation>Sannerud R, Esselens C, Ejsmont P, Mattera R, Rochin L, Tharkeshwar AK, De Baets G, De Wever V, Habets R, Baert V, Vermeire W, Michiels C, Groot AJ, Wouters R, Dillen K, Vints K, Baatsen P, Munck S, Derua R, Waelkens E, Basi GS, Mercken M, Vooijs M, Bollen M, Schymkowitz J, Rousseau F, Bonifacino JS, Van Niel G, De Strooper B, Annaert W. Restricted location of PSEN2/&#x3b3;-Secretase determines substrate specificity and generates an intracellular a&#x3b2; pool. Cell. 2016;166:193&#x2013;208. doi: 10.1016/j.cell.2016.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.05.020</ArticleId><ArticleId IdType="pmc">PMC7439524</ArticleId><ArticleId IdType="pubmed">27293189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Diehl TS, Narayanan S, Funamoto S, Ihara Y, De Strooper B, Steiner H, Haass C, Wolfe MS. Active gamma-secretase complexes contain only one of each component. Journal of Biological Chemistry. 2007;282:33985&#x2013;33993. doi: 10.1074/jbc.M705248200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M705248200</ArticleId><ArticleId IdType="pubmed">17911105</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, Kandel ER, Duff K, Kirkwood A, Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36. doi: 10.1016/S0896-6273(04)00182-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(04)00182-5</ArticleId><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton MJ. Single-particle tracking: models of directed transport. Biophysical Journal. 1994;67:2110&#x2013;2119. doi: 10.1016/S0006-3495(94)80694-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3495(94)80694-0</ArticleId><ArticleId IdType="pmc">PMC1225586</ArticleId><ArticleId IdType="pubmed">7858148</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton MJ, Jacobson K. SINGLE-PARTICLE TRACKING:Applications to Membrane Dynamics. Annual Review of Biophysics and Biomolecular Structure. 1997;26:373&#x2013;399. doi: 10.1146/annurev.biophys.26.1.373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biophys.26.1.373</ArticleId><ArticleId IdType="pubmed">9241424</ArticleId></ArticleIdList></Reference><Reference><Citation>Schermelleh L, Ferrand A, Huser T, Eggeling C, Sauer M, Biehlmaier O, Drummen GPC. Super-resolution microscopy demystified. Nature Cell Biology. 2019;21:72&#x2013;84. doi: 10.1038/s41556-018-0251-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-018-0251-8</ArticleId><ArticleId IdType="pubmed">30602772</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. Fiji: an open-source platform for biological-image analysis. Nature Methods. 2012;9:676&#x2013;682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25&#xa0;years. EMBO Molecular Medicine. 2016;8:595&#x2013;608. doi: 10.15252/emmm.201606210.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibarita JB. High-density single-particle tracking: quantifying molecule organization and dynamics at the nanoscale. Histochemistry and Cell Biology. 2014;141:587&#x2013;595. doi: 10.1007/s00418-014-1214-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00418-014-1214-1</ArticleId><ArticleId IdType="pubmed">24671496</ArticleId></ArticleIdList></Reference><Reference><Citation>Spasic D, Raemaekers T, Dillen K, Declerck I, Baert V, Serneels L, F&#xfc;llekrug J, Annaert W. Rer1p competes with APH-1 for binding to nicastrin and regulates gamma-secretase complex assembly in the early secretory pathway. Journal of Cell Biology. 2007;176:629&#x2013;640. doi: 10.1083/jcb.200609180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200609180</ArticleId><ArticleId IdType="pmc">PMC2064021</ArticleId><ArticleId IdType="pubmed">17325205</ArticleId></ArticleIdList></Reference><Reference><Citation>Stall A, AC Technologies 4&#x2013;7Qr and Br in BD FACSDiva v6 Software: Parameters for Characterizing Detector Performance. 2008</Citation></Reference><Reference><Citation>Steiner H, Winkler E, Edbauer D, Prokop S, Basset G, Yamasaki A, Kostka M, Haass C. PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin. Journal of Biological Chemistry. 2002;277:39062&#x2013;39065. doi: 10.1074/jbc.C200469200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C200469200</ArticleId><ArticleId IdType="pubmed">12198112</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki KG, Kasai RS, Hirosawa KM, Nemoto YL, Ishibashi M, Miwa Y, Fujiwara TK, Kusumi A. Transient GPI-anchored protein homodimers are units for raft organization and function. Nature Chemical Biology. 2012;8:774&#x2013;783. doi: 10.1038/nchembio.1028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1028</ArticleId><ArticleId IdType="pubmed">22820419</ArticleId></ArticleIdList></Reference><Reference><Citation>Szaruga M, Munteanu B, Lismont S, Veugelen S, Horr&#xe9; K, Mercken M, Saido TC, Ryan NS, De Vos T, Savvides SN, Gallardo R, Schymkowitz J, Rousseau F, Fox NC, Hopf C, De Strooper B, Ch&#xe1;vez-Guti&#xe9;rrez L. Alzheimer's-Causing Mutations Shift A&#x3b2; Length by Destabilizing &#x3b3;-Secretase-A&#x3b2;n Interactions. Cell. 2017;170:443&#x2013;456. doi: 10.1016/j.cell.2017.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.004</ArticleId><ArticleId IdType="pubmed">28753424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ta H, Keller J, Haltmeier M, Saka SK, Schmied J, Opazo F, Tinnefeld P, Munk A, Hell SW. Mapping molecules in scanning far-field fluorescence nanoscopy. Nature Communications. 2015;6:7977. doi: 10.1038/ncomms8977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8977</ArticleId><ArticleId IdType="pmc">PMC4557268</ArticleId><ArticleId IdType="pubmed">26269133</ArticleId></ArticleIdList></Reference><Reference><Citation>Tharkeshwar AK, Trekker J, Vermeire W, Pauwels J, Sannerud R, Priestman DA, Te Vruchte D, Vints K, Baatsen P, Decuypere JP, Lu H, Martin S, Vangheluwe P, Swinnen JV, Lagae L, Impens F, Platt FM, Gevaert K, Annaert W. A novel approach to analyze lysosomal dysfunctions through subcellular proteomics and lipidomics: the case of NPC1 deficiency. Scientific Reports. 2017;7:41408. doi: 10.1038/srep41408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep41408</ArticleId><ArticleId IdType="pmc">PMC5278418</ArticleId><ArticleId IdType="pubmed">28134274</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin SJ, Wakefield DL, Jones V, Liu X, Schmolze D, Jovanovi&#x107;-Talisman T. Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2. Scientific Reports. 2018;8:15154. doi: 10.1038/s41598-018-33225-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-33225-0</ArticleId><ArticleId IdType="pmc">PMC6181918</ArticleId><ArticleId IdType="pubmed">30310083</ArticleId></ArticleIdList></Reference><Reference><Citation>Tousseyn T, Thathiah A, Jorissen E, Raemaekers T, Konietzko U, Reiss K, Maes E, Snellinx A, Serneels L, Nyabi O, Annaert W, Saftig P, Hartmann D, De Strooper B. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. Journal of Biological Chemistry. 2009;284:11738&#x2013;11747. doi: 10.1074/jbc.M805894200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M805894200</ArticleId><ArticleId IdType="pmc">PMC2670177</ArticleId><ArticleId IdType="pubmed">19213735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulbrich MH, Isacoff EY. Subunit counting in membrane-bound proteins. Nature Methods. 2007;4:319&#x2013;321. doi: 10.1038/nmeth1024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth1024</ArticleId><ArticleId IdType="pmc">PMC2744285</ArticleId><ArticleId IdType="pubmed">17369835</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, Wong PC, Xu H, Thinakaran G. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. Journal of Biological Chemistry. 2004;279:44945&#x2013;44954. doi: 10.1074/jbc.M407986200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407986200</ArticleId><ArticleId IdType="pmc">PMC1201506</ArticleId><ArticleId IdType="pubmed">15322084</ArticleId></ArticleIdList></Reference><Reference><Citation>Voytyuk I, De Strooper B, Ch&#xe1;vez-Guti&#xe9;rrez L. Modulation of &#x3b3;- and &#x3b2;-Secretases as early prevention against Alzheimer's Disease. Biological Psychiatry. 2018;83:320&#x2013;327. doi: 10.1016/j.biopsych.2017.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2017.08.001</ArticleId><ArticleId IdType="pubmed">28918941</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi T, Craessaerts K, Bammens L, Bentahir M, Borgions F, Herdewijn P, Staes A, Timmerman E, Vandekerckhove J, Rubinstein E, Boucheix C, Gevaert K, De Strooper B. Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains. Nature Cell Biology. 2009;11:1340&#x2013;1346. doi: 10.1038/ncb1978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1978</ArticleId><ArticleId IdType="pubmed">19838174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M. Beta-secretase/BACE1 promotes APP endocytosis and processing in the endosomes and on cell membrane. Neuroscience. 2018;685:63&#x2013;67. doi: 10.1016/j.neulet.2018.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.08.016</ArticleId><ArticleId IdType="pubmed">30120949</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessel D, Fl&#xfc;gge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Analytical Biochemistry. 1984;138:141&#x2013;143. doi: 10.1016/0003-2697(84)90782-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-2697(84)90782-6</ArticleId><ArticleId IdType="pubmed">6731838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. Structure and function of the &#x3b3;-Secretase complex. Biochemistry. 2019;58:2953&#x2013;2966. doi: 10.1021/acs.biochem.9b00401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.9b00401</ArticleId><ArticleId IdType="pmc">PMC6618299</ArticleId><ArticleId IdType="pubmed">31198028</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Zhou R, Zhou Q, Guo X, Yan C, Ke M, Lei J, Shi Y. Structural basis of notch recognition by human &#x3b3;-secretase. Nature. 2019;565:192&#x2013;197. doi: 10.1038/s41586-018-0813-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0813-8</ArticleId><ArticleId IdType="pubmed">30598546</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, Song YQ, Rogaeva E, Chen F, Kawarai T, Supala A, Levesque L, Yu H, Yang DS, Holmes E, Milman P, Liang Y, Zhang DM, Xu DH, Sato C, Rogaev E, Smith M, Janus C, Zhang Y, Aebersold R, Farrer LS, Sorbi S, Bruni A, Fraser P, St George-Hyslop P. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature. 2000;407:48&#x2013;54. doi: 10.1038/35024009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35024009</ArticleId><ArticleId IdType="pubmed">10993067</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Han SW, McKeel DW, Goate A, Wu JY. Interaction of presenilins with the filamin family of actin-binding proteins. The Journal of Neuroscience. 1998;18:914&#x2013;922. doi: 10.1523/JNEUROSCI.18-03-00914.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.18-03-00914.1998</ArticleId><ArticleId IdType="pmc">PMC2042137</ArticleId><ArticleId IdType="pubmed">9437013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R, Yang G, Guo X, Zhou Q, Lei J, Shi Y. Recognition of the amyloid precursor protein by human &#x3b3;-secretase. Science. 2019;363:eaaw0930. doi: 10.1126/science.aaw0930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaw0930</ArticleId><ArticleId IdType="pubmed">30630874</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuidscherwoude M, G&#xf6;ttfert F, Dunlock VM, Figdor CG, van den Bogaart G, van Spriel AB. The tetraspanin web revisited by super-resolution microscopy. Scientific Reports. 2015;5:12201. doi: 10.1038/srep12201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12201</ArticleId><ArticleId IdType="pmc">PMC4505338</ArticleId><ArticleId IdType="pubmed">26183063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32646997</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>369</Volume><Issue>6500</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain.</ArticleTitle><Pagination><StartPage>167</StartPage><EndPage>173</EndPage><MedlinePgn>167-173</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aaw2622</ELocationID><Abstract><AbstractText>Reversing brain aging may be possible through systemic interventions such as exercise. We found that administration of circulating blood factors in plasma from exercised aged mice transferred the effects of exercise on adult neurogenesis and cognition to sedentary aged mice. Plasma concentrations of glycosylphosphatidylinositol (GPI)-specific phospholipase D1 (Gpld1), a GPI-degrading enzyme derived from liver, were found to increase after exercise and to correlate with improved cognitive function in aged mice, and concentrations of Gpld1 in blood were increased in active, healthy elderly humans. Increasing systemic concentrations of Gpld1 in aged mice ameliorated age-related regenerative and cognitive impairments by altering signaling cascades downstream of GPI-anchored substrate cleavage. We thus identify a liver-to-brain axis by which blood factors can transfer the benefits of exercise in old age.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Horowitz</LastName><ForeName>Alana M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-3899-6424</Identifier><AffiliationInfo><Affiliation>Department of Anatomy, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fan</LastName><ForeName>Xuelai</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-5113-1092</Identifier><AffiliationInfo><Affiliation>Department of Anatomy, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieri</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0737-231X</Identifier><AffiliationInfo><Affiliation>Department of Anatomy, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Lucas K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Department of Anatomy, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Diaz</LastName><ForeName>Cesar I</ForeName><Initials>CI</Initials><Identifier Source="ORCID">0000-0001-5761-0457</Identifier><AffiliationInfo><Affiliation>Department of Anatomy, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroer</LastName><ForeName>Adam B</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0002-4038-733X</Identifier><AffiliationInfo><Affiliation>Department of Anatomy, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gontier</LastName><ForeName>Geraldine</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2894-7282</Identifier><AffiliationInfo><Affiliation>Department of Anatomy, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casaletto</LastName><ForeName>Kaitlin B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0002-9124-2034</Identifier><AffiliationInfo><Affiliation>Sandler-Moore Mass Spectrometry Core Facility, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villeda</LastName><ForeName>Saul A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-2726-9582</Identifier><AffiliationInfo><Affiliation>Department of Anatomy, University of California, San Francisco, CA, USA. saul.villeda@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Therapy and Rehabilitation Science, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053382</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG064823</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG032289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG058752</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG067740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017261">Glycosylphosphatidylinositols</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="D010739">Phospholipase D</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.50</RegistryNumber><NameOfSubstance UI="C065017">glycoprotein phospholipase D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2020 Jul 10;369(6500):144-145. doi: 10.1126/science.abc8830.</RefSource><PMID Version="1">32646988</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Signal Transduct Target Ther. 2020 Sep 3;5(1):184. doi: 10.1038/s41392-020-00305-5.</RefSource><PMID Version="1">32883950</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001775" MajorTopicYN="N">Blood Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017261" MajorTopicYN="N">Glycosylphosphatidylinositols</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="Y">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010739" MajorTopicYN="N">Phospholipase D</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010805" MajorTopicYN="Y">Physical Conditioning, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012038" MajorTopicYN="N">Regeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> The authors declare no conflict of interest. A.M.H., X.F., and S.A.V. are named as inventors on a patent application arising from this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32646997</ArticleId><ArticleId IdType="mid">NIHMS1658458</ArticleId><ArticleId IdType="pmc">PMC7879650</ArticleId><ArticleId IdType="doi">10.1126/science.aaw2622</ArticleId><ArticleId IdType="pii">369/6500/167</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Erickson KI et al., Proc. Natl. Acad. Sci. U.S.A 108, 3017&#x2013;3022 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041121</ArticleId><ArticleId IdType="pubmed">21282661</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A et al., Mol. Psychiatry 20, 585&#x2013;593 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25311366</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz AM, Villeda SA, F1000 Res. 6, 1291 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539850</ArticleId><ArticleId IdType="pubmed">28815019</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes RE et al., Sports Med. 28, 397&#x2013;411 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10623983</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Shubert T, Zhao C, Gage FH, J. Neurosci 25, 8680&#x2013;8685 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360197</ArticleId><ArticleId IdType="pubmed">16177036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Rani A, Tchigranova O, Lee W-H, Foster TC, Neuroblol. Aging 33, 828.e1&#x2013;828.e17 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3226902</ArticleId><ArticleId IdType="pubmed">21820213</ArticleId></ArticleIdList></Reference><Reference><Citation>Speisman RB, Kumar A, Rani A, Foster TC, Ormerod BK, Brain Behav. Immun 28, 25&#x2013;43 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3545095</ArticleId><ArticleId IdType="pubmed">23078985</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto I et al., PLOS Biol. 13, e1002279 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626092</ArticleId><ArticleId IdType="pubmed">26512759</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X, Wheatley EG, Villeda SA, Annu. Rev. Neurosci 40, 251&#x2013;272 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28441118</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA et al., Nature 477, 90&#x2013;94 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="pubmed">21886162</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA et al., Nat. Med 20, 659&#x2013;663 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsimpardi L et al., Science 344, 630&#x2013;634 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123747</ArticleId><ArticleId IdType="pubmed">24797482</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM et al., Nature 544, 488&#x2013;492 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5586222</ArticleId><ArticleId IdType="pubmed">28424512</ArticleId></ArticleIdList></Reference><Reference><Citation>Khrimian L et al., J. Exp. Med 214, 2859&#x2013;2873 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626410</ArticleId><ArticleId IdType="pubmed">28851741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gontier G et al., Cell Rep. 22, 1974&#x2013;1981 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5870899</ArticleId><ArticleId IdType="pubmed">29466726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-W et al., J. Appl. Physiol 105, 1585&#x2013;1594 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18801961</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Christie BR, Sejnowski TJ, Gage FH, Proc. Natl. Acad. Sci. U.S.A 96, 13427&#x2013;13431 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23964</ArticleId><ArticleId IdType="pubmed">10557337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugert S et al., Cell Stem Cell 6, 445&#x2013;456 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20452319</ArticleId></ArticleIdList></Reference><Reference><Citation>Creer DJ, Romberg C, Saksida LM, van Praag H, Bussey TJ, Proc. Natl. Acad. Sci. U.S.A 107, 2367&#x2013;2372 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836679</ArticleId><ArticleId IdType="pubmed">20133882</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabula Muris Consortium Nature 562, 367&#x2013;372 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642641</ArticleId><ArticleId IdType="pubmed">30283141</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M et al., Science 347, 1260419 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Scallon BJ et al., Science 252, 446&#x2013;448 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2017684</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire GA, Gossner A, Ann. Clin. Biochem 32, 74&#x2013;78 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7762954</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwinn &#x39c;K et al., ACS Chem. Biol 13, 467&#x2013;474 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28892606</ArticleId></ArticleIdList></Reference><Reference><Citation>Davitz MA et al., Science 238, 81&#x2013;84 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">2443973</ArticleId></ArticleIdList></Reference><Reference><Citation>Metz CN et al., EMBO J. 13, 1741&#x2013;1751 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395007</ArticleId><ArticleId IdType="pubmed">7512501</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujihara Y, Ikawa M, J. Lipid Res 57, 538&#x2013;545 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4808780</ArticleId><ArticleId IdType="pubmed">26593072</ArticleId></ArticleIdList></Reference><Reference><Citation>Low MG, Prasad ARS, Proc. Natl. Acad. Sci. U.S.A 85, 980&#x2013;984 (1988).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC279684</ArticleId><ArticleId IdType="pubmed">3422494</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rosso M et al., Curr. Pharm. Des 17, 1924&#x2013;1943 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21711238</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasi F, Sidenius N, FEBS Lett. 584, 1923&#x2013;1930 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20036661</ArticleId></ArticleIdList></Reference><Reference><Citation>Raikwar NS, Bowen RF, Deeg MA, Biochem. J 391, 285&#x2013;289 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276926</ArticleId><ArticleId IdType="pubmed">15943582</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrells SF et al., Nature 555, 377&#x2013;381 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6179355</ArticleId><ArticleId IdType="pubmed">29513649</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Jim&#xe9;nez EP et al., Nat. Med 25, 554&#x2013;560 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30911133</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin MK et al., Cell Stem Cell 24, 974&#x2013;982.e3 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608595</ArticleId><ArticleId IdType="pubmed">31130513</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautenschlager NT et al., JAMA 300, 1027&#x2013;1037 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18768414</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE et al., Arch. Neurol 67, 80&#x2013;86 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919839</ArticleId><ArticleId IdType="pubmed">20065133</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller S et al., Alzheimers Dement. 14, 1427&#x2013;1437 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6322213</ArticleId><ArticleId IdType="pubmed">30266303</ArticleId></ArticleIdList></Reference><Reference><Citation>Intlekofer KA, Cotman CW, Neurobiol. Dis 57, 47&#x2013;55 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22750524</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH et al., Science 361, eaan8821 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley CD et al., Cell Rep. 28, 3329&#x2013;3337.e5 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6907691</ArticleId><ArticleId IdType="pubmed">31553904</ArticleId></ArticleIdList></Reference><Reference><Citation>Naito AT et al., Cell 149, 1298&#x2013;1313 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529917</ArticleId><ArticleId IdType="pubmed">22682250</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SK et al., Proc. Natl. Acad. Sci. U.S.A 115, E9687&#x2013;E9696 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6187132</ArticleId><ArticleId IdType="pubmed">30254165</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw MA et al., J. Neurosci 37, 3776&#x2013;3788 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5394895</ArticleId><ArticleId IdType="pubmed">28275164</ArticleId></ArticleIdList></Reference><Reference><Citation>Conboy IM et al., Nature 433, 760&#x2013;764 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15716955</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha M et al., Science 344, 649&#x2013;652 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104429</ArticleId><ArticleId IdType="pubmed">24797481</ArticleId></ArticleIdList></Reference><Reference><Citation>Baht GS et al., Nat. Commun 6, 7131 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479006</ArticleId><ArticleId IdType="pubmed">25988592</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32647257</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.</ArticleTitle><Pagination><StartPage>5766</StartPage><EndPage>5788</EndPage><MedlinePgn>5766-5788</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-020-0806-5</ELocationID><Abstract><AbstractText>A population of more than six million people worldwide at high risk of Alzheimer's disease (AD) are those with Down Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom develop dementia during lifetime, caused by an extra copy of &#x3b2;-amyloid-(A&#x3b2;)-precursor-protein gene. We report AD-like pathology in cerebral organoids grown in vitro from non-invasively sampled strands of hair from 71% of DS donors. The pathology consisted of extracellular diffuse and fibrillar A&#x3b2; deposits, hyperphosphorylated/pathologically conformed Tau, and premature neuronal loss. Presence/absence of AD-like pathology was donor-specific (reproducible between individual organoids/iPSC lines/experiments). Pathology could be triggered in pathology-negative T21 organoids by CRISPR/Cas9-mediated elimination of the third copy of chromosome 21 gene BACE2, but prevented by combined chemical &#x3b2; and &#x3b3;-secretase inhibition. We found that T21 organoids secrete increased proportions of A&#x3b2;-preventing (A&#x3b2;1-19) and A&#x3b2;-degradation products (A&#x3b2;1-20 and A&#x3b2;1-34). We show these profiles mirror in cerebrospinal fluid of people with DS. We demonstrate that this protective mechanism is mediated by BACE2-trisomy and cross-inhibited by clinically trialled BACE1 inhibitors. Combined, our data prove the physiological role of BACE2 as a dose-sensitive AD-suppressor gene, potentially explaining the dementia delay in ~30% of people with DS. We also show that DS cerebral organoids could be explored as pre-morbid AD-risk population detector and a system for hypothesis-free drug screens as well as identification of natural suppressor genes for neurodegenerative diseases.</AbstractText><CopyrightInformation>&#xa9; 2020. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ali&#x107;</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-8125-8198</Identifier><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Blizard Institute, Barts &amp; The London School of Medicine, Queen Mary University of London, London, E1 2AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Histology and Embryology, Faculty of Veterinary Medicine, University of Zagreb, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Goh</LastName><ForeName>Pollyanna A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>The Blizard Institute, Barts &amp; The London School of Medicine, Queen Mary University of London, London, E1 2AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LonDownS Consortium, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Murray</LastName><ForeName>Aoife</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4780-3957</Identifier><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, S-405 30, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkanatsiou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, S-405 30, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gough</LastName><ForeName>Gillian</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5837-0176</Identifier><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Kin Y</ForeName><Initials>KY</Initials><Identifier Source="ORCID">0000-0003-3145-880X</Identifier><AffiliationInfo><Affiliation>LonDownS Consortium, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Institute &amp; Reta Lila Weston Institute, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koschut</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunmeir</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeap</LastName><ForeName>Yee Jie</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Niamh L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>The Blizard Institute, Barts &amp; The London School of Medicine, Queen Mary University of London, London, E1 2AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LonDownS Consortium, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groet</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Blizard Institute, Barts &amp; The London School of Medicine, Queen Mary University of London, London, E1 2AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LonDownS Consortium, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-8855-4619</Identifier><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Havlicek</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, 138672, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunn</LastName><ForeName>N Ray</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kvartsberg</LastName><ForeName>Hlin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, S-405 30, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinkmalm</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6958-2393</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, S-405 30, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hithersay</LastName><ForeName>Rosalyn</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>LonDownS Consortium, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Startin</LastName><ForeName>Carla</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9261-9924</Identifier><AffiliationInfo><Affiliation>LonDownS Consortium, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamburg</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>LonDownS Consortium, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, Nanyang Technological University, Singapore, 639798, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pervushin</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, Nanyang Technological University, Singapore, 639798, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turmaine</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Biosciences, University College London, Gower Street, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology and CNR-MAJ, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovelet-Lecrux</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology and CNR-MAJ, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2785-9937</Identifier><AffiliationInfo><Affiliation>University of Eastern Finland, Institute of Clinical Medicine/Neurology, Kuopio, FI-70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volpi</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2422-9104</Identifier><AffiliationInfo><Affiliation>School of Life Sciences, University of Westminster, London, W1W 6UW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Joanne E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0003-2828-7253</Identifier><AffiliationInfo><Affiliation>The Blizard Institute, Barts &amp; The London School of Medicine, Queen Mary University of London, London, E1 2AT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foo</LastName><ForeName>Jia Nee</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, 138672, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rostagno</LastName><ForeName>Agueda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology &amp; Department of Psychiatry, New York University School of Medicine, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghiso</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0870-0437</Identifier><AffiliationInfo><Affiliation>Department of Pathology &amp; Department of Psychiatry, New York University School of Medicine, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krsnik</LastName><ForeName>&#x17d;eljka</ForeName><Initials>&#x17d;</Initials><AffiliationInfo><Affiliation>Croatian Institute for Brain Research, School of Medicine, University of Zagreb, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x160;imi&#x107;</LastName><ForeName>Goran</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Croatian Institute for Brain Research, School of Medicine, University of Zagreb, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostovi&#x107;</LastName><ForeName>Ivica</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Croatian Institute for Brain Research, School of Medicine, University of Zagreb, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitre&#x10d;i&#x107;</LastName><ForeName>Dinko</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4836-1721</Identifier><AffiliationInfo><Affiliation>Croatian Institute for Brain Research, School of Medicine, University of Zagreb, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>LonDownS Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>Paul T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, King's College London, London, SE1 1UL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1890-4193</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, S-405 30, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strydom</LastName><ForeName>Andre</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2502-6704</Identifier><AffiliationInfo><Affiliation>LonDownS Consortium, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>LonDownS Consortium, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Institute &amp; Reta Lila Weston Institute, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, S-405 30, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Institute &amp; Reta Lila Weston Institute, Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni&#x17e;eti&#x107;</LastName><ForeName>Dean</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5486-5761</Identifier><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore. d.nizetic@qmul.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Blizard Institute, Barts &amp; The London School of Medicine, Queen Mary University of London, London, E1 2AT, UK. d.nizetic@qmul.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LonDownS Consortium, London, UK. d.nizetic@qmul.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/R024901/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501542/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S011277/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG059695</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>098330</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N026004/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>217199</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.45</RegistryNumber><NameOfSubstance UI="C509284">BACE2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Mol Psychiatry. 2021 Oct;26(10):5789. doi: 10.1038/s41380-021-01206-x.</RefSource><PMID Version="1">34272490</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="Y">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016153" MajorTopicYN="N">Genes, Suppressor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009940" MajorTopicYN="N">Organoids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014314" MajorTopicYN="N">Trisomy</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>HZ has served at scientific advisory boards for CogRx, Roche Diagnostics, Samumed, and Wave and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (all unrelated to the submitted work). JEM chairs the MNDA Research Advisory Board and is a director of Biomoti, a cancer drug-delivery company.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Strydom</LastName><ForeName>Andre</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiseman</LastName><ForeName>Frances</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nizetic</LastName><ForeName>Dean</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tybulewicz</LastName><ForeName>Victor</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karmiloff-Smith</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32647257</ArticleId><ArticleId IdType="mid">NIHMS1698945</ArticleId><ArticleId IdType="pmc">PMC8190957</ArticleId><ArticleId IdType="doi">10.1038/s41380-020-0806-5</ArticleId><ArticleId IdType="pii">10.1038/s41380-020-0806-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879045</ArticleId><ArticleId IdType="pubmed">20139999</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985;4245&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer&#x2019;s disease. Science. 2010;330:1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer&#x2019;s disease. Lancet. 2016;388:505&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Hithersay R, Startin CM, Hamburg S, Mok KY, Hardy J, Fisher EMC, et al. Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years. JAMANeurol. 2018;76:52&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439956</ArticleId><ArticleId IdType="pubmed">30452522</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VL, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015;16:564&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4678594</ArticleId><ArticleId IdType="pubmed">26243569</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, et al. eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature. 2015;526:443&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570618</ArticleId><ArticleId IdType="pubmed">26322584</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem. 2014;130:4&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086641</ArticleId><ArticleId IdType="pubmed">24646365</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R. Physiological Functions of the beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2. Front Mol Neurosci 2017;10:97 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395628</ArticleId><ArticleId IdType="pubmed">28469554</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Hay SO, Sahara T, McBride M, Kang D, Leissring MA. Identification of BACE2 as an avid ss-amyloid-degrading protease. Mol Neurodegener. 2012;7:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3470943</ArticleId><ArticleId IdType="pubmed">22986058</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluhrer R, Capell A, Westmeyer G, Willem M, Hartung B, Condron MM, et al. A non-amyloidogenic function of BACE-2 in the secretory pathway. J Neurochem. 2002;81:1011&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065613</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi XP, Tugusheva K, Bruce JE, Lucka A, Wu GX, Chen-Dodson E, et al. Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity. J Biol Chem. 2003;278:21286&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">12665519</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, He G, Song W. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer&#x2019;s disease in Down syndrome. FASEB J. 2006;20:1369&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">16816112</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, et al. Increased App expression in a mouse model of Down&#x2019;s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron. 2006;51:29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815330</ArticleId></ArticleIdList></Reference><Reference><Citation>Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down&#x2019;s syndrome. Nature medicine. 1996;2:93&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8564851</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray A, Letourneau A, Canzonetta C, Stathaki E, Gimelli S, Sloan-Bena F, et al. Isogenic Induced Pluripotent Stem Cell Lines from an Adult with Mosaic Down Syndrome Model Accelerated neuronal Ageing and Neurodegeneration. Stem Cell. 2015;33:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4737213</ArticleId><ArticleId IdType="pubmed">25694335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster MA, Knoblich JA. Generation of cerebral organoids from human pluripotent stem cells. Nature protocols. 2014;9:2329&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4160653</ArticleId><ArticleId IdType="pubmed">25188634</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007;6:4433&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17927230</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nature genetics. 2006;38:24&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Holtta M, Soininen H, Bjerke M, Zetterberg H, Westerlund A, et al. Altered cerebrospinal fluid levels of amyloid beta and amyloid precursor-like protein 1 peptides in Down&#x2019;s syndrome. Neuromolecular Med. 2014;16:510&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24740518</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera E, Mathews P, Mezhericher E, Beach TG, Deng J, Neubert TA, et al. Abeta truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biophys Acta. 2018;1864:208&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5875988</ArticleId><ArticleId IdType="pubmed">28711595</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, et al. Macroautophagy&#x2013;a novel Beta-amyloid peptide-generating pathway activated in Alzheimer&#x2019;s disease. J Cell Biol. 2005;171:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmued L, Raymick J, Tolleson W, Sarkar S, Zhang YH, Bell-Cohn A. Introducing Amylo-Glo, a novel fluorescent amyloid specific histochemical tracer especially suited for multiple labeling and large scale quantification studies. J Neurosci Methods. 2012;209:120&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22705750</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok KY, Jones EL, Hanney M, Harold D, Sims R, Williams J, et al. Polymorphisms in BACE2 may affect the age of onset Alzheimer&#x2019;s dementia in Down syndrome. Neurobiol Aging. 2014;35:1513 e1511&#x2013;1515. doi: 10.1016/j.neurobiolaging.2013.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.12.022</ArticleId><ArticleId IdType="pmc">PMC3969241</ArticleId><ArticleId IdType="pubmed">24462566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RR, Holler CJ, Webb RL, Li F, Beckett TL, Murphy MP. BACE1 and BACE2 enzymatic activities in Alzheimer&#x2019;s disease. J Neurochem. 2010;112:1045&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819564</ArticleId><ArticleId IdType="pubmed">19968762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett BD, Babu-Khan S, Loeloff R, Louis JC, Curran E, Citron M, et al. Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem. 2000;275:20647&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">10749877</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler CJ, Webb RL, Laux AL, Beckett TL, Niedowicz DM, Ahmed RR, et al. BACE2 expression increases in human neurodegenerative disease. Am J Pathol. 2012;180:337&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338345</ArticleId><ArticleId IdType="pubmed">22074738</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockley JH, Ravid R, O&#x2019;Neill C. Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer&#x2019;s disease brain. FEBS Lett. 2006;580:6550&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">17113083</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolska Zakaria JA, Vassar RJ. A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer&#x2019;s disease. EMBO Mol Med. 2018;10:e9717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6220261</ArticleId><ArticleId IdType="pubmed">30322841</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, et al. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer&#x2019;s disease. EMBO Mol Med. 2018;10:pii:e9316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6220303</ArticleId><ArticleId IdType="pubmed">30224383</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2014;6:89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304279</ArticleId><ArticleId IdType="pubmed">25621019</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005;280:30797&#x2013;806. doi: 10.1074/jbc.M505249200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M505249200</ArticleId><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Myllykangas L, Wavrant-De Vrieze F, Polvikoski T, Notkola IL, Sulkava R, Niinisto L, et al. Chromosome 21 BACE2 haplotype associates with Alzheimer&#x2019;s disease: a two-stage study. J Neurol Sci. 2005;236:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023140</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Charbonnier C, Wallon D, Nicolas G, Seaman MN, Pottier C, et al. De novo deleterious genetic variations target a biological network centered on Abeta peptide in early-onset Alzheimer disease. Mol Psychiatry. 2015;20:1046&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">26194182</ArticleId></ArticleIdList></Reference><Reference><Citation>Evin G. Future Therapeutics in Alzheimer&#x2019;s Disease: Development Status of BACE Inhibitors. BioDrugs. 2016;30:173&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">27023706</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Guillamon M, Mawhirt S, Blais S, Montaner J, Neubert TA, Rostagno A, et al. Sequential Amyloid-beta Degradation by the Matrix Metalloproteases MMP-2 and MMP-9. J Biol Chem. 2015;290:15078&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463451</ArticleId><ArticleId IdType="pubmed">25897080</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido T, Leissring MA. Proteolytic degradation of amyloid beta-protein. Cold Spring Harb Perspect Med. 2012;2:a006379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367539</ArticleId><ArticleId IdType="pubmed">22675659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH, Siddoway B, Kaeser GE, Segota I, Rivera R, Romanow WJ, et al. Somatic APP gene recombination in Alzheimer&#x2019;s disease and normal neurons. Nature. 2018;563:39&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391999</ArticleId><ArticleId IdType="pubmed">30464338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, et al. Trisomy of human chromosome 21 enhances amyloid-beta deposition independently of an extra copy of APP. Brain. 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6061702</ArticleId><ArticleId IdType="pubmed">29945247</ArticleId></ArticleIdList></Reference><Reference><Citation>Azkona G, Levannon D, Groner Y, Dierssen M. In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model. Amino Acids. 2010;39:1571&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">20596738</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez C, Armijo E, Bravo-Alegria J, Becerra-Calixto A, Mays CE, Soto C. Modeling amyloid beta and tau pathology in human cerebral organoids. Mol Psychiatry. 2018;23:2363&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6594704</ArticleId><ArticleId IdType="pubmed">30171212</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DMA, Davidson YS, Robinson AC, Allen N, Hashimoto T, Richardson A, et al. Patterns and severity of vascular amyloid in Alzheimer&#x2019;s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer&#x2019;s disease. Acta Neuropathol. 2018;136:569&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132946</ArticleId><ArticleId IdType="pubmed">29770843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovchinnikov DA, Korn O, Virshup I, Wells CA, Wolvetang EJ. The Impact of APP on Alzheimer-like Pathogenesis and Gene Expression in Down Syndrome iPSC-Derived Neurons. Stem Cell Reports. 2018;11:32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6066957</ArticleId><ArticleId IdType="pubmed">29861166</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo AM, Dice JF. Unique properties of lamp2a compared to other lamp2 isoforms. J Cell Sci. 2000;113:4441&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">11082038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. Nat Rev Mol Cell Biol. 2018;19:365&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6399518</ArticleId><ArticleId IdType="pubmed">29626215</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Kim DH, Yoon SY. Regulation of amyloid precursor protein processing by its KFERQ motif. BMB Rep. 2016;49:337&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070722</ArticleId><ArticleId IdType="pubmed">26779997</ArticleId></ArticleIdList></Reference><Reference><Citation>Solovei I, Cremer M. 3D-FISH on cultured cells combined with immunostaining. Methods Mol Biol. 2010;659:117&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">20809307</ArticleId></ArticleIdList></Reference><Reference><Citation>Espuny-Camacho I, Arranz AM, Fiers M, Snellinx A, Ando K, Munck S, et al. Hallmarks of Alzheimer&#x2019;s Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain. Neuron. 2017;93:1066&#x2013;81 e1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">28238547</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetano J. Holm-Bonferroni sequential correction: An EXCEL calculator (1.2) [Microsoft Excel workbook]. 2013; 10.13140/RG.2.1.3920.0481.</Citation></Reference><Reference><Citation>Startin CM, Hamburg S, Hithersay R, Al-Janabi T, Mok KY, Hardy J, et al. Cognitive markers of preclinical and prodromal Alzheimer&#x2019;s disease in Down syndrome. Alzheimers Dement. 2019;15:245&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6374283</ArticleId><ArticleId IdType="pubmed">30503169</ArticleId></ArticleIdList></Reference><Reference><Citation>Strydom A, Heslegrave A, Startin CM, Mok KY, Hardy J, Groet J, et al. Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimers Res Ther. 2018;10:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5891918</ArticleId><ArticleId IdType="pubmed">29631614</ArticleId></ArticleIdList></Reference><Reference><Citation>Startin CM, Hamburg S, Hithersay R, Davies A, Rodger E, Aggarwal N, et al. The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndrome. Wellcome Open Res. 2016;1:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5176078</ArticleId><ArticleId IdType="pubmed">28018980</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutsch S, Choudhury U, Merla G, Howald C, Sylvan A, Antonarakis SE. Detection of aneuploidies by paralogous sequence quantification. J Med Genet. 2004;41:908&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735643</ArticleId><ArticleId IdType="pubmed">15591276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529:490&#x2013;5. doi: 10.1038/nature16526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature16526</ArticleId><ArticleId IdType="pmc">PMC4851738</ArticleId><ArticleId IdType="pubmed">26735016</ArticleId></ArticleIdList></Reference><Reference><Citation>Stemmer M, Thumberger T, Del Sol Keyer M, Wittbrodt J, Mateo JL. CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool. PloS ONE. 2015;10:e0124633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4409221</ArticleId><ArticleId IdType="pubmed">25909470</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32697942</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Disrupted Place Cell Remapping and Impaired Grid Cells in a Knockin Model of Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>1095</StartPage><EndPage>1112.e6</EndPage><MedlinePgn>1095-1112.e6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2020.06.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(20)30477-3</ELocationID><Abstract><AbstractText>Patients with Alzheimer's disease (AD) suffer from spatial memory impairment and wandering behavior, but the brain circuit mechanisms causing such symptoms remain largely unclear. In healthy brains, spatially tuned hippocampal place cells and entorhinal grid cells exhibit distinct spike patterns in different environments, a circuit function called "remapping." We tested remapping in amyloid precursor protein knockin (APP-KI) mice with impaired spatial memory. CA1 neurons, including place cells, showed disrupted remapping, although their spatial tuning was only mildly diminished. Medial entorhinal cortex (MEC) neurons severely lost their spatial tuning and grid cells were almost absent. Fast gamma oscillatory coupling between the MEC and CA1 was also impaired. Mild disruption of MEC grid cells emerged in younger APP-KI mice, although the spatial memory and CA1 remapping of the animals remained intact. These results point to remapping impairment in the hippocampus, possibly linked to grid cell disruption, as circuit mechanisms underlying spatial memory impairment in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Heechul</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, University of California, Irvine, Irvine, CA, USA; Center for the Neurobiology of Learning and Memory, University of California, Irvine, Irvine, CA, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA. Electronic address: heechulj@hs.uci.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bramian</LastName><ForeName>Allen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soma</LastName><ForeName>Shogo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Lab for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Saitama 351-0106, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Lab for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Saitama 351-0106, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Igarashi</LastName><ForeName>Kei M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, University of California, Irvine, Irvine, CA, USA; Center for the Neurobiology of Learning and Memory, University of California, Irvine, Irvine, CA, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA; Japan Science and Technology Agency, Tokyo, Japan. Electronic address: kei.igarashi@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM008620</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH121736</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG069500</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG063864</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066806</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000705833">APP protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2020 Sep 23;107(6):990-991. doi: 10.1016/j.neuron.2020.08.016.</RefSource><PMID Version="1">32970999</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056547" MajorTopicYN="N">CA1 Region, Hippocampal</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063132" MajorTopicYN="Y">Connectome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065818" MajorTopicYN="N">Gamma Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">gamma oscillations</Keyword><Keyword MajorTopicYN="N">grid cells</Keyword><Keyword MajorTopicYN="N">knockin</Keyword><Keyword MajorTopicYN="N">place cells</Keyword><Keyword MajorTopicYN="N">remapping</Keyword></KeywordList><CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32697942</ArticleId><ArticleId IdType="mid">NIHMS1608607</ArticleId><ArticleId IdType="pmc">PMC7529950</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2020.06.023</ArticleId><ArticleId IdType="pii">S0896-6273(20)30477-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alme CB, Miao C, Jezek K, Treves A, Moser EI, and Moser MB (2014). Place cells in the hippocampus: eleven maps for eleven rooms. Proceedings of the National Academy of Sciences of the United States of America 111, 18428&#x2013;18435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284589</ArticleId><ArticleId IdType="pubmed">25489089</ArticleId></ArticleIdList></Reference><Reference><Citation>Axmacher N, Henseler MM, Jensen O, Weinreich I, Elger CE, and Fell J (2010). Cross-frequency coupling supports multi-item working memory in the human hippocampus. Proceedings of the National Academy of Sciences of the United States of America 107, 3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840289</ArticleId><ArticleId IdType="pubmed">20133762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartho P, Hirase H, Monconduit L, Zugaro M, Harris KD, and Buzsaki G (2004). Characterization of neocortical principal cells and interneurons by network interactions and extracellular features. J Neurophysiol 92, 600&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bragin A, Jando G, Nadasdy Z, Hetke J, Wise K, and Buzsaki G (1995). Gamma (40&#x2013;100 Hz) oscillation in the hippocampus of the behaving rat. J Neurosci 15, 47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578273</ArticleId><ArticleId IdType="pubmed">7823151</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, and Garaschuk O (2008). Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer&#x2019;s disease. Science 321, 1686&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacucci F, Yi M, Wills TJ, Chapman P, and O&#x2019;Keefe J (2008). Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model. Proceedings of the National Academy of Sciences of the United States of America 105, 7863&#x2013;7868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396558</ArticleId><ArticleId IdType="pubmed">18505838</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrobak JJ, and Buzsaki G (1998). Gamma oscillations in the entorhinal cortex of the freely behaving rat. J Neurosci 18, 388&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793397</ArticleId><ArticleId IdType="pubmed">9412515</ArticleId></ArticleIdList></Reference><Reference><Citation>Colgin LL, Denninger T, Fyhn M, Hafting T, Bonnevie T, Jensen O, Moser MB, and Moser EI (2009). Frequency of gamma oscillations routes flow of information in the hippocampus. Nature 462, 353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">19924214</ArticleId></ArticleIdList></Reference><Reference><Citation>Colgin LL, Moser EI, and Moser MB (2008). Understanding memory through hippocampal remapping. Trends in neurosciences 31, 469&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">18687478</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmukh SS, Yoganarasimha D, Voicu H, and Knierim JJ (2010). Theta modulation in the medial and the lateral entorhinal cortices. J Neurophysiol 104, 994&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2934945</ArticleId><ArticleId IdType="pubmed">20505130</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl GW, Hon OJ, Leutgeb S, and Leutgeb JK (2017). Grid and Nongrid Cells in Medial Entorhinal Cortex Represent Spatial Location and Environmental Features with Complementary Coding Schemes. Neuron 94, 83&#x2013;92 e86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444540</ArticleId><ArticleId IdType="pubmed">28343867</ArticleId></ArticleIdList></Reference><Reference><Citation>Doeller CF, Barry C, and Burgess N (2010). Evidence for grid cells in a human memory network. Nature 463, 657&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3173857</ArticleId><ArticleId IdType="pubmed">20090680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekstrom AD, Kahana MJ, Caplan JB, Fields TA, Isham EA, Newman EL, and Fried I (2003). Cellular networks underlying human spatial navigation. Nature 425, 184&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">12968182</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Rodriguez GA, Herman M, Emrani S, Nahmani E, Barrett G, Figueroa HY, Goldberg E, Hussaini SA, and Duff KE (2017). Tau Pathology Induces Excitatory Neuron Loss, Grid Cell Dysfunction, and Spatial Memory Deficits Reminiscent of Early Alzheimer&#x2019;s Disease. Neuron 93, 533&#x2013;541 e535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363269</ArticleId><ArticleId IdType="pubmed">28111080</ArticleId></ArticleIdList></Reference><Reference><Citation>Fyhn M, Hafting T, Treves A, Moser MB, and Moser EI (2007). Hippocampal remapping and grid realignment in entorhinal cortex. Nature 446, 190&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">17322902</ArticleId></ArticleIdList></Reference><Reference><Citation>Fyhn M, Molden S, Witter MP, Moser EI, and Moser MB (2004). Spatial representation in the entorhinal cortex. Science 305, 1258&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pubmed">15333832</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamache J, Benzow K, Forster C, Kemper L, Hlynialuk C, Furrow E, Ashe KH, and Koob MD (2019). Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice. Nat Commun 10, 2479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554306</ArticleId><ArticleId IdType="pubmed">31171783</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW Jr., Morris JC, Growdon JH, and Hyman BT (1996). Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci 16, 4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardcastle K, Maheswaranathan N, Ganguli S, and Giocomo LM (2017). A Multiplexed, Heterogeneous, and Adaptive Code for Navigation in Medial Entorhinal Cortex. Neuron 94, 375&#x2013;387 e377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5498174</ArticleId><ArticleId IdType="pubmed">28392071</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksen EJ, Colgin LL, Barnes CA, Witter MP, Moser MB, and Moser EI (2010). Spatial representation along the proximodistal axis of CA1. Neuron 68, 127&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093538</ArticleId><ArticleId IdType="pubmed">20920796</ArticleId></ArticleIdList></Reference><Reference><Citation>Hope T, Tilling KM, Gedling K, Keene JM, Cooper SD, and Fairburn CG (1994). The Structure of Wandering in Dementia. Int J Geriatr Psych 9, 149&#x2013;155.</Citation></Reference><Reference><Citation>Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, et al. (2016). Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 540, 230&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656389</ArticleId><ArticleId IdType="pubmed">27929004</ArticleId></ArticleIdList></Reference><Reference><Citation>Igarashi KM, Lu L, Colgin LL, Moser MB, and Moser EI (2014). Coordination of entorhinal-hippocampal ensemble activity during associative learning. Nature 510, 143&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">24739966</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery KJ, Gilbert A, Burton S, and Strudwick A (2003). Preserved performance in a hippocampal-dependent spatial task despite complete place cell remapping. Hippocampus 13, 175&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">12699326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanter BR, Lykken CM, Avesar D, Weible A, Dickinson J, Dunn B, Borgesius NZ, Roudi Y, and Kentros CG (2017). A Novel Mechanism for the Grid-to-Place Cell Transformation Revealed by Transgenic Depolarization of Medial Entorhinal Cortex Layer II. Neuron 93, 1480&#x2013;1492 e1486.</Citation><ArticleIdList><ArticleId IdType="pubmed">28334610</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, Mayeux R, Duff KE, and Small SA (2014). Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer&#x2019;s disease. Nature neuroscience 17, 304&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044925</ArticleId><ArticleId IdType="pubmed">24362760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunz L, Schroder TN, Lee H, Montag C, Lachmann B, Sariyska R, Reuter M, Stirnberg R, Stocker T, Messing-Floeter PC, et al. (2015). Reduced grid-cell-like representations in adults at genetic risk for Alzheimer&#x2019;s disease. Science 350, 430&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">26494756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyle CT, Stokes JD, Lieberman JS, Hassan AS, and Ekstrom AD (2015). Successful retrieval of competing spatial environments in humans involves hippocampal pattern separation mechanisms. Elife 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4733045</ArticleId><ArticleId IdType="pubmed">26613414</ArticleId></ArticleIdList></Reference><Reference><Citation>Langston RF, Ainge JA, Couey JJ, Canto CB, Bjerknes TL, Witter MP, Moser EI, and Moser MB (2010). Development of the spatial representation system in the rat. Science 328, 1576&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">20558721</ArticleId></ArticleIdList></Reference><Reference><Citation>Leutgeb JK, Leutgeb S, Moser MB, and Moser EI (2007). Pattern separation in the dentate gyrus and CA3 of the hippocampus. Science 315, 961&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">17303747</ArticleId></ArticleIdList></Reference><Reference><Citation>Leutgeb JK, Leutgeb S, Treves A, Meyer R, Barnes CA, McNaughton BL, Moser MB, and Moser EI (2005a). Progressive transformation of hippocampal neuronal representations in &#x201c;morphed&#x201d; environments. Neuron 48, 345&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242413</ArticleId></ArticleIdList></Reference><Reference><Citation>Leutgeb S, Leutgeb JK, Barnes CA, Moser EI, McNaughton BL, and Moser MB (2005b). Independent codes for spatial and episodic memory in hippocampal neuronal ensembles. Science 309, 619&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">16040709</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang L, Oline SN, Kirk JC, Schmitt LI, Komorowski RW, Remondes M, and Halassa MM (2017). Scalable, Lightweight, Integrated and Quick-to-Assemble (SLIQ) Hyperdrives for Functional Circuit Dissection. Front Neural Circuits 11, 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5303737</ArticleId><ArticleId IdType="pubmed">28243194</ArticleId></ArticleIdList></Reference><Reference><Citation>Mably AJ, Gereke BJ, Jones DT, and Colgin LL (2017). Impairments in spatial representations and rhythmic coordination of place cells in the 3xTg mouse model of Alzheimer&#x2019;s disease. Hippocampus 27, 378&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">28032686</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh TJ, Jones MW, Quinn JJ, Balthasar N, Coppari R, Elmquist JK, Lowell BB, Fanselow MS, Wilson MA, and Tonegawa S (2007). Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network. Science 317, 94&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556551</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao C, Cao Q, Ito HT, Yamahachi H, Witter MP, Moser MB, and Moser EI (2015). Hippocampal Remapping after Partial Inactivation of the Medial Entorhinal Cortex. Neuron 88, 590&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">26539894</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao C, Cao Q, Moser MB, and Moser EI (2017). Parvalbumin and Somatostatin Interneurons Control Different Space-Coding Networks in the Medial Entorhinal Cortex. Cell 171, 507&#x2013;521 e517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651217</ArticleId><ArticleId IdType="pubmed">28965758</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Garrud P, Rawlins JN, and O&#x2019;Keefe J (1982). Place navigation impaired in rats with hippocampal lesions. Nature 297, 681&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">7088155</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser EI, Moser MB, and Roudi Y (2014). Network mechanisms of grid cells. Philosophical transactions of the Royal Society of London Series B, Biological sciences 369, 20120511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3866436</ArticleId><ArticleId IdType="pubmed">24366126</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser MB, Rowland DC, and Moser EI (2015). Place cells, grid cells, and memory. Cold Spring Harb Perspect Biol 7, a021808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4315928</ArticleId><ArticleId IdType="pubmed">25646382</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller RU, and Kubie JL (1987). The effects of changes in the environment on the spatial firing of hippocampal complex-spike cells. J Neurosci 7, 1951&#x2013;1968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568940</ArticleId><ArticleId IdType="pubmed">3612226</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazono T, Jun H, Blurton-Jones M, Green KN, and Igarashi KM (2018). Gamma oscillations in the entorhinal-hippocampal circuit underlying memory and dementia. Neurosci Res 129, 40&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7059556</ArticleId><ArticleId IdType="pubmed">29438778</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazono T, Lam TN, Patel AY, Kitazawa M, Saito T, Saido TC, and Igarashi KM (2017). Impaired in vivo gamma oscillations in the medial entorhinal cortex of knock-in Alzheimer model. Front Syst Neurosci 11, 48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5491963</ArticleId><ArticleId IdType="pubmed">28713250</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilssen ES, Doan TP, Nigro MJ, Ohara S, and Witter MP (2019). Neurons and networks in the entorhinal cortex: A reappraisal of the lateral and medial entorhinal subdivisions mediating parallel cortical pathways. Hippocampus 29, 1238&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">31408260</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keefe J, and Dostrovsky J (1971). The hippocampus as a spatial map. Preliminary evidence from unit activity in the freely-moving rat. Brain research 34, 171&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">5124915</ArticleId></ArticleIdList></Reference><Reference><Citation>Quilichini P, Sirota A, and Buzsaki G (2010). Intrinsic circuit organization and theta-gamma oscillation dynamics in the entorhinal cortex of the rat. J Neurosci 30, 11128&#x2013;11142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2937273</ArticleId><ArticleId IdType="pubmed">20720120</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, and Saido TC (2014). Single App knock-in mouse models of Alzheimer&#x2019;s disease. Nature neuroscience 17, 661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sargolini F, Fyhn M, Hafting T, McNaughton BL, Witter MP, Moser MB, and Moser EI (2006). Conjunctive representation of position, direction, and velocity in entorhinal cortex. Science 312, 758&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">16675704</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, and Saido TC (2017). APP mouse models for Alzheimer&#x2019;s disease preclinical studies. EMBO J 36, 2473&#x2013;2487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5579350</ArticleId><ArticleId IdType="pubmed">28768718</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlesiger MI, Boublil BL, Hales JB, Leutgeb JK, and Leutgeb S (2018). Hippocampal Global Remapping Can Occur without Input from the Medial Entorhinal Cortex. Cell Rep 22, 3152&#x2013;3159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5929481</ArticleId><ArticleId IdType="pubmed">29562172</ArticleId></ArticleIdList></Reference><Reference><Citation>Schomburg EW, Fernandez-Ruiz A, Mizuseki K, Berenyi A, Anastassiou CA, Koch C, and Buzsaki G (2014). Theta phase segregation of input-specific gamma patterns in entorhinal-hippocampal networks. Neuron 84, 470&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253689</ArticleId><ArticleId IdType="pubmed">25263753</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoville WB, and Milner B (1957). Loss of recent memory after bilateral hippocampal lesions. Journal of neurology, neurosurgery, and psychiatry 20, 11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC497229</ArticleId><ArticleId IdType="pubmed">13406589</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaggs WE, McNaughton BL, Gothard KM, and Markus EJ (1993). An information-theoretic approach to deciphering the hippocampal code . In Advances in Neural Processing Systems, Vol 5 Eds: Hanson SJ, Cowan JD &amp; Giles CL (San Mateo, Morgan Kaufmann; ), pp. 1030&#x2013;1037.</Citation></Reference><Reference><Citation>Steffenach HA, Witter M, Moser MB, and Moser EI (2005). Spatial memory in the rat requires the dorsolateral band of the entorhinal cortex. Neuron 45, 301&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">15664181</ArticleId></ArticleIdList></Reference><Reference><Citation>Tort AB, Komorowski RW, Manns JR, Kopell NJ, and Eichenbaum H (2009). Theta-gamma coupling increases during the learning of item-context associations. Proceedings of the National Academy of Sciences of the United States of America 106, 20942&#x2013;20947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791641</ArticleId><ArticleId IdType="pubmed">19934062</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosh JL, Rickman M, Rhymes E, Norona FE, Clayton E, Mucke L, Isaacs AM, Fisher EMC, and Wiseman FK (2017). The integration site of the APP transgene in the J20 mouse model of Alzheimer&#x2019;s disease. Wellcome Open Res 2, 84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5645710</ArticleId><ArticleId IdType="pubmed">29062914</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoesen GW, Hyman BT, and Damasio AR (1991). Entorhinal cortex pathology in Alzheimer&#x2019;s disease. Hippocampus 1, 1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669339</ArticleId></ArticleIdList></Reference><Reference><Citation>Witter MP, and Amaral DG (2004). Hippocampal Formation In The Rat Nervous System 3rd edn (ed Paxinos G), Paxinos G, ed. (Amsterdam, The Netherlands: Elsevier; ).</Citation></Reference><Reference><Citation>Yassa MA, and Stark CE (2011). Pattern separation in the hippocampus. Trends in neurosciences 34, 515&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183227</ArticleId><ArticleId IdType="pubmed">21788086</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32702314</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>182</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>976</StartPage><EndPage>991.e19</EndPage><MedlinePgn>976-991.e19</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2020.06.038</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(20)30815-1</ELocationID><Abstract><AbstractText>Although complex inflammatory-like alterations are observed around the amyloid plaques of Alzheimer's disease (AD), little is known about the molecular changes and cellular interactions that characterize this response. We investigate here, in an AD mouse model, the transcriptional changes occurring in tissue domains in a 100-&#x3bc;m diameter around amyloid plaques using spatial transcriptomics. We demonstrate early alterations in a gene co-expression network enriched for myelin and oligodendrocyte genes (OLIGs), whereas a multicellular gene co-expression network of plaque-induced genes (PIGs) involving the complement system, oxidative stress, lysosomes, and inflammation is prominent in the later phase of the disease. We confirm the majority of the observed alterations at the cellular level using in situ sequencing on mouse and human brain sections. Genome-wide spatial transcriptomics analysis provides an unprecedented approach to untangle the dysregulated cellular network in the vicinity of pathogenic hallmarks of AD and other brain diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei-Ting</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craessaerts</LastName><ForeName>Katleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavie</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium; VIB Bio Imaging Core, Gent 9052, Belgium; VIB Bio Imaging Core, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sala Frigerio</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium; UK Dementia Research Institute at University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corthout</LastName><ForeName>Nikky</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium; VIB Bio Imaging Core, Gent 9052, Belgium; VIB Bio Imaging Core, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Cartana AB, Nobels v&#xe4;g 16, Solna 17165, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lal&#xe1;kov&#xe1;</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cartana AB, Nobels v&#xe4;g 16, Solna 17165, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;hnemund</LastName><ForeName>Malte</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cartana AB, Nobels v&#xe4;g 16, Solna 17165, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voytyuk</LastName><ForeName>Iryna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfs</LastName><ForeName>Leen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancuso</LastName><ForeName>Renzo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salta</LastName><ForeName>Evgenia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balusu</LastName><ForeName>Sriram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snellinx</LastName><ForeName>An</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munck</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium; VIB Bio Imaging Core, Gent 9052, Belgium; VIB Bio Imaging Core, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jurek</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Solna, Stockholm 17121, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez Navarro</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Solna, Stockholm 17121, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huitinga</LastName><ForeName>Inge</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neuroimmunology, Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam 1105BA, the Netherlands; Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam 1098XH, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundeberg</LastName><ForeName>Joakim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Solna, Stockholm 17121, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiers</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium; UK Dementia Research Institute at University College London, London WC1E 6BT, UK. Electronic address: mark.fiers@kuleuven.vib.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven 3000, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven 3000, Belgium; UK Dementia Research Institute at University College London, London WC1E 6BT, UK. Electronic address: b.strooper@ukdri.ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-36-7</RegistryNumber><NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Genome Biol. 2024 Apr 19;25(1):103. doi: 10.1186/s13059-024-03245-3.</RefSource><PMID Version="1">38641849</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyloid plaque</Keyword><Keyword MajorTopicYN="N">astrocyte</Keyword><Keyword MajorTopicYN="N">cellular phase</Keyword><Keyword MajorTopicYN="N">complement cascade</Keyword><Keyword MajorTopicYN="N">in situ sequencing</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">myelination</Keyword><Keyword MajorTopicYN="N">oligodendrocyte</Keyword><Keyword MajorTopicYN="N">spatial transcriptomics</Keyword></KeywordList><CoiStatement>Declaration of Interests X.Q., J.L., and M.K. are employees of CARTANA AB. A.J. is an employee of, J.L. is a scientific advisor for, and J.F.N. has an IP agreement with 10X Genomics. B.D.S. is consultant for several companies but has no COI with the current manuscript. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32702314</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.06.038</ArticleId><ArticleId IdType="pii">S0092-8674(20)30815-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32709662</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1550-6606</ISSN><JournalIssue CitedMedium="Internet"><Volume>205</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of immunology (Baltimore, Md. : 1950)</Title><ISOAbbreviation>J Immunol</ISOAbbreviation></Journal><ArticleTitle>An Ig &#x3b3; Marker Genotype Is a Strong Risk Factor for Alzheimer Disease, Independent of Apolipoprotein E &#x3b5;4 Genotype.</ArticleTitle><Pagination><StartPage>1318</StartPage><EndPage>1322</EndPage><MedlinePgn>1318-1322</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.2000351</ELocationID><Abstract><AbstractText>Increasing evidence implicates HSV type 1 (HSV1) in the pathogenesis of late-onset Alzheimer disease (AD). HSV1 has evolved highly sophisticated strategies to evade host immunosurveillance. One strategy involves encoding a decoy Fc&#x3b3; receptor (Fc&#x3b3;R), which blocks Fc-mediated effector functions, such as Ab-dependent cellular cytotoxicity. Ig &#x3b3; marker (GM) allotypes, encoded by highly polymorphic <i>IGHG</i> genes on chromosome 14q32, modulate this immunoevasion strategy, and thus may act as effect modifiers of the HSV1-AD association. In this nested case-control human study, 365 closely matched case-control pairs-whose blood was drawn on average 9.6 y before AD diagnosis-were typed for GM alleles by a TaqMan genotyping assay. <i>APOE</i> genotype and a genetic risk score based on nine additional previously known AD risk genes (<i>ABCA7, BIN1, CD33, CLU, CR1, EPHA1, MS4A4E, NECTIN2</i>, and <i>PICALM</i>) were extracted from a genome-wide association study analysis. Antiviral Abs were measured by ELISA. Conditional logistic regression models were applied. The distribution of GM 3/17 genotypes differed significantly between AD cases and controls, with higher frequency of GM 17/17 homozygotes in AD cases as compared with controls (19.8 versus 10.7%, <i>p</i> = 0.001). The GM 17/17 genotype was associated with a 4-fold increased risk of AD (odds ratio 4.142, <i>p</i> &lt; 0.001). In conclusion, the results of this study demonstrate that Ig GM 17/17 genotype contributes to the risk of later AD development, independent of apolipoprotein &#x3b5;4 genotype and other AD risk genes, and explain, at least in part, why every HSV1-infected person is not equally likely to develop HSV1-associated AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 by The American Association of Immunologists, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Janardan P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0001-9992-4737</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425; pandeyj@musc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Jan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9094-319X</Identifier><AffiliationInfo><Affiliation>Division of Virology, Department of Clinical Microbiology, Ume&#xe5; University, 901 85 Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weidung</LastName><ForeName>Bodil</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-3232-6227</Identifier><AffiliationInfo><Affiliation>Division of Geriatric Medicine, Department of Public Health and Caring Sciences, Uppsala University, 751 05 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kothera</LastName><ForeName>Ronald T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johansson</LastName><ForeName>Anders</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3847-6827</Identifier><AffiliationInfo><Affiliation>Department of Odontology, Ume&#xe5; University, Ume&#xe5;, 901 85, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Sustainable Health, Department of Public Health and Clinical Medicine, Ume&#xe5; University, 901 85 Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksson</LastName><ForeName>Sture</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3098-3787</Identifier><AffiliationInfo><Affiliation>Division of Sustainable Health, Department of Public Health and Clinical Medicine, Ume&#xe5; University, 901 85 Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Geriatric Medicine, Department of Community Medicine and Rehabilitation, Ume&#xe5; University, 901 85 Ume&#xe5;, Sweden; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallmans</LastName><ForeName>G&#xf6;ran</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Sustainable Health, Department of Public Health and Clinical Medicine, Ume&#xe5; University, 901 85 Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elgh</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Virology, Department of Clinical Microbiology, Ume&#xe5; University, 901 85 Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;vheim</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5271-4780</Identifier><AffiliationInfo><Affiliation>Division of Geriatric Medicine, Department of Community Medicine and Rehabilitation, Ume&#xe5; University, 901 85 Ume&#xe5;, Sweden; and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular Medicine, Ume&#xe5; University, 901 85 Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG058489</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Immunol</MedlineTA><NlmUniqueID>2985117R</NlmUniqueID><ISSNLinking>0022-1767</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C029702">prolactin-binding protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Immunol. 2020 Dec 1;205(11):3230. doi: 10.4049/jimmunol.2001135.</RefSource><PMID Version="1">33127824</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32709662</ArticleId><ArticleId IdType="mid">NIHMS1609166</ArticleId><ArticleId IdType="pmc">PMC8973829</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.2000351</ArticleId><ArticleId IdType="pii">jimmunol.2000351</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Itzhaki RF 2018. Corroboration of a major role for herpes simplex virus type 1 in Alzheimer&#x2019;s disease. Front. Aging Neurosci 10: 324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6202583</ArticleId><ArticleId IdType="pubmed">30405395</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangold CA, and Szpara ML. 2019. Persistent infection with herpes simplex virus 1 and Alzheimer&#x2019;s disease&#x2014;a call to study how variability in both virus and host may impact disease. Viruses Oct 20;11(10). pii: E966. doi: 10.3390/v11100966.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11100966</ArticleId><ArticleId IdType="pmc">PMC6833100</ArticleId><ArticleId IdType="pubmed">31635156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball MJ 1982. Limbic predilection in Alzheimer dementia: is reactivated herpes virus involved? Can. J. Neurol. Sci 9:303&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">7116237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeng NS, Chung CH, Lin FH, et al. 2018. Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections&#x2014;a nationwide, population-based cohort study in Taiwan. Neurotherapeutics 15:417&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935641</ArticleId><ArticleId IdType="pubmed">29488144</ArticleId></ArticleIdList></Reference><Reference><Citation>Letenneur L, Peres K, Fleury H, et al. 2008. Seropositivity to herpes simplex virus antibodies and risk of Alzheimer&#x2019;s disease: a population-based cohort study. PLoS ONE 3, e3637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572852</ArticleId><ArticleId IdType="pubmed">18982063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H, Gilthorpe J, Adolfsson R, Nilsson LG, and Elgh F. 2015. Reactivated herpes simplex infection increases the risk of Alzheimer&#x2019;s disease. Alzheimers Dement. 11: 593&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">25043910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H, Gilthorpe J, Johansson A, Eriksson S, Hallmans G, Elgh F. 2015. Herpes simplex infection and the risk of Alzheimer&#x2019;s disease: A nested case-control study. Alzheimers Dement. 11:587&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">25304990</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopatko Lindman K, Weidung B, Olsson J, et al. 2019. A genetic signature including apolipoprotein Eepsilon4 potentiates the risk of herpes simplex-associated Alzheimer&#x2019;s disease. Alzheimers Dement. (N. Y.) 5:697&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6944738</ArticleId><ArticleId IdType="pubmed">31921962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H, Norman T, Weidung B, et al. 2019. Herpes simplex virus, APOE&#x3b5;4, and cognitive decline in old age: Results from the Betula cohort study. J. Alzheimers Dis 67: 211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">30636735</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B, Haure-Mirande JV, Funk CC, et al. 2018. Multiscale analysis of independent Alzheimer&#x2019;s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron 99:64&#x2013;82.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551233</ArticleId><ArticleId IdType="pubmed">29937276</ArticleId></ArticleIdList></Reference><Reference><Citation>De Chiara G, Piacentini R, Fabiani M, et al. 2019. Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. PLoS Pathog. 15: e1007617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417650</ArticleId><ArticleId IdType="pubmed">30870531</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns DM, Rouleau N, Parker RN, et al. 2020. A 3D human brain&#x2013;like tissue model of herpes-induced Alzheimer&#x2019;s disease. Sci. Adv 6: eaay8828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202879</ArticleId><ArticleId IdType="pubmed">32494701</ArticleId></ArticleIdList></Reference><Reference><Citation>Doll JR, Hoebe K, Thompson RL, and Sawtell NM. 2020. Resolution of herpes simplex virus reactivation in vivo results in neuronal destruction. PLoS Pathog. 16: e1008296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7058292</ArticleId><ArticleId IdType="pubmed">32134994</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson J, Kok E, Adolfsson R, L&#xf6;vheim H, and Elgh F. 2017. Herpes virus seroepidemiology in the adult Swedish population. Immun. Ageing 14:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5424393</ArticleId><ArticleId IdType="pubmed">28491117</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank I, and Friedman HM. 1989. A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J. Virol 63:4479&#x2013;4488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC251078</ArticleId><ArticleId IdType="pubmed">2552134</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprague ER, Wang C, Baker D, and Bjorkman PJ. 2006. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol. 4(6):e148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1450327</ArticleId><ArticleId IdType="pubmed">16646632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubinski JM, Lazear HM, Awasthi S, Wang F, and Friedman HM. 2011. The herpes simplex virus 1 IgG Fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. J. Virol 85:3239&#x2013;3249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067879</ArticleId><ArticleId IdType="pubmed">21228231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndjamen B, Farley AH, Lee T, Fraser SE, and Bjorkman PJ. 2014. The herpes virus Fc receptor gE-gI mediates antibody bipolar bridging to clear viral antigens from the cell surface. PLoS Pathog. 10: e1003961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946383</ArticleId><ArticleId IdType="pubmed">24604090</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxelius VA, and Pandey JP. 2013. Human immunoglobulin constant heavy G chain (IGHG) (Fc&#x3b3;) (GM) genes, defining innate variants of IgG molecules and B cells, have impact on disease and therapy. Clin. Immunol 149:475&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">24239836</ArticleId></ArticleIdList></Reference><Reference><Citation>Atherton A, Armour KL, Bell S, Minson AC, and Clark MR. 2000. The herpes simplex virus type 1 Fc receptor discriminates between IgG1 allotypes. Eur. J. Immunol 30:2540&#x2013;2547.</Citation><ArticleIdList><ArticleId IdType="pubmed">11009087</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey JP 2009. Immunoglobulin GM genes as functional risk and protective factors for the development of Alzheimer&#x2019;s disease. J. Alzheimer&#x2019;s Dis 17:753&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">19542624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallmans G, Agren A, Johansson G, et al. 2003. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort - evaluation of risk factors and their interactions. Scand. J. Public Health Suppl 61:18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">14660243</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey JP, Kothera RT, Liu S, Costa AS, Mancuso R, and Agostini S. 2019. Immunoglobulin genes and immunity to HSV1 in Alzheimer&#x2019;s disease. J. Alzheimer&#x2019;s Dis 70:917&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">31306125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H, Olsson J, Weidung B, et al. 2018. Interaction between cytomegalovirus and herpes simplex virus type 1 associated with the risk of Alzheimer&#x2019;s disease development. J. Alzheimers Dis 61: 939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">29254081</ArticleId></ArticleIdList></Reference><Reference><Citation>Moraru M, Black LE, Muntasell A, et al. 2015. NK cells and immunoglobulins interplay in defense against herpes simplex virus type 1: epistatic interaction of CD16A and IgG1 allotypes of variable affinity modulates antibody-dependent cellular cytotoxicity and susceptibility to clinical reactivation. J. Immunol 195:1676&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">26179905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D, Choi SH, Washicosky KJ, et al. Amyloid-&#x3b2; peptide protects against microbial infection in mouse and worm models of Alzheimer&#x2019;s disease. Sci. Transl. Med 2016; 8: 340ra72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505565</ArticleId><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey JP 2010. Candidate gene approach&#x2019;s missing link. Science 329:1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">20813938</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey JP 2010. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med 363:2076&#x2013;2077.</Citation><ArticleIdList><ArticleId IdType="pubmed">21083406</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32722745</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>324</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.</ArticleTitle><Pagination><StartPage>772</StartPage><EndPage>781</EndPage><MedlinePgn>772-781</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2020.12134</ELocationID><Abstract><AbstractText Label="IMPORTANCE">There are limitations in current diagnostic testing approaches for Alzheimer disease (AD).</AbstractText><AbstractText Label="OBJECTIVE">To examine plasma tau phosphorylated at threonine 217 (P-tau217) as a diagnostic biomarker for AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Three cross-sectional cohorts: an Arizona-based neuropathology cohort (cohort 1), including 34 participants with AD and 47 without AD (dates of enrollment, May 2007-January 2019); the Swedish BioFINDER-2 cohort (cohort 2), including cognitively unimpaired participants (n&#x2009;=&#x2009;301) and clinically diagnosed patients with mild cognitive impairment (MCI) (n&#x2009;=&#x2009;178), AD dementia (n&#x2009;=&#x2009;121), and other neurodegenerative diseases (n&#x2009;=&#x2009;99) (April 2017-September 2019); and a Colombian autosomal-dominant AD kindred (cohort 3), including 365 PSEN1 E280A mutation carriers and 257 mutation noncarriers (December 2013-February 2017).</AbstractText><AbstractText Label="EXPOSURES">Plasma P-tau217.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Primary outcome was the discriminative accuracy of plasma P-tau217 for AD (clinical or neuropathological diagnosis). Secondary outcome was the association with tau pathology (determined using neuropathology or positron emission tomography [PET]).</AbstractText><AbstractText Label="RESULTS">Mean age was 83.5 (SD, 8.5) years in cohort 1, 69.1 (SD, 10.3) years in cohort 2, and 35.8 (SD, 10.7) years in cohort 3; 38% were women in cohort 1, 51% in cohort 2, and 57% in cohort 3. In cohort 1, antemortem plasma P-tau217 differentiated neuropathologically defined AD from non-AD (area under the curve [AUC], 0.89 [95% CI, 0.81-0.97]) with significantly higher accuracy than plasma P-tau181 and neurofilament light chain (NfL) (AUC range, 0.50-0.72; P&#x2009;&lt;&#x2009;.05). The discriminative accuracy of plasma P-tau217 in cohort 2 for clinical AD dementia vs other neurodegenerative diseases (AUC, 0.96 [95% CI, 0.93-0.98]) was significantly higher than plasma P-tau181, plasma NfL, and MRI measures (AUC range, 0.50-0.81; P&#x2009;&lt;&#x2009;.001) but not significantly different compared with cerebrospinal fluid (CSF) P-tau217, CSF P-tau181, and tau-PET (AUC range, 0.90-0.99; P&#x2009;&gt;&#x2009;.15). In cohort 3, plasma P-tau217 levels were significantly greater among PSEN1 mutation carriers, compared with noncarriers, from approximately 25 years and older, which is 20 years prior to estimated onset of MCI among mutation carriers. Plasma P-tau217 levels correlated with tau tangles in participants with (Spearman &#x3c1;&#x2009;=&#x2009;0.64; P&#x2009;&lt;&#x2009;.001), but not without (Spearman &#x3c1;&#x2009;=&#x2009;0.15; P&#x2009;=&#x2009;.33), &#x3b2;-amyloid plaques in cohort 1. In cohort 2, plasma P-tau217 discriminated abnormal vs normal tau-PET scans (AUC, 0.93 [95% CI, 0.91-0.96]) with significantly higher accuracy than plasma P-tau181, plasma NfL, CSF P-tau181, CSF A&#x3b2;42:A&#x3b2;40 ratio, and MRI measures (AUC range, 0.67-0.90; P&#x2009;&lt;&#x2009;.05), but its performance was not significantly different compared with CSF P-tau217 (AUC, 0.96; P&#x2009;=&#x2009;.22).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Among 1402 participants from 3 selected cohorts, plasma P-tau217 discriminated AD from other neurodegenerative diseases, with significantly higher accuracy than established plasma- and MRI-based biomarkers, and its performance was not significantly different from key CSF- or PET-based measures. Further research is needed to optimize the assay, validate the findings in unselected and diverse populations, and determine its potential role in clinical care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medellin, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medellin, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yinghua</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Geidy E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Sun City, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leuzy</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson-Carlgren</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villegas</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medellin, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulveda-Falla</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medellin, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Neuropathology of Alzheimer's Disease (MoNeA), Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Xiyun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proctor</LastName><ForeName>Nicholas K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Sun City, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dage</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Arizona, Phoenix.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Arizona State University, Phoenix.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Genomics Research Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Oct;16(10):521. doi: 10.1038/s41582-020-0401-z.</RefSource><PMID Version="1">32792665</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Quiroz reported receiving grants from the National Institutes of Health (NIH) and Massachusetts General Hospital. Dr Zetterberg reported receiving grants from The Knut and Alice Wallenberg Foundation, European Research Council, and Swedish Research Council; receiving personal fees from Samumed, Roche Diagnostics, CogRx, Wave, Alzecure, and Biogen; and that he is cofounder of Brain Biomarker Solutions in Gothenburg AB. Dr Lopera reported receiving grants from the NIH and Genentech/Roche/Banner and receiving personal fees from the NIH. Dr Su reported receiving grants from the NIH, the State of Arizona, BrightFocus Foundation, and Alzheimer's Association and receiving personal fees from Green Valley Pharmaceutical LLC. Dr Chai reported a patent to pTau217 assay and its use, antibodies pending. Dr Beach reported receiving grants from the State of Arizona; receiving personal fees from Prothena Biosciences, Vivid Genomics, and Avid Radiopharmaceuticals; and holding stock options with Vivid Genomics. Dr Blennow reported receiving personal fees from Abcam, Axon, Biogen, Lilly, MagQu, Novartis, and Roche Diagnostics and that he is cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Dr Dage reported a patent pending for compounds and methods targeting human tau. Dr Reiman reported receiving grants from National Institute on Aging and the State of Arizona; receiving philanthropic funding from the Banner Alzheimer&#x2019;s Foundation, Sun Health Foundation, and Roche/Roche Diagnostics; receiving personal fees from Alkahest, Alzheon, Aural Analytics, Denali, Green Valley, MagQ, Takeda/Zinfandel, United Neuroscience; that he has since submission of manuscript become a cofounder of AlzPath, which aims to further develop P-tau217 and fluid biomarkers and advance their use in research, drug development, and clinical settings; holding a patent owned by Banner Health for a strategy to use biomarkers to accelerate evaluation of Alzheimer prevention therapies; and that he is a principal investigator of prevention trials that include research agreements with Genentech/Roche and Novartis/Amgen, PET studies that include research agreements with Avid/Lilly, and several NIH and Foundation-supported research studies. Dr Hansson reported receiving grants from Roche, Biogen, and Pfizer and receiving nonfinancial support from GE Healthcare, AVID Radiopharmaceuticals, and Euroimmun. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32722745</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pii">2768841</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimers Dement. 2007;3(3):186-191. doi:10.1016/j.jalz.2007.04.381</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2007.04.381</ArticleId><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Action Plan on the Public Health Response to Dementia 2017-2025. World Health Organization; 2017.</Citation></Reference><Reference><Citation>Abbasi J. Promising results in 18-month analysis of Alzheimer drug candidate. JAMA. 2018;320(10):965. doi:10.1001/jama.2018.13027</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.13027</ArticleId><ArticleId IdType="pubmed">30208438</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussi&#xe8;re T, et al. . The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature. 2016;537(7618):50-56. doi:10.1038/nature19323</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Gatsonis C, Apgar C, et al. . Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286-1294. doi:10.1001/jama.2019.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.2000</ArticleId><ArticleId IdType="pmc">PMC6450276</ArticleId><ArticleId IdType="pubmed">30938796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Rabinovici GD, Smith R, et al. . Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320(11):1151-1162. doi:10.1001/jama.2018.12917</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.12917</ArticleId><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, et al. . CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385-393. doi:10.1001/jama.2009.1064</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.1064</ArticleId><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Smith R, et al. . Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer&#x2019;s disease. Nat Commun. 2020;11(1):1683. doi:10.1038/s41467-020-15436-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15436-0</ArticleId><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Duits FH, Martinez-Lage P, Paquet C, et al. . Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement. 2016;12(2):154-163. doi:10.1016/j.jalz.2015.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.08.003</ArticleId><ArticleId IdType="pubmed">26368321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V, Ramsey KN, Mawuenyega KG, et al. . Amyloid &#x3b2; concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841-849. doi:10.1016/j.jalz.2017.06.2266</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2266</ArticleId><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Stomrud E, et al. . Performance of fully automated plasma assays as screening tests for Alzheimer disease&#x2013;related &#x3b2;-amyloid status. JAMA Neurol. 2019;76(9):1060-1069. doi:10.1001/jamaneurol.2019.1632</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1632</ArticleId><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="pubmed">31233127</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, et al. . Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med. 2020;26(3):379-386. doi:10.1038/s41591-020-0755-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, et al. ; Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Investigators . Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387-397. doi:10.1038/s41591-020-0762-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Adler CH, Sue LI, et al. . Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology. 2015;35(4):354-389. doi:10.1111/neup.12189</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12189</ArticleId><ArticleId IdType="pmc">PMC4593391</ArticleId><ArticleId IdType="pubmed">25619230</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer&#x2019;s Disease Consensus recommendations for the postmortem diagnosis of Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18(4)(suppl):S1-S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. . The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD), II: standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479-486. doi:10.1212/WNL.41.4.479</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.41.4.479</ArticleId><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259. doi:10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition). American Psychiatric Association; 2013.</Citation></Reference><Reference><Citation>Tariot PN, Lopera F, Langbaum JB, et al. ; Alzheimer&#x2019;s Prevention Initiative . The Alzheimer&#x2019;s Prevention Initiative Autosomal-Dominant Alzheimer&#x2019;s Disease Trial: a study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer&#x2019;s disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y). 2018;4:150-160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6021543</ArticleId><ArticleId IdType="pubmed">29955659</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Heyman A, Mohs RC, et al. . The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD), I: clinical and neuropsychological assessment of Alzheimer&#x2019;s disease. Neurology. 1989;39(9):1159-1165. doi:10.1212/WNL.39.9.1159</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.39.9.1159</ArticleId><ArticleId IdType="pubmed">2771064</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Insel PS, Stomrud E, et al. . Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer&#x2019;s disease. EMBO Mol Med. 2019;11(12):e11170. doi:10.15252/emmm.201911170</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911170</ArticleId><ArticleId IdType="pmc">PMC6895602</ArticleId><ArticleId IdType="pubmed">31709776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Xu J, et al. . Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989-997. doi:10.1016/j.jalz.2018.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Smith R, Ossenkoppele R, et al. . Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. Published online May 11, 2020. doi:10.1001/jamaneurol.2020.0989</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0989</ArticleId><ArticleId IdType="pmc">PMC7215644</ArticleId><ArticleId IdType="pubmed">32391858</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-845. doi:10.2307/2531595</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531595</ArticleId><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Zetterberg H, Reiman EM, et al. . Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer&#x2019;s disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurol. 2020;19(6):513-521. doi:10.1016/S1474-4422(20)30137-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30137-X</ArticleId><ArticleId IdType="pmc">PMC7417082</ArticleId><ArticleId IdType="pubmed">32470423</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Bateman RJ, Hirtz C, et al. . Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer&#x2019;s disease and PET amyloid-positive patient identification. Alzheimers Res Ther. 2020;12(1):26. doi:10.1186/s13195-020-00596-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00596-4</ArticleId><ArticleId IdType="pmc">PMC7079453</ArticleId><ArticleId IdType="pubmed">32183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Li Y, Joseph-Mathurin N, et al. ; Dominantly Inherited Alzheimer Network . A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat Med. 2020;26(3):398-407. doi:10.1038/s41591-020-0781-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0781-z</ArticleId><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Andersson E, Janelidze S, et al. . A&#x3b2; deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer&#x2019;s disease. Sci Adv. 2020;6(16):eaaz2387. doi:10.1126/sciadv.aaz2387</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2387</ArticleId><ArticleId IdType="pmc">PMC7159908</ArticleId><ArticleId IdType="pubmed">32426454</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Janelidze S, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative Investigators . Plasma tau in Alzheimer disease. Neurology. 2016;87(17):1827-1835. doi:10.1212/WNL.0000000000003246</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003246</ArticleId><ArticleId IdType="pmc">PMC5089525</ArticleId><ArticleId IdType="pubmed">27694257</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Insel PS, Zetterberg H, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Swedish BioFINDER study . Accurate risk estimation of &#x3b2;-amyloid positivity to identify prodromal Alzheimer&#x2019;s disease: cross-validation study of practical algorithms. Alzheimers Dement. 2019;15(2):194-204. doi:10.1016/j.jalz.2018.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.08.014</ArticleId><ArticleId IdType="pmc">PMC6374284</ArticleId><ArticleId IdType="pubmed">30365928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Wilson D, Andreasson U, et al. . Plasma tau levels in Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2013;5(2):9. doi:10.1186/alzrt163</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt163</ArticleId><ArticleId IdType="pmc">PMC3707015</ArticleId><ArticleId IdType="pubmed">23551972</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, Goozee K, Sohrabi HR, et al. . Association of plasma neurofilament light chain with neocortical amyloid-&#x3b2; load and cognitive performance in cognitively normal elderly participants. J Alzheimers Dis. 2018;63(2):479-487. doi:10.3233/JAD-180025</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180025</ArticleId><ArticleId IdType="pubmed">29630554</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K; Alzheimer&#x2019;s Disease Neuroimaging Intiative . Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557-566. doi:10.1001/jamaneurol.2016.6117</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6117</ArticleId><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Zhang J, Ye F, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Plasma neurofilament light chain levels in Alzheimer&#x2019;s disease. Neurosci Lett. 2017;650:60-64. doi:10.1016/j.neulet.2017.04.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.04.027</ArticleId><ArticleId IdType="pubmed">28428015</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey TM, Christensen J, et al. . Tau PET in autosomal dominant Alzheimer&#x2019;s disease: relationship with cognition, dementia and other biomarkers. Brain. 2019;142(4):1063-1076. doi:10.1093/brain/awz019</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz019</ArticleId><ArticleId IdType="pmc">PMC6439328</ArticleId><ArticleId IdType="pubmed">30753379</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Sperling RA, Norton DJ, et al. . Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol. 2018;75(5):548-556. doi:10.1001/jamaneurol.2017.4907</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.4907</ArticleId><ArticleId IdType="pmc">PMC5885174</ArticleId><ArticleId IdType="pubmed">29435558</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Barthelemy NR, Mawuenyega KG, et al. . Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97(6):1284-1298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann J, Andreasson U, Pannee J, et al. ; IFCC Working Group on Standardization of CSF proteins (WG-CSF) . CSF A&#x3b2;1-42&#x2014;an excellent but complicated Alzheimer&#x2019;s biomarker&#x2014;a route to standardisation. Clin Chim Acta. 2017;467:27-33. doi:10.1016/j.cca.2016.05.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2016.05.014</ArticleId><ArticleId IdType="pubmed">27216941</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32725127</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>217</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e20200861</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20200861</ELocationID><Abstract><AbstractText>Highly sensitive and specific plasma biomarkers for Alzheimer's disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of &#x3b2;-amyloidosis at asymptomatic and symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms to detect AD pathology and investigate CSF and plasma tau isoforms' profile relationships. Plasma tau was truncated as previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92), p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC = 0.75).</AbstractText><CopyrightInformation>&#xa9; 2020 Barthelemy et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barth&#xe9;lemy</LastName><ForeName>Nicolas R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horie</LastName><ForeName>Kanta</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095773</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2020 Oct;16(10):521. doi: 10.1038/s41582-020-0401-z.</RefSource><PMID Version="1">32792665</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: N.R. Barth&#xe9;lemy reported a patent to the US patent office for "blood-based assay for diagnosing and treating based on site-specific tau phosphorylation" pending, and a patent to the US patent office for "methods of diagnosing and treating based on site-specific tau phosphorylation" issued. Washington University and R.J. Bateman have equity ownership interest in C2N Diagnostics. R.J. Bateman and N.R. Barth&#xe9;lemy may receive royalty income based on technology (methods of diagnosing AD with phosphorylation changes) pending license by Washington University to C2N Diagnostics. R.J. Bateman receives income from C2N Diagnostics for serving on the scientific advisory board. K. Horie is a visiting scholar at Washington University and employed by Eisai Co., Ltd. K. Hori may receive income based on technology (methods of diagnosing AD with phosphorylation changes) pending license by Washington University to C2N Diagnostics. C. Sato may receive income based on technology (methods of diagnosing AD with phosphorylation changes) pending license by Washington University to C2N Diagnostics. R.J. Bateman reported "other" from C2N Diagnostics, personal fees from Eisai, AC Immune, Amgen, Pfizer, Hoffman LaRoche, and Janssen; and grants from AbbVie, Biogen, and Eli Lilly and Co. outside the submitted work. In addition, R.J. Bateman had a patent to "blood-based assay for diagnosing and treating based on site-specific tau phosphorylation" pending and a patent to "methods of diagnosing and treating based on site-specific tau phosphorylation" pending. Washington University and R.J. Bateman have equity ownership interest in C2N Diagnostics and may receive royalty income based on technology (methods of diagnosing AD with phosphorylation changes) pending license by Washington University to C2N Diagnostics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32725127</ArticleId><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="doi">10.1084/jem.20200861</ArticleId><ArticleId IdType="pii">151982</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bacioglu M., Maia L.F., Preische O., Schelle J., Apel A., Kaeser S.A., Schweighauser M., Eninger T., Lambert M., Pilotto A., et al. . 2016. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron. 91:56&#x2013;66. 10.1016/j.neuron.2016.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.018</ArticleId><ArticleId IdType="pubmed">27292537</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy N., Hirtz C., Schraen S., Seveno M., Bateman R., Marin P., Becher F., Gabelle A., et al. . 2015. Mass spectrometry follow-up of t181, s199, s202, t205, and T217 tau phosphorylation in cerebrospinal fluid from patients revealed a specific Alzheimer&#x2019;s disease pattern. Alzheimers Dement. 11(7S_Part_19):870 10.1016/j.jalz.2015.08.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.08.063</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy N.R., Fenaille F., Hirtz C., Sergeant N., Schraen-Maschke S., Vialaret J., Bu&#xe9;e L., Gabelle A., Junot C., Lehmann S., et al. . 2016. Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. J. Proteome Res. 15:667&#x2013;676. 10.1021/acs.jproteome.5b01001</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.5b01001</ArticleId><ArticleId IdType="pubmed">26742856</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy N.R., Bateman R.J., Marin P., Becher F., Sato C., Lehmann S., and Gabelle A.. 2017. Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-&#x3b2; pathology. bioRxiv 10.1101/226977 (Preprint posted November 30, 2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/226977</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy N.R., Li Y., Wang G., Fagan A.M., Morris J.C., Benzinger T.L.S., Goate A., Hassenstab J., et al. . 2018. MASS SPECTROMETRY&#x2013;BASED MEASUREMENT OF LONGITUDINAL CSF TAU IDENTIFIES DIFFERENT PHOSPHORYLATED SITES THAT TRACK DISTINCT STAGES OF PRESYMPTOMATIC DOMINANTLY INHERITED AD. Alzheimers Dement. 14(7S_Part_4):273-P274. 10.1016/j.jalz.2018.06.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.06.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy N.R., Mallipeddi N., Moiseyev P., Sato C., and Bateman R.J.. 2019. Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer&#x2019;s Disease. Front. Aging Neurosci. 11:121 10.3389/fnagi.2019.00121</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00121</ArticleId><ArticleId IdType="pmc">PMC6537657</ArticleId><ArticleId IdType="pubmed">31178717</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy N.R., Li Y., Joseph-Mathurin N., Gordon B.A., Hassenstab J., Benzinger T.L.S., Buckles V., Fagan A.M., Perrin R.J., Goate A.M., et al. . Dominantly Inherited Alzheimer Network . 2020a A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat. Med. 26:398&#x2013;407. 10.1038/s41591-020-0781-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0781-z</ArticleId><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy N.R., Bateman R.J., Hirtz C., Marin P., Becher F., Sato C., Gabelle A., and Lehmann S.. 2020b Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer&#x2019;s disease and PET amyloid-positive patient identification. Alzheimers Res. Ther. 12:26 10.1186/s13195-020-00596-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00596-4</ArticleId><ArticleId IdType="pmc">PMC7079453</ArticleId><ArticleId IdType="pubmed">32183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman R.J., Xiong C., Benzinger T.L.S., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., et al. ; Dominantly Inherited Alzheimer Network . 2012. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med. 367:795&#x2013;804. 10.1056/NEJMoa1202753</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogoslovsky T., Wilson D., Chen Y., Hanlon D., Gill J., Jeromin A., Song L., Moore C., Gong Y., Kenney K., et al. . 2017. Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid &#x3b2; up to 90 Days after Traumatic Brain Injury. J. Neurotrauma. 34:66&#x2013;73. 10.1089/neu.2015.4333</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2015.4333</ArticleId><ArticleId IdType="pmc">PMC5198034</ArticleId><ArticleId IdType="pubmed">27312416</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulut M., Koksal O., Dogan S., Bolca N., Ozguc H., Korfali E., Ilcol Y.O., and Parklak M.. 2006. Tau protein as a serum marker of brain damage in mild traumatic brain injury: preliminary results. Adv. Ther. 23:12&#x2013;22. 10.1007/BF02850342</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02850342</ArticleId><ArticleId IdType="pubmed">16644603</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicognola C., Brinkmalm G., Wahlgren J., Portelius E., Gobom J., Cullen N.C., Hansson O., Parnetti L., Constantinescu R., Wildsmith K., et al. . 2019. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer&#x2019;s disease. Acta Neuropathol. 137:279&#x2013;296. 10.1007/s00401-018-1948-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1948-2</ArticleId><ArticleId IdType="pmc">PMC6514201</ArticleId><ArticleId IdType="pubmed">30547227</ArticleId></ArticleIdList></Reference><Reference><Citation>Darlix A., Hirtz C., Thezenas S., Maceski A., Gabelle A., Lopez-Crapez E., De Forges H., Firmin N., Guiu S., Jacot W., et al. . 2019. The prognostic value of the&#xa0;Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer. 19:110 10.1186/s12885-019-5287-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-019-5287-z</ArticleId><ArticleId IdType="pmc">PMC6354387</ArticleId><ArticleId IdType="pubmed">30700265</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., and Holtzman D.M.. 2007. Cerebrospinal fluid tau/&#x3b2;-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64:343&#x2013;349. 10.1001/archneur.64.3.noc60123</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.3.noc60123</ArticleId><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A.M., Xiong C., Jasielec M.S., Bateman R.J., Goate A.M., Benzinger T.L.S., Ghetti B., Martins R.N., Masters C.L., Mayeux R., et al. ; Dominantly Inherited Alzheimer Network . 2014. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci. Transl. Med. 6 226ra30 10.1126/scitranslmed.3007901</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007901</ArticleId><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Geyer P.E., Holdt L.M., Teupser D., and Mann M.. 2017. Revisiting biomarker discovery by plasma&#xa0;proteomics. Mol. Syst. Biol. 13:942 10.15252/msb.20156297</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.20156297</ArticleId><ArticleId IdType="pmc">PMC5615924</ArticleId><ArticleId IdType="pubmed">28951502</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S., Mattsson N., Palmqvist S., Smith R., Beach T.G., Serrano G.E., Chai X., Proctor N.K., Eichenlaub U., Zetterberg H., et al. . 2020a Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat. Med. 26:379&#x2013;386. 10.1038/s41591-020-0755-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S., Stomrud E., Smith R., Palmqvist S., Mattsson N., Airey D.C., Proctor N.K., Chai X., Shcherbinin S., Sims J.R., et al. . 2020b Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer&#x2019;s disease. Nat. Commun. 11:1683 10.1038/s41467-020-15436-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15436-0</ArticleId><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T., Tatebe H., Kondo M., Ishii R., Ohmichi T., Yeung W.T.E., Morimoto M., Chiyonobu T., Terada N., Allsop D., et al. . 2017. Increased levels of plasma total tau in adult Down syndrome. PLoS One. 12 e0188802 10.1371/journal.pone.0188802</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0188802</ArticleId><ArticleId IdType="pmc">PMC5708632</ArticleId><ArticleId IdType="pubmed">29190730</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N., Zetterberg H., Janelidze S., Insel P.S., Andreasson U., Stomrud E., Palmqvist S., Baker D., Tan Hehir C.A., Jeromin A., et al. ; ADNI Investigators . 2016. Plasma tau in Alzheimer disease. Neurology. 87:1827&#x2013;1835. 10.1212/WNL.0000000000003246</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003246</ArticleId><ArticleId IdType="pmc">PMC5089525</ArticleId><ArticleId IdType="pubmed">27694257</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke M.M., Hagen C.E., Wennberg A.M.V., Airey D.C., Savica R., Knopman D.S., Machulda M.M., Roberts R.O., Jack C.R. Jr., Petersen R.C., et al. . 2017. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. JAMA Neurol. 74:1073&#x2013;1080. 10.1001/jamaneurol.2017.1359</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1359</ArticleId><ArticleId IdType="pmc">PMC5710182</ArticleId><ArticleId IdType="pubmed">28692710</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke M.M., Hagen C.E., Xu J., Chai X., Vemuri P., Lowe V.J., Airey D.C., Knopman D.S., Roberts R.O., Machulda M.M., et al. . 2018. Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14:989&#x2013;997. 10.1016/j.jalz.2018.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A., Kaneko N., Villemagne V.L., Kato T., Doecke J., Dor&#xe9; V., Fowler C., Li Q.-X., Martins R., Rowe C., et al. . 2018. High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature. 554:249&#x2013;254. 10.1038/nature25456</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Neselius S., Zetterberg H., Blennow K., Randall J., Wilson D., Marcusson J., and Brisby H.. 2013. Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Inj. 27:425&#x2013;433. 10.3109/02699052.2012.750752</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/02699052.2012.750752</ArticleId><ArticleId IdType="pubmed">23473386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V., Ramsey K.N., Mawuenyega K.G., Bollinger J.G., Hicks T., Schneider T., Sullivan M., Paumier K., Holtzman D.M., Morris J.C., et al. . 2017. Amyloid &#x3b2; concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 13:841&#x2013;849. 10.1016/j.jalz.2017.06.2266</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2266</ArticleId><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.W., Elbert D.L., Mawuenyega K.G., Kasten T., Ovod V., Ma S., Xiong C., Chott R., Yarasheski K., Sigurdson W., et al. . 2015. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann. Neurol. 78:439&#x2013;453. 10.1002/ana.24454</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24454</ArticleId><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R., Patterson B.W., Elbert D.L., Ovod V., Kasten T., Sigurdson W., Mawuenyega K., Blazey T., Goate A., Chott R., et al. . 2013. Increased in vivo amyloid-&#x3b2;42 production, exchange, and loss in presenilin mutation carriers. Sci. Transl. Med. 5 189ra77 10.1126/scitranslmed.3005615</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3005615</ArticleId><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O., Schultz S.A., Apel A., Kuhle J., Kaeser S.A., Barro C., Gr&#xe4;ber S., Kuder-Buletta E., LaFougere C., Laske C., et al. ; Dominantly Inherited Alzheimer Network . 2019. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nat. Med. 25:277&#x2013;283. 10.1038/s41591-018-0304-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0304-3</ArticleId><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts K.F., Elbert D.L., Kasten T.P., Patterson B.W., Sigurdson W.C., Connors R.E., Ovod V., Munsell L.Y., Mawuenyega K.G., Miller-Thomas M.M., et al. . 2014. Amyloid-&#x3b2; efflux from the central nervous system into the plasma. Ann. Neurol. 76:837&#x2013;844. 10.1002/ana.24270</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24270</ArticleId><ArticleId IdType="pmc">PMC4355962</ArticleId><ArticleId IdType="pubmed">25205593</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenstein R., Chang B., Yue J.K., Chiu A., Winkler E.A., Puccio A.M., Diaz-Arrastia R., Yuh E.L., Mukherjee P., Valadka A.B., et al. ; the TRACK-TBI Investigators . 2017. Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers. JAMA Neurol. 74:1063&#x2013;1072. 10.1001/jamaneurol.2017.0655</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0655</ArticleId><ArticleId IdType="pmc">PMC5710183</ArticleId><ArticleId IdType="pubmed">28738126</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C., Barth&#xe9;lemy N.R., Mawuenyega K.G., Patterson B.W., Gordon B.A., Jockel-Balsarotti J., Sullivan M., Crisp M.J., Kasten T., Kirmess K.M., et al. . 2018. Tau Kinetics in Neurons and the Human Central Nervous System. Neuron. 97:1284&#x2013;1298.e7. 10.1016/j.neuron.2018.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.015</ArticleId><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler S.E., Bollinger J.G., Ovod V., Mawuenyega K.G., Li Y., Gordon B.A., Holtzman D.M., Morris J.C., Benzinger T.L.S., Xiong C., et al. . 2019. High-precision plasma &#x3b2;-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 93:e1647&#x2013;e1659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebe H., Kasai T., Ohmichi T., Kishi Y., Kakeya T., Waragai M., Kondo M., Allsop D., and Tokuda T.. 2017. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer&#x2019;s disease and down syndrome. Mol. Neurodegener. 12:63 10.1186/s13024-017-0206-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0206-8</ArticleId><ArticleId IdType="pmc">PMC5582385</ArticleId><ArticleId IdType="pubmed">28866979</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen E.H., La Joie R., Wolf A., Strom A., Wang P., Iaccarino L., Bourakova V., Cobigo Y., Heuer H., Spina S., et al. ; Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators . 2020. Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat. Med. 26:387&#x2013;397. 10.1038/s41591-020-0762-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H. 2017. Review: Tau in biofluids - relation to pathology, imaging and clinical features. Neuropathol. Appl. Neurobiol. 43:194&#x2013;199. 10.1111/nan.12378</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12378</ArticleId><ArticleId IdType="pubmed">28054371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H., Wilson D., Andreasson U., Minthon L., Blennow K., Randall J., and Hansson O.. 2013. Plasma tau levels in Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 5:9 10.1186/alzrt163</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt163</ArticleId><ArticleId IdType="pmc">PMC3707015</ArticleId><ArticleId IdType="pubmed">23551972</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32738937</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>396</Volume><Issue>10248</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.</ArticleTitle><Pagination><StartPage>413</StartPage><EndPage>446</EndPage><MedlinePgn>413-446</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(20)30367-6</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(20)30367-6</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK. Electronic address: g.livingston@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huntley</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sommerlad</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Ageing Research Institute and Academic Unit for Psychiatry of Old Age, University of Melbourne, Royal Melbourne Hospital, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Sube</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Health: Medicine, Dentistry and Human Sciences, University of Plymouth, Plymouth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen-Mansfield</LastName><ForeName>Jiska</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health Promotion, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Heczeg Institute on Aging, Tel Aviv University, Tel Aviv, Israel; Minerva Center for Interdisciplinary Study of End of Life, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costafreda</LastName><ForeName>Sergi G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dias</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Preventive and Social Medicine, Goa Medical College, Goa, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, UK Dementia Research Institute, University College London, London, UK; Institute of Neurology, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitlin</LastName><ForeName>Laura N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Center for Innovative Care in Aging, Johns Hopkins University, Baltimore, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kales</LastName><ForeName>Helen C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, UC Davis School of Medicine, University of California, Sacramento, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivim&#xe4;ki</LastName><ForeName>Mika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogunniyi</LastName><ForeName>Adesola</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University College Hospital, Ibadan, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orgeta</LastName><ForeName>Vasiliki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Inserm, Unit 1061, Neuropsychiatry: Epidemiological and Clinical Research, La Colombi&#xe8;re Hospital, University of Montpellier, Montpellier, France; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rockwood</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for the Health Care of Elderly People, Geriatric Medicine Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampson</LastName><ForeName>Elizabeth L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Barnet, Enfield, and Haringey Mental Health Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samus</LastName><ForeName>Quincy</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and the Behavioural Sciences and Department of Neurology, Keck School of Medicine, Leonard Davis School of Gerontology of the University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selb&#xe6;k</LastName><ForeName>Geir</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, T&#xf8;nsberg, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Geriatric Department, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teri</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department Psychosocial and Community Health, School of Nursing, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukadam</LastName><ForeName>Naaheed</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0802594</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0601022</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG066530</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MCCC-FCO-11-U</GrantID><Acronym>MCCC_</Acronym><Agency>Marie Curie</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S011676/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G9901400</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/R024227/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Gerontol Nurs. 2023 Sep;49(9):3-5. doi: 10.3928/00989134-20230815-01.</RefSource><PMID Version="1">37650850</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet. 2023 Sep 30;402(10408):1132. doi: 10.1016/S0140-6736(23)02043-3.</RefSource><PMID Version="1">37777334</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000397" MajorTopicYN="N">Air Pollution</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006259" MajorTopicYN="N">Craniocerebral Trauma</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006291" MajorTopicYN="Y">Health Policy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054625" MajorTopicYN="N">Healthcare Disparities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070497" MajorTopicYN="Y">Healthy Lifestyle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32738937</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30367-6</ArticleId><ArticleId IdType="pii">S0140-6736(20)30367-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Patterson C. Alzheimer's Disease International; London: 2018. World Alzheimer report 2018.</Citation></Reference><Reference><Citation>Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390:2673&#x2013;2734.</Citation><ArticleIdList><ArticleId IdType="pubmed">28735855</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators GBDD. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6291454</ArticleId><ArticleId IdType="pubmed">30497964</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y-T, Beiser AS, Breteler MMB, et al. The changing prevalence and incidence of dementia over time - current evidence. Nat Rev Neurol. 2017;13:327&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">28497805</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston A, Comas-Herrera A, Jagger C. Forecasting the care needs of the older population in England over the next 20 years: estimates from the Population Ageing and Care Simulation (PACSim) modelling study. Lancet Public Health. 2018;3:e447&#x2013;e455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123499</ArticleId><ArticleId IdType="pubmed">30174210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Burney HN, Callahan CM, Purnell CE, Hendrie HC. Incidence of dementia and alzheimer disease over time: a meta-analysis. J Am Geriatr Soc. 2019;67:1361&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6612587</ArticleId><ArticleId IdType="pubmed">31220336</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich MJ. Global obesity epidemic worsening. JAMA. 2017;318:603.</Citation><ArticleIdList><ArticleId IdType="pubmed">28810033</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh-Manoux A, Dugravot A, Shipley M, et al. Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II study. Alzheimers Dement. 2018;14:178&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5805839</ArticleId><ArticleId IdType="pubmed">28943197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi-Abhari S, Guzman-Castillo M, Bandosz P, et al. Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study. BMJ. 2017;358</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5497174</ArticleId><ArticleId IdType="pubmed">28679494</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivim&#xe4;ki M, Luukkonen R, Batty GD, et al. Body mass index and risk of dementia: analysis of individual-level data from 1&#xb7;3 million individuals. Alzheimers Dement. 2018;14:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948099</ArticleId><ArticleId IdType="pubmed">29169013</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath ER, Beiser AS, DeCarli C, et al. Blood pressure from mid- to late life and risk of incident dementia. Neurology. 2017;89:2447&#x2013;2454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5729797</ArticleId><ArticleId IdType="pubmed">29117954</ArticleId></ArticleIdList></Reference><Reference><Citation>Abell JG, Kivim&#xe4;ki M, Dugravot A, et al. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. Eur Heart J. 2018;39:3119&#x2013;3125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6122131</ArticleId><ArticleId IdType="pubmed">29901708</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado J, Bowman K, Ble A, et al. Blood pressure trajectories in the 20 years before death. JAMA Intern Med. 2018;178:93&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833502</ArticleId><ArticleId IdType="pubmed">29204655</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Arenaza-Urquijo EM, Bartr&#xe9;s-Faz D, et al. Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement. 2020 doi: 10.1016/j.jalz.2018.07.219. published online Jan 6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.07.219</ArticleId><ArticleId IdType="pmc">PMC6417987</ArticleId><ArticleId IdType="pubmed">30222945</ArticleId></ArticleIdList></Reference><Reference><Citation>Perneczky R, Kempermann G, Korczyn AD, et al. Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups. BMC Med. 2019;17:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391801</ArticleId><ArticleId IdType="pubmed">30808345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholerton B, Larson EB, Baker LD, et al. Neuropathologic correlates of cognition in a population-based sample. J Alzheimers Dis. 2013;36:699&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3737376</ArticleId><ArticleId IdType="pubmed">23666176</ArticleId></ArticleIdList></Reference><Reference><Citation>Latimer CS, Keene CD, Flanagan ME, et al. Resistance to Alzheimer disease neuropathologic changes and apparent cognitive resilience in the Nun and Honolulu-Asia Aging Studies. J Neuropathol Exp Neurol. 2017;76:458&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6334750</ArticleId><ArticleId IdType="pubmed">28499012</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaza-Urquijo EM, Przybelski SA, Lesnick TL, et al. The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain. 2019;142:1134&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439329</ArticleId><ArticleId IdType="pubmed">30851100</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N, D&#xfc;zel E, Jessen F, et al. Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. Brain. 2018;141:1186&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5888938</ArticleId><ArticleId IdType="pubmed">29462334</ArticleId></ArticleIdList></Reference><Reference><Citation>Neitzel J, Franzmeier N, Rubinski A, Ewers M. Left frontal connectivity attenuates the adverse effect of entorhinal tau pathology on memory. Neurology. 2019;93:e347&#x2013;e357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6669934</ArticleId><ArticleId IdType="pubmed">31235661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace LMK, Theou O, Godin J, Andrew MK, Bennett DA, Rockwood K. Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project. Lancet Neurol. 2019;18:177&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11062500</ArticleId><ArticleId IdType="pubmed">30663607</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Lee SJ, Teunissen CE, Pool R, et al. Circulating metabolites and general cognitive ability and dementia: evidence from 11 cohort studies. Alzheimers Dement. 2018;14:707&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">29316447</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters R, Ee N, Peters J, Booth A, Mudway I, Anstey KJ. Air pollution and dementia: a systematic review. J Alzheimers Dis. 2019;70:S145&#x2013;S163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700631</ArticleId><ArticleId IdType="pubmed">30775976</ArticleId></ArticleIdList></Reference><Reference><Citation>Chieffi S, Messina G, Villano I, et al. exercise influence on hippocampal function: possible involvement of orexin-A. Front Physiol. 2017;8:85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5306252</ArticleId><ArticleId IdType="pubmed">28261108</ArticleId></ArticleIdList></Reference><Reference><Citation>Parbo P, Ismail R, Hansen KV, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. Brain. 2017;140:2002&#x2013;2011.</Citation><ArticleIdList><ArticleId IdType="pubmed">28575151</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstey KJ, Ee N, Eramudugolla R, Jagger C, Peters R. A systematic review of meta-analyses that evaluate risk factors for dementia to evaluate the quantity, quality, and global representativeness of evidence. J Alzheimers Dis. 2019;70:S165&#x2013;S186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700718</ArticleId><ArticleId IdType="pubmed">31306123</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Ferri CP, Acosta D, et al. The protocols for the 10/66 dementia research group population-based research programme. BMC Public Health. 2007;7:165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1965476</ArticleId><ArticleId IdType="pubmed">17659078</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukadam N, Sommerlad A, Huntley J, Livingston G. Population attributable fractions for risk factors for dementia in low-income and middle-income countries: an analysis using cross-sectional survey data. Lancet Glob Health. 2019;7:e596&#x2013;e603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7617123</ArticleId><ArticleId IdType="pubmed">31000129</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YT, Ali GC, Guerchet M, et al. Prevalence of dementia in mainland China, Hong Kong and Taiwan: an updated systematic review and meta-analysis. Int J Epidemiol. 2018;47:709&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6005065</ArticleId><ArticleId IdType="pubmed">29444280</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman SJ, Mammone J, Rogers Van Katwyk S, et al. Cigarette consumption estimates for 71 countries from 1970 to 2015: systematic collection of comparable data to facilitate quasi-experimental evaluations of national and global tobacco control interventions. BMJ. 2019;365</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6582269</ArticleId><ArticleId IdType="pubmed">31217224</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia L, Quan M, Fu Y, et al. Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol. 2019;19:81&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">31494009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabia S, Dugravot A, Dartigues JF, et al. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. BMJ. 2017;357</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480222</ArticleId><ArticleId IdType="pubmed">28642251</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh-Manoux A, Dugravot A, Fournier A, et al. Trajectories of depressive symptoms before diagnosis of dementia: a 28-year follow-up study. JAMA Psychiatry. 2017;74:712&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710246</ArticleId><ArticleId IdType="pubmed">28514478</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014;13:788&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">25030513</ArticleId></ArticleIdList></Reference><Reference><Citation>Satizabal CL, Beiser AS, Chouraki V, Ch&#xea;ne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham heart study. N Engl J Med. 2016;374:523&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4943081</ArticleId><ArticleId IdType="pubmed">26863354</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson SC, Traylor M, Malik R, Dichgans M, Burgess S, Markus HS. Modifiable pathways in Alzheimer's disease: Mendelian randomisation analysis. BMJ. 2017;359</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5717765</ArticleId><ArticleId IdType="pubmed">29212772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremen WS, Beck A, Elman JA, et al. Influence of young adult cognitive ability and additional education on later-life cognition. Proc Natl Acad Sci USA. 2019;116:2021&#x2013;2026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369818</ArticleId><ArticleId IdType="pubmed">30670647</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Weuve J. Brain exercise and brain outcomes: does cognitive activity really work to maintain your brain? JAMA Psychiatry. 2018;75:703&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">29847611</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee ATC, Richards M, Chan WC, Chiu HFK, Lee RSY, Lam LCW. Association of daily intellectual activities with lower risk of incident dementia among older Chinese adults. JAMA Psychiatry. 2018;75:697&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583858</ArticleId><ArticleId IdType="pubmed">29847678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan D, Shafto M, Kievit R, et al. Lifestyle activities in mid-life contribute to cognitive reserve in late-life, independent of education, occupation, and late-life activities. Neurobiol Aging. 2018;70:180&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6805221</ArticleId><ArticleId IdType="pubmed">30025291</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff RT, Hogan MJ, Williams DS, Whalley LJ. Intellectual engagement and cognitive ability in later life (the &#x201c;use it or lose it&#x201d; conjecture): longitudinal, prospective study. BMJ. 2018;363</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6287118</ArticleId><ArticleId IdType="pubmed">30530522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajitani S, Sakata K, McKenzie C. Occupation, retirement and cognitive functioning. Ageing Soc. 2017;37:1568&#x2013;1596.</Citation></Reference><Reference><Citation>Xue B, Cadar D, Fleischmann M, et al. Effect of retirement on cognitive function: the Whitehall II cohort study. Eur J Epidemiol. 2018;33:989&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6153553</ArticleId><ArticleId IdType="pubmed">29280030</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng A, Nex&#xf8; MA, Borg V. The impact of retirement on age related cognitive decline - a systematic review. BMC Geriatr. 2017;17:160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520232</ArticleId><ArticleId IdType="pubmed">28732489</ArticleId></ArticleIdList></Reference><Reference><Citation>Grotz C, Meillon C, Amieva H, et al. Why is later age at retirement beneficial for cognition? Results from a French population-based study. J Nutr Health Aging. 2016;20:514&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">27102789</ArticleId></ArticleIdList></Reference><Reference><Citation>Denier N, Clouston SAP, Richards M, Hofer SM. Retirement and cognition: a life course view. Adv Life Course Res. 2017;31:11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539912</ArticleId><ArticleId IdType="pubmed">28781588</ArticleId></ArticleIdList></Reference><Reference><Citation>Clouston SA, Denier N. Mental retirement and health selection: analyses from the US health and retirement study. Soc Sci Med. 2017;178:78&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5400287</ArticleId><ArticleId IdType="pubmed">28213301</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohwedder S, Willis RJ. Mental retirement. J Econ Perspect. 2010;24:119&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958696</ArticleId><ArticleId IdType="pubmed">20975927</ArticleId></ArticleIdList></Reference><Reference><Citation>Gates NJ, Sachdev PS, Fiatarone Singh MA, Valenzuela M. Cognitive and memory training in adults at risk of dementia: a systematic review. BMC Geriatr. 2011;11:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191477</ArticleId><ArticleId IdType="pubmed">21942932</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavelin HLA, Hallock H, Sabates J, Bahar-Fuchs A. Cognition-oriented treatments for older adults: a systematic overview of systematic reviews. Neuropsychol Rev. 2020;30:167&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305099</ArticleId><ArticleId IdType="pubmed">32266520</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane RLBM, Fink HA, Brasure M, et al. Agency for Healthcare Research and Quality; Rockville, MD: 2017. Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia.</Citation><ArticleIdList><ArticleId IdType="pubmed">28759193</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler M, McCreedy E, Nelson VA, et al. Does cognitive training prevent cognitive decline? A systematic review. Ann Intern Med. 2018;168:63&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">29255842</ArticleId></ArticleIdList></Reference><Reference><Citation>Gates NJ, Rutjes AW, Di Nisio M, et al. Computerised cognitive training for maintaining cognitive function in cognitively healthy people in midlife. Cochrane Database Syst Rev. 2019;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6415131</ArticleId><ArticleId IdType="pubmed">30864746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill NT, Mowszowski L, Naismith SL, Chadwick VL, Valenzuela M, Lampit A. Computerized cognitive training in older adults with mild cognitive impairment or dementia: a systematic review and meta-analysis. Am J Psychiatry. 2017;174:329&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">27838936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandler MJ, Parks AC, Marsiske M, Rotblatt LJ, Smith GE. Everyday impact of cognitive interventions in mild cognitive impairment: a systematic review and meta-analysis. Neuropsychol Rev. 2016;26:225&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5048589</ArticleId><ArticleId IdType="pubmed">27632385</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovner BW, Casten RJ, Hegel MT, Leiby B. Preventing cognitive decline in Black individuals with mild cognitive impairment: a randomized clinical trial. JAMA Neurol. 2018;75:1487&#x2013;1493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583200</ArticleId><ArticleId IdType="pubmed">30208380</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughrey DG, Kelly ME, Kelley GA, Brennan S, Lawlor BA. Association of age-related hearing loss with cognitive function, cognitive impairment, and dementia: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2018;144:115&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5824986</ArticleId><ArticleId IdType="pubmed">29222544</ArticleId></ArticleIdList></Reference><Reference><Citation>Golub JS, Brickman AM, Ciarleglio AJ, Schupf N, Luchsinger JA. Association of subclinical hearing loss with cognitive performance. JAMA Otolaryngol Head Neck Surg. 2019;146:57&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865840</ArticleId><ArticleId IdType="pubmed">31725853</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong NM, An Y, Doshi J, et al. Association of midlife hearing impairment with late-life temporal lobe volume loss. JAMA Otolaryngol Head Neck Surg. 2019;145:794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613307</ArticleId><ArticleId IdType="pubmed">31268512</ArticleId></ArticleIdList></Reference><Reference><Citation>Amieva H, Ouvrard C, Meillon C, Rullier L, Dartigues JF. Death, depression, disability, and dementia associated with self-reported hearing problems: a 25-year study. J Gerontol A Biol Sci Med Sci. 2018;73:1383&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">29304204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray J, Popli G, Fell G. Association of cognition and age-related hearing impairment in the English longitudinal study of ageing. JAMA Otolaryngol Head Neck Surg. 2018;144:876&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233824</ArticleId><ArticleId IdType="pubmed">30193368</ArticleId></ArticleIdList></Reference><Reference><Citation>Maharani A, Dawes P, Nazroo J, Tampubolon G, Pendleton N. Longitudinal relationship between hearing aid use and cognitive function in older Americans. J Am Geriatr Soc. 2018;66:1130&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">29637544</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanier ER, Bertani I, Sammali E, et al. Induction of a transmissible tau pathology by traumatic brain injury. Brain. 2018;141:2685&#x2013;2699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6113646</ArticleId><ArticleId IdType="pubmed">30084913</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, Gaamouch FE, Meabon JS, et al. ApoE4-associated phospholipid dysregulation contributes to development of tau hyper-phosphorylation after traumatic brain injury. Sci Rep. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5595858</ArticleId><ArticleId IdType="pubmed">28900205</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruns J, Jr, Hauser WA. The epidemiology of traumatic brain injury: a review. Epilepsia. 2003;44:2&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">14511388</ArticleId></ArticleIdList></Reference><Reference><Citation>Fann JR, Ribe AR, Pedersen HS, et al. Long-term risk of dementia among people with traumatic brain injury in Denmark: a population-based observational cohort study. Lancet Psychiatry. 2018;5:424&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">29653873</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstr&#xf6;m A, Nordstr&#xf6;m P. Traumatic brain injury and the risk of dementia diagnosis: a nationwide cohort study. PLoS Med. 2018;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790223</ArticleId><ArticleId IdType="pubmed">29381704</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolppanen AM, Taipale H, Hartikainen S. Head or brain injuries and Alzheimer's disease: a nested case-control register study. Alzheimers Dement. 2017;13:1371&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">28599121</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Byers AL, Gardner RC, Seal KH, Boscardin WJ, Yaffe K. Association of mild traumatic brain injury with and without loss of consciousness with dementia in US military veterans. JAMA Neurol. 2018;75:1055&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6143113</ArticleId><ArticleId IdType="pubmed">29801145</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Lwi SJ, Hoang TD, et al. Military-related risk factors in female veterans and risk of dementia. Neurology. 2019;92:e205&#x2013;e211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6340384</ArticleId><ArticleId IdType="pubmed">30541865</ArticleId></ArticleIdList></Reference><Reference><Citation>Redelmeier DA, Manzoor F, Thiruchelvam D. Association between statin use and risk of dementia after a concussion. JAMA Neurol. 2019;76:887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537780</ArticleId><ArticleId IdType="pubmed">31107515</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Johnson VE, Trojanowski JQ, Stewart W. Chronic traumatic encephalopathy - confusion and controversies. Nat Rev Neurol. 2019;15:179&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6532781</ArticleId><ArticleId IdType="pubmed">30664683</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay DF, Russell ER, Stewart K, MacLean JA, Pell JP, Stewart W. Neurodegenerative disease mortality among former professional soccer players. N Engl J Med. 2019;381:1801&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8747032</ArticleId><ArticleId IdType="pubmed">31633894</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, Beiser A, Enserro D, et al. Association of ideal cardiovascular health with vascular brain injury and incident dementia. Stroke. 2016;47:1201&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006676</ArticleId><ArticleId IdType="pubmed">27073239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane CA, Barnes J, Nicholas JM, et al. Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurol. 2019;18:942&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6744368</ArticleId><ArticleId IdType="pubmed">31444142</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker KA, Sharrett AR, Wu A, et al. Association of midlife to late-life blood pressure patterns with incident dementia. JAMA. 2019;322:535&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6692677</ArticleId><ArticleId IdType="pubmed">31408138</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged &#x2265;75 years: a randomized clinical trial. JAMA. 2016;315:2673&#x2013;2682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4988796</ArticleId><ArticleId IdType="pubmed">27195814</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JD, Pajewski NM, Auchus AP, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439590</ArticleId><ArticleId IdType="pubmed">30688979</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K. Prevention of cognitive impairment with intensive systolic blood pressure control. JAMA. 2019;321:548&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">30688980</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters R, Warwick J, Anstey KJ, Anderson CS. Blood pressure and dementia: what the SPRINT-MIND trial adds and what we still need to know. Neurology. 2019;92:1017&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">31019101</ArticleId></ArticleIdList></Reference><Reference><Citation>Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and incident dementia risk: a systematic review, meta-analysis and meta-regression of prospective studies. J Hypertens. 2016;34:1027&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pubmed">26886565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, Davis-Plourde KL, Sedaghat S, et al. Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020;19:61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391421</ArticleId><ArticleId IdType="pubmed">31706889</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain S, Singh A, Rahman SO, Habib A, Najmi AK. Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: a meta-analysis of prospective studies. Neurosci Lett. 2018;671:120&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">29452176</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters R, Yasar S, Anderson CS, et al. An investigation of antihypertensive class, dementia, and cognitive decline: a meta-analysis. Neurology. 2019;94:e267&#x2013;e281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108807</ArticleId><ArticleId IdType="pubmed">31827004</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016;1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9346344</ArticleId><ArticleId IdType="pubmed">26727124</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379:1499&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426126</ArticleId><ArticleId IdType="pubmed">30221596</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersi M, Irvine B, Gupta P, Gomes J, Birkett N, Krewski D. Risk factors associated with the onset and progression of Alzheimer's disease: a systematic review of the evidence. Neurotoxicology. 2017;61:143&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">28363508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zotcheva E, Bergh S, Selb&#xe6;k G, et al. Midlife physical activity, psychological distress, and dementia risk: the HUNT study. J Alzheimers Dis. 2018;66:825&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">30320592</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;rder H, Johansson L, Guo X, et al. Midlife cardiovascular fitness and dementia: a 44-year longitudinal population study in women. Neurology. 2018;90:e1298&#x2013;e1305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5894933</ArticleId><ArticleId IdType="pubmed">29540588</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivim&#xe4;ki M, Singh-Manoux A, Pentti J, et al. Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. BMJ. 2019;365</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6468884</ArticleId><ArticleId IdType="pubmed">30995986</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Maurice PF, Coughlan D, Kelly SP, et al. Association of leisure-time physical activity across the adult life course with all-cause and cause-specific mortality. JAMA Netw Open. 2019;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484624</ArticleId><ArticleId IdType="pubmed">30848809</ArticleId></ArticleIdList></Reference><Reference><Citation>Northey JM, Cherbuin N, Pumpa KL, Smee DJ, Rattray B. Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. Br J Sports Med. 2018;52:154&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">28438770</ArticleId></ArticleIdList></Reference><Reference><Citation>Song D, Yu DSF, Li PWC, Lei Y. The effectiveness of physical exercise on cognitive and psychological outcomes in individuals with mild cognitive impairment: a systematic review and meta-analysis. Int J Nurs Stud. 2018;79:155&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">29334638</ArticleId></ArticleIdList></Reference><Reference><Citation>de Souto Barreto P, Demougeot L, Vellas B, Rolland Y. Exercise training for preventing dementia, mild cognitive impairment, and clinically meaningful cognitive decline: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2018;73:1504&#x2013;1511.</Citation><ArticleIdList><ArticleId IdType="pubmed">29216339</ArticleId></ArticleIdList></Reference><Reference><Citation>Barha CK, Davis JC, Falck RS, Nagamatsu LS, Liu-Ambrose T. Sex differences in exercise efficacy to improve cognition: a systematic review and meta-analysis of randomized controlled trials in older humans. Front Neuroendocrinol. 2017;46:71&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">28442274</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . World Health Organization; Geneva: 2019. Risk reduction of cognitive decline and dementia: WHO guidelines.</Citation><ArticleIdList><ArticleId IdType="pubmed">31219687</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Peters SA, Woodward M, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2&#xb7;3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39:300&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4722942</ArticleId><ArticleId IdType="pubmed">26681727</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan JM, Mele BS, Hogan DB, Leung AA. Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2018;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6254737</ArticleId><ArticleId IdType="pubmed">30487973</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabia S, Fayosse A, Dumurgier J, et al. Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. BMJ. 2019;366</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6664261</ArticleId><ArticleId IdType="pubmed">31391187</ArticleId></ArticleIdList></Reference><Reference><Citation>Areosa Sastre A, Vernooij RW, Gonz&#xe1;lez-Cola&#xe7;o Harmand M, Mart&#xed;nez G. Effect of the treatment of type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2017;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6481422</ArticleId><ArticleId IdType="pubmed">28617932</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehm J, Hasan OSM, Black SE, Shield KD, Schwarzinger M. Alcohol use and dementia: a systematic scoping review. Alzheimers Res Ther. 2019;11:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6320619</ArticleId><ArticleId IdType="pubmed">30611304</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzinger M, Pollock BG, Hasan OSM, et al. Contribution of alcohol use disorders to the burden of dementia in France 2008&#x2013;13: a nationwide retrospective cohort study. Lancet Public Health. 2018;3:e124&#x2013;e132.</Citation><ArticleIdList><ArticleId IdType="pubmed">29475810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilomaki J, Jokanovic N, Tan ECK, Lonnroos E. Alcohol consumption, dementia, and cognitive decline: an overview of systematic reviews. Curr Clin Pharmacol. 2015;10:204&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">26338173</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch M, Fitzpatrick AL, Rapp SR, et al. Alcohol Consumption and risk of dementia and cognitive decline among older adults with or without mild cognitive impairment. JAMA Netw Open. 2019;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6777245</ArticleId><ArticleId IdType="pubmed">31560382</ArticleId></ArticleIdList></Reference><Reference><Citation>Piumatti G, Moore SC, Berridge DM, Sarkar C, Gallacher J. The relationship between alcohol use and long-term cognitive decline in middle and late life: a longitudinal analysis using UK Biobank. J Public Health (Oxf) 2018;40:304&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6051452</ArticleId><ArticleId IdType="pubmed">29325150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabia S, Fayosse A, Dumurgier J, et al. Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study. BMJ. 2018;362</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6066998</ArticleId><ArticleId IdType="pubmed">30068508</ArticleId></ArticleIdList></Reference><Reference><Citation>Topiwala A, Allan CL, Valkanova V, et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. BMJ. 2017;357</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5460586</ArticleId><ArticleId IdType="pubmed">28588063</ArticleId></ArticleIdList></Reference><Reference><Citation>Albanese E, Launer LJ, Egger M, et al. Body mass index in midlife and dementia: systematic review and meta-regression analysis of 589,649 men and women followed in longitudinal studies. Alzheimers Dement (Amst) 2017;8:165&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520956</ArticleId><ArticleId IdType="pubmed">28761927</ArticleId></ArticleIdList></Reference><Reference><Citation>Veronese N, Facchini S, Stubbs B, et al. Weight loss is associated with improvements in cognitive function among overweight and obese people: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2017;72:87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">27890688</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC, Zhao Y, Lee CW, Ganguli M. Smoking, death, and Alzheimer disease: a case of competing risks. Alzheimer Dis Assoc Disord. 2012;26:300&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321062</ArticleId><ArticleId IdType="pubmed">22185783</ArticleId></ArticleIdList></Reference><Reference><Citation>Debanne SM, Bielefeld RA, Cheruvu VK, Fritsch T, Rowland DY. Alzheimer's disease and smoking: bias in cohort studies. J Alzheimers Dis. 2007;11:313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">17851182</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi D, Choi S, Park SM. Effect of smoking cessation on the risk of dementia: a longitudinal study. Ann Clin Transl Neurol. 2018;5:1192&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6186929</ArticleId><ArticleId IdType="pubmed">30349854</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberg M, Jaakkola MS, Woodward A, Peruga A, Pr&#xfc;ss-Ust&#xfc;n A. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. Lancet. 2011;377:139&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">21112082</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan X, Luo Y, Roberts AR. Secondhand Smoke and Women's Cognitive Function in China. Am J Epidemiol. 2018;187:911&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">29370335</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince MJA, Albanese E, Guerchet M, Prina M. Alzheimer's Disease International; London: 2014. The World Alzheimer Report 2014. Dementia and risk reduction. An analysis of protective and modifiable factors.</Citation></Reference><Reference><Citation>Almeida OP, Hankey GJ, Yeap BB, Golledge J, Flicker L. Depression as a modifiable factor to decrease the risk of dementia. Transl Psychiatry. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5534958</ArticleId><ArticleId IdType="pubmed">28463236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly ME, Duff H, Kelly S, et al. The impact of social activities, social networks, social support and social relationships on the cognitive functioning of healthy older adults: a systematic review. Syst Rev. 2017;6:259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5735742</ArticleId><ArticleId IdType="pubmed">29258596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels C, Wagner M, Wolfsgruber S, Ehrenreich H, Schneider A. Alzheimer's disease neuroimaging I. Impact of SSRI therapy on risk of conversion rrom mild cognitive impairment to Alzheimer's dementia in individuals with previous depression. Am J Psychiatry. 2018;175:232&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">29179578</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommerlad A, Ruegger J, Singh-Manoux A, Lewis G, Livingston G. Marriage and risk of dementia: systematic review and meta-analysis of observational studies. J Neurol Neurosurg Psychiatry. 2018;89:231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5869449</ArticleId><ArticleId IdType="pubmed">29183957</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans IEM, Martyr A, Collins R, Brayne C, Clare L. Social isolation and cognitive function in later life: a systematic review and meta-analysis. J Alzheimers Dis. 2019;70:S119&#x2013;S144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700717</ArticleId><ArticleId IdType="pubmed">30372678</ArticleId></ArticleIdList></Reference><Reference><Citation>Penninkilampi R, Casey AN, Singh MF, Brodaty H. The association between social engagement, loneliness, and risk of dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2018;66:1619&#x2013;1633.</Citation><ArticleIdList><ArticleId IdType="pubmed">30452410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommerlad A, Sabia S, Singh-Manoux A, Lewis G, Livingston G. Association of social contact with dementia and cognition: 28-year follow-up of the Whitehall II cohort study. PLoS Med. 2019;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6677303</ArticleId><ArticleId IdType="pubmed">31374073</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Murata C, Saito M, Takeda T, Kondo K. Influence of social relationship domains and their combinations on incident dementia: a prospective cohort study. J Epidemiol Community Health. 2018;72:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753026</ArticleId><ArticleId IdType="pubmed">29089367</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Adar SD, Yanosky JD, Weuve J. Exposure to air pollution as a potential contributor to cognitive function, cognitive decline, brain imaging, and dementia: a systematic review of epidemiologic research. Neurotoxicology. 2016;56:235&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5048530</ArticleId><ArticleId IdType="pubmed">27328897</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Kwong JC, Copes R, et al. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. Lancet. 2017;389:718&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">28063597</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudin A, Segersson D, Adolfsson R, Forsberg B. Association between air pollution from residential wood burning and dementia incidence in a longitudinal study in Northern Sweden. PLoS One. 2018;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5999109</ArticleId><ArticleId IdType="pubmed">29897947</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudin A, Forsberg B, Adolfsson AN, et al. Traffic-related air pollution and dementia incidence in northern Sweden: a longitudinal study. Environ Health Perspect. 2016;124:306&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786976</ArticleId><ArticleId IdType="pubmed">26305859</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey IM, Anderson HR, Atkinson RW, et al. Are noise and air pollution related to the incidence of dementia? A cohort study in London, England. BMJ Open. 2018;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6144407</ArticleId><ArticleId IdType="pubmed">30206085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Yan Y, Al-Aly Z. Burden of cause-specific mortality associated with PM2.5 air pollution in the United States. JAMA Netw Open. 2019;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902821</ArticleId><ArticleId IdType="pubmed">31747037</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, Gamaldo AA, An Y, et al. Self-reported sleep and &#x3b2;-amyloid deposition in community-dwelling older adults. JAMA Neurol. 2013;70:1537&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918480</ArticleId><ArticleId IdType="pubmed">24145859</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo AC, Balouch S, Tabet N. Is sleep disruption a risk factor for Alzheimer's disease? J Alzheimers Dis. 2017;58:993&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">28550253</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med. 2015;47:e148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351409</ArticleId><ArticleId IdType="pubmed">25766617</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Falvey CM, Hoang T. Connections between sleep and cognition in older adults. Lancet Neurol. 2014;13:1017&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">25231524</ArticleId></ArticleIdList></Reference><Reference><Citation>Sindi S, K&#xe5;reholt I, Johansson L, et al. Sleep disturbances and dementia risk: a multicenter study. Alzheimers Dement. 2018;14:1235&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">30030112</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin MR, Vitiello MV. Implications of sleep disturbance and inflammation for Alzheimer's disease dementia. Lancet Neurol. 2019;18:296&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">30661858</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L, Chen SJ, Ma MY, et al. Sleep disturbances increase the risk of dementia: a systematic review and meta-analysis. Sleep Med Rev. 2018;40:4&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">28890168</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubu OM, Brannick M, Mortimer J, et al. Sleep, Cognitive impairment, and Alzheimer's disease: a systematic review and meta-analysis. Sleep. 2017;40</Citation><ArticleIdList><ArticleId IdType="pubmed">28364458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohara T, Honda T, Hata J, et al. Association between daily sleep duration and risk of dementia and mortality in a Japanese community. J Am Geriatr Soc. 2018;66:1911&#x2013;1918.</Citation><ArticleIdList><ArticleId IdType="pubmed">29873398</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Ogrodnik M, Kolachalama VB, Lin H, Au R. Assessment of the mid-life demographic and lifestyle risk factors of dementia using data from the framingham heart study offspring cohort. J Alzheimers Dis. 2018;63:1119&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">29710704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutsey PL, Misialek JR, Mosley TH, et al. Sleep characteristics and risk of dementia and Alzheimer's disease: the atherosclerosis risk in communities study. Alzheimers Dement. 2018;14:157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5776061</ArticleId><ArticleId IdType="pubmed">28738188</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Sugawara Y, Zhang S, Tomata Y, Tsuji I. Changes in sleep duration and the risk of incident dementia in the elderly Japanese: the Ohsaki Cohort 2006 Study. Sleep. 2018;41</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6187102</ArticleId><ArticleId IdType="pubmed">30053239</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson K, Mattishent K, Loke YK, et al. History of benzodiazepine prescriptions and risk of dementia: possible bias due to prevalent users and covariate measurement timing in a nested case-control study. Am J Epidemiol. 2019;188:1228&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6601519</ArticleId><ArticleId IdType="pubmed">31111865</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronskill SE, Campitelli MA, Iaboni A, et al. Low-dose trazodone, benzodiazepines, and fall-related injuries in nursing homes: a matched-cohort study. J Am Geriatr Soc. 2018;66:1963&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">30247773</ArticleId></ArticleIdList></Reference><Reference><Citation>Pistollato F, Iglesias RC, Ruiz R, et al. Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer's disease: a focus on human studies. Pharmacol Res. 2018;131:32&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">29555333</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris MC, Wang Y, Barnes LL, Bennett DA, Dawson-Hughes B, Booth SL. Nutrients and bioactives in green leafy vegetables and cognitive decline: Prospective study. Neurology. 2018;90:e214&#x2013;e222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5772164</ArticleId><ArticleId IdType="pubmed">29263222</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbaraly TN, Singh-Manoux A, Dugravot A, Brunner EJ, Kivim&#xe4;ki M, Sabia S. Association of midlife diet with subsequent risk for dementia. JAMA. 2019;321:957&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6436698</ArticleId><ArticleId IdType="pubmed">30860560</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Cunha NM, Georgousopoulou EN, Dadigamuwage L, et al. Effect of long-term nutraceutical and dietary supplement use on cognition in the elderly: a 10-year systematic review of randomised controlled trials. Br J Nutr. 2018;119:280&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">29310724</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutjes AW, Denton DA, Di Nisio M, et al. Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life. Cochrane Database Syst Rev. 2018;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6353240</ArticleId><ArticleId IdType="pubmed">30556597</ArticleId></ArticleIdList></Reference><Reference><Citation>McCleery J, Abraham RP, Denton DA, et al. Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment. Cochrane Database Syst Rev. 2018;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378925</ArticleId><ArticleId IdType="pubmed">30383288</ArticleId></ArticleIdList></Reference><Reference><Citation>Farina N, Isaac MGEKN, Clark AR, Rusted J, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2017;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6478142</ArticleId><ArticleId IdType="pubmed">28418065</ArticleId></ArticleIdList></Reference><Reference><Citation>Soininen H, Solomon A, Visser PJ, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:965&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5697936</ArticleId><ArticleId IdType="pubmed">29097166</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughrey DG, Lavecchia S, Brennan S, Lawlor BA, Kelly ME. The impact of the mediterranean diet on the cognitive functioning of healthy older adults: a systematic review and meta-analysis. Adv Nutr. 2017;8:571&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502874</ArticleId><ArticleId IdType="pubmed">28710144</ArticleId></ArticleIdList></Reference><Reference><Citation>Radd-Vagenas S, Duffy SL, Naismith SL, Brew BJ, Flood VM, Fiatarone Singh MA. Effect of the Mediterranean diet on cognition and brain morphology and function: a systematic review of randomized controlled trials. Am J Clin Nutr. 2018;107:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">29566197</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg A, Ngandu T, Rusanen M, et al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial. Alzheimers Dement. 2018;14:263&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">29055814</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephen R, Liu Y, Ngandu T, et al. Brain volumes and cortical thickness on MRI in the Finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER) Alzheimers Res Ther. 2019;11:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6549301</ArticleId><ArticleId IdType="pubmed">31164160</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard E, Jongstra S, Soininen H, et al. Healthy ageing through internet counselling in the elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment. BMJ Open. 2016;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4908903</ArticleId><ArticleId IdType="pubmed">27288376</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard E, Moll van Charante EP, Hoevenaar-Blom MP, et al. Healthy ageing through internet counselling in the elderly (HATICE): a multinational, randomised controlled trial. Lancet Digital Health. 2019;1:e424&#x2013;e434.</Citation><ArticleIdList><ArticleId IdType="pubmed">33323224</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS Digital  Health Survey for England 2014: health, social care and lifestyles: summary of key findings, 2014. Dec 16, 2015. https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/health-survey-for-england-2014</Citation></Reference><Reference><Citation>Xu W, Wang H, Wan Y, et al. Alcohol consumption and dementia risk: a dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2017;32:31&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">28097521</ArticleId></ArticleIdList></Reference><Reference><Citation>Britton A, Ben-Shlomo Y, Benzeval M, Kuh D, Bell S. Life course trajectories of alcohol consumption in the United Kingdom using longitudinal data from nine cohort studies. BMC Med. 2015;13:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351673</ArticleId><ArticleId IdType="pubmed">25858476</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;rvenp&#xe4;&#xe4; T, Rinne JO, Koskenvuo M, R&#xe4;ih&#xe4; I, Kaprio J. Binge drinking in midlife and dementia risk. Epidemiology. 2005;16:766&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">16222166</ArticleId></ArticleIdList></Reference><Reference><Citation>Handing EP, Andel R, Kadlecova P, Gatz M, Pedersen NL. Midlife alcohol consumption and risk of dementia over 43 years of follow-up: a population-based study from the Swedish twin registry. J Gerontol A Biol Sci Med Sci. 2015;70:1248&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">25881581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shor E, Roelfs D, Vang ZM. The &#x201c;Hispanic mortality paradox&#x201d; revisited: meta-analysis and meta-regression of life-course differentials in Latin American and Caribbean immigrants' mortality. Soc Sci Med. 2017;186:20&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">28577458</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman DG. Chapman and Hall/CRC press; London: 1990. Practical statistics for medical research.</Citation></Reference><Reference><Citation>Huang CH, Lin CW, Lee YC, et al. Is traumatic brain injury a risk factor for neurodegeneration? A meta-analysis of population-based studies. BMC Neurol. 2018;18:184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6217762</ArticleId><ArticleId IdType="pubmed">30396335</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pubmed">9832001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu SF, Chiu WT, Lin HW, Chiang YH, Liou TH. Hazard ratio and repeat injury for dementia in patients with and without a history of traumatic brain injury: a population-based secondary data analysis in Taiwan. Asia Pac J Public Health. 2016;28:519&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">27614252</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost RB, Farrer TJ, Primosch M, Hedges DW. Prevalence of traumatic brain injury in the general adult population: a meta-analysis. Neuroepidemiology. 2013;40:154&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">23257914</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Kwong JC, Copes R, et al. Exposure to ambient air pollution and the incidence of dementia: a population-based cohort study. Environ Int. 2017;108:271&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">28917207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourida I, Hannon E, Littlejohns TJ, et al. Association of lifestyle and genetic risk with incidence of dementia. JAMA. 2019;322:430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6628594</ArticleId><ArticleId IdType="pubmed">31302669</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon A, Turunen H, Ngandu T, et al. Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial. JAMA Neurol. 2018;75:462&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885273</ArticleId><ArticleId IdType="pubmed">29356827</ArticleId></ArticleIdList></Reference><Reference><Citation>Licher S, Ahmad S, Karamuji&#x107;-&#x10c;omi&#x107; H, et al. Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population. Nat Med. 2019;25:1364&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6739225</ArticleId><ArticleId IdType="pubmed">31451782</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K, Wallace LMK, Davis DH. Genetic predisposition and modifiable risks for late-life dementia. Nat Med. 2019;25:1331&#x2013;1332.</Citation><ArticleIdList><ArticleId IdType="pubmed">31451783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie K, Carri&#xe8;re I, Ritchie CW, Berr C, Artero S, Ancelin ML. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ. 2010;341</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917002</ArticleId><ArticleId IdType="pubmed">20688841</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . American Psychiatric Press; Washington, DC: 1996. DSM-IV sourcebook.</Citation></Reference><Reference><Citation>American Psychiatric Association . 5th edn. American Psychiatric Association; Washington, DC: 2013. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5.</Citation></Reference><Reference><Citation>Roberts RO, Aakre JA, Kremers WK, et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol. 2018;75:970&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6142936</ArticleId><ArticleId IdType="pubmed">29710225</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice L, Bisdas S. The diagnostic value of FDG and amyloid PET in Alzheimer's disease-a systematic review. Eur J Radiol. 2017;94:16&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">28941755</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang C, Harrington KD, Lim YY, et al. Relationship between amyloid-&#x3b2; positivity and progression to mild cognitive impairment or dementia over 8 years in cognitively normal older adults. J Alzheimers Dis. 2018;65:1313&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pubmed">30149452</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Abdalla N. Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 2018;14:981&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097953</ArticleId><ArticleId IdType="pubmed">29802030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Therneau TM, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321:2316&#x2013;2325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6582267</ArticleId><ArticleId IdType="pubmed">31211344</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450276</ArticleId><ArticleId IdType="pubmed">30938796</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer's disease. Nature. 2018;554:249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid &#x3b2; concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Palmqvist S, et al. Plasma &#x3b2;-amyloid in Alzheimer's disease and vascular disease. Sci Rep. 2016;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4886210</ArticleId><ArticleId IdType="pubmed">27241045</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Mattsson N, Sch&#xf6;ll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci. 2015;36:297&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">25840462</ArticleId></ArticleIdList></Reference><Reference><Citation>Herukka SK, Simonsen AH, Andreasen N, et al. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement. 2017;13:285&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">28341066</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne LM, Rodrigues FB, Blennow K, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurol. 2017;16:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5507767</ArticleId><ArticleId IdType="pubmed">28601473</ArticleId></ArticleIdList></Reference><Reference><Citation>Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81:857&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519945</ArticleId><ArticleId IdType="pubmed">28512753</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Patnode CD, Perdue LA, Rossom RC, et al. The Agency for Healthcare Research and Quality Publication; Rockville, MD: 2020. Screening for cognitive impairment in older adults: an evidence update for the US Preventive Services Task Force [Internet]</Citation><ArticleIdList><ArticleId IdType="pubmed">32129963</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler NR, Perkins AJ, Gao S, Sachs GA, Boustani MA. Risks and benefits of screening for dementia in primary care: the Indiana University cognitive health outcomes investigation of the comparative effectiveness of dementia screening (IU CHOICE) trial. J Am Geriatr Soc. 2019;68:535&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187902</ArticleId><ArticleId IdType="pubmed">31792940</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler NR, Perkins AJ, Gao S, Sachs GA, Uebelhor AK, Boustani MA. Patient characteristics associated with screening positive for Alzheimer's disease and related dementia. Clin Interv Aging. 2018;13:1779&#x2013;1785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6152607</ArticleId><ArticleId IdType="pubmed">30271133</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE . National Institute for Health and Care Excellence; London: 2018. Dementia: Assessment, management and support for people living with dementia and their carers.</Citation><ArticleIdList><ArticleId IdType="pubmed">30011160</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6513124</ArticleId><ArticleId IdType="pubmed">29923184</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh S, King E, Brayne C. France removes state funding for dementia drugs. BMJ. 2019;367</Citation><ArticleIdList><ArticleId IdType="pubmed">31888870</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Tariot PN, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. N Engl J Med. 2018;378:1691&#x2013;1703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776074</ArticleId><ArticleId IdType="pubmed">29719179</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawlor B, Segurado R, Kennelly S, et al. Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial. PLoS Med. 2018;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6152871</ArticleId><ArticleId IdType="pubmed">30248105</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews M, Tousi B, Sabbagh MN. 5HT6 antagonists in the treatment of Alzheimer's dementia: current progress. Neurol Ther. 2018;7:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990506</ArticleId><ArticleId IdType="pubmed">29728891</ArticleId></ArticleIdList></Reference><Reference><Citation>Voytyuk I, De Strooper B, Ch&#xe1;vez-Guti&#xe9;rrez L. Modulation of &#x3b3;- and &#x3b2;-secretases as early prevention against Alzheimer's disease. Biol Psychiatry. 2018;83:320&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">28918941</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer's disease. N Engl J Med. 2019;380:1408&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776078</ArticleId><ArticleId IdType="pubmed">30970186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahar-Fuchs A, Martyr A, Goh AM, Sabates J, Clare L. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433473</ArticleId><ArticleId IdType="pubmed">30909318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb SE, Sheehan B, Atherton N, et al. Dementia and physical activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial. BMJ. 2018;361</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5953238</ArticleId><ArticleId IdType="pubmed">29769247</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Logsdon RG, McCurry AM, Pike KC, McGough EL. Translating an evidence-based multicomponent intervention for older adults with dementia and caregivers. Gerontologist. 2020;60:548&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7117621</ArticleId><ArticleId IdType="pubmed">30304477</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenberg AJ, Suemoto CK, Fran&#xe7;a Resende EP, et al. Neuropathologic correlates of psychiatric symptoms in Alzheimer's disease. J Alzheimers Dis. 2018;66:115&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6381997</ArticleId><ArticleId IdType="pubmed">30223398</ArticleId></ArticleIdList></Reference><Reference><Citation>Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. Lancet Public Health. 2017;2:e149&#x2013;e156.</Citation><ArticleIdList><ArticleId IdType="pubmed">29253388</ArticleId></ArticleIdList></Reference><Reference><Citation>Thyrian JR, Hertel J, Wucherer D, et al. Effectiveness and safety of dementia care management in primary care: a randomized clinical trial. JAMA Psychiatry. 2017;74:996&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710469</ArticleId><ArticleId IdType="pubmed">28746708</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin LN, Arthur P, Piersol C, et al. Targeting behavioral symptoms and functional decline in dementia: a randomized clinical trial. J Am Geriatr Soc. 2018;66:339&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">29192967</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudas R, Malouf R, McCleery J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. 2018;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6513376</ArticleId><ArticleId IdType="pubmed">30168578</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgeta V, Tabet N, Nilforooshan R, Howard R. Efficacy of antidepressants for depression in Alzheimer's disease: systematic review and meta-analysis. J Alzheimers Dis. 2017;58:725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467718</ArticleId><ArticleId IdType="pubmed">28505970</ArticleId></ArticleIdList></Reference><Reference><Citation>Panca M, Livingston G, Barber J, et al. Healthcare resource utilisation and costs of agitation in people with dementia living in care homes in England - the managing agitation and raising quality of life in dementia (MARQUE) study. PLoS One. 2019;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391021</ArticleId><ArticleId IdType="pubmed">30807569</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Barber J, Marston L, et al. Prevalence of and associations with agitation in residents with dementia living in care homes: MARQUE cross-sectional study. BJPsych Open. 2017;3:171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5530006</ArticleId><ArticleId IdType="pubmed">28794896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper C, Marston L, Barber J, et al. Do care homes deliver person-centred care? A cross-sectional survey of staff-reported abusive and positive behaviours towards residents from the MARQUE (managing agitation and raising quality of life) English national care home survey. PLoS One. 2018;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5862450</ArticleId><ArticleId IdType="pubmed">29561867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Corbett A, Orrell M, et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial. PLoS Med. 2018;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800565</ArticleId><ArticleId IdType="pubmed">29408901</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtwarck B, Selbaek G, Kirkevold &#xd8;, et al. Targeted interdisciplinary model for evaluation and treatment of neuropsychiatric symptoms: a cluster randomized controlled trial. Am J Geriatr Psychiatry. 2018;26:25&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">28669575</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62:762&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146407</ArticleId><ArticleId IdType="pubmed">24635665</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Barber J, Marston L, et al. Clinical and cost-effectiveness of the managing agitation and raising quality of life (MARQUE) intervention for agitation in people with dementia in care homes: a single-blind, cluster-randomised controlled trial. Lancet Psychiatry. 2019;6:293&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">30872010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus. Int Psychogeriatr. 2018;31:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">30068400</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Leeuwen E, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8407230</ArticleId><ArticleId IdType="pubmed">29605970</ArticleId></ArticleIdList></Reference><Reference><Citation>Cossette B, Bruneau MA, Couturier Y, et al. Optimizing practices, use, care and services-antipsychotics (OPUS-AP) in long-term care centers in Quebec, Canada: a strategy for best practices. J Am Med Dir Assoc. 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31669289</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Do reports on personal preferences of persons with dementia predict their responses to group activities? Dement Geriatr Cogn Disord. 2018;46:100&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">30145591</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. The impact of group activities and their content on persons with dementia attending them. Alzheimers Res Ther. 2018;10:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5887184</ArticleId><ArticleId IdType="pubmed">29622034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanct&#xf4;t KL. Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database Syst Rev. 2018;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494556</ArticleId><ArticleId IdType="pubmed">29727467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinnunen KM, Vikhanova A, Livingston G. The management of sleep disorders in dementia: an update. Curr Opin Psychiatry. 2017;30:491&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">28858007</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Barber JA, Kinnunen KM, et al. DREAMS-START (Dementia RElAted Manual for Sleep; STrAtegies for RelaTives) for people with dementia and sleep disturbances: a single-blind feasibility and acceptability randomized controlled trial. Int Psychogeriatr. 2018;31:251&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6474714</ArticleId><ArticleId IdType="pubmed">30221615</ArticleId></ArticleIdList></Reference><Reference><Citation>Maust DT, Kales HC, McCammon RJ, Blow FC, Leggett A, Langa KM. Distress associated with dementia-related psychosis and agitation in relation to healthcare utilization and costs. Am J Geriatr Psychiatry. 2017;25:1074&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5600647</ArticleId><ArticleId IdType="pubmed">28754586</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Manela M, O'Keeffe A, et al. Clinical effectiveness of the START (STrAtegies for RelaTives) psychological intervention for family carers and the effects on the cost of care for people with dementia: 6-year follow-up of a randomised controlled trial. Br J Psychiatry. 2020;216:35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">31298169</ArticleId></ArticleIdList></Reference><Reference><Citation>Guterman EL, Allen IE, Josephson SA, et al. Association between caregiver depression and emergency department use among patients with dementia. JAMA Neurol. 2019;76:1166&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618767</ArticleId><ArticleId IdType="pubmed">31282955</ArticleId></ArticleIdList></Reference><Reference><Citation>Clare L, Kudlicka A, Oyebode JR, et al. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT. Health Technol Assess. 2019;23:1&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6441850</ArticleId><ArticleId IdType="pubmed">30879470</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott I, Cooper C, Leverton M, et al. Effects of nonpharmacological interventions on functioning of people living with dementia at home: a systematic review of randomised controlled trials. Int J Geriatr Psychiatry. 2019;34:1386&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">31026082</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Mueller C, Stewart R, et al. Predictors of falls and fractures leading to hospitalization in people with dementia: a representative cohort study. J Am Med Dir Assoc. 2018;19:607&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">29752159</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper C, Lodwick R, Walters K, et al. Inequalities in receipt of mental and physical healthcare in people with dementia in the UK. Age Ageing. 2017;46:393&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378291</ArticleId><ArticleId IdType="pubmed">27916749</ArticleId></ArticleIdList></Reference><Reference><Citation>Fereshtehnejad SM, Garcia-Ptacek S, Religa D, et al. Dental care utilization in patients with different types of dementia: a longitudinal nationwide study of 58,037 individuals. Alzheimers Dement. 2018;14:10&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">28692821</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunn F, Goodman C, Reece Jones P, et al. What works for whom in the management of diabetes in people living with dementia: a realist review. BMC Med. 2017;15:141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5532771</ArticleId><ArticleId IdType="pubmed">28750628</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S, Farina N, Daley S, et al. How do we enhance undergraduate healthcare education in dementia? A review of the role of innovative approaches and development of the Time for Dementia Programme. Int J Geriatr Psychiatry. 2017;32:68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6055850</ArticleId><ArticleId IdType="pubmed">27723124</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne J, Edwards DA, Rhodes KM, Brimicombe DJ, Payne RA. Association of comorbidity and health service usage among patients with dementia in the UK: a population-based study. BMJ Open. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5353300</ArticleId><ArticleId IdType="pubmed">28279992</ArticleId></ArticleIdList></Reference><Reference><Citation>Poblador-Plou B, Calder&#xf3;n-Larra&#xf1;aga A, Marta-Moreno J, et al. Comorbidity of dementia: a cross-sectional study of primary care older patients. BMC Psychiatry. 2014;14:84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3994526</ArticleId><ArticleId IdType="pubmed">24645776</ArticleId></ArticleIdList></Reference><Reference><Citation>Rait G, Walters K, Bottomley C, Petersen I, Iliffe S, Nazareth I. Survival of people with clinical diagnosis of dementia in primary care: cohort study. BMJ. 2010;341</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917003</ArticleId><ArticleId IdType="pubmed">20688840</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer K, Schwarzkopf L, Graessel E, Holle R. A claims data-based comparison of comorbidity in individuals with and without dementia. BMC Geriatr. 2014;14:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3909381</ArticleId><ArticleId IdType="pubmed">24472217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunn F, Burn A-M, Goodman C, et al. Comorbidity and dementia: a scoping review of the literature. BMC Med. 2014;12:192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229610</ArticleId><ArticleId IdType="pubmed">25358236</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett HQ, Norton S, Bunn F, et al. The impact of dementia on service use by individuals with a comorbid health condition: a comparison of two cross-sectional analyses conducted approximately 10 years apart. BMC Med. 2018;16:114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6056993</ArticleId><ArticleId IdType="pubmed">30037332</ArticleId></ArticleIdList></Reference><Reference><Citation>Melis RJ, Marengoni A, Rizzuto D, et al. The influence of multimorbidity on clinical progression of dementia in a population-based cohort. PLoS One. 2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875493</ArticleId><ArticleId IdType="pubmed">24386324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Garc&#xed;a S, Rodr&#xed;guez-Bl&#xe1;zquez C, Mart&#xed;nez-L&#xf3;pez I, Mart&#xed;nez-Mart&#xed;n P, Forjaz MJ. Comorbidity, health status, and quality of life in institutionalized older people with and without dementia. Int Psychogeriatr. 2013;25:1077&#x2013;1084.</Citation><ArticleIdList><ArticleId IdType="pubmed">23575107</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:669&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158570</ArticleId><ArticleId IdType="pubmed">32240634</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7098485</ArticleId><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics  Impact of coronavirus in care homes in England: 26 May to 19 June 2020. 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/impactofcoronavirusincarehomesinenglandvivaldi/26mayto19june2020</Citation></Reference><Reference><Citation>Livingston G, Weidner W. COVID-19 and dementia: difficult decisions about hospital admission and triage. 2020. https://www.alz.co.uk/news/adi-releases-position-paper-on-covid-19-and-dementia</Citation></Reference><Reference><Citation>Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020;87:34&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7152874</ArticleId><ArticleId IdType="pubmed">32298803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie K, Chan D, Watermeyer T. The neurological consequences of the COVID-19 epidemic: collateral damage? Brain Communications. 2020 doi: 10.1093/braincomms/fcaa069. published online May 28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa069</ArticleId><ArticleId IdType="pmc">PMC7314157</ArticleId><ArticleId IdType="pubmed">33074266</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicol GE, Piccirillo JF, Mulsant BH, Lenze EJ. Action at a distance: geriatric research during a pandemic. J Am Geriatr Soc. 2020;68:922&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228241</ArticleId><ArticleId IdType="pubmed">32207542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li T, Barbarino P, et al. Dementia care during COVID-19. Lancet. 2020;395:1190&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146671</ArticleId><ArticleId IdType="pubmed">32240625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau-Ng R, Caruso LB, Perls TT. COVID-19 deaths in long term care facilities - a critical piece of the pandemic puzzle. J Am Geriatr Soc. 2020 doi: 10.1111/jgs.16669. published online June 5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.16669</ArticleId><ArticleId IdType="pmc">PMC7300761</ArticleId><ArticleId IdType="pubmed">32501537</ArticleId></ArticleIdList></Reference><Reference><Citation>Comas-Herrera A, Zalakain J, Litwin C, Hsu AT, Fefnandez-Plotka JL. Mortality associated with COVID-19 outbreaks in care homes: early international evidence. 2020. https://ltccovid.org/2020/04/12/mortality-associated-with-covid-19-outbreaks-in-care-homes-early-international-evidence/</Citation></Reference><Reference><Citation>McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. N Engl J Med. 2020;382:2005&#x2013;2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121761</ArticleId><ArticleId IdType="pubmed">32220208</ArticleId></ArticleIdList></Reference><Reference><Citation>CarePort Health  COVID-19 report. 2020. https://careporthealth.com/wp-content/uploads/2020/05/COVID-19-Report-3.pdf</Citation></Reference><Reference><Citation>Zhan M, Qin Y, Xue X, Zhu S. Death from Covid-19 of 23 Health care workers in China. N Engl J Med. 2020;382:2267&#x2013;2268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179960</ArticleId><ArticleId IdType="pubmed">32294342</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>White N, Leurent B, Lord K, Scott S, Jones L, Sampson EL. The management of behavioural and psychological symptoms of dementia in the acute general medical hospital: a longitudinal cohort study. Int J Geriatr Psychiatry. 2017;32:297&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5324689</ArticleId><ArticleId IdType="pubmed">27019375</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone DC, McLaughlin TP, Wahl PM, et al. Burden of Alzheimer's disease and association with negative health outcomes. Am J Manag Care. 2009;15:481&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">19670951</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager MA, Rudberg MA, Jalaluddin M, et al. Hospital admission risk profile (HARP): identifying older patients at risk for functional decline following acute medical illness and hospitalization. J Am Geriatr Soc. 1996;44:251&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">8600192</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan EA, Borson S, Grothaus L, Balch S, Larson EB. Association of incident dementia with hospitalizations. JAMA. 2012;307:165&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312921</ArticleId><ArticleId IdType="pubmed">22235087</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Kuo TC, Weir S, Kramer MS, Ash AS. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Serv Res. 2008;8:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2424046</ArticleId><ArticleId IdType="pubmed">18498638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bynum JP, Rabins PV, Weller W, Niefeld M, Anderson GF, Wu AW. The relationship between a dementia diagnosis, chronic illness, Medicare expenditures, and hospital use. J Am Geriatr Soc. 2004;52:187&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">14728626</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd H, Livingston G, Chan J, Sommerlad A. Hospitalisation rates and predictors in people with dementia: a systematic review and meta-analysis. BMC Med. 2019;17:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6628507</ArticleId><ArticleId IdType="pubmed">31303173</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu CW, Cosentino S, Ornstein K, Gu Y, Andrews H, Stern Y. Use and cost of hospitalization in dementia: longitudinal results from a community-based study. Int J Geriatr Psychiatry. 2015;30:833&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4414886</ArticleId><ArticleId IdType="pubmed">25351909</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu CW, Cosentino S, Ornstein KA, Gu Y, Andrews H, Stern Y. interactive effects of dementia severity and comorbidities on medicare expenditures. J Alzheimers Dis. 2017;57:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5461168</ArticleId><ArticleId IdType="pubmed">28222520</ArticleId></ArticleIdList></Reference><Reference><Citation>MacNeil Vroomen J, Bosmans JE, Eekhout I, et al. The cost-effectiveness of two forms of case management compared to a control group for persons with dementia and their informal caregivers from a societal perspective. PLoS One. 2016;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5031395</ArticleId><ArticleId IdType="pubmed">27655234</ArticleId></ArticleIdList></Reference><Reference><Citation>Intrator O, Zinn J, Mor V. Nursing home characteristics and potentially preventable hospitalizations of long-stay residents. J Am Geriatr Soc. 2004;52:1730&#x2013;1736.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450053</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan EA, Debnam KJ, Anderson LA, Owens SB. A systematic review of intervention studies to prevent hospitalizations of community-dwelling older adults with dementia. Med Care. 2015;53:207&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310672</ArticleId><ArticleId IdType="pubmed">25588136</ArticleId></ArticleIdList></Reference><Reference><Citation>Naylor MD, Brooten D, Campbell R, et al. Comprehensive discharge planning and home follow-up of hospitalized elders: a randomized clinical trial. JAMA. 1999;281:613&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">10029122</ArticleId></ArticleIdList></Reference><Reference><Citation>Handley M, Bunn F, Goodman C. Dementia-friendly interventions to improve the care of people living with dementia admitted to hospitals: a realist review. BMJ Open. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5541590</ArticleId><ArticleId IdType="pubmed">28713073</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health . Department of Health; Leeds: 2012. Using the Commissioning for Quality and Innovation (CQUIN) payment framework Guidance on new national goals for 2012&#x2013;13.</Citation></Reference><Reference><Citation>Wilkinson T, Ly A, Schnier C, et al. Identifying dementia cases with routinely collected health data: a systematic review. Alzheimers Dement. 2018;14:1038&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105076</ArticleId><ArticleId IdType="pubmed">29621480</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommerlad A, Perera G, Singh-Manoux A, Lewis G, Stewart R, Livingston G. Accuracy of general hospital dementia diagnoses in England: sensitivity, specificity, and predictors of diagnostic accuracy 2008-2013. Alzheimers Dement. 2018;14:933&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6057268</ArticleId><ArticleId IdType="pubmed">29703698</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan DJ, O'Regan NA, Caoimh R&#xd3;, et al. Delirium in an adult acute hospital population: predictors, prevalence and detection. BMJ Open. 2013;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549230</ArticleId><ArticleId IdType="pubmed">23299110</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson TA, MacLullich AM, Gladman JR, Lord JM, Sheehan B. Undiagnosed long-term cognitive impairment in acutely hospitalised older medical patients with delirium: a prospective cohort study. Age Ageing. 2016;45:493&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">27076525</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DHJ, Muniz-Terrera G, Keage HAD, et al. Association of delirium with cognitive decline in late life: a neuropathologic study of 3 population-based cohort studies. JAMA Psychiatry. 2017;74:244&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6037291</ArticleId><ArticleId IdType="pubmed">28114436</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Wilson RS, Capuano AW, et al. Cognitive decline after elective and nonelective hospitalizations in older adults. Neurology. 2019;92:e690&#x2013;e699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382369</ArticleId><ArticleId IdType="pubmed">30635482</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong TG, Davis D, Growdon ME, Albuquerque A, Inouye SK. The interface between delirium and dementia in elderly adults. Lancet Neurol. 2015;14:823&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4535349</ArticleId><ArticleId IdType="pubmed">26139023</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi N, Harrison JK, Clegg A, et al. Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2016;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10431752</ArticleId><ArticleId IdType="pubmed">26967259</ArticleId></ArticleIdList></Reference><Reference><Citation>Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotic medication for prevention and treatment of delirium in hospitalized adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2016;64:705&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840067</ArticleId><ArticleId IdType="pubmed">27004732</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbateskovic M, Krauss SR, Collet MO, et al. Pharmacological interventions for prevention and management of delirium in intensive care patients: a systematic overview of reviews and meta-analyses. BMJ Open. 2019;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377549</ArticleId><ArticleId IdType="pubmed">30782910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hshieh TT, Yang T, Gartaganis SL, Yue J, Inouye SK. Hospital elder life program: systematic review and meta-analysis of effectiveness. Am J Geriatr Psychiatry. 2018;26:1015&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6362826</ArticleId><ArticleId IdType="pubmed">30076080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YC, Tseng PT, Tu YK, et al. Association of delirium response and safety of pharmacological interventions for the management and prevention of delirium: a network meta-analysis. JAMA Psychiatry. 2019;76:526&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6495351</ArticleId><ArticleId IdType="pubmed">30810723</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg SE, Bradshaw LE, Kearney FC, et al. Care in specialist medical and mental health unit compared with standard care for older people with cognitive impairment admitted to general hospital: randomised controlled trial (NIHR TEAM trial) BMJ. 2013;347</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3698942</ArticleId><ArticleId IdType="pubmed">23819964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolanowski A, Fick D, Litaker M, et al. Effect of cognitively stimulating activities on symptom management of delirium superimposed on dementia: A randomized controlled trial. J Am Geriatr Soc. 2016;64:2424&#x2013;2432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173415</ArticleId><ArticleId IdType="pubmed">27861718</ArticleId></ArticleIdList></Reference><Reference><Citation>Burry L, Mehta S, Perreault MM, et al. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2018;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6513380</ArticleId><ArticleId IdType="pubmed">29920656</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu A, Wu S, Zhang Z, et al. Cholinesterase inhibitors for the treatment of delirium in non-ICU settings. Cochrane Database Syst Rev. 2018;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6513030</ArticleId><ArticleId IdType="pubmed">29952000</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonergan E, Luxenberg J, Areosa Sastre A, Wyller T. Benzodiazepines for delirium. Cochrane Database Syst Rev. 2009;4</Citation><ArticleIdList><ArticleId IdType="pubmed">19160280</ArticleId></ArticleIdList></Reference><Reference><Citation>The American Geriatrics Society 2015 Beers Criteria Update Expert Panel American Geriatrics Society 2015 Updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227&#x2013;2246.</Citation><ArticleIdList><ArticleId IdType="pubmed">26446832</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson TA, Gladman JR, Harwood RH, et al. Challenges and opportunities in understanding dementia and delirium in the acute hospital. PLoS Med. 2017;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349650</ArticleId><ArticleId IdType="pubmed">28291818</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Leurgans SE, et al. Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85:114&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10128614</ArticleId><ArticleId IdType="pubmed">30421454</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83:74&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876116</ArticleId><ArticleId IdType="pubmed">29244218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace L, Theou O, Rockwood K, Andrew MK. Relationship between frailty and Alzheimer's disease biomarkers: a scoping review. Alzheimers Dement (Amst) 2018;10:394&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6072899</ArticleId><ArticleId IdType="pubmed">30094326</ArticleId></ArticleIdList></Reference><Reference><Citation>Aworinde J, Werbeloff N, Lewis G, Livingston G, Sommerlad A. Dementia severity at death: a register-based cohort study. BMC Psychiatry. 2018;18:355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6211473</ArticleId><ArticleId IdType="pubmed">30382865</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeussen K, Van den Block L, Echteld M, et al. Older people dying with dementia: a nationwide study. Int Psychogeriatr. 2012;24:1581&#x2013;1591.</Citation><ArticleIdList><ArticleId IdType="pubmed">22647226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson EL, Candy B, Davis S, et al. Living and dying with advanced dementia: A prospective cohort study of symptoms, service use and care at the end of life. Palliat Med. 2018;32:668&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5987852</ArticleId><ArticleId IdType="pubmed">28922625</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosemond C, Hanson LC, Zimmerman S. Goals of care or goals of trust? how family members perceive goals for dying nursing home residents. J Palliat Med. 2017;20:360&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385445</ArticleId><ArticleId IdType="pubmed">27898281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson LC, Zimmerman S, Song MK, et al. Effect of the Goals of care intervention for advanced dementia: a randomized clinical trial. JAMA Intern Med. 2017;177:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5234328</ArticleId><ArticleId IdType="pubmed">27893884</ArticleId></ArticleIdList></Reference><Reference><Citation>Dening KH, King M, Jones L, Sampson EL. Healthcare decision-making: past present and future, in light of a diagnosis of dementia. Int J Palliat Nurs. 2017;23:4&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">28132606</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaster B, Larson EB, Curtis JR. Advance directives for dementia: meeting a unique challenge. JAMA. 2017;318:2175&#x2013;2176.</Citation><ArticleIdList><ArticleId IdType="pubmed">29114779</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison Dening K, King M, Jones L, Vickestaff V, Sampson EL. Advance care planning in dementia: do family carers know the treatment preferences of people with early dementia? PLoS One. 2016;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4943594</ArticleId><ArticleId IdType="pubmed">27410259</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazil K, Carter G, Cardwell C, et al. Effectiveness of advance care planning with family carers in dementia nursing homes: a paired cluster randomized controlled trial. Palliat Med. 2018;32:603&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">28786323</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah SM, Carey IM, Harris T, DeWilde S, Victor CR, Cook DG. The mental health and mortality impact of death of a partner with dementia. Int J Geriatr Psychiatry. 2016;31:929&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">26833866</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore KJ, Davis S, Gola A, et al. Experiences of end of life amongst family carers of people with advanced dementia: longitudinal cohort study with mixed methods. BMC Geriatr. 2017;17:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496359</ArticleId><ArticleId IdType="pubmed">28673257</ArticleId></ArticleIdList></Reference><Reference><Citation>Agar M, Luckett T, Luscombe G, et al. Effects of facilitated family case conferencing for advanced dementia: a cluster randomised clinical trial. PLoS One. 2017;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546584</ArticleId><ArticleId IdType="pubmed">28786995</ArticleId></ArticleIdList></Reference><Reference><Citation>Luckett T, Chenoweth L, Phillips J, et al. A facilitated approach to family case conferencing for people with advanced dementia living in nursing homes: perceptions of palliative care planning coordinators and other health professionals in the IDEAL study. Int Psychogeriatr. 2017;29:1713&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">28651659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickett J, Bird C, Ballard C, et al. A roadmap to advance dementia research in prevention, diagnosis, intervention, and care by 2025. Int J Geriatr Psychiatry. 2018;33:900&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6033035</ArticleId><ArticleId IdType="pubmed">29468724</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Uncited References</Title><Reference><Citation>Abner EL, Nelson PT, Schmitt FA, et al. Self-reported head injury and risk of late-life impairment and AD pathology in an AD center cohort. Dement Geriatr Cogn Dis. 2014;37:294&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057973</ArticleId><ArticleId IdType="pubmed">24401791</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner RC, Burke JF, Nettiksimmons J, Kaup A, Barnes DE, Yaffe K. Dementia risk after traumatic brain injury vs nonbrain trauma: the role of age and severity. JAMA Neurology. 2014;71:1490&#x2013;1497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4318558</ArticleId><ArticleId IdType="pubmed">25347255</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstr&#xf6;m P, Micha&#xeb;lsson K, Gustafson Y, Nordstr&#xf6;m A. Traumatic brain injury and young onset dementia: a nationwide cohort study. Ann Neurol. 2014;75:374&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">24812697</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Lin S, Sung P, et al. Population based study on patients with traumatic brain injury suggests increased risk of dementia. J Neurol Neurosurg Psychiatry. 2012;83:1080&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">22842203</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32761777</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-3178</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>EMBO reports</Title><ISOAbbreviation>EMBO Rep</ISOAbbreviation></Journal><ArticleTitle>Loss of Tmem106b exacerbates FTLD pathologies and causes motor deficits in progranulin-deficient mice.</ArticleTitle><Pagination><StartPage>e50197</StartPage><MedlinePgn>e50197</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e50197</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/embr.202050197</ELocationID><Abstract><AbstractText>Progranulin (PGRN) and transmembrane protein 106B (TMEM106B) are important lysosomal proteins implicated in frontotemporal lobar degeneration (FTLD) and other neurodegenerative disorders. Loss-of-function mutations in progranulin (GRN) are a common cause of FTLD, while TMEM106B variants have been shown to act as disease modifiers in FTLD. Overexpression of TMEM106B leads to lysosomal dysfunction, while loss of Tmem106b ameliorates lysosomal and FTLD-related pathologies in young Grn<sup>-/-</sup> mice, suggesting that lowering TMEM106B might be an attractive strategy for therapeutic treatment of FTLD-GRN. Here, we generate and characterize older Tmem106b<sup>-/-</sup> Grn<sup>-/-</sup> double knockout mice, which unexpectedly show severe motor deficits and spinal cord motor neuron and myelin loss, leading to paralysis and premature death at 11-12&#xa0;months. Compared to Grn<sup>-/-</sup> , Tmem106b<sup>-/-</sup> Grn<sup>-/-</sup> mice have exacerbated FTLD-related pathologies, including microgliosis, astrogliosis, ubiquitin, and phospho-Tdp43 inclusions, as well as worsening of lysosomal and autophagic deficits. Our findings confirm a functional interaction between Tmem106b and Pgrn and underscore the need to rethink whether modulating TMEM106B levels is a viable therapeutic strategy.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaolai</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-4531-4658</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Mieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Peizhou</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koga</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuberi</LastName><ForeName>Aamir R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>The Rare and Orphan Disease Center, JAX Center for Precision Genetics, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parsons</LastName><ForeName>Tammee M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castanedes-Casey</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Librero</LastName><ForeName>Ariston L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurti</LastName><ForeName>Aishe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fryer</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutz</LastName><ForeName>Cathleen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Rare and Orphan Disease Center, JAX Center for Precision Genetics, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4049-0863</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied and Translational Neurogenomics, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 OD020351</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097261</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>The Bluefield Project to Cure FTD</Agency><Country/></Grant><Grant><Agency>the Jackson Laboratory's Genetic Engineering Technologies Scientific Service</Agency><Country/></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO Rep</MedlineTA><NlmUniqueID>100963049</NlmUniqueID><ISSNLinking>1469-221X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000632372">Tmem106b protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Tdp-43</Keyword><Keyword MajorTopicYN="N">Tmem106b</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">lysosomes</Keyword><Keyword MajorTopicYN="N">progranulin</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32761777</ArticleId><ArticleId IdType="pmc">PMC7534638</ArticleId><ArticleId IdType="doi">10.15252/embr.202050197</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S et&#xa0;al (2010) Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol 177: 311&#x2013;324</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893674</ArticleId><ArticleId IdType="pubmed">20522652</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida MR, Macario MC, Ramos L, Baldeiras I, Ribeiro MH, Santana I (2016) Portuguese family with the co&#x2010;occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiol Aging 41: 200.e201&#x2013;200.e205</Citation><ArticleIdList><ArticleId IdType="pubmed">27021778</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrant AE, Filiano AJ, Warmus BA, Hall AM, Roberson ED (2016) Progranulin haploinsufficiency causes biphasic social dominance abnormalities in the tube test. Genes Brain Behav 15: 588&#x2013;603</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5943713</ArticleId><ArticleId IdType="pubmed">27213486</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrant AE, Nicholson AM, Zhou X, Rademakers R, Roberson ED (2018) Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency. Mol Neurodegener 13: 32</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013889</ArticleId><ArticleId IdType="pubmed">29929528</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrant AE, Roth JR, Boyle NR, Kashyap SN, Hoffmann MQ, Murchison CF, Ramos EM, Nana AL, Spina S, Grinberg LT et&#xa0;al (2019) Impaired beta&#x2010;glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations. Acta Neuropathol Commun 7: 218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929503</ArticleId><ArticleId IdType="pubmed">31870439</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel S, Moisse M, Damme M, De Muynck L, Robberecht W, Van Den Bosch L, Saftig P, Van Damme P (2017) Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in&#xa0;vivo . Hum Mol Genet 26: 2850&#x2013;2863</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886064</ArticleId><ArticleId IdType="pubmed">28453791</ArticleId></ArticleIdList></Reference><Reference><Citation>Belgrad J, De Pace R, Fields RD (2020) Autophagy in myelinating glia. J Neurosci 40: 256&#x2013;266</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6948934</ArticleId><ArticleId IdType="pubmed">31744863</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird T, Knopman D, VanSwieten J, Rosso S, Feldman H, Tanabe H, Graff&#x2010;Raford N, Geschwind D, Verpillat P, Hutton M (2003) Epidemiology and genetics of frontotemporal dementia/Pick's disease. Ann Neurol 54(Suppl 5): S29&#x2013;S31</Citation><ArticleIdList><ArticleId IdType="pubmed">12833366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch ME, Kielian T (2015) Neuroinflammatory paradigms in lysosomal storage diseases. Front Neurosci 9: 417</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4627351</ArticleId><ArticleId IdType="pubmed">26578874</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Zhou X, Hu F (2014) Regulated intramembrane proteolysis of the frontotemporal lobar degeneration risk factor, TMEM106B, by signal peptide peptidase&#x2010;like 2a (SPPL2a). J Biol Chem 289: 19670&#x2013;19680</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4094077</ArticleId><ArticleId IdType="pubmed">24872421</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright F, Werry EL, Dobson&#x2010;Stone C, Piguet O, Ittner LM, Halliday GM, Hodges JR, Kiernan MC, Loy CT, Kassiou M et&#xa0;al (2019) Neuroinflammation in frontotemporal dementia. Nat Rev Neurol 15: 540&#x2013;555</Citation><ArticleIdList><ArticleId IdType="pubmed">31324897</ArticleId></ArticleIdList></Reference><Reference><Citation>Burk K, Pasterkamp RJ (2019) Disrupted neuronal trafficking in amyotrophic lateral sclerosis. Acta Neuropathol 137: 859&#x2013;877</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6531423</ArticleId><ArticleId IdType="pubmed">30721407</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch JI, Martinez&#x2010;Lage M, Ashbridge E, Grossman M, Van Deerlin VM, Hu F, Lee VM, Trojanowski JQ, Chen&#x2010;Plotkin AS (2013) Expression of TMEM106B, the frontotemporal lobar degeneration&#x2010;associated protein, in normal and diseased human brain. Acta Neuropathol Commun 1: 36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893524</ArticleId><ArticleId IdType="pubmed">24252750</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler VJ, Cortopassi WA, Gururaj S, Wang AL, Pierce OM, Jacobson MP, Kao AW (2019) Multi&#x2010;granulin domain peptides bind to pro&#x2010;cathepsin D and stimulate its enzymatic activity more effectively than progranulin in&#xa0;vitro . Biochemistry 58: 2670&#x2013;2674</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666309</ArticleId><ArticleId IdType="pubmed">31099551</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitramuthu BP, Bennett HPJ, Bateman A (2017) Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. Brain 140: 3081&#x2013;3104</Citation><ArticleIdList><ArticleId IdType="pubmed">29053785</ArticleId></ArticleIdList></Reference><Reference><Citation>Faust PL, Kaye EM, Powers JM (2010) Myelin lesions associated with lysosomal and peroxisomal disorders. Expert Rev Neurother 10: 1449&#x2013;1466</Citation><ArticleIdList><ArticleId IdType="pubmed">20819015</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng T, Mai S, Roscoe JM, Sheng RR, Ullah M, Zhang J, Katz II, Yu H, Xiong W, Hu F (2020) Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice. EMBO Rep 21: e50219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534636</ArticleId><ArticleId IdType="pubmed">32852886</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ, Martens LH, Young AH, Warmus BA, Zhou P, Diaz&#x2010;Ramirez G, Jiao J, Zhang Z, Huang EJ, Gao FB et&#xa0;al (2013) Dissociation of frontotemporal dementia&#x2010;related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci 33: 5352&#x2013;5361</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740510</ArticleId><ArticleId IdType="pubmed">23516300</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus&#x2010;Hernandez M, Crook R, Hunter T, Ghidoni R, Benussi L et&#xa0;al (2011) TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 76: 467&#x2013;474</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034409</ArticleId><ArticleId IdType="pubmed">21178100</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkerth RD (1999) Abnormalities of developing white matter in lysosomal storage diseases. J Neuropathol Exp Neurol 58: 887&#x2013;902</Citation><ArticleIdList><ArticleId IdType="pubmed">10499433</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Posavi M, Huang P, Unger TL, Berlyand Y, Gruenewald AL, Chesi A, Manduchi E, Wells AD, Grant SFA et&#xa0;al (2017) A dementia&#x2010;associated risk variant near TMEM106B alters chromatin architecture and gene expression. Am J Hum Genet 101: 643&#x2013;663</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5673619</ArticleId><ArticleId IdType="pubmed">29056226</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyenet SJ, Furrer SA, Damian VM, Baughan TD, La Spada AR, Garden GA (2010) A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp 39: 1787</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121238</ArticleId><ArticleId IdType="pubmed">20495529</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler CJ, Taylor G, Deng Q, Kukar T (2017) Intracellular proteolysis of progranulin generates stable, lysosomal granulins that are haploinsufficient in patients with frontotemporal dementia caused by GRN mutations. eNeuro 4: ENEURO.0100&#x2010;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5562298</ArticleId><ArticleId IdType="pubmed">28828399</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM (2010) Sortilin&#x2010;mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68: 654&#x2013;667</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990962</ArticleId><ArticleId IdType="pubmed">21092856</ArticleId></ArticleIdList></Reference><Reference><Citation>Huin V, Barbier M, Bottani A, Lobrinus JA, Clot F, Lamari F, Chat L, Rucheton B, Fluchere F, Auvin S et&#xa0;al (2020) Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms. Brain 143: 303&#x2013;319</Citation><ArticleIdList><ArticleId IdType="pubmed">31855245</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian J, Zhao S, Tian QY, Liu H, Zhao Y, Chen WC, Grunig G, Torres PA, Wang BC, Zeng B et&#xa0;al (2016) Association between progranulin and gaucher disease. EBioMedicine 11: 127&#x2013;137</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5049935</ArticleId><ArticleId IdType="pubmed">27515686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AW, Eisenhut RJ, Martens LH, Nakamura A, Huang A, Bagley JA, Zhou P, de Luis A, Neukomm LJ, Cabello J et&#xa0;al (2011) A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. Proc Natl Acad Sci USA 108: 4441&#x2013;4446</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060230</ArticleId><ArticleId IdType="pubmed">21368173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AW, McKay A, Singh PP, Brunet A, Huang EJ (2017) Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci 18: 325&#x2013;333</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6040832</ArticleId><ArticleId IdType="pubmed">28435163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D, Thangavel R, Natteru PA, Selvakumar GP, Saeed D, Zahoor H, Zaheer S, Iyer SS, Zaheer A (2016) Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 1: 1003</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5260818</ArticleId><ArticleId IdType="pubmed">28127589</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT, Strittmatter SM (2017) Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia&#x2010;related phenotypes in progranulin&#x2010;deficient mice. Neuron 95: 281&#x2013;296.e286</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558861</ArticleId><ArticleId IdType="pubmed">28728022</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K et&#xa0;al (2016) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 12: 1&#x2013;222</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835977</ArticleId><ArticleId IdType="pubmed">26799652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R, Strazielle C (2011) Brain regions and genes affecting limb&#x2010;clasping responses. Brain Res Rev 67: 252&#x2013;259</Citation><ArticleIdList><ArticleId IdType="pubmed">21356243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang CM, Fellerer K, Schwenk BM, Kuhn PH, Kremmer E, Edbauer D, Capell A, Haass C (2012) Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J Biol Chem 287: 19355&#x2013;19365</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365973</ArticleId><ArticleId IdType="pubmed">22511793</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Stankowski JN, Chew J, Cook CN, Lam YW, Almeida S, Carlomagno Y, Lau KF, Prudencio M, Gao FB et&#xa0;al (2017) The lysosomal protein cathepsin L is a progranulin protease. Mol Neurodegener 12: 55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526245</ArticleId><ArticleId IdType="pubmed">28743268</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Farias FHG, Dube U, Del&#x2010;Aguila JL, Mihindukulasuriya KA, Fernandez MV, Ibanez L, Budde JP, Wang F, Lake AM et&#xa0;al (2020) The TMEM106B FTLD&#x2010;protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol 139: 45&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942643</ArticleId><ArticleId IdType="pubmed">31456032</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE et&#xa0;al (2009) Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 117: 15&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710877</ArticleId><ArticleId IdType="pubmed">19015862</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, Min SW, Gan L, Finkbeiner S, Huang EJ et&#xa0;al (2012) Progranulin deficiency promotes neuroinflammation and neuron loss following toxin&#x2010;induced injury. J Clin Invest 122: 3955&#x2013;3959</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484443</ArticleId><ArticleId IdType="pubmed">23041626</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuwaki T, Kobayashi A, Mase K, Nakamura K, Nakano S, Miyoshi T, Yamanouchi K, Nishihara M (2015) Possible involvement of the cerebellum in motor&#x2010;function impairment in progranulin&#x2010;deficient mice. NeuroReport 26: 877&#x2013;881</Citation><ArticleIdList><ArticleId IdType="pubmed">26302163</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Cannon A, Graff&#x2010;Radford NR, Liesinger AM, Rutherford NJ, Ross OA, Duara R, Carrasquillo MM, Rademakers R, Dickson DW (2014) Differential clinicopathologic and genetic features of late&#x2010;onset amnestic dementias. Acta Neuropathol 128: 411&#x2013;421</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412022</ArticleId><ArticleId IdType="pubmed">24899141</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM et&#xa0;al (2006) Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Finch NA, Wojtas A, Baker MC, Perkerson RB 3rd, Castanedes&#x2010;Casey M, Rousseau L, Benussi L, Binetti G, Ghidoni R et&#xa0;al (2013) TMEM106B p. T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J Neurochem 126: 781&#x2013;791</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766501</ArticleId><ArticleId IdType="pubmed">23742080</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Rademakers R (2016) What we know about TMEM106B in neurodegeneration. Acta Neuropathol 132: 639&#x2013;651</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5074873</ArticleId><ArticleId IdType="pubmed">27543298</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Zhou X, Perkerson RB, Parsons TM, Chew J, Brooks M, DeJesus&#x2010;Hernandez M, Finch NA, Matchett BJ, Kurti A et&#xa0;al (2018) Loss of Tmem106b is unable to ameliorate frontotemporal dementia&#x2010;like phenotypes in an AAV mouse model of C9ORF72&#x2010;repeat induced toxicity. Acta Neuropathol Commun 6: 42</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984311</ArticleId><ArticleId IdType="pubmed">29855382</ArticleId></ArticleIdList></Reference><Reference><Citation>Paushter DH, Du H, Feng T, Hu F (2018) The lysosomal function of progranulin, a guardian against neurodegeneration. Acta Neuropathol 136: 1&#x2013;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6117207</ArticleId><ArticleId IdType="pubmed">29744576</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkau TL, Neal SJ, Milnerwood A, Mew A, Hill AM, Orban P, Gregg J, Lu G, Feldman HH, Mackenzie IR et&#xa0;al (2012) Synaptic dysfunction in progranulin&#x2010;deficient mice. Neurobiol Dis 45: 711&#x2013;722</Citation><ArticleIdList><ArticleId IdType="pubmed">22062772</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkau TL, Hill A, Leavitt BR (2016) Core neuropathological abnormalities in progranulin&#x2010;deficient mice are penetrant on multiple genetic backgrounds. Neuroscience 315: 175&#x2013;195</Citation><ArticleIdList><ArticleId IdType="pubmed">26701296</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Zhou X, Perkerson RB 3rd, Baker M, Jenkins GD, Serie DJ, Ghidoni R, Benussi L, Binetti G, Lopez de Munain A et&#xa0;al (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome&#x2010;wide association study. Lancet Neurol 17: 548&#x2013;558</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237181</ArticleId><ArticleId IdType="pubmed">29724592</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Neumann M, Mackenzie IR (2012) Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 8: 423&#x2013;434</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, van Blitterswijk M, Allen M, Carrasquillo MM, Reddy JS, Wang X, Beach TG, Dickson DW, Ertekin&#x2010;Taner N, Asmann YW et&#xa0;al (2018) TMEM106B haplotypes have distinct gene expression patterns in aged brain. Mol Neurodegener 13: 35</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029036</ArticleId><ArticleId IdType="pubmed">29970152</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, Abeliovich A (2017) Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes. Cell Syst 4: 404&#x2013;415.e405</Citation><ArticleIdList><ArticleId IdType="pubmed">28330615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Carrasquillo MM, Li M, Bisceglio G, Menke J, Josephs KA, Parisi JE, Petersen RC, Graff&#x2010;Radford NR, Younkin SG et&#xa0;al (2012) TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology 79: 717&#x2013;718</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467659</ArticleId><ArticleId IdType="pubmed">22855871</ArticleId></ArticleIdList></Reference><Reference><Citation>Seltman RE, Matthews BR (2012) Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs 26: 841&#x2013;870</Citation><ArticleIdList><ArticleId IdType="pubmed">22950490</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons C, Dyment D, Bent SJ, Crawford J, D'Hooghe M, Kohlschutter A, Venkateswaran S, Helman G, Poll&#x2010;The BT, Makowski CC et&#xa0;al (2017) A recurrent de novo mutation in TMEM106B causes hypomyelinating leukodystrophy. Brain 140: 3105&#x2013;3111</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841038</ArticleId><ArticleId IdType="pubmed">29186371</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF et&#xa0;al (2012) Strikingly different clinicopathological phenotypes determined by progranulin&#x2010;mutation dosage. Am J Hum Genet 90: 1102&#x2013;1107</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Trajkovic K, Dhaunchak AS, Goncalves JT, Wenzel D, Schneider A, Bunt G, Nave KA, Simons M (2006) Neuron to glia signaling triggers myelin membrane exocytosis from endosomal storage sites. J Cell Biol 172: 937&#x2013;948</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063736</ArticleId><ArticleId IdType="pubmed">16520383</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez C, Wong YC, Schwake M, Bu G, Wszolek ZK, Krainc D (2017) Progranulin&#x2010;mediated deficiency of cathepsin D results in FTD and NCL&#x2010;like phenotypes in neurons derived from FTD patients. Hum Mol Genet 26: 4861&#x2013;4872</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886207</ArticleId><ArticleId IdType="pubmed">29036611</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez C, Ysselstein D, Young TJ, Zheng J, Krainc D (2020) Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. Hum Mol Genet 29: 716&#x2013;726</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7104673</ArticleId><ArticleId IdType="pubmed">31600775</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez&#x2010;Lage M, Chen&#x2010;Plotkin A, Wang LS, Graff&#x2010;Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M et&#xa0;al (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP&#x2010;43 inclusions. Nat Genet 42: 234&#x2013;239</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME, Taubes A, Chen R, Miller BL, Sephton CF, Gelfand JM, Minami S, Boscardin J, Martens LH, Seeley WW et&#xa0;al (2014) Early retinal neurodegeneration and impaired Ran&#x2010;mediated nuclear import of TDP&#x2010;43 in progranulin&#x2010;deficient FTLD. J Exp Med 211: 1937&#x2013;1945</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172214</ArticleId><ArticleId IdType="pubmed">25155018</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner G, Damme M, Schludi M, Gn&#xf6;rich J, Wind K, Fellerer K, Wefers B, Wurst W, Edbauer D, Brendel M et&#xa0;al (2020) Loss of TMEM106B potentiates lysosomal and FTD&#x2010;like pathology in progranulin deficient mice. EMBO Rep 21: e50241</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534633</ArticleId><ArticleId IdType="pubmed">32929860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Pereson S, Janssens J, Capell A, Van Dam D, Cuijt I, Joris G, De Deyn PP, Haass C et&#xa0;al (2012) Cellular ageing, increased mortality and FTLD&#x2010;TDP&#x2010;associated neuropathology in progranulin knockout mice. J Pathol 228: 67&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pubmed">22733568</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiwatpanit T, Remis NN, Ahmad A, Zhou Y, Clancy JC, Cheatham MA, Garcia&#x2010;Anoveros J (2018) Codeficiency of lysosomal mucolipins 3 and 1 in cochlear hair cells diminishes outer hair cell longevity and accelerates age&#x2010;related hearing loss. J Neurosci 38: 3177&#x2013;3189</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884457</ArticleId><ArticleId IdType="pubmed">29453205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF et&#xa0;al (2010a) Exaggerated inflammation, impaired host defense, and neuropathology in progranulin&#x2010;deficient mice. J Exp Med 207: 117&#x2013;128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812536</ArticleId><ArticleId IdType="pubmed">20026663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, Beal MF, Nathan C, Thomas B, Ding A (2010b) Behavioral deficits and progressive neuropathology in progranulin&#x2010;deficient mice: a mouse model of frontotemporal dementia. FASEB J 24: 4639&#x2013;4647</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992364</ArticleId><ArticleId IdType="pubmed">20667979</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Bastos de Oliveira F, Qi X, Brown WJ, Smolka MB, Sun Y, Hu F (2015) Prosaposin facilitates sortilin&#x2010;independent lysosomal trafficking of progranulin. J Cell Biol 210: 991&#x2013;1002</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576858</ArticleId><ArticleId IdType="pubmed">26370502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Paushter DH, Feng T, Pardon CM, Mendoza CS, Hu F (2017a) Regulation of cathepsin D activity by the FTLD protein progranulin. Acta Neuropathol 134: 151&#x2013;153</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568051</ArticleId><ArticleId IdType="pubmed">28493053</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Paushter DH, Feng T, Sun L, Reinheckel T, Hu F (2017b) Lysosomal processing of progranulin. Mol Neurodegener 12: 62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5569495</ArticleId><ArticleId IdType="pubmed">28835281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Bracko O, Choi JW, Jia Y, Nana AL, Brady OA, Hernandez JCC, Nishimura N, Seeley WW et&#xa0;al (2017c) Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations. Nat Commun 8: 15277</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477518</ArticleId><ArticleId IdType="pubmed">28541286</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Brady OA, Murphy KA, Hu F (2017d) Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency. Acta Neuropathol Commun 5: 9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5270347</ArticleId><ArticleId IdType="pubmed">28126008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Paushter DH, Pagan MD, Kim D, Nunez Santos M, Lieberman RL, Overkleeft HS, Sun Y, Smolka MB, Hu F (2019) Progranulin deficiency leads to reduced glucocerebrosidase activity. PLoS ONE 14: e0212382</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619604</ArticleId><ArticleId IdType="pubmed">31291241</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32623451</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1758-535X</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>The journals of gerontology. Series A, Biological sciences and medical sciences</Title><ISOAbbreviation>J Gerontol A Biol Sci Med Sci</ISOAbbreviation></Journal><ArticleTitle>ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank.</ArticleTitle><Pagination><StartPage>1801</StartPage><EndPage>1803</EndPage><MedlinePgn>1801-1803</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/gerona/glaa169</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Chia-Ling</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Connecticut Convergence Institute for Translation in Regenerative Engineering, University of Connecticut Health, Farmington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center on Aging, University of Connecticut Health, Farmington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilling</LastName><ForeName>Luke C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Center on Aging, University of Connecticut Health, Farmington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology and Public Health Group, University of Exeter Medical School, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atkins</LastName><ForeName>Janice L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Epidemiology and Public Health Group, University of Exeter Medical School, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masoli</LastName><ForeName>Jane A H</ForeName><Initials>JAH</Initials><AffiliationInfo><Affiliation>Epidemiology and Public Health Group, University of Exeter Medical School, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Healthcare for Older People, Royal Devon and Exeter Hospital, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delgado</LastName><ForeName>Jo&#xe3;o</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Epidemiology and Public Health Group, University of Exeter Medical School, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuchel</LastName><ForeName>George A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Center on Aging, University of Connecticut Health, Farmington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melzer</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center on Aging, University of Connecticut Health, Farmington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology and Public Health Group, University of Exeter Medical School, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/S009892/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R21 AG060018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Gerontol A Biol Sci Med Sci</MedlineTA><NlmUniqueID>9502837</NlmUniqueID><ISSNLinking>1079-5006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2231-2232. doi: 10.1093/gerona/glaa131.</RefSource><PMID Version="1">32451547</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018070" MajorTopicYN="Y">Biological Specimen Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32623451</ArticleId><ArticleId IdType="pmc">PMC7337688</ArticleId><ArticleId IdType="doi">10.1093/gerona/glaa169</ArticleId><ArticleId IdType="pii">5867501</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kuo C-L, Pilling LC, Atkins JL, et al. . APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci [Internet]. 2020. doi:10.1093/gerona/glaa131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glaa131</ArticleId><ArticleId IdType="pmc">PMC7314139</ArticleId><ArticleId IdType="pubmed">32451547</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong J, Rudkin JK, Allen N, et al. . Dynamic linkage of COVID-19 test results between Public Health England&#x2019;s Second Generation Surveillance System and UK Biobank. Microb Genom. 2020. doi:10.1099/mgen.0.000397</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000397</ArticleId><ArticleId IdType="pmc">PMC7478634</ArticleId><ArticleId IdType="pubmed">32553051</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilling LC, Tamosauskaite J, Jones G, et al. . Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ. 2019;364:k5222. doi:10.1136/bmj.k5222</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k5222</ArticleId><ArticleId IdType="pmc">PMC6334179</ArticleId><ArticleId IdType="pubmed">30651232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo C-L, Pilling LC, Atkins JL, Kuchel GA, Melzer D. ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants. Aging (Albany NY). 2020;12(12):12222&#x2013;12233. doi:10.18632/aging.103405</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103405</ArticleId><ArticleId IdType="pmc">PMC7343499</ArticleId><ArticleId IdType="pubmed">32511104</ArticleId></ArticleIdList></Reference><Reference><Citation>
Atkins JL, Masoli JAH, Delgado J, et al. . 
Preexisting comorbidities predicting severe covid-19 in older adults in the UK Biobank community cohort. medRxiv. 2020. 
http://medrxiv.org/content/early/2020/05/08/2020.05.06.20092700.abstract. Accessed June 15, 2020.</Citation></Reference><Reference><Citation>Ellinghaus D, Degenhardt F, Bujanda L, et al. . Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med [Internet]. 2020. doi:10.1056/NEJMoa2020283</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2020283</ArticleId><ArticleId IdType="pmc">PMC7315890</ArticleId><ArticleId IdType="pubmed">32558485</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32471486</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation.</ArticleTitle><Pagination><StartPage>74</StartPage><MedlinePgn>74</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">74</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-020-00948-z</ELocationID><Abstract><AbstractText>Immunotherapies targeting pathological tau have recently emerged as a promising approach for treatment of neurodegenerative disorders. We have previously showed that the mouse antibody DC8E8 discriminates between healthy and pathological tau, reduces tau pathology in murine tauopathy models and inhibits neuronal internalization of AD tau species in vitro.Here we show, that DC8E8 and antibodies elicited against the first-in-man tau vaccine, AADvac1, which is based on the DC8E8 epitope peptide, both promote uptake of pathological tau by mouse primary microglia. IgG1 and IgG4 isotypes of AX004, the humanized versions of DC8E8, accelerate tau uptake by human primary microglia isolated from post-mortem aged and diseased brains. This promoting activity requires the presence of the Fc-domain of the antibodies.The IgG1 isotype of AX004 showed greater ability to promote tau uptake compared to the IgG4 isotype, while none of the antibody-tau complexes provoked increased pro-inflammatory activity of microglia. Our data suggest that IgG1 has better suitability for therapeutic development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zilkova</LastName><ForeName>Monika</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5978-1695</Identifier><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic. zilkova@axon-neuroscience.eu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nolle</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam Neuroscience, De Boelelaan, 1117, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacech</LastName><ForeName>Branislav</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kontsekova</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weisova</LastName><ForeName>Petronela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filipcik</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skrabana</LastName><ForeName>Rostislav</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prcina</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hromadka</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cehlar</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolkova</LastName><ForeName>Gabriela Paulikova</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maderova</LastName><ForeName>Denisa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Axon Neuroscience SE, Arch. Makariou &amp; Kalogreon 4, Larnaca, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zilka</LastName><ForeName>Norbert</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Axon Neuroscience R&amp;D Services SE, Dvorakovo nabrezie, 10, Bratislava, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoozemans</LastName><ForeName>Jeroen J M</ForeName><Initials>JJM</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam Neuroscience, De Boelelaan, 1117, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000709631">AADvac1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023582">Alzheimer Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023582" MajorTopicYN="N">Alzheimer Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Human microglia</Keyword><Keyword MajorTopicYN="N">Humanized antibody</Keyword><Keyword MajorTopicYN="N">Tau immunotherapy</Keyword><Keyword MajorTopicYN="N">Tau uptake</Keyword></KeywordList><CoiStatement>This study was supported by AXON Neuroscience R&amp;D Services SE. Some of the authors are the employees of AXON Neuroscience R&amp;D Services SE. The authors have no other competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32471486</ArticleId><ArticleId IdType="pmc">PMC7257136</ArticleId><ArticleId IdType="doi">10.1186/s40478-020-00948-z</ArticleId><ArticleId IdType="pii">10.1186/s40478-020-00948-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci. 2012;32:9677&#x2013;9689. doi: 10.1523/JNEUROSCI.4742-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4742-11.2012</ArticleId><ArticleId IdType="pmc">PMC6622286</ArticleId><ArticleId IdType="pubmed">22787053</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson CR, Falsig J, Stavenhagen JB, Christensen S, Kartberg F, Rosenqvist N, Finsen B, Pedersen JT. Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcgamma-receptor binding and functional lysosomes. Sci Rep. 2019;9:4658. doi: 10.1038/s41598-019-41105-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41105-4</ArticleId><ArticleId IdType="pmc">PMC6420568</ArticleId><ArticleId IdType="pubmed">30874605</ArticleId></ArticleIdList></Reference><Reference><Citation>Apetri A, Crespo R, Juraszek J, Pascual G, Janson R, Zhu X, Zhang H, Keogh E, Holland T, Wadia J, et al. A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities. Acta Neuropathol Commun. 2018;6:43. doi: 10.1186/s40478-018-0543-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0543-z</ArticleId><ArticleId IdType="pmc">PMC5984341</ArticleId><ArticleId IdType="pubmed">29855358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett RE, Bryant A, Hu M, Robbins AB, Hopp SC, Hyman BT. Partial reduction of microglia does not affect tau pathology in aged mice. J Neuroinflammation. 2018;15:311. doi: 10.1186/s12974-018-1348-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1348-5</ArticleId><ArticleId IdType="pmc">PMC6230271</ArticleId><ArticleId IdType="pubmed">30413160</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournazos S, DiLillo DJ, Ravetch JV. The role of fc-FcgammaR interactions in IgG-mediated microbial neutralization. J Exp Med. 2015;212:1361&#x2013;1369. doi: 10.1084/jem.20151267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151267</ArticleId><ArticleId IdType="pmc">PMC4548051</ArticleId><ArticleId IdType="pubmed">26282878</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournazos S, Ravetch JV. Fcgamma receptor function and the design of vaccination strategies. Immunity. 2017;47:224&#x2013;233. doi: 10.1016/j.immuni.2017.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.07.009</ArticleId><ArticleId IdType="pmc">PMC5573140</ArticleId><ArticleId IdType="pubmed">28813656</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143. doi: 10.1038/nn.3599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3599</ArticleId><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cehlar O, Skrabana R, Kovac A, Kovacech B, Novak M. Crystallization and preliminary X-ray diffraction analysis of tau protein microtubule-binding motifs in complex with Tau5 and DC25 antibody fab fragments. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012;68:1181&#x2013;1185. doi: 10.1107/S1744309112030382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S1744309112030382</ArticleId><ArticleId IdType="pmc">PMC3497975</ArticleId><ArticleId IdType="pubmed">23027743</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, et al. Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem. 2011;286:34457&#x2013;34467. doi: 10.1074/jbc.M111.229633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.229633</ArticleId><ArticleId IdType="pmc">PMC3190817</ArticleId><ArticleId IdType="pubmed">21841002</ArticleId></ArticleIdList></Reference><Reference><Citation>Csokova N, Skrabana R, Liebig HD, Mederlyova A, Kontsek P, Novak M. Rapid purification of truncated tau proteins: model approach to purification of functionally active fragments of disordered proteins, implication for neurodegenerative diseases. Protein Expr Purif. 2004;35:366&#x2013;372. doi: 10.1016/j.pep.2004.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pep.2004.01.012</ArticleId><ArticleId IdType="pubmed">15135415</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot CJ, Hulshof S, Hoozemans JJ, Veerhuis R. Establishment of microglial cell cultures derived from postmortem human adult brain tissue: immunophenotypical and functional characterization. Microsc Res Tech. 2001;54:34&#x2013;39. doi: 10.1002/jemt.1118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jemt.1118</ArticleId><ArticleId IdType="pubmed">11526955</ArticleId></ArticleIdList></Reference><Reference><Citation>de Taeye Steven W., Rispens Theo, Vidarsson Gestur. The Ligands for Human IgG and Their Effector Functions. Antibodies. 2019;8(2):30. doi: 10.3390/antib8020030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib8020030</ArticleId><ArticleId IdType="pmc">PMC6640714</ArticleId><ArticleId IdType="pubmed">31544836</ArticleId></ArticleIdList></Reference><Reference><Citation>Durafourt BA, Moore CS, Blain M, Antel JP. Isolating, culturing, and polarizing primary human adult and fetal microglia. Methods Mol Biol. 2013;1041:199&#x2013;211. doi: 10.1007/978-1-62703-520-0_19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-520-0_19</ArticleId><ArticleId IdType="pubmed">23813381</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer's disease not evident in mouse models. Cell Rep. 2018;22:832&#x2013;847. doi: 10.1016/j.celrep.2017.12.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.12.066</ArticleId><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI. Distinct therapeutic mechanisms of tau antibodies: promoting microglial clearance versus blocking neuronal uptake. J Biol Chem. 2015;290:21652&#x2013;21662. doi: 10.1074/jbc.M115.657924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.657924</ArticleId><ArticleId IdType="pmc">PMC4571888</ArticleId><ArticleId IdType="pubmed">26126828</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, Veras MM, Pereira TF, Leite REP, Moller T, et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat Neurosci. 2017;20:1162&#x2013;1171. doi: 10.1038/nn.4597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4597</ArticleId><ArticleId IdType="pubmed">28671693</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Baker TJ. Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci. 1986;6:2163&#x2013;2178. doi: 10.1523/JNEUROSCI.06-08-02163.1986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.06-08-02163.1986</ArticleId><ArticleId IdType="pmc">PMC6568755</ArticleId><ArticleId IdType="pubmed">3018187</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin David, Skola Dylan, Coufal Nicole G., Holtman Inge R., Schlachetzki Johannes C. M., Sajti Eniko, Jaeger Baptiste N., O&#x2019;Connor Carolyn, Fitzpatrick Conor, Pasillas Martina P., Pena Monique, Adair Amy, Gonda David D., Levy Michael L., Ransohoff Richard M., Gage Fred H., Glass Christopher K. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017;356(6344):eaal3222. doi: 10.1126/science.aal3222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal3222</ArticleId><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Congdon EE, Sigurdsson EM. Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau protein pathology. J Biol Chem. 2013;288:33081&#x2013;33095. doi: 10.1074/jbc.M113.494922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.494922</ArticleId><ArticleId IdType="pmc">PMC3829157</ArticleId><ArticleId IdType="pubmed">24089520</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell. 2017;169:1276&#x2013;1290. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura Y, Taniguchi T, Kimura H, Nomura Y, Gebicke-Haerter PJ. Interleukin-4-inhibited mRNA expression in mixed rat glial and in isolated microglial cultures. J Neuroimmunol. 2000;106:95&#x2013;104. doi: 10.1016/S0165-5728(00)00239-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(00)00239-3</ArticleId><ArticleId IdType="pubmed">10814787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther. 2014;6:44. doi: 10.1186/alzrt278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt278</ArticleId><ArticleId IdType="pmc">PMC4255368</ArticleId><ArticleId IdType="pubmed">25478017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontsekova E, Zilka N, Kovacech B, Skrabana R, Novak M. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Alzheimers Res Ther. 2014;6:45. doi: 10.1186/alzrt277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt277</ArticleId><ArticleId IdType="pmc">PMC4255369</ArticleId><ArticleId IdType="pubmed">25478018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovac A, Zilka N, Kazmerova Z, Cente M, Zilkova M, Novak M. Misfolded truncated protein tau induces innate immune response via MAPK pathway. J Immunol. 2011;187:2732&#x2013;2739. doi: 10.4049/jimmunol.1100216.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1100216</ArticleId><ArticleId IdType="pubmed">21813771</ArticleId></ArticleIdList></Reference><Reference><Citation>Krajciova G, Skrabana R, Filipcik P, Novak M. Preserving free thiols of intrinsically disordered tau protein without the use of a reducing agent. Anal Biochem. 2008;383:343&#x2013;345. doi: 10.1016/j.ab.2008.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2008.09.022</ArticleId><ArticleId IdType="pubmed">18834853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledeboer A, Breve JJ, Poole S, Tilders FJ, Van Dam AM. Interleukin-10, interleukin-4, and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia. 2000;30:134&#x2013;142. doi: 10.1002/(SICI)1098-1136(200004)30:2&lt;134::AID-GLIA3&gt;3.0.CO;2-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-1136(200004)30:2&lt;134::AID-GLIA3&gt;3.0.CO;2-3</ArticleId><ArticleId IdType="pubmed">10719355</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Le Pichon CE, Adolfsson O, Gafner V, Pihlgren M, Lin H, Solanoy H, Brendza R, Ngu H, Foreman O, et al. Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Rep. 2016;16:1690&#x2013;1700. doi: 10.1016/j.celrep.2016.06.099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.06.099</ArticleId><ArticleId IdType="pubmed">27475227</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener. 2017;12:50. doi: 10.1186/s13024-017-0192-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0192-x</ArticleId><ArticleId IdType="pmc">PMC5492997</ArticleId><ArticleId IdType="pubmed">28662669</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, et al. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology. 2018;90:e877&#x2013;e886. doi: 10.1212/WNL.0000000000005060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005060</ArticleId><ArticleId IdType="pubmed">29429971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lively S, Schlichter LC. Microglia responses to pro-inflammatory stimuli (LPS, IFNgamma+TNFalpha) and reprogramming by resolving cytokines (IL-4, IL-10) Front Cell Neurosci. 2018;12:215. doi: 10.3389/fncel.2018.00215.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00215</ArticleId><ArticleId IdType="pmc">PMC6066613</ArticleId><ArticleId IdType="pubmed">30087595</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W, Liu W, Hu X, Hanna M, Caravaca A, Paul SM. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci Rep. 2015;5:11161. doi: 10.1038/srep11161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep11161</ArticleId><ArticleId IdType="pmc">PMC4460904</ArticleId><ArticleId IdType="pubmed">26057852</ArticleId></ArticleIdList></Reference><Reference><Citation>Macikova I, Dedek L, Vrzal V, Kontsekova E, Kontsek P, Ciampor F, Novak M. Common and different antigenic properties of the rabies virus glycoprotein of strains SAD-Vnukovo and pitman-Moore. Acta Virol. 1992;36:541&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">1284868</ArticleId></ArticleIdList></Reference><Reference><Citation>Majerova P, Zilkova M, Kazmerova Z, Kovac A, Paholikova K, Kovacech B, Zilka N, Novak M. Microglia display modest phagocytic capacity for extracellular tau oligomers. J Neuroinflammation. 2014;11:161. doi: 10.1186/s12974-014-0161-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-014-0161-z</ArticleId><ArticleId IdType="pmc">PMC4172893</ArticleId><ArticleId IdType="pubmed">25217135</ArticleId></ArticleIdList></Reference><Reference><Citation>Melief J, Sneeboer MA, Litjens M, Ormel PR, Palmen SJ, Huitinga I, Kahn RS, Hol EM, de Witte LD. Characterizing primary human microglia: a comparative study with myeloid subsets and culture models. Glia. 2016;64:1857&#x2013;1868. doi: 10.1002/glia.23023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23023</ArticleId><ArticleId IdType="pubmed">27442614</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizee MR, Miedema SS, van der Poel M, Adelia SKG, van Strien ME, Melief J, Smolders J, Hendrickx DA, Heutinck KM, et al. Isolation of primary microglia from the human post-mortem brain: effects of ante- and post-mortem variables. Acta Neuropathol Commun. 2017;5:16. doi: 10.1186/s40478-017-0418-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0418-8</ArticleId><ArticleId IdType="pmc">PMC5316206</ArticleId><ArticleId IdType="pubmed">28212663</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak P, Kontsekova E, Zilka N, Novak M. Ten years of tau-targeted immunotherapy: the path walked and the roads ahead. Front Neurosci. 2018;12:798. doi: 10.3389/fnins.2018.00798.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00798</ArticleId><ArticleId IdType="pmc">PMC6224648</ArticleId><ArticleId IdType="pubmed">30450030</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak P, Schmidt R, Kontsekova E, Kovacech B, Smolek T, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimers Res Ther. 2018;10:108. doi: 10.1186/s13195-018-0436-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0436-1</ArticleId><ArticleId IdType="pmc">PMC6201586</ArticleId><ArticleId IdType="pubmed">30355322</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, Patrick E, Villani AC, Xu J, White CC, Ryan KJ, Piehowski P, Kapasi A, Nejad P, Cimpean M, et al. A transcriptomic atlas of aged human microglia. Nat Commun. 2018;9:539. doi: 10.1038/s41467-018-02926-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-02926-5</ArticleId><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimers Res Ther. 2017;9:95. doi: 10.1186/s13195-017-0318-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0318-y</ArticleId><ArticleId IdType="pmc">PMC5723032</ArticleId><ArticleId IdType="pubmed">29221491</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE) Alzheimers Res Ther. 2018;10:96. doi: 10.1186/s13195-018-0424-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0424-5</ArticleId><ArticleId IdType="pmc">PMC6146627</ArticleId><ArticleId IdType="pubmed">30231896</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J, Tusell JM, Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia. 2003;44:183&#x2013;189. doi: 10.1002/glia.10274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.10274</ArticleId><ArticleId IdType="pubmed">14603460</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature. 2016;537:50&#x2013;56. doi: 10.1038/nature19323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A, Abiega O, Shahraz A, Neumann H. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. Front Cell Neurosci. 2013;7:6. doi: 10.3389/fncel.2013.00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00006</ArticleId><ArticleId IdType="pmc">PMC3558702</ArticleId><ArticleId IdType="pubmed">23386811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Tau immunotherapies for Alzheimer's disease and related Tauopathies: Progress and potential pitfalls. J Alzheimers Dis. 2018;66:855&#x2013;856. doi: 10.3233/JAD-189010.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-189010</ArticleId><ArticleId IdType="pubmed">30400102</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AM, Dragunow M. The human side of microglia. Trends Neurosci. 2014;37:125&#x2013;135. doi: 10.1016/j.tins.2013.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2013.12.001</ArticleId><ArticleId IdType="pubmed">24388427</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittau B. Aging microglia-phenotypes, functions and implications for age-related neurodegenerative diseases. Front Aging Neurosci. 2017;9:194. doi: 10.3389/fnagi.2017.00194.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00194</ArticleId><ArticleId IdType="pmc">PMC5469878</ArticleId><ArticleId IdType="pubmed">28659790</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Xue QS, Tischer J, Bechmann I. Microglial pathology. Acta Neuropathol Commun. 2014;2:142. doi: 10.1186/s40478-014-0142-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0142-6</ArticleId><ArticleId IdType="pmc">PMC4180960</ArticleId><ArticleId IdType="pubmed">25257319</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczepanik AM, Funes S, Petko W, Ringheim GE. IL-4, IL-10 and IL-13 modulate a beta(1--42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J Neuroimmunol. 2001;113:49&#x2013;62. doi: 10.1016/S0165-5728(00)00404-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(00)00404-5</ArticleId><ArticleId IdType="pubmed">11137576</ArticleId></ArticleIdList></Reference><Reference><Citation>Voet Sofie, Prinz Marco, van Loo Geert. Microglia in Central Nervous System Inflammation and Multiple Sclerosis Pathology. Trends in Molecular Medicine. 2019;25(2):112&#x2013;123. doi: 10.1016/j.molmed.2018.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2018.11.005</ArticleId><ArticleId IdType="pubmed">30578090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med. 2015;3:136. doi: 10.3978/j.issn.2305-5839.2015.03.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.3978/j.issn.2305-5839.2015.03.49</ArticleId><ArticleId IdType="pmc">PMC4486922</ArticleId><ArticleId IdType="pubmed">26207229</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisova P, Cehlar O, Skrabana R, Zilkova M, Filipcik P, Kovacech B, Prcina M, Wojciakova L, Fialova L, Smolek T, et al. Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans. Acta Neuropathol Commun. 2019;7:129. doi: 10.1186/s40478-019-0770-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0770-y</ArticleId><ArticleId IdType="pmc">PMC6685285</ArticleId><ArticleId IdType="pubmed">31391090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wes PD, Sayed FA, Bard F, Gan L. Targeting microglia for the treatment of Alzheimer's disease. Glia. 2016;64:1710&#x2013;1732. doi: 10.1002/glia.22988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22988</ArticleId><ArticleId IdType="pubmed">27100611</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402&#x2013;414. doi: 10.1016/j.neuron.2013.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.046</ArticleId><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C, Zhou XW, Wang JZ. The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-alpha, TGF-beta and IFN-gamma. Transl Neurodegener. 2016;5:7. doi: 10.1186/s40035-016-0054-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-016-0054-4</ArticleId><ArticleId IdType="pmc">PMC4822284</ArticleId><ArticleId IdType="pubmed">27054030</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nat Med. 2020;26:131&#x2013;142. doi: 10.1038/s41591-019-0695-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32777042</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1758-535X</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>The journals of gerontology. Series A, Biological sciences and medical sciences</Title><ISOAbbreviation>J Gerontol A Biol Sci Med Sci</ISOAbbreviation></Journal><ArticleTitle>The ApoE Locus and COVID-19: Are We Going Where We Have Been?</ArticleTitle><Pagination><StartPage>e1</StartPage><EndPage>e3</EndPage><MedlinePgn>e1-e3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/gerona/glaa200</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Finch</LastName><ForeName>Caleb E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Center with Leonard Davis School of Gerontology and Dornsife College, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulminski</LastName><ForeName>Alexander M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG055367</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066530</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG070488</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG065477</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061853</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Gerontol A Biol Sci Med Sci</MedlineTA><NlmUniqueID>9502837</NlmUniqueID><ISSNLinking>1079-5006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="Y">Genetic Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32777042</ArticleId><ArticleId IdType="pmc">PMC7454416</ArticleId><ArticleId IdType="doi">10.1093/gerona/glaa200</ArticleId><ArticleId IdType="pii">5890467</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 1985;37:268&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1684560</ArticleId><ArticleId IdType="pubmed">3985008</ArticleId></ArticleIdList></Reference><Reference><Citation>Davignon J, Bouthillier D, Nestruck AC, Sing CF. Apolipoprotein E polymorphism and atherosclerosis: insight from a study in octogenarians. Trans Am Clin Climatol Assoc. 1988;99:100&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376437</ArticleId><ArticleId IdType="pubmed">3503432</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Weisgraber KH, Huang DY, et al. &#xa0;Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:8098&#x2013;8102. doi:10.1073/pnas.90.17.8098</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.17.8098</ArticleId><ArticleId IdType="pmc">PMC47295</ArticleId><ArticleId IdType="pubmed">8367470</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, et al. &#xa0;Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180&#x2013;184. doi:10.1038/ng0694-180</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0694-180</ArticleId><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe4;chter F, Faure-Delanef L, Gu&#xe9;not F, et al. &#xa0;Genetic associations with human longevity at the APOE and ACE loci. Nat Genet. 1994;6:29&#x2013;32. doi:10.1038/ng0194-29</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0194-29</ArticleId><ArticleId IdType="pubmed">8136829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanlon CS, Rubinsztein DC. Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the ancestral state in humans. Atherosclerosis. 1995;112:85&#x2013;90. doi:10.1016/0021-9150(94)05402-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9150(94)05402-5</ArticleId><ArticleId IdType="pubmed">7772071</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch CE, Sapolsky RM. The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms. Neurobiol Aging. 1999;20:407&#x2013;428. doi:10.1016/s0197-4580(99)00053-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0197-4580(99)00053-6</ArticleId><ArticleId IdType="pubmed">10604433</ArticleId></ArticleIdList></Reference><Reference><Citation>Fullerton SM, Clark AG, Weiss KM, et al. &#xa0;Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet. 2000;67:881&#x2013;900. doi:10.1086/303070</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/303070</ArticleId><ArticleId IdType="pmc">PMC1287893</ArticleId><ArticleId IdType="pubmed">10986041</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GM. APOE alleles and lipophylic pathogens. Neurobiol Aging. 1999;20:441&#x2013;443. doi:10.1016/s0197-4580(99)00078-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0197-4580(99)00078-0</ArticleId><ArticleId IdType="pubmed">10604437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL; Trent HCV Study Group Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology. 2002;36:456&#x2013;463. doi:10.1053/jhep.2002.34745</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jhep.2002.34745</ArticleId><ArticleId IdType="pubmed">12143056</ArticleId></ArticleIdList></Reference><Reference><Citation>van Exel E, Koopman JJE, Bodegom DV, et al. &#xa0;Effect of APOE &#x3b5;4 allele on survival and fertility in an adverse environment. PLoS One. 2017;12:e0179497. doi:10.1371/journal.pone.0179497</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0179497</ArticleId><ArticleId IdType="pmc">PMC5500260</ArticleId><ArticleId IdType="pubmed">28683096</ArticleId></ArticleIdList></Reference><Reference><Citation>Trumble BC, Finch CE. The exposome in human evolution: from dust to diesel. Q Rev Biol. 2019;94:333&#x2013;394. doi:10.1086/706768</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/706768</ArticleId><ArticleId IdType="pmc">PMC7141577</ArticleId><ArticleId IdType="pubmed">32269391</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitter SS, Ori&#xe1; RB, Kvalsund MP, et al. &#xa0;Apolipoprotein E4 influences growth and cognitive responses to micronutrient supplementation in shantytown children from northeast Brazil. Clinics (Sao Paulo). 2012;67:11&#x2013;18. doi:10.6061/clinics/2012(01)03</Citation><ArticleIdList><ArticleId IdType="doi">10.6061/clinics/2012(01)03</ArticleId><ArticleId IdType="pmc">PMC3248595</ArticleId><ArticleId IdType="pubmed">22249475</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins JL, Masoli JAH, Delgado J, et al. &#xa0;Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci. 2020. doi:10.1093/gerona/glaa183</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glaa183</ArticleId><ArticleId IdType="pmc">PMC7454409</ArticleId><ArticleId IdType="pubmed">32687551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. 2020;395:1544&#x2013;1545. doi:10.1016/S0140-6736(20)31024-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31024-2</ArticleId><ArticleId IdType="pmc">PMC7196905</ArticleId><ArticleId IdType="pubmed">32380044</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzik TJ, Mohiddin SA, Dimarco A, et al. &#xa0;COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116:1666&#x2013;1687. doi:10.1093/cvr/cvaa106</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa106</ArticleId><ArticleId IdType="pmc">PMC7197627</ArticleId><ArticleId IdType="pubmed">32352535</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo CL, Pilling LC, Atkins JL, et al. &#xa0;APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci. 2020. doi:10.1093/gerona/glaa131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glaa131</ArticleId><ArticleId IdType="pmc">PMC7314139</ArticleId><ArticleId IdType="pubmed">32451547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo CL, Pilling LC, Atkins JL, et al. &#xa0;ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank. J Gerontol A Biol Sci Med Sci. 2020. doi:10.1093/gerona/glaa169</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glaa169</ArticleId><ArticleId IdType="pmc">PMC7337688</ArticleId><ArticleId IdType="pubmed">32623451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulminski AM, Shu L, Loika Y, et al. &#xa0;Genetic and regulatory architecture of Alzheimer&#x2019;s disease in the APOE region. Alzheimers Dement (Amst). 2020;12:e12008. doi:10.1002/dad2.12008</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12008</ArticleId><ArticleId IdType="pmc">PMC7085286</ArticleId><ArticleId IdType="pubmed">32211503</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CE, Seltman H, Peskind ER, et al. &#xa0;Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer&#x2019;s disease: patterns of linkage disequilibrium and disease/marker association. Genomics. 2007;89:655&#x2013;665. doi:10.1016/j.ygeno.2007.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2007.02.002</ArticleId><ArticleId IdType="pmc">PMC1978251</ArticleId><ArticleId IdType="pubmed">17434289</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei N, Miyashita A, Tsukie T, et al. ; Japanese Genetic Study Consortium for Alzheimer Disease Genetic association study on in and around the APOE in late-onset Alzheimer disease in Japanese. Genomics. 2009;93:441&#x2013;448. doi:10.1016/j.ygeno.2009.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2009.01.003</ArticleId><ArticleId IdType="pubmed">19442637</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulminski AM, Shu L, Loika Y, et al. &#xa0;APOE region molecular signatures of Alzheimer&#x2019;s disease across races/ethnicities. Neurobiol Aging. 2020;87:141.e1&#x2013;141.e8. doi:10.1016/j.neurobiolaging.2019.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.11.007</ArticleId><ArticleId IdType="pmc">PMC7064423</ArticleId><ArticleId IdType="pubmed">31813627</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E, Hannequin D, Wallon D, et al. &#xa0;APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16:903&#x2013;907. doi:10.1038/mp.2011.52</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2011.52</ArticleId><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD, Lutz MW, Amrine-Madsen H, et al. &#xa0;A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer&#x2019;s disease. Pharmacogenomics J. 2010;10:375&#x2013;384. doi:10.1038/tpj.2009.69</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tpj.2009.69</ArticleId><ArticleId IdType="pmc">PMC2946560</ArticleId><ArticleId IdType="pubmed">20029386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz MW, Crenshaw D, Welsh-Bohmer KA, Burns DK, Roses AD. New genetic approaches to AD: lessons from APOE-TOMM40 phylogenetics. Curr Neurol Neurosci Rep. 2016;16:48. doi:10.1007/s11910-016-0643-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-016-0643-8</ArticleId><ArticleId IdType="pubmed">27039903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lescai F, Chiamenti AM, Codemo A, et al. &#xa0;An APOE haplotype associated with decreased &#x3b5;4 expression increases the risk of late onset Alzheimer&#x2019;s disease. J Alzheimers Dis. 2011;24:235&#x2013;245. doi:10.3233/JAD-2011-101764</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-101764</ArticleId><ArticleId IdType="pubmed">21263195</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Chen Y, Mok KY, et al. &#xa0;Non-coding variability at the APOE locus contributes to the Alzheimer&#x2019;s risk. Nat Commun. 2019;10:3310. doi:10.1038/s41467-019-10945-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10945-z</ArticleId><ArticleId IdType="pmc">PMC6658518</ArticleId><ArticleId IdType="pubmed">31346172</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman A, Atzmon G, Ye K, MacCarthy T, Barzilai N. Buffering mechanisms in aging: a systems approach toward uncovering the genetic component of aging. PLoS Comput Biol. 2007;3:e170. doi:10.1371/journal.pcbi.0030170</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.0030170</ArticleId><ArticleId IdType="pmc">PMC1963511</ArticleId><ArticleId IdType="pubmed">17784782</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott J, Knott TJ, Shaw DJ, Brook JD. Localization of genes encoding apolipoproteins CI, CII, and E to the p13&#x2013;&#x2013;cen region of human chromosome 19. Hum Genet. 1985;71:144&#x2013;146. doi:10.1007/BF00283370</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00283370</ArticleId><ArticleId IdType="pubmed">2995235</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier T, Masson D, de Barros JP, et al. &#xa0;Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J Biol Chem. 2000;275:37504&#x2013;37509. doi:10.1074/jbc.M007210200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M007210200</ArticleId><ArticleId IdType="pubmed">10978346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouillet B, Gautier T, Blache D, et al. &#xa0;Glycation of apolipoprotein C1 impairs its CETP inhibitory property: pathophysiological relevance in patients with type 1 and type 2 diabetes. Diabetes Care. 2014;37:1148&#x2013;1156. doi:10.2337/dc13-1467</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-1467</ArticleId><ArticleId IdType="pubmed">24574346</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillois X, Gautier T, Bouillet B, et al. &#xa0;Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease. J Lipid Res. 2012;53:1200&#x2013;1209. doi:10.1194/jlr.M022988</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M022988</ArticleId><ArticleId IdType="pmc">PMC3351827</ArticleId><ArticleId IdType="pubmed">22474067</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan CM, Taylor JM. Expression of a novel human apolipoprotein (apoC-IV) causes hypertriglyceridemia in transgenic mice. J Lipid Res. 1996;37:1510&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pubmed">8827523</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Schmidt EM, Sengupta S, et al. ; Global Lipids Genetics Consortium Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274&#x2013;1283. doi:10.1038/ng.2797</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2797</ArticleId><ArticleId IdType="pmc">PMC3838666</ArticleId><ArticleId IdType="pubmed">24097068</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassine HN, Finch CE. APOE alleles and diet in brain aging and Alzheimer&#x2019;s disease. Front Aging Neurosci. 2020;12:150. doi:10.3389/fnagi.2020.00150</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00150</ArticleId><ArticleId IdType="pmc">PMC7297981</ArticleId><ArticleId IdType="pubmed">32587511</ArticleId></ArticleIdList></Reference><Reference><Citation>Divani AA, Andalib S, Di Napoli M, et al. &#xa0;Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights. J Stroke Cerebrovasc Dis. 2020;29:104941. doi:10.1016/j.jstrokecerebrovasdis.2020.104941</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2020.104941</ArticleId><ArticleId IdType="pmc">PMC7214348</ArticleId><ArticleId IdType="pubmed">32689643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116:1097&#x2013;1100. doi:10.1093/cvr/cvaa078</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa078</ArticleId><ArticleId IdType="pmc">PMC7184507</ArticleId><ArticleId IdType="pubmed">32227090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R. Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age. ACS Chem Neurosci. 2020;11:1555&#x2013;1562. doi:10.1021/acschemneuro.0c00210</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00210</ArticleId><ArticleId IdType="pmc">PMC7241737</ArticleId><ArticleId IdType="pubmed">32379417</ArticleId></ArticleIdList></Reference><Reference><Citation>Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY). 2020;12:6511&#x2013;6517. doi:10.18632/aging.103001</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103001</ArticleId><ArticleId IdType="pmc">PMC7202514</ArticleId><ArticleId IdType="pubmed">32229706</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859. doi:10.1016/j.phrs.2020.104859</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104859</ArticleId><ArticleId IdType="pmc">PMC7189851</ArticleId><ArticleId IdType="pubmed">32360480</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Wu X, Tang H, Luo G. Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors. PLoS ONE. 2013;8:e67982. doi:10.1371/journal.pone.0067982</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067982</ArticleId><ArticleId IdType="pmc">PMC3699494</ArticleId><ArticleId IdType="pubmed">23844141</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuior EV, Gafencu AV. Apolipoprotein C1: its pleiotropic effects in lipid metabolism and beyond. Int J Mol Sci. 2019;20. doi:10.3390/ijms20235939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20235939</ArticleId><ArticleId IdType="pmc">PMC6928722</ArticleId><ArticleId IdType="pubmed">31779116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulminski AM, Loika Y, Culminskaya I, et al. ; Long Life Family Study Research Group Independent associations of TOMM40 and APOE variants with body mass index. Aging Cell. 2019;18:e12869. doi:10.1111/acel.12869</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12869</ArticleId><ArticleId IdType="pmc">PMC6351823</ArticleId><ArticleId IdType="pubmed">30462377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulminski AM, Raghavachari N, Arbeev KG, et al. &#xa0;Protective role of the apolipoprotein E2 allele in age-related disease traits and survival: evidence from the Long Life Family Study. Biogerontology. 2016;17:893&#x2013;905. doi:10.1007/s10522-016-9659-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10522-016-9659-3</ArticleId><ArticleId IdType="pmc">PMC5065761</ArticleId><ArticleId IdType="pubmed">27447179</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32778793</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Tau induces PSD95-neuronal NOS uncoupling and neurovascular dysfunction independent of neurodegeneration.</ArticleTitle><Pagination><StartPage>1079</StartPage><EndPage>1089</EndPage><MedlinePgn>1079-1089</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-020-0686-7</ELocationID><Abstract><AbstractText>Cerebrovascular abnormalities have emerged as a preclinical manifestation of Alzheimer's disease and frontotemporal dementia, diseases characterized by the accumulation of hyperphosphorylated forms of the microtubule-associated protein tau. However, it is unclear whether tau contributes to these neurovascular alterations independent of neurodegeneration. We report that mice expressing mutated tau exhibit a selective suppression of neural activity-induced cerebral blood flow increases that precedes tau pathology and cognitive impairment. This dysfunction is attributable to a reduced vasodilatation of intracerebral arterioles and is reversible by reducing tau production. Mechanistically, the failure of neurovascular coupling involves a tau-induced dissociation of neuronal nitric oxide synthase (nNOS) from postsynaptic density 95 (PSD95) and a reduced production of the potent vasodilator nitric oxide during glutamatergic synaptic activity. These data identify glutamatergic signaling dysfunction and nitric oxide deficiency as yet-undescribed early manifestations of tau pathobiology, independent of neurodegeneration, and provide a mechanism for the neurovascular alterations observed in the preclinical stages of tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Laibaik</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7601-663X</Identifier><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. lap2003@med.cornell.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochrainer</LastName><ForeName>Karin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5147-0633</Identifier><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Yorito</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Sung Ji</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0001-8836-8069</Identifier><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anfray</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uekawa</LastName><ForeName>Ken</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8952-7009</Identifier><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palfini</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanco</LastName><ForeName>Ismary</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acosta</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eliezer</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1311-7537</Identifier><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anrather</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iadecola</LastName><ForeName>Costantino</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9797-073X</Identifier><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. coi2001@med.cornell.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS037853</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097805</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG019391</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095441</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS109588</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076122">Disks Large Homolog 4 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501447">Dlg4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052248">Nitric Oxide Synthase Type I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2020 Sep;23(9):1035-1036. doi: 10.1038/s41593-020-0691-x.</RefSource><PMID Version="1">32778790</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurosci Bull. 2021 Mar;37(3):433-435. doi: 10.1007/s12264-021-00637-4.</RefSource><PMID Version="1">33512634</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076122" MajorTopicYN="N">Disks Large Homolog 4 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069336" MajorTopicYN="N">Neurovascular Coupling</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052248" MajorTopicYN="N">Nitric Oxide Synthase Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing financial interest. CI serves on the advisory board of Broadview Ventures. The other authors have no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32778793</ArticleId><ArticleId IdType="mid">NIHMS1609145</ArticleId><ArticleId IdType="pmc">PMC7896353</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-0686-7</ArticleId><ArticleId IdType="pii">10.1038/s41593-020-0686-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cummings J, Lee G, Ritter A &amp; Zhong K Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (N Y) 4, 195&#x2013;214 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6021548</ArticleId><ArticleId IdType="pubmed">29955663</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Hyman BT &amp; Spires-Jones TL Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. Nat Rev Neurosci 20, 94&#x2013;108 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545070</ArticleId><ArticleId IdType="pubmed">30643230</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS Lowering of Amyloid-Beta by beta-Secretase Inhibitors - Some Informative Failures. N Engl J Med 380, 1476&#x2013;1478 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30970194</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, et al. Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies. Ann Neurol 85, 114&#x2013;124 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10128614</ArticleId><ArticleId IdType="pubmed">30421454</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C &amp; Gottesman RF Cerebrovascular Alterations in Alzheimer Disease. Circ Res 123, 406&#x2013;408 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6214471</ArticleId><ArticleId IdType="pubmed">30355253</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y, et al. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun 7, 11934 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4919512</ArticleId><ArticleId IdType="pubmed">27327500</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS, et al. Vascular Risk and beta-Amyloid Are Synergistically Associated with Cortical Tau. Ann Neurol 85, 272&#x2013;279 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351182</ArticleId><ArticleId IdType="pubmed">30565287</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron 96, 17&#x2013;42 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657612</ArticleId><ArticleId IdType="pubmed">28957666</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, et al. Alzheimer's disease. Lancet 388, 505&#x2013;517 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Dopper EG, et al. Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study. Neuroimage Clin 12, 460&#x2013;465 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5011170</ArticleId><ArticleId IdType="pubmed">27625986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurata T, et al. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage. Intern Med 50, 2775&#x2013;2781 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22082889</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunau L, et al. Presymptomatic cerebral blood flow changes in CHMP2B mutation carriers of familial frontotemporal dementia (FTD-3), measured with MRI. BMJ Open 2, e000368 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307039</ArticleId><ArticleId IdType="pubmed">22422914</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C The pathobiology of vascular dementia. Neuron 80, 844&#x2013;866 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842016</ArticleId><ArticleId IdType="pubmed">24267647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD, Kisler K, Montagne A, Toga AW &amp; Zlokovic BV The role of brain vasculature in neurodegenerative disorders. Nat Neurosci 21, 1318&#x2013;1331 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6198802</ArticleId><ArticleId IdType="pubmed">30250261</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenman JE, et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell 84, 757&#x2013;767 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8625413</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopherson KS, Hillier BJ, Lim WA &amp; Bredt DS PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem 274, 27467&#x2013;27473 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10488080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornau HC, Schenker LT, Kennedy MB &amp; Seeburg PH Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 269, 1737&#x2013;1740 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7569905</ArticleId></ArticleIdList></Reference><Reference><Citation>Girouard H, et al. NMDA receptor activation increases free radical production through nitric oxide and NOX2. J Neurosci 29, 2545&#x2013;2552 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669930</ArticleId><ArticleId IdType="pubmed">19244529</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A, et al. Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles. Nat Neurosci 19, 1619&#x2013;1627 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5131849</ArticleId><ArticleId IdType="pubmed">27775719</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, et al. Key role of tissue plasminogen activator in neurovascular coupling. Proc Natl Acad Sci U S A 105, 1073&#x2013;1078 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2242693</ArticleId><ArticleId IdType="pubmed">18195371</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett RE, et al. Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer's disease. Proc Natl Acad Sci U S A 115, E1289&#x2013;E1298 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819390</ArticleId><ArticleId IdType="pubmed">29358399</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair LJ, et al. Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol Commun 3, 8 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4353464</ArticleId><ArticleId IdType="pubmed">25775028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A &amp; Ittner LM Dendritic Tau in Alzheimer's Disease. Neuron 99, 13&#x2013;27 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30001506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondragon-Rodriguez S, et al. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J Biol Chem 287, 32040&#x2013;32053 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3442535</ArticleId><ArticleId IdType="pubmed">22833681</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476&#x2013;481 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067&#x2013;1081 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25, 10637&#x2013;10647 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, Haensel C, Ross ME &amp; Iadecola C Cyclooxygenase-1 participates in selected vasodilator responses of the cerebral circulation. Circ Res 88, 600&#x2013;608 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11282894</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C Does nitric oxide mediate the increases in cerebral blood flow elicited by hypercapnia? Proc Natl Acad Sci U S A 89, 3913&#x2013;3916 (1992).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC525601</ArticleId><ArticleId IdType="pubmed">1570313</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Pelligrino DA, Moskowitz MA &amp; Lassen NA Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metab 14, 175&#x2013;192 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7509338</ArticleId></ArticleIdList></Reference><Reference><Citation>Uekawa K, et al. Obligatory Role of EP1 Receptors in the Increase in Cerebral Blood Flow Produced by Hypercapnia in the Mice. PLoS One 11, e0163329 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5033465</ArticleId><ArticleId IdType="pubmed">27657726</ArticleId></ArticleIdList></Reference><Reference><Citation>Fa M, et al. Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. Sci Rep 6, 19393 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4726138</ArticleId><ArticleId IdType="pubmed">26786552</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 31, 13110&#x2013;13117 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Brochner CB, Holst CB &amp; Mollgard K Outer brain barriers in rat and human development. Front Neurosci 9, 75 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4360706</ArticleId><ArticleId IdType="pubmed">25852456</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykova E Diffusion properties of the brain in health and disease. Neurochem Int 45, 453&#x2013;466 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15186911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen BR, Kozberg MG, Bouchard MB, Shaik MA &amp; Hillman EM A critical role for the vascular endothelium in functional neurovascular coupling in the brain. J Am Heart Assoc 3, e000787 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4309064</ArticleId><ArticleId IdType="pubmed">24926076</ArticleId></ArticleIdList></Reference><Reference><Citation>Longden TA, et al. Capillary K(+)-sensing initiates retrograde hyperpolarization to increase local cerebral blood flow. Nat Neurosci 20, 717&#x2013;726 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404963</ArticleId><ArticleId IdType="pubmed">28319610</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecrux C, et al. Pyramidal neurons are "neurogenic hubs" in the neurovascular coupling response to whisker stimulation. J Neurosci 31, 9836&#x2013;9847 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6703330</ArticleId><ArticleId IdType="pubmed">21734275</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerk DG, Ances BM, Greenberg JH &amp; Detre JA Temporal dynamics of brain tissue nitric oxide during functional forepaw stimulation in rats. Neuroimage 18, 1&#x2013;9 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12507439</ArticleId></ArticleIdList></Reference><Reference><Citation>Koizumi K, et al. Apoepsilon4 disrupts neurovascular regulation and undermines white matter integrity and cognitive function. Nat Commun 9, 3816 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6145902</ArticleId><ArticleId IdType="pubmed">30232327</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattler R, et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284, 1845&#x2013;1848 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10364559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopeikina KJ, et al. Synaptic alterations in the rTg4510 mouse model of tauopathy. J Comp Neurol 521, 1334&#x2013;1353 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725804</ArticleId><ArticleId IdType="pubmed">23047530</ArticleId></ArticleIdList></Reference><Reference><Citation>Warmus BA, et al. Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia. J Neurosci 34, 16482&#x2013;16495 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252555</ArticleId><ArticleId IdType="pubmed">25471585</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamache J, et al. Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice. Nat Commun 10, 2479 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554306</ArticleId><ArticleId IdType="pubmed">31171783</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin LO, et al. Large-scale discovery of mouse transgenic integration sites reveals frequent structural variation and insertional mutagenesis. Genome Res 29, 494&#x2013;505 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6396414</ArticleId><ArticleId IdType="pubmed">30659012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham N, Dachtler J &amp; Fox K The role of nitric oxide in pre-synaptic plasticity and homeostasis. Front Cell Neurosci 7, 190 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3813972</ArticleId><ArticleId IdType="pubmed">24198758</ArticleId></ArticleIdList></Reference><Reference><Citation>Garthwaite J NO as a multimodal transmitter in the brain: discovery and current status. Br J Pharmacol 176, 197&#x2013;211 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6295412</ArticleId><ArticleId IdType="pubmed">30399649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Shang Y &amp; Zhang M Mechanistic basis of MAGUK-organized complexes in synaptic development and signalling. Nat Rev Neurosci 17, 209&#x2013;223 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26988743</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Method-only References</Title><Reference><Citation>Karp NA, et al. Applying the ARRIVE Guidelines to an In Vivo Database. PLoS Biol 13, e1002151 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439173</ArticleId><ArticleId IdType="pubmed">25992600</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KBJ &amp; Paxinos G The mouse brain in stereotaxic coordinates (Academic Press, 1997).</Citation></Reference><Reference><Citation>Jackman K, et al. Progranulin deficiency promotes post-ischemic blood-brain barrier disruption. J Neurosci 33, 19579&#x2013;19589 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858627</ArticleId><ArticleId IdType="pubmed">24336722</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, et al. Age-dependent neurovascular dysfunction and damage in a mouse model of cerebral amyloid angiopathy. Stroke 45, 1815&#x2013;1821 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284427</ArticleId><ArticleId IdType="pubmed">24781082</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, et al. The key role of transient receptor potential melastatin-2 channels in amyloid-beta-induced neurovascular dysfunction. Nat Commun 5, 5318 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4283829</ArticleId><ArticleId IdType="pubmed">25351853</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C Nitric oxide participates in the cerebrovasodilation elicited from cerebellar fastigial nucleus. Am J Physiol 263, R1156&#x2013;1161 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1443234</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, et al. Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc Natl Acad Sci U S A 108, 5063&#x2013;5068 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064396</ArticleId><ArticleId IdType="pubmed">21383152</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz Hernandez JC, et al. Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer's disease mouse models. Nat Neurosci 22, 413&#x2013;420 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508667</ArticleId><ArticleId IdType="pubmed">30742116</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih AY, Mateo C, Drew PJ, Tsai PS &amp; Kleinfeld D A polished and reinforced thinned-skull window for long-term imaging of the mouse brain. J Vis Exp (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460568</ArticleId><ArticleId IdType="pubmed">22433225</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn AK, Bolay H, Moskowitz MA &amp; Boas DA Dynamic imaging of cerebral blood flow using laser speckle. J Cereb Blood Flow Metab 21, 195&#x2013;201 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11295873</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, et al. Exogenous NADPH increases cerebral blood flow through NADPH oxidase-dependent and -independent mechanisms. Arterioscler Thromb Vasc Biol 24, 1860&#x2013;1865 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15308559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazama K, Wang G, Frys K, Anrather J &amp; Iadecola C Angiotensin II attenuates functional hyperemia in the mouse somatosensory cortex. Am J Physiol Heart Circ Physiol 285, H1890&#x2013;1899 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12907423</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman CG, et al. Chronic intermittent hypoxia induces NMDA receptor-dependent plasticity and suppresses nitric oxide signaling in the mouse hypothalamic paraventricular nucleus. J Neurosci 30, 12103&#x2013;12112 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951676</ArticleId><ArticleId IdType="pubmed">20826673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, et al. Angiotensin II slow-pressor hypertension enhances NMDA currents and NOX2-dependent superoxide production in hypothalamic paraventricular neurons. Am J Physiol Regul Integr Comp Physiol 304, R1096&#x2013;1106 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680791</ArticleId><ArticleId IdType="pubmed">23576605</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano T, et al. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12, 225&#x2013;229 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16432513</ArticleId></ArticleIdList></Reference><Reference><Citation>Machida S, et al. Cycloamylose as an efficient artificial chaperone for protein refolding. FEBS Lett 486, 131&#x2013;135 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11113453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387&#x2013;397 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng HM, Morishima Y, Pratt WB &amp; Osawa Y Modulation of heme/substrate binding cleft of neuronal nitric-oxide synthase (nNOS) regulates binding of Hsp90 and Hsp70 proteins and nNOS ubiquitination. J Biol Chem 287, 1556&#x2013;1565 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256889</ArticleId><ArticleId IdType="pubmed">22128174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochrainer K, et al. The ubiquitin ligase HERC3 attenuates NF-kappaB-dependent transcription independently of its enzymatic activity by delivering the RelA subunit for degradation. Nucleic Acids Res 43, 9889&#x2013;9904 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4787756</ArticleId><ArticleId IdType="pubmed">26476452</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G, et al. Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension. J Clin Invest 126, 4674&#x2013;4689 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127678</ArticleId><ArticleId IdType="pubmed">27841763</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34158479</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>22</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>3825</StartPage><MedlinePgn>3825</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3825</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-021-23755-z</ELocationID><Abstract><AbstractText>Klotho-VS heterozygosity (KL-VS<sup>het</sup>) is associated with reduced risk of Alzheimer's disease (AD). However, whether KL-VS<sup>het</sup> is associated with lower levels of pathologic tau, i.e., the key AD pathology driving neurodegeneration and cognitive decline, is unknown. Here, we assessed the interaction between KL-VS<sup>het</sup> and levels of beta-amyloid, a key driver of tau pathology, on the levels of PET-assessed neurofibrillary tau in 551 controls and patients across the AD continuum. KL-VS<sup>het</sup> showed lower cross-sectional and longitudinal increase in tau-PET per unit increase in amyloid-PET when compared to that of non-carriers. This association of KL-VS<sup>het</sup> on tau-PET was stronger in Klotho mRNA-expressing brain regions mapped onto a gene expression atlas. KL-VS<sup>het</sup> was related to better memory functions in amyloid-positive participants and this association was mediated by lower tau-PET. Amyloid-PET levels did not differ between KL-VS<sup>het</sup> carriers versus non-carriers. Together, our findings provide evidence to suggest a protective role of KL-VS<sup>het</sup> against amyloid-related tau pathology and tau-related memory impairments in elderly humans at risk of AD dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neitzel</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5739-466X</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t LMU, Munich, Germany. j.neitzel@erasmusmc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands. j.neitzel@erasmusmc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands. j.neitzel@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzmeier</LastName><ForeName>Nicolai</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9736-2283</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t LMU, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubinski</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t LMU, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dichgans</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0654-387X</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t LMU, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9247-2843</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t LMU, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI)</CollectiveName></Author><Author ValidYN="Y"><LastName>Malik</LastName><ForeName>Rainer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t LMU, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5231-1714</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t LMU, Munich, Germany. Michael.Ewers@med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. Michael.Ewers@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D005966">Glucuronidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D000090265">Klotho Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005966" MajorTopicYN="N">Glucuronidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090265" MajorTopicYN="N">Klotho Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>M.B. received speaker honoraria from GE healthcare and LMI and is an advisor of LMI. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiminez</LastName><ForeName>Gus</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCArli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borowski</LastName><ForeName>Bret</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Householder</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reinwald</LastName><ForeName>Lisa Taylor</ForeName><Initials>LT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figurski</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelley</LastName><ForeName>Faber</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungeun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>Raina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beccera</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teodoro</LastName><ForeName>Liberty</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albers</LastName><ForeName>Colleen S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyer</LastName><ForeName>Javier Villanueva</ForeName><Initials>JV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rountree</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dang</LastName><ForeName>Mimi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>OliverNG</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockington</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greig</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvin</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pogorelec</LastName><ForeName>Dana M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerbone</LastName><ForeName>Brittany</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>Christina A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Terence Z</ForeName><Initials>TZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinha</LastName><ForeName>Partha</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oates</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mc Adams Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arrastia</LastName><ForeName>Ramon Diaz</ForeName><Initials>RD</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>Kristen Martin</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tingus</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woo</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DHS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Radford</LastName><ForeName>Neill R Graff</ForeName><Initials>NRG</Initials></Investigator><Investigator ValidYN="Y"><LastName>ParfittH</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kendall</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging Yuek Robin</ForeName><Initials>GYR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Past</LastName><ForeName>Michele Assaly</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sirrel</LastName><ForeName>Sherye A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolday</LastName><ForeName>Saba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allard</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adeli</LastName><ForeName>Anahita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kitzmiller</LastName><ForeName>Tamar J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>SinkS</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabether</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasternak</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>Nunzio</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>Raymundo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarrael</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponto</LastName><ForeName>Laura L Boles</ForeName><Initials>LLB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Hyungsub</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Karen Elizabeth</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raudin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Balebail Ashok</ForeName><Initials>BA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34158479</ArticleId><ArticleId IdType="pmc">PMC8219708</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-23755-z</ArticleId><ArticleId IdType="pii">10.1038/s41467-021-23755-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kuro-o M, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45&#x2013;51. doi: 10.1038/36285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/36285</ArticleId><ArticleId IdType="pubmed">9363890</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, et al. Klotho gene polymorphisms are associated with healthy aging and longevity: Evidence from a meta-analysis. Mech. Ageing Dev. 2019;178:33&#x2013;40. doi: 10.1016/j.mad.2018.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2018.12.003</ArticleId><ArticleId IdType="pubmed">30633899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuro-o M. The Klotho proteins in health and disease. Nat. Rev. Nephrol. 2019;15:27&#x2013;44. doi: 10.1038/s41581-018-0078-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-018-0078-3</ArticleId><ArticleId IdType="pubmed">30455427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu H, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309:1829&#x2013;1833. doi: 10.1126/science.1112766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1112766</ArticleId><ArticleId IdType="pmc">PMC2536606</ArticleId><ArticleId IdType="pubmed">16123266</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, et al. Life extension factor klotho enhances cognition. Cell Rep. 2014;7:1065&#x2013;1076. doi: 10.1016/j.celrep.2014.03.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.076</ArticleId><ArticleId IdType="pmc">PMC4176932</ArticleId><ArticleId IdType="pubmed">24813892</ArticleId></ArticleIdList></Reference><Reference><Citation>Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ. Res. 2005;96:412&#x2013;418. doi: 10.1161/01.RES.0000157171.04054.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000157171.04054.30</ArticleId><ArticleId IdType="pubmed">15677572</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengel-From J, et al. Genetic variants in KLOTHO associate with cognitive function in the oldest old group. J. Gerontol. A Biol. Sci. Med Sci. 2016;71:1151&#x2013;1159. doi: 10.1093/gerona/glv163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glv163</ArticleId><ArticleId IdType="pmc">PMC4978356</ArticleId><ArticleId IdType="pubmed">26405063</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama JS, et al. Variation in longevity gene KLOTHO is associated with greater cortical volumes. Ann. Clin. Transl. Neurol. 2015;2:215&#x2013;230. doi: 10.1002/acn3.161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.161</ArticleId><ArticleId IdType="pmc">PMC4369272</ArticleId><ArticleId IdType="pubmed">25815349</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, et al. KLOTHO genotype and cognitive ability in childhood and old age in the same individuals. Neurosc Lett. 2005;378:22&#x2013;27. doi: 10.1016/j.neulet.2004.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2004.12.005</ArticleId><ArticleId IdType="pubmed">15763166</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries CF, et al. Klotho, APOE&#x3b5;4, cognitive ability, brain size, atrophy, and survival: a study in the Aberdeen Birth Cohort of 1936. Neurobiol. Aging. 2017;55:91&#x2013;98. doi: 10.1016/j.neurobiolaging.2017.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.02.019</ArticleId><ArticleId IdType="pubmed">28431289</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C-Y, et al. Lentiviral vector&#x2013;mediated overexpression of Klotho in the brain improves Alzheimer&#x2019;s disease&#x2013;like pathology and cognitive deficits in mice. Neurobiol. Aging. 2019;78:18&#x2013;28. doi: 10.1016/j.neurobiolaging.2019.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.02.003</ArticleId><ArticleId IdType="pubmed">30851437</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker WW, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis. Assoc. Disord. 2002;16:203&#x2013;212. doi: 10.1097/00002093-200210000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-200210000-00001</ArticleId><ArticleId IdType="pubmed">12468894</ArticleId></ArticleIdList></Reference><Reference><Citation>Belloy ME, et al. Association of Klotho-VS heterozygosity with risk of Alzheimer disease in individuals who carry APOE4. JAMA Neurol. 2020;7:849&#x2013;862. doi: 10.1001/jamaneurol.2020.0414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0414</ArticleId><ArticleId IdType="pmc">PMC7154955</ArticleId><ArticleId IdType="pubmed">32282020</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924&#x2013;1938. doi: 10.1001/jama.2015.4668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson CM, et al. KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD. Neurology. 2019;92:e1878&#x2013;e1889. doi: 10.1212/WNL.0000000000007323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007323</ArticleId><ArticleId IdType="pmc">PMC6550504</ArticleId><ArticleId IdType="pubmed">30867273</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x2019;s disease. Brain. 2017;140:3286&#x2013;3300. doi: 10.1093/brain/awx243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx243</ArticleId><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med. 2012;367:795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, et al. Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer&#x2019;s disease. Sci. Adv. 2020;6:eaaz2387. doi: 10.1126/sciadv.aaz2387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2387</ArticleId><ArticleId IdType="pmc">PMC7159908</ArticleId><ArticleId IdType="pubmed">32426454</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971&#x2013;982. doi: 10.1016/j.neuron.2016.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, T. et al. Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer&#x2019;s Disease pathophysiology. Biol. Psychiatry89, 786&#x2013;794 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9682985</ArticleId><ArticleId IdType="pubmed">32919611</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Predicting future rates of tau accumulation on PET. Brain. 2020;143:3136&#x2013;3150. doi: 10.1093/brain/awaa248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa248</ArticleId><ArticleId IdType="pmc">PMC7586089</ArticleId><ArticleId IdType="pubmed">33094327</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, et al. Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Ann. Neurol. 2019;85:229&#x2013;240. doi: 10.1002/ana.25406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25406</ArticleId><ArticleId IdType="pmc">PMC6579738</ArticleId><ArticleId IdType="pubmed">30597624</ArticleId></ArticleIdList></Reference><Reference><Citation>LaPoint MR, et al. The association between tau PET and retrospective cortical thinning in clinically normal elderly. Neuroimage. 2017;157:612&#x2013;622. doi: 10.1016/j.neuroimage.2017.05.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.05.049</ArticleId><ArticleId IdType="pmc">PMC5772972</ArticleId><ArticleId IdType="pubmed">28545932</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, et al. Fluorodeoxyglucose metabolism associated with tau&#x2010;amyloid interaction predicts memory decline. Ann. Neurol. 2017;81:583&#x2013;596. doi: 10.1002/ana.24910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24910</ArticleId><ArticleId IdType="pmc">PMC5404378</ArticleId><ArticleId IdType="pubmed">28253546</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 2016;79:110&#x2013;119. doi: 10.1002/ana.24546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, et al. Associations between tau, A&#x3b2;, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92:e601&#x2013;e612. doi: 10.1212/WNL.0000000000006875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006875</ArticleId><ArticleId IdType="pmc">PMC6382060</ArticleId><ArticleId IdType="pubmed">30626656</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschenbrenner AJ, Gordon BA, Benzinger TL, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018;91:e859&#x2013;e866. doi: 10.1212/WNL.0000000000006075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006075</ArticleId><ArticleId IdType="pmc">PMC6133625</ArticleId><ArticleId IdType="pubmed">30068637</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, et al. Prospective longitudinal atrophy in Alzheimer&#x2019;s disease correlates with the intensity and topography of baseline tau-PET. Sci. Transl. Med. 2020;12:eaau5732. doi: 10.1126/scitranslmed.aau5732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau5732</ArticleId><ArticleId IdType="pmc">PMC7035952</ArticleId><ArticleId IdType="pubmed">31894103</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuang X, et al. Klotho upregulation contributes to the neuroprotection of ligustilide in an Alzheimer&#x2019;s disease mouse model. Neurobiol. Aging. 2014;35:169&#x2013;178. doi: 10.1016/j.neurobiolaging.2013.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.07.019</ArticleId><ArticleId IdType="pubmed">23973442</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, et al. Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. J. Neurosci. 2015;35:2358&#x2013;2371. doi: 10.1523/JNEUROSCI.5791-12.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5791-12.2015</ArticleId><ArticleId IdType="pmc">PMC4323521</ArticleId><ArticleId IdType="pubmed">25673831</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimers Dement. 2017;13:561&#x2013;571. doi: 10.1016/j.jalz.2016.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.10.006</ArticleId><ArticleId IdType="pmc">PMC5536850</ArticleId><ArticleId IdType="pubmed">27931796</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrylycz MJ, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012;489:391&#x2013;399. doi: 10.1038/nature11405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11405</ArticleId><ArticleId IdType="pmc">PMC4243026</ArticleId><ArticleId IdType="pubmed">22996553</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrylycz M, et al. Canonical genetic signatures of the adult human brain. Nat. Neurosci. 2015;18:1832. doi: 10.1038/nn.4171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4171</ArticleId><ArticleId IdType="pmc">PMC4700510</ArticleId><ArticleId IdType="pubmed">26571460</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382945</ArticleId><ArticleId IdType="pubmed">28077397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart SN, et al. Amyloid and tau PET demonstrate region-specific associations in normal older people. Neuroimage. 2017;150:191&#x2013;199. doi: 10.1016/j.neuroimage.2017.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.02.051</ArticleId><ArticleId IdType="pmc">PMC5391247</ArticleId><ArticleId IdType="pubmed">28232190</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, et al. In vivo tau, amyloid, and gray matter profiles in the aging brain. J. Neurosci. 2016;36:7364&#x2013;7374. doi: 10.1523/JNEUROSCI.0639-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0639-16.2016</ArticleId><ArticleId IdType="pmc">PMC4945661</ArticleId><ArticleId IdType="pubmed">27413148</ArticleId></ArticleIdList></Reference><Reference><Citation>French L, Paus T. A FreeSurfer view of the cortical transcriptome generated from the Allen Human Brain Atlas. Front Neurosci. 2015;9:323. doi: 10.3389/fnins.2015.00323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2015.00323</ArticleId><ArticleId IdType="pmc">PMC4584957</ArticleId><ArticleId IdType="pubmed">26441498</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, et al. Development and assessment of a composite score for memory in the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) Brain Imaging Behav. 2012;6:502&#x2013;516. doi: 10.1007/s11682-012-9186-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-012-9186-z</ArticleId><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumitrescu L, et al. Genetic variants and functional pathways associated with resilience to Alzheimer&#x2019;s disease. Brain. 2020;143:2561&#x2013;2575. doi: 10.1093/brain/awaa209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa209</ArticleId><ArticleId IdType="pmc">PMC7447518</ArticleId><ArticleId IdType="pubmed">32844198</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier, N. et al. The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer&#x2019;s disease. Mol. Psychiatry26, 614&#x2013;628 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6754794</ArticleId><ArticleId IdType="pubmed">30899092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Dumitrescu L, Cox NJ, Jefferson AL. Genetic resilience to amyloid related cognitive decline. Brain Imaging Behav. 2017;11:401&#x2013;409. doi: 10.1007/s11682-016-9615-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-016-9615-5</ArticleId><ArticleId IdType="pmc">PMC5392179</ArticleId><ArticleId IdType="pubmed">27743375</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleineidam L, et al. PLCG2 protective variant p. P522R modulates Tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathol. 2020;139:1025&#x2013;1044. doi: 10.1007/s00401-020-02138-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02138-6</ArticleId><ArticleId IdType="pmc">PMC7244617</ArticleId><ArticleId IdType="pubmed">32166339</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter T, et al. Klotho allele status is not associated with Abeta and APOE epsilon4-related cognitive decline in preclinical Alzheimer&#x2019;s disease. Neurobiol. Aging. 2019;76:162&#x2013;165. doi: 10.1016/j.neurobiolaging.2018.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.12.014</ArticleId><ArticleId IdType="pubmed">30716541</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakawa I, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770&#x2013;774. doi: 10.1038/nature05315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05315</ArticleId><ArticleId IdType="pubmed">17086194</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeldich E, et al. The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. J. Biol. Chem. 2014;289:24700&#x2013;24715. doi: 10.1074/jbc.M114.567321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.567321</ArticleId><ArticleId IdType="pmc">PMC4148892</ArticleId><ArticleId IdType="pubmed">25037225</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Q, et al. The b-glucuronidase Klotho hydrolyzes and activates the TRPV5 channel. Science. 2005;310:490&#x2013;493. doi: 10.1126/science.1114245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1114245</ArticleId><ArticleId IdType="pubmed">16239475</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez AF, et al. Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice. Nature. 2018;558:136&#x2013;140. doi: 10.1038/s41586-018-0162-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0162-7</ArticleId><ArticleId IdType="pmc">PMC5992097</ArticleId><ArticleId IdType="pubmed">29849149</ArticleId></ArticleIdList></Reference><Reference><Citation>Uddin MS, et al. Autophagy and Alzheimer&#x2019;s disease: from molecular mechanisms to therapeutic implications. Front Aging Neurosci. 2018;10:4. doi: 10.3389/fnagi.2018.00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00004</ArticleId><ArticleId IdType="pmc">PMC5797541</ArticleId><ArticleId IdType="pubmed">29441009</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuang X, et al. Neuroprotective effect of ligustilide through induction of &#x3b1;-secretase processing of both APP and Klotho in a mouse model of Alzheimer&#x2019;s disease. Front Aging Neurosci. 2017;9:353. doi: 10.3389/fnagi.2017.00353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00353</ArticleId><ArticleId IdType="pmc">PMC5673635</ArticleId><ArticleId IdType="pubmed">29163135</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 2018;14:399&#x2013;415. doi: 10.1038/s41582-018-0013-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0013-z</ArticleId><ArticleId IdType="pmc">PMC6463489</ArticleId><ArticleId IdType="pubmed">29895964</ArticleId></ArticleIdList></Reference><Reference><Citation>Semba RD, et al. Klotho in the cerebrospinal fluid of adults with and without Alzheimer&#x2019;s disease. Neurosci. Lett. 2014;558:37&#x2013;40. doi: 10.1016/j.neulet.2013.10.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.10.058</ArticleId><ArticleId IdType="pmc">PMC4037850</ArticleId><ArticleId IdType="pubmed">24211693</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee E, et al. Relationship between polymorphisms G395A in promoter and C1818T in exon 4 of the KLOTHO gene with glucose metabolism and cardiovascular risk factors in Korean women. J. Endocrinol. Invest. 2006;29:613&#x2013;618. doi: 10.1007/BF03344160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03344160</ArticleId><ArticleId IdType="pubmed">16957409</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, et al. Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys. Res Commun. 2010;398:513&#x2013;518. doi: 10.1016/j.bbrc.2010.06.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2010.06.110</ArticleId><ArticleId IdType="pmc">PMC4130489</ArticleId><ArticleId IdType="pubmed">20599764</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama JS, et al. Systemic klotho is associated with KLOTHO variation and predicts intrinsic cortical connectivity in healthy human aging. Brain Imaging Behav. 2017;11:391&#x2013;400. doi: 10.1007/s11682-016-9598-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-016-9598-2</ArticleId><ArticleId IdType="pmc">PMC5382127</ArticleId><ArticleId IdType="pubmed">27714549</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole MA, Seabrook GR. On the horizon&#x2014;the value and promise of the global pipeline of Alzheimer&#x2019;s disease therapeutics. Alzheimers Dement. 2020;6:e12009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217086</ArticleId><ArticleId IdType="pubmed">32405530</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968&#x2013;980. doi: 10.1016/j.neuroimage.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.01.021</ArticleId><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012;72:578&#x2013;586. doi: 10.1002/ana.23650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23650</ArticleId><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer&#x2019;s disease. Neuroimage. 2017;157:448&#x2013;463. doi: 10.1016/j.neuroimage.2017.05.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.05.058</ArticleId><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 2015;78:787&#x2013;800. doi: 10.1002/ana.24517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24517</ArticleId><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe MJ, et al. Molecular properties underlying regional vulnerability to Alzheimer&#x2019;s disease pathology. Brain. 2018;141:2755&#x2013;2771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6113636</ArticleId><ArticleId IdType="pubmed">30016411</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N, Rubinski A, Neitzel J, Ewers M. The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. Nat. Commun. 2019;10:1&#x2013;12. doi: 10.1038/s41467-019-09564-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09564-5</ArticleId><ArticleId IdType="pmc">PMC6467911</ArticleId><ArticleId IdType="pubmed">30992433</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>